CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and  bbbbb1 trianisylchloroethylene eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta ( bbbbb1 E2 eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and  bbbbb1 monohydroxytamoxifen eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [ bbbbb1 estradiol-17 beta eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene ( bbbbb1 TACE eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of  bbbbb1 tamoxifen eeeee1  bbbbb2 estrogen receptor eeeee2  and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with alcoholic liver disease,  bbbbb1 nonalcoholic eeeee1  bbbbb2 keratin 8 eeeee2  (K8) and K18 and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with alcoholic liver disease,  bbbbb1 nonalcoholic eeeee1  bbbbb2 K8 eeeee2 ) and K18 and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with alcoholic liver disease,  bbbbb1 nonalcoholic eeeee1  bbbbb2 K18 eeeee2  and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with  bbbbb1 alcoholic eeeee1  bbbbb2 keratin 8 eeeee2  (K8) and K18 and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with  bbbbb1 alcoholic eeeee1  bbbbb2 K8 eeeee2 ) and K18 and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Mallory bodies (MBs) are cytoplasmic inclusions that contain keratin 8 (K8) and K18 and are present in hepatocytes of individuals with  bbbbb1 alcoholic eeeee1  bbbbb2 K18 eeeee2  and are present in hepatocytes of individuals with alcoholic liver disease, nonalcoholic steatohepatitis, or benign or malignant hepatocellular neoplasia
CRP11	Overexpression of K18 in HepG2, HeLa, or COS-7 cells also induced the formation of intracellular aggregates that stained with antibodies to ubiquitin and with  bbbbb1 rhodamine B eeeee1  bbbbb2 K18 eeeee2  in HepG2, HeLa, or COS-7 cells also induced the formation of intracellular aggregates that stained with antibodies to ubiquitin and with rhodamine B (characteristics of MBs formed in vivo), eventually leading to cell death
CRP11	Overexpression of K18 in HepG2, HeLa, or COS-7 cells also induced the formation of intracellular aggregates that stained with antibodies to ubiquitin and with  bbbbb1 rhodamine B eeeee1  bbbbb2 ubiquitin eeeee2  and with rhodamine B (characteristics of MBs formed in vivo), eventually leading to cell death
CRP11	In mechanistic studies, Silibinin decreased the protein level of p34cdc2, which might be the possible molecular mechanism of  bbbbb1 Silibinin eeeee1  bbbbb2 p34cdc2 eeeee2 , which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells
CRP11	In this report, we evaluated the growth-inhibitory effects of  bbbbb1 sulindac sulfide eeeee1 , a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit  bbbbb2 COX eeeee2  enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of  bbbbb1 sulindac sulfide eeeee1 , a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a  bbbbb2 lipoxygenase eeeee2  inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid ( bbbbb1 NDGA eeeee1  bbbbb2 COX-1 eeeee2  and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid ( bbbbb1 NDGA eeeee1  bbbbb2 COX eeeee2  enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid ( bbbbb1 NDGA eeeee1  bbbbb2 COX-2 eeeee2  inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind ( bbbbb1 sulindac sulfone eeeee1  bbbbb2 COX-1 eeeee2  and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind ( bbbbb1 sulindac sulfone eeeee1 ), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a  bbbbb2 lipoxygenase eeeee2  inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind ( bbbbb1 sulindac sulfone eeeee1  bbbbb2 COX-2 eeeee2  inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and  bbbbb1 nordihydroguaiaretic acid eeeee1  bbbbb2 COX-1 eeeee2  and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and  bbbbb1 nordihydroguaiaretic acid eeeee1  bbbbb2 COX eeeee2  enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and  bbbbb1 nordihydroguaiaretic acid eeeee1  bbbbb2 COX-2 eeeee2  inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor;  bbbbb1 exisulind eeeee1  bbbbb2 COX-1 eeeee2  and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor;  bbbbb1 exisulind eeeee1  (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a  bbbbb2 lipoxygenase eeeee2  inhibitor on human lung cancer cell lines
CRP11	In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor;  bbbbb1 exisulind eeeee1  bbbbb2 COX-2 eeeee2  inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines
CRP11	Many lung cancers also express 12-lipoxygenase RNA and 12-lipoxygenase protein and biosynthesize  bbbbb1 12(S)-hydroxyeicosatetraenoic acid eeeee1  bbbbb2 12-lipoxygenase eeeee2  RNA and 12-lipoxygenase protein and biosynthesize 12(S)-hydroxyeicosatetraenoic acid, which correlates with their metastatic potential
CRP11	Many lung cancers also express 12-lipoxygenase RNA and 12-lipoxygenase protein and biosynthesize  bbbbb1 12(S)-hydroxyeicosatetraenoic acid eeeee1  bbbbb2 12-lipoxygenase eeeee2  protein and biosynthesize 12(S)-hydroxyeicosatetraenoic acid, which correlates with their metastatic potential
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor  bbbbb1 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate eeeee1 . 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and  bbbbb2 sulfatase eeeee2  inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor  bbbbb1 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate eeeee1 . 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual  bbbbb2 aromatase eeeee2  and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl,  bbbbb1 Br eeeee1  bbbbb2 Sulfatase eeeee2  Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl,  bbbbb1 Br eeeee1  bbbbb2 Aromatase eeeee2 -Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ( bbbbb1 F eeeee1  bbbbb2 Sulfatase eeeee2  Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ( bbbbb1 F eeeee1  bbbbb2 Aromatase eeeee2 -Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.  bbbbb1 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate eeeee1  bbbbb2 Sulfatase eeeee2  Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.  bbbbb1 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate eeeee1  bbbbb2 Aromatase eeeee2 -Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F,  bbbbb1 Cl eeeee1  bbbbb2 Sulfatase eeeee2  Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F,  bbbbb1 Cl eeeee1  bbbbb2 Aromatase eeeee2 -Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)
CRP11	Here, we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing FST315 to a murine IgG(1) Fc and removing the intrinsic heparan  bbbbb1 sulfate eeeee1  bbbbb2 murine IgG(1) Fc eeeee2  and removing the intrinsic heparan sulfate-binding activity of follistatin
CRP11	Here, we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing FST315 to a murine IgG(1) Fc and removing the intrinsic heparan  bbbbb1 sulfate eeeee1  bbbbb2 FST315 eeeee2  to a murine IgG(1) Fc and removing the intrinsic heparan sulfate-binding activity of follistatin
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb1 phenylalanine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	 bbbbb1 N(5)-Substituted H(4)biopterin eeeee1  derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	 bbbbb1 N(5)-Substituted H(4)biopterin eeeee1  derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb2 phenylalanine hydroxylase eeeee2 , whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase:  bbbbb1 N(5)-methyl eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase:  bbbbb1 N(5)-methyl eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and  bbbbb1 N(5)-hydroxymethyl H(4)biopterin eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and  bbbbb1 N(5)-hydroxymethyl H(4)biopterin eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and  bbbbb1 N(5)-acetyl H(4)biopterin eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and  bbbbb1 N(5)-acetyl H(4)biopterin eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  bbbbb1 phenylalanine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  bbbbb1 phenylalanine eeeee1  hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb2 phenylalanine hydroxylase eeeee2 , whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas  bbbbb1 N(5)-formyl eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas  bbbbb1 N(5)-formyl eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for  bbbbb1 dihydropteridine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for  bbbbb1 dihydropteridine eeeee1  reductase and,depending on the substituent, were competitive inhibitors of  bbbbb2 phenylalanine hydroxylase eeeee2 : N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for  bbbbb1 dihydropteridine eeeee1  reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited  bbbbb2 phenylalanine hydroxylase eeeee2 , whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect
CRP11	Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin,  bbbbb1 H(4)biopterin eeeee1 ] is one of several cofactors of nitric oxide synthases ( bbbbb2 EC 1.14.13.39 eeeee2 )
CRP11	Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthases eeeee2  (EC 1.14.13.39)
CRP11	Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of  bbbbb1 nitric oxide eeeee1  synthases ( bbbbb2 EC 1.14.13.39 eeeee2 )
CRP11	Tetrahydrobiopterin [ bbbbb1 (6R)-5,6,7,8-tetrahydro-L-biopterin eeeee1 , H(4)biopterin] is one of several cofactors of nitric oxide synthases ( bbbbb2 EC 1.14.13.39 eeeee2 )
CRP11	Substitution at N(5) occurs at a position critical to the redox cycle of the cofactor in phenylalanine hydroxylase/ bbbbb1 dihydropteridine eeeee1  bbbbb2 dihydropteridine reductase eeeee2 
CRP11	Substitution at N(5) occurs at a position critical to the redox cycle of the cofactor in phenylalanine hydroxylase/ bbbbb1 dihydropteridine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 /dihydropteridine reductase
CRP11	Substitution at  bbbbb1 N(5) eeeee1  occurs at a position critical to the redox cycle of the cofactor in phenylalanine hydroxylase/ bbbbb2 dihydropteridine reductase eeeee2 
CRP11	Substitution at  bbbbb1 N(5) eeeee1  occurs at a position critical to the redox cycle of the cofactor in  bbbbb2 phenylalanine hydroxylase eeeee2 /dihydropteridine reductase
CRP11	Substitution at N(5) occurs at a position critical to the redox cycle of the cofactor in  bbbbb1 phenylalanine eeeee1  hydroxylase/ bbbbb2 dihydropteridine reductase eeeee2 
CRP11	Substitution at N(5) occurs at a position critical to the redox cycle of the cofactor in  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 /dihydropteridine reductase
CRP11	Our data demonstrate differences in the mechanism of stimulation of phenylalanine hydroxylase and nitric oxide synth bbbbb1 ase by H(4)b eeeee1  bbbbb2 ase by H(4)biopterin eeeee2 
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal  bbbbb1 nitric oxide eeeee1  synthase with their effects on dihydropteridine reductase ( bbbbb2 EC 1.6.99.7 eeeee2 ) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal  bbbbb1 nitric oxide eeeee1  synthase with their effects on  bbbbb2 dihydropteridine reductase eeeee2  (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal  bbbbb1 nitric oxide eeeee1  bbbbb2 rat neuronal nitric oxide synthase eeeee2  with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal  bbbbb1 nitric oxide eeeee1  synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase ( bbbbb2 EC 1.14.16.1 eeeee2 ),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal  bbbbb1 nitric oxide eeeee1  synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb2 phenylalanine hydroxylase eeeee2  (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb1 phenylalanine eeeee1  bbbbb2 EC 1.6.99.7 eeeee2 ) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb1 phenylalanine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb1 phenylalanine eeeee1  bbbbb2 rat neuronal nitric oxide synthase eeeee2  with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb1 phenylalanine eeeee1  hydroxylase ( bbbbb2 EC 1.14.16.1 eeeee2 ),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2  (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical  bbbbb1 H(4)biopterin eeeee1  bbbbb2 EC 1.6.99.7 eeeee2 ) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical  bbbbb1 H(4)biopterin eeeee1  bbbbb2 dihydropteridine reductase eeeee2  (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical  bbbbb1 H(4)biopterin eeeee1  bbbbb2 rat neuronal nitric oxide synthase eeeee2  with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical  bbbbb1 H(4)biopterin eeeee1  bbbbb2 EC 1.14.16.1 eeeee2 ),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical  bbbbb1 H(4)biopterin eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2  (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on  bbbbb1 dihydropteridine eeeee1  reductase ( bbbbb2 EC 1.6.99.7 eeeee2 ) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on  bbbbb1 dihydropteridine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on  bbbbb1 dihydropteridine eeeee1  bbbbb2 rat neuronal nitric oxide synthase eeeee2  with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on  bbbbb1 dihydropteridine eeeee1  reductase (EC 1.6.99.7) and phenylalanine hydroxylase ( bbbbb2 EC 1.14.16.1 eeeee2 ),the well-studied classical H(4)biopterin-dependent reactions
CRP11	Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on  bbbbb1 dihydropteridine eeeee1  reductase (EC 1.6.99.7) and  bbbbb2 phenylalanine hydroxylase eeeee2  (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions
CRP11	As compared with N(5)-methyl H(4)biopterin, N(5)-formyl H(4)biopterin bound with twice the capacity but stimulated  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2  to a lesser extent
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase,  bbbbb1 dihydropteridine eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and nitric oxide synthase
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase,  bbbbb1 dihydropteridine eeeee1  reductase and  bbbbb2 nitric oxide synthase eeeee2 
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase,  bbbbb1 dihydropteridine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , dihydropteridine reductase and nitric oxide synthase
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase, dihydropteridine reductase and  bbbbb1 nitric oxide eeeee1  bbbbb2 dihydropteridine reductase eeeee2  and nitric oxide synthase
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase, dihydropteridine reductase and  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2 
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on phenylalanine hydroxylase, dihydropteridine reductase and  bbbbb1 nitric oxide eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , dihydropteridine reductase and nitric oxide synthase
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on  bbbbb1 phenylalanine eeeee1  hydroxylase,  bbbbb2 dihydropteridine reductase eeeee2  and nitric oxide synthase
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on  bbbbb1 phenylalanine eeeee1  hydroxylase, dihydropteridine reductase and  bbbbb2 nitric oxide synthase eeeee2 
CRP11	Contrasting effects of N5-substituted tetrahydrobiopterin derivatives on  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , dihydropteridine reductase and nitric oxide synthase
CRP11	Because gastric AADC and COMT degrade  bbbbb1 levodopa eeeee1 , the drug is given with inhibitors of  bbbbb2 AADC eeeee2  (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use
CRP11	Because gastric AADC and COMT degrade  bbbbb1 levodopa eeeee1 , the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of  bbbbb2 COMT eeeee2  will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or  bbbbb1 benserazide eeeee1  bbbbb2 AADC eeeee2  and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or  bbbbb1 benserazide eeeee1 ), and inhibitors of  bbbbb2 COMT eeeee2  will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or  bbbbb1 benserazide eeeee1  bbbbb2 COMT eeeee2  degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC ( bbbbb1 carbidopa eeeee1  bbbbb2 AADC eeeee2  and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC ( bbbbb1 carbidopa eeeee1  or benserazide), and inhibitors of  bbbbb2 COMT eeeee2  will also enter clinical use
CRP11	Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC ( bbbbb1 carbidopa eeeee1  bbbbb2 COMT eeeee2  degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic- bbbbb1 L-amino-acid eeeee1  decarboxylase ( bbbbb2 AADC eeeee2 ) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic- bbbbb1 L-amino-acid eeeee1  bbbbb2 aromatic-L-amino-acid decarboxylase eeeee2  (AADC) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic- bbbbb1 L-amino-acid eeeee1  decarboxylase (AADC) and  bbbbb2 catechol-O-methyltransferase eeeee2  (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic- bbbbb1 L-amino-acid eeeee1  decarboxylase (AADC) and catechol-O-methyltransferase ( bbbbb2 COMT eeeee2 )
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol- bbbbb1 O eeeee1  bbbbb2 AADC eeeee2 ) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol- bbbbb1 O eeeee1  bbbbb2 aromatic-L-amino-acid decarboxylase eeeee2  (AADC) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol- bbbbb1 O eeeee1  bbbbb2 catechol-O-methyltransferase eeeee2  (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol- bbbbb1 O eeeee1 -methyltransferase ( bbbbb2 COMT eeeee2 )
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  bbbbb1 catechol eeeee1  bbbbb2 AADC eeeee2 ) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  bbbbb1 catechol eeeee1  bbbbb2 aromatic-L-amino-acid decarboxylase eeeee2  (AADC) and catechol-O-methyltransferase (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  bbbbb1 catechol eeeee1  bbbbb2 catechol-O-methyltransferase eeeee2  (COMT)
CRP11	Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  bbbbb1 catechol eeeee1 -O-methyltransferase ( bbbbb2 COMT eeeee2 )
CRP11	Newly synthesized dopamine is stored in the terminals and then released, stimulating postsynaptic  bbbbb1 dopamine eeeee1  bbbbb2 dopamine receptors eeeee2  and mediating the antiparkinsonian action of levodopa
CRP11	Newly synthesized dopamine is stored in the terminals and then released, stimulating postsynaptic dopamine receptors and mediating the antiparkinsonian action of  bbbbb1 levodopa eeeee1  bbbbb2 dopamine receptors eeeee2  and mediating the antiparkinsonian action of levodopa
CRP11	Although the exact site of decarboxylation of exogenous  bbbbb1 levodopa eeeee1  to dopamine in the brain is unknown, most striatal  bbbbb2 AADC eeeee2  is located in nigrostriatal dopaminergic nerve terminals
CRP11	Although the exact site of decarboxylation of exogenous levodopa to  bbbbb1 dopamine eeeee1  in the brain is unknown, most striatal  bbbbb2 AADC eeeee2  is located in nigrostriatal dopaminergic nerve terminals
CRP11	However, more recently, it is clear that PXR is also an important mediator of adverse xeno- (e.g., enhances  bbbbb1 acetaminophen eeeee1  bbbbb2 PXR eeeee2  is also an important mediator of adverse xeno- (e.g., enhances acetaminophen toxicity) and endobiotic (e.g., hepatic steatosis) metabolic phenotypes
CRP11	Adopted orphan nuclear receptor (NR),  bbbbb1 pregnane eeeee1  bbbbb2 NR eeeee2 ), pregnane X receptor (PXR), plays a central role in the regulation of xeno- and endobiotic metabolism
CRP11	Adopted orphan nuclear receptor (NR),  bbbbb1 pregnane eeeee1  bbbbb2 pregnane X receptor eeeee2  (PXR), plays a central role in the regulation of xeno- and endobiotic metabolism
CRP11	Adopted orphan nuclear receptor (NR),  bbbbb1 pregnane eeeee1  bbbbb2 orphan nuclear receptor eeeee2  (NR), pregnane X receptor (PXR), plays a central role in the regulation of xeno- and endobiotic metabolism
CRP11	Adopted orphan nuclear receptor (NR),  bbbbb1 pregnane eeeee1  X receptor ( bbbbb2 PXR eeeee2 ), plays a central role in the regulation of xeno- and endobiotic metabolism
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the human glucocorticoid receptor ( bbbbb2 hGR eeeee2 ) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with  bbbbb2 hGR eeeee2  and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and  bbbbb2 hAR eeeee2 
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  bbbbb2 human androgen receptor eeeee2  (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating  bbbbb2 hAR eeeee2  and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the  bbbbb2 human glucocorticoid receptor eeeee2  (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor ( bbbbb2 hAR eeeee2 ) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human  bbbbb1 androgen eeeee1  receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the  bbbbb2 hGR eeeee2  and hAR
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  bbbbb2 hGR eeeee2 ) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and  bbbbb2 hAR eeeee2 
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  bbbbb2 human androgen receptor eeeee2  (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  bbbbb2 human glucocorticoid receptor eeeee2  (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  bbbbb2 hAR eeeee2 ) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR
CRP11	Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  bbbbb1 steroids eeeee1  (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the  bbbbb2 hGR eeeee2  and hAR
CRP11	The data obtained agrees with the existing quali bbbbb1 tat eeeee1  bbbbb2 tat eeeee2 ive data and adds an important ligand-dependent kinetic component to hAR and hGR transport
CRP11	Effect of anabolic-androgenic  bbbbb1 steroids eeeee1  and glucocorticoids on the kinetics of hAR and  bbbbb2 hGR eeeee2  nucleocytoplasmic translocation
CRP11	Effect of anabolic-androgenic  bbbbb1 steroids eeeee1  and glucocorticoids on the kinetics of  bbbbb2 hAR eeeee2  and hGR nucleocytoplasmic translocation
CRP11	G, 1, and 3 were the most potent cytotoxic compounds bbbbb1 , wi eeeee1  bbbbb2  were t eeeee2 he most potent cytotoxic compounds, with EGCG and 3 selectively killing OATP1B3-expressing cells
CRP11	G, 1, and 3 were the most potent cytotoxic compounds, with EGCG and 3 sel bbbbb1 ectively  eeeee1  bbbbb2  were t eeeee2 he most potent cytotoxic compounds, with EGCG and 3 selectively killing OATP1B3-expressing cells
CRP11	When HUVECs were stimulated by thrombin in the presence of 100 microM  bbbbb1 L-arginine eeeee1  bbbbb2 thrombin eeeee2  in the presence of 100 microM L-arginine, NOS activity and NO release were similar in untreated and Nor-NOHA-treated cells
CRP11	When HUVECs were stimulated by thrombin in the presence of 100 microM  bbbbb1 L-arginine eeeee1 ,  bbbbb2 NOS eeeee2  activity and NO release were similar in untreated and Nor-NOHA-treated cells
CRP11	When HUVECs were stimulated by thrombin in the presence of 100 microM L-arginine, NOS activity and NO release were similar in untreated and  bbbbb1 Nor-NOHA eeeee1  bbbbb2 thrombin eeeee2  in the presence of 100 microM L-arginine, NOS activity and NO release were similar in untreated and Nor-NOHA-treated cells
CRP11	When HUVECs were stimulated by thrombin in the presence of 100 microM L-arginine, NOS activity and  bbbbb1 NO eeeee1  bbbbb2 thrombin eeeee2  in the presence of 100 microM L-arginine, NOS activity and NO release were similar in untreated and Nor-NOHA-treated cells
CRP11	When HUVECs were stimulated by thrombin in the presence of 100 microM L-arginine, NOS activity and  bbbbb1 NO eeeee1  bbbbb2 NOS eeeee2  activity and NO release were similar in untreated and Nor-NOHA-treated cells
CRP11	Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive  bbbbb1 nitric-oxide eeeee1  synthase (NOS) and cytosolic  bbbbb2 arginase I eeeee2  and mitochondrial arginase II
CRP11	Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive  bbbbb1 nitric-oxide eeeee1  bbbbb2 constitutive nitric-oxide synthase eeeee2  (NOS) and cytosolic arginase I and mitochondrial arginase II
CRP11	Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive  bbbbb1 nitric-oxide eeeee1  synthase (NOS) and cytosolic arginase I and  bbbbb2 mitochondrial arginase II eeeee2 
CRP11	Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive  bbbbb1 nitric-oxide eeeee1  synthase ( bbbbb2 NOS eeeee2 ) and cytosolic arginase I and mitochondrial arginase II
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine ( bbbbb1 Nor-NOHA eeeee1  bbbbb2 arginases eeeee2  modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor  bbbbb1 N(omega)-hydroxy-nor-L-arginine eeeee1  bbbbb2 arginases eeeee2  modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb1 L-arginine eeeee1  bbbbb2 arginases eeeee2 , and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb1 L-arginine eeeee1  bbbbb2 arginase eeeee2  inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb1 L-arginine eeeee1  bbbbb2 arginases eeeee2  modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb1 L-arginine eeeee1  bbbbb2 NOS eeeee2 , arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb1 L-arginine eeeee1  bbbbb2 L-arginine transporter eeeee2  and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial  bbbbb1 NO eeeee1  synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS,  bbbbb2 arginases eeeee2 , and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial  bbbbb1 NO eeeee1  synthesis, we investigated the effects of the competitive  bbbbb2 arginase eeeee2  inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial  bbbbb1 NO eeeee1  synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of  bbbbb2 NOS eeeee2 , arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial  bbbbb1 NO eeeee1  synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and  bbbbb2 L-arginine transporter eeeee2  and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on  bbbbb1 NO eeeee1  bbbbb2 arginases eeeee2 , and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on  bbbbb1 NO eeeee1  bbbbb2 arginase eeeee2  inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on  bbbbb1 NO eeeee1  bbbbb2 arginases eeeee2  modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on  bbbbb1 NO eeeee1  bbbbb2 NOS eeeee2 , arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on  bbbbb1 NO eeeee1  bbbbb2 L-arginine transporter eeeee2  and on NO release at surface of human umbilical vein endothelial cells (HUVECs)
CRP11	Interestingly, the mitochondrial arginase II was constitutively expressed, whereas the cytosolic arginase I  bbbbb1 was barely eeeee1  bbbbb2 hereas the  eeeee2 cytosolic arginase I was barely detectable in HUVECs
CRP11	When HUVECs were stimulated by thrombin without extracellular L-arginine,  bbbbb1 Nor-NOHA eeeee1  bbbbb2 thrombin eeeee2  without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the NO release with maximal effects at 20 microM
CRP11	When HUVECs were stimulated by thrombin without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the  bbbbb1 NO eeeee1  bbbbb2 NOS eeeee2  activity and the NO release with maximal effects at 20 microM
CRP11	When HUVECs were stimulated by thrombin without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the  bbbbb1 NO eeeee1  bbbbb2 thrombin eeeee2  without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the NO release with maximal effects at 20 microM
CRP11	When HUVECs were stimulated by thrombin without extracellular  bbbbb1 L-arginine eeeee1 , Nor-NOHA dose-dependently increased the  bbbbb2 NOS eeeee2  activity and the NO release with maximal effects at 20 microM
CRP11	When HUVECs were stimulated by thrombin without extracellular  bbbbb1 L-arginine eeeee1  bbbbb2 thrombin eeeee2  without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the NO release with maximal effects at 20 microM
CRP11	Extracellular L-arginine also dose-dependently increased  bbbbb1 NO eeeee1  release and  bbbbb2 arginase eeeee2  activity
CRP11	However, despite activation of  bbbbb1 L-arginine eeeee1  uptake, the inhibition of  bbbbb2 arginase eeeee2  activity by Nor-NOHA was still significant
CRP11	H is well known to produce effects on the  bbbbb1 monoamine eeeee1  systems but it is unclear how METH affects  bbbbb2 SERT eeeee2  and memory
CRP11	Autoradiographic study of  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  during memory formation
CRP11	CTS SODIUM IODIDE SYMPORTER (NIS) EXPRESSION AND INDUCES  bbbbb1 ¹³¹I eeeee1  bbbbb2 SODIUM IODIDE SYMPORTER eeeee2  (NIS) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS
CRP11	CTS SODIUM IODIDE SYMPORTER (NIS) EXPRESSION AND INDUCES  bbbbb1 ¹³¹I eeeee1  bbbbb2 NIS eeeee2 ) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS
CRP11	CTS  bbbbb1 SODIUM IODIDE eeeee1  bbbbb2 SODIUM IODIDE SYMPORTER eeeee2  (NIS) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS
CRP11	CTS  bbbbb1 SODIUM IODIDE eeeee1  SYMPORTER ( bbbbb2 NIS eeeee2 ) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS
CRP11	The resistance of anaplastic thyroid cancer to  bbbbb1 radioiodine eeeee1  treatment is principally due to the absence of expression of the  bbbbb2 sodium iodide symporter eeeee2  (NIS), mainly due to epigenetic silencing
CRP11	The resistance of anaplastic thyroid cancer to  bbbbb1 radioiodine eeeee1  treatment is principally due to the absence of expression of the sodium iodide symporter ( bbbbb2 NIS eeeee2 ), mainly due to epigenetic silencing
CRP11	The resistance of anaplastic thyroid cancer to radioiodine treatment is principally due to the absence of expression of the  bbbbb1 sodium iodide eeeee1  bbbbb2 sodium iodide symporter eeeee2  (NIS), mainly due to epigenetic silencing
CRP11	The resistance of anaplastic thyroid cancer to radioiodine treatment is principally due to the absence of expression of the  bbbbb1 sodium iodide eeeee1  symporter ( bbbbb2 NIS eeeee2 ), mainly due to epigenetic silencing
CRP11	Oral administration of  bbbbb1 tetrahydrobiopterin eeeee1  prevents endothelial dysfunction and vascular oxidative stress in the aortas of  bbbbb2 insulin eeeee2 -resistant rats
CRP11	Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid  bbbbb1 peroxide eeeee1  content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  bbbbb2 nuclear factor-kappaB eeeee2  and activating protein-1, which were increased in fructose-fed rats
CRP11	Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid  bbbbb1 peroxide eeeee1  content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  bbbbb2 activating protein-1 eeeee2 , which were increased in fructose-fed rats
CRP11	The BH(4) treatment of contr bbbbb1 ol ra eeeee1 ts did not have any significant effects on these parameters bbbbb2  eeeee2 
CRP11	The BH(4) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum triglyceride concentration, in the  bbbbb1 fructose eeeee1  bbbbb2 insulin eeeee2  sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats
CRP11	The BH(4) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum  bbbbb1 triglyceride eeeee1  bbbbb2 insulin eeeee2  sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats
CRP11	The BH(4) treatment was associated with a 2-fold increase in eNOS activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in  bbbbb1 fructose eeeee1  bbbbb2 eNOS eeeee2  activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats
CRP11	The BH(4) treatment was associated with a 2-fold increase in eNOS activity as well as a 70% reduction in endothelial  bbbbb1 O(2)(-) eeeee1  bbbbb2 eNOS eeeee2  activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats
CRP11	We have reported that a deficiency of tetrahydrobiopterin ( bbbbb1 BH(4) eeeee1 ), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the  bbbbb2 insulin eeeee2 -resistant state
CRP11	We have reported that a deficiency of  bbbbb1 tetrahydrobiopterin eeeee1  (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the  bbbbb2 insulin eeeee2 -resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased  bbbbb1 superoxide anion eeeee1  bbbbb2 eNOS eeeee2  activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased  bbbbb1 superoxide anion eeeee1  bbbbb2 endothelial NO synthase eeeee2  (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased  bbbbb1 superoxide anion eeeee1  bbbbb2 eNOS eeeee2 ), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased  bbbbb1 superoxide anion eeeee1  (O(2)(-)) generation in the  bbbbb2 insulin eeeee2 -resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial  bbbbb1 NO eeeee1  synthase (eNOS), contributes to the endothelial dysfunction through reduced  bbbbb2 eNOS eeeee2  activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial  bbbbb1 NO eeeee1  bbbbb2 endothelial NO synthase eeeee2  (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial  bbbbb1 NO eeeee1  synthase ( bbbbb2 eNOS eeeee2 ), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial  bbbbb1 NO eeeee1  synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the  bbbbb2 insulin eeeee2 -resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion ( bbbbb1 O(2)(-) eeeee1  bbbbb2 eNOS eeeee2  activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion ( bbbbb1 O(2)(-) eeeee1  bbbbb2 endothelial NO synthase eeeee2  (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion ( bbbbb1 O(2)(-) eeeee1  bbbbb2 eNOS eeeee2 ), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state
CRP11	We have reported that a deficiency of tetrahydrobiopterin (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion ( bbbbb1 O(2)(-) eeeee1 ) generation in the  bbbbb2 insulin eeeee2 -resistant state
CRP11	Both drugs target the alpha-subunit of the  bbbbb1 sodium eeeee1  bbbbb2 alpha-subunit of the sodium channel eeeee2 , encoded by the SCN family of genes
CRP11	Both drugs target the alpha-subunit of the  bbbbb1 sodium eeeee1  channel, encoded by the  bbbbb2 SCN eeeee2  family of genes
CRP11	IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by  bbbbb1 auranofin eeeee1  bbbbb2 MyD88 eeeee2 -independent signaling components, TRIF and TBK1, was also downregulated by auranofin
CRP11	Furthermore,  bbbbb1 auranofin eeeee1  inhibited NF-kappaB activation induced by  bbbbb2 MyD88 eeeee2 -dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65
CRP11	Furthermore,  bbbbb1 auranofin eeeee1  inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and  bbbbb2 p65 eeeee2 
CRP11	Furthermore,  bbbbb1 auranofin eeeee1  inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4,  bbbbb2 MyD88 eeeee2 , IKKbeta, and p65
CRP11	Furthermore,  bbbbb1 auranofin eeeee1  inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88,  bbbbb2 IKKbeta eeeee2 , and p65
CRP11	Furthermore,  bbbbb1 auranofin eeeee1  inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of  bbbbb2 TLR4 eeeee2 , MyD88, IKKbeta, and p65
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the  bbbbb1 chloramphenicol eeeee1  bbbbb2 copP eeeee2  associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the  bbbbb1 chloramphenicol eeeee1  bbbbb2 copA eeeee2  and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the  bbbbb1 chloramphenicol eeeee1  bbbbb2 frdA eeeee2  gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the  bbbbb1 chloramphenicol eeeee1  bbbbb2 subunit A of FRD eeeee2 , and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of  bbbbb1 copper eeeee1  bbbbb2 frdA eeeee2  gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of  bbbbb1 copper eeeee1  bbbbb2 subunit A of FRD eeeee2 , and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes
CRP11	 bbbbb1 Fumarate eeeee1  bbbbb2 Fumarate reductase eeeee2  is essential for Helicobacter pylori colonization of the mouse stomach
CRP11	For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal  bbbbb1 citrate eeeee1  bbbbb2 plasmin eeeee2  activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)
CRP11	For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered  bbbbb1 EDTA eeeee1  bbbbb2 plasmin eeeee2  activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)
CRP11	For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM  bbbbb1 CT eeeee1  bbbbb2 plasmin eeeee2  activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)
CRP11	For determination of [PA+Pli]-activity,  bbbbb1 arginine eeeee1  was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [ bbbbb2 PA eeeee2 +Pli]-Pli = PA
CRP11	For determination of [PA+Pli]-activity,  bbbbb1 arginine eeeee1  was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+ bbbbb2 Pli eeeee2 ]-Pli = PA
CRP11	For determination of [PA+Pli]-activity,  bbbbb1 arginine eeeee1  was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]- bbbbb2 Pli eeeee2  = PA
CRP11	For determination of [PA+Pli]-activity,  bbbbb1 arginine eeeee1  was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]-Pli =  bbbbb2 PA eeeee2 
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1 -pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [ bbbbb2 PA eeeee2 +Pli]-Pli = PA
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1 -pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+ bbbbb2 Pli eeeee2 ]-Pli = PA
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1  bbbbb2 Pli eeeee2 ]-activity, arginine was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]-Pli = PA
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1 -pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]- bbbbb2 Pli eeeee2  = PA
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1  bbbbb2 PA eeeee2 +Pli]-activity, arginine was added after this incubation. 25-microL 6 mM Val-Leu-Lys-pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]-Pli = PA
CRP11	For determination of [PA+Pli]-activity, arginine was added after this incubation. 25-microL 6 mM  bbbbb1 Val-Leu-Lys eeeee1 -pNA were added and deltaA/h at room temperature (RT) was monitored, using a microtiterplate reader. [PA+Pli]-Pli =  bbbbb2 PA eeeee2 
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the  bbbbb1 singlet oxygen eeeee1  (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-anti bbbbb2 plasmin eeeee2 
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the  bbbbb1 singlet oxygen eeeee1  bbbbb2 urokinase eeeee2  was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T ( bbbbb1 CT eeeee1  bbbbb2 urokinase eeeee2  was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor  bbbbb1 chloramine T eeeee1  bbbbb2 urokinase eeeee2  was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen ( bbbbb1 1O2 eeeee1 ) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-anti bbbbb2 plasmin eeeee2 
CRP11	Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen ( bbbbb1 1O2 eeeee1  bbbbb2 urokinase eeeee2  was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin
CRP11	Therefore, we investigated the hippocampal gene expression of  bbbbb1 estrogen eeeee1  receptors α and β ( bbbbb2 ERα, β eeeee2 ) in 8-week-old, 12-week-old and 24-week-old male rats
CRP11	Therefore, we investigated the hippocampal gene expression of  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptors α and β eeeee2  (ERα, β) in 8-week-old, 12-week-old and 24-week-old male rats
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  receptors (AR), corticosterone-binding  bbbbb2 glucocorticoid receptors eeeee2  (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and  bbbbb2 mineralocorticoid receptors eeeee2  (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors ( bbbbb2 MR eeeee2 ) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  bbbbb2 androgen receptors eeeee2  (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  receptors (AR), corticosterone-binding glucocorticoid receptors ( bbbbb2 GR eeeee2 ) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  bbbbb2 estrogen receptor eeeee2  genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  bbbbb2 steroid receptors eeeee2 , androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors,  bbbbb1 androgen eeeee1  receptors ( bbbbb2 AR eeeee2 ), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors, androgen receptors (AR), corticosterone-binding  bbbbb2 glucocorticoid receptors eeeee2  (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and  bbbbb2 mineralocorticoid receptors eeeee2  (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors ( bbbbb2 MR eeeee2 ) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors,  bbbbb2 androgen receptors eeeee2  (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors ( bbbbb2 GR eeeee2 ) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  bbbbb2 estrogen receptor eeeee2  genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  bbbbb2 steroid receptors eeeee2 , androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related  bbbbb1 steroid eeeee1  receptors, androgen receptors ( bbbbb2 AR eeeee2 ), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding  bbbbb2 glucocorticoid receptors eeeee2  (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and  bbbbb2 mineralocorticoid receptors eeeee2  (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors ( bbbbb2 MR eeeee2 ) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors,  bbbbb2 androgen receptors eeeee2  (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors ( bbbbb2 GR eeeee2 ) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related  bbbbb2 steroid receptors eeeee2 , androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the  bbbbb1 estrogen eeeee1  receptor genes and other learning-related steroid receptors, androgen receptors ( bbbbb2 AR eeeee2 ), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR),  bbbbb1 corticosterone eeeee1  bbbbb2 androgen receptors eeeee2  (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR),  bbbbb1 corticosterone eeeee1  bbbbb2 estrogen receptor eeeee2  genes and other learning-related steroid receptors, androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR),  bbbbb1 corticosterone eeeee1  bbbbb2 steroid receptors eeeee2 , androgen receptors (AR), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR),  bbbbb1 corticosterone eeeee1  bbbbb2 AR eeeee2 ), corticosterone-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) were also measured
CRP11	In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of  bbbbb1 racemic sibutramine eeeee1  bbbbb2 CYP3A eeeee2  inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans
CRP11	In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of  bbbbb1 racemic sibutramine eeeee1  bbbbb2 CYP2B6 eeeee2  and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans
CRP11	In this study, we assessed the effects of clopidogrel and  bbbbb1 clarithromycin eeeee1 , known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with  bbbbb2 CYP2B6 eeeee2  polymorphisms in humans
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated  bbbbb1 Ca(2+) eeeee1  entry by inhibiting the endothelial  bbbbb2 SERCA eeeee2  pump
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated  bbbbb1 Ca(2+) eeeee1  bbbbb2 G protein-coupled receptor eeeee2  agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump
CRP11	Endothelium-dependent relaxations, nitric oxide ( bbbbb1 NO eeeee1 ) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial  bbbbb2 SERCA eeeee2  pump
CRP11	Endothelium-dependent relaxations, nitric oxide ( bbbbb1 NO eeeee1 ) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  bbbbb2 G protein-coupled receptor eeeee2  agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by  bbbbb1 cyclopiazonic acid eeeee1  bbbbb2 G protein-coupled receptor eeeee2  agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump
CRP11	Endothelium-dependent relaxations,  bbbbb1 nitric oxide eeeee1  (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial  bbbbb2 SERCA eeeee2  pump
CRP11	Endothelium-dependent relaxations,  bbbbb1 nitric oxide eeeee1  (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  bbbbb2 G protein-coupled receptor eeeee2  agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist  bbbbb1 acetylcholine eeeee1  (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial  bbbbb2 SERCA eeeee2  pump
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine ( bbbbb1 ACh eeeee1 ) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial  bbbbb2 SERCA eeeee2  pump
CRP11	Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid ( bbbbb1 CPA eeeee1  bbbbb2 G protein-coupled receptor eeeee2  agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the  bbbbb1 NADPH eeeee1  bbbbb2 catalase eeeee2 , the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the  bbbbb1 NADPH eeeee1  bbbbb2 catalase eeeee2 /superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the  bbbbb1 NADPH eeeee1  bbbbb2 superoxide dismutase eeeee2  mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic  bbbbb1 manganese porphyrin eeeee1  bbbbb2 catalase eeeee2 , the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic  bbbbb1 manganese porphyrin eeeee1  and the  bbbbb2 NADPH oxidase eeeee2  inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic  bbbbb1 manganese porphyrin eeeee1  bbbbb2 catalase eeeee2 /superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic  bbbbb1 manganese porphyrin eeeee1  bbbbb2 superoxide dismutase eeeee2  mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/ bbbbb1 superoxide eeeee1  bbbbb2 catalase eeeee2 , the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/ bbbbb1 superoxide eeeee1  dismutase mimetic manganese porphyrin and the  bbbbb2 NADPH oxidase eeeee2  inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/ bbbbb1 superoxide eeeee1  bbbbb2 catalase eeeee2 /superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/ bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor  bbbbb1 apocynin eeeee1  bbbbb2 catalase eeeee2 , the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor  bbbbb1 apocynin eeeee1  bbbbb2 catalase eeeee2 /superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor  bbbbb1 apocynin eeeee1  bbbbb2 superoxide dismutase eeeee2  mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin
CRP11	The effect of inorganic  bbbbb1 arsenic eeeee1  on endothelium-dependent relaxation: Role of  bbbbb2 NADPH oxidase eeeee2  and hydrogen peroxide
CRP11	The effect of inorganic arsenic on endothelium-dependent relaxation: Role of  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  and hydrogen peroxide
CRP11	The effect of inorganic arsenic on endothelium-dependent relaxation: Role of NADPH oxidase and  bbbbb1 hydrogen peroxide eeeee1  bbbbb2 NADPH oxidase eeeee2  and hydrogen peroxide
CRP11	Using a mouse peptidergic (gonadotrophin-releasing hormone,  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 ) neuronal cell line which possesses Transport-P, we have studied the interaction of alpha(1) adrenoceptors with Transport-P
CRP11	Using a mouse peptidergic (gonadotrophin-releasing hormone,  bbbbb1 GnRH eeeee1  bbbbb2 gonadotrophin-releasing hormone eeeee2 , GnRH) neuronal cell line which possesses Transport-P, we have studied the interaction of alpha(1) adrenoceptors with Transport-P
CRP11	Using a mouse peptidergic (gonadotrophin-releasing hormone,  bbbbb1 GnRH eeeee1 ) neuronal cell line which possesses Transport-P, we have studied the interaction of  bbbbb2 alpha(1) adrenoceptors eeeee2  with Transport-P
CRP11	Using a mouse peptidergic ( bbbbb1 gonadotrophin-releasing hormone eeeee1 ,  bbbbb2 GnRH eeeee2 ) neuronal cell line which possesses Transport-P, we have studied the interaction of alpha(1) adrenoceptors with Transport-P
CRP11	Using a mouse peptidergic ( bbbbb1 gonadotrophin-releasing hormone eeeee1  bbbbb2 gonadotrophin-releasing hormone eeeee2 , GnRH) neuronal cell line which possesses Transport-P, we have studied the interaction of alpha(1) adrenoceptors with Transport-P
CRP11	Using a mouse peptidergic ( bbbbb1 gonadotrophin-releasing hormone eeeee1 , GnRH) neuronal cell line which possesses Transport-P, we have studied the interaction of  bbbbb2 alpha(1) adrenoceptors eeeee2  with Transport-P
CRP11	alpha(1B) adrenergic receptors in  bbbbb1 gonadotrophin-releasing hormone eeeee1  bbbbb2 gonadotrophin-releasing hormone eeeee2  neurones: relation to Transport-P. 1
CRP11	alpha(1B) adrenergic receptors in  bbbbb1 gonadotrophin-releasing hormone eeeee1  bbbbb2 alpha(1B) adrenergic receptors eeeee2  in gonadotrophin-releasing hormone neurones: relation to Transport-P. 1
CRP11	Peptidergic neurones accumulate  bbbbb1 amines eeeee1  via an unusual uptake process, designated Transport-P. [(3)H]-prazosin binds to  bbbbb2 alpha(1) adrenoceptors eeeee2  on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M
CRP11	Hence, the  bbbbb1 prazosin eeeee1  paradox is not due to some function of  bbbbb2 alpha(1) adrenoceptors eeeee2 , such as internalization of ligand-receptor complexes. 4
CRP11	PDE4B wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to  bbbbb1 rolipram eeeee1  at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting  bbbbb2 PDE4B eeeee2  is involved, at least in part, with the activity of rolipram
CRP11	PDE4B wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to  bbbbb1 rolipram eeeee1  bbbbb2 PDE4B eeeee2  wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting PDE4B is involved, at least in part, with the activity of rolipram
CRP11	PDE4B wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting PDE4B is involved, at least in part, with the activity of  bbbbb1 rolipram eeeee1  bbbbb2 PDE4B eeeee2  wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting PDE4B is involved, at least in part, with the activity of rolipram
CRP11	PDE4B wild-type mice,  bbbbb1 rolipram eeeee1  dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting  bbbbb2 PDE4B eeeee2  is involved, at least in part, with the activity of rolipram
CRP11	PDE4B wild-type mice,  bbbbb1 rolipram eeeee1  bbbbb2 PDE4B eeeee2  wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting PDE4B is involved, at least in part, with the activity of rolipram
CRP11	NS: Rolipram has a pharmacologic profile similar to that of the atypical antipsychotics and has low extrapyramidal s bbbbb1 ymptom liability eeeee1  bbbbb2 logic eeeee2  profile similar to that of the atypical antipsychotics and has low extrapyramidal symptom liability
CRP11	NS: Rolipram has a pharmacologic profile similar to that of the atypica bbbbb1 l antips eeeee1 ychotics and has low  bbbbb2 extra eeeee2 pyramidal symptom liability
CRP11	In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and  bbbbb1 mifepristone eeeee1  bbbbb2 progestin eeeee2  and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone
CRP11	In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914,  bbbbb1 CDB-4124 eeeee1  bbbbb2 progestin eeeee2  and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone
CRP11	In vitro antiprogestational/antiglucocorticoid activity and  bbbbb1 progestin eeeee1  and  bbbbb2 glucocorticoid receptor eeeee2  binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone
CRP11	In vitro antiprogestational/antiglucocorticoid activity and  bbbbb1 progestin eeeee1  bbbbb2 progestin eeeee2  and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone
CRP11	In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of  bbbbb1 CDB-2914 eeeee1  bbbbb2 progestin eeeee2  and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone
CRP11	O cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)- bbbbb1 thymidine eeeee1  bbbbb2 thymidine kinase eeeee2  (tk)-luciferase (LUC) reporter plasmid in transient transfections
CRP11	O cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)- bbbbb1 thymidine eeeee1  bbbbb2 PRE(2) eeeee2 -thymidine kinase (tk)-luciferase (LUC) reporter plasmid in transient transfections
CRP11	O cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)- bbbbb1 thymidine eeeee1  bbbbb2 alkaline phosphatase eeeee2  activity and transactivation of the PRE(2)-thymidine kinase (tk)-luciferase (LUC) reporter plasmid in transient transfections
CRP11	O cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)- bbbbb1 thymidine eeeee1  kinase ( bbbbb2 tk eeeee2 )-luciferase (LUC) reporter plasmid in transient transfections
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the  bbbbb1 17alpha-hydroxy eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the  bbbbb1 17alpha-hydroxy eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the  bbbbb1 17alpha-hydroxy eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the  bbbbb1 17alpha-hydroxy eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and  bbbbb1 CDB-4124 eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and  bbbbb1 CDB-4124 eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and  bbbbb1 CDB-4124 eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and  bbbbb1 CDB-4124 eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of  bbbbb1 CDB-2914 eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of  bbbbb1 CDB-2914 eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of  bbbbb1 CDB-2914 eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of  bbbbb1 CDB-2914 eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of  bbbbb1 CDB-2914 eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of  bbbbb1 CDB-2914 eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of  bbbbb1 CDB-2914 eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of  bbbbb1 CDB-2914 eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and  bbbbb1 mifepristone eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and  bbbbb1 mifepristone eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and  bbbbb1 mifepristone eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and  bbbbb1 mifepristone eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914,  bbbbb1 CDB-4124 eeeee1  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914,  bbbbb1 CDB-4124 eeeee1  bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914,  bbbbb1 CDB-4124 eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914,  bbbbb1 CDB-4124 eeeee1  bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for  bbbbb1 progesterone eeeee1  receptors (PR) and  bbbbb2 glucocorticoid receptors eeeee2  (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for  bbbbb1 progesterone eeeee1  receptors (PR) and glucocorticoid receptors ( bbbbb2 GR eeeee2 ) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptors eeeee2  (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for  bbbbb1 progesterone eeeee1  receptors ( bbbbb2 PR eeeee2 ) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124
CRP11	At 10(-6)M in transcription assays, none of these compounds showed  bbbbb1 progestin eeeee1  bbbbb2 progestin eeeee2  agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity
CRP11	At 10(-6)M in transcription assays, none of these compounds showed  bbbbb1 progestin eeeee1  agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight  bbbbb2 glucocorticoid eeeee2  agonist activity
CRP11	At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas  bbbbb1 mifepristone eeeee1  bbbbb2 progestin eeeee2  agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity
CRP11	We have identified >50 potential IAP substrates of both cytosolic and mitochondrial origin that bear hallmark  bbbbb1 N eeeee1  bbbbb2 IAP eeeee2  substrates of both cytosolic and mitochondrial origin that bear hallmark N-terminal IAP binding motifs
CRP11	We also examined the level of I-κBε and sub-cellular distribution of c-Rel by western blotting and immunofluorescence respectively in CSE-treated A549 cells with or without  bbbbb1 vitamin C eeeee1  bbbbb2 I-κBε eeeee2  and sub-cellular distribution of c-Rel by western blotting and immunofluorescence respectively in CSE-treated A549 cells with or without vitamin C pretreatment
CRP11	We also examined the level of I-κBε and sub-cellular distribution of c-Rel by western blotting and immunofluorescence respectively in CSE-treated A549 cells with or without  bbbbb1 vitamin C eeeee1  bbbbb2 c-Rel eeeee2  by western blotting and immunofluorescence respectively in CSE-treated A549 cells with or without vitamin C pretreatment
CRP11	To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with  bbbbb1 vitamin C eeeee1  bbbbb2 c-Rel eeeee2  in lungs of CS-exposed guinea pigs treated or untreated with vitamin C
CRP11	Therefore, to examine the hypothesis, we verified the effect of  bbbbb1 vitamin C eeeee1  on CS-induced expression of NF-κB driven luciferase reporter and  bbbbb2 NF-κB eeeee2  binding at its target DNA by EMSA in alveolar epithelial A549 cells
CRP11	Therefore, to examine the hypothesis, we verified the effect of  bbbbb1 vitamin C eeeee1  on CS-induced expression of  bbbbb2 NF-κB eeeee2  driven luciferase reporter and NF-κB binding at its target DNA by EMSA in alveolar epithelial A549 cells
CRP11	The 25- and the 27- bbbbb1 cholesterol eeeee1  bbbbb2 25- and the 27-cholesterol hydroxylases eeeee2 , present in almost all tissues, are possible candidates
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in  bbbbb1 cholesterol eeeee1  synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to  bbbbb2 Insig-1 eeeee2 , Insig-2 and liver X receptors
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in  bbbbb1 cholesterol eeeee1  synthesis,  bbbbb2 3-hydroxy-3-methylglutaryl CoA reductase eeeee2 , by binding to Insig-1, Insig-2 and liver X receptors
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in  bbbbb1 cholesterol eeeee1  synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to Insig-1, Insig-2 and  bbbbb2 liver X receptors eeeee2 
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in  bbbbb1 cholesterol eeeee1  synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to Insig-1,  bbbbb2 Insig-2 eeeee2  and liver X receptors
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis,  bbbbb1 3-hydroxy-3-methylglutaryl CoA eeeee1  reductase, by binding to  bbbbb2 Insig-1 eeeee2 , Insig-2 and liver X receptors
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis,  bbbbb1 3-hydroxy-3-methylglutaryl CoA eeeee1  bbbbb2 3-hydroxy-3-methylglutaryl CoA reductase eeeee2 , by binding to Insig-1, Insig-2 and liver X receptors
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis,  bbbbb1 3-hydroxy-3-methylglutaryl CoA eeeee1  reductase, by binding to Insig-1, Insig-2 and  bbbbb2 liver X receptors eeeee2 
CRP11	The mechanisms by which oxysterols may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis,  bbbbb1 3-hydroxy-3-methylglutaryl CoA eeeee1  reductase, by binding to Insig-1,  bbbbb2 Insig-2 eeeee2  and liver X receptors
CRP11	The mechanisms by which  bbbbb1 oxysterols eeeee1  may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to  bbbbb2 Insig-1 eeeee2 , Insig-2 and liver X receptors
CRP11	The mechanisms by which  bbbbb1 oxysterols eeeee1  may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis,  bbbbb2 3-hydroxy-3-methylglutaryl CoA reductase eeeee2 , by binding to Insig-1, Insig-2 and liver X receptors
CRP11	The mechanisms by which  bbbbb1 oxysterols eeeee1  may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to Insig-1, Insig-2 and  bbbbb2 liver X receptors eeeee2 
CRP11	The mechanisms by which  bbbbb1 oxysterols eeeee1  may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl CoA reductase, by binding to Insig-1,  bbbbb2 Insig-2 eeeee2  and liver X receptors
CRP11	The profile of a range of alpha 1 adrenoceptor antagonists was determined in vitro against cloned human alpha 1A, alpha 1B and alpha 1D adrenoceptors and against  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1 adrenoceptor eeeee2  antagonists was determined in vitro against cloned human alpha 1A, alpha 1B and alpha 1D adrenoceptors and against noradrenaline-mediated contractions of rat aorta and human prostate
CRP11	The profile of a range of alpha 1 adrenoceptor antagonists was determined in vitro against cloned human alpha 1A, alpha 1B and alpha 1D adrenoceptors and against  bbbbb1 noradrenaline eeeee1  bbbbb2 human alpha 1A, alpha 1B and alpha 1D adrenoceptors eeeee2  and against noradrenaline-mediated contractions of rat aorta and human prostate
CRP11	The affinity estimate for  bbbbb1 prazosin eeeee1  on human prostate was lower than the corresponding binding affinity determined at alpha 1A adrenoceptors and RS 17053 was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned  bbbbb2 human alpha 1A adrenoceptors eeeee2 . 5
CRP11	The affinity estimate for prazosin on human prostate was lower than the corresponding binding affinity determined at alpha 1A adrenoceptors and  bbbbb1 RS 17053 eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  and RS 17053 was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned human alpha 1A adrenoceptors. 5
CRP11	Data in this study suggest that the alpha 1 adrenoceptor mediating noradrenaline-induced contractions of human prostate, whilst having some of the characteristics of an alpha 1A adrenoceptor, cannot be bbbbb1  satisfactori eeeee1  bbbbb2  an alpha 1A adr eeeee2 enoceptor, cannot be satisfactorily aligned with cloned alpha 1A, alpha 1B or alpha 1D adrenoceptors
CRP11	Data in this study suggest that the alpha 1 adrenoceptor mediating noradrenaline-induced contractions of human prostate, whilst having some of the characteristics of an alpha 1A adrenoceptor, cannot be bbbbb1  satisfactori eeeee1  bbbbb2  whilst having some o eeeee2 f the characteristics of an alpha 1A adrenoceptor, cannot be satisfactorily aligned with cloned alpha 1A, alpha 1B or alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and  bbbbb1 RS 17053 eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and  bbbbb1 RS 17053 eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and  bbbbb1 RS 17053 eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3.  bbbbb1 (+)-Tamsulosin eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3.  bbbbb1 (+)-Tamsulosin eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3.  bbbbb1 (+)-Tamsulosin eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591,  bbbbb1 Rec 15/2739 eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591,  bbbbb1 Rec 15/2739 eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591,  bbbbb1 Rec 15/2739 eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	 bbbbb1 RS 17053 eeeee1  showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  bbbbb2 human alpha 1D adrenoceptors eeeee2 
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739,  bbbbb1 SNAP 1069 eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739,  bbbbb1 SNAP 1069 eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739,  bbbbb1 SNAP 1069 eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of  bbbbb1 noradrenaline eeeee1 -mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  bbbbb2 human alpha 1D adrenoceptors eeeee2 
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin,  bbbbb1 SL 89,0591 eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin,  bbbbb1 SL 89,0591 eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin,  bbbbb1 SL 89,0591 eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin,  bbbbb1 (-)-tamsulosin eeeee1  bbbbb2 alpha 1D eeeee2  (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin,  bbbbb1 (-)-tamsulosin eeeee1  bbbbb2 alpha 1B eeeee2  (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	RS 17053 showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin,  bbbbb1 (-)-tamsulosin eeeee1  bbbbb2 alpha 1A adrenoceptors eeeee2  (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes. 3. (+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors
CRP11	Indoramin and  bbbbb1 SNAP 1069 eeeee1  showed selectivity for  bbbbb2 alpha 1A and alpha 1B adrenoceptors eeeee2  relative to the alpha 1D subtype
CRP11	 bbbbb1 Indoramin eeeee1  and SNAP 1069 showed selectivity for  bbbbb2 alpha 1A and alpha 1B adrenoceptors eeeee2  relative to the alpha 1D subtype
CRP11	Rec 15/2739, WB 4101,  bbbbb1 SL 89,0591 eeeee1 , (+)- and (-)- tamsulosin showed selectivity for  bbbbb2 alpha 1A and alpha 1D adrenoceptors eeeee2  relative to the alpha 1B subtype
CRP11	Rec 15/2739,  bbbbb1 WB 4101 eeeee1 , SL 89,0591, (+)- and (-)- tamsulosin showed selectivity for  bbbbb2 alpha 1A and alpha 1D adrenoceptors eeeee2  relative to the alpha 1B subtype
CRP11	Rec 15/2739, WB 4101, SL 89,0591,  bbbbb1 (+)- and (-)- tamsulosin eeeee1  showed selectivity for  bbbbb2 alpha 1A and alpha 1D adrenoceptors eeeee2  relative to the alpha 1B subtype
CRP11	 bbbbb1 Rec 15/2739 eeeee1 , WB 4101, SL 89,0591, (+)- and (-)- tamsulosin showed selectivity for  bbbbb2 alpha 1A and alpha 1D adrenoceptors eeeee2  relative to the alpha 1B subtype
CRP11	Butein also increased  bbbbb1 heme eeeee1  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) protein expression and HO activity
CRP11	Butein also increased  bbbbb1 heme eeeee1  oxygenase-1 ( bbbbb2 HO-1 eeeee2 ) protein expression and HO activity
CRP11	Butein also increased  bbbbb1 heme eeeee1  oxygenase-1 (HO-1) protein expression and  bbbbb2 HO eeeee2  activity
CRP11	Butein protects human dental pulp cells from  bbbbb1 hydrogen peroxide eeeee1 -induced oxidative toxicity via Nrf2 pathway-dependent  bbbbb2 heme oxygenase-1 eeeee2  expressions
CRP11	Butein protects human dental pulp cells from  bbbbb1 hydrogen peroxide eeeee1 -induced oxidative toxicity via  bbbbb2 Nrf2 eeeee2  pathway-dependent heme oxygenase-1 expressions
CRP11	In addition, butein-dependent HO-1 expression was required for the inhibition of  bbbbb1 H2O2 eeeee1  bbbbb2 HO-1 eeeee2  expression was required for the inhibition of H2O2-induced cell death and ROS generation
CRP11	Promoter assay revealed that prunetin inhibits LPS-induced  bbbbb1 nitric oxide eeeee1  and prostaglandin E2 production through the suppression of iNOS and  bbbbb2 COX-2 eeeee2  at the transcriptional level
CRP11	Promoter assay revealed that prunetin inhibits LPS-induced  bbbbb1 nitric oxide eeeee1  and prostaglandin E2 production through the suppression of  bbbbb2 iNOS eeeee2  and COX-2 at the transcriptional level
CRP11	Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and  bbbbb1 prostaglandin E2 eeeee1  production through the suppression of iNOS and  bbbbb2 COX-2 eeeee2  at the transcriptional level
CRP11	Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and  bbbbb1 prostaglandin E2 eeeee1  production through the suppression of  bbbbb2 iNOS eeeee2  and COX-2 at the transcriptional level
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS),  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α),  bbbbb2 interleukin-6 eeeee2  (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2),  bbbbb2 tumor necrosis factor-α eeeee2  (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α ( bbbbb2 TNF-α eeeee2 ), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β ( bbbbb2 IL-1β eeeee2 ) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 Inducible nitric oxide synthase eeeee2  (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 ( bbbbb2 IL-6 eeeee2 ), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and  bbbbb2 interleukin-1β eeeee2  (IL-1β) expressions were determined by western blot and or realtime-PCR (RT-PCR)
CRP11	Helix A of IL-2 wedges tightly between IL-2R beta and gamma(c) to form a three-way junc bbbbb1 tion tha eeeee1 t coalesces into a composite binding site for the final gamma(c) recruitment bbbbb2  eeeee2 
CRP11	Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting  bbbbb1 glucose eeeee1  bbbbb2 low-density lipoprotein eeeee2 , blood pressure, and fasting glucose and insulin concentrations
CRP11	Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting  bbbbb1 glucose eeeee1  and  bbbbb2 insulin eeeee2  concentrations
CRP11	Orlistat treatment also results in modest improvements in total  bbbbb1 cholesterol eeeee1 ,  bbbbb2 low-density lipoprotein eeeee2 , blood pressure, and fasting glucose and insulin concentrations
CRP11	Orlistat treatment also results in modest improvements in total  bbbbb1 cholesterol eeeee1 , low-density lipoprotein, blood pressure, and fasting glucose and  bbbbb2 insulin eeeee2  concentrations
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe;  bbbbb1 organoselenium eeeee1 ) and sodium selenate (inorganic Se) on adenosine deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe;  bbbbb1 organoselenium eeeee1 ) and sodium selenate (inorganic Se) on  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of  bbbbb1 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one eeeee1  (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of  bbbbb1 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one eeeee1  (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on  bbbbb1 adenosine eeeee1  deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on  bbbbb1 adenosine eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic  bbbbb1 Se eeeee1 ) on adenosine deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic  bbbbb1 Se eeeee1 ) on  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and  bbbbb1 sodium selenate eeeee1  (inorganic Se) on adenosine deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and  bbbbb1 sodium selenate eeeee1  (inorganic Se) on  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one ( bbbbb1 C21H2HOSe eeeee1 ; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase ( bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one ( bbbbb1 C21H2HOSe eeeee1 ; organoselenium) and sodium selenate (inorganic Se) on  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of  bbbbb1 nitric oxide eeeee1  bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of  bbbbb1 nitric oxide eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein  bbbbb1 thiols eeeee1  bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein  bbbbb1 thiols eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP- bbbbb1 SH eeeee1  bbbbb2 ADA eeeee2 ) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; organoselenium) and sodium selenate (inorganic Se) on adenosine deaminase (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP- bbbbb1 SH eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats
CRP11	Differential effects of organic and inorganic  bbbbb1 selenium eeeee1  compounds on  bbbbb2 adenosine deaminase eeeee2  activity and scavenger capacity in cerebral cortex slices of young rats
CRP11	Differential effects of organic and inorganic selenium compounds on  bbbbb1 adenosine eeeee1  bbbbb2 adenosine deaminase eeeee2  activity and scavenger capacity in cerebral cortex slices of young rats
CRP11	Transient overexpression of the MCT2 isoform led to reduced vulnerability to the cytotoxicity of  bbbbb1 hydrogen peroxide eeeee1  bbbbb2 MCT2 eeeee2  isoform led to reduced vulnerability to the cytotoxicity of hydrogen peroxide with an increased activity of [14C]pyruvate accumulation in murine osteoblastic MC3T3-E1 cells
CRP11	Transient overexpression of the MCT2 isoform led to reduced vulnerability to the cytotoxicity of hydrogen peroxide with an increased activity of  bbbbb1 [14C]pyruvate eeeee1  bbbbb2 MCT2 eeeee2  isoform led to reduced vulnerability to the cytotoxicity of hydrogen peroxide with an increased activity of [14C]pyruvate accumulation in murine osteoblastic MC3T3-E1 cells
CRP11	The accumulation of [14C]pyruvate occurred in a temperature- and pH-dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific MCT inhibitor, whereas  bbbbb1 pyruvate eeeee1  bbbbb2 MCT eeeee2  inhibitor, whereas pyruvate was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the MCT inhibitor
CRP11	The accumulation of [14C]pyruvate occurred in a temperature- and pH-dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific MCT inhibitor, whereas  bbbbb1 pyruvate eeeee1  was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the  bbbbb2 MCT eeeee2  inhibitor
CRP11	The accumulation of  bbbbb1 [14C]pyruvate eeeee1  occurred in a temperature- and pH-dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific  bbbbb2 MCT eeeee2  inhibitor, whereas pyruvate was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the MCT inhibitor
CRP11	The accumulation of  bbbbb1 [14C]pyruvate eeeee1  occurred in a temperature- and pH-dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific MCT inhibitor, whereas pyruvate was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the  bbbbb2 MCT eeeee2  inhibitor
CRP11	Ovariectomy significantly decreased the content of pyruvate in femoral bone marrows in mice in vivo, whereas daily i.p. administration of pyruvate at 0.25 g bbbbb1 /kg sign eeeee1  bbbbb2 ecre eeeee2 ased the content of pyruvate in femoral bone marrows in mice in vivo, whereas daily i.p. administration of pyruvate at 0.25 g/kg significantly prevented alterations of several histomorphometric parameters as well as cancellous bone loss in femurs by ovariectomy on 28 days after the operation
CRP11	 bbbbb1 Sodium eeeee1  bbbbb2 Sodium channel eeeee2  blockers currently used to treat neuropathic pain are poorly tolerated
CRP11	Voltage-gated  bbbbb1 sodium eeeee1  bbbbb2 Voltage-gated sodium channels eeeee2  dysregulation is important for hyperexcitability leading to pain persistence
CRP11	A series of xanthine derivatives in which a  bbbbb1 methylene eeeee1  was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ( bbbbb2 DPP-4 eeeee2 ) for the treatment of type 2 diabetes
CRP11	A series of xanthine derivatives in which a  bbbbb1 methylene eeeee1  was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of  bbbbb2 dipeptidyl peptidase 4 eeeee2  (DPP-4) for the treatment of type 2 diabetes
CRP11	Synthesis and biological evaluation of  bbbbb1 xanthine eeeee1  derivatives on  bbbbb2 dipeptidyl peptidase 4 eeeee2 
CRP11	Zolmitriptan (Zomig;  bbbbb1 formerly eeeee1  311C90) is a novel  bbbbb2 5-hydroxytryptamine (5HT)1B/1D eeeee2  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura
CRP11	Zolmitriptan (Zomig; formerly 311C90) is a novel  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 5-hydroxytryptamine (5HT)1B/1D eeeee2  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura
CRP11	Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine ( bbbbb1 5HT eeeee1  bbbbb2 5-hydroxytryptamine (5HT)1B/1D eeeee2  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura
CRP11	Pre-clinical pharmacology of zolmitriptan (Zomig;  bbbbb1 formerly eeeee1  311C90), a centrally and peripherally acting  bbbbb2 5HT1B/1D eeeee2  agonist for migraine
CRP11	Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates  bbbbb1 trichostatin eeeee1  bbbbb2 uc002mbe.2 eeeee2  mediates trichostatin-induced apoptosis of liver cancer cells
CRP11	The TSA-induced uc002mbe.2 expression was positively correlated with the apoptotic effect of  bbbbb1 TSA eeeee1  bbbbb2 uc002mbe.2 eeeee2  expression was positively correlated with the apoptotic effect of TSA in HCC cells
CRP11	In addition bbbbb1 , k eeeee1 nockdown the expression of uc002mbe.2 significantly reduced TSA-induced apoptosis  bbbbb2 of Huh7cel eeeee2 ls
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced  bbbbb1 prostaglandin E2 eeeee1  (PGE2) production in RAW264.7 mouse macrophages, and  bbbbb2 interleukin 6 eeeee2  (IL-6) and tumor necrosis factor (TNF) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced  bbbbb1 prostaglandin E2 eeeee1  (PGE2) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and tumor necrosis factor ( bbbbb2 TNF eeeee2 ) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced  bbbbb1 prostaglandin E2 eeeee1  (PGE2) production in RAW264.7 mouse macrophages, and interleukin 6 ( bbbbb2 IL-6 eeeee2 ) and tumor necrosis factor (TNF) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced  bbbbb1 prostaglandin E2 eeeee1  (PGE2) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and  bbbbb2 tumor necrosis factor eeeee2  (TNF) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) production in RAW264.7 mouse macrophages, and  bbbbb2 interleukin 6 eeeee2  (IL-6) and tumor necrosis factor (TNF) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and tumor necrosis factor ( bbbbb2 TNF eeeee2 ) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) production in RAW264.7 mouse macrophages, and interleukin 6 ( bbbbb2 IL-6 eeeee2 ) and tumor necrosis factor (TNF) production in human U937 monocytes
CRP11	ALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and  bbbbb2 tumor necrosis factor eeeee2  (TNF) production in human U937 monocytes
CRP11	The plant ethanolic extracts effectively suppressed  bbbbb1 PGE2 eeeee1 , IL-6 and  bbbbb2 TNF eeeee2  release with an IC50 less than 50μg/ml
CRP11	The plant ethanolic extracts effectively suppressed  bbbbb1 PGE2 eeeee1 ,  bbbbb2 IL-6 eeeee2  and TNF release with an IC50 less than 50μg/ml
CRP11	This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on  bbbbb1 Ser eeeee1  bbbbb2 ICAM-1 eeeee2  gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on Ser536, did not change
CRP11	This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on  bbbbb1 Ser eeeee1  bbbbb2 IL-8 eeeee2  transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on Ser536, did not change
CRP11	This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on  bbbbb1 Ser eeeee1  bbbbb2 NF-κB eeeee2  complex containing a form of p65 phosphorylated on Ser536, did not change
CRP11	Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of  bbbbb1 2,4,6-trisubstituted 1,3,5-triazines eeeee1  bbbbb2 cannabinoid receptor eeeee2  ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists. 3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development
CRP11	Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of  bbbbb1 2,4,6-trisubstituted 1,3,5-triazines eeeee1  as CB2 agonists. 3D ligand-based virtual screening was employed to identify novel scaffolds for  bbbbb2 cannabinoid receptor eeeee2  ligand development
CRP11	Decreased expression of VKORC1 resulting from the -1639G>A substitution has also been implicated in lower  bbbbb1 warfarin eeeee1  bbbbb2 -1639G>A eeeee2  substitution has also been implicated in lower warfarin dose requirements
CRP11	Mean  bbbbb1 warfarin eeeee1  doses (SD) were 6.7 (3.3), 4.3 (2.2), and 2.7 (1.2) mg/day for patients with the  bbbbb2 VKORC1 eeeee2  -1639GG, GA, and AA genotypes, respectively
CRP11	Steady-state plasma concentrations of  bbbbb1 S-warfarin eeeee1  were lowest in patients with the  bbbbb2 VKORC1 eeeee2  -1639AA genotype and demonstrated a positive association with the VKORC1 -1639G allele copy number (trend P = 0.012)
CRP11	Steady-state plasma concentrations of  bbbbb1 S-warfarin eeeee1  were lowest in patients with the VKORC1 -1639AA genotype and demonstrated a positive association with the  bbbbb2 VKORC1 eeeee2  -1639G allele copy number (trend P = 0.012)
CRP11	Higher plasma S-warfarin concentrations corresponding to increased warfarin maintenance dosa bbbbb1 ges supp eeeee1  bbbbb2 lasma  eeeee2 S-warfarin concentrations corresponding to increased warfarin maintenance dosages support a hypothesis for increased expression of the VKORC1 -1639G allele
CRP11	Astemizole, a potent  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels
CRP11	Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels
CRP11	The efficacy of astemizole, a new, long acting, oral  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982
CRP11	The crystal structure of  bbbbb1 L-serine eeeee1  bbbbb2 L-serine dehydratase eeeee2  from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement
CRP11	The crystal structure of  bbbbb1 L-serine eeeee1  dehydratase from human liver ( bbbbb2 hSDH eeeee2 ) has been solved at 2.5 A-resolution by molecular replacement
CRP11	L-serine dehydratase (SDH), a member of the beta-family of  bbbbb1 pyridoxal phosphate eeeee1  bbbbb2 SDH eeeee2 ), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate
CRP11	L-serine dehydratase (SDH), a member of the beta-family of  bbbbb1 pyridoxal phosphate eeeee1  bbbbb2 L-serine dehydratase eeeee2  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate
CRP11	 bbbbb1 L-serine eeeee1  dehydratase ( bbbbb2 SDH eeeee2 ), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate
CRP11	 bbbbb1 L-serine eeeee1  bbbbb2 L-serine dehydratase eeeee2  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate
CRP11	Crystal structure of the  bbbbb1 pyridoxal-5'-phosphate eeeee1 -dependent  bbbbb2 serine dehydratase eeeee2  from human liver
CRP11	Crystal structure of the pyridoxal-5'-phosphate-dependent  bbbbb1 serine eeeee1  bbbbb2 serine dehydratase eeeee2  from human liver
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and  bbbbb1 fentanyl eeeee1  as well as  bbbbb2 endogenous opioid peptides eeeee2  enkephalins and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and  bbbbb1 fentanyl eeeee1  as well as endogenous opioid peptides enkephalins and  bbbbb2 endorphins eeeee2 
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and  bbbbb1 fentanyl eeeee1  as well as endogenous opioid peptides  bbbbb2 enkephalins eeeee2  and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and fentanyl as well as endogenous opioid peptides  bbbbb1 enkephalins eeeee1  bbbbb2 endogenous opioid peptides eeeee2  enkephalins and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and fentanyl as well as endogenous opioid peptides  bbbbb1 enkephalins eeeee1  bbbbb2 Opioid receptors eeeee2  are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and fentanyl as well as endogenous opioid peptides enkephalins and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and fentanyl as well as endogenous opioid peptides  bbbbb1 enkephalins eeeee1  and  bbbbb2 endorphins eeeee2 
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and fentanyl as well as endogenous opioid peptides  bbbbb1 enkephalins eeeee1  bbbbb2 enkephalins eeeee2  and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as  bbbbb1 morphine eeeee1  and fentanyl as well as  bbbbb2 endogenous opioid peptides eeeee2  enkephalins and endorphins
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as  bbbbb1 morphine eeeee1  and fentanyl as well as endogenous opioid peptides enkephalins and  bbbbb2 endorphins eeeee2 
CRP11	Opioid receptors are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as  bbbbb1 morphine eeeee1  and fentanyl as well as endogenous opioid peptides  bbbbb2 enkephalins eeeee2  and endorphins
CRP11	The use of A3 receptor agonist IB-MECA at bbbbb1 tenuates  eeeee1  bbbbb2 tenuates EAP eeeee2 
CRP11	The use of A3 receptor agonist IB-MECA attenuates EAP bbbbb1  eeeee1  bbbbb2 tenuates EAP eeeee2 
CRP11	The role of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A3 receptors eeeee2  and their distribution in the gastrointestinal tract have been widely investigated
CRP11	The effects of the adenosine A3 receptor agonist IB-MECA on  bbbbb1 sodium taurocholate eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis
CRP11	The effects of the  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis
CRP11	The aim of this study is (Ed note: Purpose statements should be in present tense) to evaluate the effects of the  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist on the course of sodium taurocholate-induced experimental acute pancreatitis (EAP)
CRP11	The aim of this study is (Ed note: Purpose statements should be in present tense) to evaluate the effects of the adenosine A3 receptor agonist on the course of  bbbbb1 sodium taurocholate eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist on the course of sodium taurocholate-induced experimental acute pancreatitis (EAP)
CRP11	However, the role of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist in pancreatitis has not been well established
CRP11	The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the adenosine A3 receptor agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w. i.p. at 48, 24, 12 and 1 h before and 1 h after the injection of 5 %  bbbbb1 sodium taurocholate eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w. i.p. at 48, 24, 12 and 1 h before and 1 h after the injection of 5 % sodium taurocholate solution into the biliary-pancreatic duct
CRP11	The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A3 receptor eeeee2  agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w. i.p. at 48, 24, 12 and 1 h before and 1 h after the injection of 5 % sodium taurocholate solution into the biliary-pancreatic duct
CRP11	 bbbbb1 Iron eeeee1  and zinc bioavailability in Caco-2 cells: influence of  bbbbb2 caseinophosphopeptides eeeee2 
CRP11	Iron and  bbbbb1 zinc eeeee1  bioavailability in Caco-2 cells: influence of  bbbbb2 caseinophosphopeptides eeeee2 
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells.  bbbbb2 α-CPP eeeee2  and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 α(s1)-CN eeeee2 (64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 ferritin eeeee2  synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 CN eeeee2 ) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 α(s2)-CN eeeee2 (1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells. α-CPP and β-CPP pools did not improve  bbbbb2 ferritin eeeee2  synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 CPPs eeeee2 ) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 CPPs eeeee2  (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate,  bbbbb2 β-CN eeeee2 (1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells. α-CPP and  bbbbb2 β-CPP eeeee2  pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific  bbbbb2 CPPs eeeee2  showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 β-CN eeeee2 (1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1 ) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in  bbbbb2 ferritin eeeee2  synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 α(s)- and β-casein eeeee2  (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of  bbbbb1 zinc eeeee1  bbbbb2 caseinophosphopeptides eeeee2  (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells.  bbbbb2 α-CPP eeeee2  and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 α(s1)-CN eeeee2 (64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability ( bbbbb2 ferritin eeeee2  synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 CN eeeee2 ) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 α(s2)-CN eeeee2 (1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve  bbbbb2 ferritin eeeee2  synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 CPPs eeeee2 ) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 CPPs eeeee2  (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate,  bbbbb2 β-CN eeeee2 (1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and  bbbbb2 β-CPP eeeee2  pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific  bbbbb2 CPPs eeeee2  showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 β-CN eeeee2 (1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in  bbbbb2 ferritin eeeee2  synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 α(s)- and β-casein eeeee2  (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on  bbbbb1 iron eeeee1  bbbbb2 caseinophosphopeptides eeeee2  (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 α-CPP eeeee2  and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 α(s1)-CN eeeee2 (64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 ferritin eeeee2  synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 CN eeeee2 ) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 α(s2)-CN eeeee2 (1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 ferritin eeeee2  synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 CPPs eeeee2 ) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 CPPs eeeee2  (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1 ,  bbbbb2 β-CN eeeee2 (1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 β-CPP eeeee2  pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 CPPs eeeee2  showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 β-CN eeeee2 (1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 ferritin eeeee2  synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 α(s)- and β-casein eeeee2  (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus  bbbbb1 iron sulphate eeeee1  bbbbb2 caseinophosphopeptides eeeee2  (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells.  bbbbb2 α-CPP eeeee2  and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 α(s1)-CN eeeee2 (64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 ferritin eeeee2  synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 CN eeeee2 ) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 α(s2)-CN eeeee2 (1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve  bbbbb2 ferritin eeeee2  synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 CPPs eeeee2 ) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 CPPs eeeee2  (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate,  bbbbb2 β-CN eeeee2 (1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and  bbbbb2 β-CPP eeeee2  pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific  bbbbb2 CPPs eeeee2  showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 β-CN eeeee2 (1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in  bbbbb2 ferritin eeeee2  synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 α(s)- and β-casein eeeee2  (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and  bbbbb1 zinc eeeee1  bbbbb2 caseinophosphopeptides eeeee2  (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and zinc bioavailability (retention, transport and uptake of zinc) in Caco-2 cells. α-CPP and β-CPP pools did not improve ferritin synthesis, but the three specific CPPs showed an increase in ferritin synthesis in Caco-2 cells versus iron sulphate, β-CN(1-25)4P being the most effective
CRP11	Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the "weak"  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2 -dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia
CRP11	Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the "weak"  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  by memantine could theoretically confer disease-modifying activity in AD by inhibiting the "weak" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia
CRP11	Blockade of  bbbbb1 NMDA eeeee1  receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the "weak"  bbbbb2 NMDA receptor eeeee2 -dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia
CRP11	Blockade of  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  by memantine could theoretically confer disease-modifying activity in AD by inhibiting the "weak" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia
CRP11	Like other  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists, memantine at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory
CRP11	However,  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  appear to be a key target of memantine at therapeutic concentrations
CRP11	Memantine is an uncompetitive (channel blocking)  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  antagonist
CRP11	Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents ( bbbbb1 phencyclidine eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)
CRP11	Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)
CRP11	Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine,  bbbbb1 MK-801 eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)
CRP11	Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine,  bbbbb1 ketamine eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)
CRP11	Conivaptan: a dual  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin receptor v1a/v2 eeeee2  antagonist [corrected]
CRP11	The actions of  bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2  are mediated by three receptor subtypes V1a, V2, and V1b
CRP11	Conivaptan is a nonpeptide dual V1a/V2  bbbbb1 AVP eeeee1  bbbbb2 V1a/V2 AVP receptor eeeee2  antagonist
CRP11	Several fluid retentive states such as heart failure, cirrhosis of the liver, and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of  bbbbb1 arginine vasopressin eeeee1  ( bbbbb2 AVP eeeee2 ), a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis
CRP11	Several fluid retentive states such as heart failure, cirrhosis of the liver, and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin eeeee2  (AVP), a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis
CRP11	Several fluid retentive states such as heart failure, cirrhosis of the liver, and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of arginine vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2 ), a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis
CRP11	Several fluid retentive states such as heart failure, cirrhosis of the liver, and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of arginine vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 arginine vasopressin eeeee2  (AVP), a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb1 carbohydrate eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1 ), malondialdehyde (MDA),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1 ),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase ( bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK),  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase ( bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of  bbbbb1 creatine eeeee1  kinase ( bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  (MDA),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO),  bbbbb1 malondialdehyde eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT),  bbbbb1 superoxide eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α,  bbbbb2 alpha-fetoprotein eeeee2  (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein ( bbbbb2 AFP eeeee2 ), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and  bbbbb2 carcinoembrionic antigen eeeee2  (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen ( bbbbb2 CEA eeeee2 ) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 γ-GT eeeee2 ), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 gamma-glutamyltranspeptidase eeeee2  (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2,  bbbbb2 tumor necrosis factors (TNF)α eeeee2 , alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 SOD eeeee2 ), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP),  bbbbb2 carbohydrate antigen (CA) 19.9 eeeee2  and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 creatine kinase eeeee2  (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  (NO), malondialdehyde (MDA),  bbbbb2 interleukin (IL)-2 eeeee2 , tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Total blood count, blood indices of creatine kinase (CK), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD),  bbbbb1 nitric oxide eeeee1  bbbbb2 CK eeeee2 ), gamma-glutamyltranspeptidase (γ-GT), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), interleukin (IL)-2, tumor necrosis factors (TNF)α, alpha-fetoprotein (AFP), carbohydrate antigen (CA) 19.9 and carcinoembrionic antigen (CEA) were assayed
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1 , AFP,  bbbbb2 IL-2 eeeee2 , and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1  bbbbb2 SOD eeeee2 , NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1 , AFP, IL-2, and  bbbbb2 TNFα eeeee2  were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1  bbbbb2 CK eeeee2 , γ-GT, SOD, NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1  bbbbb2 γ-GT eeeee2 , SOD, NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD, NO,  bbbbb1 MDA eeeee1 ,  bbbbb2 AFP eeeee2 , IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1 , MDA, AFP,  bbbbb2 IL-2 eeeee2 , and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1  bbbbb2 SOD eeeee2 , NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1 , MDA, AFP, IL-2, and  bbbbb2 TNFα eeeee2  were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1  bbbbb2 CK eeeee2 , γ-GT, SOD, NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1  bbbbb2 γ-GT eeeee2 , SOD, NO, MDA, AFP, IL-2, and TNFα were recorded
CRP11	Significant increases in the levels of CK, γ-GT, SOD,  bbbbb1 NO eeeee1 , MDA,  bbbbb2 AFP eeeee2 , IL-2, and TNFα were recorded
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of phenformin into mitochondria of organic cation/ bbbbb1 carnitine eeeee1  bbbbb2 organic cation/carnitine transporter 1 eeeee2  (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of phenformin into mitochondria of organic cation/ bbbbb1 carnitine eeeee1  transporter 1 ( bbbbb2 OCTN1 eeeee2 ) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of phenformin into mitochondria of organic cation/carnitine transporter 1 (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of  bbbbb1 TEA eeeee1  bbbbb2 organic cation/carnitine transporter 1 eeeee2  (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of phenformin into mitochondria of organic cation/carnitine transporter 1 (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of  bbbbb1 TEA eeeee1  bbbbb2 OCTN1 eeeee2 ) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of  bbbbb1 TEA eeeee1 ; however, uptake of phenformin into mitochondria of  bbbbb2 organic cation/carnitine transporter 1 eeeee2  (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of  bbbbb1 TEA eeeee1 ; however, uptake of phenformin into mitochondria of organic cation/carnitine transporter 1 ( bbbbb2 OCTN1 eeeee2 ) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of  bbbbb1 phenformin eeeee1  into mitochondria of  bbbbb2 organic cation/carnitine transporter 1 eeeee2  (OCTN1) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Similar characteristics were also observed for uptake of TEA; however, uptake of  bbbbb1 phenformin eeeee1  into mitochondria of organic cation/carnitine transporter 1 ( bbbbb2 OCTN1 eeeee2 ) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria
CRP11	Lactic acidosis provoked by iv infusion of  bbbbb1 phenformin eeeee1  was weaker in  bbbbb2 octn1 eeeee2 (-/-) mice than that in wild-type mice
CRP11	Role of organic cation/ bbbbb1 carnitine eeeee1  bbbbb2 organic cation/carnitine transporter 1 eeeee2  in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria
CRP11	Role of organic cation/ bbbbb1 carnitine eeeee1  transporter 1 in uptake of phenformin and inhibitory effect on  bbbbb2 complex I eeeee2  respiration in mitochondria
CRP11	Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of  bbbbb1 phenformin eeeee1  bbbbb2 complex I eeeee2  respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts
CRP11	Inhibition by  bbbbb1 phenformin eeeee1  of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on  bbbbb2 complex I eeeee2  respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts
CRP11	Inhibition by phenformin of  bbbbb1 oxygen eeeee1  consumption via  bbbbb2 complex I eeeee2  respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts
CRP11	Inhibition by phenformin of  bbbbb1 oxygen eeeee1  consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on  bbbbb2 complex I eeeee2  respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts
CRP11	In this study, uptake of phenformin and [(14)C]tetraethylammonium ( bbbbb1 TEA eeeee1 ) and  bbbbb2 complex I eeeee2  inhibition by phenformin were examined in isolated liver and heart mitochondria
CRP11	In this study, uptake of phenformin and  bbbbb1 [(14)C]tetraethylammonium eeeee1  (TEA) and  bbbbb2 complex I eeeee2  inhibition by phenformin were examined in isolated liver and heart mitochondria
CRP11	In this study, uptake of  bbbbb1 phenformin eeeee1  and [(14)C]tetraethylammonium (TEA) and  bbbbb2 complex I eeeee2  inhibition by phenformin were examined in isolated liver and heart mitochondria
CRP11	The tissue-selective toxicity of  bbbbb1 DCBN eeeee1  in mouse nasal mucosa is largely dependent on target tissue bioactivation by  bbbbb2 CYP2A5 eeeee2 
CRP11	The human orthologues of CYP2A5, CYP2A6 and CYP2A13, are both expressed in nasal mucosa and are capable of activating  bbbbb1 DCBN eeeee1  bbbbb2 CYP2A6 eeeee2  and CYP2A13, are both expressed in nasal mucosa and are capable of activating DCBN
CRP11	The human orthologues of CYP2A5, CYP2A6 and CYP2A13, are both expressed in nasal mucosa and are capable of activating  bbbbb1 DCBN eeeee1  bbbbb2 CYP2A13 eeeee2 , are both expressed in nasal mucosa and are capable of activating DCBN
CRP11	The human orthologues of CYP2A5, CYP2A6 and CYP2A13, are both expressed in nasal mucosa and are capable of activating  bbbbb1 DCBN eeeee1  bbbbb2 CYP2A5 eeeee2 , CYP2A6 and CYP2A13, are both expressed in nasal mucosa and are capable of activating DCBN
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular  bbbbb1 Ca(2+) eeeee1  release TMB-8, incubation in Ca(2+)-free experimental medium, and  bbbbb2 PKC eeeee2  desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular  bbbbb1 Ca(2+) eeeee1  bbbbb2 D(2) eeeee2  antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular  bbbbb1 Ca(2+) eeeee1  bbbbb2 pertussis toxin eeeee2 , the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in  bbbbb1 Ca(2+) eeeee1 -free experimental medium, and  bbbbb2 PKC eeeee2  desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in  bbbbb1 Ca(2+) eeeee1  bbbbb2 D(2) eeeee2  antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist eticlopride, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in  bbbbb1 Ca(2+) eeeee1  bbbbb2 pertussis toxin eeeee2 , the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist  bbbbb1 eticlopride eeeee1 , pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and  bbbbb2 PKC eeeee2  desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The effect was counteracted by the D(2) antagonist  bbbbb1 eticlopride eeeee1 ,  bbbbb2 pertussis toxin eeeee2 , the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA
CRP11	The results reinforce previous assum bbbbb1 ptions t eeeee1 hat dopamine may interact with eicosanoid metabolism by means of D bbbbb2 (2) receptor  eeeee2 activation, and implicate an involvement of cPLA(2) and COX-2 in this effect
CRP11	We have earlier demonstrated that dopamine stimulates the liberation of the prostaglandin E(2) (PGE(2)) precursor,  bbbbb1 arachidonic acid eeeee1 , in Chinese hamster ovary cells transfected with the  bbbbb2 rat dopamine D(2) receptor (long isoform) eeeee2 , also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8]
CRP11	We have earlier demonstrated that dopamine stimulates the liberation of the prostaglandin E(2) (PGE(2)) precursor, arachidonic acid, in Chinese hamster ovary cells transfected with the rat  bbbbb1 dopamine eeeee1  bbbbb2 rat dopamine D(2) receptor (long isoform) eeeee2 , also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8]
CRP11	We have earlier demonstrated that dopamine stimulates the liberation of the  bbbbb1 prostaglandin E(2) eeeee1  (PGE(2)) precursor, arachidonic acid, in Chinese hamster ovary cells transfected with the  bbbbb2 rat dopamine D(2) receptor (long isoform) eeeee2 , also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8]
CRP11	We have earlier demonstrated that dopamine stimulates the liberation of the prostaglandin E(2) (PGE(2)) precursor, arachidonic acid, in Chinese hamster ovary cells transfected with the rat dopamine D(2) receptor (long isoform), also without concomitant administration of a  bbbbb1 Ca(2+) eeeee1  bbbbb2 rat dopamine D(2) receptor (long isoform) eeeee2 , also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8]
CRP11	We have earlier demonstrated that dopamine stimulates the liberation of the prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1 ) precursor, arachidonic acid, in Chinese hamster ovary cells transfected with the  bbbbb2 rat dopamine D(2) receptor (long isoform) eeeee2 , also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8]
CRP11	Dopamine D(2) receptor-induced COX-2-mediated production of  bbbbb1 prostaglandin E(2) eeeee1  bbbbb2 Dopamine D(2) receptor eeeee2 -induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	Dopamine D(2) receptor-induced COX-2-mediated production of  bbbbb1 prostaglandin E(2) eeeee1  in  bbbbb2 D(2) eeeee2 -transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	 bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine D(2) receptor eeeee2 -induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	 bbbbb1 Dopamine eeeee1  D(2) receptor-induced  bbbbb2 COX-2 eeeee2 -mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	 bbbbb1 Dopamine eeeee1  D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in  bbbbb2 D(2) eeeee2 -transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a  bbbbb1 Ca(2+) eeeee1  bbbbb2 Dopamine D(2) receptor eeeee2 -induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a  bbbbb1 Ca(2+) eeeee1  bbbbb2 COX-2 eeeee2 -mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a  bbbbb1 Ca(2+) eeeee1  bbbbb2 D(2) eeeee2 -transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor,  bbbbb1 indomethacin eeeee1 , and by the selective  bbbbb2 COX-2 eeeee2  inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor,  bbbbb1 indomethacin eeeee1 , and by the selective COX-2 inhibitor, NS-398, but not by the specific  bbbbb2 COX-1 eeeee2  inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor,  bbbbb1 NS-398 eeeee1  bbbbb2 cyclooxygenase eeeee2  (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor,  bbbbb1 NS-398 eeeee1  bbbbb2 COX eeeee2 ) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor,  bbbbb1 NS-398 eeeee1 , but not by the specific  bbbbb2 COX-1 eeeee2  inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor,  bbbbb1 valeryl salicylate eeeee1  bbbbb2 cyclooxygenase eeeee2  (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor,  bbbbb1 valeryl salicylate eeeee1  bbbbb2 COX eeeee2 ) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor,  bbbbb1 valeryl salicylate eeeee1  bbbbb2 COX-2 eeeee2  inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate
CRP11	Both the non-specific phospholipase A(2) inhibitor,  bbbbb1 quinacrine eeeee1 , and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective  bbbbb2 sPLA(2) eeeee2  inhibitor, TAPC, were ineffective
CRP11	Both the non-specific phospholipase A(2) inhibitor,  bbbbb1 quinacrine eeeee1 , and an inhibitor of cPLA(2) and  bbbbb2 iPLA(2) eeeee2 , AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective
CRP11	Both the non-specific phospholipase A(2) inhibitor,  bbbbb1 quinacrine eeeee1 , and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective  bbbbb2 iPLA(2) eeeee2  inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective
CRP11	Both the non-specific phospholipase A(2) inhibitor,  bbbbb1 quinacrine eeeee1 , and an inhibitor of  bbbbb2 cPLA(2) eeeee2  and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective
CRP11	 bbbbb1 Monocarboxylate eeeee1  bbbbb2 Monocarboxylate transporters eeeee2  in the central nervous system: distribution, regulation and function
CRP11	 bbbbb1 Monocarboxylate eeeee1  transporters ( bbbbb2 MCTs eeeee2 ) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies
CRP11	 bbbbb1 Monocarboxylate eeeee1  bbbbb2 Monocarboxylate transporters eeeee2  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies
CRP11	By contrast, the predominant neuronal  bbbbb1 monocarboxylate eeeee1  transporter is  bbbbb2 MCT2 eeeee2 
CRP11	By contrast, the predominant neuronal  bbbbb1 monocarboxylate eeeee1  bbbbb2 monocarboxylate transporter eeeee2  is MCT2
CRP11	Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to  bbbbb1 foscarnet eeeee1  bbbbb2 UL54 eeeee2  gene thought to render HCMV resistant to foscarnet
CRP11	Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to  bbbbb1 foscarnet eeeee1  bbbbb2 human cytomegalovirus (HCMV) pUL54 eeeee2  DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet
CRP11	Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to  bbbbb1 foscarnet eeeee1  bbbbb2 DNA polymerase eeeee2  is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet
CRP11	The activity of polymerases containing mutations known to confer resistance to  bbbbb1 foscarnet eeeee1  (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type  bbbbb2 polymerases eeeee2 
CRP11	The activity of polymerases containing mutations known to confer resistance to  bbbbb1 foscarnet eeeee1  bbbbb2 polymerases eeeee2  containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases
CRP11	In this study, an in-house non-isotopic method for assessing polymerase enzymatic activity in the presence and absence of  bbbbb1 foscarnet eeeee1  was developed and its utility for  bbbbb2 HCMV polymerase eeeee2  phenotyping evaluated
CRP11	 bbbbb1 Licofelone eeeee1 , a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that  bbbbb2 cycloxygenase-2 eeeee2  inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability
CRP11	We examined the anti-inflammatory effect of  bbbbb1 licofelone eeeee1  on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of  bbbbb2 COX-2 eeeee2 , rofecoxib
CRP11	Fractionated bulb extracts and the two isolated steroidal glycoalkaloids (1) and (2) induced  bbbbb1 NO eeeee1  production and  bbbbb2 TGF-β receptor I eeeee2  mRNA expression in fibroblast cell culture
CRP11	Labetalol (> or = 3 x 10(-8) M) and  bbbbb1 dilevalol eeeee1  (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional  bbbbb2 beta 1- and beta 2-adrenoceptors eeeee2 
CRP11	 bbbbb1 Labetalol eeeee1  (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional  bbbbb2 beta 1- and beta 2-adrenoceptors eeeee2 
CRP11	Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the  bbbbb1 isoprenaline eeeee1  responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional  bbbbb2 beta 1- and beta 2-adrenoceptors eeeee2 
CRP11	 bbbbb1 Labetalol eeeee1  and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to labetalol at 10(-6) M was abolished by ICI 118,551 which illustrates that the labetalol-induced attenuation is  bbbbb2 beta 2-adrenoceptor eeeee2  mediated
CRP11	Labetalol and  bbbbb1 dilevalol eeeee1  (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to labetalol at 10(-6) M was abolished by ICI 118,551 which illustrates that the labetalol-induced attenuation is  bbbbb2 beta 2-adrenoceptor eeeee2  mediated
CRP11	Labetalol and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to  bbbbb1 labetalol eeeee1  at 10(-6) M was abolished by ICI 118,551 which illustrates that the labetalol-induced attenuation is  bbbbb2 beta 2-adrenoceptor eeeee2  mediated
CRP11	Anastrozole and letrozole are both non- bbbbb1 steroidal eeeee1   bbbbb2 aromatase eeeee2  inhibitors that compete with the substrate for binding to the enzyme active site
CRP11	Estrogens are biosynthesised from  bbbbb1 androgens eeeee1  by the  bbbbb2 CYP450 eeeee2  enzyme complex called aromatase
CRP11	These third-generation aromatase inhibitors are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic  bbbbb1 estrogen eeeee1  bbbbb2 aromatase eeeee2  inhibitors are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer
CRP11	The potent and selective third-generation aromatase inhibitors anastrozole, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti- bbbbb1 estrogen eeeee1  bbbbb2 aromatase eeeee2  inhibitors anastrozole, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies
CRP11	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in  bbbbb1 estrogen eeeee1  bbbbb2 aromatase eeeee2  is an important approach for reducing growth stimulatory effects of estrogens in estrogen-dependent breast cancer
CRP11	Inhibition of aromatase is an important approach for reducing growth stimulatory effects of  bbbbb1 estrogens eeeee1  bbbbb2 aromatase eeeee2  is an important approach for reducing growth stimulatory effects of estrogens in estrogen-dependent breast cancer
CRP11	Exemestane is a mechanism-based  bbbbb1 steroidal eeeee1  inhibitor that mimics the substrate, is converted by the enzyme to a reactive intermediate, and results in inactivation of  bbbbb2 aromatase eeeee2 
CRP11	The use of an aromatase inhibitor as initial therapy, or after treatment with  bbbbb1 tamoxifen eeeee1  bbbbb2 aromatase eeeee2  inhibitor as initial therapy, or after treatment with tamoxifen, is now recommended as adjuvant hormonal therapy for postmenopausal women with hormone-dependent breast cancer
CRP11	 bbbbb1 PTE eeeee1  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and  bbbbb2 cyclin-dependent kinase eeeee2  inhibitors such as p21 and p27
CRP11	Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at  bbbbb1 Tyr eeeee1  1007 and the downstream activation of  bbbbb2 STAT3 eeeee2 
CRP11	 bbbbb1 Aldo-keto eeeee1  reductases ( bbbbb2 AKRs eeeee2 ) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis
CRP11	 bbbbb1 Aldo-keto eeeee1  bbbbb2 Aldo-keto reductases eeeee2  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis
CRP11	In the smoker group, there is a statistically significant positive association between AKR1A1, AKR1C1, and AKR1C3 mRNA induction and urine  bbbbb1 cotinine eeeee1  bbbbb2 AKR1C3 eeeee2  mRNA induction and urine cotinine levels in individuals with a body mass index (BMI) less than 25
CRP11	In the smoker group, there is a statistically significant positive association between AKR1A1, AKR1C1, and AKR1C3 mRNA induction and urine  bbbbb1 cotinine eeeee1  bbbbb2 AKR1C1 eeeee2 , and AKR1C3 mRNA induction and urine cotinine levels in individuals with a body mass index (BMI) less than 25
CRP11	In the smoker group, there is a statistically significant positive association between AKR1A1, AKR1C1, and AKR1C3 mRNA induction and urine  bbbbb1 cotinine eeeee1  bbbbb2 AKR1A1 eeeee2 , AKR1C1, and AKR1C3 mRNA induction and urine cotinine levels in individuals with a body mass index (BMI) less than 25
CRP11	However, AKR1A1*2 and AKR1C3*2 alleles did not influence AKR1A1 and AKR1C1-AKR1C3 mRNA levels bbbbb1  eeeee1  bbbbb2 3*2  eeeee2 alleles did not influence AKR1A1 and AKR1C1-AKR1C3 mRNA levels
CRP11	Despite the importance of AKRs in PAHs metabolism, there are no studies that evaluate, in general human populations, the effect of  bbbbb1 PAHs eeeee1  bbbbb2 AKRs eeeee2  in PAHs metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs)
CRP11	Despite the importance of AKRs in  bbbbb1 PAHs eeeee1  metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on  bbbbb2 AKRs eeeee2  expression in peripheral blood lymphocytes (PBLs)
CRP11	The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride ( bbbbb1 2-PAM eeeee1 ), is under consideration for replacement with a more effective  bbbbb2 acetylcholinesterase eeeee2  reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4)
CRP11	The current U.S. military and civilian oxime countermeasure,  bbbbb1 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride eeeee1  (2-PAM), is under consideration for replacement with a more effective  bbbbb2 acetylcholinesterase eeeee2  reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4)
CRP11	The current U.S. military and civilian  bbbbb1 oxime eeeee1  countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective  bbbbb2 acetylcholinesterase eeeee2  reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4)
CRP11	Based on a previous model structure for the organophosphate  bbbbb1 diisopropylfluorophosphate eeeee1 , the model includes key sites of  bbbbb2 acetylcholinesterase eeeee2  inhibition (brain and diaphragm), as well as fat, kidney, liver, rapidly perfused tissues and slowly perfused tissues
CRP11	Based on a previous model structure for the  bbbbb1 organophosphate eeeee1  diisopropylfluorophosphate, the model includes key sites of  bbbbb2 acetylcholinesterase eeeee2  inhibition (brain and diaphragm), as well as fat, kidney, liver, rapidly perfused tissues and slowly perfused tissues
CRP11	Moreover, the values of delta Cp for alpha-, zeta- and gamma T-thrombin interaction with p-ABZ were found to be linearly correlated to the free energy of activ bbbbb1 ation for both fib eeeee1 rinogen and CPR cleavage bbbbb2  eeeee2 
CRP11	Moreover, the values of delta Cp for alpha-, zeta- and gamma T-thrombin interaction with p-ABZ were found to be linearly correlated to the free energy of activ bbbbb1 ation for both fib eeeee1 rinogen and CPR cleavage bbbbb2  eeeee2 
CRP11	Moreover, the values of delta Cp for alpha-, zeta- and gamma T-thrombin interaction with p-ABZ were found to be linearly correlated to the free energy of activ bbbbb1 ation for both fib eeeee1  bbbbb2 tio eeeee2 n with p-ABZ were found to be linearly correlated to the free energy of activation for both fibrinogen and CPR cleavage
CRP11	A phenomenological analysis of thermodynamic data showed that the  bbbbb1 amide eeeee1  substrates and p-ABZ interactions with  bbbbb2 zeta-thrombin eeeee2  were respectively, associated with a chemical compensation (i.e. the linear relationship between entropy and enthalpy of binding) and a hydrophobic phenomenon (i.e. a change in the standard heat capacity)
CRP11	These interactions were studied by following fibrinopeptide A (FpA) release and by measuring intraplatelet  bbbbb1 Ca2+ eeeee1  bbbbb2 FpA eeeee2 ) release and by measuring intraplatelet Ca2+ changes induced by thrombin-CPR interaction
CRP11	These interactions were studied by following fibrinopeptide A (FpA) release and by measuring intraplatelet  bbbbb1 Ca2+ eeeee1  bbbbb2 fibrinopeptide A eeeee2  (FpA) release and by measuring intraplatelet Ca2+ changes induced by thrombin-CPR interaction
CRP11	These interactions were studied by following fibrinopeptide A (FpA) release and by measuring intraplatelet  bbbbb1 Ca2+ eeeee1  changes induced by thrombin- bbbbb2 CPR eeeee2  interaction
CRP11	These interactions were studied by following fibrinopeptide A (FpA) release and by measuring intraplatelet  bbbbb1 Ca2+ eeeee1  changes induced by  bbbbb2 thrombin eeeee2 -CPR interaction
CRP11	An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (p-ABZ) and  bbbbb1 proflavin eeeee1  binding to the catalytic site of two proteolyzed forms of alpha-thrombin, i.e.  bbbbb2 zeta- and gamma T-thrombin eeeee2 
CRP11	An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of  bbbbb1 amide eeeee1 -substrates, p-aminobenzamidine (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of  bbbbb2 alpha-thrombin eeeee2 , i.e. zeta- and gamma T-thrombin
CRP11	An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of  bbbbb1 amide eeeee1 -substrates, p-aminobenzamidine (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of alpha-thrombin, i.e.  bbbbb2 zeta- and gamma T-thrombin eeeee2 
CRP11	An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine ( bbbbb1 p-ABZ eeeee1 ) and proflavin binding to the catalytic site of two proteolyzed forms of alpha-thrombin, i.e.  bbbbb2 zeta- and gamma T-thrombin eeeee2 
CRP11	An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates,  bbbbb1 p-aminobenzamidine eeeee1  (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of alpha-thrombin, i.e.  bbbbb2 zeta- and gamma T-thrombin eeeee2 
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of  bbbbb1 vitamin D eeeee1  measurement,  bbbbb2 LDL eeeee2  and HDL cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of  bbbbb1 vitamin D eeeee1  measurement, LDL and  bbbbb2 HDL eeeee2  cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, LDL and HDL cholesterol,  bbbbb1 triglycerides eeeee1  bbbbb2 LDL eeeee2  and HDL cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, LDL and HDL cholesterol,  bbbbb1 triglycerides eeeee1  bbbbb2 HDL eeeee2  cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, LDL and HDL  bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2  and HDL cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, LDL and HDL  bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2  cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between 25-OHD and the risk of progression to IFG and diabetes
CRP11	Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and  bbbbb1 8Br-cAMP eeeee1  bbbbb2 NR5A eeeee2  family and 8Br-cAMP treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN
CRP11	Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and  bbbbb1 8Br-cAMP eeeee1  treatment through two SF-1 binding sites and a  bbbbb2 CRE eeeee2 -like sequence in a human ovarian granulosa cell line, KGN
CRP11	Knockdown of FDX1 attenuated progesterone production in KGN cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Knockdown of FDX1 attenuated progesterone production in KGN cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an  bbbbb1 iron eeeee1  bbbbb2 FDX1 eeeee2 ; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an  bbbbb1 iron eeeee1  bbbbb2 Ferredoxin 1 eeeee2  (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an  bbbbb1 iron eeeee1  bbbbb2 adrenodoxin eeeee2 ) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an iron- bbbbb1 sulfur eeeee1  bbbbb2 FDX1 eeeee2 ; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an iron- bbbbb1 sulfur eeeee1  bbbbb2 Ferredoxin 1 eeeee2  (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Ferredoxin 1 (FDX1; adrenodoxin) is an iron- bbbbb1 sulfur eeeee1  bbbbb2 adrenodoxin eeeee2 ) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues
CRP11	Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the  bbbbb1 anandamide eeeee1  bbbbb2 CB2 eeeee2  agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects
CRP11	 bbbbb1 Methanandamide eeeee1  (10.0 mg/kg) had lesser effect than other CB agonists, and the  bbbbb2 CB2 eeeee2  agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects
CRP11	Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist  bbbbb1 rimonabant eeeee1  bbbbb2 CB2 eeeee2  agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects
CRP11	Block of human ether-a-go-go related gene (hERG)  bbbbb1 K(+) eeeee1  bbbbb2 human ether-a-go-go related gene (hERG) K(+) channels eeeee2  by otherwise useful drugs is the most common cause of long QT syndrome, a disorder of cardiac repolarization that predisposes patients to potentially fatal arrhythmias
CRP11	Indomethacin and SC-236, a selective cyclooxygenase-2 (COX-2) inhibitor, exerted a similar effect as  bbbbb1 sulindac eeeee1  bbbbb2 COX-2 eeeee2 ) inhibitor, exerted a similar effect as sulindac
CRP11	Indomethacin and SC-236, a selective cyclooxygenase-2 (COX-2) inhibitor, exerted a similar effect as  bbbbb1 sulindac eeeee1  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2) inhibitor, exerted a similar effect as sulindac
CRP11	To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of  bbbbb1 sulindac eeeee1  bbbbb2 14-3-3 eeeee2  in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells
CRP11	Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM;  bbbbb1 repaglinide eeeee1  bbbbb2 SUR1 eeeee2  expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site
CRP11	Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values:  bbbbb1 mitiglinide eeeee1  bbbbb2 SUR1 eeeee2  expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site
CRP11	Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM;  bbbbb1 nateglinide eeeee1  bbbbb2 SUR1 eeeee2  expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site
CRP11	Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a  bbbbb1 glibenclamide eeeee1  bbbbb2 SUR1 eeeee2  expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site
CRP11	Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of  bbbbb1 [3H]glibenclamide eeeee1  bbbbb2 SUR1 eeeee2  expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site
CRP11	However, its selectivity for the various K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channels eeeee2  is not known
CRP11	However, its selectivity for the various  bbbbb1 K eeeee1  bbbbb2 K(ATP) channels eeeee2  is not known
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 SUR2B eeeee2 ) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 K(ATP) channels eeeee2  (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 SUR1 eeeee2 , Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 SUR2A eeeee2 , and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound,  bbbbb1 nateglinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/ bbbbb2 SUR2B eeeee2 ) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1  bbbbb2 K(ATP) channels eeeee2  (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels (Kir6.2/ bbbbb2 SUR1 eeeee2 , Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and  bbbbb2 Kir6.2 eeeee2 /SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels (Kir6.2/SUR1, Kir6.2/ bbbbb2 SUR2A eeeee2 , and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels ( bbbbb2 Kir6.2 eeeee2 /SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned  bbbbb1 K eeeee1 (ATP) channels (Kir6.2/SUR1,  bbbbb2 Kir6.2 eeeee2 /SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 SUR2B eeeee2 ) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 K(ATP) channels eeeee2  (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 SUR1 eeeee2 , Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 SUR2A eeeee2 , and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another  bbbbb1 meglitinide eeeee1  bbbbb2 Kir6.2 eeeee2 /SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/ bbbbb2 SUR2B eeeee2 ) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channels eeeee2  (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels (Kir6.2/ bbbbb2 SUR1 eeeee2 , Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and  bbbbb2 Kir6.2 eeeee2 /SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels (Kir6.2/SUR1, Kir6.2/ bbbbb2 SUR2A eeeee2 , and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels ( bbbbb2 Kir6.2 eeeee2 /SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of mitiglinide on various cloned K( bbbbb1 ATP eeeee1 ) channels (Kir6.2/SUR1,  bbbbb2 Kir6.2 eeeee2 /SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/ bbbbb2 SUR2B eeeee2 ) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned  bbbbb2 K(ATP) channels eeeee2  (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels (Kir6.2/ bbbbb2 SUR1 eeeee2 , Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and  bbbbb2 Kir6.2 eeeee2 /SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/ bbbbb2 SUR2A eeeee2 , and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels ( bbbbb2 Kir6.2 eeeee2 /SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	In this study, we examined the effects of  bbbbb1 mitiglinide eeeee1  on various cloned K(ATP) channels (Kir6.2/SUR1,  bbbbb2 Kir6.2 eeeee2 /SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive  bbbbb1 K+ eeeee1  bbbbb2 ATP-sensitive K+ (K(ATP)) channels eeeee2  in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive  bbbbb1 K+ eeeee1  bbbbb2 insulin eeeee2  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ (K(ATP)) channels eeeee2  in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K( bbbbb1 ATP eeeee1  bbbbb2 insulin eeeee2  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ (K(ATP)) channels eeeee2  in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the  bbbbb1 ATP eeeee1  bbbbb2 insulin eeeee2  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ ( bbbbb1 K eeeee1  bbbbb2 ATP-sensitive K+ (K(ATP)) channels eeeee2  in pancreatic beta-cells
CRP11	Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ ( bbbbb1 K eeeee1  bbbbb2 insulin eeeee2  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide tr bbbbb1 e eeeee1  bbbbb2 c mi eeeee2 tiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide tr bbbbb1 e eeeee1  bbbbb2 eatment were c eeeee2 omparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide tr bbbbb1 e eeeee1  bbbbb2  chron eeeee2 ic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those  bbbbb1 after chron eeeee1  bbbbb2 c mi eeeee2 tiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those  bbbbb1 after chron eeeee1  bbbbb2  chron eeeee2 ic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide trea bbbbb1 tme eeeee1  bbbbb2 c mi eeeee2 tiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide trea bbbbb1 tme eeeee1  bbbbb2 eatment were c eeeee2 omparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide trea bbbbb1 tme eeeee1  bbbbb2  chron eeeee2 ic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The insulin responses to glucose, mitiglinide, tolbutamide, bbbbb1  and gliben eeeee1 clamide in MIN6 cells after bbbbb2  chron eeeee2 ic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment
CRP11	The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and  bbbbb1 nateglinide eeeee1  bbbbb2 ATP-sensitive K+ channels eeeee2  and insulin secretion: comparison with the sulfonylureas and nateglinide
CRP11	The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and  bbbbb1 nateglinide eeeee1  bbbbb2 insulin eeeee2  secretion: comparison with the sulfonylureas and nateglinide
CRP11	The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the  bbbbb1 sulfonylureas eeeee1  bbbbb2 ATP-sensitive K+ channels eeeee2  and insulin secretion: comparison with the sulfonylureas and nateglinide
CRP11	The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the  bbbbb1 sulfonylureas eeeee1  bbbbb2 insulin eeeee2  secretion: comparison with the sulfonylureas and nateglinide
CRP11	Functional affinities for compounds determined against  bbbbb1 noradrenaline eeeee1 -mediated contractions of rat aorta correlated well with binding affinities at cloned  bbbbb2 alpha 1D-adrenoceptors eeeee2  (r = 0.96), but not with alpha 1A (r = 0.61) or alpha 1B (r = 0.46) subtypes. 6
CRP11	 bbbbb1 Spiperone eeeee1  displayed high affinity and selectivity for alpha 1B adrenoceptors (pKi 8.8 +/- 0.16). 5-Methyl-urapidil was selective for cloned  bbbbb2 alpha 1A adrenoceptors eeeee2 . 3
CRP11	Spiperone displayed high affinity and selectivity for alpha 1B adrenoceptors (pKi 8.8 +/- 0.16).  bbbbb1 5-Methyl-urapidil eeeee1  bbbbb2 alpha 1B adrenoceptors eeeee2  (pKi 8.8 +/- 0.16). 5-Methyl-urapidil was selective for cloned alpha 1A adrenoceptors. 3
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2 of C eeeee2 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is  bbbbb1 ascribabl eeeee1 e to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is  bbbbb1 ascribabl eeeee1 e to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is  bbbbb1 ascribabl eeeee1 e to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2 of C eeeee2 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord
CRP11	These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect  bbbbb1 of C eeeee1 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect  bbbbb1 of C eeeee1 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	These findings suggest that the anti-allodynia effect  bbbbb1 of C eeeee1  bbbbb2 of C eeeee2 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord
CRP11	These findings suggest that the anti-allodynia effect  bbbbb1 of C eeeee1 P-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord bbbbb2  eeeee2 
CRP11	In order to examine the site of action of an NR2B subtype-selective  bbbbb1 NMDA eeeee1  bbbbb2 NR2B eeeee2  subtype-selective NMDA antagonist CP-101,606, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration
CRP11	In order to examine the site of action of an NR2B subtype-selective  bbbbb1 NMDA eeeee1  bbbbb2 NMDA eeeee2  antagonist CP-101,606, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration
CRP11	 bbbbb1 Glutamic acid eeeee1  decarboxylase (GAD,  bbbbb2 EC 4.1.1.15 eeeee2 ) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)
CRP11	 bbbbb1 Glutamic acid eeeee1  bbbbb2 Glutamic acid decarboxylase eeeee2  (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)
CRP11	 bbbbb1 Glutamic acid eeeee1  decarboxylase ( bbbbb2 GAD eeeee2 , EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)
CRP11	A hybrid cDNA was created by fusing a human cDNA for  bbbbb1 amino acids eeeee1  1-101 of GAD67 to a human cDNA for amino acids 96-585 of GAD65; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to  bbbbb2 mammalian brain GAD eeeee2  with diabetes sera
CRP11	A hybrid cDNA was created by fusing a human cDNA for  bbbbb1 amino acids eeeee1  1-101 of GAD67 to a human cDNA for amino acids 96-585 of  bbbbb2 GAD65 eeeee2 ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera
CRP11	A hybrid cDNA was created by fusing a human cDNA for amino acids 1-101 of GAD67 to a human cDNA for  bbbbb1 amino acids eeeee1  96-585 of GAD65; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to  bbbbb2 mammalian brain GAD eeeee2  with diabetes sera
CRP11	A hybrid cDNA was created by fusing a human cDNA for amino acids 1-101 of GAD67 to a human cDNA for  bbbbb1 amino acids eeeee1  bbbbb2 GAD67 eeeee2  to a human cDNA for amino acids 96-585 of GAD65; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera
CRP11	The Hill coefficient values were < 1 and, in kinetic analyses, onset and recovery from block were well fit by double exponential functions, indicating binding to more than one blocking site on the  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  channel complex
CRP11	We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a/NR2B subunits bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM  bbbbb1 glycine eeeee1  in human embryonic kidney 293 cells expressing the  bbbbb2 rat NR1a eeeee2  subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM  bbbbb1 glycine eeeee1  in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or  bbbbb2 NR2C eeeee2  subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM  bbbbb1 glycine eeeee1  in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the  bbbbb2 NR2A eeeee2 , NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM  bbbbb1 glycine eeeee1  in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A,  bbbbb2 NR2B eeeee2  or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM  bbbbb1 NMDA eeeee1  and 10 microM glycine in human embryonic kidney 293 cells expressing the  bbbbb2 rat NR1a eeeee2  subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM  bbbbb1 NMDA eeeee1  and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or  bbbbb2 NR2C eeeee2  subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM  bbbbb1 NMDA eeeee1  and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the  bbbbb2 NR2A eeeee2 , NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM  bbbbb1 NMDA eeeee1  and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A,  bbbbb2 NR2B eeeee2  or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)
CRP11	Felbamate block of recombinant  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate receptors eeeee2 : selectivity for the NR2B subunit
CRP11	Felbamate block of recombinant  bbbbb1 N-methyl-D-aspartate eeeee1  receptors: selectivity for the  bbbbb2 NR2B eeeee2  subunit
CRP11	The anticonvulsant felbamate blocks N-methyl-D-asparate ( bbbbb1 NMDA eeeee1 ) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  bbbbb2 NMDA receptor eeeee2  antagonists
CRP11	The anticonvulsant felbamate blocks N-methyl-D-asparate ( bbbbb1 NMDA eeeee1  bbbbb2 N-methyl-D-asparate (NMDA) receptors eeeee2  but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists
CRP11	The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  antagonists
CRP11	The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  bbbbb1 NMDA eeeee1  bbbbb2 N-methyl-D-asparate (NMDA) receptors eeeee2  but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists
CRP11	The anticonvulsant felbamate blocks  bbbbb1 N-methyl-D-asparate eeeee1  (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  bbbbb2 NMDA receptor eeeee2  antagonists
CRP11	The anticonvulsant felbamate blocks  bbbbb1 N-methyl-D-asparate eeeee1  bbbbb2 N-methyl-D-asparate (NMDA) receptors eeeee2  but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of  bbbbb1 felbamate eeeee1  bbbbb2 NMDA receptor eeeee2  subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to  bbbbb1 NMDA eeeee1  receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various  bbbbb2 NR2 eeeee2  subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to  bbbbb1 NMDA eeeee1  receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the  bbbbb2 NR1a eeeee2  subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to  bbbbb1 NMDA eeeee1  receptor subtype selectivity, we examined the specificity of felbamate block of recombinant  bbbbb2 NMDA receptors eeeee2  composed of the NR1a subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant  bbbbb1 NMDA eeeee1  receptors composed of the NR1a subunit and various  bbbbb2 NR2 eeeee2  subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant  bbbbb1 NMDA eeeee1  receptors composed of the  bbbbb2 NR1a eeeee2  subunit and various NR2 subunits
CRP11	To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  composed of the NR1a subunit and various NR2 subunits
CRP11	The higher affinity of felbamate block of  bbbbb1 NMDA eeeee1  receptors containing the  bbbbb2 NR2B eeeee2  subunit could be accounted for by more rapid association and slower dissociation from these sites
CRP11	The higher affinity of felbamate block of  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites
CRP11	Alexander cells, only when they were transfected with FXR+RXR,  bbbbb1 GW4064 eeeee1  bbbbb2 RXR eeeee2 , GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1
CRP11	Alexander cells, only when they were transfected with FXR+RXR,  bbbbb1 GW4064 eeeee1  bbbbb2 FXR eeeee2 +RXR, GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1
CRP11	An article presented in this issue of Molecular Pharmacology (p. 1527) provides an intriguing example of how  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitors can be put to many uses
CRP11	Both pharmacologic inhibitors target several  bbbbb1 tyrosine eeeee1  kinases, including Bcr-Abl and the  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR)
CRP11	Both pharmacologic inhibitors target several  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2 , including Bcr-Abl and the platelet-derived growth factor receptor (PDGFR)
CRP11	Both pharmacologic inhibitors target several  bbbbb1 tyrosine eeeee1  kinases, including Bcr-Abl and the platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 )
CRP11	Both pharmacologic inhibitors target several  bbbbb1 tyrosine eeeee1  kinases, including Bcr- bbbbb2 Abl eeeee2  and the platelet-derived growth factor receptor (PDGFR)
CRP11	Both pharmacologic inhibitors target several  bbbbb1 tyrosine eeeee1  kinases, including  bbbbb2 Bcr eeeee2 -Abl and the platelet-derived growth factor receptor (PDGFR)
CRP11	In vitro inhibitory effects of non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant  bbbbb2 human UDP-glucuronosyltransferase 1A9 eeeee2 --potent inhibition by niflumic acid
CRP11	In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human  bbbbb1 UDP eeeee1  bbbbb2 human UDP-glucuronosyltransferase 1A9 eeeee2 --potent inhibition by niflumic acid
CRP11	In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on  bbbbb1 4-methylumbelliferone eeeee1  glucuronidation in recombinant  bbbbb2 human UDP-glucuronosyltransferase 1A9 eeeee2 --potent inhibition by niflumic acid
CRP11	The inhibitory potencies of non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) on  bbbbb2 UDP-glucuronosyltransferase (UGT) 1A9 eeeee2  activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant  bbbbb2 human UGT1A9 eeeee2  using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone ( bbbbb1 4-MU eeeee1  bbbbb2 UDP-glucuronosyltransferase (UGT) 1A9 eeeee2  activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone ( bbbbb1 4-MU eeeee1  bbbbb2 human UGT1A9 eeeee2  using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation.  bbbbb1 4-MU eeeee1  bbbbb2 UDP-glucuronosyltransferase (UGT) 1A9 eeeee2  activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation.  bbbbb1 4-MU eeeee1  bbbbb2 human UGT1A9 eeeee2  using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using  bbbbb1 4-methylumbelliferone eeeee1  bbbbb2 UDP-glucuronosyltransferase (UGT) 1A9 eeeee2  activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using  bbbbb1 4-methylumbelliferone eeeee1  bbbbb2 human UGT1A9 eeeee2  using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on  bbbbb1 UDP eeeee1  bbbbb2 UDP-glucuronosyltransferase (UGT) 1A9 eeeee2  activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on  bbbbb1 UDP eeeee1 -glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant  bbbbb2 human UGT1A9 eeeee2  using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM
CRP11	O significantly inhibited nitric oxide (NO) and  bbbbb1 prostaglandin E2 eeeee1  (PGE2) by suppressing the protein expression of  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited nitric oxide (NO) and  bbbbb1 prostaglandin E2 eeeee1  (PGE2) by suppressing the protein expression of inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited  bbbbb1 nitric oxide eeeee1  (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and  bbbbb2 cyclooxygenase (COX)-2 eeeee2 , respectively
CRP11	O significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS) and  bbbbb2 cyclooxygenase (COX)-2 eeeee2 , respectively
CRP11	O significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited nitric oxide (NO) and prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) by suppressing the protein expression of  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited nitric oxide (NO) and prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) by suppressing the protein expression of inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ) and cyclooxygenase (COX)-2, respectively
CRP11	O significantly inhibited nitric oxide ( bbbbb1 NO eeeee1 ) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and  bbbbb2 cyclooxygenase (COX)-2 eeeee2 , respectively
CRP11	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by  bbbbb1 betazole eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	ORF 17583, a  bbbbb1 histamine eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine,  bbbbb1 tetragastrin eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.),  bbbbb1 histamine eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin,  bbbbb1 bethanechol eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol,  bbbbb1 2-deoxy-D-glucose eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.)
CRP11	The nonspecific inhibition of gastric acid by  bbbbb1 ORF 17583 eeeee1  supports the existence of interdependence between  bbbbb2 histamine and the gastrin and cholinergic receptors eeeee2  on the parietal cell surface
CRP11	The nonspecific inhibition of gastric acid by ORF 17583 supports the existence of interdependence between  bbbbb1 histamine eeeee1  bbbbb2 histamine and the gastrin and cholinergic receptors eeeee2  on the parietal cell surface
CRP11	Effects of ORF 17583, other  bbbbb1 histamine eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonists and omeprazole on gastric acid secretory states in rats and dogs
CRP11	Effects of ORF 17583, other histamine H2-receptor antagonists and  bbbbb1 omeprazole eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonists and omeprazole on gastric acid secretory states in rats and dogs
CRP11	A cocaine-sensitive Drosophila  bbbbb1 serotonin eeeee1  bbbbb2 Drosophila serotonin transporter eeeee2 : cloning, expression, and electrophysiological characterization
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian  bbbbb1 catecholamine eeeee1  bbbbb2 mammalian catecholamine transporters eeeee2  than to mammalian 5HT transporters
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian  bbbbb1 catecholamine eeeee1  transporters than to  bbbbb2 mammalian 5HT transporters eeeee2 
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian  bbbbb1 catecholamine eeeee1  bbbbb2 dSERT1 eeeee2 , including sensitivity to antidepressants, are more similar to those of mammalian catecholamine transporters than to mammalian 5HT transporters
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian catecholamine transporters than to mammalian  bbbbb1 5HT eeeee1  bbbbb2 mammalian catecholamine transporters eeeee2  than to mammalian 5HT transporters
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian catecholamine transporters than to mammalian  bbbbb1 5HT eeeee1  bbbbb2 mammalian 5HT transporters eeeee2 
CRP11	Interestingly, the pharmacological properties of dSERT1, including sensitivity to antidepressants, are more similar to those of mammalian catecholamine transporters than to mammalian  bbbbb1 5HT eeeee1  bbbbb2 dSERT1 eeeee2 , including sensitivity to antidepressants, are more similar to those of mammalian catecholamine transporters than to mammalian 5HT transporters
CRP11	Two-electrode voltage-clamp analysis demonstrated 5HT-induced, voltage-dependent currents bbbbb1  eeeee1  bbbbb2 ysis d eeeee2 emonstrated 5HT-induced, voltage-dependent currents
CRP11	Two-electrode voltage-clamp analysis demonstrated 5HT-induced, voltage-dependent currents bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian  bbbbb1 5HT eeeee1  bbbbb2 mammalian 5HT, norepinephrine, and dopamine transporters eeeee2 
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian  bbbbb1 5HT eeeee1  bbbbb2 dSERT1 eeeee2  and mammalian 5HT, norepinephrine, and dopamine transporters
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian 5HT, norepinephrine, and  bbbbb1 dopamine eeeee1  bbbbb2 mammalian 5HT, norepinephrine, and dopamine transporters eeeee2 
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian 5HT, norepinephrine, and  bbbbb1 dopamine eeeee1  bbbbb2 dSERT1 eeeee2  and mammalian 5HT, norepinephrine, and dopamine transporters
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian 5HT,  bbbbb1 norepinephrine eeeee1  bbbbb2 mammalian 5HT, norepinephrine, and dopamine transporters eeeee2 
CRP11	Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among dSERT1 and mammalian 5HT,  bbbbb1 norepinephrine eeeee1  bbbbb2 dSERT1 eeeee2  and mammalian 5HT, norepinephrine, and dopamine transporters
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine;  bbbbb1 5HT eeeee1 ) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes.  bbbbb2 dSERT1 eeeee2  shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine;  bbbbb1 5HT eeeee1 ) transporter cDNA, denoted  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine;  bbbbb1 5HT eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and  bbbbb1 Cl- eeeee1  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and  bbbbb1 Cl- eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila  bbbbb1 serotonin eeeee1  (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes.  bbbbb2 dSERT1 eeeee2  shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila  bbbbb1 serotonin eeeee1  (5-hydroxytryptamine; 5HT) transporter cDNA, denoted  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila  bbbbb1 serotonin eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin ( bbbbb1 5-hydroxytryptamine eeeee1 ; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes.  bbbbb2 dSERT1 eeeee2  shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin ( bbbbb1 5-hydroxytryptamine eeeee1 ; 5HT) transporter cDNA, denoted  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin ( bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other  bbbbb1 monoamines eeeee1  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other  bbbbb1 monoamines eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A  bbbbb1 cocaine eeeee1 -sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes.  bbbbb2 dSERT1 eeeee2  shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is  bbbbb1 Na+ eeeee1  bbbbb2 dSERT1 eeeee2 , was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	A cocaine-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is  bbbbb1 Na+ eeeee1  bbbbb2 Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter eeeee2  cDNA, denoted dSERT1, was isolated and characterized in oocytes. dSERT1 shows little transport of other monoamines and is Na+ and Cl- dependent
CRP11	Knockdown of COL8A2 blocked enhancement in the early stage of cell adhesion by  bbbbb1 atRA eeeee1  bbbbb2 COL8A2 eeeee2  blocked enhancement in the early stage of cell adhesion by atRA treatment
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  triad nucleotide binding protein 3 ( bbbbb2 HINT3 eeeee2 ), miR-1282 and cytochrome P450 family 26 subfamily B polypeptide 1 (CYP26B1), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  triad nucleotide binding protein 3 (HINT3), miR-1282 and  bbbbb2 cytochrome P450 family 26 subfamily B polypeptide 1 eeeee2  (CYP26B1), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  triad nucleotide binding protein 3 (HINT3), miR-1282 and cytochrome P450 family 26 subfamily B polypeptide 1 ( bbbbb2 CYP26B1 eeeee2 ), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  bbbbb2 CYP26A1 eeeee2 ), histidine triad nucleotide binding protein 3 (HINT3), miR-1282 and cytochrome P450 family 26 subfamily B polypeptide 1 (CYP26B1), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  triad nucleotide binding protein 3 (HINT3),  bbbbb2 miR-1282 eeeee2  and cytochrome P450 family 26 subfamily B polypeptide 1 (CYP26B1), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  bbbbb2 cytochrome P450 family 26 subfamily A polypeptide 1 eeeee2  (CYP26A1), histidine triad nucleotide binding protein 3 (HINT3), miR-1282 and cytochrome P450 family 26 subfamily B polypeptide 1 (CYP26B1), which showed more than fivefold greater expression
CRP11	The most upregulated genes are cytochrome P450 family 26 subfamily A polypeptide 1 (CYP26A1),  bbbbb1 histidine eeeee1  bbbbb2 histidine triad nucleotide binding protein 3 eeeee2  (HINT3), miR-1282 and cytochrome P450 family 26 subfamily B polypeptide 1 (CYP26B1), which showed more than fivefold greater expression
CRP11	Thus, COL8A2 wa bbbbb1 s id eeeee1 entified as the key protein involved in the enhancement of cell adhesion of atRA under serum-fre bbbbb2 e cond eeeee2 itions
CRP11	T-R, AXL is  bbbbb1 tyrosine eeeee1  phosphorylated and its ligand  bbbbb2 growth-arrest-specific gene 6 eeeee2  is overexpressed implying autocrine activation
CRP11	Further, the two  bbbbb1 IM eeeee1  resistant GIST patients express AXL and not  bbbbb2 c-Kit eeeee2 , seen by immunohistochemistry (IHC)
CRP11	Further, the two  bbbbb1 IM eeeee1  resistant GIST patients express  bbbbb2 AXL eeeee2  and not c-Kit, seen by immunohistochemistry (IHC)
CRP11	A novel  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
CRP11	Instead, GIST-R cells have acquired  bbbbb1 IM eeeee1  resistance by overexpressing the oncogenic receptor tyrosine kinase -  bbbbb2 AXL eeeee2  - in a 'kinase switch'
CRP11	Instead, GIST-R cells have acquired  bbbbb1 IM eeeee1  resistance by overexpressing the  bbbbb2 oncogenic receptor tyrosine kinase eeeee2  - AXL - in a 'kinase switch'
CRP11	Instead, GIST-R cells have acquired  bbbbb1 IM eeeee1  resistance by overexpressing the oncogenic receptor tyrosine kinase - AXL - in a ' bbbbb2 kinase eeeee2  switch'
CRP11	Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor  bbbbb1 tyrosine eeeee1  kinase -  bbbbb2 AXL eeeee2  - in a 'kinase switch'
CRP11	Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor  bbbbb1 tyrosine eeeee1  bbbbb2 oncogenic receptor tyrosine kinase eeeee2  - AXL - in a 'kinase switch'
CRP11	Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor  bbbbb1 tyrosine eeeee1  kinase - AXL - in a ' bbbbb2 kinase eeeee2  switch'
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the  bbbbb1 chenodeoxycholic acid eeeee1  bbbbb2 nuclear receptor eeeee2  for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the  bbbbb1 chenodeoxycholic acid eeeee1  bbbbb2 farnesoid X receptor eeeee2  (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the  bbbbb1 chenodeoxycholic acid eeeee1  bbbbb2 FXR eeeee2 ), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ( bbbbb1 CDCA eeeee1  bbbbb2 nuclear receptor eeeee2  for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ( bbbbb1 CDCA eeeee1  bbbbb2 farnesoid X receptor eeeee2  (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ( bbbbb1 CDCA eeeee1  bbbbb2 FXR eeeee2 ), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)
CRP11	The production of acetate esters was enhanced by mid-range ammo bbbbb1 nium eeeee1  supplementation and the p bbbbb2 roduction of acyl  eeeee2 esters by high ammonium supplementation
CRP11	The production of acetate esters was enhanced by mid-range ammo bbbbb1 nium eeeee1  bbbbb2 nge ammonium supplementation  eeeee2 and the production of acyl esters by high ammonium supplementation
CRP11	The production of acetate esters was enhanced by mid-ra bbbbb1 nge amm eeeee1 onium supplementation and the p bbbbb2 roduction of acyl  eeeee2 esters by high ammonium supplementation
CRP11	The production of acetate esters was enhanced by mid-ra bbbbb1 nge amm eeeee1  bbbbb2 nge ammonium supplementation  eeeee2 and the production of acyl esters by high ammonium supplementation
CRP11	The production of acetate esters was enhanced by mid-range ammonium supplementation and the p bbbbb1 rodu eeeee1  bbbbb2 roduction of acyl  eeeee2 esters by high ammonium supplementation
CRP11	The production of acetate esters was enhanced by mid-range ammonium supplementation and the p bbbbb1 rodu eeeee1  bbbbb2 nge ammonium supplementation  eeeee2 and the production of acyl esters by high ammonium supplementation
CRP11	Overall, higher  bbbbb1 alcohol eeeee1  production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the  bbbbb2 Ehrlich pathway eeeee2 
CRP11	Overall, higher  bbbbb1 alcohol eeeee1  production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding  bbbbb2 decarboxylases eeeee2  and dehydrogenases of the Ehrlich pathway
CRP11	Overall, higher  bbbbb1 alcohol eeeee1  production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and  bbbbb2 dehydrogenases eeeee2  of the Ehrlich pathway
CRP11	The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compar bbbbb1 ed  eeeee1  bbbbb2 ed to eeeee2  that in the wild type
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers  bbbbb1 Glc eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers  bbbbb1 Glc eeeee1  bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers  bbbbb1 Glc eeeee1  from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers  bbbbb1 Glc eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion ( bbbbb1 Gal eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion ( bbbbb1 Gal eeeee1  bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion ( bbbbb1 Gal eeeee1 -T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion ( bbbbb1 Gal eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb1 Glc eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb1 Glc eeeee1  bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb1 Glc eeeee1  bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb1 Glc eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from  bbbbb1 UDP-Glc eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from  bbbbb1 UDP-Glc eeeee1  bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from  bbbbb1 UDP-Glc eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to  bbbbb1 GlcNAc eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to  bbbbb1 GlcNAc eeeee1  in the presence of Mn(2+) ion ( bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to  bbbbb1 GlcNAc eeeee1  in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to  bbbbb1 GlcNAc eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to  bbbbb1 GlcNAc eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to  bbbbb1 GlcNAc eeeee1  bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to  bbbbb1 GlcNAc eeeee1  ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to  bbbbb1 GlcNAc eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of  bbbbb1 Mn(2+) eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of  bbbbb1 Mn(2+) eeeee1  ion ( bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of  bbbbb1 Mn(2+) eeeee1  ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of  bbbbb1 Mn(2+) eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from  bbbbb1 UDP-Gal eeeee1  to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers  bbbbb1 Gal eeeee1  bbbbb2 beta4Gal-T1 eeeee2 ) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers  bbbbb1 Gal eeeee1  from UDP-Gal to GlcNAc in the presence of Mn(2+) ion ( bbbbb2 Gal-T eeeee2  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers  bbbbb1 Gal eeeee1  from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc ( bbbbb2 Glc-T eeeee2  activity), albeit at only 0.3% efficiency
CRP11	Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers  bbbbb1 Gal eeeee1  bbbbb2 Beta-1,4-galactosyltransferase I eeeee2  (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency
CRP11	In addition, alpha-lactalbumin (LA) enhances this  bbbbb1 Glc eeeee1  bbbbb2 Glc-T eeeee2  activity more than 25 times
CRP11	In addition, alpha-lactalbumin (LA) enhances this  bbbbb1 Glc eeeee1  bbbbb2 alpha-lactalbumin eeeee2  (LA) enhances this Glc-T activity more than 25 times
CRP11	In addition, alpha-lactalbumin (LA) enhances this  bbbbb1 Glc eeeee1  bbbbb2 LA eeeee2 ) enhances this Glc-T activity more than 25 times
CRP11	The kinetic parameters indicate that the main effect of the mutation of Arg228 to  bbbbb1 lysine eeeee1  is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the  bbbbb2 Gal-T eeeee2  reaction is reduced 30-fold
CRP11	The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the  bbbbb1 Gal eeeee1  bbbbb2 Glc-T eeeee2 , which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold
CRP11	The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the  bbbbb1 Gal eeeee1  bbbbb2 Gal-T eeeee2  reaction is reduced 30-fold
CRP11	The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of  bbbbb1 Glc eeeee1  bbbbb2 Glc-T eeeee2 , which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold
CRP11	The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of  bbbbb1 Glc eeeee1 -T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the  bbbbb2 Gal-T eeeee2  reaction is reduced 30-fold
CRP11	Mutation of  bbbbb1 arginine eeeee1  228 to lysine enhances the  bbbbb2 glucosyltransferase eeeee2  activity of bovine beta-1,4-galactosyltransferase I
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K- bbbbb1 Gal eeeee1 -T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the  bbbbb2 Gal-T eeeee2  activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K- bbbbb1 Gal eeeee1 -T1) results in a 15-fold higher  bbbbb2 Glc-T eeeee2  activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K- bbbbb1 Gal eeeee1  bbbbb2 Gal-T1 eeeee2 ) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K- bbbbb1 Gal eeeee1  bbbbb2 R228K eeeee2 -Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher  bbbbb1 Glc eeeee1 -T activity, which is further enhanced by LA to nearly 25% of the  bbbbb2 Gal-T eeeee2  activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher  bbbbb1 Glc eeeee1  bbbbb2 Glc-T eeeee2  activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher  bbbbb1 Glc eeeee1  bbbbb2 Gal-T1 eeeee2 ) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher  bbbbb1 Glc eeeee1  bbbbb2 R228K eeeee2 -Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to  bbbbb1 lysine eeeee1  ( bbbbb2 R228K eeeee2 -Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the  bbbbb1 Gal eeeee1  bbbbb2 Gal-T eeeee2  activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the  bbbbb1 Gal eeeee1  bbbbb2 Glc-T eeeee2  activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the  bbbbb1 Gal eeeee1  bbbbb2 Gal-T1 eeeee2 ) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the  bbbbb1 Gal eeeee1  bbbbb2 R228K eeeee2 -Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type
CRP11	The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low  bbbbb1 Glc eeeee1  bbbbb2 Glc-T eeeee2  activity
CRP11	Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and  bbbbb1 Glc eeeee1  bbbbb2 beta4Gal-T1 eeeee2  reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317
CRP11	Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the  bbbbb1 O4 hydroxyl eeeee1  bbbbb2 beta4Gal-T1 eeeee2  reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317
CRP11	Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a  bbbbb1 hydrogen eeeee1  bbbbb2 beta4Gal-T1 eeeee2  reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317
CRP11	Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both  bbbbb1 Gal eeeee1  bbbbb2 beta4Gal-T1 eeeee2  reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317
CRP11	Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, acco bbbbb1 mpanied  eeeee1  bbbbb2 tumo eeeee2 r cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with phosphatidylinositol 3-kinase, and down-regulation of Akt activity
CRP11	Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, acco bbbbb1 mpanied  eeeee1  bbbbb2  HE eeeee2 R3, accompanied by the loss of association of HER3 with phosphatidylinositol 3-kinase, and down-regulation of Akt activity
CRP11	The tyrosine kinase inhibitor  bbbbb1 ZD1839 eeeee1  ("Iressa") inhibits HER2-driven signaling and suppresses the growth of  bbbbb2 HER2 eeeee2 -overexpressing tumor cells
CRP11	The  bbbbb1 tyrosine eeeee1  kinase inhibitor ZD1839 ("Iressa") inhibits  bbbbb2 HER2 eeeee2 -driven signaling and suppresses the growth of HER2-overexpressing tumor cells
CRP11	The  bbbbb1 tyrosine eeeee1  kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of  bbbbb2 HER2 eeeee2 -overexpressing tumor cells
CRP11	ZD1839 ("Iressa"), a  bbbbb1 quinazoline tyrosine eeeee1  kinase inhibitor selective for the  bbbbb2 EGFR eeeee2 , has shown good activity in preclinical studies and in the early phase of clinical trials
CRP11	 bbbbb1 Thiazolidinediones eeeee1  (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on  bbbbb2 aromatase eeeee2 
CRP11	Thiazolidinediones ( bbbbb1 TZDs eeeee1 ) affect osteoblast viability and biomarkers independently of the TZD effects on  bbbbb2 aromatase eeeee2 
CRP11	We also shortly discuss the ongoing debate on whether NO is the actual reaction product of NOS catalysis, as well as the phenomenon of  bbbbb1 NO eeeee1  bbbbb2 NOS eeeee2  catalysis, as well as the phenomenon of NO-mediated autoinhibition
CRP11	First we give a brief general description of the structure and catalytic mechanism of NOS, with special emphasis on those aspects of catalysis that are actively debated, and that directly or indirectly involve  bbbbb1 BH4 eeeee1  bbbbb2 NOS eeeee2 , with special emphasis on those aspects of catalysis that are actively debated, and that directly or indirectly involve BH4
CRP11	Next we turn our attention to what is now becoming accepted as the central func bbbbb1 tion of BH4: its cap eeeee1  bbbbb2 tion of BH4: its capacity to  eeeee2 act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	Next we turn our attention to what is now becoming accepted as the central func bbbbb1 tion of BH4: its cap eeeee1  bbbbb2 acc eeeee2 epted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	Next we turn our attention to what is now becoming accepted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyferrous co bbbbb1 mp eeeee1  bbbbb2 tion of BH4: its capacity to  eeeee2 act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	Next we turn our attention to what is now becoming accepted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyferrous co bbbbb1 mp eeeee1  bbbbb2 acc eeeee2 epted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	Next we turn our attention to what is now becoming accepted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyfer bbbbb1 rou eeeee1  bbbbb2 tion of BH4: its capacity to  eeeee2 act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	Next we turn our attention to what is now becoming accepted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyfer bbbbb1 rou eeeee1  bbbbb2 acc eeeee2 epted as the central function of BH4: its capacity to act as a 1-electron donor during reductive activation of the oxyferrous complex of the heme
CRP11	We describe the function of  bbbbb1 BH4 eeeee1  in aromatic amino acid hydroxylation, and discuss the allosteric and structural effects that BH4 exerts on  bbbbb2 NOS eeeee2 
CRP11	We describe the function of BH4 in  bbbbb1 aromatic amino acid eeeee1  hydroxylation, and discuss the allosteric and structural effects that BH4 exerts on  bbbbb2 NOS eeeee2 
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)),  bbbbb1 [(11)C]SCH23390 eeeee1  (striatal  bbbbb2 D(1) eeeee2 ) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)),  bbbbb1 [(11)C]SCH23390 eeeee1  bbbbb2 5-HT(2A) eeeee2 ), [(11)C]SCH23390 (striatal D(1)) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)),  bbbbb1 [(11)C]SCH23390 eeeee1  (striatal D(1)) or [(11)C]raclopride (striatal  bbbbb2 D(2) eeeee2 )
CRP11	ALS AND METHODS: Each patient underwent two PET scans with  bbbbb1 3-N-[(11)C]methylspiperone eeeee1  (target: frontal 5-HT(2A)), [(11)C]SCH23390 (striatal  bbbbb2 D(1) eeeee2 ) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with  bbbbb1 3-N-[(11)C]methylspiperone eeeee1  (target: frontal  bbbbb2 5-HT(2A) eeeee2 ), [(11)C]SCH23390 (striatal D(1)) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with  bbbbb1 3-N-[(11)C]methylspiperone eeeee1  (target: frontal 5-HT(2A)), [(11)C]SCH23390 (striatal D(1)) or [(11)C]raclopride (striatal  bbbbb2 D(2) eeeee2 )
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)), [(11)C]SCH23390 (striatal D(1)) or  bbbbb1 [(11)C]raclopride eeeee1  bbbbb2 D(1) eeeee2 ) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)), [(11)C]SCH23390 (striatal D(1)) or  bbbbb1 [(11)C]raclopride eeeee1  bbbbb2 5-HT(2A) eeeee2 ), [(11)C]SCH23390 (striatal D(1)) or [(11)C]raclopride (striatal D(2))
CRP11	ALS AND METHODS: Each patient underwent two PET scans with 3-N-[(11)C]methylspiperone (target: frontal 5-HT(2A)), [(11)C]SCH23390 (striatal D(1)) or  bbbbb1 [(11)C]raclopride eeeee1  (striatal  bbbbb2 D(2) eeeee2 )
CRP11	Moreover, in rat hepatoma H4-II-E cells, the esterified-BM failed to induce  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine aminotransferase eeeee2 , which is regulated by GR-mediated transactivation activity
CRP11	Moreover, in rat hepatoma H4-II-E cells, the esterified-BM failed to induce  bbbbb1 tyrosine eeeee1  aminotransferase, which is regulated by  bbbbb2 GR eeeee2 -mediated transactivation activity
CRP11	(+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of  bbbbb1 inositol phosphates eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart
CRP11	The influence of  bbbbb1 (+/-)-tamsulosin eeeee1 , a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another  bbbbb2 alpha 1A-adrenoceptor eeeee2  ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of  bbbbb1 (+/-)-tamsulosin eeeee1 , a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via  bbbbb2 alpha 1-adrenoceptors eeeee2  was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of  bbbbb1 inositol phosphates eeeee1  that are induced via alpha 1-adrenoceptors was studied in comparison with that of another  bbbbb2 alpha 1A-adrenoceptor eeeee2  ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of  bbbbb1 inositol phosphates eeeee1  that are induced via  bbbbb2 alpha 1-adrenoceptors eeeee2  was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of  bbbbb1 inositol phosphates eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand  bbbbb1 oxymetazoline eeeee1  bbbbb2 alpha 1-adrenoceptors eeeee2  was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand  bbbbb1 oxymetazoline eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.  bbbbb1 (+/-)-Tamsulosin eeeee1  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the  bbbbb1 (+/-)-tamsulosin eeeee1  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the  bbbbb1 (+/-)-tamsulosin eeeee1 -sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM  bbbbb1 phenylephrine eeeee1  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM  bbbbb1 phenylephrine eeeee1  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of  bbbbb1 [3H]inositol phosphates eeeee1  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of  bbbbb1 [3H]inositol phosphates eeeee1  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of  bbbbb1 phenylephrine eeeee1  even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine.  bbbbb1 (+/-)-Tamsulosin eeeee1  effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to  bbbbb1 chlorethylclonidine eeeee1  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to  bbbbb1 chlorethylclonidine eeeee1 . (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to phenylephrine. (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with  bbbbb1 chlorethylclonidine eeeee1 , which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to  bbbbb1 phenylephrine eeeee1 . (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of  bbbbb2 alpha 1B-adrenoceptors eeeee2  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	At 100 nM and higher, it suppressed the maximal response to  bbbbb1 phenylephrine eeeee1 . (+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine. (+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by  bbbbb2 alpha 1-adrenoceptors eeeee2 , did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine
CRP11	Statins ( bbbbb1 HMG-CoA eeeee1  reductase inhibitors) have consistently been shown to decrease both  bbbbb2 LDL eeeee2 -C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis
CRP11	Statins ( bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis
CRP11	L Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein  bbbbb1 cholesterol eeeee1  ( bbbbb2 LDL eeeee2 -C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD)
CRP11	L Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein  bbbbb1 cholesterol eeeee1  bbbbb2 low-density lipoprotein eeeee2  cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD)
CRP11	L  bbbbb1 Cholesterol eeeee1  Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that low-density lipoprotein cholesterol ( bbbbb2 LDL eeeee2 -C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD)
CRP11	L  bbbbb1 Cholesterol eeeee1  Goals in High-Risk Patients: How Low Do We Go and How Do We Get There? It is widely recognised that  bbbbb2 low-density lipoprotein eeeee2  cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD)
CRP11	In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or  bbbbb1 fibrates eeeee1  bbbbb2 LDL eeeee2 -C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered
CRP11	In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe,  bbbbb1 bile acid eeeee1  bbbbb2 LDL eeeee2 -C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered
CRP11	In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g.  bbbbb1 ezetimibe eeeee1  bbbbb2 LDL eeeee2 -C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  bbbbb1 glutamate eeeee1  bbbbb2 glutamate synthase eeeee2 , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  bbbbb1 glutamate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  bbbbb1 glutamate eeeee1  bbbbb2 glutamate dehydrogenase eeeee2 , promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  bbbbb1 glutamate eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  bbbbb1 glutamine eeeee1  synthetase,  bbbbb2 glutamate synthase eeeee2 , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  bbbbb1 glutamine eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  bbbbb1 glutamine eeeee1  synthetase, glutamate synthase, and  bbbbb2 glutamate dehydrogenase eeeee2 , promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  bbbbb1 glutamine eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting  bbbbb1 amino acid eeeee1  bbbbb2 glutamate synthase eeeee2 , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting  bbbbb1 amino acid eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting  bbbbb1 amino acid eeeee1  bbbbb2 glutamate dehydrogenase eeeee2 , promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting  bbbbb1 amino acid eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 glutamate synthase eeeee2 , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  synthase, and  bbbbb2 glutamate dehydrogenase eeeee2 , promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of  bbbbb1 nitrate eeeee1  reductase, glutamine synthetase,  bbbbb2 glutamate synthase eeeee2 , and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of  bbbbb1 nitrate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of  bbbbb1 nitrate eeeee1  reductase, glutamine synthetase, glutamate synthase, and  bbbbb2 glutamate dehydrogenase eeeee2 , promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	The pretreatment with 20 mg L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of  bbbbb1 nitrate eeeee1  reductase,  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the  bbbbb1 nitrogen eeeee1  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the  bbbbb1 nitrogen eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the  bbbbb1 nitrogen eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes ( bbbbb1 nitrate eeeee1  reductase, glutamine synthetase,  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes ( bbbbb1 nitrate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes ( bbbbb1 nitrate eeeee1  reductase,  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase,  bbbbb1 glutamate eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase,  bbbbb1 glutamine eeeee1  synthetase,  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase,  bbbbb1 glutamine eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase,  bbbbb1 glutamine eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of  bbbbb1 amino acid eeeee1  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of  bbbbb1 amino acid eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of  bbbbb1 amino acid eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of  bbbbb1 nitrate eeeee1  bbbbb2 glutamate synthase eeeee2 ) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of  bbbbb1 nitrate eeeee1  bbbbb2 nitrate reductase eeeee2 , glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	B radiation led to the inhibition in the activities of the key enzymes (nitrate reductase, glutamine synthetase, glutamate synthase) in the nitrogen assimilation, the decrease in the contents of  bbbbb1 nitrate eeeee1  bbbbb2 glutamine synthetase eeeee2 , glutamate synthase) in the nitrogen assimilation, the decrease in the contents of nitrate and soluble proteins, as well as the increase in the content of amino acid in soybean seedlings
CRP11	Statins are  bbbbb1 3-hydroxy-3-methylglutaryl-CoA eeeee1  bbbbb2 3-hydroxy-3-methylglutaryl-CoA reductase eeeee2  inhibitors broadly used for the control of hypercholesterolemia
CRP11	The intravenous anesthetic  bbbbb1 etomidate eeeee1  exhibits structural similarities to specific  bbbbb2 alpha2-adrenoceptor eeeee2  agonists of the type such as dexmedetomidine
CRP11	In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist,  bbbbb1 [3H]RX821002 eeeee1 , with higher potency from  bbbbb2 alpha2B- and alpha2C-receptors eeeee2  than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)
CRP11	In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of etomidate in wild-type and in alpha2A-receptor-deficient mice, indicating that the hypnotic effect of  bbbbb1 etomidate eeeee1  bbbbb2 alpha2A-receptor eeeee2 -deficient mice, indicating that the hypnotic effect of etomidate in mice does not require the alpha2A-receptor subtype
CRP11	In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of  bbbbb1 etomidate eeeee1  in wild-type and in alpha2A-receptor-deficient mice, indicating that the hypnotic effect of etomidate in mice does not require the  bbbbb2 alpha2A-receptor eeeee2  subtype
CRP11	Platelet activation by ADP and  bbbbb1 ATP eeeee1  plays a crucial role in haemostasis and thrombosis, and their so-called  bbbbb2 P2 receptors eeeee2  are potential targets for antithrombotic drugs
CRP11	Platelet activation by  bbbbb1 ADP eeeee1  and ATP plays a crucial role in haemostasis and thrombosis, and their so-called  bbbbb2 P2 receptors eeeee2  are potential targets for antithrombotic drugs
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to  bbbbb1 ADP eeeee1  and to all platelet agonists, including thromboxane A2 (TXA2),  bbbbb2 thrombin eeeee2 , and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to  bbbbb1 ADP eeeee1  bbbbb2 P2Y1 eeeee2  receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to  bbbbb1 ADP eeeee1  bbbbb2 P2Y12 eeeee2  receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to  bbbbb1 ADP eeeee1  and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and  bbbbb2 collagen eeeee2 
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 ( bbbbb1 TXA2 eeeee1 ),  bbbbb2 thrombin eeeee2 , and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 ( bbbbb1 TXA2 eeeee1  bbbbb2 P2Y1 eeeee2  receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 ( bbbbb1 TXA2 eeeee1  bbbbb2 P2Y12 eeeee2  receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 ( bbbbb1 TXA2 eeeee1 ), thrombin, and  bbbbb2 collagen eeeee2 
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including  bbbbb1 thromboxane A2 eeeee1  (TXA2),  bbbbb2 thrombin eeeee2 , and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including  bbbbb1 thromboxane A2 eeeee1  bbbbb2 P2Y1 eeeee2  receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including  bbbbb1 thromboxane A2 eeeee1  bbbbb2 P2Y12 eeeee2  receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including  bbbbb1 thromboxane A2 eeeee1  (TXA2), thrombin, and  bbbbb2 collagen eeeee2 
CRP11	The P2Y1 receptor is responsible for  bbbbb1 ADP eeeee1 -induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2),  bbbbb2 thrombin eeeee2 , and collagen
CRP11	The P2Y1 receptor is responsible for  bbbbb1 ADP eeeee1  bbbbb2 P2Y1 eeeee2  receptor is responsible for ADP-induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for  bbbbb1 ADP eeeee1 -induced shape change and weak and transient aggregation, while the  bbbbb2 P2Y12 eeeee2  receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and collagen
CRP11	The P2Y1 receptor is responsible for  bbbbb1 ADP eeeee1 -induced shape change and weak and transient aggregation, while the P2Y12 receptor is responsible for the completion and amplification of the response to ADP and to all platelet agonists, including thromboxane A2 (TXA2), thrombin, and  bbbbb2 collagen eeeee2 
CRP11	The  bbbbb1 ATP eeeee1 -gated channel P2X1 and the 2  bbbbb2 G protein-coupled P2Y1 eeeee2  and P2Y12 ADP receptors selectively contribute to platelet aggregation
CRP11	The  bbbbb1 ATP eeeee1  bbbbb2 ATP-gated channel P2X1 eeeee2  and the 2 G protein-coupled P2Y1 and P2Y12 ADP receptors selectively contribute to platelet aggregation
CRP11	The  bbbbb1 ATP eeeee1 -gated channel P2X1 and the 2 G protein-coupled P2Y1 and P2Y12  bbbbb2 ADP receptors eeeee2  selectively contribute to platelet aggregation
CRP11	The  bbbbb1 ATP eeeee1 -gated channel P2X1 and the 2 G protein-coupled P2Y1 and  bbbbb2 P2Y12 eeeee2  ADP receptors selectively contribute to platelet aggregation
CRP11	Thus, exposure of p65 knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to  bbbbb1 DOX eeeee1  bbbbb2 p65 eeeee2  knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to DOX resulted in a decrease in cell survival, culture density and cell proliferation, which was found to be more prominent in p65(-/-) MEFs
CRP11	Thus, exposure of p65 knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to  bbbbb1 DOX eeeee1  bbbbb2 p65 eeeee2 (-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to DOX resulted in a decrease in cell survival, culture density and cell proliferation, which was found to be more prominent in p65(-/-) MEFs
CRP11	Thus, exposure of p65 knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to  bbbbb1 DOX eeeee1  resulted in a decrease in cell survival, culture density and cell proliferation, which was found to be more prominent in  bbbbb2 p65 eeeee2 (-/-) MEFs
CRP11	Those phenomena were accompanied by a  bbbbb1 DOX eeeee1 -induced increase in the proportion of apoptotic cells, which was demonstrated only in  bbbbb2 p65 eeeee2 (-/-) cells and a G2/M arrest, which was found to be more prominent in WT cells
CRP11	Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug  bbbbb1 Doxorubicin eeeee1  bbbbb2 NF-κB eeeee2  in the embryonic response to the anti-cancer drug Doxorubicin (DOX)
CRP11	Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug  bbbbb1 Doxorubicin eeeee1  bbbbb2 p65 eeeee2  subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin (DOX)
CRP11	Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin ( bbbbb1 DOX eeeee1  bbbbb2 NF-κB eeeee2  in the embryonic response to the anti-cancer drug Doxorubicin (DOX)
CRP11	Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin ( bbbbb1 DOX eeeee1  bbbbb2 p65 eeeee2  subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin (DOX)
CRP11	Furthermore, DOX-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the  bbbbb1 per eeeee1  bbbbb2 ssi eeeee2 on of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter
CRP11	 bbbbb1 CGP 12177A eeeee1  was a nonconventional partial agonist (pD(2) 6.34+/-0.09), increasing inotropy and lusitropy, with an intrinsic activity of 0.34 and antagonised by bupranolol. 3.  bbbbb2 beta(1)-adrenoceptor eeeee2  overexpression enhanced the inotropic potency of isoprenaline by 11.7-fold (pD(2) 8.76+/-0.14) and CGP 12177A by 5.9-fold (7.11+/-0.10), respectively
CRP11	CGP 12177A was a nonconventional partial agonist (pD(2) 6.34+/-0.09), increasing inotropy and lusitropy, with an intrinsic activity of 0.34 and antagonised by  bbbbb1 bupranolol eeeee1 . 3.  bbbbb2 beta(1)-adrenoceptor eeeee2  overexpression enhanced the inotropic potency of isoprenaline by 11.7-fold (pD(2) 8.76+/-0.14) and CGP 12177A by 5.9-fold (7.11+/-0.10), respectively
CRP11	This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/ bbbbb1 cAMP eeeee1  signalling pathway bbbbb2  eeeee2 
CRP11	This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/ bbbbb1 cAMP eeeee1  signalling pathway bbbbb2  eeeee2 
CRP11	This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/ bbbbb1 cAMP eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2 , mediated by a Gs/cAMP signalling pathway
CRP11	This study demonstrates enhanced cardiostimulation by  bbbbb1 CGP 12177A eeeee1  (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/cAMP signalling pathway bbbbb2  eeeee2 
CRP11	This study demonstrates enhanced cardiostimulation by  bbbbb1 CGP 12177A eeeee1  (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/cAMP signalling pathway bbbbb2  eeeee2 
CRP11	This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of  bbbbb1 propranolol eeeee1 ) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/cAMP signalling pathway bbbbb2  eeeee2 
CRP11	This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of  bbbbb1 propranolol eeeee1 ) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a Gs/cAMP signalling pathway bbbbb2  eeeee2 
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5.  bbbbb1 (125)I-Cyanopindolol eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5.  bbbbb1 (125)I-Cyanopindolol eeeee1  saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of  bbbbb2 beta(1)-adrenoceptors eeeee2 . 6
CRP11	CGP 12177A but not  bbbbb1 isoprenaline eeeee1  initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in  bbbbb2 beta(1)-adrenoceptors eeeee2 . (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	CGP 12177A but not  bbbbb1 isoprenaline eeeee1  initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of  bbbbb2 beta(1)-adrenoceptors eeeee2 . 6
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of  bbbbb1 propranolol eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of  bbbbb1 propranolol eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2 . (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	 bbbbb1 CGP 12177A eeeee1  but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in  bbbbb2 beta(1)-adrenoceptors eeeee2 . (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	 bbbbb1 CGP 12177A eeeee1  but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of  bbbbb2 beta(1)-adrenoceptors eeeee2 . 6
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors.  bbbbb1 (3)H-CGP 12177A eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors.  bbbbb1 (3)H-CGP 12177A eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2 . (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6
CRP11	The cardiostimulant effects of CGP 12177A were enhanced by IBMX (phosphodiesterase inhibitor) and decreased by Rp-cAMPS ( bbbbb1 cAMP eeeee1  bbbbb2 phosphodiesterase eeeee2  inhibitor) and decreased by Rp-cAMPS (cAMP antagonist)
CRP11	The cardiostimulant effects of  bbbbb1 CGP 12177A eeeee1  were enhanced by IBMX ( bbbbb2 phosphodiesterase eeeee2  inhibitor) and decreased by Rp-cAMPS (cAMP antagonist)
CRP11	The cardiostimulant effects of CGP 12177A were enhanced by IBMX (phosphodiesterase inhibitor) and decreased by  bbbbb1 Rp-cAMPS eeeee1  bbbbb2 phosphodiesterase eeeee2  inhibitor) and decreased by Rp-cAMPS (cAMP antagonist)
CRP11	Preincubating hMSC with Ptx prevented 90% of the suppressive effect of  bbbbb1 As(III) eeeee1  bbbbb2 Ptx eeeee2  prevented 90% of the suppressive effect of As(III)
CRP11	 bbbbb1 Arsenic eeeee1  activates endothelin-1  bbbbb2 Gi protein-coupled receptor eeeee2  signaling to inhibit stem cell differentiation in adipogenesis
CRP11	III) (0.1-1.0 µM) suppressed  bbbbb1 dexamethasone eeeee1 /insulin-induced hMSC adipogenesis, as indicated by decreased transcriptional promoters of differentiation, decreased fat droplet formation, and decreased expression of differentiated adipocyte markers, such as adiponectin and  bbbbb2 perilipin eeeee2 
CRP11	III) (0.1-1.0 µM) suppressed  bbbbb1 dexamethasone eeeee1 /insulin-induced hMSC adipogenesis, as indicated by decreased transcriptional promoters of differentiation, decreased fat droplet formation, and decreased expression of differentiated adipocyte markers, such as  bbbbb2 adiponectin eeeee2  and perilipin
CRP11	We hypothesized that  bbbbb1 As(III) eeeee1  signals through the  bbbbb2 Pertussis toxin eeeee2  (Ptx) sensitive, Gi protein-coupled receptor (GPCR) to impair adipogenesis, as previously demonstrated for its stimulation of vascular oxidant generation, angiogenesis, and remodeling
CRP11	We hypothesized that  bbbbb1 As(III) eeeee1  signals through the Pertussis toxin (Ptx) sensitive, Gi protein-coupled receptor ( bbbbb2 GPCR eeeee2 ) to impair adipogenesis, as previously demonstrated for its stimulation of vascular oxidant generation, angiogenesis, and remodeling
CRP11	We hypothesized that  bbbbb1 As(III) eeeee1  signals through the Pertussis toxin ( bbbbb2 Ptx eeeee2 ) sensitive, Gi protein-coupled receptor (GPCR) to impair adipogenesis, as previously demonstrated for its stimulation of vascular oxidant generation, angiogenesis, and remodeling
CRP11	We hypothesized that  bbbbb1 As(III) eeeee1  signals through the Pertussis toxin (Ptx) sensitive,  bbbbb2 Gi protein-coupled receptor eeeee2  (GPCR) to impair adipogenesis, as previously demonstrated for its stimulation of vascular oxidant generation, angiogenesis, and remodeling
CRP11	In contrast, antagonists to the  bbbbb1 sphingosine-1-phosphate eeeee1  type 1 receptor (previously shown to mediate As(III) vascular effects) or the  bbbbb2 angiotensin II type 1 receptor eeeee2  were ineffective in blocking As(III) effects
CRP11	In contrast, antagonists to the  bbbbb1 sphingosine-1-phosphate eeeee1  bbbbb2 sphingosine-1-phosphate type 1 receptor eeeee2  (previously shown to mediate As(III) vascular effects) or the angiotensin II type 1 receptor were ineffective in blocking As(III) effects
CRP11	In contrast, antagonists to the sphingosine-1-phosphate type 1 receptor (previously shown to mediate As(III) vascular effects) or the angiotensin II type 1 receptor were ineffective in blocking  bbbbb1 As(III) eeeee1  bbbbb2 angiotensin II type 1 receptor eeeee2  were ineffective in blocking As(III) effects
CRP11	In contrast, antagonists to the sphingosine-1-phosphate type 1 receptor (previously shown to mediate As(III) vascular effects) or the angiotensin II type 1 receptor were ineffective in blocking  bbbbb1 As(III) eeeee1  bbbbb2 sphingosine-1-phosphate type 1 receptor eeeee2  (previously shown to mediate As(III) vascular effects) or the angiotensin II type 1 receptor were ineffective in blocking As(III) effects
CRP11	In contrast, antagonists to the sphingosine-1-phosphate type 1 receptor (previously shown to mediate  bbbbb1 As(III) eeeee1  vascular effects) or the  bbbbb2 angiotensin II type 1 receptor eeeee2  were ineffective in blocking As(III) effects
CRP11	In contrast, antagonists to the sphingosine-1-phosphate type 1 receptor (previously shown to mediate  bbbbb1 As(III) eeeee1  bbbbb2 sphingosine-1-phosphate type 1 receptor eeeee2  (previously shown to mediate As(III) vascular effects) or the angiotensin II type 1 receptor were ineffective in blocking As(III) effects
CRP11	Selective competitive antagonists of Gi-coupled endothelin-1 type A and B receptors were ~60% effective in blocking  bbbbb1 As(III) eeeee1  bbbbb2 endothelin-1 type A and B receptors eeeee2  were ~60% effective in blocking As(III) inhibition and combination of antagonists to both receptors were 85% effective
CRP11	Selective competitive antagonists of Gi-coupled endothelin-1 type A and B receptors were ~60% effective in blocking  bbbbb1 As(III) eeeee1  bbbbb2 Gi eeeee2 -coupled endothelin-1 type A and B receptors were ~60% effective in blocking As(III) inhibition and combination of antagonists to both receptors were 85% effective
CRP11	The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ) reflecting  bbbbb2 cyclooxygenase (COX)-2 eeeee2 -mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively
CRP11	The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of  bbbbb1 prostaglandin E2 eeeee1  (PGE2) reflecting  bbbbb2 cyclooxygenase (COX)-2 eeeee2 -mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively
CRP11	The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting cyclooxygenase (COX)-2-mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound  bbbbb1 L745337 eeeee1  bbbbb2 cyclooxygenase (COX)-2 eeeee2 -mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively
CRP11	The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting cyclooxygenase (COX)-2-mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and  bbbbb1 rofecoxib eeeee1  bbbbb2 cyclooxygenase (COX)-2 eeeee2 -mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively
CRP11	IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 E-selectin eeeee2 , VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells
CRP11	IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 VEGF eeeee2 , and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells
CRP11	IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 IL-4 eeeee2  stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells
CRP11	IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 CXCL-8 eeeee2 , E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells
CRP11	IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  mRNA by equine pulmonary artery endothelial cells
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on  bbbbb2 CXCL-8 eeeee2 
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 vascular endothelial growth factor eeeee2  (VEGF), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and  bbbbb2 tumor necrosis factor-alpha eeeee2  (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 E-selectin eeeee2 , vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha ( bbbbb2 TNF-alpha eeeee2 ) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 VEGF eeeee2 ), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	L-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 CXCL-8 eeeee2 , E-selectin, vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8
CRP11	 bbbbb1 The eeeee1 se findin bbbbb2 gs s eeeee2 uggest that Th2-type cytokines may contribute to pulmonary neutrophilia during allergic inflammation by the increased expression of neutrophil chemokines and adhesion molecules by endothelial cells
CRP11	Dexamethasone ( bbbbb1 DXM eeeee1 ) decreased the expression of CXCL-8, VEGF, and iNOS induced by  bbbbb2 reIL-4 eeeee2 , while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone ( bbbbb1 DXM eeeee1 ) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and  bbbbb2 iNOS eeeee2 
CRP11	Dexamethasone ( bbbbb1 DXM eeeee1 ) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of  bbbbb2 E-selectin eeeee2 , VEGF, and iNOS
CRP11	Dexamethasone ( bbbbb1 DXM eeeee1 ) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin,  bbbbb2 VEGF eeeee2 , and iNOS
CRP11	Dexamethasone ( bbbbb1 DXM eeeee1 ) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of  bbbbb2 iNOS eeeee2 , decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  bbbbb1 1400W dihydrochloride eeeee1  bbbbb2 reIL-4 eeeee2 , while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  bbbbb1 1400W dihydrochloride eeeee1  bbbbb2 VEGF eeeee2 , and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  bbbbb1 1400W dihydrochloride eeeee1  bbbbb2 iNOS eeeee2  induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  bbbbb1 1400W dihydrochloride eeeee1  bbbbb2 CXCL-8 eeeee2 , VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	 bbbbb1 Dexamethasone eeeee1  (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by  bbbbb2 reIL-4 eeeee2 , while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	 bbbbb1 Dexamethasone eeeee1  (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and  bbbbb2 iNOS eeeee2 
CRP11	 bbbbb1 Dexamethasone eeeee1  (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of  bbbbb2 E-selectin eeeee2 , VEGF, and iNOS
CRP11	 bbbbb1 Dexamethasone eeeee1  (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin,  bbbbb2 VEGF eeeee2 , and iNOS
CRP11	 bbbbb1 Dexamethasone eeeee1  (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of  bbbbb2 iNOS eeeee2 , decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ( bbbbb1 1400W eeeee1  bbbbb2 reIL-4 eeeee2 , while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ( bbbbb1 1400W eeeee1  bbbbb2 VEGF eeeee2 , and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ( bbbbb1 1400W eeeee1  bbbbb2 iNOS eeeee2  induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ( bbbbb1 1400W eeeee1  bbbbb2 CXCL-8 eeeee2 , VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS
CRP11	DXM and  bbbbb1 1400W eeeee1  attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of  bbbbb2 reIL-4 eeeee2 , reTNF-alpha, and LPS
CRP11	DXM and  bbbbb1 1400W eeeee1  attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4,  bbbbb2 reTNF-alpha eeeee2 , and LPS
CRP11	 bbbbb1 DXM eeeee1  and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of  bbbbb2 reIL-4 eeeee2 , reTNF-alpha, and LPS
CRP11	 bbbbb1 DXM eeeee1  and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4,  bbbbb2 reTNF-alpha eeeee2 , and LPS
CRP11	Disposition and Metabolism of  bbbbb1 GSK2251052 eeeee1  in Humans: A Novel Boron-Containing Antibiotic. (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits  bbbbb2 bacterial leucyl tRNA synthetase eeeee2 , and that has been in development for the treatment of serious Gram-negative infections
CRP11	Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic. (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel  bbbbb1 boron eeeee1 -containing antibiotic that inhibits  bbbbb2 bacterial leucyl tRNA synthetase eeeee2 , and that has been in development for the treatment of serious Gram-negative infections
CRP11	Disposition and Metabolism of GSK2251052 in Humans: A Novel  bbbbb1 Boron eeeee1 -Containing Antibiotic. (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits  bbbbb2 bacterial leucyl tRNA synthetase eeeee2 , and that has been in development for the treatment of serious Gram-negative infections
CRP11	Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic. (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial  bbbbb1 leucyl eeeee1  bbbbb2 bacterial leucyl tRNA synthetase eeeee2 , and that has been in development for the treatment of serious Gram-negative infections
CRP11	Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioactivity elimination half-life bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioactivity elimination half-life bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioactivity elimination half-life bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioactivity elimination half-life bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioac bbbbb1 tivity eliminati eeeee1 on half-life bbbbb2  eeeee2 
CRP11	Herein, we determined that a  bbbbb1 fiveamino acid eeeee1  C-terminal deletion of  bbbbb2 LeuRS eeeee2 , which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner
CRP11	 bbbbb1 Leucyl eeeee1 -tRNA synthetase ( bbbbb2 LeuRS eeeee2 ) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria
CRP11	The x-ray co-crystal structure of LeuRS showed that a  bbbbb1 C eeeee1  bbbbb2 LeuRS eeeee2  showed that a C-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the LeuRSs and interacts with the corner of the L-shaped tRNALeu
CRP11	The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60  bbbbb1 amino acids eeeee1  bbbbb2 LeuRS eeeee2  showed that a C-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the LeuRSs and interacts with the corner of the L-shaped tRNALeu
CRP11	A soluble form of the enzyme, isolated from fetal bovine serum, showed bbbbb1  the  eeeee1 same subunit structure bbbbb2  eeeee2 
CRP11	A soluble form of the enzyme, isolated from fetal bovine serum, showed bbbbb1  the  eeeee1 same subunit structure bbbbb2  eeeee2 
CRP11	The data indicate that bovine phosphodiester alpha-GlcNAcase is a 272,000-Da complex of four identical 68,000-Da glycoprotein subunits arranged as two  bbbbb1 disulfide eeeee1  bbbbb2 phosphodiester alpha-GlcNAcase eeeee2  is a 272,000-Da complex of four identical 68,000-Da glycoprotein subunits arranged as two disulfide-linked homodimers
CRP11	The data indicate that bovine  bbbbb1 phosphodiester eeeee1  bbbbb2 phosphodiester alpha-GlcNAcase eeeee2  is a 272,000-Da complex of four identical 68,000-Da glycoprotein subunits arranged as two disulfide-linked homodimers
CRP11	Purification and multimeric structure of bovine N-acetylglucosamine-1-phosphodiester alpha- bbbbb1 N eeeee1  bbbbb2 N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase eeeee2 
CRP11	Purification and multimeric structure of bovine  bbbbb1 N-acetylglucosamine-1-phosphodiester eeeee1  bbbbb2 N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase eeeee2 
CRP11	 bbbbb1 N-Acetylglucosamine-1-phosphodiester eeeee1  bbbbb2 N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase eeeee2  (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	 bbbbb1 N-Acetylglucosamine-1-phosphodiester eeeee1  alpha-N-Acetylglucosaminidase ( bbbbb2 EC 3.1.4.45 eeeee2 ; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	 bbbbb1 N-Acetylglucosamine-1-phosphodiester eeeee1  alpha-N-Acetylglucosaminidase (EC 3.1.4.45;  bbbbb2 phosphodiester alpha-GlcNAcase eeeee2 ) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	N-Acetylglucosamine-1-phosphodiester alpha- bbbbb1 N eeeee1  bbbbb2 N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase eeeee2  (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	N-Acetylglucosamine-1-phosphodiester alpha- bbbbb1 N eeeee1 -Acetylglucosaminidase ( bbbbb2 EC 3.1.4.45 eeeee2 ; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	N-Acetylglucosamine-1-phosphodiester alpha- bbbbb1 N eeeee1 -Acetylglucosaminidase (EC 3.1.4.45;  bbbbb2 phosphodiester alpha-GlcNAcase eeeee2 ) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome
CRP11	The newly synthesized compounds were tested for their in vitro COX inhibition and in vivo carrageenan induced hind paw edema in rats and  bbbbb1 acetic acid eeeee1  bbbbb2 COX eeeee2  inhibition and in vivo carrageenan induced hind paw edema in rats and acetic acid induced vascular permeability in mice
CRP11	Effect of  bbbbb1 ifenprodil eeeee1  on GluN1/GluN2B  bbbbb2 N-methyl-D-aspartate receptor eeeee2  gating
CRP11	Effect of  bbbbb1 ifenprodil eeeee1  on GluN1/ bbbbb2 GluN2B eeeee2  N-methyl-D-aspartate receptor gating
CRP11	Effect of  bbbbb1 ifenprodil eeeee1  on  bbbbb2 GluN1 eeeee2 /GluN2B N-methyl-D-aspartate receptor gating
CRP11	Effect of ifenprodil on GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate receptor eeeee2  gating
CRP11	Effect of ifenprodil on GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 GluN2B eeeee2  N-methyl-D-aspartate receptor gating
CRP11	Effect of ifenprodil on GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 GluN1 eeeee2 /GluN2B N-methyl-D-aspartate receptor gating
CRP11	Interestingly, recent crystallographic evidence identified that ifenprodil, unlike  bbbbb1 zinc eeeee1 , binds at the interface of the  bbbbb2 GluN1 eeeee2 /GluN2B amino terminal domain dimer by an induced-fit mechanism
CRP11	Interestingly, recent crystallographic evidence identified that ifenprodil, unlike  bbbbb1 zinc eeeee1 , binds at the interface of the GluN1/ bbbbb2 GluN2B eeeee2  amino terminal domain dimer by an induced-fit mechanism
CRP11	We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of  bbbbb1 zinc eeeee1  bbbbb2 GluN2B eeeee2  in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites
CRP11	We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of  bbbbb1 zinc eeeee1  bbbbb2 GluN1 eeeee2 /GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites
CRP11	We found distinct differences in the action of  bbbbb1 ifenprodil eeeee1  at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/ bbbbb2 GluN2A eeeee2  gating, which may arise due to their unique binding sites
CRP11	We found distinct differences in the action of  bbbbb1 ifenprodil eeeee1  at GluN1/GluN2B in comparison with previous studies on the effect of zinc on  bbbbb2 GluN1 eeeee2 /GluN2A gating, which may arise due to their unique binding sites
CRP11	Ifenprodil is an allosteric inhibitor of GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 GluN1 eeeee2 /GluN2B N-methyl-D-aspartate receptors
CRP11	Ifenprodil is an allosteric inhibitor of GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 GluN2B eeeee2  N-methyl-D-aspartate receptors
CRP11	Ifenprodil is an allosteric inhibitor of GluN1/GluN2B  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate receptors eeeee2 
CRP11	Phosphatidylserine ( bbbbb1 PtdSer eeeee1 ) is made in mammalian cells by two PtdSer synthases,  bbbbb2 PSS1 eeeee2  and PSS2
CRP11	Phosphatidylserine ( bbbbb1 PtdSer eeeee1 ) is made in mammalian cells by two PtdSer synthases, PSS1 and  bbbbb2 PSS2 eeeee2 
CRP11	Phosphatidylserine ( bbbbb1 PtdSer eeeee1 ) is made in mammalian cells by two  bbbbb2 PtdSer synthases eeeee2 , PSS1 and PSS2
CRP11	Phosphatidylserine (PtdSer) is made in mammalian cells by two  bbbbb1 PtdSer eeeee1  synthases,  bbbbb2 PSS1 eeeee2  and PSS2
CRP11	Phosphatidylserine (PtdSer) is made in mammalian cells by two  bbbbb1 PtdSer eeeee1  synthases, PSS1 and  bbbbb2 PSS2 eeeee2 
CRP11	Phosphatidylserine (PtdSer) is made in mammalian cells by two  bbbbb1 PtdSer eeeee1  bbbbb2 PtdSer synthases eeeee2 , PSS1 and PSS2
CRP11	We induced apoptosis with  bbbbb1 staurosporine eeeee1  in four Chinese hamster ovary (CHO) cell lines that are deficient in PSS1 and/or  bbbbb2 PSS2 eeeee2  to determine if PtdSer generated by either of these enzymes is required for externalization on the cell surface during apoptosis
CRP11	We induced apoptosis with  bbbbb1 staurosporine eeeee1  in four Chinese hamster ovary (CHO) cell lines that are deficient in  bbbbb2 PSS1 eeeee2  and/or PSS2 to determine if PtdSer generated by either of these enzymes is required for externalization on the cell surface during apoptosis
CRP11	We induced apoptosis with staurosporine in four Chinese hamster ovary (CHO) cell lines that are deficient in PSS1 and/or PSS2 to determine if  bbbbb1 PtdSer eeeee1  bbbbb2 PSS2 eeeee2  to determine if PtdSer generated by either of these enzymes is required for externalization on the cell surface during apoptosis
CRP11	We induced apoptosis with staurosporine in four Chinese hamster ovary (CHO) cell lines that are deficient in PSS1 and/or PSS2 to determine if  bbbbb1 PtdSer eeeee1  bbbbb2 PSS1 eeeee2  and/or PSS2 to determine if PtdSer generated by either of these enzymes is required for externalization on the cell surface during apoptosis
CRP11	Externalization of  bbbbb1 phosphatidylserine eeeee1  during apoptosis does not specifically require either isoform of  bbbbb2 phosphatidylserine synthase eeeee2 
CRP11	Externalization of phosphatidylserine during apoptosis does not specifically require either isoform of  bbbbb1 phosphatidylserine eeeee1  bbbbb2 phosphatidylserine synthase eeeee2 
CRP11	Cells that were deficient in either PSS1 or PSS2, as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of  bbbbb1 PtdSer eeeee1  bbbbb2 PSS1 eeeee2  and PSS2, externalized normal amounts of PtdSer
CRP11	Cells that were deficient in either PSS1 or PSS2, as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of  bbbbb1 PtdSer eeeee1  bbbbb2 PSS2 eeeee2 , as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of PtdSer
CRP11	Cells that were deficient in either PSS1 or PSS2, as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of  bbbbb1 PtdSer eeeee1  bbbbb2 PSS1 eeeee2  or PSS2, as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of PtdSer
CRP11	Cells that were deficient in either PSS1 or PSS2, as well as cells that were deficient in both PSS1 and PSS2, externalized normal amounts of  bbbbb1 PtdSer eeeee1  bbbbb2 PSS2 eeeee2 , externalized normal amounts of PtdSer
CRP11	Inhibition of HSD11B1 activity in utero prevented conceptus elongation, whereas IFNT rescu bbbbb1 ed conceptus eeeee1  bbbbb2 ity in  eeeee2 utero prevented conceptus elongation, whereas IFNT rescued conceptus elongation in PF-infused ewes
CRP11	Inhibition of HSD11B1 activity in utero prevented conceptus elongation, whereas IFNT rescu bbbbb1 ed conceptus eeeee1  elongation in PF-infused ewes bbbbb2  eeeee2 
CRP11	Inhibition of HSD11B1 activity in utero prevented conceptus elongation, whereas IFNT rescued conceptus elongation in PF-infused ewes bbbbb1  eeeee1  bbbbb2 ity in  eeeee2 utero prevented conceptus elongation, whereas IFNT rescued conceptus elongation in PF-infused ewes
CRP11	Inhibition of HSD11B1 activity in utero prevented conceptus elongation, whereas IFNT rescued conceptus elongation in PF-infused ewes bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Inhibition of HSD11B1 activity in utero pre bbbbb1 vented c eeeee1 onceptus elongation, whereas IFNT rescued conceptus elongation in PF-infused ewes bbbbb2  eeeee2 
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce  bbbbb1 prostaglandins eeeee1  (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 ( bbbbb2 HSD11B1 eeeee2 )
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce  bbbbb1 prostaglandins eeeee1  bbbbb2 interferon-τ eeeee2  (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce  bbbbb1 prostaglandins eeeee1  bbbbb2 IFNT eeeee2 ) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce  bbbbb1 prostaglandins eeeee1  (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb2 hydroxysteroid (11-β) dehydrogenase 1 eeeee2  (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  (11-β) dehydrogenase 1 ( bbbbb2 HSD11B1 eeeee2 )
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  bbbbb2 interferon-τ eeeee2  (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  bbbbb2 IFNT eeeee2 ) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  bbbbb2 hydroxysteroid (11-β) dehydrogenase 1 eeeee2  (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  bbbbb2 PTGS2 eeeee2 ) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via  bbbbb1 hydroxysteroid eeeee1  bbbbb2 PG synthase 2 eeeee2  (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  bbbbb1 cortisol eeeee1  bbbbb2 interferon-τ eeeee2  (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  bbbbb1 cortisol eeeee1  bbbbb2 IFNT eeeee2 ) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  bbbbb1 cortisol eeeee1  bbbbb2 PTGS2 eeeee2 ) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  bbbbb1 cortisol eeeee1  bbbbb2 PG synthase 2 eeeee2  (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1)
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2),  bbbbb1 cortisol eeeee1  bbbbb2 PTGS2 eeeee2 ), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2),  bbbbb1 cortisol eeeee1  and meloxicam, recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2),  bbbbb1 cortisol eeeee1  and meloxicam, recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2),  bbbbb1 cortisol eeeee1  bbbbb2 HSD11B1 eeeee2 ), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol,  bbbbb1 PF 915275 eeeee1  (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of  bbbbb2 PTGS2 eeeee2 ), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol,  bbbbb1 PF 915275 eeeee1  (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol,  bbbbb1 PF 915275 eeeee1  (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF,  bbbbb1 meloxicam eeeee1  (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF,  bbbbb1 meloxicam eeeee1  (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF,  bbbbb1 meloxicam eeeee1  bbbbb2 HSD11B1 eeeee2 ), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1),  bbbbb1 cortisol eeeee1  and PF, meloxicam (a selective inhibitor of  bbbbb2 PTGS2 eeeee2 ), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1),  bbbbb1 cortisol eeeee1  and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1),  bbbbb1 cortisol eeeee1  and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1),  bbbbb1 cortisol eeeee1  bbbbb2 HSD11B1 eeeee2 ), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and  bbbbb1 meloxicam eeeee1  bbbbb2 PTGS2 eeeee2 ), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and  bbbbb1 meloxicam eeeee1 , recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and  bbbbb1 meloxicam eeeee1 , recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and  bbbbb1 meloxicam eeeee1  bbbbb2 HSD11B1 eeeee2 ), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle,  bbbbb1 cortisol eeeee1 , PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of  bbbbb2 PTGS2 eeeee2 ), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle,  bbbbb1 cortisol eeeee1 , PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant  bbbbb2 ovine IFNT eeeee2 , or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle,  bbbbb1 cortisol eeeee1 , PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or  bbbbb2 IFNT eeeee2  and PF into the uterus from day 10 to day14 after estrus
CRP11	In study 1, cyclic ewes received vehicle,  bbbbb1 cortisol eeeee1 , PF 915275 (PF; a selective inhibitor of  bbbbb2 HSD11B1 eeeee2 ), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus
CRP11	 bbbbb1 Cortisol eeeee1  and  bbbbb2 IFNT eeeee2  stimulated endometrial HSD11B1 expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium
CRP11	Some effects of  bbbbb1 cortisol eeeee1  and IFNT were mediated by  bbbbb2 PTGS2 eeeee2 -derived PG
CRP11	Some effects of  bbbbb1 cortisol eeeee1  and  bbbbb2 IFNT eeeee2  were mediated by PTGS2-derived PG
CRP11	In study 2, bred ewes received  bbbbb1 PF 915275 eeeee1  or recombinant  bbbbb2 ovine IFNT eeeee2  and into the uterus from day 10 to day 14 after mating
CRP11	Ovarian progesterone induces and PG and IFNT stimulates endometrial HSD11B1 expression and  bbbbb1 keto eeeee1  bbbbb2 keto-reductase eeeee2  activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Ovarian progesterone induces and PG and IFNT stimulates endometrial HSD11B1 expression and  bbbbb1 keto eeeee1  bbbbb2 IFNT eeeee2  stimulates endometrial HSD11B1 expression and keto-reductase activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Ovarian progesterone induces and PG and IFNT stimulates endometrial HSD11B1 expression and  bbbbb1 keto eeeee1  bbbbb2 HSD11B1 eeeee2  expression and keto-reductase activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Ovarian  bbbbb1 progesterone eeeee1  induces and PG and IFNT stimulates endometrial HSD11B1 expression and  bbbbb2 keto-reductase eeeee2  activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Ovarian  bbbbb1 progesterone eeeee1  induces and PG and  bbbbb2 IFNT eeeee2  stimulates endometrial HSD11B1 expression and keto-reductase activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Ovarian  bbbbb1 progesterone eeeee1  induces and PG and IFNT stimulates endometrial  bbbbb2 HSD11B1 eeeee2  expression and keto-reductase activity as well as many epithelial genes that govern trophectoderm proliferation, migration, and attachment during elongation
CRP11	Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while  bbbbb1 TDCPP eeeee1  bbbbb2 cytochrome P450 (CYP) 3A37 eeeee2  mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1
CRP11	Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while  bbbbb1 TDCPP eeeee1  bbbbb2 Type I deiodinase eeeee2 , liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1
CRP11	Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while  bbbbb1 TDCPP eeeee1  bbbbb2 liver fatty-acid binding protein eeeee2  and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1
CRP11	Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by  bbbbb1 TCPP eeeee1 , while TDCPP induced  bbbbb2 CYP3A37 eeeee2  and CYP2H1
CRP11	Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by  bbbbb1 TCPP eeeee1 , while TDCPP induced CYP3A37 and  bbbbb2 CYP2H1 eeeee2 
CRP11	 bbbbb1 Testosterone eeeee1 -to-estradiol ratio levels in infertile men improve during treatment with the  bbbbb2 aromatase eeeee2  inhibitor, testolactone, and resulting changes in semen parameters
CRP11	Testosterone-to- bbbbb1 estradiol eeeee1  ratio levels in infertile men improve during treatment with the  bbbbb2 aromatase eeeee2  inhibitor, testolactone, and resulting changes in semen parameters
CRP11	NS: Men who are infertile with a low serum testosterone-to- bbbbb1 estradiol eeeee1  ratio can be treated with an  bbbbb2 aromatase eeeee2  inhibitor
CRP11	NS: Men who are infertile with a low serum  bbbbb1 testosterone eeeee1 -to-estradiol ratio can be treated with an  bbbbb2 aromatase eeeee2  inhibitor
CRP11	Several PIs have been implicated to activate the nuclear receptor  bbbbb1 pregnane eeeee1  X receptor ( bbbbb2 PXR eeeee2 ), which acts as a xenobiotic sensor to regulate xenobiotic metabolism in the liver and intestine
CRP11	Several PIs have been implicated to activate the nuclear receptor  bbbbb1 pregnane eeeee1  bbbbb2 pregnane X receptor eeeee2  (PXR), which acts as a xenobiotic sensor to regulate xenobiotic metabolism in the liver and intestine
CRP11	Short-term exposure to amprenavir significantly increased plasma total  bbbbb1 cholesterol eeeee1  and atherogenic low-density lipoprotein cholesterol levels in wild-type mice, but not in  bbbbb2 PXR eeeee2 -deficient mice
CRP11	Short-term exposure to amprenavir significantly increased plasma total cholesterol and atherogenic low-density lipoprotein  bbbbb1 cholesterol eeeee1  levels in wild-type mice, but not in  bbbbb2 PXR eeeee2 -deficient mice
CRP11	Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor  bbbbb1 Amprenavir eeeee1  bbbbb2 Pregnane X Receptor eeeee2  Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice
CRP11	 bbbbb1 Pregnane eeeee1  X Receptor Mediates Dyslipidemia Induced by the  bbbbb2 HIV Protease eeeee2  Inhibitor Amprenavir in Mice
CRP11	 bbbbb1 Pregnane eeeee1  bbbbb2 Pregnane X Receptor eeeee2  Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice
CRP11	Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced  bbbbb1 U50,488H eeeee1  bbbbb2 arrestin-2 eeeee2 (319-418) or dynamin I-K44A significantly reduced U50,488H-induced down-regulation of the hkor
CRP11	Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced  bbbbb1 U50,488H eeeee1  bbbbb2 dynamin I eeeee2 -K44A significantly reduced U50,488H-induced down-regulation of the hkor
CRP11	Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced  bbbbb1 U50,488H eeeee1  bbbbb2 K44A eeeee2  significantly reduced U50,488H-induced down-regulation of the hkor
CRP11	A combination of chloroquine and proteasome inhibitor I abolished  bbbbb1 U50,488H eeeee1  bbbbb2 proteasome eeeee2  inhibitor I abolished U50,488H-induced down-regulation
CRP11	A combination of  bbbbb1 chloroquine eeeee1  and  bbbbb2 proteasome eeeee2  inhibitor I abolished U50,488H-induced down-regulation
CRP11	Coexpression of GRK2 or GRK2 and arrestin-2 permitted  bbbbb1 etorphine eeeee1  bbbbb2 arrestin-2 eeeee2  permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not
CRP11	Coexpression of GRK2 or GRK2 and arrestin-2 permitted  bbbbb1 etorphine eeeee1  bbbbb2 GRK2 eeeee2  or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not
CRP11	Coexpression of GRK2 or GRK2 and arrestin-2 permitted  bbbbb1 etorphine eeeee1  to induce down-regulation of the hkor, although expression of  bbbbb2 arrestin-2 eeeee2  or dynamin I alone did not
CRP11	Coexpression of GRK2 or GRK2 and arrestin-2 permitted  bbbbb1 etorphine eeeee1  to induce down-regulation of the hkor, although expression of arrestin-2 or  bbbbb2 dynamin I eeeee2  alone did not
CRP11	Coexpression of GRK2 or GRK2 and arrestin-2 permitted  bbbbb1 etorphine eeeee1  bbbbb2 GRK2 eeeee2  and arrestin-2 permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves GRK-, arrestin-2-,  bbbbb2 dynamin eeeee2 -, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves GRK-, arrestin-2-, dynamin-, rab5-, and  bbbbb2 rab7 eeeee2 -dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves  bbbbb2 GRK eeeee2 -, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and  bbbbb2 proteasomes eeeee2  for degradation
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves GRK-, arrestin-2-, dynamin-,  bbbbb2 rab5 eeeee2 -, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation
CRP11	These results indicate that  bbbbb1 U50,488H eeeee1 -induced down-regulation of the hkor involves GRK-,  bbbbb2 arrestin-2 eeeee2 -, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation
CRP11	Pretreatment with lysosomal enzyme inhibitors  bbbbb1 [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] eeeee1  or proteasome inhibitors ( bbbbb2 proteasome eeeee2  inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	Pretreatment with lysosomal enzyme inhibitors  bbbbb1 [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] eeeee1  or  bbbbb2 proteasome eeeee2  inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of  bbbbb1 U50,488H eeeee1  bbbbb2 proteasome eeeee2  inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of  bbbbb1 U50,488H eeeee1  bbbbb2 proteasome eeeee2  inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or  bbbbb1 lactacystin eeeee1  bbbbb2 proteasome eeeee2  inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I,  bbbbb1 MG-132 eeeee1  bbbbb2 proteasome eeeee2  inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but  bbbbb1 clenbuterol eeeee1  bbbbb2 beta(1)-Adrenoceptor eeeee2  antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but  bbbbb1 clenbuterol eeeee1 -induced apoptosis could also be prevented by 96% (P < 0.05) by  bbbbb2 beta(2)-AR eeeee2  antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and  bbbbb1 clenbuterol eeeee1 , 0.4 +/- 0.07%; P < 0.05).  bbbbb2 beta(1)-Adrenoceptor eeeee2  antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and  bbbbb1 clenbuterol eeeee1 , 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by  bbbbb2 beta(2)-AR eeeee2  antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis ( bbbbb1 fenoterol eeeee1 , 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05).  bbbbb2 beta(1)-Adrenoceptor eeeee2  antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis ( bbbbb1 fenoterol eeeee1 , 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by  bbbbb2 beta(2)-AR eeeee2  antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1)  bbbbb1 bisoprolol eeeee1 ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by  bbbbb2 beta(2)-AR eeeee2  antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%;  bbbbb1 isoprenaline eeeee1 , 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05).  bbbbb2 beta(1)-Adrenoceptor eeeee2  antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)
CRP11	At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%;  bbbbb1 isoprenaline eeeee1 , 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by  bbbbb2 beta(2)-AR eeeee2  antagonism (10 mg kg(-1) ICI 118 551)
CRP11	Dabrafenib is a BRAF (gene encoding serine/ bbbbb1 threonine eeeee1  bbbbb2 serine/threonine-protein kinase B-Raf eeeee2 ) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/ bbbbb1 threonine eeeee1 -protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF( bbbbb2 V600E eeeee2 )), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/ bbbbb1 threonine eeeee1 -protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb2 valine 600 to glutamic acid eeeee2  substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/ bbbbb1 threonine eeeee1 -protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution ( bbbbb2 BRAF eeeee2 (V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/ bbbbb1 threonine eeeee1  bbbbb2 BRAF eeeee2  (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb1 valine eeeee1  bbbbb2 serine/threonine-protein kinase B-Raf eeeee2 ) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb1 valine eeeee1  600 to glutamic acid substitution (BRAF( bbbbb2 V600E eeeee2 )), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb1 valine eeeee1  bbbbb2 valine 600 to glutamic acid eeeee2  substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb1 valine eeeee1  bbbbb2 BRAF eeeee2  (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding  bbbbb1 serine eeeee1  bbbbb2 serine/threonine-protein kinase B-Raf eeeee2 ) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding  bbbbb1 serine eeeee1 /threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF( bbbbb2 V600E eeeee2 )), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding  bbbbb1 serine eeeee1 /threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the  bbbbb2 valine 600 to glutamic acid eeeee2  substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding  bbbbb1 serine eeeee1 /threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution ( bbbbb2 BRAF eeeee2 (V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding  bbbbb1 serine eeeee1  bbbbb2 BRAF eeeee2  (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to  bbbbb1 glutamic acid eeeee1  bbbbb2 serine/threonine-protein kinase B-Raf eeeee2 ) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to  bbbbb1 glutamic acid eeeee1  substitution (BRAF( bbbbb2 V600E eeeee2 )), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to  bbbbb1 glutamic acid eeeee1  bbbbb2 valine 600 to glutamic acid eeeee2  substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to  bbbbb1 glutamic acid eeeee1  bbbbb2 BRAF eeeee2  (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma
CRP11	Thus, the objective of the current study was to evaluate the brain distribution of  bbbbb1 dabrafenib eeeee1  in mice, and to see whether active efflux by P-glycoprotein (P-gp) and breast cancer resistance protein ( bbbbb2 BCRP eeeee2 ) restricts its delivery across the blood-brain barrier (BBB)
CRP11	Thus, the objective of the current study was to evaluate the brain distribution of  bbbbb1 dabrafenib eeeee1  in mice, and to see whether active efflux by P-glycoprotein (P-gp) and  bbbbb2 breast cancer resistance protein eeeee2  (BCRP) restricts its delivery across the blood-brain barrier (BBB)
CRP11	Thus, the objective of the current study was to evaluate the brain distribution of  bbbbb1 dabrafenib eeeee1  in mice, and to see whether active efflux by  bbbbb2 P-glycoprotein eeeee2  (P-gp) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB)
CRP11	Thus, the objective of the current study was to evaluate the brain distribution of  bbbbb1 dabrafenib eeeee1  in mice, and to see whether active efflux by P-glycoprotein ( bbbbb2 P-gp eeeee2 ) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB)
CRP11	 bbbbb1 Dabrafenib eeeee1  plasma exposure was ∼2-fold greater in  bbbbb2 Mdr1 a/b eeeee2 (-/-)Bcrp1(-/-) mice as compared with wild-type with an oral dose (25 mg/kg); however, the brain distribution was increased by ~10-fold with a resulting K(p) of 0.25
CRP11	 bbbbb1 Dabrafenib eeeee1  plasma exposure was ∼2-fold greater in Mdr1 a/b(-/-) bbbbb2 Bcrp1 eeeee2 (-/-) mice as compared with wild-type with an oral dose (25 mg/kg); however, the brain distribution was increased by ~10-fold with a resulting K(p) of 0.25
CRP11	In vivo, the ratio of area under the concentration-time curve (AUC)(brain) to AUC(plasma) (K(p)) of  bbbbb1 dabrafenib eeeee1  after an i.v. dose (2.5 mg/kg) was 0.023, which increased by 18-fold in  bbbbb2 Mdr1 a/b eeeee2 (-/-)Bcrp1(-/-) mice to 0.42
CRP11	In vivo, the ratio of area under the concentration-time curve (AUC)(brain) to AUC(plasma) (K(p)) of  bbbbb1 dabrafenib eeeee1  after an i.v. dose (2.5 mg/kg) was 0.023, which increased by 18-fold in Mdr1 a/b(-/-) bbbbb2 Bcrp1 eeeee2 (-/-) mice to 0.42
CRP11	Mechanisms limiting distribution of the  bbbbb1 threonine eeeee1 -protein kinase B-RaF( bbbbb2 V600E eeeee2 ) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases
CRP11	Mechanisms limiting distribution of the  bbbbb1 threonine eeeee1  bbbbb2 threonine-protein kinase B-RaF eeeee2 (V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases
CRP11	 bbbbb1 Triacsin C eeeee1 , a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive  bbbbb2 ACS eeeee2  is present in mitochondria
CRP11	Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified  bbbbb1 triacsin eeeee1  bbbbb2 ACS4 eeeee2 , inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria
CRP11	Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified  bbbbb1 triacsin eeeee1  bbbbb2 ACS eeeee2  activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria
CRP11	Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified  bbbbb1 triacsin eeeee1  bbbbb2 ACS1 eeeee2  and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria
CRP11	These results suggest that ACS1 and AC bbbbb1 S4 may be eeeee1  linked to triacylglycerol synthesis bbbbb2  eeeee2 
CRP11	 bbbbb1 Acyl-CoA eeeee1  bbbbb2 Acyl-CoA synthetase isoforms 1, 4, and 5 eeeee2  are present in different subcellular membranes in rat liver and can be inhibited independently
CRP11	Inhibition studies have suggested that  bbbbb1 acyl-CoA eeeee1  bbbbb2 acyl-CoA synthetase eeeee2  (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways
CRP11	Inhibition studies have suggested that  bbbbb1 acyl-CoA eeeee1  synthetase ( bbbbb2 ACS eeeee2 , EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways
CRP11	Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of  bbbbb1 acyl-CoAs eeeee1  bbbbb2 acyl-CoA synthetase eeeee2  (ACS, EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways
CRP11	Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC ) isoforms might regulate the use of  bbbbb1 acyl-CoAs eeeee1  bbbbb2 ACS eeeee2 , EC ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways
CRP11	We report the results of a double-blind, randomized prospective trial on D2 and 5-HT2 receptor occupancy and the clinical effects of olanzapine versus  bbbbb1 clozapine eeeee1  bbbbb2 D2 and 5-HT2 receptor eeeee2  occupancy and the clinical effects of olanzapine versus clozapine in a sample of neuroleptic-refractory schizophrenic patients
CRP11	We report the results of a double-blind, randomized prospective trial on D2 and 5-HT2 receptor occupancy and the clinical effects of  bbbbb1 olanzapine eeeee1  bbbbb2 D2 and 5-HT2 receptor eeeee2  occupancy and the clinical effects of olanzapine versus clozapine in a sample of neuroleptic-refractory schizophrenic patients
CRP11	Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with  bbbbb1 olanzapine eeeee1  bbbbb2 D2 and 5-HT2 receptor eeeee2  occupancy in Schizophrenic patients treated with olanzapine or clozapine
CRP11	Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or  bbbbb1 clozapine eeeee1  bbbbb2 D2 and 5-HT2 receptor eeeee2  occupancy in Schizophrenic patients treated with olanzapine or clozapine
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST- bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST- bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione ( bbbbb1 GSH eeeee1  bbbbb2 GST-4 eeeee2 -HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione ( bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione ( bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal  bbbbb1 glutathione eeeee1  bbbbb2 GST-4 eeeee2 -HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal  bbbbb1 glutathione eeeee1  bbbbb2 hGSTA4 eeeee2  vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	G2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal  bbbbb1 glutathione eeeee1  bbbbb2 hGSTA4 eeeee2  mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells
CRP11	Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of  bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE
CRP11	Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive  bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE
CRP11	Specifically, hGSTA4 cells had significantly higher  bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury.  bbbbb1 4-Hydroxynonenal eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione  bbbbb1 S eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione  bbbbb1 S eeeee1 -transferase ( bbbbb2 GST eeeee2 ) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal ( bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against  bbbbb1 4-hydroxynonenal eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against  bbbbb1 4-hydroxynonenal eeeee1 -mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ( bbbbb2 GST eeeee2 ) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against  bbbbb1 4-hydroxynonenal eeeee1 -mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  bbbbb2 glutathione S-transferase eeeee2  (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  bbbbb1 glutathione eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  bbbbb1 glutathione eeeee1  S-transferase ( bbbbb2 GST eeeee2 ) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST) isoforms
CRP11	Transfection of HepG2 cells with hGSTA4 provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic  bbbbb1 alpha,beta-unsaturated aldehyde eeeee1  bbbbb2 hGSTA4 eeeee2  provides protection against 4-hydroxynonenal-mediated oxidative injury. 4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms
CRP11	However, hGST4-4 expression is low in most human cells and there are other  bbbbb1 aldehyde eeeee1  bbbbb2 hGST4-4 eeeee2  expression is low in most human cells and there are other aldehyde metabolizing enzymes that detoxify 4-HNE
CRP11	However, hGST4-4 expression is low in most human cells and there are other aldehyde metabolizing enzymes that detoxify  bbbbb1 4-HNE eeeee1  bbbbb2 hGST4-4 eeeee2  expression is low in most human cells and there are other aldehyde metabolizing enzymes that detoxify 4-HNE
CRP11	However, the hGSTA4 cells did not exhibit a growth advantage relative to control cells at higher 4-HNE exposures associated with increased  bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  cells did not exhibit a growth advantage relative to control cells at higher 4-HNE exposures associated with increased GSH utilization
CRP11	However, the hGSTA4 cells did not exhibit a growth advantage relative to control cells at higher  bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  cells did not exhibit a growth advantage relative to control cells at higher 4-HNE exposures associated with increased GSH utilization
CRP11	The hGSTA4 cells exhibited a significant growth advantage relative to control cells in the absence of 4-HNE, and a trend towards increased growth at low dose exposures to  bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  cells exhibited a significant growth advantage relative to control cells in the absence of 4-HNE, and a trend towards increased growth at low dose exposures to 4-HNE
CRP11	The hGSTA4 cells exhibited a significant growth advantage relative to control cells in the absence of  bbbbb1 4-HNE eeeee1  bbbbb2 hGSTA4 eeeee2  cells exhibited a significant growth advantage relative to control cells in the absence of 4-HNE, and a trend towards increased growth at low dose exposures to 4-HNE
CRP11	Exposure to 4-HNE elicited an increase in GSH concentrations in the control and hGSTA4 cells, although the dose-response of  bbbbb1 GSH eeeee1  bbbbb2 hGSTA4 eeeee2  cells, although the dose-response of GSH induction differed among the two cell types
CRP11	Exposure to 4-HNE elicited an increase in  bbbbb1 GSH eeeee1  concentrations in the control and  bbbbb2 hGSTA4 eeeee2  cells, although the dose-response of GSH induction differed among the two cell types
CRP11	Exposure to  bbbbb1 4-HNE eeeee1  elicited an increase in GSH concentrations in the control and  bbbbb2 hGSTA4 eeeee2  cells, although the dose-response of GSH induction differed among the two cell types
CRP11	In summary, our data indicates that over-expression of hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to H bbbbb1 epG2 cel eeeee1  bbbbb2 sion o eeeee2 f hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury
CRP11	In summary, our data indicates that over-expression of hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE  bbbbb1 oxi eeeee1  bbbbb2 sion o eeeee2 f hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury
CRP11	In summary, our data indicates that over-expression of hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury bbbbb1  eeeee1  bbbbb2 sion o eeeee2 f hGSTA4 at levels conferring high GST-4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury
CRP11	Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that escitalopram binds with high affinity to the human  bbbbb1 serotonin eeeee1  bbbbb2 human serotonin transporter eeeee2 
CRP11	Preclinical studies demonstrate that the therapeutic activity of  bbbbb1 citalopram eeeee1  resides in the S-isomer and that escitalopram binds with high affinity to the  bbbbb2 human serotonin transporter eeeee2 
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist  bbbbb1 SCH 39166 eeeee1  ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of  bbbbb1 dimethocaine eeeee1  (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of  bbbbb1 dimethocaine eeeee1  (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist  bbbbb1 raclopride eeeee1  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  bbbbb1 dopamine eeeee1  D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ( bbbbb1 (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine eeeee1 ) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and  bbbbb1 cocaine eeeee1  (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and  bbbbb1 cocaine eeeee1  (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for  bbbbb1 cocaine eeeee1  were administered in combination with the  bbbbb2 dopamine D1 receptor eeeee2  antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for  bbbbb1 cocaine eeeee1  were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  bbbbb2 dopamine D2 receptor eeeee2  antagonist raclopride (both at 0.003-0.03 mg/kg)
CRP11	It has been suggested that the affinity of these compounds for a site on the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2 , and not their local anesthetic actions, is responsible for these abuse-related behavioral effects
CRP11	Inhibitors of the Janus protein  bbbbb1 tyrosine eeeee1  bbbbb2 Janus protein tyrosine kinase (JAK)-3 eeeee2  show some selectivity for cells of the lymphoid lineage and have been shown to be effective in late preclinical transplant models
CRP11	Fingolimod (FTY720), a synthetic  bbbbb1 sphingosine phosphate eeeee1  bbbbb2 sphingosine phosphate receptor eeeee2  modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic  bbbbb1 malononitrilamide eeeee1  bbbbb2 JAK3 eeeee2  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials. bbbbb1 FK778 eeeee1  bbbbb2 JAK3 eeeee2  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis,  bbbbb1 dihydroorotic acid eeeee1  dehydrogenase, and  bbbbb2 receptor-associated tyrosine kinases eeeee2  has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis,  bbbbb1 dihydroorotic acid eeeee1  bbbbb2 JAK3 eeeee2  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis,  bbbbb1 dihydroorotic acid eeeee1  bbbbb2 dihydroorotic acid dehydrogenase eeeee2 , and receptor-associated tyrosine kinases has completed phase II trials
CRP11	 bbbbb1 CP-690550 eeeee1 , a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and  bbbbb2 receptor-associated tyrosine kinases eeeee2  has completed phase II trials
CRP11	 bbbbb1 CP-690550 eeeee1 , a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis,  bbbbb2 dihydroorotic acid dehydrogenase eeeee2 , and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo  bbbbb1 pyrimidine eeeee1  synthesis, dihydroorotic acid dehydrogenase, and  bbbbb2 receptor-associated tyrosine kinases eeeee2  has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo  bbbbb1 pyrimidine eeeee1  bbbbb2 JAK3 eeeee2  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo  bbbbb1 pyrimidine eeeee1  synthesis,  bbbbb2 dihydroorotic acid dehydrogenase eeeee2 , and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated  bbbbb1 tyrosine eeeee1  bbbbb2 receptor-associated tyrosine kinases eeeee2  has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated  bbbbb1 tyrosine eeeee1  bbbbb2 JAK3 eeeee2  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials
CRP11	CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated  bbbbb1 tyrosine eeeee1  bbbbb2 dihydroorotic acid dehydrogenase eeeee2 , and receptor-associated tyrosine kinases has completed phase II trials
CRP11	NS: We conclude that the majority of dif bbbbb1 ferentiated  eeeee1 thyroid cancers (74%) express TP and low levels of TS (63% undetectable) bbbbb2  eeeee2 
CRP11	NS: We conclude that the majority of dif bbbbb1 ferentiated  eeeee1 thyroid cancers (74%) express TP and low levels of TS (63% undetectable) bbbbb2  eeeee2 
CRP11	NS: We conclude that the majority of dif bbbbb1 ferentiated  eeeee1 thyroid cancers (74%) express TP and low levels of TS (63% undetectable) bbbbb2  eeeee2 
CRP11	The fluoropyrimidine carbamate ( bbbbb1 capecitabine eeeee1 ) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate ( bbbbb1 capecitabine eeeee1 ) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate ( bbbbb1 capecitabine eeeee1 ) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate ( bbbbb1 capecitabine eeeee1 ) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  bbbbb2 TP eeeee2 ) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb1 dihydropyrimidine eeeee1  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( bbbbb1 5-FU eeeee1 ) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( bbbbb1 5-FU eeeee1 ) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( bbbbb1 5-FU eeeee1 ) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( bbbbb1 5-FU eeeee1 ) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  phosphorylase ( bbbbb2 TP eeeee2 ) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by  bbbbb1 thymidine eeeee1  phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  bbbbb2 TP eeeee2 ) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb1 thymidylate eeeee1  synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.  bbbbb1 5-FU eeeee1  interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.  bbbbb1 5-FU eeeee1  bbbbb2 TP eeeee2 ) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.  bbbbb1 5-FU eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.  bbbbb1 5-FU eeeee1  interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to  bbbbb1 5-fluorouracil eeeee1  (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to  bbbbb1 5-fluorouracil eeeee1  (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to  bbbbb1 5-fluorouracil eeeee1  (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The fluoropyrimidine carbamate (capecitabine) is converted to  bbbbb1 5-fluorouracil eeeee1  (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	The  bbbbb1 fluoropyrimidine carbamate eeeee1  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase ( bbbbb2 TS eeeee2 ) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The  bbbbb1 fluoropyrimidine carbamate eeeee1  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ( bbbbb2 DPD eeeee2 )
CRP11	The  bbbbb1 fluoropyrimidine carbamate eeeee1  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking  bbbbb2 thymidylate synthase eeeee2  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)
CRP11	The  bbbbb1 fluoropyrimidine carbamate eeeee1  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues. 5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by  bbbbb2 dihydropyrimidine dehydrogenase eeeee2  (DPD)
CRP11	Only five tumors failed to express TP but four of these expressed DPD, suggesting  bbbbb1 capecitabine eeeee1  bbbbb2 TP eeeee2  but four of these expressed DPD, suggesting capecitabine resistance
CRP11	The beta 1- and beta 2-adrenoceptor blocking properties of orally administered  bbbbb1 R- and S-timolol eeeee1  bbbbb2 beta 1- and beta 2-adrenoceptor eeeee2  blocking properties of orally administered R- and S-timolol were compared in a double-blind placebo controlled trial in two groups of healthy men
CRP11	Therapeutic interventions that block the renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases
CRP11	Therapeutic interventions that block the renin- bbbbb1 angiotensin eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases
CRP11	Therapeutic interventions that block the renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases
CRP11	Therapeutic interventions that block the renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases
CRP11	Clinical trials have demonstrated that candesartan is well tolerated in combination with diuretics or  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  blockers (CCBs), making it a suitable treatment option for patients whose hypertension is not adequately controlled by monotherapy
CRP11	In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin receptor eeeee2  blockers (ARBs) have emerged as effective and well-tolerated alternatives to an angiotensin-converting enzyme inhibitor (ACEi) for RAAS blockade
CRP11	In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor (ACEi) for RAAS blockade
CRP11	In recent years,  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin receptor eeeee2  blockers (ARBs) have emerged as effective and well-tolerated alternatives to an angiotensin-converting enzyme inhibitor (ACEi) for RAAS blockade
CRP11	In recent years,  bbbbb1 angiotensin eeeee1  receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor (ACEi) for RAAS blockade
CRP11	GS: Compared with other ARBs, candesartan demonstrates the strongest binding affinity to the  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II type 1 receptor eeeee2 
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls  bbbbb1 fatty acid eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls  bbbbb1 fatty acid eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls  bbbbb1 fatty acid eeeee1  homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3- bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls  bbbbb1 fatty acid eeeee1  homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting.  bbbbb2 cAspAT eeeee2  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione ( bbbbb1 TZD eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione ( bbbbb1 TZD eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione ( bbbbb1 TZD eeeee1  bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting  bbbbb1 glycerol 3-phosphate eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting  bbbbb1 glycerol 3-phosphate eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting  bbbbb1 glycerol 3-phosphate eeeee1  formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3- bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting  bbbbb1 glycerol 3-phosphate eeeee1  formation for fatty acid re-esterification during fasting.  bbbbb2 cAspAT eeeee2  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic  bbbbb1 aspartate eeeee1  aminotransferase ( bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic  bbbbb1 aspartate eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic  bbbbb1 aspartate eeeee1  aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3- bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic  bbbbb1 aspartate eeeee1  aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting.  bbbbb2 cAspAT eeeee2  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD)  bbbbb1 rosiglitazone eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD)  bbbbb1 rosiglitazone eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD)  bbbbb1 rosiglitazone eeeee1  bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for  bbbbb1 fatty acid eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for  bbbbb1 fatty acid eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for  bbbbb1 fatty acid eeeee1  re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3- bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for  bbbbb1 fatty acid eeeee1  re-esterification during fasting.  bbbbb2 cAspAT eeeee2  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of  bbbbb1 [(14)C]aspartate eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of  bbbbb1 [(14)C]aspartate eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of  bbbbb1 [(14)C]aspartate eeeee1  into the neutral lipid fraction of 3T3- bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of  bbbbb1 [(14)C]aspartate eeeee1  bbbbb2 cAspAT eeeee2  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the  bbbbb1 thiazolidinedione eeeee1  bbbbb2 cAspAT eeeee2 ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the  bbbbb1 thiazolidinedione eeeee1  bbbbb2 cytosolic aspartate aminotransferase eeeee2  (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the  bbbbb1 thiazolidinedione eeeee1  bbbbb2 F442A eeeee2  adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone
CRP11	Nevertheless, PPARgamma is indirectly necessary for both cAspAT basal expression and  bbbbb1 TZD eeeee1  responsiveness because they are, respectively, diminished and abolished by ectopic overexpression of a dominant negative  bbbbb2 PPARgamma eeeee2 
CRP11	Nevertheless, PPARgamma is indirectly necessary for both cAspAT basal expression and  bbbbb1 TZD eeeee1  bbbbb2 cAspAT eeeee2  basal expression and TZD responsiveness because they are, respectively, diminished and abolished by ectopic overexpression of a dominant negative PPARgamma
CRP11	Cytosolic  bbbbb1 aspartate eeeee1  bbbbb2 Cytosolic aspartate aminotransferase eeeee2 , a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione
CRP11	The cAspAT  bbbbb1 TZD eeeee1 -responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific  bbbbb2 RORalpha eeeee2  binding
CRP11	The cAspAT TZD-responsive site was restricted to a single  bbbbb1 AGGACA eeeee1  hexanucleotide located at -381 to -376 bp whose mutation impaired the specific  bbbbb2 RORalpha eeeee2  binding
CRP11	The cAspAT TZD-responsive site was restricted to a single AGGACA  bbbbb1 hexanucleotide eeeee1  located at -381 to -376 bp whose mutation impaired the specific  bbbbb2 RORalpha eeeee2  binding
CRP11	RORalpha ectopic expression activated the cAspAT gene transcription in absence of  bbbbb1 rosiglitazone eeeee1  bbbbb2 cAspAT eeeee2  gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes
CRP11	RORalpha ectopic expression activated the cAspAT gene transcription in absence of  bbbbb1 rosiglitazone eeeee1  bbbbb2 RORalpha eeeee2  ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes
CRP11	In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting  bbbbb1 E217βG eeeee1  bbbbb2 MRP2 eeeee2  varied with two (V-4, V-6) inhibiting E217βG transport (IC50's 2.0, 9.2 μM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect
CRP11	Five classes of chalcogenopyrylium dyes ( bbbbb1 CGPs eeeee1 ) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217βG) (a prototypical MRP substrate) into  bbbbb2 MRP eeeee2 -enriched inside-out membrane vesicles
CRP11	Five classes of  bbbbb1 chalcogenopyrylium eeeee1  dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217βG) (a prototypical MRP substrate) into  bbbbb2 MRP eeeee2 -enriched inside-out membrane vesicles
CRP11	Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of  bbbbb1 [(3)H]estradiol glucuronide eeeee1  (E217βG) (a prototypical MRP substrate) into  bbbbb2 MRP eeeee2 -enriched inside-out membrane vesicles
CRP11	Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide ( bbbbb1 E217βG eeeee1 ) (a prototypical MRP substrate) into  bbbbb2 MRP eeeee2 -enriched inside-out membrane vesicles
CRP11	Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity,  bbbbb1 they ar eeeee1 e structurally identical except for their chalcogen atom (Se versus Te) bbbbb2  eeeee2 
CRP11	Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity, they are structurally identical except for their chalcogen atom (Se versus Te) bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity, they are structurally identical except for their chalcogen atom (Se versus Te) bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity, they are structurally identical except for their chalcog bbbbb1 en atom  eeeee1 (Se versus Te) bbbbb2  eeeee2 
CRP11	Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity, they are st bbbbb1 ructurally eeeee1  identical except for their chalcogen atom (Se versus Te) bbbbb2  eeeee2 
CRP11	Multidrug resistance proteins (MRPs) mediate the  bbbbb1 ATP eeeee1  bbbbb2 Multidrug resistance proteins eeeee2  (MRPs) mediate the ATP-dependent efflux of structurally diverse compounds, including anticancer drugs and physiological organic anions
CRP11	Multidrug resistance proteins (MRPs) mediate the  bbbbb1 ATP eeeee1  bbbbb2 MRPs eeeee2 ) mediate the ATP-dependent efflux of structurally diverse compounds, including anticancer drugs and physiological organic anions
CRP11	Miglustat, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits  bbbbb1 glucosylceramide eeeee1  bbbbb2 glucosylceramide synthase eeeee2 , which catalyses the first committed step in glycosphingolipid synthesis
CRP11	The ATP-sensitive potassium channel (K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2 ) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K( bbbbb1 ATP eeeee1 )) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb2 sulfonylurea receptor eeeee2  subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K( bbbbb1 ATP eeeee1 )) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit ( bbbbb2 Kir6.1 eeeee2 ) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K( bbbbb1 ATP eeeee1 )) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit ( bbbbb2 SUR2B eeeee2 )
CRP11	The ATP-sensitive potassium channel (K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2  (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel ( bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2 ) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel ( bbbbb1 K eeeee1 (ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb2 sulfonylurea receptor eeeee2  subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel ( bbbbb1 K eeeee1 (ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit ( bbbbb2 Kir6.1 eeeee2 ) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel ( bbbbb1 K eeeee1 (ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit ( bbbbb2 SUR2B eeeee2 )
CRP11	The ATP-sensitive potassium channel ( bbbbb1 K eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2  (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb1 sulfonylurea eeeee1  bbbbb2 K(ATP) eeeee2 ) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb1 sulfonylurea eeeee1  bbbbb2 sulfonylurea receptor eeeee2  subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb1 sulfonylurea eeeee1  bbbbb2 Kir6.1 eeeee2 ) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb1 sulfonylurea eeeee1  receptor subunit ( bbbbb2 SUR2B eeeee2 )
CRP11	The ATP-sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb1 sulfonylurea eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2  (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The  bbbbb1 ATP eeeee1 -sensitive potassium channel ( bbbbb2 K(ATP) eeeee2 ) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The  bbbbb1 ATP eeeee1 -sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb2 sulfonylurea receptor eeeee2  subunit (SUR2B)
CRP11	The  bbbbb1 ATP eeeee1 -sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit ( bbbbb2 Kir6.1 eeeee2 ) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The  bbbbb1 ATP eeeee1 -sensitive potassium channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit ( bbbbb2 SUR2B eeeee2 )
CRP11	The  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2  (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  channel ( bbbbb2 K(ATP) eeeee2 ) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a  bbbbb2 sulfonylurea receptor eeeee2  subunit (SUR2B)
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit ( bbbbb2 Kir6.1 eeeee2 ) and a sulfonylurea receptor subunit (SUR2B)
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  channel (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit ( bbbbb2 SUR2B eeeee2 )
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2  (K(ATP)) in mouse colonic smooth muscle cell is a complex containing a pore-forming subunit (Kir6.1) and a sulfonylurea receptor subunit (SUR2B)
CRP11	Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and coloni bbbbb1 c eeeee1  bbbbb2  (SUR eeeee2 2B) was induced by NaHS and colonic inflammation
CRP11	Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and colonic  bbbbb1 inf eeeee1  bbbbb2  (SUR eeeee2 2B) was induced by NaHS and colonic inflammation
CRP11	Whole-cell voltage-clamp techniques were used to study the alterations in K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channels eeeee2  in smooth muscle cells in experimental colitis
CRP11	Whole-cell voltage-clamp techniques were used to study the alterations in  bbbbb1 K eeeee1  bbbbb2 K(ATP) channels eeeee2  in smooth muscle cells in experimental colitis
CRP11	Hydrogen sulfide as an allosteric modulator of  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium channels eeeee2  in colonic inflammation
CRP11	Hydrogen sulfide as an allosteric modulator of ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium channels eeeee2  in colonic inflammation
CRP11	The concentration response to levcromakalim (LEVC), a K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channel eeeee2  opener, was significantly shifted to the left in the inflamed smooth-muscle cells
CRP11	The concentration response to levcromakalim (LEVC), a  bbbbb1 K eeeee1  bbbbb2 K(ATP) channel eeeee2  opener, was significantly shifted to the left in the inflamed smooth-muscle cells
CRP11	Pyrrolopyrazines as Selective Spleen  bbbbb1 Tyrosine eeeee1  bbbbb2 Spleen Tyrosine Kinase eeeee2  Inhibitors
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 M6PR eeeee2 ) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 AP-1 eeeee2  and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 Arf eeeee2 -dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 adaptors eeeee2  (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 mannose-6-phosphate receptor eeeee2  (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 furin eeeee2 , mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 M6PR eeeee2  lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 GGAs eeeee2 ) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a  bbbbb1 C eeeee1  bbbbb2 cargo proteins eeeee2  (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  receptor ( bbbbb2 M6PR eeeee2 ) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 AP-1 eeeee2  and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 Arf eeeee2 -dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 adaptors eeeee2  (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 mannose-6-phosphate receptor eeeee2  (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 furin eeeee2 , mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  receptor (M6PR) and  bbbbb2 M6PR eeeee2  lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 GGAs eeeee2 ) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  receptor (M6PR) and M6PR lacking a C-terminal domain  bbbbb2 M6PRΔC eeeee2 )
CRP11	We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin,  bbbbb1 mannose-6-phosphate eeeee1  bbbbb2 cargo proteins eeeee2  (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a C-terminal domain M6PRΔC)
CRP11	Role for Cargo in the Activation of  bbbbb1 ADP eeeee1  bbbbb2 Cargo eeeee2  in the Activation of ADP-Ribosylation Factors (Arf) and Adaptor Recruitment
CRP11	Role for Cargo in the Activation of  bbbbb1 ADP eeeee1  bbbbb2 ADP-Ribosylation Factors eeeee2  (Arf) and Adaptor Recruitment
CRP11	Role for Cargo in the Activation of  bbbbb1 ADP eeeee1 -Ribosylation Factors ( bbbbb2 Arf eeeee2 ) and Adaptor Recruitment
CRP11	Role for Cargo in the Activation of  bbbbb1 ADP eeeee1 -Ribosylation Factors (Arf) and  bbbbb2 Adaptor eeeee2  Recruitment
CRP11	These effects were fully counteracted by dietary phenolics which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of  bbbbb1 glutathione eeeee1 -associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of  bbbbb2 p66Shc eeeee2  signalling molecule
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05), glutathione reductase and  bbbbb1 gamma-glutamylcysteine eeeee1  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05), glutathione reductase and  bbbbb1 gamma-glutamylcysteine eeeee1  bbbbb2 glutathione peroxidase eeeee2  (6 h after treatment: P<.05), glutathione reductase and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05), glutathione reductase and  bbbbb1 gamma-glutamylcysteine eeeee1  bbbbb2 glutathione reductase eeeee2  and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of  bbbbb1 glutathione eeeee1  peroxidase (6 h after treatment: P<.05), glutathione reductase and  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (6 h after treatment: P<.05), glutathione reductase and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of  bbbbb1 glutathione eeeee1  peroxidase (6 h after treatment: P<.05),  bbbbb2 glutathione reductase eeeee2  and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05),  bbbbb1 glutathione eeeee1  reductase and  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05),  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (6 h after treatment: P<.05), glutathione reductase and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	In response to the induced oxidative stress, we observed significant overexpression of glutathione peroxidase (6 h after treatment: P<.05),  bbbbb1 glutathione eeeee1  bbbbb2 glutathione reductase eeeee2  and gamma-glutamylcysteine synthetase (12 h after treatment: P<.05)
CRP11	Apoptosis induced by oxidized lipids is associated with up-regulation of p66Shc in intestinal Caco-2 cells: protective effects of  bbbbb1 phenolic eeeee1  bbbbb2 p66Shc eeeee2  in intestinal Caco-2 cells: protective effects of phenolic compounds
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase,  bbbbb2 catalase eeeee2  and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  bbbbb2 oxLDL eeeee2  (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05:  bbbbb2 LipE eeeee2  vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb2 glutathione peroxidase eeeee2 
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  bbbbb2 LipE eeeee2 ) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  production, respectively, P<.05:  bbbbb2 LipE eeeee2  vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and  bbbbb1 H2O2 eeeee1  production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb2 superoxide dismutase eeeee2 , catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase,  bbbbb2 catalase eeeee2  and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  bbbbb2 oxLDL eeeee2  (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05:  bbbbb2 LipE eeeee2  vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb2 glutathione peroxidase eeeee2 
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  bbbbb2 LipE eeeee2 ) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  and H2O2 production, respectively, P<.05:  bbbbb2 LipE eeeee2  vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of  bbbbb1 O*2 eeeee1  and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb2 superoxide dismutase eeeee2 , catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 oxLDL eeeee2  (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 LipE eeeee2  vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2 
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 LipE eeeee2 ) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 LipE eeeee2  vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  dismutase,  bbbbb2 catalase eeeee2  and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  bbbbb2 oxLDL eeeee2  (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  bbbbb2 LipE eeeee2  vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  dismutase, catalase and  bbbbb2 glutathione peroxidase eeeee2 
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  bbbbb2 LipE eeeee2 ) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  bbbbb2 LipE eeeee2  vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of superoxide dismutase, catalase and glutathione peroxidase
CRP11	We found that oxidized lipids extracted from oxLDL (LipE) induced oxidative stress by determining, 6 h after treatment, ROS overproduction (about a 100% and a 43% increase of O*2 and H2O2 production, respectively, P<.05: LipE vs. control) and, 12 h after treatment, GSH depletion (about a 26% decrease, P<.05: LipE vs. control), and by impairing the activities of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase and glutathione peroxidase
CRP11	In this study, we investigated the alterations of the redox balance induced by the lipid fraction of oxLDL in Caco-2 intestinal cells, and the effects of tyrosol and  bbbbb1 protocatechuic acid eeeee1  bbbbb2 oxLDL eeeee2  in Caco-2 intestinal cells, and the effects of tyrosol and protocatechuic acid, two dietary phenolic compounds
CRP11	In this study, we investigated the alterations of the redox balance induced by the lipid fraction of oxLDL in Caco-2 intestinal cells, and the effects of  bbbbb1 tyrosol eeeee1  bbbbb2 oxLDL eeeee2  in Caco-2 intestinal cells, and the effects of tyrosol and protocatechuic acid, two dietary phenolic compounds
CRP11	In this study, we investigated the alterations of the redox balance induced by the lipid fraction of oxLDL in Caco-2 intestinal cells, and the effects of tyrosol and protocatechuic acid, two dietary  bbbbb1 phenolic eeeee1  bbbbb2 oxLDL eeeee2  in Caco-2 intestinal cells, and the effects of tyrosol and protocatechuic acid, two dietary phenolic compounds
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb2 ascorbate peroxidase eeeee2  (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  ammonia-lyase (PAL) and  bbbbb2 chalcone synthase eeeee2  (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase ( bbbbb2 APX eeeee2 )
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  bbbbb2 l-phenylalanine ammonia-lyase eeeee2  (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  ammonia-lyase ( bbbbb2 PAL eeeee2 ) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as  bbbbb1 l-phenylalanine eeeee1  ammonia-lyase (PAL) and chalcone synthase ( bbbbb2 CHS eeeee2 ), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  synthase (CHS), and an antioxidant enzyme such as  bbbbb2 ascorbate peroxidase eeeee2  (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  bbbbb2 chalcone synthase eeeee2  (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase ( bbbbb2 APX eeeee2 )
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  bbbbb2 l-phenylalanine ammonia-lyase eeeee2  (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  bbbbb2 PAL eeeee2 ) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  bbbbb1 chalcone eeeee1  synthase ( bbbbb2 CHS eeeee2 ), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1 -lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb2 ascorbate peroxidase eeeee2  (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1 -lyase (PAL) and  bbbbb2 chalcone synthase eeeee2  (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1 -lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase ( bbbbb2 APX eeeee2 )
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1  bbbbb2 l-phenylalanine ammonia-lyase eeeee2  (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1 -lyase ( bbbbb2 PAL eeeee2 ) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine  bbbbb1 ammonia eeeee1 -lyase (PAL) and chalcone synthase ( bbbbb2 CHS eeeee2 ), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  bbbbb2 ascorbate peroxidase eeeee2  (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  bbbbb2 chalcone synthase eeeee2  (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  peroxidase ( bbbbb2 APX eeeee2 )
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  bbbbb2 l-phenylalanine ammonia-lyase eeeee2  (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  bbbbb2 PAL eeeee2 ) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  bbbbb1 ascorbate eeeee1  bbbbb2 CHS eeeee2 ), and an antioxidant enzyme such as ascorbate peroxidase (APX)
CRP11	This study further demonstrates the existence of a specific site, distinct from the active site on CaMPDE, that exhibits high-affinity binding of these drugs bbbbb1  eeeee1  bbbbb2 te, di eeeee2 stinct from the active site on CaMPDE, that exhibits high-affinity binding of these drugs
CRP11	This study further demonstrates the existence of a specific site, distinct from the active site on CaMPDE, that exhibits high-affinity binding of these drugs bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	 bbbbb1 This study eeeee1  further demonstrates the existence of a specific site, distinct from the active site on CaMPDE, that exhibits high-affinity binding of these drugs bbbbb2  eeeee2 
CRP11	This study furt bbbbb1 her demonst eeeee1 rates the existence of a specific site, distinct from the active site on CaMPDE, that exhibits high-affinity binding of these drugs bbbbb2  eeeee2 
CRP11	A variety of pharmacological agents have been used to inhibit CaMPDE, and this inhibition occurs mostly via  bbbbb1 Ca2+ eeeee1  bbbbb2 CaMPDE eeeee2 , and this inhibition occurs mostly via Ca2+-dependent association with the proteins
CRP11	The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two  bbbbb1 Ca2+ eeeee1  bbbbb2 CaMPDE eeeee2  isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other
CRP11	The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two  bbbbb1 Ca2+ eeeee1  bbbbb2 PDE 1B1 eeeee2 ) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other
CRP11	The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two  bbbbb1 Ca2+ eeeee1  bbbbb2 PDE 1A2 eeeee2 ) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other
CRP11	Mechanisms of inhibition of calmodulin-stimulated cyclic  bbbbb1 nucleotide eeeee1  bbbbb2 calmodulin-stimulated cyclic nucleotide phosphodiesterase eeeee2  by dihydropyridine calcium antagonists
CRP11	We have examined the effect of  bbbbb1 dihydropyridine eeeee1  Ca2+-channel blockers felodipine and nicardipine on  bbbbb2 CaMPDE eeeee2 
CRP11	We have examined the effect of dihydropyridine Ca2+-channel blockers  bbbbb1 felodipine eeeee1  and nicardipine on  bbbbb2 CaMPDE eeeee2 
CRP11	We have examined the effect of dihydropyridine  bbbbb1 Ca2+ eeeee1 -channel blockers felodipine and nicardipine on  bbbbb2 CaMPDE eeeee2 
CRP11	We have examined the effect of dihydropyridine  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+-channel eeeee2  blockers felodipine and nicardipine on CaMPDE
CRP11	We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and  bbbbb1 nicardipine eeeee1  on  bbbbb2 CaMPDE eeeee2 
CRP11	Cotreatment with U0126 and  bbbbb1 YC-1 eeeee1  synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on  bbbbb2 ERK1/2 eeeee2 , JNK, and beta-catenin
CRP11	Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of  bbbbb1 sulindac eeeee1  treatment on  bbbbb2 ERK1/2 eeeee2 , JNK, and beta-catenin
CRP11	Cotreatment with  bbbbb1 U0126 eeeee1  and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on  bbbbb2 ERK1/2 eeeee2 , JNK, and beta-catenin
CRP11	These results indicate that  bbbbb1 sulindac eeeee1  metabolites modulate  bbbbb2 ERK1/2 eeeee2  and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway
CRP11	These results indicate that sulindac metabolites modulate ERK1/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of  bbbbb1 sulindac eeeee1  bbbbb2 ERK1/2 eeeee2  and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway
CRP11	These results indicate that sulindac metabolites modulate ERK1/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of  bbbbb1 sulindac eeeee1  bbbbb2 PKG eeeee2  pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway
CRP11	Sulindac independently modulates extracellular signal-regulated kinase 1/2 and  bbbbb1 cyclic GMP eeeee1  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  and cyclic GMP-dependent protein kinase signaling pathways
CRP11	Sulindac independently modulates extracellular signal-regulated kinase 1/2 and  bbbbb1 cyclic GMP eeeee1  bbbbb2 cyclic GMP-dependent protein kinase eeeee2  signaling pathways
CRP11	 bbbbb1 Sulindac eeeee1  independently modulates  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  and cyclic GMP-dependent protein kinase signaling pathways
CRP11	The purpose of this study was to determine if PKG, ERK1/2, JNK, and beta-catenin are independent targets for  bbbbb1 sulindac eeeee1  bbbbb2 JNK eeeee2 , and beta-catenin are independent targets for sulindac in vitro
CRP11	The purpose of this study was to determine if PKG, ERK1/2, JNK, and beta-catenin are independent targets for  bbbbb1 sulindac eeeee1  bbbbb2 beta-catenin eeeee2  are independent targets for sulindac in vitro
CRP11	The purpose of this study was to determine if PKG, ERK1/2, JNK, and beta-catenin are independent targets for  bbbbb1 sulindac eeeee1  bbbbb2 ERK1/2 eeeee2 , JNK, and beta-catenin are independent targets for sulindac in vitro
CRP11	The purpose of this study was to determine if PKG, ERK1/2, JNK, and beta-catenin are independent targets for  bbbbb1 sulindac eeeee1  bbbbb2 PKG eeeee2 , ERK1/2, JNK, and beta-catenin are independent targets for sulindac in vitro
CRP11	Pharmacologic activation of PKG with  bbbbb1 YC-1 eeeee1  increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or  bbbbb2 beta-catenin eeeee2  protein expression
CRP11	Pharmacologic activation of PKG with  bbbbb1 YC-1 eeeee1  increases  bbbbb2 JNK eeeee2  phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or beta-catenin protein expression
CRP11	Pharmacologic activation of PKG with  bbbbb1 YC-1 eeeee1  increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating  bbbbb2 ERK1/2 eeeee2  phosphorylation or beta-catenin protein expression
CRP11	Pharmacologic activation of PKG with  bbbbb1 YC-1 eeeee1  bbbbb2 PKG eeeee2  with YC-1 increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or beta-catenin protein expression
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 ( bbbbb2 ERK1/2 eeeee2 ); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate  bbbbb2 cyclic GMP-dependent protein kinase eeeee2  (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase ( bbbbb2 JNK eeeee2 ); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease  bbbbb2 beta-catenin eeeee2  protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase ( bbbbb2 PKG eeeee2 ); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular  bbbbb1 cyclic GMP eeeee1  and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate  bbbbb2 c-jun NH2-terminal kinase eeeee2  (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	 bbbbb1 Sulindac eeeee1  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 ( bbbbb2 ERK1/2 eeeee2 ); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	 bbbbb1 Sulindac eeeee1  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 ( bbbbb2 ERK1/2 eeeee2 ); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1  bbbbb2 cyclic GMP-dependent protein kinase eeeee2  (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase ( bbbbb2 JNK eeeee2 ); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease  bbbbb2 beta-catenin eeeee2  protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase ( bbbbb2 PKG eeeee2 ); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  bbbbb1 cyclic GMP eeeee1 -dependent protein kinase (PKG); (b) activate  bbbbb2 c-jun NH2-terminal kinase eeeee2  (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 ( bbbbb2 ERK1/2 eeeee2 ); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1  bbbbb2 cyclic GMP-dependent protein kinase eeeee2  (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK); (c) inhibit  bbbbb2 extracellular signal-regulated kinase 1/2 eeeee2  (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1 -terminal kinase ( bbbbb2 JNK eeeee2 ); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease  bbbbb2 beta-catenin eeeee2  protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1  bbbbb2 PKG eeeee2 ); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun  bbbbb1 NH2 eeeee1  bbbbb2 c-jun NH2-terminal kinase eeeee2  (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis
CRP11	Inhibition of ERK1/2 with  bbbbb1 U0126 eeeee1  bbbbb2 ERK1/2 eeeee2  with U0126 induces apoptosis but fails to activate JNK phosphorylation or down-regulate beta-catenin protein expression
CRP11	The M1766L mutation caused a significant decrease in the  bbbbb1 sodium eeeee1  bbbbb2 M1766L eeeee2  mutation caused a significant decrease in the sodium channel expression
CRP11	In addition to this pronounced loss of function, M1766L also showed a 10-fold increase in the persistent late sodium current bbbbb1  eeeee1  bbbbb2 oss of eeeee2  function, M1766L also showed a 10-fold increase in the persistent late sodium current
CRP11	In addition to this pronounced loss of function, M1766L also showed a 10-fold increase in the persistent late sodium current bbbbb1  eeeee1  bbbbb2 funct eeeee2 ion, M1766L also showed a 10-fold increase in the persistent late sodium current
CRP11	In this study, we performed live imaging analyses of Neuro-2a cells expressing SCAT3, a caspase-3 cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus, to determine whether sodium arsenite ( bbbbb1 NaAsO(2) eeeee1  bbbbb2 caspase-3 eeeee2  cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus, to determine whether sodium arsenite (NaAsO(2); 0, 1, 5, or 10 μM) affects both neurite outgrowth and/or induces apoptosis with the same doses and in the same cell cultures
CRP11	In this study, we performed live imaging analyses of Neuro-2a cells expressing SCAT3, a caspase-3 cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus, to determine whether  bbbbb1 sodium arsenite eeeee1  bbbbb2 caspase-3 eeeee2  cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus, to determine whether sodium arsenite (NaAsO(2); 0, 1, 5, or 10 μM) affects both neurite outgrowth and/or induces apoptosis with the same doses and in the same cell cultures
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interaction be bbbbb1 twee eeeee1  bbbbb2 d an eeeee2  interaction between PKD1 and PI4KIIIβ following aldosterone treatment
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interaction be bbbbb1 twee eeeee1 n PKD1 and PI4KIIIβ following aldosterone treat bbbbb2 ment eeeee2 
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interaction be bbbbb1 twee eeeee1  bbbbb2 ion between PKD1  eeeee2 and PI4KIIIβ following aldosterone treatment
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interaction be bbbbb1 twee eeeee1 n PKD1 and PI4KIIIβ following aldosterone  bbbbb2 trea eeeee2 tment
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interact bbbbb1 ion b eeeee1  bbbbb2 d an eeeee2  interaction between PKD1 and PI4KIIIβ following aldosterone treatment
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interact bbbbb1 ion b eeeee1 etween PKD1 and PI4KIIIβ following aldosterone treat bbbbb2 ment eeeee2 
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interact bbbbb1 ion b eeeee1  bbbbb2 ion between PKD1  eeeee2 and PI4KIIIβ following aldosterone treatment
CRP11	PKD1 and PI4KIIIβ localize to the TGN, and aldosterone induced an interact bbbbb1 ion b eeeee1 etween PKD1 and PI4KIIIβ following aldosterone  bbbbb2 trea eeeee2 tment
CRP11	PKD1-deficient cells, the ouabain-sensitive current was significantly reduced and  bbbbb1 Na(+) eeeee1  bbbbb2 PKD1 eeeee2 -deficient cells, the ouabain-sensitive current was significantly reduced and Na(+)/K(+)-ATPase α and β subunits showed aberrant localization
CRP11	PKD1-deficient cells, the ouabain-sensitive current was significantly reduced and  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase α and β eeeee2  subunits showed aberrant localization
CRP11	PKD1-deficient cells, the  bbbbb1 ouabain eeeee1  bbbbb2 PKD1 eeeee2 -deficient cells, the ouabain-sensitive current was significantly reduced and Na(+)/K(+)-ATPase α and β subunits showed aberrant localization
CRP11	PKD1-deficient cells, the  bbbbb1 ouabain eeeee1 -sensitive current was significantly reduced and  bbbbb2 Na(+)/K(+)-ATPase α and β eeeee2  subunits showed aberrant localization
CRP11	PKD1-deficient cells, the ouabain-sensitive current was significantly reduced and Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 PKD1 eeeee2 -deficient cells, the ouabain-sensitive current was significantly reduced and Na(+)/K(+)-ATPase α and β subunits showed aberrant localization
CRP11	PKD1-deficient cells, the ouabain-sensitive current was significantly reduced and Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase α and β eeeee2  subunits showed aberrant localization
CRP11	Aldosterone-induced ENaC and basal Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase eeeee2  trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/ bbbbb1 K(+) eeeee1 -ATPase trafficking via  bbbbb2 protein kinase D1 eeeee2 -phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/ bbbbb1 K(+) eeeee1 -ATPase trafficking via protein kinase D1- bbbbb2 phosphatidylinositol 4-kinaseIIIβ eeeee2  trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 ENaC eeeee2  and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase eeeee2  trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal  bbbbb1 Na(+) eeeee1 /K(+)-ATPase trafficking via  bbbbb2 protein kinase D1 eeeee2 -phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal  bbbbb1 Na(+) eeeee1 /K(+)-ATPase trafficking via protein kinase D1- bbbbb2 phosphatidylinositol 4-kinaseIIIβ eeeee2  trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal  bbbbb1 Na(+) eeeee1  bbbbb2 ENaC eeeee2  and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1- bbbbb1 phosphatidylinositol eeeee1  bbbbb2 Na(+)/K(+)-ATPase eeeee2  trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1- bbbbb1 phosphatidylinositol eeeee1  bbbbb2 protein kinase D1 eeeee2 -phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1- bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 4-kinaseIIIβ eeeee2  trans Golgi signalling in M1 cortical collecting duct cells
CRP11	Aldosterone-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1- bbbbb1 phosphatidylinositol eeeee1  bbbbb2 ENaC eeeee2  and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells
CRP11	PKD isoforms regulate protein trafficking, by the control of vesicle fission from the trans Golgi network (TGN) through activation of  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 PKD eeeee2  isoforms regulate protein trafficking, by the control of vesicle fission from the trans Golgi network (TGN) through activation of phosphatidylinositol 4-kinaseIIIβ (PI4KIIIβ)
CRP11	PKD isoforms regulate protein trafficking, by the control of vesicle fission from the trans Golgi network (TGN) through activation of  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 4-kinaseIIIβ eeeee2  (PI4KIIIβ)
CRP11	PKD isoforms regulate protein trafficking, by the control of vesicle fission from the trans Golgi network (TGN) through activation of  bbbbb1 phosphatidylinositol eeeee1  4-kinaseIIIβ ( bbbbb2 PI4KIIIβ eeeee2 )
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 ENaC eeeee2 ) and Na(+)/K(+)-ATPase subunits
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase eeeee2  subunits
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 sodium channel eeeee2  (ENaC) and Na(+)/K(+)-ATPase subunits
CRP11	Aldosterone regulates  bbbbb1 Na(+) eeeee1  transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel ( bbbbb2 ENaC eeeee2 ) and Na(+)/K(+)-ATPase subunits
CRP11	Aldosterone regulates  bbbbb1 Na(+) eeeee1  transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and  bbbbb2 Na(+)/K(+)-ATPase eeeee2  subunits
CRP11	Aldosterone regulates  bbbbb1 Na(+) eeeee1  transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial  bbbbb2 sodium channel eeeee2  (ENaC) and Na(+)/K(+)-ATPase subunits
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and  bbbbb1 Na(+) eeeee1  bbbbb2 ENaC eeeee2 ) and Na(+)/K(+)-ATPase subunits
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)-ATPase eeeee2  subunits
CRP11	Aldosterone regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and  bbbbb1 Na(+) eeeee1  bbbbb2 sodium channel eeeee2  (ENaC) and Na(+)/K(+)-ATPase subunits
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  bbbbb2 glutamic acid decarboxylase eeeee2  (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  bbbbb2 major diabetes autoantigen eeeee2 , glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the  bbbbb2 P2C protein eeeee2  of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb2 PEVKEK eeeee2 , to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and  bbbbb2 GAD65 eeeee2  can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen,  bbbbb1 glutamic acid eeeee1  decarboxylase ( bbbbb2 GAD65 eeeee2 ), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1  bbbbb2 glutamic acid decarboxylase eeeee2  (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1  bbbbb2 major diabetes autoantigen eeeee2 , glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1 , to the  bbbbb2 P2C protein eeeee2  of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1  bbbbb2 PEVKEK eeeee2 , to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1 , to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and  bbbbb2 GAD65 eeeee2  can initiate autoimmune diabetes
CRP11	The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues  bbbbb1 PEVKEK eeeee1  bbbbb2 GAD65 eeeee2 ), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes
CRP11	The identified peptide sequences could be mapped to a homology model of the pyridoxal phosphate ( bbbbb1 PLP eeeee1 ) binding domain of  bbbbb2 GAD65 eeeee2 
CRP11	The identified peptide sequences could be mapped to a homology model of the pyridoxal phosphate ( bbbbb1 PLP eeeee1  bbbbb2 pyridoxal phosphate (PLP) binding domain eeeee2  of GAD65
CRP11	The identified peptide sequences could be mapped to a homology model of the  bbbbb1 pyridoxal phosphate eeeee1  (PLP) binding domain of  bbbbb2 GAD65 eeeee2 
CRP11	The identified peptide sequences could be mapped to a homology model of the  bbbbb1 pyridoxal phosphate eeeee1  bbbbb2 pyridoxal phosphate (PLP) binding domain eeeee2  of GAD65
CRP11	Also, the two phage most reactive with MICA4 encoded the motif VALxG, and the reverse of this sequence, LAV, was located in this same region bbbbb1  eeeee1  bbbbb2 he mo eeeee2 tif VALxG, and the reverse of this sequence, LAV, was located in this same region
CRP11	Also, the two phage most reactive with MICA4 encoded the motif VALxG, and the reverse of this sequence, LAV, was located in this same region bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing amino acids, and the surface of the GAD65  bbbbb1 PLP eeeee1  bbbbb2 GAD65 PLP-binding domain eeeee2  surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids
CRP11	Peptide sequences selected using MICA4 were rich in basic or  bbbbb1 hydroxyl eeeee1 -containing amino acids, and the surface of the  bbbbb2 GAD65 PLP-binding domain eeeee2  surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids
CRP11	To confirm that the loop containing the  bbbbb1 PEVKEK eeeee1  bbbbb2 PEVKEK eeeee2  sequence contributes to the MICA3 epitope, this loop was deleted by mutagenesis
CRP11	For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the  bbbbb1 C eeeee1  bbbbb2 PLP binding domain eeeee2  as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the  bbbbb1 C eeeee1  bbbbb2 PEVKEK eeeee2  and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence  bbbbb1 PEVKEK eeeee1  and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the C terminus of  bbbbb2 GAD65 eeeee2  that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence  bbbbb1 PEVKEK eeeee1  and two adjacent exposed helixes were identified in the  bbbbb2 PLP binding domain eeeee2  as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence  bbbbb1 PEVKEK eeeee1  bbbbb2 PEVKEK eeeee2  and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the  bbbbb1 PLP eeeee1  binding domain as well as a region of the C terminus of  bbbbb2 GAD65 eeeee2  that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the  bbbbb1 PLP eeeee1  bbbbb2 PLP binding domain eeeee2  as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the  bbbbb1 PLP eeeee1  bbbbb2 PEVKEK eeeee2  and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding
CRP11	However, pretreatment with agents that block late I( bbbbb1 Na eeeee1 ), like lidocaine, mexiletine, and RSD1235, a novel mixed  bbbbb2 ion channel eeeee2  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I( bbbbb1 Na eeeee1 ), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb1 Na eeeee1  bbbbb2 ion channel eeeee2  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb1 Na eeeee1  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I( bbbbb1 Na eeeee1  bbbbb2 ion channel eeeee2  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I( bbbbb1 Na eeeee1  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and  bbbbb1 RSD1235 eeeee1 , a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like  bbbbb1 lidocaine eeeee1 , mexiletine, and RSD1235, a novel mixed  bbbbb2 ion channel eeeee2  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like  bbbbb1 lidocaine eeeee1 , mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine,  bbbbb1 mexiletine eeeee1 , and RSD1235, a novel mixed  bbbbb2 ion channel eeeee2  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	However, pretreatment with agents that block late I(Na), like lidocaine,  bbbbb1 mexiletine eeeee1 , and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays  bbbbb2 Na channel eeeee2  inactivation and amplifies late I(Na) greatly, mimicking LQT3
CRP11	Further,  bbbbb1 TCDD eeeee1  exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of  bbbbb2 NF-κB p65 eeeee2  from the cytosol to the nucleus in this microglial cell line
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM),  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM),  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  bbbbb2 PDE7 eeeee2  [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM],  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 ( bbbbb1 8-methoxymethyl-3-isobutyl-1-methylxanthine eeeee1 , 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM),  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1 , 10 microM; cGMP, 10 microM),  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1 , 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1 , 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  bbbbb2 PDE7 eeeee2  [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ( bbbbb1 milrinone eeeee1 , 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM),  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [ bbbbb1 BRL-50481 eeeee1  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ( bbbbb1 5-nitro-2,N,N-trimethylbenzenesulfonamide eeeee1  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ( bbbbb1 zaprinast eeeee1  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ( bbbbb1 zaprinast eeeee1  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ( bbbbb1 zaprinast eeeee1 , 30 microM), and  bbbbb2 PDE7 eeeee2  [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ( bbbbb1 zaprinast eeeee1  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ( bbbbb1 zaprinast eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1 , 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM),  bbbbb2 PDE4 eeeee2  (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1 , 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1 , 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  bbbbb2 PDE7 eeeee2  [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1 , 30 microM],  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [ bbbbb1 erythro-9-(2-hydroxy-3-nonyl)adenine eeeee1 , 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM),  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1 ], 100 microM), PDE5 and  bbbbb2 PDE6 eeeee2  (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1  bbbbb2 PDE2 eeeee2  [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1 ], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  bbbbb2 PDE7 eeeee2  [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1  bbbbb2 PDE3 eeeee2  (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1  bbbbb2 PDE1 eeeee2  (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [ bbbbb1 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one eeeee1 ], 100 microM),  bbbbb2 PDE5 eeeee2  and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to  bbbbb1 adenosine eeeee1  bbbbb2 adenylyl cyclase eeeee2  causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to  bbbbb1 adenosine eeeee1  bbbbb2 phosphodiesterase eeeee2 , and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of  bbbbb1 cAMP eeeee1  to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by  bbbbb2 ecto-5'-nucleotidase eeeee2 
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of  bbbbb1 cAMP eeeee1  bbbbb2 adenylyl cyclase eeeee2  causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of  bbbbb1 cAMP eeeee1 , conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by  bbbbb2 ecto-5'-nucleotidase eeeee2 
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of  bbbbb1 cAMP eeeee1  bbbbb2 adenylyl cyclase eeeee2  causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of  bbbbb1 cAMP eeeee1 , conversion of cAMP to AMP by ecto- bbbbb2 phosphodiesterase eeeee2 , and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of  bbbbb1 AMP eeeee1  bbbbb2 adenylyl cyclase eeeee2  causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of  bbbbb1 AMP eeeee1  bbbbb2 phosphodiesterase eeeee2 , and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to  bbbbb1 AMP eeeee1  by ecto-phosphodiesterase, and metabolism of AMP to adenosine by  bbbbb2 ecto-5'-nucleotidase eeeee2 
CRP11	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to  bbbbb1 AMP eeeee1  bbbbb2 adenylyl cyclase eeeee2  causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor ( bbbbb1 1,3-dipropyl-8-p-sulfophenylxanthine eeeee1  bbbbb2 PDE eeeee2 ) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor ( bbbbb1 1,3-dipropyl-8-p-sulfophenylxanthine eeeee1  bbbbb2 phosphodiesterase eeeee2  (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated  bbbbb1 cAMP eeeee1  bbbbb2 PDE eeeee2 ) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated  bbbbb1 cAMP eeeee1  bbbbb2 phosphodiesterase eeeee2  (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced  bbbbb1 AMP eeeee1  bbbbb2 PDE eeeee2 ) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced  bbbbb1 AMP eeeee1  bbbbb2 phosphodiesterase eeeee2  (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively
CRP11	After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and  bbbbb1 histamine eeeee1  bbbbb2 muscarinic receptor eeeee2  agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine
CRP11	After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist  bbbbb1 methacholine eeeee1 , the partial  bbbbb2 muscarinic receptor eeeee2  agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine
CRP11	After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist  bbbbb1 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium eeeee1  bbbbb2 muscarinic receptor eeeee2  agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine
CRP11	After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium ( bbbbb1 McN-A-343 eeeee1  bbbbb2 muscarinic receptor eeeee2  agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine
CRP11	After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium ( bbbbb1 McN-A-343 eeeee1  bbbbb2 muscarinic receptor eeeee2  agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine
CRP11	In the present study, we investigated the effect of  bbbbb1 fenoterol eeeee1 -induced constitutive beta(2)-adrenoceptor activity on  bbbbb2 muscarinic receptor eeeee2  agonist- and histamine-induced bovine tracheal smooth muscle contractions
CRP11	In the present study, we investigated the effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on muscarinic receptor agonist- and  bbbbb1 histamine eeeee1  bbbbb2 muscarinic receptor eeeee2  agonist- and histamine-induced bovine tracheal smooth muscle contractions
CRP11	In the present study, we investigated the effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on muscarinic receptor agonist- and  bbbbb1 histamine eeeee1  bbbbb2 beta(2)-adrenoceptor eeeee2  activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions
CRP11	Mouse brain  bbbbb1 serine eeeee1  bbbbb2 Mouse brain serine racemase eeeee2  catalyzes specific elimination of L-serine to pyruvate
CRP11	D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA)-type receptors eeeee2 
CRP11	D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA)-type receptors eeeee2 
CRP11	A receptor overactivation has been implicated in a number of pathological conditions and inhibitors of  bbbbb1 serine eeeee1  bbbbb2 serine racemase eeeee2  are thus potentially interesting targets for therapy
CRP11	We expressed recombinant mouse  bbbbb1 serine eeeee1  bbbbb2 mouse serine racemase eeeee2  in insect cells and purified it to near homogeneity
CRP11	We have expressed and characterized recombinant, N-terminally His-tagged human  bbbbb1 adenine eeeee1  bbbbb2 human adenine phosphoribosyltransferase eeeee2 
CRP11	We have expressed and characterized recombinant, N-terminally  bbbbb1 His eeeee1 -tagged  bbbbb2 human adenine phosphoribosyltransferase eeeee2 
CRP11	Ultimately, the scintillation proximity assay format  bbbbb1 was cho eeeee1  bbbbb2 was chosen because of automated s eeeee2 creening compatibility limitations of the coupled assay
CRP11	Adenine phosphoribosyltransferase plays a role in  bbbbb1 purine eeeee1  bbbbb2 Adenine phosphoribosyltransferase eeeee2  plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate
CRP11	 bbbbb1 Adenine eeeee1  bbbbb2 Adenine phosphoribosyltransferase eeeee2  plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate
CRP11	The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes  bbbbb1 adenine eeeee1  bbbbb2 adenine phosphoribosyltransferase eeeee2  a potential target for oncology drug discovery
CRP11	The involvement of the  bbbbb1 purine eeeee1  salvage pathway in tumor proliferation and angiogenesis makes  bbbbb2 adenine phosphoribosyltransferase eeeee2  a potential target for oncology drug discovery
CRP11	Configuration of a scintillation proximity assay for the activity assessment of recombinant human  bbbbb1 adenine eeeee1  bbbbb2 human adenine phosphoribosyltransferase eeeee2 
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor  bbbbb1 U0126 eeeee1  bbbbb2 glucocorticoid receptor eeeee2  (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor  bbbbb1 U0126 eeeee1  rather than  bbbbb2 estrogen receptor α eeeee2  antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor  bbbbb1 U0126 eeeee1  bbbbb2 GR eeeee2 ) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist  bbbbb1 RU486 eeeee1  or  bbbbb2 p-ERK eeeee2  inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist  bbbbb1 RU486 eeeee1  or p-ERK inhibitor U0126 rather than  bbbbb2 estrogen receptor α eeeee2  antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist  bbbbb1 ICI 82,780 eeeee1  bbbbb2 p-ERK eeeee2  inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist  bbbbb1 ICI 82,780 eeeee1  bbbbb2 glucocorticoid receptor eeeee2  (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist  bbbbb1 ICI 82,780 eeeee1  bbbbb2 GR eeeee2 ) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  bbbbb1 estrogen eeeee1  bbbbb2 p-ERK eeeee2  inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  bbbbb1 estrogen eeeee1  bbbbb2 glucocorticoid receptor eeeee2  (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor α eeeee2  antagonist ICI 82,780
CRP11	These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  bbbbb1 estrogen eeeee1  bbbbb2 GR eeeee2 ) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780
CRP11	Present study attempted to evaluate the potential mechanisms of Aβ-mediated insult and the protective effects of  bbbbb1 Rg1 eeeee1  bbbbb2 Aβ eeeee2 -mediated insult and the protective effects of Rg1 on human endothelial cells
CRP11	Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive  bbbbb1 nitrogen eeeee1  bbbbb2 Aβ25-35 eeeee2 -associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination
CRP11	Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive  bbbbb1 nitrogen eeeee1  bbbbb2 HIF-1α eeeee2  expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/ bbbbb1 H(+) eeeee1  cotransporter or a  bbbbb2 F(-)/OH(-) antiporter eeeee2 
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/ bbbbb1 H(+) eeeee1  bbbbb2 F(-)/H(+) cotransporter eeeee2  or a F(-)/OH(-) antiporter
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a F(-)/ bbbbb1 OH(-) eeeee1  bbbbb2 F(-)/OH(-) antiporter eeeee2 
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a F(-)/ bbbbb1 OH(-) eeeee1  bbbbb2 F(-)/H(+) cotransporter eeeee2  or a F(-)/OH(-) antiporter
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a  bbbbb1 F(-) eeeee1 /H(+) cotransporter or a  bbbbb2 F(-)/OH(-) antiporter eeeee2 
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a  bbbbb1 F(-) eeeee1  bbbbb2 F(-)/H(+) cotransporter eeeee2  or a F(-)/OH(-) antiporter
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a  bbbbb1 F(-) eeeee1  bbbbb2 F(-)/OH(-) antiporter eeeee2 
CRP11	Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a  bbbbb1 F(-) eeeee1  bbbbb2 F(-)/H(+) cotransporter eeeee2  or a F(-)/OH(-) antiporter
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde ( bbbbb1 MDA eeeee1 ), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B ( bbbbb2 NF-κB eeeee2 ) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde ( bbbbb1 MDA eeeee1 ), tumor necrosis factor alpha (TNF-α),  bbbbb2 nuclear factor kappa B eeeee2  (NF-κB) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde ( bbbbb1 MDA eeeee1 ), tumor necrosis factor alpha ( bbbbb2 TNF-α eeeee2 ), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde ( bbbbb1 MDA eeeee1 ),  bbbbb2 tumor necrosis factor alpha eeeee2  (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal  bbbbb1 malondialdehyde eeeee1  (MDA), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B ( bbbbb2 NF-κB eeeee2 ) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal  bbbbb1 malondialdehyde eeeee1  (MDA), tumor necrosis factor alpha (TNF-α),  bbbbb2 nuclear factor kappa B eeeee2  (NF-κB) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal  bbbbb1 malondialdehyde eeeee1  (MDA), tumor necrosis factor alpha ( bbbbb2 TNF-α eeeee2 ), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats
CRP11	The obtained results showed that pioglitazone improved the renal function, structural changes, renal  bbbbb1 malondialdehyde eeeee1  (MDA),  bbbbb2 tumor necrosis factor alpha eeeee2  (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats
CRP11	Pioglitazone,  bbbbb1 Bisphenol A diglycidyl ether eeeee1 , BADGE, IP injected ( bbbbb2 Peroxisome proliferator- activated receptor gamma eeeee2  (PPAR-γ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	Pioglitazone,  bbbbb1 Bisphenol A diglycidyl ether eeeee1 , BADGE, IP injected (Peroxisome proliferator- activated receptor gamma ( bbbbb2 PPAR-γ eeeee2 ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	 bbbbb1 Pioglitazone eeeee1 , Bisphenol A diglycidyl ether, BADGE, IP injected ( bbbbb2 Peroxisome proliferator- activated receptor gamma eeeee2  (PPAR-γ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	 bbbbb1 Pioglitazone eeeee1 , Bisphenol A diglycidyl ether, BADGE, IP injected (Peroxisome proliferator- activated receptor gamma ( bbbbb2 PPAR-γ eeeee2 ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	Pioglitazone, Bisphenol A diglycidyl ether, BADGE, IP injected (Peroxisome proliferator- activated receptor gamma (PPAR-γ) antagonist), or their combination were administered to rats one hour before  bbbbb1 cisplatin eeeee1  bbbbb2 Peroxisome proliferator- activated receptor gamma eeeee2  (PPAR-γ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	Pioglitazone, Bisphenol A diglycidyl ether, BADGE, IP injected (Peroxisome proliferator- activated receptor gamma (PPAR-γ) antagonist), or their combination were administered to rats one hour before  bbbbb1 cisplatin eeeee1  bbbbb2 PPAR-γ eeeee2 ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	Pioglitazone, Bisphenol A diglycidyl ether,  bbbbb1 BADGE eeeee1 , IP injected ( bbbbb2 Peroxisome proliferator- activated receptor gamma eeeee2  (PPAR-γ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	Pioglitazone, Bisphenol A diglycidyl ether,  bbbbb1 BADGE eeeee1 , IP injected (Peroxisome proliferator- activated receptor gamma ( bbbbb2 PPAR-γ eeeee2 ) antagonist), or their combination were administered to rats one hour before cisplatin injection
CRP11	It increased both renal reduced glutathione ( bbbbb1 GSH eeeee1 ) content and  bbbbb2 PPAR-γ eeeee2  gene expression
CRP11	It increased both renal reduced  bbbbb1 glutathione eeeee1  (GSH) content and  bbbbb2 PPAR-γ eeeee2  gene expression
CRP11	Further, 5HHMF increased specific DNA-binding activity of Nr bbbbb1 f2 eeeee1 , and transient knockdown with Nrf bbbbb2 2 si eeeee2 RNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity
CRP11	In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of  bbbbb1 5HHMF eeeee1  bbbbb2 HO-1 eeeee2  inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production
CRP11	In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced  bbbbb1 NO eeeee1  bbbbb2 HO-1 eeeee2  inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production
CRP11	In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated  bbbbb1 NO eeeee1  production by suppressing the expression of  bbbbb2 inducible NO synthase eeeee2  (iNOS) in BV2 microglia
CRP11	In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated  bbbbb1 NO eeeee1  production by suppressing the expression of inducible NO synthase ( bbbbb2 iNOS eeeee2 ) in BV2 microglia
CRP11	In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible  bbbbb1 NO eeeee1  bbbbb2 inducible NO synthase eeeee2  (iNOS) in BV2 microglia
CRP11	In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible  bbbbb1 NO eeeee1  synthase ( bbbbb2 iNOS eeeee2 ) in BV2 microglia
CRP11	Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that  bbbbb1 5HHMF eeeee1  bbbbb2 iNOS eeeee2  expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity
CRP11	Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that  bbbbb1 5HHMF eeeee1  bbbbb2 20S proteasome eeeee2  inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity
CRP11	Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that  bbbbb1 5HHMF eeeee1  bbbbb2 NF-κB eeeee2  inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity
CRP11	 bbbbb1 Pyrrolidine dithiocarbamate eeeee1  (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing  bbbbb2 NF-κB eeeee2  activity
CRP11	 bbbbb1 Pyrrolidine dithiocarbamate eeeee1  (PDTC), a specific NF-κB inhibitor, along with  bbbbb2 20S proteasome eeeee2  inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity
CRP11	 bbbbb1 Pyrrolidine dithiocarbamate eeeee1  (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated  bbbbb2 iNOS eeeee2  expression by suppressing NF-κB activity
CRP11	Pyrrolidine dithiocarbamate ( bbbbb1 PDTC eeeee1 ), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing  bbbbb2 NF-κB eeeee2  activity
CRP11	Pyrrolidine dithiocarbamate ( bbbbb1 PDTC eeeee1 ), a specific NF-κB inhibitor, along with  bbbbb2 20S proteasome eeeee2  inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity
CRP11	Pyrrolidine dithiocarbamate ( bbbbb1 PDTC eeeee1 ), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated  bbbbb2 iNOS eeeee2  expression by suppressing NF-κB activity
CRP11	Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits  bbbbb1 nitric oxide eeeee1  production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and  bbbbb2 Nrf-2 eeeee2 -dependent heme oxygenase-1 induction
CRP11	Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits  bbbbb1 nitric oxide eeeee1  production in lipopolysaccharide-stimulated BV2 microglia via  bbbbb2 NF-κB eeeee2  suppression and Nrf-2-dependent heme oxygenase-1 induction
CRP11	Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits  bbbbb1 nitric oxide eeeee1  production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent  bbbbb2 heme oxygenase-1 eeeee2  induction
CRP11	In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced  bbbbb1 NO eeeee1  bbbbb2 HO-1 eeeee2  inducer, predominantly suppressed LPS-induced NO production
CRP11	Field excitatory post-synaptic potentials (fEPSPs) evoked by stimulation of the temporo-ammonic path (TAP) input to CA1 stratum lacunosum moleculare (SLM) were inhibited by  bbbbb1 LY541850 eeeee1  in  bbbbb2 mGlu3 eeeee2 -/- mice (EC(50) 38 nM) and wild-type littermates (EC(50) 42 nM) to a similar extent but were not significantly affected in mGlu2-/- mice
CRP11	Field excitatory post-synaptic potentials (fEPSPs) evoked by stimulation of the temporo-ammonic path (TAP) input to CA1 stratum lacunosum moleculare (SLM) were inhibited by  bbbbb1 LY541850 eeeee1  in mGlu3-/- mice (EC(50) 38 nM) and wild-type littermates (EC(50) 42 nM) to a similar extent but were not significantly affected in  bbbbb2 mGlu2 eeeee2 -/- mice
CRP11	Differentiating the roles of mGlu2 and mGlu3 receptors using  bbbbb1 LY541850 eeeee1  bbbbb2 mGlu2 eeeee2  and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist
CRP11	Differentiating the roles of mGlu2 and mGlu3 receptors using  bbbbb1 LY541850 eeeee1  bbbbb2 mGlu3 eeeee2  receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist
CRP11	Co-application of DCG-IV and  bbbbb1 LY541850 eeeee1  in  bbbbb2 mGlu3 eeeee2 -/- and wild-type littermates resulted in an additive effect, whereas in mGlu2-/- mice, LY541850 reversed the inhibitory action of DCG-IV
CRP11	Co-application of DCG-IV and  bbbbb1 LY541850 eeeee1  in mGlu3-/- and wild-type littermates resulted in an additive effect, whereas in  bbbbb2 mGlu2 eeeee2 -/- mice, LY541850 reversed the inhibitory action of DCG-IV
CRP11	Co-application of DCG-IV and LY541850 in mGlu3-/- and wild-type littermates resulted in an additive effect, whereas in mGlu2-/- mice,  bbbbb1 LY541850 eeeee1  bbbbb2 mGlu3 eeeee2 -/- and wild-type littermates resulted in an additive effect, whereas in mGlu2-/- mice, LY541850 reversed the inhibitory action of DCG-IV
CRP11	Co-application of DCG-IV and LY541850 in mGlu3-/- and wild-type littermates resulted in an additive effect, whereas in mGlu2-/- mice,  bbbbb1 LY541850 eeeee1  bbbbb2 mGlu2 eeeee2 -/- mice, LY541850 reversed the inhibitory action of DCG-IV
CRP11	Despite the potential therapeutic relevance of group II metabotropic  bbbbb1 glutamate eeeee1  (mGlu) receptors, there has been a lack of pharmacological tools for separating the roles of mGlu2 and  bbbbb2 mGlu3 eeeee2  receptor subtypes
CRP11	Despite the potential therapeutic relevance of group II metabotropic  bbbbb1 glutamate eeeee1  (mGlu) receptors, there has been a lack of pharmacological tools for separating the roles of  bbbbb2 mGlu2 eeeee2  and mGlu3 receptor subtypes
CRP11	Despite the potential therapeutic relevance of group II metabotropic  bbbbb1 glutamate eeeee1  bbbbb2 group II metabotropic glutamate (mGlu) receptors eeeee2 , there has been a lack of pharmacological tools for separating the roles of mGlu2 and mGlu3 receptor subtypes
CRP11	These data support the hypothesis that mGlu2 receptors mediate  bbbbb1 the antip eeeee1  bbbbb2 tors mediate the antipsychotic e eeeee2 ffects of mixed group II agonists
CRP11	Of the two  bbbbb1 lactate eeeee1  transporters studied,  bbbbb2 MCT4 eeeee2  mRNA and protein level are increased under hypoxia
CRP11	In this study, we further investigated the role of hypoxia in primary trophoblast cells and a cultured cell line, JEG3 cells, to obtain a better understanding of how it affects the activities of  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2 , lactate production and regulatory genes, as a possible model for preeclampsia
CRP11	In this study, we further investigated the role of hypoxia in primary trophoblast cells and a cultured cell line, JEG3 cells, to obtain a better understanding of how it affects the activities of lactate dehydrogenase,  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2 , lactate production and regulatory genes, as a possible model for preeclampsia
CRP11	Two  bbbbb1 lactate eeeee1  transporters (MCT1 and  bbbbb2 MCT4 eeeee2 ) mRNA and protein expression were also studied under hypoxia
CRP11	Two  bbbbb1 lactate eeeee1  bbbbb2 lactate transporters eeeee2  (MCT1 and MCT4) mRNA and protein expression were also studied under hypoxia
CRP11	Two  bbbbb1 lactate eeeee1  transporters ( bbbbb2 MCT1 eeeee2  and MCT4) mRNA and protein expression were also studied under hypoxia
CRP11	Differential expression of  bbbbb1 lactate eeeee1  dehydrogenase isozymes ( bbbbb2 LDH eeeee2 ) in human placenta with high expression of LDH-A(4) isozyme in the endothelial cells of pre-eclampsia villi
CRP11	Differential expression of  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  isozymes (LDH) in human placenta with high expression of LDH-A(4) isozyme in the endothelial cells of pre-eclampsia villi
CRP11	Differential expression of  bbbbb1 lactate eeeee1  dehydrogenase isozymes (LDH) in human placenta with high expression of  bbbbb2 LDH-A(4) eeeee2  isozyme in the endothelial cells of pre-eclampsia villi
CRP11	We previously reported that the enzyme  bbbbb1 lactate eeeee1  dehydrogenase ( bbbbb2 LDH eeeee2 ) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM, Zheng J, Xu F, Kay HH
CRP11	We previously reported that the enzyme  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM, Zheng J, Xu F, Kay HH
CRP11	LTD4 also induced expression of  bbbbb1 cysteinyl leukotriene eeeee1  receptor 1 (CysLT(1)R) and NF-κB  bbbbb2 p65 eeeee2  in the hippocampus and cortex
CRP11	LTD4 also induced expression of  bbbbb1 cysteinyl leukotriene eeeee1  receptor 1 (CysLT(1)R) and  bbbbb2 NF-κB eeeee2  p65 in the hippocampus and cortex
CRP11	LTD4 also induced expression of  bbbbb1 cysteinyl leukotriene eeeee1  receptor 1 ( bbbbb2 CysLT(1)R eeeee2 ) and NF-κB p65 in the hippocampus and cortex
CRP11	LTD4 also induced expression of  bbbbb1 cysteinyl leukotriene eeeee1  bbbbb2 cysteinyl leukotriene receptor 1 eeeee2  (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex
CRP11	 bbbbb1 Leukotriene A(4) eeeee1  hydrolase ( bbbbb2 LTA(4)H eeeee2 ) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)
CRP11	 bbbbb1 Leukotriene A(4) eeeee1  bbbbb2 Leukotriene A(4) hydrolase eeeee2  (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)
CRP11	Identification of benzofuran central cores for the inhibition of  bbbbb1 leukotriene A(4) eeeee1  bbbbb2 leukotriene A(4) hydrolase eeeee2 
CRP11	The results of apoptosis and flow cytometry (FCM) demonstrate bbbbb1 d t eeeee1  bbbbb2 d that eeeee2  compound 7a induce cell apoptosis by the inhibition of MetAP2 pathway
CRP11	Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent  bbbbb1 methionine eeeee1  bbbbb2 methionine aminopeptidase type II eeeee2  inhibitors
CRP11	Experimental as well as clinical reports support the hypothesis that  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  blockers such as verapamil may be an appropriate therapeutic approach in LQTS
CRP11	In 8 Langendorff-perfused rabbit hearts, veratridine (0.1 microM), an inhibitor of  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3
CRP11	ALS AND METHODS: To determine the  bbbbb1 estrogen eeeee1 -like effect of Cyperi Rhizoma extract (CRE), we measured luciferase expression after transfection of a promoter construct containing an  bbbbb2 estrogen response element eeeee2  (ERE) and treatment of CRE
CRP11	ALS AND METHODS: To determine the  bbbbb1 estrogen eeeee1 -like effect of Cyperi Rhizoma extract (CRE), we measured luciferase expression after transfection of a promoter construct containing an estrogen response element ( bbbbb2 ERE eeeee2 ) and treatment of CRE
CRP11	ALS AND METHODS: To determine the estrogen-like effect of Cyperi Rhizoma extract (CRE), we measured luciferase expression after transfection of a promoter construct containing an  bbbbb1 estrogen eeeee1  bbbbb2 estrogen response element eeeee2  (ERE) and treatment of CRE
CRP11	ALS AND METHODS: To determine the estrogen-like effect of Cyperi Rhizoma extract (CRE), we measured luciferase expression after transfection of a promoter construct containing an  bbbbb1 estrogen eeeee1  response element ( bbbbb2 ERE eeeee2 ) and treatment of CRE
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of  bbbbb1 ceramide eeeee1  bbbbb2 RhoA eeeee2 , C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of  bbbbb1 ceramide eeeee1  bbbbb2 SRE eeeee2  activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of  bbbbb1 ceramide eeeee1  bbbbb2 Rac1 eeeee2  or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of  bbbbb1 ceramide eeeee1  bbbbb2 Rac1 eeeee2 , suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of  bbbbb1 ceramide eeeee1  bbbbb2 Cdc42 eeeee2 , Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  bbbbb1 C2-ceramide eeeee1  bbbbb2 RhoA eeeee2 , C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  bbbbb1 C2-ceramide eeeee1 -induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that  bbbbb2 Rac eeeee2  activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  bbbbb1 C2-ceramide eeeee1  bbbbb2 Rac1 eeeee2  or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  bbbbb1 C2-ceramide eeeee1 -induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of  bbbbb2 Rac1 eeeee2 , suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  bbbbb1 C2-ceramide eeeee1  bbbbb2 Cdc42 eeeee2 , Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus
CRP11	Next, we examined the role of Rho family GTPases in the  bbbbb1 ceramide eeeee1  bbbbb2 GTPases eeeee2  in the ceramide-induced signalling to SRE activation
CRP11	Next, we examined the role of Rho family GTPases in the  bbbbb1 ceramide eeeee1  bbbbb2 Rho eeeee2  family GTPases in the ceramide-induced signalling to SRE activation
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in  bbbbb1 C2-ceramide eeeee1  bbbbb2 SRE eeeee2  activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in  bbbbb1 C2-ceramide eeeee1  bbbbb2 Rac eeeee2  in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in  bbbbb1 C2-ceramide eeeee1  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in  bbbbb1 C2-ceramide eeeee1  bbbbb2 cPLA2 eeeee2 ) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with  bbbbb1 mepacrine eeeee1 , a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced  bbbbb2 SRE eeeee2  activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with  bbbbb1 mepacrine eeeee1  bbbbb2 Rac eeeee2  in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with  bbbbb1 mepacrine eeeee1 , a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with  bbbbb1 mepacrine eeeee1 , a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 ( bbbbb2 cPLA2 eeeee2 ) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with  bbbbb1 mepacrine eeeee1 , a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of  bbbbb2 cPLA2 eeeee2  in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the  bbbbb1 C2-ceramide eeeee1  bbbbb2 Rac eeeee2  in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the  bbbbb1 C2-ceramide eeeee1  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the  bbbbb1 C2-ceramide eeeee1  bbbbb2 cPLA2 eeeee2 ) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the  bbbbb1 C2-ceramide eeeee1 -induced SRE activation selectively, implying a critical role of  bbbbb2 cPLA2 eeeee2  in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the  bbbbb1 ceramide eeeee1 -signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced  bbbbb2 SRE eeeee2  activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the  bbbbb1 ceramide eeeee1  bbbbb2 Rac eeeee2  in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the  bbbbb1 ceramide eeeee1 -signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the  bbbbb1 ceramide eeeee1 -signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 ( bbbbb2 cPLA2 eeeee2 ) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus
CRP11	In a further study to analyse the downstream mediator of Rac in the  bbbbb1 ceramide eeeee1 -signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of  bbbbb2 cPLA2 eeeee2  in C2-ceramide-induced signalling to nucleus
CRP11	 bbbbb1 Ceramide eeeee1  is an important regulatory molecule implicated in a variety of biological processes in response to stress and  bbbbb2 cytokines eeeee2 
CRP11	To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether  bbbbb1 C2-ceramide eeeee1 , a cell permeable ceramide, activates  bbbbb2 c-fos serum response element eeeee2  (SRE)
CRP11	To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether  bbbbb1 C2-ceramide eeeee1 , a cell permeable ceramide, activates c-fos serum response element ( bbbbb2 SRE eeeee2 )
CRP11	To understand the signal transduction pathway of  bbbbb1 ceramide eeeee1  to the nucleus, in the present study, we examined whether C2-ceramide, a cell permeable ceramide, activates  bbbbb2 c-fos serum response element eeeee2  (SRE)
CRP11	To understand the signal transduction pathway of  bbbbb1 ceramide eeeee1  to the nucleus, in the present study, we examined whether C2-ceramide, a cell permeable ceramide, activates c-fos serum response element ( bbbbb2 SRE eeeee2 )
CRP11	To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether C2-ceramide, a cell permeable  bbbbb1 ceramide eeeee1 , activates  bbbbb2 c-fos serum response element eeeee2  (SRE)
CRP11	To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether C2-ceramide, a cell permeable  bbbbb1 ceramide eeeee1 , activates c-fos serum response element ( bbbbb2 SRE eeeee2 )
CRP11	In another experiment, cyanopindolol, an antagonist of the serotonin terminal autoreceptor, also prolonged the clearance of 5-HT from the CA3 region bbbbb1  eeeee1  bbbbb2 r, also prolonged the  eeeee2 clearance of 5-HT from the CA3 region
CRP11	In another experiment, cyanopindolol, an antagonist of the serotonin terminal autoreceptor, also prolonged the clearance of 5-HT from the CA3 region bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In another experiment, cyanopindolol, an antagonist of the serotonin terminal autorecepto bbbbb1 r, also p eeeee1  bbbbb2 r, also prolonged the  eeeee2 clearance of 5-HT from the CA3 region
CRP11	In another experiment, cyanopindolol, an antagonist of the serotonin terminal autorecepto bbbbb1 r, also p eeeee1 rolonged the clearance of 5-HT from the CA3 region bbbbb2  eeeee2 
CRP11	 bbbbb1 Serotonin eeeee1  bbbbb2 Serotonin transporter eeeee2  function in vivo: assessment by chronoamperometry
CRP11	Spiro heterocycles as potential inhibitors of SIRT1:  bbbbb1 Pd eeeee1  bbbbb2 SIRT1 eeeee2 : Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines
CRP11	Spiro heterocycles as potential inhibitors of SIRT1: Pd/ bbbbb1 C eeeee1  bbbbb2 SIRT1 eeeee2 : Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines
CRP11	Threshold concentrations of endothelin-1: the effects on contractions induced by  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 endothelin-1 eeeee2 : the effects on contractions induced by 5-hydroxytryptamine in isolated rat cerebral and mesenteric arteries
CRP11	Prostaglandins and ATP-sensitive  bbbbb1 K+ eeeee1  bbbbb2 ATP-sensitive K+ channels eeeee2  are involved in this inhibitory action
CRP11	 bbbbb1 Prostaglandins eeeee1  and  bbbbb2 ATP-sensitive K+ channels eeeee2  are involved in this inhibitory action
CRP11	Prostaglandins and  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ channels eeeee2  are involved in this inhibitory action
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of 5-HT, U46619, and  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin eeeee2 
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of 5-HT, U46619, and  bbbbb1 vasopressin eeeee1  bbbbb2 endothelin-1 eeeee2  potentiates the contractile effects of 5-HT, U46619, and vasopressin
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of 5-HT,  bbbbb1 U46619 eeeee1 , and  bbbbb2 vasopressin eeeee2 
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of 5-HT,  bbbbb1 U46619 eeeee1  bbbbb2 endothelin-1 eeeee2  potentiates the contractile effects of 5-HT, U46619, and vasopressin
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of  bbbbb1 5-HT eeeee1 , U46619, and  bbbbb2 vasopressin eeeee2 
CRP11	In mesenteric arteries, endothelin-1 potentiates the contractile effects of  bbbbb1 5-HT eeeee1  bbbbb2 endothelin-1 eeeee2  potentiates the contractile effects of 5-HT, U46619, and vasopressin
CRP11	The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by indomethacin, or by  bbbbb1 glibenclamide eeeee1  bbbbb2 endothelin ET(B) receptor eeeee2  antagonist RES 701-1, by indomethacin, or by glibenclamide
CRP11	The inhibitory effect of endothelin-1 on the contraction induced by  bbbbb1 5-HT eeeee1  bbbbb2 endothelin-1 eeeee2  on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by indomethacin, or by glibenclamide
CRP11	The inhibitory effect of endothelin-1 on the contraction induced by  bbbbb1 5-HT eeeee1  is abolished by deendothelialization, by the  bbbbb2 endothelin ET(B) receptor eeeee2  antagonist RES 701-1, by indomethacin, or by glibenclamide
CRP11	The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by  bbbbb1 indomethacin eeeee1  bbbbb2 endothelin ET(B) receptor eeeee2  antagonist RES 701-1, by indomethacin, or by glibenclamide
CRP11	The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the  bbbbb1 thromboxane A2 eeeee1  bbbbb2 thromboxane A2 receptor eeeee2  antagonists GR32191 and ridogrel
CRP11	The potentiation of the contractile effect induced by  bbbbb1 5-HT eeeee1  is only somewhat modified by deendothelialization, but abolished by the  bbbbb2 thromboxane A2 receptor eeeee2  antagonists GR32191 and ridogrel
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by  bbbbb1 5-hydroxytryptamine eeeee1  (5-HT), by the thromboxane A2 agonist U46619, and by  bbbbb2 vasopressin eeeee2 
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 endothelin-1 eeeee2  reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by vasopressin
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist  bbbbb1 U46619 eeeee1 , and by  bbbbb2 vasopressin eeeee2 
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist  bbbbb1 U46619 eeeee1  bbbbb2 endothelin-1 eeeee2  reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by vasopressin
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the  bbbbb1 thromboxane A2 eeeee1  agonist U46619, and by  bbbbb2 vasopressin eeeee2 
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the  bbbbb1 thromboxane A2 eeeee1  bbbbb2 endothelin-1 eeeee2  reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by vasopressin
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 ), by the thromboxane A2 agonist U46619, and by  bbbbb2 vasopressin eeeee2 
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine ( bbbbb1 5-HT eeeee1  bbbbb2 endothelin-1 eeeee2  reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by vasopressin
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin eeeee2 
CRP11	In basilar arteries, endothelin-1 reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by  bbbbb1 vasopressin eeeee1  bbbbb2 endothelin-1 eeeee2  reduces the contractions induced by 5-hydroxytryptamine (5-HT), by the thromboxane A2 agonist U46619, and by vasopressin
CRP11	HbA1c level in DM12W group was higher than in DM4W group, HbA1c level in  bbbbb1 EtOH eeeee1  bbbbb2 HbA1c eeeee2  level in DM12W group was higher than in DM4W group, HbA1c level in EtOH+DM8W group was lower than in DM8W group
CRP11	This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator  bbbbb1 ethanol eeeee1  bbbbb2 ALDH2 eeeee2  expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH)
CRP11	This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol ( bbbbb1 EtOH eeeee1  bbbbb2 ALDH2 eeeee2  expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH)
CRP11	Compared with DM8W group, SOD and ALDH2 in EtOH+DM8W group was increased,  bbbbb1 MDA eeeee1  bbbbb2 SOD eeeee2  and ALDH2 in EtOH+DM8W group was increased, MDA was decreased
CRP11	Compared with DM8W group, SOD and ALDH2 in EtOH+DM8W group was increased,  bbbbb1 MDA eeeee1  bbbbb2 ALDH2 eeeee2  in EtOH+DM8W group was increased, MDA was decreased
CRP11	Compared with control group, fasting blood  bbbbb1 glucose eeeee1  (FBG) and  bbbbb2 glycosylated hemoglobin eeeee2  (HbA1c) levels were increased in DM groups
CRP11	Compared with control group, fasting blood  bbbbb1 glucose eeeee1  (FBG) and glycosylated hemoglobin ( bbbbb2 HbA1c eeeee2 ) levels were increased in DM groups
CRP11	DM groups, SOD activity, ALDH2 mRNA and protein levels were reduced,  bbbbb1 MDA eeeee1  bbbbb2 SOD eeeee2  activity, ALDH2 mRNA and protein levels were reduced, MDA content was increased compared with control group; which decreased further as diabetes progressed
CRP11	DM groups, SOD activity, ALDH2 mRNA and protein levels were reduced,  bbbbb1 MDA eeeee1  bbbbb2 ALDH2 eeeee2  mRNA and protein levels were reduced, MDA content was increased compared with control group; which decreased further as diabetes progressed
CRP11	Pranlukast, a  bbbbb1 cysteinyl leukotriene eeeee1  bbbbb2 cysteinyl leukotriene receptor 1 eeeee2  (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation
CRP11	Pranlukast, a  bbbbb1 cysteinyl leukotriene eeeee1  receptor 1 ( bbbbb2 CysLTR1 eeeee2 ) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation
CRP11	Anti-diabetic Activity of  bbbbb1 Swertiamarin eeeee1  is due to an Active Metabolite, Gentianine, that Upregulates  bbbbb2 PPAR-γ eeeee2  Gene Expression in 3T3-L1 cells
CRP11	Consistent with studies demonstrating that LRRK2 plays a role in the phosphorylation o bbbbb1 f  eeeee1  bbbbb2 RRK2  eeeee2 plays a role in the phosphorylation of p38, our results similarly demonstrate a decrease in p38 activation in LRRK2 knock-down cells
CRP11	Consistent with studies demonstrating that LRRK2 plays a role in the phosphorylation of p38, our results similarly demonstrate a decrease bbbbb1  in p38 a eeeee1  bbbbb2 RRK2  eeeee2 plays a role in the phosphorylation of p38, our results similarly demonstrate a decrease in p38 activation in LRRK2 knock-down cells
CRP11	Genes linked to early onset of Parkinsonism which includes ATP13A2 and parkin have already been suggested to promote development of  bbbbb1 Mn eeeee1  bbbbb2 parkin eeeee2  have already been suggested to promote development of Mn toxicity
CRP11	Genes linked to early onset of Parkinsonism which includes ATP13A2 and parkin have already been suggested to promote development of  bbbbb1 Mn eeeee1  bbbbb2 ATP13A2 eeeee2  and parkin have already been suggested to promote development of Mn toxicity
CRP11	Combined treatment of  bbbbb1 Mn eeeee1  and DA further augments cell toxicity, ROS production and JNK phosphorylation in  bbbbb2 LRRK2 eeeee2  deficient cells compared to controls
CRP11	Results demonstrate that LRRK2 down-regulation potentiates  bbbbb1 Mn eeeee1  bbbbb2 LRRK2 eeeee2  down-regulation potentiates Mn toxicity in both control and DAT-transfected cell as well as potentiates DA toxicity
CRP11	Down-regulation of LRRK2 in control and DAT transfected HEK cells increases  bbbbb1 manganese eeeee1  bbbbb2 LRRK2 eeeee2  in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity
CRP11	Down-regulation of LRRK2 in control and DAT transfected HEK cells increases  bbbbb1 manganese eeeee1  bbbbb2 DAT eeeee2  transfected HEK cells increases manganese-induced oxidative stress and cell toxicity
CRP11	In this paper the effect of shRNA LRRK2 knock-down on  bbbbb1 Mn eeeee1  bbbbb2 LRRK2 eeeee2  knock-down on Mn toxicity was examined in control and DAT transfected HEK293 cells
CRP11	Of the other Parkinson-linked genes, mutations in LRRK2, an autosomal dominant gene, represent another likely candidate involved in the development of  bbbbb1 manganism eeeee1  bbbbb2 LRRK2 eeeee2 , an autosomal dominant gene, represent another likely candidate involved in the development of manganism
CRP11	To investigate a role for inducible  bbbbb1 nitric oxide eeeee1  in DEC's activity, DEC and ivermectin were administered to microfilaraemic  bbbbb2 iNOS eeeee2 -/- mice and their background strain (129/SV)
CRP11	To investigate a role for inducible nitric oxide in DEC's activity,  bbbbb1 DEC eeeee1  and ivermectin were administered to microfilaraemic  bbbbb2 iNOS eeeee2 -/- mice and their background strain (129/SV)
CRP11	To investigate a role for inducible nitric oxide in DEC's activity, DEC and  bbbbb1 ivermectin eeeee1  were administered to microfilaraemic  bbbbb2 iNOS eeeee2 -/- mice and their background strain (129/SV)
CRP11	Pre-treatment of animals with dexamethasone or indomethacin reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the  bbbbb1 arachidonic acid eeeee1  and  bbbbb2 cyclooxygenase eeeee2  pathways in vivo
CRP11	Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2  could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes
CRP11	Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with  bbbbb1 arginine eeeee1  bbbbb2 arginine-depleting enzymes eeeee2 
CRP11	Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2  and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes
CRP11	Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2  could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes
CRP11	Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2  and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes
CRP11	Nevertheless, many ASS-positive HCC cell lines are found to be resistant to ADI treatment, although most require  bbbbb1 arginine eeeee1  bbbbb2 ADI eeeee2  treatment, although most require arginine for proliferation
CRP11	Nevertheless, many ASS-positive HCC cell lines are found to be resistant to ADI treatment, although most require  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2 -positive HCC cell lines are found to be resistant to ADI treatment, although most require arginine for proliferation
CRP11	Thus far, an  bbbbb1 arginine eeeee1 -depleting enzyme for killing  bbbbb2 ASS eeeee2 -positive tumors has not been reported
CRP11	Thus far, an  bbbbb1 arginine eeeee1  bbbbb2 arginine-depleting enzyme eeeee2  for killing ASS-positive tumors has not been reported
CRP11	The successful use of the  bbbbb1 arginine eeeee1 -depleting enzyme arginine deiminase (ADI) to treat  bbbbb2 ASS eeeee2 -deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the  bbbbb1 arginine eeeee1 -depleting enzyme arginine deiminase ( bbbbb2 ADI eeeee2 ) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the  bbbbb1 arginine eeeee1  bbbbb2 arginine-depleting enzyme eeeee2  arginine deiminase (ADI) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the  bbbbb1 arginine eeeee1 -depleting enzyme  bbbbb2 arginine deiminase eeeee2  (ADI) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the arginine-depleting enzyme  bbbbb1 arginine eeeee1  deiminase (ADI) to treat  bbbbb2 ASS eeeee2 -deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the arginine-depleting enzyme  bbbbb1 arginine eeeee1  deiminase ( bbbbb2 ADI eeeee2 ) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the arginine-depleting enzyme  bbbbb1 arginine eeeee1  bbbbb2 arginine-depleting enzyme eeeee2  arginine deiminase (ADI) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	The successful use of the arginine-depleting enzyme  bbbbb1 arginine eeeee1  bbbbb2 arginine deiminase eeeee2  (ADI) to treat ASS-deficient tumors has opened up new possibilities for effective cancer therapy
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  bbbbb1 arginine eeeee1  with rhArg, to citrulline, which is converted back to arginine via  bbbbb2 ASS eeeee2 
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2 ), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  bbbbb1 arginine eeeee1  bbbbb2 ornithine transcarbamylase eeeee2  (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2 , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not  bbbbb1 ornithine eeeee1  transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via  bbbbb2 ASS eeeee2 
CRP11	They all expressed ASS, but not  bbbbb1 ornithine eeeee1  transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with  bbbbb2 rhArg eeeee2 , to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not  bbbbb1 ornithine eeeee1  transcarbamylase ( bbbbb2 OTC eeeee2 ), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not  bbbbb1 ornithine eeeee1  bbbbb2 ornithine transcarbamylase eeeee2  (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not  bbbbb1 ornithine eeeee1  bbbbb2 ASS eeeee2 , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts  bbbbb1 ornithine eeeee1 , the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via  bbbbb2 ASS eeeee2 
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts  bbbbb1 ornithine eeeee1 , the product of degradation of arginine with  bbbbb2 rhArg eeeee2 , to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts  bbbbb1 ornithine eeeee1  bbbbb2 ASS eeeee2 , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to  bbbbb1 arginine eeeee1  bbbbb2 rhArg eeeee2 , to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2 ), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to  bbbbb1 arginine eeeee1  bbbbb2 ornithine transcarbamylase eeeee2  (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2 , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to  bbbbb1 citrulline eeeee1 , which is converted back to arginine via  bbbbb2 ASS eeeee2 
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to  bbbbb1 citrulline eeeee1  bbbbb2 OTC eeeee2 ), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to  bbbbb1 citrulline eeeee1  bbbbb2 ornithine transcarbamylase eeeee2  (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to  bbbbb1 citrulline eeeee1  bbbbb2 ASS eeeee2 , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS
CRP11	Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through  bbbbb1 arginine eeeee1  bbbbb2 rhArg eeeee2 -peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
CRP11	Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through  bbbbb1 arginine eeeee1  bbbbb2 Pegylated recombinant human arginase eeeee2  (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
CRP11	This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2  expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated arginine depletion
CRP11	This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated  bbbbb1 arginine eeeee1  bbbbb2 OTC eeeee2 -deficient HCCs are sensitive to rhArg-mediated arginine depletion
CRP11	This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated  bbbbb1 arginine eeeee1  bbbbb2 ASS eeeee2 -positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated arginine depletion
CRP11	Hepatocellular carcinoma (HCC) is believed to be auxotrophic for arginine through the lack of expression of  bbbbb1 argininosuccinate eeeee1  synthetase ( bbbbb2 ASS eeeee2 )
CRP11	Hepatocellular carcinoma (HCC) is believed to be auxotrophic for arginine through the lack of expression of  bbbbb1 argininosuccinate eeeee1  bbbbb2 argininosuccinate synthetase eeeee2  (ASS)
CRP11	Hepatocellular carcinoma (HCC) is believed to be auxotrophic for  bbbbb1 arginine eeeee1  through the lack of expression of argininosuccinate synthetase ( bbbbb2 ASS eeeee2 )
CRP11	Hepatocellular carcinoma (HCC) is believed to be auxotrophic for  bbbbb1 arginine eeeee1  through the lack of expression of  bbbbb2 argininosuccinate synthetase eeeee2  (ASS)
CRP11	Several purinergic receptors have been described on platelets; P2X (1), a  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2 , and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by clopidogrel
CRP11	Several purinergic receptors have been described on platelets; P2X (1), a  bbbbb1 calcium eeeee1  bbbbb2 purinergic receptors eeeee2  have been described on platelets; P2X (1), a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by clopidogrel
CRP11	Several purinergic receptors have been described on platelets; P2X (1), a  bbbbb1 calcium eeeee1  bbbbb2 P2X (1) eeeee2 , a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by clopidogrel
CRP11	Several purinergic receptors have been described on platelets; P2X (1), a  bbbbb1 calcium eeeee1  channel, and  bbbbb2 P2Y1 eeeee2  a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by clopidogrel
CRP11	Several purinergic receptors have been described on platelets; P2X (1), a  bbbbb1 calcium eeeee1  channel, and P2Y1 a  bbbbb2 Gq-coupled seven-transmembrane domain receptor eeeee2 , have been found not to be antagonized by clopidogrel
CRP11	Y12, a new platelet  bbbbb1 ADP eeeee1  bbbbb2 ADP receptor eeeee2 , target of clopidogrel
CRP11	Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme bbbbb1  eeeee1  bbbbb2 t  eeeee2 indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme
CRP11	N2B-containing  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  are involved in many important physiological functions and play a pivotal role in mediating pain as well as in several neurodegenerative disorders
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of NMDA-induced  bbbbb1 Ca(2+) eeeee1  influx by calcium imaging experiments on HEK293 cells transfected with the cDNA encoding for GluN1-1A and  bbbbb2 GluN2B eeeee2 
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of NMDA-induced  bbbbb1 Ca(2+) eeeee1  influx by calcium imaging experiments on HEK293 cells transfected with the cDNA encoding for  bbbbb2 GluN1-1A eeeee2  and GluN2B
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of NMDA-induced Ca(2+) influx by  bbbbb1 calcium eeeee1  imaging experiments on HEK293 cells transfected with the cDNA encoding for GluN1-1A and  bbbbb2 GluN2B eeeee2 
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of NMDA-induced Ca(2+) influx by  bbbbb1 calcium eeeee1  imaging experiments on HEK293 cells transfected with the cDNA encoding for  bbbbb2 GluN1-1A eeeee2  and GluN2B
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of  bbbbb1 NMDA eeeee1 -induced Ca(2+) influx by calcium imaging experiments on HEK293 cells transfected with the cDNA encoding for GluN1-1A and  bbbbb2 GluN2B eeeee2 
CRP11	The previously developed probe was found to display the greatest activity in the inhibition of  bbbbb1 NMDA eeeee1 -induced Ca(2+) influx by calcium imaging experiments on HEK293 cells transfected with the cDNA encoding for  bbbbb2 GluN1-1A eeeee2  and GluN2B
CRP11	The tetra- bbbbb1 aspartate eeeee1  bbbbb2 tetra-aspartate motif eeeee2  in the trypsinogen activation peptide binds calcium (KD ~1.6 mM), which stimulates autoactivation
CRP11	C stimulates trypsinogen autoactivation by processing the activation peptide to a shorter form but also promotes degradation by cleaving the  bbbbb1 calcium eeeee1  bbbbb2 calcium binding loop eeeee2  in trypsinogen
CRP11	The endogenous ligand for  bbbbb1 imidazoline eeeee1  bbbbb2 imidazoline receptors eeeee2  may be a clonidine-displacing substance, a small molecule isolated from bovine brain
CRP11	Its biosynthetic enzyme, arginine decarboxylase, is present in brain bbbbb1  eeeee1  bbbbb2  in brain eeeee2 
CRP11	Its biosynthetic enzyme, arginine decarboxylase, is present in brain bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Its biosynthetic enzyme, arginine decarboxylase, is present bbbbb1  in brain eeeee1  bbbbb2  in brain eeeee2 
CRP11	Its biosynthetic enzyme, arginine decarboxylase, is present bbbbb1  in brain eeeee1  bbbbb2  eeeee2 
CRP11	Clonidine, an antihypertensive drug, binds to alpha 2-adrenergic and  bbbbb1 imidazoline eeeee1  bbbbb2 alpha 2-adrenergic and imidazoline receptors eeeee2 
CRP11	Agmatine binds to alpha 2-adrenergic and  bbbbb1 imidazoline eeeee1  bbbbb2 alpha 2-adrenergic and imidazoline receptors eeeee2  and stimulates release of catecholamines from adrenal chromaffin cells
CRP11	Agmatine binds to alpha 2-adrenergic and imidazoline receptors and stimulates release of  bbbbb1 catecholamines eeeee1  bbbbb2 alpha 2-adrenergic and imidazoline receptors eeeee2  and stimulates release of catecholamines from adrenal chromaffin cells
CRP11	Radiosequence analysis of [(14)C]halothane-labeled rhodopsin revealed that  bbbbb1 halothane eeeee1  bbbbb2 rhodopsin eeeee2  revealed that halothane contacts an amino acid residue (Trp265) lining the ligand binding cavity in the transmembrane core of the receptor
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  was administered was not a significant factor in the induction of either hepatic or intestinal  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times  bbbbb1 DEX-P eeeee1  was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  bbbbb1 midazolam eeeee1  (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  bbbbb1 midazolam eeeee1  (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  bbbbb1 midazolam eeeee1  (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  bbbbb1 midazolam eeeee1  (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1 , whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of  bbbbb1 DEX-P eeeee1  by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of  bbbbb1 DEX-P eeeee1  multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using  bbbbb1 dexamethasone 21-phosphate eeeee1  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using  bbbbb1 dexamethasone 21-phosphate eeeee1  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using  bbbbb1 dexamethasone 21-phosphate eeeee1  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using  bbbbb1 dexamethasone 21-phosphate eeeee1  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( bbbbb1 MDZ eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( bbbbb1 MDZ eeeee1 ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( bbbbb1 MDZ eeeee1 ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( bbbbb1 MDZ eeeee1 ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( bbbbb1 MDZ eeeee1 ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1 . 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ( bbbbb1 DEX-P eeeee1 ) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ( bbbbb1 DEX-P eeeee1 ) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in  bbbbb2 CYP3A eeeee2  activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ( bbbbb1 DEX-P eeeee1 ) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ( bbbbb1 DEX-P eeeee1 ) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3.  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 cytochrome P450 3A eeeee2  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 ; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 , respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2 . 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively. 2. The number of times DEX-P was administered was not a significant factor in the induction of either hepatic or intestinal CYP3A; however, administration of DEX-P multiple times markedly decreased the bioavailability of DEX-P by self-induction of CYP3A. 3. CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after  bbbbb1 DEX-P eeeee1  bbbbb2 CYP3A eeeee2  induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a  bbbbb1 threonine eeeee1  bbbbb2 A > G eeeee2  substitution leading to a threonine-to-alanine (T198A) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a  bbbbb1 threonine eeeee1 -to-alanine ( bbbbb2 T198A eeeee2 ) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a  bbbbb1 threonine eeeee1  bbbbb2 KYNU eeeee2  encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to-alanine (T198A) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a  bbbbb1 threonine eeeee1  bbbbb2 threonine-to-alanine eeeee2  (T198A) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to- bbbbb1 alanine eeeee1  bbbbb2 A > G eeeee2  substitution leading to a threonine-to-alanine (T198A) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to- bbbbb1 alanine eeeee1  ( bbbbb2 T198A eeeee2 ) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to- bbbbb1 alanine eeeee1  bbbbb2 KYNU eeeee2  encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to-alanine (T198A) shift
CRP11	Mutation analysis of KYNU encoding kynureninase of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to- bbbbb1 alanine eeeee1  bbbbb2 threonine-to-alanine eeeee2  (T198A) shift
CRP11	Massive urinary excretion of xanthurenic acid, 3-hydroxykynurenine and  bbbbb1 kynurenine eeeee1 , known as xanthurenic aciduria or hydroxykynureninuria, in a young Somali boy suggested  bbbbb2 kynureninase eeeee2  deficiency
CRP11	Massive urinary excretion of xanthurenic acid,  bbbbb1 3-hydroxykynurenine eeeee1  and kynurenine, known as xanthurenic aciduria or hydroxykynureninuria, in a young Somali boy suggested  bbbbb2 kynureninase eeeee2  deficiency
CRP11	Massive urinary excretion of  bbbbb1 xanthurenic acid eeeee1 , 3-hydroxykynurenine and kynurenine, known as xanthurenic aciduria or hydroxykynureninuria, in a young Somali boy suggested  bbbbb2 kynureninase eeeee2  deficiency
CRP11	Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  by Tomudex
CRP11	Twenty-four hours following the initial 2-h treatment with  bbbbb1 Tomudex eeeee1 , human A253 head and neck squamous carcinoma cells, not expressing p53 and  bbbbb2 p21 eeeee2 (WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases
CRP11	Twenty-four hours following the initial 2-h treatment with  bbbbb1 Tomudex eeeee1 , human A253 head and neck squamous carcinoma cells, not expressing p53 and p21( bbbbb2 WAF1 eeeee2 ), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases
CRP11	Twenty-four hours following the initial 2-h treatment with  bbbbb1 Tomudex eeeee1 , human A253 head and neck squamous carcinoma cells, not expressing  bbbbb2 p53 eeeee2  and p21(WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases
CRP11	Tomudex (ZD1694) is a specific antifolate-based  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  inhibitor active in a variety of solid tumor malignancies
CRP11	Tomudex ( bbbbb1 ZD1694 eeeee1 ) is a specific antifolate-based  bbbbb2 thymidylate synthase eeeee2  inhibitor active in a variety of solid tumor malignancies
CRP11	Activation of cyclin E and cdk2 kinases allows cells to transit from G1 to S phase accompanied by  bbbbb1 the inh eeeee1 ibition o bbbbb2 f D eeeee2 NA synthesis
CRP11	These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities
CRP11	These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  bbbbb1 thymidylate eeeee1  synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in  bbbbb2 cyclin E eeeee2  and cdk2 kinase activities
CRP11	These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  bbbbb1 thymidylate eeeee1  synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2  bbbbb2 kinase eeeee2  activities
CRP11	These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  bbbbb1 thymidylate eeeee1  synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and  bbbbb2 cdk2 eeeee2  kinase activities
CRP11	These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  bbbbb1 thymidylate eeeee1  synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of  bbbbb2 p27(kip1) eeeee2  expression and the increase in cyclin E and cdk2 kinase activities
CRP11	Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the  bbbbb1 thymidylate eeeee1  bbbbb2 Cyclin E eeeee2 -cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
CRP11	Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  inhibitor Tomudex
CRP11	Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the  bbbbb1 thymidylate eeeee1  bbbbb2 cdk2 eeeee2  activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
CRP11	Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor  bbbbb1 Tomudex eeeee1  bbbbb2 Cyclin E eeeee2 -cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
CRP11	Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor  bbbbb1 Tomudex eeeee1  bbbbb2 cdk2 eeeee2  activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
CRP11	The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 cyclin E eeeee2 -cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance
CRP11	The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  and resultant dNTP pool imbalance
CRP11	The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 cdk2 eeeee2  protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance
CRP11	The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 cdk2 eeeee2  protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance
CRP11	The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 cyclin E eeeee2 -cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance
CRP11	When cultured in liquid minimal medium, yeast cells expressing the mutated gamma-glutamyl kinase were found to accumulate intracellular  bbbbb1 L-proline eeeee1  and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type  bbbbb2 PRO1 eeeee2  gene
CRP11	When cultured in liquid minimal medium, yeast cells expressing the mutated  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 gamma-glutamyl kinase eeeee2  were found to accumulate intracellular L-proline and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene
CRP11	When cultured in liquid minimal medium, yeast cells expressing the mutated  bbbbb1 gamma-glutamyl eeeee1  kinase were found to accumulate intracellular L-proline and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type  bbbbb2 PRO1 eeeee2  gene
CRP11	 bbbbb1 L-proline eeeee1  accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase
CRP11	L-proline accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 gamma-glutamyl kinase eeeee2 
CRP11	L-proline accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from  bbbbb1 L-glutamate eeeee1  bbbbb2 PRO1 eeeee2  was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 PRO1 eeeee2  was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 gamma-glutamyl kinase eeeee2  and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of  bbbbb1 gamma-glutamyl eeeee1  kinase and  bbbbb2 gamma-glutamyl phosphate reductase eeeee2 , both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of  bbbbb1 L-proline eeeee1  bbbbb2 PRO1 eeeee2  was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  bbbbb1 gamma-glutamyl phosphate eeeee1  bbbbb2 PRO1 eeeee2  was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  bbbbb1 gamma-glutamyl phosphate eeeee1  bbbbb2 gamma-glutamyl kinase eeeee2  and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  bbbbb1 gamma-glutamyl phosphate eeeee1  bbbbb2 gamma-glutamyl phosphate reductase eeeee2 , both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo
CRP11	By introducing the mutant-derived genomic library into a non- bbbbb1 L-proline eeeee1 -utilizing strain, the mutant was found to carry an allele of the wild-type  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non- bbbbb1 L-proline eeeee1 -utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp ( bbbbb2 GAC eeeee2 ) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non- bbbbb1 L-proline eeeee1 -utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn ( bbbbb2 AAC eeeee2 )
CRP11	By introducing the mutant-derived genomic library into a non- bbbbb1 L-proline eeeee1 -utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding  bbbbb2 gamma-glutamyl kinase eeeee2 , which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single  bbbbb1 amino acid eeeee1  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single  bbbbb1 amino acid eeeee1  replacement; Asp ( bbbbb2 GAC eeeee2 ) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single  bbbbb1 amino acid eeeee1  replacement; Asp (GAC) at position 154 was replaced by Asn ( bbbbb2 AAC eeeee2 )
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  kinase, which resulted in a single amino acid replacement; Asp ( bbbbb2 GAC eeeee2 ) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn ( bbbbb2 AAC eeeee2 )
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding  bbbbb1 gamma-glutamyl eeeee1  bbbbb2 gamma-glutamyl kinase eeeee2 , which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement;  bbbbb1 Asp eeeee1  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement;  bbbbb1 Asp eeeee1  ( bbbbb2 GAC eeeee2 ) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement;  bbbbb1 Asp eeeee1  (GAC) at position 154 was replaced by Asn ( bbbbb2 AAC eeeee2 )
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by  bbbbb1 Asn eeeee1  bbbbb2 PRO1 eeeee2  gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by  bbbbb1 Asn eeeee1  bbbbb2 GAC eeeee2 ) at position 154 was replaced by Asn (AAC)
CRP11	By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding gamma-glutamyl kinase, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by  bbbbb1 Asn eeeee1  ( bbbbb2 AAC eeeee2 )
CRP11	All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and  bbbbb1 pentobarbital eeeee1  bbbbb2 GABA(A)R eeeee2  modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation
CRP11	All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and  bbbbb1 pentobarbital eeeee1  bbbbb2 Ca(v)1.3 eeeee2  channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation
CRP11	All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only  bbbbb1 BDZs eeeee1  bbbbb2 GABA(A)R eeeee2  modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation
CRP11	All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only  bbbbb1 BDZs eeeee1  bbbbb2 Ca(v)1.3 eeeee2  channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation
CRP11	Mutation of the high-affinity  bbbbb1 DHP eeeee1  binding site ( bbbbb2 T1039Y eeeee2  and Q1043M) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity  bbbbb1 DHP eeeee1  binding site (T1039Y and Q1043M) in  bbbbb2 Ca(v)1.2 eeeee2  channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity  bbbbb1 DHP eeeee1  bbbbb2 high-affinity DHP binding site eeeee2  (T1039Y and Q1043M) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity  bbbbb1 DHP eeeee1  binding site (T1039Y and  bbbbb2 Q1043M eeeee2 ) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity DHP binding site (T1039Y and Q1043M) in Ca(v)1.2 channels reduced  bbbbb1 pentobarbital eeeee1  bbbbb2 T1039Y eeeee2  and Q1043M) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity DHP binding site (T1039Y and Q1043M) in Ca(v)1.2 channels reduced  bbbbb1 pentobarbital eeeee1  bbbbb2 Ca(v)1.2 eeeee2  channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity DHP binding site (T1039Y and Q1043M) in Ca(v)1.2 channels reduced  bbbbb1 pentobarbital eeeee1  bbbbb2 high-affinity DHP binding site eeeee2  (T1039Y and Q1043M) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Mutation of the high-affinity DHP binding site (T1039Y and Q1043M) in Ca(v)1.2 channels reduced  bbbbb1 pentobarbital eeeee1  bbbbb2 Q1043M eeeee2 ) in Ca(v)1.2 channels reduced pentobarbital potency
CRP11	Ca(v)1.3 channels were less sensitive to  bbbbb1 pentobarbital eeeee1  inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP)  bbbbb2 L-VGCC eeeee2  antagonists
CRP11	Inhibition of recombinant L-type voltage-gated  bbbbb1 calcium eeeee1  bbbbb2 L-type voltage-gated calcium channels eeeee2  by positive allosteric modulators of GABAA receptors
CRP11	Inhibition of recombinant L-type voltage-gated  bbbbb1 calcium eeeee1  channels by positive allosteric modulators of  bbbbb2 GABAA receptors eeeee2 
CRP11	Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency bbbbb1  eeeee1  bbbbb2 he str eeeee2 uctural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency
CRP11	Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Despite the structural similar bbbbb1 ity  eeeee1 between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency bbbbb2  eeeee2 
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone,  bbbbb1 pentobarbital eeeee1 , and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone,  bbbbb1 pentobarbital eeeee1 , and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone,  bbbbb1 pentobarbital eeeee1 , and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs ( bbbbb1 diazepam eeeee1 , flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs ( bbbbb1 diazepam eeeee1 , flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs ( bbbbb1 diazepam eeeee1 , flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell  bbbbb1 Ba(2+) eeeee1  currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell  bbbbb1 Ba(2+) eeeee1  currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell  bbbbb1 Ba(2+) eeeee1  currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and  bbbbb1 desalkylflurazepam eeeee1 ), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and  bbbbb1 desalkylflurazepam eeeee1 ), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and  bbbbb1 desalkylflurazepam eeeee1 ), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam),  bbbbb1 allopregnanolone eeeee1 , pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam),  bbbbb1 allopregnanolone eeeee1 , pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam),  bbbbb1 allopregnanolone eeeee1 , pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam,  bbbbb1 flurazepam eeeee1 , and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam,  bbbbb1 flurazepam eeeee1 , and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam,  bbbbb1 flurazepam eeeee1 , and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and  bbbbb1 ethanol eeeee1  on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and  bbbbb1 ethanol eeeee1  on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and  bbbbb1 ethanol eeeee1  on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of  bbbbb1 BDZs eeeee1  (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of  bbbbb1 BDZs eeeee1  (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3  bbbbb2 L-VGCCs eeeee2  expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	The current studies assessed the effects of  bbbbb1 BDZs eeeee1  (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells
CRP11	BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated  bbbbb1 calcium eeeee1  bbbbb2 GABA(A)R eeeee2  modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability
CRP11	BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated  bbbbb1 calcium eeeee1  channels ( bbbbb2 L-VGCCs eeeee2 ), which could contribute to reduced neuronal excitability
CRP11	BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated  bbbbb1 calcium eeeee1  bbbbb2 L-type voltage-gated calcium channels eeeee2  (L-VGCCs), which could contribute to reduced neuronal excitability
CRP11	 bbbbb1 Jaspamide eeeee1  was tested in a patch clamp assay to determine its effect on selected  bbbbb2 cardiac ion channels eeeee2 
CRP11	Constitutive  bbbbb1 androstane eeeee1  bbbbb2 Constitutive androstane receptor eeeee2  (CAR) translocates into the nucleus in accordance with 5'-AMP-activated protein kinase and thus confers transactivation
CRP11	Constitutive  bbbbb1 androstane eeeee1  receptor (CAR) translocates into the nucleus in accordance with  bbbbb2 5'-AMP-activated protein kinase eeeee2  and thus confers transactivation
CRP11	Constitutive  bbbbb1 androstane eeeee1  receptor ( bbbbb2 CAR eeeee2 ) translocates into the nucleus in accordance with 5'-AMP-activated protein kinase and thus confers transactivation
CRP11	Constitutive androstane receptor (CAR) translocates into the nucleus in accordance with  bbbbb1 5'-AMP eeeee1  bbbbb2 Constitutive androstane receptor eeeee2  (CAR) translocates into the nucleus in accordance with 5'-AMP-activated protein kinase and thus confers transactivation
CRP11	Constitutive androstane receptor (CAR) translocates into the nucleus in accordance with  bbbbb1 5'-AMP eeeee1  bbbbb2 5'-AMP-activated protein kinase eeeee2  and thus confers transactivation
CRP11	Constitutive androstane receptor (CAR) translocates into the nucleus in accordance with  bbbbb1 5'-AMP eeeee1  bbbbb2 CAR eeeee2 ) translocates into the nucleus in accordance with 5'-AMP-activated protein kinase and thus confers transactivation
CRP11	Cross-talk between constitutive  bbbbb1 androstane eeeee1  bbbbb2 constitutive androstane receptor eeeee2  and hypoxia-inducible factor in the regulation of gene expression
CRP11	Cross-talk between constitutive  bbbbb1 androstane eeeee1  receptor and  bbbbb2 hypoxia-inducible factor eeeee2  in the regulation of gene expression
CRP11	Hypoxia inducible factor (HIF) and  bbbbb1 5'-AMP eeeee1  bbbbb2 HIF eeeee2 ) and 5'-AMP-activated protein kinase are often activated under similar physiological conditions
CRP11	Hypoxia inducible factor (HIF) and  bbbbb1 5'-AMP eeeee1  bbbbb2 Hypoxia inducible factor eeeee2  (HIF) and 5'-AMP-activated protein kinase are often activated under similar physiological conditions
CRP11	Hypoxia inducible factor (HIF) and  bbbbb1 5'-AMP eeeee1  bbbbb2 5'-AMP-activated protein kinase eeeee2  are often activated under similar physiological conditions
CRP11	Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2, and buffer alone (100 mM  bbbbb1 potassium phosphate eeeee1  bbbbb2 hCES1 eeeee2 , hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated
CRP11	Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2, and buffer alone (100 mM  bbbbb1 potassium phosphate eeeee1  bbbbb2 hCES2 eeeee2 , and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if  bbbbb1 acyl glucuronides eeeee1  bbbbb2 carboxylesterases eeeee2  and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if  bbbbb1 acyl glucuronides eeeee1 , being esters, also interact with  bbbbb2 carboxylesterases eeeee2 
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize  bbbbb1 carboxylic acids eeeee1  to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with  bbbbb2 carboxylesterases eeeee2 
CRP11	 bbbbb1 Uridine 5'-diphosphate eeeee1  bbbbb2 Uridine 5'-diphosphate- glucuronosyltransferases eeeee2  are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases
CRP11	 bbbbb1 Uridine 5'-diphosphate eeeee1 - glucuronosyltransferases are colocalized with  bbbbb2 carboxylesterases eeeee2  and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases
CRP11	 bbbbb1 Uridine 5'-diphosphate eeeee1 - glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with  bbbbb2 carboxylesterases eeeee2 
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being  bbbbb1 esters eeeee1  bbbbb2 Uridine 5'-diphosphate- glucuronosyltransferases eeeee2  are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being  bbbbb1 esters eeeee1  bbbbb2 carboxylesterases eeeee2  and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being  bbbbb1 esters eeeee1 , also interact with  bbbbb2 carboxylesterases eeeee2 
CRP11	Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to  bbbbb1 acyl glucuronides eeeee1 , but it is currently unknown if acyl glucuronides, being esters, also interact with  bbbbb2 carboxylesterases eeeee2 
CRP11	The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac  bbbbb1 K(+) eeeee1  channel known as HERG (human ether-a-go-go-related gene;  bbbbb2 erg1 eeeee2 )
CRP11	The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac  bbbbb1 K(+) eeeee1  channel known as  bbbbb2 HERG eeeee2  (human ether-a-go-go-related gene; erg1)
CRP11	The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac  bbbbb1 K(+) eeeee1  bbbbb2 cardiac K(+) channel eeeee2  known as HERG (human ether-a-go-go-related gene; erg1)
CRP11	The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac  bbbbb1 K(+) eeeee1  channel known as HERG ( bbbbb2 human ether-a-go-go-related gene eeeee2 ; erg1)
CRP11	We conclude that erg3 can be b bbbbb1 lock eeeee1  bbbbb2 at e eeeee2 rg3 can be blocked by certain antipsychotic drugs like sertindole and pimozide
CRP11	We conclude that erg3 can be b bbbbb1 lock eeeee1  bbbbb2 locked by cer eeeee2 tain antipsychotic drugs like sertindole and pimozide
CRP11	We wished to test whether these drugs also displayed high affinity for the related neuronal  bbbbb1 K(+) eeeee1  channel  bbbbb2 erg3 eeeee2 
CRP11	We wished to test whether these drugs also displayed high affinity for the related neuronal  bbbbb1 K(+) eeeee1  bbbbb2 neuronal K(+) channel eeeee2  erg3
CRP11	The antipsychotic drugs sertindole and pimozide block erg3, a human brain  bbbbb1 K(+) eeeee1  bbbbb2 human brain K(+) channel eeeee2 
CRP11	The antipsychotic drugs sertindole and pimozide block erg3, a human brain  bbbbb1 K(+) eeeee1  bbbbb2 erg3 eeeee2 , a human brain K(+) channel
CRP11	Transient expression of erg3 in Chinese hamster ovary cells produced outwardly directed  bbbbb1 K(+) eeeee1  bbbbb2 erg3 eeeee2  in Chinese hamster ovary cells produced outwardly directed K(+) currents that activated at approximately -50 mV and produced a large transient component at positive membrane potentials
CRP11	Adenosine, an enzymatic ATP degradation product, acts at prejunctional A1  bbbbb1 adenosine eeeee1  receptors ( bbbbb2 A1Rs eeeee2 ) to inhibit NE release
CRP11	Adenosine, an enzymatic ATP degradation product, acts at prejunctional A1  bbbbb1 adenosine eeeee1  bbbbb2 A1 adenosine receptors eeeee2  (A1Rs) to inhibit NE release
CRP11	Adenosine, an enzymatic  bbbbb1 ATP eeeee1  degradation product, acts at prejunctional A1 adenosine receptors ( bbbbb2 A1Rs eeeee2 ) to inhibit NE release
CRP11	Adenosine, an enzymatic  bbbbb1 ATP eeeee1  degradation product, acts at prejunctional  bbbbb2 A1 adenosine receptors eeeee2  (A1Rs) to inhibit NE release
CRP11	 bbbbb1 Adenosine eeeee1 , an enzymatic ATP degradation product, acts at prejunctional A1 adenosine receptors ( bbbbb2 A1Rs eeeee2 ) to inhibit NE release
CRP11	We tested the hypothesis that prejunctional A1R function is impaired in sympathetic nerves supplying mesenteric arteries (MAs) and veins (MVs) of  bbbbb1 DOCA eeeee1  bbbbb2 A1R eeeee2  function is impaired in sympathetic nerves supplying mesenteric arteries (MAs) and veins (MVs) of DOCA-salt rats
CRP11	The A2A  bbbbb1 adenosine eeeee1  bbbbb2 A2A adenosine receptor eeeee2  agonist CGS21680 (C23H29N7O6.HCl.xH2O) (0.001-0.1 μM) did not alter NE oxidation currents
CRP11	NE acts at prejunctional α2-adrenergic receptors (α2ARs) to inhibit NE release, and α2AR function is impaired in  bbbbb1 DOCA eeeee1  bbbbb2 α2ARs eeeee2 ) to inhibit NE release, and α2AR function is impaired in DOCA-salt rats
CRP11	NE acts at prejunctional α2-adrenergic receptors (α2ARs) to inhibit NE release, and α2AR function is impaired in  bbbbb1 DOCA eeeee1  bbbbb2 α2-adrenergic receptors eeeee2  (α2ARs) to inhibit NE release, and α2AR function is impaired in DOCA-salt rats
CRP11	NE acts at prejunctional α2-adrenergic receptors (α2ARs) to inhibit NE release, and α2AR function is impaired in  bbbbb1 DOCA eeeee1  bbbbb2 α2AR eeeee2  function is impaired in DOCA-salt rats
CRP11	Impaired function of prejunctional adenosine A1 receptors expressed by perivascular sympathetic nerves in  bbbbb1 DOCA eeeee1  bbbbb2 adenosine A1 receptors eeeee2  expressed by perivascular sympathetic nerves in DOCA-salt hypertensive rats
CRP11	Impaired function of prejunctional  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A1 receptors eeeee2  expressed by perivascular sympathetic nerves in DOCA-salt hypertensive rats
CRP11	Immunohistochemical methods were used to localize  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2  (TH) and A1Rs in perivascular sympathetic nerves
CRP11	Immunohistochemical methods were used to localize  bbbbb1 tyrosine eeeee1  hydroxylase (TH) and  bbbbb2 A1Rs eeeee2  in perivascular sympathetic nerves
CRP11	Immunohistochemical methods were used to localize  bbbbb1 tyrosine eeeee1  hydroxylase ( bbbbb2 TH eeeee2 ) and A1Rs in perivascular sympathetic nerves
CRP11	Prejunctional A1R function is impaired in arteries, but not veins, from DOCA-salt rats bbbbb1  eeeee1  bbbbb2 not v eeeee2 eins, from DOCA-salt rats
CRP11	This agent has a good safety profile with a low propensity for systemic side effects, such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and a low incidence of local side effects such as pruritus, burning, bbbbb1  or skin atrophy eeeee1  bbbbb2 ic-pituitary-adrenal (H eeeee2 PA) axis, and a low incidence of local side effects such as pruritus, burning, or skin atrophy
CRP11	Voltage-dependent  bbbbb1 calcium eeeee1  bbbbb2 Voltage-dependent calcium channels eeeee2  (VDCCs) are multimeric complexes composed of a pore-forming alpha(1) subunit together with several accessory subunits, including alpha(2)delta, beta, and, in some cases, gamma subunits
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by  bbbbb1 quinpirole eeeee1  bbbbb2 somatostatin receptor subtype 2 eeeee2  (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by  bbbbb1 quinpirole eeeee1  bbbbb2 sst2 eeeee2 ) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by  bbbbb1 somatostatin-14 eeeee1  or activation of transiently transfected  bbbbb2 rat D2 dopamine receptors eeeee2  (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by  bbbbb1 somatostatin-14 eeeee1  or activation of transiently transfected rat D2 dopamine receptors ( bbbbb2 rD2 eeeee2 (long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2  bbbbb1 dopamine eeeee1  bbbbb2 somatostatin receptor subtype 2 eeeee2  (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2  bbbbb1 dopamine eeeee1  bbbbb2 rat D2 dopamine receptors eeeee2  (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2  bbbbb1 dopamine eeeee1  receptors ( bbbbb2 rD2 eeeee2 (long)) by quinpirole had no effect
CRP11	Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2  bbbbb1 dopamine eeeee1  bbbbb2 sst2 eeeee2 ) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor subtype 2 eeeee2  (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous  bbbbb1 somatostatin eeeee1  receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected  bbbbb2 rat D2 dopamine receptors eeeee2  (rD2(long)) by quinpirole had no effect
CRP11	Activation of endogenous  bbbbb1 somatostatin eeeee1  receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors ( bbbbb2 rD2 eeeee2 (long)) by quinpirole had no effect
CRP11	Activation of endogenous  bbbbb1 somatostatin eeeee1  receptor subtype 2 ( bbbbb2 sst2 eeeee2 ) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D)  bbbbb1 calcium eeeee1  channels, we have examined  bbbbb2 calcium channel eeeee2  currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D)  bbbbb1 calcium eeeee1  bbbbb2 G-protein eeeee2  modulation of alpha(1D) calcium channels, we have examined calcium channel currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D)  bbbbb1 calcium eeeee1  bbbbb2 alpha(1D) calcium channels eeeee2 , we have examined calcium channel currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D)  bbbbb1 calcium eeeee1  channels, we have examined calcium channel currents formed by the  bbbbb2 human neuronal L-type alpha(1D) eeeee2  subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D) calcium channels, we have examined  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D) calcium channels, we have examined  bbbbb1 calcium eeeee1  bbbbb2 G-protein eeeee2  modulation of alpha(1D) calcium channels, we have examined calcium channel currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D) calcium channels, we have examined  bbbbb1 calcium eeeee1  bbbbb2 alpha(1D) calcium channels eeeee2 , we have examined calcium channel currents formed by the human neuronal L-type alpha(1D) subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	To investigate the biophysical and pharmacological properties and role of G-protein modulation of alpha(1D) calcium channels, we have examined  bbbbb1 calcium eeeee1  channel currents formed by the  bbbbb2 human neuronal L-type alpha(1D) eeeee2  subunit, co-expressed with alpha(2)delta-1 and beta(3a), stably expressed in a human embryonic kidney (HEK) 293 cell line, using whole cell and perforated patch-clamp techniques
CRP11	Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent  bbbbb1 calcium eeeee1  bbbbb2 alpha(1D) eeeee2 , Ca(V)1.3) voltage-dependent calcium currents
CRP11	Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent  bbbbb1 calcium eeeee1  bbbbb2 Ca(V)1.3 eeeee2 ) voltage-dependent calcium currents
CRP11	Neuroendocrine L-type currents have a significant role in the control of neurosecretion and can be inhibited by  bbbbb1 GTP eeeee1  bbbbb2 GTP-binding (G-) proteins eeeee2 
CRP11	In vitro studies have determined that in addition to its specific  bbbbb1 methyl eeeee1 -CpG-binding domain ( bbbbb2 MBD eeeee2 ) MeCP2 also has several chromatin association domains
CRP11	In vitro studies have determined that in addition to its specific  bbbbb1 methyl eeeee1 -CpG-binding domain (MBD) MeCP2 also has several  bbbbb2 chromatin association domains eeeee2 
CRP11	In vitro studies have determined that in addition to its specific  bbbbb1 methyl eeeee1 -CpG-binding domain (MBD)  bbbbb2 MeCP2 eeeee2  also has several chromatin association domains
CRP11	In vitro studies have determined that in addition to its specific  bbbbb1 methyl eeeee1  bbbbb2 methyl-CpG-binding domain eeeee2  (MBD) MeCP2 also has several chromatin association domains
CRP11	We analysed the role of the MBD in MeCP2-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model (Mecp2(tm)(1)(.)(1)(Jae)) in which exon 3 deletion results in an  bbbbb1 N eeeee1 -terminal truncation of the protein, including most of the  bbbbb2 MBD eeeee2 
CRP11	We analysed the role of the MBD in MeCP2-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model (Mecp2(tm)(1)(.)(1)(Jae)) in which exon 3 deletion results in an  bbbbb1 N eeeee1  bbbbb2 MBD eeeee2  in MeCP2-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model (Mecp2(tm)(1)(.)(1)(Jae)) in which exon 3 deletion results in an N-terminal truncation of the protein, including most of the MBD
CRP11	P2 is a  bbbbb1 methyl eeeee1  bbbbb2 methyl-CpG-binding protein eeeee2  that is a main component of brain chromatin in vertebrates
CRP11	Recently, bupropion has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2  bbbbb1 nicotinic acetylcholine eeeee1  bbbbb2 alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) eeeee2  expressed in Xenopus oocytes or established cell lines
CRP11	Recently,  bbbbb1 bupropion eeeee1  has been reported to noncompetitively inhibit  bbbbb2 alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (nAChRs) eeeee2  expressed in Xenopus oocytes or established cell lines
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with  bbbbb1 [(3)H]norepinephrine eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with  bbbbb1 [(3)H]dopamine eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated  bbbbb1 bupropion eeeee1 -induced inhibition of native  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and  bbbbb1 nicotine eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays,  bbbbb1 nicotine eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [ bbbbb1 (3)H eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ( bbbbb1 [(3)H]DA eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ( bbbbb1 [(3)H]NE eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	The present study evaluated bupropion-induced inhibition of native alpha3beta2* and alpha3beta4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [ bbbbb1 (3)H eeeee1  bbbbb2 alpha3beta2* and alpha3beta4* nAChRs eeeee2  using functional neurotransmitter release assays, nicotine-evoked [(3)H]overflow from superfused rat striatal slices preloaded with [(3)H]dopamine ([(3)H]DA), and nicotine-evoked [(3)H]overflow from hippocampal slices preloaded with [(3)H]norepinephrine ([(3)H]NE)
CRP11	 bbbbb1 Bupropion eeeee1 , an efficacious antidepressant and smoking cessation agent, inhibits  bbbbb2 dopamine and norepinephrine transporters eeeee2  (DAT and NET, respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits  bbbbb1 dopamine eeeee1  bbbbb2 dopamine and norepinephrine transporters eeeee2  (DAT and NET, respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits  bbbbb1 dopamine eeeee1  and norepinephrine transporters (DAT and  bbbbb2 NET eeeee2 , respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits  bbbbb1 dopamine eeeee1  and norepinephrine transporters ( bbbbb2 DAT eeeee2  and NET, respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and  bbbbb1 norepinephrine eeeee1  bbbbb2 dopamine and norepinephrine transporters eeeee2  (DAT and NET, respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and  bbbbb1 norepinephrine eeeee1  transporters (DAT and  bbbbb2 NET eeeee2 , respectively)
CRP11	Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and  bbbbb1 norepinephrine eeeee1  transporters ( bbbbb2 DAT eeeee2  and NET, respectively)
CRP11	To eliminate the interaction of bupropion with DAT or NET, nomifensine or  bbbbb1 desipramine eeeee1  bbbbb2 DAT eeeee2  or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer
CRP11	To eliminate the interaction of bupropion with DAT or NET, nomifensine or  bbbbb1 desipramine eeeee1  bbbbb2 NET eeeee2 , nomifensine or desipramine, respectively, was included in the superfusion buffer
CRP11	To eliminate the interaction of bupropion with DAT or NET,  bbbbb1 nomifensine eeeee1  bbbbb2 DAT eeeee2  or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer
CRP11	To eliminate the interaction of bupropion with DAT or NET,  bbbbb1 nomifensine eeeee1  bbbbb2 NET eeeee2 , nomifensine or desipramine, respectively, was included in the superfusion buffer
CRP11	Efficient neutralization of the androgenic action at the prostatic bbbbb1  level in  eeeee1 intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at the prostatic bbbbb1  level in  eeeee1 intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at the prostatic bbbbb1  level in  eeeee1 intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb1  eeeee1  bbbbb2 n  eeeee2 of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion
CRP11	Efficient neutralization of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at  bbbbb1 the pros eeeee1 tatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at  bbbbb1 the pros eeeee1 tatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	Efficient neutralization of the androgenic action at  bbbbb1 the pros eeeee1 tatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion bbbbb2  eeeee2 
CRP11	In fact, the plasma testosterone concentration is more than doubled 6 hr after the administration of 10 mg of RU 23908 while plasma LH and  bbbbb1 testosterone eeeee1  bbbbb2 LH eeeee2  and testosterone levels are increased by 7- and 17-fold, respectively, after 14 days of similar daily treatment
CRP11	In fact, the plasma  bbbbb1 testosterone eeeee1  concentration is more than doubled 6 hr after the administration of 10 mg of RU 23908 while plasma  bbbbb2 LH eeeee2  and testosterone levels are increased by 7- and 17-fold, respectively, after 14 days of similar daily treatment
CRP11	In fact, the plasma testosterone concentration is more than doubled 6 hr after the administration of 10 mg of  bbbbb1 RU 23908 eeeee1  while plasma  bbbbb2 LH eeeee2  and testosterone levels are increased by 7- and 17-fold, respectively, after 14 days of similar daily treatment
CRP11	In intact animals, neutralization of the inhibitory feedback action of endogenous androgens leads to an increased LH and  bbbbb1 testosterone eeeee1  bbbbb2 LH eeeee2  and testosterone secretion, which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles
CRP11	In intact animals, neutralization of the inhibitory feedback action of endogenous  bbbbb1 androgens eeeee1  leads to an increased  bbbbb2 LH eeeee2  and testosterone secretion, which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles
CRP11	The nonsteroidal antiandrogen RU 23908 ( Anandron ) weakly interacts with the prostatic cytosolic  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  and shows a fast dissociation rate
CRP11	This is due to the property of the pure antiandrogen to neutralize the inhibitory feedback effect of  bbbbb1 androgens eeeee1  at the pituitary level on the LH responsiveness to  bbbbb2 LHRH eeeee2 , as illustrated in vitro in rat anterior pituitary cells in culture as well as in vivo in intact and castrated animals
CRP11	This is due to the property of the pure antiandrogen to neutralize the inhibitory feedback effect of  bbbbb1 androgens eeeee1  at the pituitary level on the  bbbbb2 LH eeeee2  responsiveness to LHRH, as illustrated in vitro in rat anterior pituitary cells in culture as well as in vivo in intact and castrated animals
CRP11	 bbbbb1 Indomethacin eeeee1  inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited  bbbbb2 hCOX-2 eeeee2 
CRP11	Indomethacin inhibited both hCOX-1 and hCOX-2, whereas  bbbbb1 NS-398 eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2
CRP11	Indomethacin inhibited both hCOX-1 and hCOX-2, whereas  bbbbb1 NS-398 eeeee1  bbbbb2 hCOX-2 eeeee2 , whereas NS-398 and Dup-697 selectively inhibited hCOX-2
CRP11	Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and  bbbbb1 Dup-697 eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2
CRP11	Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and  bbbbb1 Dup-697 eeeee1  bbbbb2 hCOX-2 eeeee2 , whereas NS-398 and Dup-697 selectively inhibited hCOX-2
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 Constitutive and inducible forms of human cyclo-oxygenase eeeee2  (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 hCOX-2 eeeee2 ) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 hCOX-1 eeeee2  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of  bbbbb1 O2 eeeee1  bbbbb2 Constitutive and inducible forms of human cyclo-oxygenase eeeee2  (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-2 eeeee2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-2 eeeee2 ) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 Constitutive and inducible forms of human cyclo-oxygenase eeeee2  (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  bbbbb1 arachidonate eeeee1  and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas  bbbbb2 hCOX-2 eeeee2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 hCOX-2 eeeee2 ) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  bbbbb1 arachidonate eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of  bbbbb1 O2 eeeee1  bbbbb2 Constitutive and inducible forms of human cyclo-oxygenase eeeee2  (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of  bbbbb1 O2 eeeee1 /mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas  bbbbb2 hCOX-2 eeeee2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-2 eeeee2 ) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of  bbbbb1 O2 eeeee1  bbbbb2 Constitutive and inducible forms of human cyclo-oxygenase eeeee2  (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-2 eeeee2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-2 eeeee2 ) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of  bbbbb1 O2 eeeee1  bbbbb2 hCOX-1 eeeee2  and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme
CRP11	Effects of some  bbbbb1 mono- and bisquaternary ammonium eeeee1  compounds on the reactivatability of soman-inhibited  bbbbb2 human acetylcholinesterase eeeee2  in vitro
CRP11	Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the  bbbbb1 soman eeeee1  bbbbb2 AChE eeeee2 ) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex
CRP11	Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the  bbbbb1 soman eeeee1  bbbbb2 Acetylcholinesterase eeeee2  (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex
CRP11	The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium,  bbbbb1 decamethonium eeeee1  and suxamethonium on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The effect of the four mono- and bisquaternary ammonium compounds  bbbbb1 tetramethylammonium eeeee1  (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and  bbbbb1 suxamethonium eeeee1  on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The effect of the four  bbbbb1 mono- and bisquaternary ammonium eeeee1  compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium ( bbbbb1 TMA eeeee1 ), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA),  bbbbb1 hexamethonium eeeee1 , decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized  bbbbb2 AChE eeeee2  from human erythrocytes was investigated in vitro
CRP11	The reactivation experiments were performed in a four-step procedure ( bbbbb1 soman eeeee1 -inhibition at 0 degree and pH 10, aging at 37 degrees and pH 7.3, reactivation by the oxime HI 6 at 37 degrees and pH 7.3 followed by  bbbbb2 AChE eeeee2  assay)
CRP11	The reactivation experiments were performed in a four-step procedure (soman-inhibition at 0 degree and pH 10, aging at 37 degrees and pH 7.3, reactivation by the  bbbbb1 oxime eeeee1  HI 6 at 37 degrees and pH 7.3 followed by  bbbbb2 AChE eeeee2  assay)
CRP11	Accordingly, PTN-/- and MK-/- mice show an increased vulnerability to  bbbbb1 amphetamine eeeee1  bbbbb2 PTN eeeee2 -/- and MK-/- mice show an increased vulnerability to amphetamine-induced neurotoxic effects
CRP11	Accordingly, PTN-/- and MK-/- mice show an increased vulnerability to  bbbbb1 amphetamine eeeee1  bbbbb2 MK eeeee2 -/- mice show an increased vulnerability to amphetamine-induced neurotoxic effects
CRP11	In an effort to uncover new pharmacological targets to prevent amphetamine neurotoxic effects, we have now used a proteomic approach to study protein phosphorylation, in which we combined phosphoprotein enrichment, by immobilized metal affinity chromatography (IMAC), with two-dimensional gel electrophoresis and mass spectrometry, in order to identify the phosphoproteins regulated in the striatum of PTN-/-, MK-/- and wild type (WT) mice treated with  bbbbb1 amphetamine eeeee1  bbbbb2 MK eeeee2 -/- and wild type (WT) mice treated with amphetamine
CRP11	In an effort to uncover new pharmacological targets to prevent amphetamine neurotoxic effects, we have now used a proteomic approach to study protein phosphorylation, in which we combined phosphoprotein enrichment, by immobilized metal affinity chromatography (IMAC), with two-dimensional gel electrophoresis and mass spectrometry, in order to identify the phosphoproteins regulated in the striatum of PTN-/-, MK-/- and wild type (WT) mice treated with  bbbbb1 amphetamine eeeee1  bbbbb2 PTN eeeee2 -/-, MK-/- and wild type (WT) mice treated with amphetamine
CRP11	In an effort to uncover new pharmacological targets to prevent  bbbbb1 amphetamine eeeee1  neurotoxic effects, we have now used a proteomic approach to study protein phosphorylation, in which we combined phosphoprotein enrichment, by immobilized metal affinity chromatography (IMAC), with two-dimensional gel electrophoresis and mass spectrometry, in order to identify the phosphoproteins regulated in the striatum of PTN-/-,  bbbbb2 MK eeeee2 -/- and wild type (WT) mice treated with amphetamine
CRP11	In an effort to uncover new pharmacological targets to prevent  bbbbb1 amphetamine eeeee1  neurotoxic effects, we have now used a proteomic approach to study protein phosphorylation, in which we combined phosphoprotein enrichment, by immobilized metal affinity chromatography (IMAC), with two-dimensional gel electrophoresis and mass spectrometry, in order to identify the phosphoproteins regulated in the striatum of  bbbbb2 PTN eeeee2 -/-, MK-/- and wild type (WT) mice treated with amphetamine
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  kinase U-type ( bbbbb2 CKMT1 eeeee2 ), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 creatine kinase U-type eeeee2  (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 ALDH1A1 eeeee2 ) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 COPS5 eeeee2 ), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 aldehyde dehydrogenase family 1 member A1 eeeee2  (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and  bbbbb2 MK eeeee2  have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 COP9 signalosome subunit 5 eeeee2  (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since  bbbbb2 PTN eeeee2  and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 annexin A7 eeeee2  (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb1 creatine eeeee1  bbbbb2 ANXA7 eeeee2 ), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 CKMT1 eeeee2 ), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 creatine kinase U-type eeeee2  (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 ALDH1A1 eeeee2 ) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 COPS5 eeeee2 ), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 aldehyde dehydrogenase family 1 member A1 eeeee2  (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 MK eeeee2  have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 COP9 signalosome subunit 5 eeeee2  (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 PTN eeeee2  and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 annexin A7 eeeee2  (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in  bbbbb1 methamphetamine eeeee1  bbbbb2 ANXA7 eeeee2 ), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type ( bbbbb2 CKMT1 eeeee2 ), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  dehydrogenase family 1 member A1 (ALDH1A1) and  bbbbb2 creatine kinase U-type eeeee2  (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  dehydrogenase family 1 member A1 ( bbbbb2 ALDH1A1 eeeee2 ) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  bbbbb2 COPS5 eeeee2 ), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  bbbbb2 aldehyde dehydrogenase family 1 member A1 eeeee2  (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and  bbbbb2 MK eeeee2  have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  bbbbb2 COP9 signalosome subunit 5 eeeee2  (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since  bbbbb2 PTN eeeee2  and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  bbbbb2 annexin A7 eeeee2  (ANXA7), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	It is very interesting to note that 4 of these phosphoproteins, annexin A7 (ANXA7), COP9 signalosome subunit 5 (COPS5),  bbbbb1 aldehyde eeeee1  bbbbb2 ANXA7 eeeee2 ), COP9 signalosome subunit 5 (COPS5), aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and creatine kinase U-type (CKMT1), are known to be involved in Parkinson's disease, a result of significant importance since PTN and MK have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in methamphetamine abusers
CRP11	Differential phosphoproteome of the striatum from pleiotrophin knockout and midkine knockout mice treated with amphetamine: Correlations with  bbbbb1 amphetamine eeeee1  bbbbb2 midkine eeeee2  knockout mice treated with amphetamine: Correlations with amphetamine-induced neurotoxicity
CRP11	Differential phosphoproteome of the striatum from pleiotrophin knockout and midkine knockout mice treated with amphetamine: Correlations with  bbbbb1 amphetamine eeeee1  bbbbb2 pleiotrophin eeeee2  knockout and midkine knockout mice treated with amphetamine: Correlations with amphetamine-induced neurotoxicity
CRP11	Differential phosphoproteome of the striatum from pleiotrophin knockout and midkine knockout mice treated with  bbbbb1 amphetamine eeeee1  bbbbb2 midkine eeeee2  knockout mice treated with amphetamine: Correlations with amphetamine-induced neurotoxicity
CRP11	Differential phosphoproteome of the striatum from pleiotrophin knockout and midkine knockout mice treated with  bbbbb1 amphetamine eeeee1  bbbbb2 pleiotrophin eeeee2  knockout and midkine knockout mice treated with amphetamine: Correlations with amphetamine-induced neurotoxicity
CRP11	S from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 amino acids long against an average length of 430-457  bbbbb1 amino acids eeeee1  bbbbb2 MjAdSS eeeee2 ) is 345 amino acids long against an average length of 430-457 amino acids for most mesophilic AdSS
CRP11	S from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345  bbbbb1 amino acids eeeee1  long against an average length of 430-457 amino acids for most mesophilic  bbbbb2 AdSS eeeee2 
CRP11	Kinetic characterization of  bbbbb1 adenylosuccinate eeeee1  bbbbb2 adenylosuccinate synthetase eeeee2  from the thermophilic archaea Methanocaldococcus jannaschii
CRP11	The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and melperone had low affinity for the  bbbbb1 dopamine eeeee1   bbbbb2 D2 receptor eeeee2  (radioligand-independent dissociation constants of 30 to 90 nM)
CRP11	Such an examination requires consistent and accurate dissociation constants for the antipsychotic drugs at the relevant  bbbbb1 dopamine eeeee1  bbbbb2 dopamine and serotonin receptors eeeee2 
CRP11	Such an examination requires consistent and accurate dissociation constants for the antipsychotic drugs at the relevant dopamine and  bbbbb1 serotonin eeeee1  bbbbb2 dopamine and serotonin receptors eeeee2 
CRP11	Atypical neuroleptics have low affinity for  bbbbb1 dopamine eeeee1  D2 receptors or are selective for  bbbbb2 D4 receptors eeeee2 
CRP11	Atypical neuroleptics have low affinity for  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptors eeeee2  or are selective for D4 receptors
CRP11	Finally, a relation was found between the neuroleptic doses for rat catalepsy and the D2:D4 ratio of the radioligand-independent K values for these two re bbbbb1 ceptors eeeee1  bbbbb2 ceptors eeeee2 
CRP11	Finally, a relation was found between the neuroleptic doses for rat catalepsy and the D2:D4 ratio of the radioligand-independent K values for these two re bbbbb1 ceptors eeeee1  bbbbb2 f the radioligand-ind eeeee2 ependent K values for these two receptors
CRP11	Finally, a relation was found between the neuroleptic doses for rat catalepsy and the D2:D4 ratio o bbbbb1 f the ra eeeee1 dioligand-independent K values for these two re bbbbb2 ceptors eeeee2 
CRP11	Finally, a relation was found between the neuroleptic doses for rat catalepsy and the D2:D4 ratio o bbbbb1 f the ra eeeee1  bbbbb2 f the radioligand-ind eeeee2 ependent K values for these two receptors
CRP11	It has long been known, however, that the dissociation constant of a given antipsychotic drug at the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptor eeeee2  varies between laboratories
CRP11	However, because clozapine competes with endogenous dopamine, the in vivo concentration of clozapine (to occupy  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D4 receptors eeeee2 ) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients
CRP11	Most typical neuroleptics have radioligand-independent values of 0.3 to 5 nM at  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptors eeeee2 , making them more resistant to displacement by endogenous dopamine
CRP11	These values are here given for  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 and D4 receptors eeeee2 , as well as for serotonin 5-HT2A receptors
CRP11	These values are here given for  bbbbb1 dopamine eeeee1  D2 and D4 receptors, as well as for  bbbbb2 serotonin 5-HT2A receptors eeeee2 
CRP11	These values are here given for dopamine D2 and D4 receptors, as well as for  bbbbb1 serotonin eeeee1  bbbbb2 dopamine D2 and D4 receptors eeeee2 , as well as for serotonin 5-HT2A receptors
CRP11	These values are here given for dopamine D2 and D4 receptors, as well as for  bbbbb1 serotonin eeeee1  bbbbb2 serotonin 5-HT2A receptors eeeee2 
CRP11	For example, clozapine revealed a radioligand-independent value of 1.6 nM at the dopamine D4 receptor, agreeing with the value directly measured with  bbbbb1 [3H]-clozapine eeeee1  bbbbb2 dopamine D4 receptor eeeee2 , agreeing with the value directly measured with [3H]-clozapine at D4
CRP11	For example,  bbbbb1 clozapine eeeee1  revealed a radioligand-independent value of 1.6 nM at the dopamine D4 receptor, agreeing with the value directly measured with [3H]-clozapine at  bbbbb2 D4 eeeee2 
CRP11	For example, clozapine revealed a radioligand-independent value of 1.6 nM at the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D4 receptor eeeee2 , agreeing with the value directly measured with [3H]-clozapine at D4
CRP11	For example, clozapine revealed a radioligand-independent value of 1.6 nM at the  bbbbb1 dopamine eeeee1  D4 receptor, agreeing with the value directly measured with [3H]-clozapine at  bbbbb2 D4 eeeee2 
CRP11	To understand the possible mechanism of  bbbbb1 PhIP eeeee1 -associated stomach cancer, the effects of PhIP on morphology, oxidative stress, gene expression of  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs were investigated
CRP11	To understand the possible mechanism of  bbbbb1 PhIP eeeee1 -associated stomach cancer, the effects of PhIP on morphology, oxidative stress, gene expression of c-fos, c-jun and  bbbbb2 p16 eeeee2  in rat stomachs were investigated
CRP11	To understand the possible mechanism of  bbbbb1 PhIP eeeee1 -associated stomach cancer, the effects of PhIP on morphology, oxidative stress, gene expression of c-fos,  bbbbb2 c-jun eeeee2  and p16 in rat stomachs were investigated
CRP11	To understand the possible mechanism of PhIP-associated stomach cancer, the effects of  bbbbb1 PhIP eeeee1  on morphology, oxidative stress, gene expression of  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs were investigated
CRP11	To understand the possible mechanism of PhIP-associated stomach cancer, the effects of  bbbbb1 PhIP eeeee1  on morphology, oxidative stress, gene expression of c-fos, c-jun and  bbbbb2 p16 eeeee2  in rat stomachs were investigated
CRP11	To understand the possible mechanism of PhIP-associated stomach cancer, the effects of  bbbbb1 PhIP eeeee1  on morphology, oxidative stress, gene expression of c-fos,  bbbbb2 c-jun eeeee2  and p16 in rat stomachs were investigated
CRP11	With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP bbbbb1  at  eeeee1  bbbbb2  coef eeeee2 ficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control
CRP11	With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP bbbbb1  at  eeeee1  bbbbb2 inks  eeeee2 (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control
CRP11	With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP bbbbb1  at  eeeee1  bbbbb2 can eeeee2 tly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines ( bbbbb1 HCAs eeeee1  bbbbb2 p16 eeeee2  in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines ( bbbbb1 HCAs eeeee1  bbbbb2 c-jun eeeee2  and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines ( bbbbb1 HCAs eeeee1  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant  bbbbb1 heterocyclic amines eeeee1  bbbbb2 p16 eeeee2  in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant  bbbbb1 heterocyclic amines eeeee1  bbbbb2 c-jun eeeee2  and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant  bbbbb1 heterocyclic amines eeeee1  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs.  bbbbb1 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine eeeee1  bbbbb2 p16 eeeee2  in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs.  bbbbb1 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine eeeee1  bbbbb2 c-jun eeeee2  and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs.  bbbbb1 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine eeeee1  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine ( bbbbb1 PhIP eeeee1  bbbbb2 p16 eeeee2  in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine ( bbbbb1 PhIP eeeee1  bbbbb2 c-jun eeeee2  and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine ( bbbbb1 PhIP eeeee1  bbbbb2 c-fos eeeee2 , c-jun and p16 in rat stomachs. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase ( bbbbb2 SOD eeeee2 ) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb2 superoxide dismutase eeeee2  (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase ( bbbbb2 CAT eeeee2 ) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased  bbbbb2 catalase eeeee2  (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and  bbbbb2 glutathioneperoxidase eeeee2  (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight  bbbbb1 PhIP eeeee1  induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase ( bbbbb2 GPx eeeee2 ) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase ( bbbbb2 CAT eeeee2 ) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased  bbbbb2 catalase eeeee2  (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  dismutase (SOD) and  bbbbb2 glutathioneperoxidase eeeee2  (GPx) activities, while increased catalase (CAT) activity compared with the control
CRP11	The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased  bbbbb1 superoxide eeeee1  dismutase (SOD) and glutathioneperoxidase ( bbbbb2 GPx eeeee2 ) activities, while increased catalase (CAT) activity compared with the control
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids  bbbbb1 eicosapentaenoic acid eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3  bbbbb1 polyunsaturated fatty acids eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and  bbbbb1 docosahexaenoic acid eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as  bbbbb1 resolvins eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid ( bbbbb1 EPA eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid ( bbbbb1 DHA eeeee1  bbbbb2 insulin eeeee2  resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
CRP11	By this mechanism, CE-responsive drug in vitro release from  bbbbb1 PEC eeeee1  bbbbb2 CE eeeee2 -responsive drug in vitro release from PEC in situ forming depots (ISFD) was conducted successfully
CRP11	Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from  bbbbb1 PEC eeeee1  bbbbb2 Cholesterol esterase eeeee2  (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated
CRP11	Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from  bbbbb1 PEC eeeee1  bbbbb2 CE eeeee2 ) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated
CRP11	 bbbbb1 Cholesterol eeeee1  bbbbb2 Cholesterol esterase eeeee2  (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated
CRP11	 bbbbb1 Cholesterol eeeee1  esterase ( bbbbb2 CE eeeee2 ) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated
CRP11	Contrary to this biological function, glut3 expression rises synchronously with  bbbbb1 (m)CpGs eeeee1  bbbbb2 glut3 eeeee2  expression rises synchronously with (m)CpGs in PN14 vs PN3 neurons
CRP11	We conclude that Glut3 is a methylation-sensitive neuronal gene that recruits Mecp2 bbbbb1  eeeee1  bbbbb2 3 is  eeeee2 a methylation-sensitive neuronal gene that recruits Mecp2
CRP11	We conclude that Glut3 is a methylation-sensitive neuronal gene that recruits Mecp2 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	We conclude that Glut3 is a methylation-sensitive neuronal gene that recruits Mecp2 bbbbb1  eeeee1  bbbbb2 t Glu eeeee2 t3 is a methylation-sensitive neuronal gene that recruits Mecp2
CRP11	We conclude that Glut3 is a methylation-sensitive neuronal gene that recruits Mecp2 bbbbb1  eeeee1  bbbbb2 thyla eeeee2 tion-sensitive neuronal gene that recruits Mecp2
CRP11	We conclude that Glut3 is a methylat bbbbb1 ion-se eeeee1  bbbbb2 3 is  eeeee2 a methylation-sensitive neuronal gene that recruits Mecp2
CRP11	We conclude that Glut3 is a methylat bbbbb1 ion-se eeeee1 nsitive neuronal gene that recruits Mecp2 bbbbb2  eeeee2 
CRP11	We conclude that Glut3 is a methylat bbbbb1 ion-se eeeee1  bbbbb2 t Glu eeeee2 t3 is a methylation-sensitive neuronal gene that recruits Mecp2
CRP11	The murine neuronal facilitative  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter isoform 3 eeeee2  (Glut3) is developmentally regulated, peaking in expression at postnatal day (PN)14
CRP11	The murine neuronal facilitative  bbbbb1 glucose eeeee1  transporter isoform 3 ( bbbbb2 Glut3 eeeee2 ) is developmentally regulated, peaking in expression at postnatal day (PN)14
CRP11	In the present study, we characterized a canonical  bbbbb1 CpG eeeee1  island spanning the 5'-flanking region of the  bbbbb2 glut3 eeeee2  gene
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ( bbbbb1 (m)CpG eeeee1 ) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of  bbbbb2 glut3 eeeee2 -luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ( bbbbb1 (m)CpG eeeee1 ) island of the  bbbbb2 glut3 eeeee2  gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ( bbbbb1 (m)CpG eeeee1 ) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit  bbbbb2 glut3 eeeee2  transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this  bbbbb1 CpG eeeee1  ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of  bbbbb2 glut3 eeeee2 -luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this  bbbbb1 CpG eeeee1  ((m)CpG) island of the  bbbbb2 glut3 eeeee2  gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this  bbbbb1 CpG eeeee1  ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit  bbbbb2 glut3 eeeee2  transcription
CRP11	Methylation-specific PCR and  bbbbb1 bisulfite eeeee1  sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of  bbbbb2 glut3 eeeee2 -luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and  bbbbb1 bisulfite eeeee1  sequencing identified methylation of this CpG ((m)CpG) island of the  bbbbb2 glut3 eeeee2  gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and  bbbbb1 bisulfite eeeee1  sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit  bbbbb2 glut3 eeeee2  transcription
CRP11	Methylation-specific PCR and  bbbbb1 bisulfite eeeee1  sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in  bbbbb2 DNA methyl transferase 3a eeeee2  concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that  bbbbb1 (m)CpGs eeeee1  bbbbb2 glut3 eeeee2 -luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that  bbbbb1 (m)CpGs eeeee1  bbbbb2 glut3 eeeee2  gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that  bbbbb1 (m)CpGs eeeee1  bbbbb2 DNA methyl transferase 3a eeeee2  concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription
CRP11	IP and coimmunolocalization confirmed that Creb1 associated with Mecp2 and cotransfection with glut3- bbbbb1 (m)CpG eeeee1  in HT22 cells enhanced  bbbbb2 glut3 eeeee2  transcription
CRP11	IP and coimmunolocalization confirmed that Creb1 associated with Mecp2 and cotransfection with glut3- bbbbb1 (m)CpG eeeee1  bbbbb2 Mecp2 eeeee2  and cotransfection with glut3-(m)CpG in HT22 cells enhanced glut3 transcription
CRP11	IP and coimmunolocalization confirmed that Creb1 associated with Mecp2 and cotransfection with glut3- bbbbb1 (m)CpG eeeee1  bbbbb2 Creb1 eeeee2  associated with Mecp2 and cotransfection with glut3-(m)CpG in HT22 cells enhanced glut3 transcription
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 glut3 eeeee2 -(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 Creb1 eeeee2  separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  reduced  bbbbb2 glut3 eeeee2  expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 Creb1 eeeee2  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 Mecp2 eeeee2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 Mecp2 eeeee2  and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  bbbbb1 trichostatin A eeeee1  reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of  bbbbb2 glut3 eeeee2 -(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  bbbbb1 trichostatin A eeeee1  reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced  bbbbb2 glut3 eeeee2  expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  bbbbb1 trichostatin A eeeee1  reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or  bbbbb2 Creb1 eeeee2  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  bbbbb1 trichostatin A eeeee1  reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting  bbbbb2 Mecp2 eeeee2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of  bbbbb2 glut3 eeeee2 -(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting Mecp2 and  bbbbb2 Creb1 eeeee2  separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced  bbbbb2 glut3 eeeee2  expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or  bbbbb2 Creb1 eeeee2  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting  bbbbb2 Mecp2 eeeee2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced  bbbbb1 (m)CpG eeeee1  and specific small interference RNAs targeting  bbbbb2 Mecp2 eeeee2  and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate  bbbbb1 5-aza-2'-deoxycytidine eeeee1  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of  bbbbb2 glut3 eeeee2 -(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate  bbbbb1 5-aza-2'-deoxycytidine eeeee1  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced  bbbbb2 glut3 eeeee2  expression in HT22 cells
CRP11	Separate  bbbbb1 5-aza-2'-deoxycytidine eeeee1  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or  bbbbb2 Creb1 eeeee2  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Separate  bbbbb1 5-aza-2'-deoxycytidine eeeee1  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting  bbbbb2 Mecp2 eeeee2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells
CRP11	Creb1-Mecp2- bbbbb1 (m)CpG eeeee1  complex transactivates postnatal murine neuronal  bbbbb2 glucose transporter isoform 3 eeeee2  expression
CRP11	Creb1-Mecp2- bbbbb1 (m)CpG eeeee1  bbbbb2 Mecp2 eeeee2 -(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression
CRP11	Creb1-Mecp2- bbbbb1 (m)CpG eeeee1  bbbbb2 Creb1 eeeee2 -Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression
CRP11	Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter isoform 3 eeeee2  expression
CRP11	Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal  bbbbb1 glucose eeeee1  bbbbb2 Mecp2 eeeee2 -(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression
CRP11	Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal  bbbbb1 glucose eeeee1  bbbbb2 Creb1 eeeee2 -Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression
CRP11	Chromatin immunoprecipitation (IP) revealed that methyl-CpG binding protein 2 (Mecp2) bound the glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 methyl-CpG binding protein 2 eeeee2  (Mecp2) bound the glut3-(m)CpGs
CRP11	Chromatin immunoprecipitation (IP) revealed that methyl-CpG binding protein 2 (Mecp2) bound the glut3- bbbbb1 (m)CpGs eeeee1  bbbbb2 Mecp2 eeeee2 ) bound the glut3-(m)CpGs
CRP11	Chromatin immunoprecipitation (IP) revealed that  bbbbb1 methyl eeeee1  bbbbb2 methyl-CpG binding protein 2 eeeee2  (Mecp2) bound the glut3-(m)CpGs
CRP11	Chromatin immunoprecipitation (IP) revealed that  bbbbb1 methyl eeeee1 -CpG binding protein 2 ( bbbbb2 Mecp2 eeeee2 ) bound the glut3-(m)CpGs
CRP11	Chromatin immunoprecipitation (IP) revealed that  bbbbb1 methyl eeeee1 -CpG binding protein 2 (Mecp2) bound the  bbbbb2 glut3 eeeee2 -(m)CpGs
CRP11	In contrast to previous concepts,  bbbbb1 acetaminophen eeeee1  inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective  bbbbb2 COX-2 eeeee2  inhibitors
CRP11	Coagulation-induced  bbbbb1 thromboxane B(2) eeeee1  and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of COX-1 and  bbbbb2 COX-2 eeeee2  activity
CRP11	Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced  bbbbb1 prostaglandin E(2) eeeee1  were measured ex vivo and in vitro in human whole blood as indices of  bbbbb2 COX-1 eeeee2  and COX-2 activity
CRP11	The fact that  bbbbb1 acetaminophen eeeee1  acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential  bbbbb2 COX-2 eeeee2  blockade
CRP11	Our data may explain acetaminophen's analgesic and antiinflammatory action as well as its superior overall gastrointestinal safety profile compa bbbbb1 red with NSAI eeeee1  bbbbb2 r ove eeeee2 rall gastrointestinal safety profile compared with NSAIDs
CRP11	A series of  bbbbb1 2-carbonyl eeeee1  analogues of the muscarinic antagonist diphenidol bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the  bbbbb2 M2 and M3 muscarinic receptor eeeee2  subtypes was evaluated by functional tests
CRP11	Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased  bbbbb1 cAMP eeeee1  bbbbb2 IL-6 eeeee2  release, and increased cAMP accumulation
CRP11	Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased  bbbbb1 glycerol eeeee1  release, reduced  bbbbb2 IL-6 eeeee2  release, and increased cAMP accumulation
CRP11	It did, however, augment IL-6 expression and modify the inhibitory effects of glucocorticoids on IL-6 release bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	It did, however, augment IL-6 expression and modify the inhibitory effects of glucocorticoids on IL-6 release bbbbb1  eeeee1  bbbbb2 and m eeeee2 odify the inhibitory effects of glucocorticoids on IL-6 release
CRP11	Qualitatively similar but significantly attenuated responses to the  bbbbb1 catecholamines eeeee1  were observed in tissue from  bbbbb2 ANXA1 eeeee2 -null mice, an effect that was not associated with changes in beta-adrenoceptor mRNA expression
CRP11	A1 gene deletion did not affect glucocorticoid receptor expression or the ability of  bbbbb1 dexamethasone eeeee1  bbbbb2 glucocorticoid receptor eeeee2  expression or the ability of dexamethasone to suppress catecholamine-induced lipolysis
CRP11	A1 gene deletion did not affect glucocorticoid receptor expression or the ability of dexamethasone to suppress  bbbbb1 catecholamine eeeee1  bbbbb2 glucocorticoid receptor eeeee2  expression or the ability of dexamethasone to suppress catecholamine-induced lipolysis
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the  bbbbb1 As(2)O(3) eeeee1  bbbbb2 catalase eeeee2  in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the  bbbbb1 As(2)O(3) eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and  bbbbb1 GSH eeeee1  bbbbb2 catalase eeeee2  in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and  bbbbb1 GSH eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of  bbbbb1 superoxide eeeee1  dismutase,  bbbbb2 catalase eeeee2  in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and  bbbbb1 arsenic eeeee1  bbbbb2 catalase eeeee2  in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and  bbbbb1 arsenic eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/ bbbbb1 GSSG eeeee1  bbbbb2 catalase eeeee2  in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	In the resveratrol+As(2)O(3) group, activities of superoxide dismutase, catalase in serum and GSH/ bbbbb1 GSSG eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group
CRP11	 bbbbb1 Carnitine eeeee1  acetyltransferases ( bbbbb2 CrAT eeeee2 ) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA
CRP11	 bbbbb1 Carnitine eeeee1  bbbbb2 Carnitine acetyltransferases eeeee2  (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain  bbbbb1 acyl-CoAs eeeee1  bbbbb2 glycine (Gly553) to methionine eeeee2  in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to  bbbbb1 methionine eeeee1  in  bbbbb2 carnitine octanoyltransferase eeeee2  (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to  bbbbb1 methionine eeeee1  bbbbb2 glycine (Gly553) to methionine eeeee2  in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to  bbbbb1 methionine eeeee1  in carnitine octanoyltransferase ( bbbbb2 COT eeeee2 ) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain  bbbbb1 acyl-CoAs eeeee1  bbbbb2 glycine (Gly553) to methionine eeeee2  in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  bbbbb1 carnitine eeeee1  bbbbb2 carnitine octanoyltransferase eeeee2  (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  bbbbb1 carnitine eeeee1  bbbbb2 glycine (Gly553) to methionine eeeee2  in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  bbbbb1 carnitine eeeee1  octanoyltransferase ( bbbbb2 COT eeeee2 ) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous  bbbbb1 glycine eeeee1  (Gly553) to methionine in  bbbbb2 carnitine octanoyltransferase eeeee2  (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous  bbbbb1 glycine eeeee1  bbbbb2 glycine (Gly553) to methionine eeeee2  in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	In the reverse case, mutation of the orthologous  bbbbb1 glycine eeeee1  (Gly553) to methionine in carnitine octanoyltransferase ( bbbbb2 COT eeeee2 ) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs
CRP11	Redesign of  bbbbb1 carnitine eeeee1  bbbbb2 carnitine acetyltransferase eeeee2  specificity by protein engineering
CRP11	Previously we have proposed that regulation of asymmetric  bbbbb1 methylarginine eeeee1  concentration by DDAH may provide a novel mechanism for the regulation of  bbbbb2 NOS eeeee2  activity in vivo
CRP11	Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2  (NOS)
CRP11	Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 NOS eeeee2 )
CRP11	The enzyme  bbbbb1 dimethylarginine eeeee1  bbbbb2 dimethylarginine dimethylaminohydrolase eeeee2  (DDAH) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines
CRP11	The enzyme  bbbbb1 dimethylarginine eeeee1  dimethylaminohydrolase ( bbbbb2 DDAH eeeee2 ) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines
CRP11	In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium bbbbb1  eeeee1  bbbbb2 ena eeeee2 l interstitium
CRP11	In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium bbbbb1  eeeee1  bbbbb2 ium eeeee2 
CRP11	Tissue-type plasminogen activator (tPA), a  bbbbb1 serine eeeee1  bbbbb2 serine protease eeeee2  well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts
CRP11	Tissue-type plasminogen activator (tPA), a  bbbbb1 serine eeeee1  bbbbb2 Tissue-type plasminogen activator eeeee2  (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts
CRP11	Tissue-type plasminogen activator (tPA), a  bbbbb1 serine eeeee1  protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 ( bbbbb2 MMP-9 eeeee2 ) gene expression and protein secretion in renal interstitial fibroblasts
CRP11	Tissue-type plasminogen activator (tPA), a  bbbbb1 serine eeeee1  bbbbb2 tPA eeeee2 ), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts
CRP11	Furthermore, tPA induced rapid  bbbbb1 tyrosine eeeee1  bbbbb2 tPA eeeee2  induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2
CRP11	This effect requires cold-induced, TRPA-1-mediated calcium influx and a  bbbbb1 calcium eeeee1 -sensitive PKC that signals to the transcription factor DAF-16/ bbbbb2 FOXO eeeee2 
CRP11	This effect requires cold-induced, TRPA-1-mediated calcium influx and a  bbbbb1 calcium eeeee1 -sensitive PKC that signals to the transcription factor  bbbbb2 DAF-16 eeeee2 /FOXO
CRP11	This effect requires cold-induced, TRPA-1-mediated calcium influx and a  bbbbb1 calcium eeeee1  bbbbb2 TRPA-1 eeeee2 -mediated calcium influx and a calcium-sensitive PKC that signals to the transcription factor DAF-16/FOXO
CRP11	This effect requires cold-induced, TRPA-1-mediated  bbbbb1 calcium eeeee1  influx and a calcium-sensitive PKC that signals to the transcription factor DAF-16/ bbbbb2 FOXO eeeee2 
CRP11	This effect requires cold-induced, TRPA-1-mediated  bbbbb1 calcium eeeee1  influx and a calcium-sensitive PKC that signals to the transcription factor  bbbbb2 DAF-16 eeeee2 /FOXO
CRP11	This effect requires cold-induced, TRPA-1-mediated  bbbbb1 calcium eeeee1  influx and a calcium-sensitive  bbbbb2 PKC eeeee2  that signals to the transcription factor DAF-16/FOXO
CRP11	This effect requires cold-induced, TRPA-1-mediated  bbbbb1 calcium eeeee1  bbbbb2 TRPA-1 eeeee2 -mediated calcium influx and a calcium-sensitive PKC that signals to the transcription factor DAF-16/FOXO
CRP11	Human TRPA1 can functionally substitute for worm TRPA-1 in promoting longevit bbbbb1 y eeeee1  bbbbb2  promoting l eeeee2 ongevity
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 GST eeeee2 ), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 CAT eeeee2 ), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 GPx eeeee2 ), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb1 glutathione eeeee1  bbbbb2 SOD eeeee2 ), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 catalase eeeee2  (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 GST eeeee2 ), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 CAT eeeee2 ), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 GPx eeeee2 ), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 SOD eeeee2 ), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 GST eeeee2 ), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 CAT eeeee2 ), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 GPx eeeee2 ), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of  bbbbb1 reduced glutathione eeeee1  bbbbb2 SOD eeeee2 ), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD),  bbbbb2 catalase eeeee2  (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and  bbbbb2 glutathione peroxidase eeeee2  (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD), catalase (CAT),  bbbbb2 glutathione S-transferase eeeee2  (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD), catalase (CAT), glutathione S-transferase ( bbbbb2 GST eeeee2 ), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD), catalase ( bbbbb2 CAT eeeee2 ), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase ( bbbbb2 GPx eeeee2 ), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  S-transferase (GST), and  bbbbb2 glutathione peroxidase eeeee2  (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  S-transferase ( bbbbb2 GST eeeee2 ), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  bbbbb2 CAT eeeee2 ), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  S-transferase (GST), and glutathione peroxidase ( bbbbb2 GPx eeeee2 ), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The animal's liver was assessed using biomarkers as activities of superoxide dismutase (SOD), catalase (CAT),  bbbbb1 glutathione eeeee1  bbbbb2 SOD eeeee2 ), catalase (CAT), glutathione S-transferase (GST), and glutathione peroxidase (GPx), and concentrations of reduced glutathione (GSH) and lipoperoxidation (LPO) and protein carbonylation (PCO)
CRP11	The results suggested the generation of reactive oxygen species, with increased activity of GPx and concentrations of LPO and  bbbbb1 GSH eeeee1  bbbbb2 GPx eeeee2  and concentrations of LPO and GSH; whereas the specific activity of SOD decreased
CRP11	The results suggested the generation of reactive oxygen species, with increased activity of GPx and concentrations of LPO and  bbbbb1 GSH eeeee1 ; whereas the specific activity of  bbbbb2 SOD eeeee2  decreased
CRP11	The results suggested the generation of reactive  bbbbb1 oxygen eeeee1  species, with increased activity of  bbbbb2 GPx eeeee2  and concentrations of LPO and GSH; whereas the specific activity of SOD decreased
CRP11	The results suggested the generation of reactive  bbbbb1 oxygen eeeee1  species, with increased activity of GPx and concentrations of LPO and GSH; whereas the specific activity of  bbbbb2 SOD eeeee2  decreased
CRP11	The 3D-structure of HmTx consists of three conserved alpha-helices: h1 (Lys24-His34),  bbbbb1 h2  eeeee1 (Cys59-Asp71), and h3 (Ala80-Phe89) bbbbb2  eeeee2 
CRP11	The 3D-structure of HmTx consists of three conserved alpha-helices: h1 (Lys24-Hi bbbbb1 s34 eeeee1 ), h2 (Cys59-Asp71), and h3 (Ala80-Phe89) bbbbb2  eeeee2 
CRP11	The 3D-structure of HmTx consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71),  bbbbb1 and eeeee1  h3 (Ala80-Phe89) bbbbb2  eeeee2 
CRP11	The 3D-structure of HmTx consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71), and h3 bbbbb1  (A eeeee1 la80-Phe89) bbbbb2  eeeee2 
CRP11	G6pc2 deletion had little effect on insulin sensitivity and  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data
CRP11	G6pc2 deletion had little effect on insulin sensitivity and  bbbbb1 glucose eeeee1  bbbbb2 G6pc2 eeeee2  deletion had little effect on insulin sensitivity and glucose tolerance, whereas body fat was reduced in female G6pc2 knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data
CRP11	G6pc2 deletion had little effect on insulin sensitivity and  bbbbb1 glucose eeeee1  tolerance, whereas body fat was reduced in female  bbbbb2 G6pc2 eeeee2  knockout (KO) mice on both a chow and high-fat diet, observations that are all consistent with human GWAS data
CRP11	As a consequence, under fasting conditions in which plasma insulin levels were identical, blood  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  levels were identical, blood glucose levels were reduced in G6pc2 KO mice, again consistent with human GWAS data
CRP11	As a consequence, under fasting conditions in which plasma insulin levels were identical, blood  bbbbb1 glucose eeeee1  levels were reduced in  bbbbb2 G6pc2 eeeee2  KO mice, again consistent with human GWAS data
CRP11	C2 encodes an islet-specific, endoplasmic reticulum-resident  bbbbb1 glucose eeeee1  bbbbb2 glucose-6-phosphatase catalytic subunit eeeee2 
CRP11	G6pc2 deletion resulted in a leftward shift in the dose-response curve for  bbbbb1 glucose eeeee1  bbbbb2 G6pc2 eeeee2  deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS)
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin or dopamine transporters eeeee2  and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the  bbbbb1 serotonin eeeee1  bbbbb2 norepinephrine transporter eeeee2  (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the  bbbbb1 serotonin eeeee1  bbbbb2 NET eeeee2 ) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or  bbbbb1 dopamine eeeee1  bbbbb2 serotonin or dopamine transporters eeeee2  and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or  bbbbb1 dopamine eeeee1  bbbbb2 norepinephrine transporter eeeee2  (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or  bbbbb1 dopamine eeeee1  bbbbb2 NET eeeee2 ) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the  bbbbb1 norepinephrine eeeee1  transporter (NET) compared to the  bbbbb2 serotonin or dopamine transporters eeeee2  and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the HED compounds would be most potent at the  bbbbb1 norepinephrine eeeee1  transporter ( bbbbb2 NET eeeee2 ) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	We hypothesized that the  bbbbb1 HED eeeee1  compounds would be most potent at the norepinephrine transporter (NET) compared to the  bbbbb2 serotonin or dopamine transporters eeeee2  and that the 1R diastereomers would be more effective than 1S diastereomers
CRP11	Stereospecific inhibition of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine uptake transporters eeeee2  by meta-hydroxyephedrine isomers
CRP11	To extend structure-activity analyses of binding sites within monoamine transporters and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [ bbbbb1 (3)H eeeee1  bbbbb2 monoamine transporters eeeee2  and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles
CRP11	To extend structure-activity analyses of binding sites within  bbbbb1 monoamine eeeee1  bbbbb2 monoamine transporters eeeee2  and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles
CRP11	We investigated the diurnal expression of clock genes and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the livers of male streptozotocin ( bbbbb1 STZ eeeee1 )-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with  bbbbb2 insulin eeeee2 
CRP11	We investigated the diurnal expression of clock genes and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the livers of male  bbbbb1 streptozotocin eeeee1  (STZ)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with  bbbbb2 insulin eeeee2 
CRP11	Diabetic  bbbbb1 STZ eeeee1  and Iddm rats, as well as  bbbbb2 insulin eeeee2 -substituted Iddm rats, exhibited a significant diurnal expression pattern of clock genes as determined by Cosinor analysis; however, the MESOR (midline estimating statistic of rhythm) of Bmal1, Per2, and Clock transcript expression was altered in Iddm and insulin-substituted Iddm rats
CRP11	Diabetic  bbbbb1 STZ eeeee1  and Iddm rats, as well as insulin-substituted Iddm rats, exhibited a significant diurnal expression pattern of clock genes as determined by Cosinor analysis; however, the MESOR (midline estimating statistic of rhythm) of  bbbbb2 Bmal1 eeeee2 , Per2, and Clock transcript expression was altered in Iddm and insulin-substituted Iddm rats
CRP11	Diabetic  bbbbb1 STZ eeeee1  and Iddm rats, as well as insulin-substituted Iddm rats, exhibited a significant diurnal expression pattern of clock genes as determined by Cosinor analysis; however, the MESOR (midline estimating statistic of rhythm) of Bmal1,  bbbbb2 Per2 eeeee2 , and Clock transcript expression was altered in Iddm and insulin-substituted Iddm rats
CRP11	Diabetic  bbbbb1 STZ eeeee1  and Iddm rats, as well as insulin-substituted Iddm rats, exhibited a significant diurnal expression pattern of clock genes as determined by Cosinor analysis; however, the MESOR (midline estimating statistic of rhythm) of Bmal1, Per2, and  bbbbb2 Clock eeeee2  transcript expression was altered in Iddm and insulin-substituted Iddm rats
CRP11	Diabetic  bbbbb1 STZ eeeee1  and Iddm rats, as well as insulin-substituted Iddm rats, exhibited a significant diurnal expression pattern of clock genes as determined by Cosinor analysis; however, the MESOR (midline estimating statistic of rhythm) of Bmal1, Per2, and Clock transcript expression was altered in Iddm and  bbbbb2 insulin eeeee2 -substituted Iddm rats
CRP11	Cosinor analysis indicated no diurnal rhythm of Pparγ expression in the livers of diabetic  bbbbb1 STZ eeeee1  or Iddm rats or in those of  bbbbb2 insulin eeeee2 -substituted Iddm rats
CRP11	Interestingly, we showed that rapamycin shares all the proteasome targeting properties not only with other two-domain, closed-ring analogs (rapalogs), but also with its single domain mimics, and with  bbbbb1 seco-rapamycin eeeee1  bbbbb2 proteasome eeeee2  targeting properties not only with other two-domain, closed-ring analogs (rapalogs), but also with its single domain mimics, and with seco-rapamycin
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb1 glutathione eeeee1  peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb1 glutathione eeeee1  peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID)  bbbbb1 amtolmetin guacyl eeeee1 , a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID)  bbbbb1 amtolmetin guacyl eeeee1 , a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase,  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID)  bbbbb1 amtolmetin guacyl eeeee1 , a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID)  bbbbb1 amtolmetin guacyl eeeee1 , a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID)  bbbbb1 amtolmetin guacyl eeeee1 , a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation,  bbbbb1 glutathione eeeee1  levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation,  bbbbb1 glutathione eeeee1  levels and activity of antioxidant enzymes (superoxide dismutase,  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation,  bbbbb1 glutathione eeeee1  levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation,  bbbbb1 glutathione eeeee1  levels and activity of antioxidant enzymes ( bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation,  bbbbb1 glutathione eeeee1  levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective ( bbbbb1 indomethacin eeeee1  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective ( bbbbb1 indomethacin eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective ( bbbbb1 indomethacin eeeee1 , diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective ( bbbbb1 indomethacin eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective ( bbbbb1 indomethacin eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non- bbbbb1 steroid eeeee1  anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non- bbbbb1 steroid eeeee1  anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase,  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non- bbbbb1 steroid eeeee1  anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non- bbbbb1 steroid eeeee1  anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non- bbbbb1 steroid eeeee1  anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective ( bbbbb1 celecoxib eeeee1  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective ( bbbbb1 celecoxib eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective ( bbbbb1 celecoxib eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective ( bbbbb1 celecoxib eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb1 glutathione eeeee1  reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb1 superoxide eeeee1  dismutase, catalase, glutathione peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb1 superoxide eeeee1  dismutase,  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb1 superoxide eeeee1  dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb1 superoxide eeeee1  dismutase, catalase,  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin,  bbbbb1 diclofenac eeeee1  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin,  bbbbb1 diclofenac eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin,  bbbbb1 diclofenac eeeee1 ) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin,  bbbbb1 diclofenac eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin,  bbbbb1 diclofenac eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID  bbbbb1 tolmetin eeeee1 , on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and  bbbbb2 glutathione reductase eeeee2 ) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID  bbbbb1 tolmetin eeeee1 , on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase,  bbbbb2 catalase eeeee2 , glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID  bbbbb1 tolmetin eeeee1 , on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and  bbbbb2 COX-2 eeeee2  selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID  bbbbb1 tolmetin eeeee1 , on lipid peroxidation, glutathione levels and activity of antioxidant enzymes ( bbbbb2 superoxide dismutase eeeee2 , catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID  bbbbb1 tolmetin eeeee1 , on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase,  bbbbb2 glutathione peroxidase eeeee2  and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and COX-2 selective (celecoxib) NSAIDs. 2
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and  bbbbb1 glucose-6-phosphate eeeee1  dehydrogenase activities and to a decrease in  bbbbb2 catalase eeeee2  activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and  bbbbb1 glucose-6-phosphate eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and  bbbbb1 glucose-6-phosphate eeeee1  bbbbb2 glucose-6-phosphate dehydrogenase eeeee2  activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and  bbbbb1 glutathione eeeee1  bbbbb2 glucose-6-phosphate dehydrogenase eeeee2  activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation,  bbbbb1 glutathione eeeee1  peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in  bbbbb2 catalase eeeee2  activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Indomethacin treatment led to an increase in lipid peroxidation,  bbbbb1 glutathione eeeee1  peroxidase and  bbbbb2 glucose-6-phosphate dehydrogenase eeeee2  activities and to a decrease in catalase activity and glutathione levels in gastric mucosa
CRP11	Am80 is specific for the retinoic-acid receptor-alpha/beta, and has therapeutic effects in  bbbbb1 all-trans retinoic acid eeeee1  bbbbb2 retinoic-acid receptor-alpha/beta eeeee2 , and has therapeutic effects in all-trans retinoic acid resistant acute promyelocytic leukemia
CRP11	Am80 is specific for the  bbbbb1 retinoic-acid eeeee1  bbbbb2 retinoic-acid receptor-alpha/beta eeeee2 , and has therapeutic effects in all-trans retinoic acid resistant acute promyelocytic leukemia
CRP11	 bbbbb1 Am80 eeeee1  is specific for the  bbbbb2 retinoic-acid receptor-alpha/beta eeeee2 , and has therapeutic effects in all-trans retinoic acid resistant acute promyelocytic leukemia
CRP11	 bbbbb1 Glyphosate eeeee1 -tolerant crops with EPSPS transgene alone or both EPSPS and  bbbbb2 gox eeeee2  transgenes have been commercialized
CRP11	 bbbbb1 Glyphosate eeeee1 -tolerant crops with  bbbbb2 EPSPS eeeee2  transgene alone or both EPSPS and gox transgenes have been commercialized
CRP11	 bbbbb1 Glyphosate eeeee1 -tolerant crops with EPSPS transgene alone or both  bbbbb2 EPSPS eeeee2  and gox transgenes have been commercialized
CRP11	A modified maize EPSPS gene and CP4-EPSPS gene from Agrobacterium sp. have been used to transform plants for target-based tolerance to  bbbbb1 glyphosate eeeee1  bbbbb2 EPSPS eeeee2  gene from Agrobacterium sp. have been used to transform plants for target-based tolerance to glyphosate
CRP11	A modified maize EPSPS gene and CP4-EPSPS gene from Agrobacterium sp. have been used to transform plants for target-based tolerance to  bbbbb1 glyphosate eeeee1  bbbbb2 maize EPSPS eeeee2  gene and CP4-EPSPS gene from Agrobacterium sp. have been used to transform plants for target-based tolerance to glyphosate
CRP11	Glyphosate affects aromatic amino acid biosynthesis by inhibiting  bbbbb1 5-enolpyruvylshikimate-3-phosphate eeeee1  synthase ( bbbbb2 EPSPS eeeee2 )
CRP11	Glyphosate affects aromatic amino acid biosynthesis by inhibiting  bbbbb1 5-enolpyruvylshikimate-3-phosphate eeeee1  bbbbb2 5-enolpyruvylshikimate-3-phosphate synthase eeeee2  (EPSPS)
CRP11	Glyphosate affects  bbbbb1 aromatic amino acid eeeee1  biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase ( bbbbb2 EPSPS eeeee2 )
CRP11	Glyphosate affects  bbbbb1 aromatic amino acid eeeee1  biosynthesis by inhibiting  bbbbb2 5-enolpyruvylshikimate-3-phosphate synthase eeeee2  (EPSPS)
CRP11	 bbbbb1 Imidazolinone eeeee1 -tolerant crops have been commercialized based on these  bbbbb2 AHAS eeeee2  gene variants
CRP11	A gox gene isolated from Ochrobactrum anthropi has also been employed to encode glyphosate oxidoreductase to detoxify  bbbbb1 glyphosate eeeee1  bbbbb2 glyphosate oxidoreductase eeeee2  to detoxify glyphosate in plants
CRP11	A gox gene isolated from Ochrobactrum anthropi has also been employed to encode glyphosate oxidoreductase to detoxify  bbbbb1 glyphosate eeeee1  bbbbb2 gox eeeee2  gene isolated from Ochrobactrum anthropi has also been employed to encode glyphosate oxidoreductase to detoxify glyphosate in plants
CRP11	A gox gene isolated from Ochrobactrum anthropi has also been employed to encode  bbbbb1 glyphosate eeeee1  bbbbb2 glyphosate oxidoreductase eeeee2  to detoxify glyphosate in plants
CRP11	A gox gene isolated from Ochrobactrum anthropi has also been employed to encode  bbbbb1 glyphosate eeeee1  bbbbb2 gox eeeee2  gene isolated from Ochrobactrum anthropi has also been employed to encode glyphosate oxidoreductase to detoxify glyphosate in plants
CRP11	Acetohydroxyacid synthase (AHAS) inhibitors interfere with  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 AHAS eeeee2 ) inhibitors interfere with branched-chain amino acid biosynthesis by inhibiting AHAS
CRP11	Acetohydroxyacid synthase (AHAS) inhibitors interfere with  bbbbb1 branched-chain amino acid eeeee1  biosynthesis by inhibiting  bbbbb2 AHAS eeeee2 
CRP11	Acetohydroxyacid synthase (AHAS) inhibitors interfere with  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 Acetohydroxyacid synthase eeeee2  (AHAS) inhibitors interfere with branched-chain amino acid biosynthesis by inhibiting AHAS
CRP11	 bbbbb1 Acetohydroxyacid eeeee1  synthase ( bbbbb2 AHAS eeeee2 ) inhibitors interfere with branched-chain amino acid biosynthesis by inhibiting AHAS
CRP11	 bbbbb1 Acetohydroxyacid eeeee1  synthase (AHAS) inhibitors interfere with branched-chain amino acid biosynthesis by inhibiting  bbbbb2 AHAS eeeee2 
CRP11	 bbbbb1 Acetohydroxyacid eeeee1  bbbbb2 Acetohydroxyacid synthase eeeee2  (AHAS) inhibitors interfere with branched-chain amino acid biosynthesis by inhibiting AHAS
CRP11	A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine,  bbbbb1 desipramine eeeee1  bbbbb2 NET eeeee2  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and imipramine
CRP11	A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and  bbbbb1 imipramine eeeee1  bbbbb2 NET eeeee2  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and imipramine
CRP11	A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as  bbbbb1 reboxetine eeeee1  bbbbb2 NET eeeee2  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and imipramine
CRP11	Effect of antidepressant drugs in mice lacking the  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2 
CRP11	Using mice lacking  bbbbb1 NE eeeee1  transporter ( bbbbb2 NET eeeee2 -/-) we examined their baseline phenotype as well as the response in the forced swim test (FST) and in the tail suspension test (TST) upon treatment with ADs that display different pharmacological profiles
CRP11	Using mice lacking  bbbbb1 NE eeeee1  bbbbb2 NE transporter eeeee2  (NET-/-) we examined their baseline phenotype as well as the response in the forced swim test (FST) and in the tail suspension test (TST) upon treatment with ADs that display different pharmacological profiles
CRP11	In the FST, reboxetine, desipramine, imipramine, and citalopram administered acutely did not reduce any further the immobility time shortened by NET knockout itself (ca 25%); however, antidepressant-like action of repeatedly (7 days) administered desipramine was observed in NET-/- mi bbbbb1 ce eeeee1  bbbbb2 min eeeee2 istered acutely did not reduce any further the immobility time shortened by NET knockout itself (ca 25%); however, antidepressant-like action of repeatedly (7 days) administered desipramine was observed in NET-/- mice, indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test
CRP11	Autoradiographic studies showed decreased binding of the beta-adrenergic ligand  bbbbb1 [3H]CGP12177 eeeee1  in the cerebral cortex of  bbbbb2 NET eeeee2 -/- mice, indicating the changes at the level of beta-adrenergic receptors similar to those obtained with ADs treatment
CRP11	 bbbbb1 Citalopram eeeee1 , which is devoid of affinity for the NET, exerted a significant reduction of immobility time in the  bbbbb2 NET eeeee2 -/- mice
CRP11	The binding of  bbbbb1 [3H]prazosin eeeee1  to alpha1-adrenergic receptors in the cerebral cortex of  bbbbb2 NET eeeee2 -/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular NE levels observed in these mice
CRP11	The binding of [3H]prazosin to alpha1-adrenergic receptors in the cerebral cortex of NET-/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular  bbbbb1 NE eeeee1  bbbbb2 NET eeeee2 -/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular NE levels observed in these mice
CRP11	The binding of [3H]prazosin to alpha1-adrenergic receptors in the cerebral cortex of NET-/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular  bbbbb1 NE eeeee1  bbbbb2 alpha1-adrenergic receptors eeeee2  in the cerebral cortex of NET-/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular NE levels observed in these mice
CRP11	The alpha 1-adrenoceptor antagonists, on the other hand, reduce the dynamic component of obstruction--relaxation of smooth muscle in the prostate, urethra and bladder neck--and provide rapid symptom relief after only a few doses, relieving LUTS more effectively than  bbbbb1 finasteride eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonists, on the other hand, reduce the dynamic component of obstruction--relaxation of smooth muscle in the prostate, urethra and bladder neck--and provide rapid symptom relief after only a few doses, relieving LUTS more effectively than finasteride and irrespective of prostate size
CRP11	Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin,  bbbbb1 prazosin eeeee1  bbbbb2 5 alpha-reductase eeeee2  inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin,  bbbbb1 doxazosin eeeee1  bbbbb2 5 alpha-reductase eeeee2  inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Both the 5 alpha-reductase inhibitor  bbbbb1 finasteride eeeee1  and  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and  bbbbb1 terazosin eeeee1  bbbbb2 5 alpha-reductase eeeee2  inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin,  bbbbb1 tamsulosin eeeee1  bbbbb2 5 alpha-reductase eeeee2  inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g.  bbbbb1 alfuzosin eeeee1  bbbbb2 5 alpha-reductase eeeee2  inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials
CRP11	Treatment with ClpP resulted in hypodiploid DNA contents, increased Bax/ Bcl-2 ratio and induction of reactive  bbbbb1 oxygen eeeee1  bbbbb2 Bcl-2 eeeee2  ratio and induction of reactive oxygen species (ROS) production
CRP11	Treatment with ClpP resulted in hypodiploid DNA contents, increased Bax/ Bcl-2 ratio and induction of reactive  bbbbb1 oxygen eeeee1  bbbbb2 ClpP eeeee2  resulted in hypodiploid DNA contents, increased Bax/ Bcl-2 ratio and induction of reactive oxygen species (ROS) production
CRP11	Treatment with ClpP resulted in hypodiploid DNA contents, increased Bax/ Bcl-2 ratio and induction of reactive  bbbbb1 oxygen eeeee1  bbbbb2 Bax eeeee2 / Bcl-2 ratio and induction of reactive oxygen species (ROS) production
CRP11	In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone ( bbbbb1 Z-VAD-fmk eeeee1 ), a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from  bbbbb2 ClpP eeeee2  toxicity
CRP11	In addition, pretreatment with  bbbbb1 Z-Val-Ala-Asp-fluoromethylketone eeeee1  (Z-VAD-fmk), a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from  bbbbb2 ClpP eeeee2  toxicity
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fl bbbbb1 uoxetine p eeeee1 roduced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fl bbbbb1 uoxetine p eeeee1 roduced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor bbbbb1  antagonists  eeeee1 with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), suggesting that this strategy may be useful in further augmenting the action o bbbbb2 f a SSRI eeeee2  in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor bbbbb1  antagonists  eeeee1 with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor bbbbb1  antagonists  eeeee1 with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced bbbbb1  additiv eeeee1 e increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), suggesting that this strategy may be useful in further augmenting the action o bbbbb2 f a SSRI eeeee2  in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced bbbbb1  additiv eeeee1 e increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced bbbbb1  additiv eeeee1 e increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potent bbbbb1 iati eeeee1 on, respectively), suggesting that this strategy may be useful in further augmenting the action o bbbbb2 f a SSRI eeeee2  in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potent bbbbb1 iati eeeee1 on, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potent bbbbb1 iati eeeee1 on, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxeti bbbbb1 ne produc eeeee1 ed additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), suggesting that this strategy may be useful in further augmenting the action o bbbbb2 f a SSRI eeeee2  in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxeti bbbbb1 ne produc eeeee1 ed additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxeti bbbbb1 ne produc eeeee1 ed additive increases in extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive in bbbbb1 creases in eeeee1  extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), suggesting that this strategy may be useful in further augmenting the action o bbbbb2 f a SSRI eeeee2  in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive in bbbbb1 creases in eeeee1  extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive in bbbbb1 creases in eeeee1  extracellular 5-HT (i.e. WAY100635+GR127935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e.  bbbbb1 WAY100635+GR1 eeeee1 27935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting tha eeeee2 t this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	Combination of both 5-HT(1A) and 5-HT(1B/1D) autoreceptor antagonists with fluoxetine produced additive increases in extracellular 5-HT (i.e.  bbbbb1 WAY100635+GR1 eeeee1 27935+fluoxetine and WAY100635+isamoltane+fluoxetine produced a four- and five-fold potentiation, respectively), sugg bbbbb2 esting that this st eeeee2 rategy may be useful in further augmenting the action of a SSRI in the treatment of depression
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol,  bbbbb1 WAY-100635 eeeee1  (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a  bbbbb2 5-HT(1B) eeeee2  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol,  bbbbb1 WAY-100635 eeeee1  (a 5-HT(1A) antagonist), GR127935 (a  bbbbb2 5-HT(1B/1D) eeeee2  antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and  bbbbb1 isamoltane eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and  bbbbb1 isamoltane eeeee1  bbbbb2 5-HT(1B/1D) eeeee2  antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of  bbbbb1 (+/-)pindolol eeeee1 , WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a  bbbbb2 5-HT(1B) eeeee2  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of  bbbbb1 (+/-)pindolol eeeee1 , WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a  bbbbb2 5-HT(1B/1D) eeeee2  antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist),  bbbbb1 GR127935 eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist),  bbbbb1 GR127935 eeeee1  (a 5-HT(1B/1D) antagonist), and isamoltane (a  bbbbb2 5-HT(1B) eeeee2  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist),  bbbbb1 GR127935 eeeee1  (a  bbbbb2 5-HT(1B/1D) eeeee2  antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with  bbbbb1 fluoxetine eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with  bbbbb1 fluoxetine eeeee1  bbbbb2 5-HT(1B) eeeee2  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with  bbbbb1 fluoxetine eeeee1  bbbbb2 5-HT(1B/1D) eeeee2  antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute  bbbbb1 fluoxetine eeeee1  bbbbb2 5-HT(1A) eeeee2  and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute  bbbbb1 fluoxetine eeeee1  bbbbb2 5-HT(1B/1D) receptors eeeee2  on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of  bbbbb1 (+/-)pindolol eeeee1  bbbbb2 5-HT(1A) eeeee2  and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of  bbbbb1 (+/-)pindolol eeeee1  bbbbb2 5-HT(1B/1D) receptors eeeee2  on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B/1D) receptors eeeee2  on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol
CRP11	Anti-IL-2 and anti-IL2R alpha blocked the  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  and anti-IL2R alpha blocked the DEX-induced increase in proliferation
CRP11	Anti-IL-2 and anti-IL2R alpha blocked the  bbbbb1 DEX eeeee1  bbbbb2 IL2R alpha eeeee2  blocked the DEX-induced increase in proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited  bbbbb2 IL-2 eeeee2  production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high  bbbbb2 IL-2 eeeee2  producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low  bbbbb2 IL-2 eeeee2  producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced  bbbbb2 IL-2R alpha eeeee2  expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked  bbbbb2 IL-2 eeeee2  production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of  bbbbb1 GCS eeeee1  on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased  bbbbb2 IL-2R alpha eeeee2  expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited  bbbbb2 IL-2 eeeee2  production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high  bbbbb2 IL-2 eeeee2  producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2R alpha eeeee2  expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers  bbbbb1 DEX eeeee1  blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced  bbbbb2 IL-2R alpha eeeee2  expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2R alpha eeeee2  expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2 eeeee2  production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers  bbbbb1 DEX eeeee1  bbbbb2 IL-2R alpha eeeee2  expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation
CRP11	In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account f bbbbb1 or the t eeeee1  bbbbb2 ved  eeeee2 either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  reductase ( bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  reductase (DHFR), and  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  reductase (DHFR), and glycinamide ribonucleotide formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb1 dihydrofolate eeeee1  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase ( bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase ( bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase ( bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of  bbbbb1 deoxycytidine eeeee1  kinase (dCK),  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  synthase (TS), dihydrofolate reductase ( bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  synthase (TS),  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb1 thymidylate eeeee1  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets,  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets, thymidylate synthase ( bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase ( bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb1 cytidine eeeee1  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of  bbbbb2 deoxycytidine kinase eeeee2  (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets,  bbbbb2 thymidylate synthase eeeee2  (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase ( bbbbb2 TS eeeee2 ), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase ( bbbbb2 DHFR eeeee2 ), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and  bbbbb2 glycinamide ribonucleotide formyltransferase eeeee2  (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and  bbbbb2 cytidine deaminase eeeee2 , whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase ( bbbbb2 GARFT eeeee2 ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase ( bbbbb2 dCK eeeee2 ), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS),  bbbbb2 dihydrofolate reductase eeeee2  (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	The role of drug metabolism in  bbbbb1 gemcitabine eeeee1  cytotoxicity was examined with inhibitors of deoxycytidine kinase (dCK),  bbbbb2 5'-nucleotidase eeeee2 , and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies
CRP11	Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human  bbbbb1 nucleoside eeeee1  bbbbb2 human nucleoside equilibrative transporter 1 eeeee2  (hENT1) in all cell lines
CRP11	Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human  bbbbb1 nucleoside eeeee1  bbbbb2 phosphorylated Akt eeeee2 , enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines
CRP11	Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human  bbbbb1 nucleoside eeeee1  equilibrative transporter 1 ( bbbbb2 hENT1 eeeee2 ) in all cell lines
CRP11	Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human  bbbbb1 nucleoside eeeee1  bbbbb2 dCK eeeee2  in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines
CRP11	PCR demonstrated a correlation between dCK expre bbbbb1 ssion and  eeeee1 gemcitabine sensitivity, whereas expression of TS, DHFR, and GARFT was predictive of pemetrexed chemosensitivity bbbbb2  eeeee2 
CRP11	PCR demonstrated a correlation between dCK expre bbbbb1 ssion and  eeeee1 gemcitabine sensitivity, whereas expression of TS, DHFR, and GARFT was predictive of pemetrexed chemosensitivity bbbbb2  eeeee2 
CRP11	PCR demonstrated a correlation b bbbbb1 etween dCK  eeeee1 expression and gemcitabine sensitivity, whereas expression of TS, DHFR, and GARFT was predictive of pemetrexed chemosensitivity bbbbb2  eeeee2 
CRP11	PCR demonstrated a correlation b bbbbb1 etween dCK  eeeee1 expression and gemcitabine sensitivity, whereas expression of TS, DHFR, and GARFT was predictive of pemetrexed chemosensitivity bbbbb2  eeeee2 
CRP11	PCR demonstrated a correlation between dCK expression and gemcitabine sensitivity, whereas expression of TS, DHFR, and GARFT was predictive of pemetrexed chemosensitivity bbbbb1  eeeee1  bbbbb2 edi eeeee2 ctive of pemetrexed chemosensitivity
CRP11	A series of novel  bbbbb1 aliphatic amido-quaternary ammonium salts eeeee1  were synthesized and evaluated for their anticancer effects involving induction of  bbbbb2 RhoB eeeee2 
CRP11	However, so far no information has been published on the human glucocorticoid receptor activity of the metabolites or degradation products of  bbbbb1 MF eeeee1  bbbbb2 human glucocorticoid receptor eeeee2  activity of the metabolites or degradation products of MF
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde-  bbbbb2 keyhole limpet hemocyanin eeeee2  (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin ( bbbbb2 KLH eeeee2 ) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin ( bbbbb2 BSA eeeee2 ) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde- bbbbb2 bovine serum albumin eeeee2  (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different  bbbbb1 aldehydes eeeee1  and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde-  bbbbb2 keyhole limpet hemocyanin eeeee2  (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin ( bbbbb2 KLH eeeee2 ) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin ( bbbbb2 BSA eeeee2 ) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde- bbbbb2 bovine serum albumin eeeee2  (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th  bbbbb1 amino acid eeeee1  residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde-  bbbbb2 keyhole limpet hemocyanin eeeee2  (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin ( bbbbb2 KLH eeeee2 ) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin ( bbbbb2 BSA eeeee2 ) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde- bbbbb2 bovine serum albumin eeeee2  (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate  bbbbb1 GTX2,3-aldehyde eeeee1  was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and  bbbbb1 GTX2,3-aldehyde eeeee1  bbbbb2 BSA eeeee2 ) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and  bbbbb1 GTX2,3-aldehyde eeeee1  bbbbb2 bovine serum albumin eeeee2  (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and  bbbbb1 GTX2,3-aldehyde eeeee1 - keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and  bbbbb1 GTX2,3-aldehyde eeeee1 - keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens  bbbbb1 GTX2,3-aldehyde eeeee1 -bovine serum albumin (BSA) and GTX2,3-aldehyde-  bbbbb2 keyhole limpet hemocyanin eeeee2  (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens  bbbbb1 GTX2,3-aldehyde eeeee1 -bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin ( bbbbb2 KLH eeeee2 ) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens  bbbbb1 GTX2,3-aldehyde eeeee1 -bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens  bbbbb1 GTX2,3-aldehyde eeeee1 -bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde-  bbbbb2 keyhole limpet hemocyanin eeeee2  (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin ( bbbbb2 KLH eeeee2 ) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin ( bbbbb2 BSA eeeee2 ) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde- bbbbb2 bovine serum albumin eeeee2  (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with  bbbbb2 BSA eeeee2  or KLH
CRP11	An intermediate GTX2,3-aldehyde was first synthesized by activating the  bbbbb1 NH2 eeeee1  group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or  bbbbb2 KLH eeeee2 
CRP11	In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective estrogen receptor modulators (raloxifene and toremifene) increased bone mineral density in GnRH agoni bbbbb1 st-treated eeeee1  men bbbbb2  eeeee2 
CRP11	Estrogens play a central role in homeostasis of the normal male skeleton, and estrogen deficiency rather than  bbbbb1 testosterone eeeee1  deficiency seems to be primarily responsible for the adverse skeletal effects of  bbbbb2 GnRH eeeee2  agonists
CRP11	 bbbbb1 Estrogens eeeee1  play a central role in homeostasis of the normal male skeleton, and estrogen deficiency rather than testosterone deficiency seems to be primarily responsible for the adverse skeletal effects of  bbbbb2 GnRH eeeee2  agonists
CRP11	Estrogens play a central role in homeostasis of the normal male skeleton, and  bbbbb1 estrogen eeeee1  deficiency rather than testosterone deficiency seems to be primarily responsible for the adverse skeletal effects of  bbbbb2 GnRH eeeee2  agonists
CRP11	Knockdown of mPGES1 by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and  bbbbb1 thymidine eeeee1  bbbbb2 mPGES1 eeeee2  small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and thymidine incorporation
CRP11	Knockdown of mPGES1 by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and  bbbbb1 thymidine eeeee1  bbbbb2 mPGES1 eeeee2  by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and thymidine incorporation
CRP11	Knockdown of mPGES1 by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in  bbbbb1 PGE2 eeeee1  bbbbb2 mPGES1 eeeee2  small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and thymidine incorporation
CRP11	Knockdown of mPGES1 by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in  bbbbb1 PGE2 eeeee1  bbbbb2 mPGES1 eeeee2  by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in PGE2 production and thymidine incorporation
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 p50 eeeee2  siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 NF-κB1 eeeee2  p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 p50 eeeee2  by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 p50 eeeee2  siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 NF-κB1 eeeee2  p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NF-κB1 p50 by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 p50 eeeee2  by p50 siRNA significantly decreased acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	The prostaglandin E synthase (PGES) responsible for acid-induced  bbbbb1 PGE2 eeeee1  bbbbb2 prostaglandin E synthase eeeee2  (PGES) responsible for acid-induced PGE2 production in BE, however, is not known
CRP11	The prostaglandin E synthase (PGES) responsible for acid-induced  bbbbb1 PGE2 eeeee1  bbbbb2 PGES eeeee2 ) responsible for acid-induced PGE2 production in BE, however, is not known
CRP11	The  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin E synthase eeeee2  (PGES) responsible for acid-induced PGE2 production in BE, however, is not known
CRP11	The  bbbbb1 prostaglandin E eeeee1  synthase ( bbbbb2 PGES eeeee2 ) responsible for acid-induced PGE2 production in BE, however, is not known
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 NADPH oxidase eeeee2 , NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 calcium-binding domains eeeee2 , by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 NOX5-S eeeee2 , a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression,  bbbbb1 thymidine eeeee1  bbbbb2 NOX5 eeeee2  siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2 , NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of  bbbbb1 NADPH eeeee1  oxidase, NOX5-S, a variant lacking  bbbbb2 calcium-binding domains eeeee2 , by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of  bbbbb1 NADPH eeeee1  oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of  bbbbb1 NADPH eeeee1  oxidase,  bbbbb2 NOX5-S eeeee2 , a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of  bbbbb1 NADPH eeeee1  oxidase, NOX5-S, a variant lacking calcium-binding domains, by  bbbbb2 NOX5 eeeee2  siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking  bbbbb1 calcium eeeee1  bbbbb2 NADPH oxidase eeeee2 , NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking  bbbbb1 calcium eeeee1  bbbbb2 calcium-binding domains eeeee2 , by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking  bbbbb1 calcium eeeee1 -binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking  bbbbb1 calcium eeeee1  bbbbb2 NOX5-S eeeee2 , a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking  bbbbb1 calcium eeeee1 -binding domains, by  bbbbb2 NOX5 eeeee2  siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 NADPH oxidase eeeee2 , NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 calcium-binding domains eeeee2 , by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 mPGES1 eeeee2  expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 NOX5-S eeeee2 , a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	Knockdown of NADPH oxidase, NOX5-S, a variant lacking calcium-binding domains, by NOX5 siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and  bbbbb1 PGE2 eeeee1  bbbbb2 NOX5 eeeee2  siRNA significantly inhibited acid-induced increase in mPGES1 expression, thymidine incorporation, and PGE2 production
CRP11	DPH Oxidase NOX5-S and Nuclear Factor κB1 Mediate Acid-Induced Microsomal  bbbbb1 Prostaglandin E eeeee1  bbbbb2 Nuclear Factor κB1 eeeee2  Mediate Acid-Induced Microsomal Prostaglandin E Synthase-1 Expression in Barrett's Esophageal Adenocarcinoma Cells
CRP11	DPH Oxidase NOX5-S and Nuclear Factor κB1 Mediate Acid-Induced Microsomal  bbbbb1 Prostaglandin E eeeee1  bbbbb2 Microsomal Prostaglandin E Synthase-1 eeeee2  Expression in Barrett's Esophageal Adenocarcinoma Cells
CRP11	Prolonged use of tolvaptan leads to increased endogenous levels of  bbbbb1 AVP eeeee1  and perhaps over-stimulation of  bbbbb2 V(1A) receptors eeeee2 
CRP11	Prolonged use of tolvaptan leads to increased endogenous levels of  bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2  and perhaps over-stimulation of V(1A) receptors
CRP11	 bbbbb1 In additi eeeee1 on, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased interactions with other medications bbbbb2  eeeee2 
CRP11	In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware bbbbb1  of eeeee1  bbbbb2  of eeeee2  the potential for increased interactions with other medications
CRP11	In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware bbbbb1  of eeeee1  the potential for increased interactions with other medications bbbbb2  eeeee2 
CRP11	Tolvaptan is a selective  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin (AVP) V(2) receptor eeeee2  blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia
CRP11	Tolvaptan is a selective arginine vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 arginine vasopressin (AVP) V(2) receptor eeeee2  blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia
CRP11	Chelation of calcium ions by BAPTA-AM or blockade of ERK1/2 activation by UO126 also prevented the NMDA effect bbbbb1 s eeeee1  bbbbb2 BAPTA-AM or bl eeeee2 ockade of ERK1/2 activation by UO126 also prevented the NMDA effects
CRP11	Chelation of calcium ions by BAPTA-AM or blockade of ERK1/2 activation by UO126 also prevented the NMDA effect bbbbb1 s eeeee1  bbbbb2  eeeee2 
CRP11	Chelation of calcium ions by  bbbbb1 BAPT eeeee1 A-AM or blockade of ERK1/2 activation by U bbbbb2 O126 also preve eeeee2 nted the NMDA effects
CRP11	Chelation of calcium ions by  bbbbb1 BAPT eeeee1  bbbbb2 BAPTA-AM or bl eeeee2 ockade of ERK1/2 activation by UO126 also prevented the NMDA effects
CRP11	Chelation of calcium ions by  bbbbb1 BAPT eeeee1 A-AM or blockade of ERK1/2 activation by UO126 also prevented the NMDA effects bbbbb2  eeeee2 
CRP11	Neurosteroids are endogenous allosteric modulators of  bbbbb1 γ amino-butyric acid eeeee1  type A receptors (GABARs), and enhance  bbbbb2 GABAR eeeee2 -mediated inhibition
CRP11	Neurosteroids are endogenous allosteric modulators of  bbbbb1 γ amino-butyric acid eeeee1  type A receptors ( bbbbb2 GABARs eeeee2 ), and enhance GABAR-mediated inhibition
CRP11	Neurosteroids are endogenous allosteric modulators of  bbbbb1 γ amino-butyric acid eeeee1  bbbbb2 γ amino-butyric acid type A receptors eeeee2  (GABARs), and enhance GABAR-mediated inhibition
CRP11	Receptor Activation Down-Regulates Expression of δ Subunit-Containing  bbbbb1 GABA eeeee1  bbbbb2 δ Subunit-Containing GABA-A Receptors eeeee2  in Cultured Hippocampal Neurons
CRP11	In this study, a novel series of 2-hydroxydiarylamide derivatives were s bbbbb1 ynthes eeeee1  bbbbb2 s were  eeeee2 synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion
CRP11	In this study, a novel series of 2-hydroxydiarylamide derivatives were s bbbbb1 ynthes eeeee1 ized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion bbbbb2  eeeee2 
CRP11	In this study, a novel series of 2-hydroxydiarylamide derivatives were s bbbbb1 ynthes eeeee1  bbbbb2 ynthesized and  eeeee2 evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters ( bbbbb1 alanine eeeee1  aminotransferase, aspartate aminotransferase,  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters ( bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters ( bbbbb1 alanine eeeee1  aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein,  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters ( bbbbb1 alanine eeeee1  aminotransferase,  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol,  bbbbb1 urea eeeee1  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol,  bbbbb1 urea eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol,  bbbbb1 urea eeeee1  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol,  bbbbb1 urea eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin,  bbbbb1 cholesterol eeeee1  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin,  bbbbb1 cholesterol eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin,  bbbbb1 cholesterol eeeee1  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin,  bbbbb1 cholesterol eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin,  bbbbb1 bilirubin eeeee1  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin,  bbbbb1 bilirubin eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin,  bbbbb1 bilirubin eeeee1  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin,  bbbbb1 bilirubin eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and  bbbbb1 creatinine eeeee1  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and  bbbbb1 creatinine eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and  bbbbb1 creatinine eeeee1  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and  bbbbb1 creatinine eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase,  bbbbb1 aspartate eeeee1  aminotransferase,  bbbbb2 alkaline phosphatase eeeee2 , total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase,  bbbbb1 aspartate eeeee1  bbbbb2 alanine aminotransferase eeeee2 , aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase,  bbbbb1 aspartate eeeee1  aminotransferase, alkaline phosphatase, total protein,  bbbbb2 albumin eeeee2 , bilirubin, cholesterol, urea and creatinine)
CRP11	The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase,  bbbbb1 aspartate eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)
CRP11	In a recent study using protein-specific anti-acetyl  bbbbb1 lysine eeeee1  antibodies and immunological methods, we demonstrated the ability of aspirin to acetylate the  bbbbb2 tumor suppressor protein p53 eeeee2 
CRP11	Through comparative analys bbbbb1 is of exp eeeee1 ression in bbbbb2  plate eeeee2 lets and other blood cells we demonstrated that G6b, G6f, and LRRC32 are restricted to the platelet lineage, whereas LAT2 and SUCNR1 were also detected in other blood cells
CRP11	Through comparative analys bbbbb1 is of exp eeeee1  bbbbb2 is of expression i eeeee2 n platelets and other blood cells we demonstrated that G6b, G6f, and LRRC32 are restricted to the platelet lineage, whereas LAT2 and SUCNR1 were also detected in other blood cells
CRP11	Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2 
CRP11	Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing  bbbbb1 NMDA eeeee1  bbbbb2 NR2B eeeee2 -containing NMDA receptors
CRP11	Neuroprotective effects of  bbbbb1 oxymatrine eeeee1  against excitotoxicity partially through down-regulation of NR2B-containing  bbbbb2 NMDA receptors eeeee2 
CRP11	Neuroprotective effects of  bbbbb1 oxymatrine eeeee1  against excitotoxicity partially through down-regulation of  bbbbb2 NR2B eeeee2 -containing NMDA receptors
CRP11	Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the  bbbbb1 NMDA eeeee1  bbbbb2 NR2B eeeee2  and inhibited the calcium overload in the cultured neurons after challenging the NMDA
CRP11	Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the  bbbbb1 calcium eeeee1  bbbbb2 NR2B eeeee2  and inhibited the calcium overload in the cultured neurons after challenging the NMDA
CRP11	Contribution of the m1 transmembrane helix and pre-m1 region to positive allosteric modulation and gating of  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 N-methyl-d-aspartate receptors eeeee2 
CRP11	Elucidating the structural determinants and mechanism of action by which allosteric regulators control gating will enhance our understanding of  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  activation and facilitate the development of novel therapeutics
CRP11	We also show that mutations within the GluN2D pre-M1 region alter open probability of the NMDA receptor bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	We also show that mutations within the GluN2D pre-M1 region alter open probability of the NMDA receptor bbbbb1  eeeee1  bbbbb2  open probabil eeeee2 ity of the NMDA receptor
CRP11	We also show that mutations within the GluN2D pre-M1 region alter bbbbb1  ope eeeee1 n probability of the NMDA receptor bbbbb2  eeeee2 
CRP11	We also show that mutations within the GluN2D pre-M1 region alter bbbbb1  ope eeeee1  bbbbb2  open probabil eeeee2 ity of the NMDA receptor
CRP11	We show that CIQ does not bind to the amino-terminal domain of the  bbbbb1 NMDA eeeee1  receptor and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or  bbbbb2 ion channel eeeee2  pore
CRP11	We show that CIQ does not bind to the amino-terminal domain of the  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or ion channel pore
CRP11	We show that CIQ does not bind to the  bbbbb1 amino eeeee1 -terminal domain of the NMDA receptor and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or  bbbbb2 ion channel eeeee2  pore
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor,  bbbbb1 batimastat eeeee1  (BB-94) and the  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat ( bbbbb1 BB-94 eeeee1 ) and the  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the  bbbbb1 angiotensin eeeee1  bbbbb2 matrix metalloproteinase eeeee2  inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the  bbbbb1 angiotensin eeeee1 -converting enzyme inhibitor, captopril, on  bbbbb2 metalloproteinase eeeee2  activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor,  bbbbb1 captopril eeeee1  bbbbb2 matrix metalloproteinase eeeee2  inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice
CRP11	At the 5-HT2C receptor, both R(-) and S(+)MDA were equipotent at stimulating  bbbbb1 PI eeeee1  hydrolysis, with the S(+) isomer of MDMA being more efficacious at the  bbbbb2 5-HT2C eeeee2  receptor compared with the R(-) isomer
CRP11	At the 5-HT2C receptor, both R(-) and S(+)MDA were equipotent at stimulating  bbbbb1 PI eeeee1  bbbbb2 5-HT2C eeeee2  receptor, both R(-) and S(+)MDA were equipotent at stimulating PI hydrolysis, with the S(+) isomer of MDMA being more efficacious at the 5-HT2C receptor compared with the R(-) isomer
CRP11	At the 5-HT2C receptor, both R(-) and S(+)MDA were equipotent at stimulating PI hydrolysis, with the  bbbbb1 S(+) isomer of MDMA eeeee1  bbbbb2 5-HT2C eeeee2  receptor, both R(-) and S(+)MDA were equipotent at stimulating PI hydrolysis, with the S(+) isomer of MDMA being more efficacious at the 5-HT2C receptor compared with the R(-) isomer
CRP11	At the 5-HT2C receptor, both  bbbbb1 R(-) and S(+)MDA eeeee1  were equipotent at stimulating PI hydrolysis, with the S(+) isomer of MDMA being more efficacious at the  bbbbb2 5-HT2C eeeee2  receptor compared with the R(-) isomer
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its  bbbbb1 N-methyl analog 3,4-methylenedioxymethamphetamine eeeee1  (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its  bbbbb1 N-methyl analog 3,4-methylenedioxymethamphetamine eeeee1  (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on  bbbbb1 [3H]inositol monophosphate eeeee1  accumulation was studied in cells expressing either  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on  bbbbb1 [3H]inositol monophosphate eeeee1  accumulation was studied in cells expressing either 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine ( bbbbb1 MDA eeeee1 ) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine ( bbbbb1 MDA eeeee1 ) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	The effect of the  bbbbb1 R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine eeeee1  (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	The effect of the  bbbbb1 R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine eeeee1  (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine (MDMA) on [3H]inositol monophosphate accumulation was studied in cells expressing either 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine ( bbbbb1 MDMA eeeee1 ) on [3H]inositol monophosphate accumulation was studied in cells expressing either  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	The effect of the R(-) and S(+) isomers of 3,4-methylenedioxyamphetamine (MDA) and its N-methyl analog 3,4-methylenedioxymethamphetamine ( bbbbb1 MDMA eeeee1 ) on [3H]inositol monophosphate accumulation was studied in cells expressing either 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	The isomers of  bbbbb1 MDA eeeee1  produced a concentration dependent increase in phosphatidyl inositol (PI) hydrolysis at the 5-HT2A receptors, with the R(-) isomer of MDA being more potent than the S(+) at the  bbbbb2 5-HT2A eeeee2  receptor
CRP11	The isomers of MDA produced a concentration dependent increase in phosphatidyl inositol (PI) hydrolysis at the 5-HT2A receptors, with the  bbbbb1 R(-) isomer of MDA eeeee1  bbbbb2 5-HT2A eeeee2  receptors, with the R(-) isomer of MDA being more potent than the S(+) at the 5-HT2A receptor
CRP11	The isomers of MDA produced a concentration dependent increase in phosphatidyl inositol ( bbbbb1 PI eeeee1 ) hydrolysis at the  bbbbb2 5-HT2A eeeee2  receptors, with the R(-) isomer of MDA being more potent than the S(+) at the 5-HT2A receptor
CRP11	The isomers of MDA produced a concentration dependent increase in phosphatidyl inositol ( bbbbb1 PI eeeee1 ) hydrolysis at the 5-HT2A receptors, with the R(-) isomer of MDA being more potent than the S(+) at the  bbbbb2 5-HT2A eeeee2  receptor
CRP11	The isomers of MDA produced a concentration dependent increase in  bbbbb1 phosphatidyl inositol eeeee1  (PI) hydrolysis at the  bbbbb2 5-HT2A eeeee2  receptors, with the R(-) isomer of MDA being more potent than the S(+) at the 5-HT2A receptor
CRP11	The isomers of MDA produced a concentration dependent increase in  bbbbb1 phosphatidyl inositol eeeee1  (PI) hydrolysis at the 5-HT2A receptors, with the R(-) isomer of MDA being more potent than the S(+) at the  bbbbb2 5-HT2A eeeee2  receptor
CRP11	Effect of the R(-) and S(+) isomers of MDA and  bbbbb1 MDMA eeeee1  on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	Effect of the R(-) and S(+) isomers of MDA and  bbbbb1 MDMA eeeee1  on phosphatidyl inositol turnover in cultured cells expressing  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	Effect of the  bbbbb1 R(-) and S(+) isomers of MDA eeeee1  and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	Effect of the  bbbbb1 R(-) and S(+) isomers of MDA eeeee1  and MDMA on phosphatidyl inositol turnover in cultured cells expressing  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	Effect of the R(-) and S(+) isomers of MDA and MDMA on  bbbbb1 phosphatidyl inositol eeeee1  turnover in cultured cells expressing 5-HT2A or  bbbbb2 5-HT2C eeeee2  receptors
CRP11	Effect of the R(-) and S(+) isomers of MDA and MDMA on  bbbbb1 phosphatidyl inositol eeeee1  turnover in cultured cells expressing  bbbbb2 5-HT2A eeeee2  or 5-HT2C receptors
CRP11	In all cases at both the 5-HT2A and 5-HT2C receptors, the affinities of the isomers of MDMA and M bbbbb1 DA were at l eeeee1  bbbbb2 rs, th eeeee2 e affinities of the isomers of MDMA and MDA were at least 2-3 orders of magnitude less than 5-HT
CRP11	In all cases at both the 5-HT2A and 5-HT2C receptors, the affinities of the isomers of MDMA and M bbbbb1 DA were at l eeeee1  bbbbb2 initie eeeee2 s of the isomers of MDMA and MDA were at least 2-3 orders of magnitude less than 5-HT
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine ( bbbbb1 Ser eeeee1  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine ( bbbbb1 Ser eeeee1  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine ( bbbbb1 Ser eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and  bbbbb1 tyrosine eeeee1  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and  bbbbb1 tyrosine eeeee1  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and  bbbbb1 tyrosine eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased  bbbbb1 DAGs eeeee1 , TAGs and  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased  bbbbb1 DAGs eeeee1 , TAGs and PTP1B expression significantly, but cells remained  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased  bbbbb1 DAGs eeeee1 , TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and  bbbbb2 PTP1B eeeee2  phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased  bbbbb1 DAGs eeeee1 , TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs,  bbbbb1 TAGs eeeee1  and  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs,  bbbbb1 TAGs eeeee1  and PTP1B expression significantly, but cells remained  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs,  bbbbb1 TAGs eeeee1  and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and  bbbbb2 PTP1B eeeee2  phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs,  bbbbb1 TAGs eeeee1  and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50,  bbbbb1 Ser eeeee1  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50,  bbbbb1 Ser eeeee1  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50,  bbbbb1 Ser eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at  bbbbb1 serine eeeee1  bbbbb2 PTP1B eeeee2  expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at  bbbbb1 serine eeeee1  bbbbb2 insulin eeeee2  sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at  bbbbb1 serine eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at serine (Ser) 50, Ser 398 and tyrosine 152
CRP11	We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free  bbbbb1 fatty acids eeeee1  bbbbb2 PTP1B eeeee2  by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM)
CRP11	We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free  bbbbb1 fatty acids eeeee1  bbbbb2 insulin eeeee2  signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM)
CRP11	Cells were also evaluated in the presence of wortmannin, an inhibitor of  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinases eeeee2  and thus AKt (0-100 nM)
CRP11	Cells were also evaluated in the presence of wortmannin, an inhibitor of  bbbbb1 phosphatidylinositol eeeee1  3-kinases and thus  bbbbb2 AKt eeeee2  (0-100 nM)
CRP11	PTP1B overexpression in the presence of excess lipids may not bbbbb1  di eeeee1 rectly cause insulin resistance bbbbb2  unless eeeee2  it is accompanied by decreased PTP1B phosphorylation
CRP11	Only FFAs that increased ceramides caused impairment of AKt and PTP1B phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at Ser 50
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  bbbbb2 insulin eeeee2  signaling through the protein kinase B (AKt) pathway and up-regulate protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  phosphatase 1B (PTP1B), a negative regulator of  bbbbb2 insulin eeeee2  signaling
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  bbbbb2 AKt eeeee2 ) pathway and up-regulate protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  phosphatase 1B ( bbbbb2 PTP1B eeeee2 ), a negative regulator of insulin signaling
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  bbbbb2 protein tyrosine phosphatase 1B eeeee2  (PTP1B), a negative regulator of insulin signaling
CRP11	Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein  bbbbb1 tyrosine eeeee1  bbbbb2 protein kinase B eeeee2  (AKt) pathway and up-regulate protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling
CRP11	Normal  bbbbb1 glucose eeeee1  regulation is achieved by having adequate  bbbbb2 insulin eeeee2  secretion and effective glucose uptake/disposal
CRP11	Normal glucose regulation is achieved by having adequate insulin secretion and effective  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  secretion and effective glucose uptake/disposal
CRP11	Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 PTP1B eeeee2 , and had AKt and PTP1B phosphorylation at Ser 50 impaired
CRP11	Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at Ser 50 impaired
CRP11	Saturated palmitic and stearic acids increased  bbbbb1 ceramides eeeee1 , up-regulated PTP1B, and had AKt and  bbbbb2 PTP1B eeeee2  phosphorylation at Ser 50 impaired
CRP11	Saturated palmitic and stearic acids increased  bbbbb1 ceramides eeeee1 , up-regulated  bbbbb2 PTP1B eeeee2 , and had AKt and PTP1B phosphorylation at Ser 50 impaired
CRP11	Saturated palmitic and stearic acids increased  bbbbb1 ceramides eeeee1 , up-regulated PTP1B, and had  bbbbb2 AKt eeeee2  and PTP1B phosphorylation at Ser 50 impaired
CRP11	On the medullary blood flow (MBF), while the lower doses of PE and AII increased the perfusion unit on the  bbbbb1 fenofibrate eeeee1  bbbbb2 AII eeeee2  increased the perfusion unit on the fenofibrate-treated group, the higher doses decreased the perfusion unit
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 e-t eeeee2 reated group
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 nof eeeee2 ibrate-treated group
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 e-t eeeee2 reated group
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 nof eeeee2 ibrate-treated group
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 e-t eeeee2 reated group
CRP11	The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group bbbbb1  eeeee1  bbbbb2 nof eeeee2 ibrate-treated group
CRP11	Effects of fenofibrate, a PPAR-α ligand, on the haemodynamics of  bbbbb1 glycerol eeeee1  bbbbb2 PPAR-α eeeee2  ligand, on the haemodynamics of glycerol-induced renal failure in rats
CRP11	The effects of PE and AII on the cortical blood flow (CBF) of  bbbbb1 fenofibrate eeeee1  bbbbb2 AII eeeee2  on the cortical blood flow (CBF) of fenofibrate-treated group is similar to that of MBF for the same group but not for ET1
CRP11	The effects of PE and AII on the cortical blood flow (CBF) of  bbbbb1 fenofibrate eeeee1 -treated group is similar to that of MBF for the same group but not for  bbbbb2 ET1 eeeee2 
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and  bbbbb1 isoproterenol eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and  bbbbb1 isoproterenol eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and  bbbbb1 isoproterenol eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and  bbbbb1 isoproterenol eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and  bbbbb1 isoproterenol eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine ( bbbbb1 Ach eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine ( bbbbb1 Ach eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine ( bbbbb1 Ach eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine ( bbbbb1 Ach eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine ( bbbbb1 Ach eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside ( bbbbb1 SNP eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside ( bbbbb1 SNP eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside ( bbbbb1 SNP eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside ( bbbbb1 SNP eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside ( bbbbb1 SNP eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach),  bbbbb1 sodium nitroprusside eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach),  bbbbb1 sodium nitroprusside eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach),  bbbbb1 sodium nitroprusside eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach),  bbbbb1 sodium nitroprusside eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach),  bbbbb1 sodium nitroprusside eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in  bbbbb1 glycerol eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in  bbbbb1 glycerol eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in  bbbbb1 glycerol eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in  bbbbb1 glycerol eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in  bbbbb1 glycerol eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of  bbbbb1 phenylepherine eeeee1  (PE), angiotensin II (AII),  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of  bbbbb1 phenylepherine eeeee1  (PE), angiotensin II ( bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of  bbbbb1 phenylepherine eeeee1  (PE), angiotensin II (AII), endothelin 1 ( bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of  bbbbb1 phenylepherine eeeee1  (PE),  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of  bbbbb1 phenylepherine eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol ( bbbbb1 ISO eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol ( bbbbb1 ISO eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol ( bbbbb1 ISO eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol ( bbbbb1 ISO eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol ( bbbbb1 ISO eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1),  bbbbb1 acetylcholine eeeee1  bbbbb2 endothelin 1 eeeee2  (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1),  bbbbb1 acetylcholine eeeee1  bbbbb2 AII eeeee2 ), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1),  bbbbb1 acetylcholine eeeee1  bbbbb2 ET1 eeeee2 ), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1),  bbbbb1 acetylcholine eeeee1  bbbbb2 angiotensin II eeeee2  (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1),  bbbbb1 acetylcholine eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2  ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats
CRP11	Human TWIK-1, which has been cloned recently, is a new structural type of weak inward rectifier  bbbbb1 K+ eeeee1  bbbbb2 inward rectifier K+ channel eeeee2 
CRP11	Human TWIK-1, which has been cloned recently, is a new structural type of weak inward rectifier  bbbbb1 K+ eeeee1  bbbbb2 Human TWIK-1 eeeee2 , which has been cloned recently, is a new structural type of weak inward rectifier K+ channel
CRP11	K+ currents generated by TWIK-1 are inwardly rectifying while  bbbbb1 K+ eeeee1  bbbbb2 TWIK-1 eeeee2  are inwardly rectifying while K+ currents generated by TREK-1 are outwardly rectifying
CRP11	K+ currents generated by TWIK-1 are inwardly rectifying while  bbbbb1 K+ eeeee1  currents generated by  bbbbb2 TREK-1 eeeee2  are outwardly rectifying
CRP11	 bbbbb1 K+ eeeee1  currents generated by  bbbbb2 TWIK-1 eeeee2  are inwardly rectifying while K+ currents generated by TREK-1 are outwardly rectifying
CRP11	 bbbbb1 K+ eeeee1  currents generated by TWIK-1 are inwardly rectifying while K+ currents generated by  bbbbb2 TREK-1 eeeee2  are outwardly rectifying
CRP11	Despite a low  bbbbb1 amino acid eeeee1  identity between TWIK-1 and TREK-1 (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two  bbbbb2 pore-forming domains eeeee2  and four transmembrane segments (TMS)
CRP11	Here we report the structural and functional properties of TREK-1, a mammalian TWIK-1-related  bbbbb1 K+ eeeee1  bbbbb2 TREK-1 eeeee2 , a mammalian TWIK-1-related K+ channel
CRP11	Here we report the structural and functional properties of TREK-1, a mammalian TWIK-1-related  bbbbb1 K+ eeeee1  bbbbb2 mammalian TWIK-1-related K+ channel eeeee2 
CRP11	Cloning, functional expression and brain localization of a novel unconventional outward rectifier  bbbbb1 K+ eeeee1  bbbbb2 outward rectifier K+ channel eeeee2 
CRP11	Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR bbbbb1  eeeee1  bbbbb2 medi eeeee2 cinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR
CRP11	Effect of water extracts from edible myrtaceae plants on uptake of  bbbbb1 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose eeeee1  in  bbbbb2 TNF-α eeeee2 -treated FL83B mouse hepatocytes
CRP11	Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest  bbbbb1 glucose eeeee1  uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the  bbbbb2 TNF-α eeeee2 -treated control group
CRP11	Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest  bbbbb1 glucose eeeee1  uptake activity, at an increment of 21% in the  bbbbb2 insulin eeeee2 -resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group
CRP11	 bbbbb1 Glucose eeeee1  uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin-resistant FL83B mouse hepatocytes as compared with the  bbbbb2 TNF-α eeeee2 -treated control group
CRP11	 bbbbb1 Glucose eeeee1  uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the  bbbbb2 insulin eeeee2 -resistant FL83B mouse hepatocytes as compared with the TNF-α-treated control group
CRP11	To facilitate the study of this enzyme, the purification and characterization of the recombinant human PAOh1/SMO  bbbbb1 polyamine eeeee1  bbbbb2 polyamine oxidase eeeee2  are reported
CRP11	To facilitate the study of this enzyme, the purification and characterization of the recombinant human PAOh1/SMO  bbbbb1 polyamine eeeee1  bbbbb2 human PAOh1 eeeee2 /SMO polyamine oxidase are reported
CRP11	To facilitate the study of this enzyme, the purification and characterization of the recombinant human PAOh1/SMO  bbbbb1 polyamine eeeee1  bbbbb2 SMO eeeee2  polyamine oxidase are reported
CRP11	The discovery of an inducible oxidase whose apparent substrate preference is spermine indicates that  bbbbb1 polyamine eeeee1  bbbbb2 oxidase eeeee2  whose apparent substrate preference is spermine indicates that polyamine catabolism is more complex than that originally proposed
CRP11	Properties of purified recombinant human  bbbbb1 polyamine eeeee1  oxidase, PAOh1/ bbbbb2 SMO eeeee2 
CRP11	Properties of purified recombinant human  bbbbb1 polyamine eeeee1  bbbbb2 human polyamine oxidase eeeee2 , PAOh1/SMO
CRP11	Properties of purified recombinant human  bbbbb1 polyamine eeeee1  oxidase,  bbbbb2 PAOh1 eeeee2 /SMO
CRP11	The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, spe bbbbb1 cific oli eeeee1  bbbbb2 antit eeeee2 umor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1/SMO
CRP11	The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, spe bbbbb1 cific oli eeeee1  bbbbb2 mor eeeee2  polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1/SMO
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  bbbbb2 caspase-1 eeeee2 , caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK)
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  bbbbb2 caspase-3 eeeee2 , inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK)
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible form of nitric oxide synthetase eeeee2  (iNOS) and p38 mitogen-activated protein kinase (MAPK)
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  synthetase (iNOS) and p38  bbbbb2 mitogen-activated protein kinase eeeee2  (MAPK)
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  synthetase ( bbbbb2 iNOS eeeee2 ) and p38 mitogen-activated protein kinase (MAPK)
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  synthetase (iNOS) and p38 mitogen-activated protein kinase ( bbbbb2 MAPK eeeee2 )
CRP11	It inhibits the activity of caspase-1, caspase-3, inducible form of  bbbbb1 nitric oxide eeeee1  synthetase (iNOS) and  bbbbb2 p38 eeeee2  mitogen-activated protein kinase (MAPK)
CRP11	Here, we identified Bcl-2 antagonist killer 1 (Bak) as a molecular target of  bbbbb1 VK2 eeeee1  bbbbb2 Bcl-2 eeeee2  antagonist killer 1 (Bak) as a molecular target of VK2-induced apoptosis
CRP11	Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  bbbbb1 VK2 eeeee1  bbbbb2 Bcl-2-associated X protein eeeee2  (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death
CRP11	Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  bbbbb1 VK2 eeeee1  bbbbb2 Bak eeeee2  is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death
CRP11	Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  bbbbb1 VK2 eeeee1  bbbbb2 Bak eeeee2  and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death
CRP11	Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  bbbbb1 VK2 eeeee1  bbbbb2 Bax eeeee2 ), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death
CRP11	Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  bbbbb1 VK2 eeeee1  bbbbb2 Bcl-2 eeeee2  family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death
CRP11	2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 5-hydroxytryptamine1-like receptors eeeee2  in the canine basilar artery
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites  bbbbb1 (+/-)-pindolol eeeee1  bbbbb2 5-HT2 receptor eeeee2  antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites  bbbbb1 (+/-)-pindolol eeeee1  (0.01-1 microM), or the  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites  bbbbb1 (+/-)-pindolol eeeee1  bbbbb2 5-HT4 eeeee2  receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites  bbbbb1 (+/-)-pindolol eeeee1  bbbbb2 5-HT3 eeeee2  and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites  bbbbb1 (+/-)-pindolol eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for  bbbbb2 5-HT1A eeeee2  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  bbbbb2 5-HT2 receptor eeeee2  antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  bbbbb2 5-HT4 eeeee2  receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  (0.01-1 microM), the  bbbbb2 beta-adrenoceptor eeeee2  blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  bbbbb2 5-HT3 eeeee2  and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist  bbbbb1 spiroxatrine eeeee1  (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and  bbbbb2 5-HT1B eeeee2  binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1A eeeee2  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT2 receptor eeeee2  antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT4 eeeee2  receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 beta-adrenoceptor eeeee2  blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT3 eeeee2  and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2  binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1 ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for  bbbbb2 5-HT1A eeeee2  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1  bbbbb2 5-HT2 receptor eeeee2  antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1 ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1 ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the  bbbbb2 beta-adrenoceptor eeeee2  blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1 ; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and  bbbbb2 5-HT1B eeeee2  binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 ( bbbbb1 tropisetron eeeee1 ; 0.1-10 microM), the  bbbbb2 5-HT1A eeeee2  receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for  bbbbb2 5-HT1A eeeee2  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and  bbbbb2 5-HT4 eeeee2  receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the  bbbbb2 beta-adrenoceptor eeeee2  blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the  bbbbb2 5-HT3 eeeee2  and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and  bbbbb2 5-HT1B eeeee2  binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist  bbbbb1 ketanserin eeeee1  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the  bbbbb2 5-HT1A eeeee2  receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for  bbbbb2 5-HT1A eeeee2  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the  bbbbb2 5-HT2 receptor eeeee2  antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  bbbbb2 alpha 1-adrenoceptor eeeee2  antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and  bbbbb2 5-HT4 eeeee2  receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the  bbbbb2 beta-adrenoceptor eeeee2  blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the  bbbbb2 5-HT3 eeeee2  and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and  bbbbb2 5-HT1B eeeee2  binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the  bbbbb2 5-HT1A eeeee2  receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)
CRP11	The contractile effects of  bbbbb1 D-1997 eeeee1  in the basilar artery were compared with those produced by 5-hydroxytryptamine (5-HT) and the  bbbbb2 5-HT receptor eeeee2  agonist quipazine
CRP11	The contractile effects of D-1997 in the basilar artery were compared with those produced by 5-hydroxytryptamine (5-HT) and the 5-HT receptor agonist  bbbbb1 quipazine eeeee1  bbbbb2 5-HT receptor eeeee2  agonist quipazine
CRP11	The contractile effects of D-1997 in the basilar artery were compared with those produced by 5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 ) and the  bbbbb2 5-HT receptor eeeee2  agonist quipazine
CRP11	The contractile effects of D-1997 in the basilar artery were compared with those produced by 5-hydroxytryptamine (5-HT) and the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT receptor eeeee2  agonist quipazine
CRP11	The contractile effects of D-1997 in the basilar artery were compared with those produced by  bbbbb1 5-hydroxytryptamine eeeee1  (5-HT) and the  bbbbb2 5-HT receptor eeeee2  agonist quipazine
CRP11	This 40 kDa  bbbbb1 PEG eeeee1 -conjugated IFNalpha(2a) ((40)PEG- bbbbb2 IFNalpha(2a) eeeee2 ) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a)
CRP11	This 40 kDa  bbbbb1 PEG eeeee1 -conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of  bbbbb2 IFNalpha(2a) eeeee2 
CRP11	This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a  bbbbb1 lysine eeeee1  bbbbb2 IFNalpha(2a) eeeee2  ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a)
CRP11	This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a  bbbbb1 lysine eeeee1  bbbbb2 IFNalpha(2a) eeeee2 ) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a)
CRP11	Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa  bbbbb1 PEG eeeee1 - bbbbb2 interferon-alpha2a eeeee2  and its individual positional isomers to the extracellular domain of the receptor IFNAR2
CRP11	Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa  bbbbb1 PEG eeeee1 -interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor  bbbbb2 IFNAR2 eeeee2 
CRP11	Felodipine and the p-chloro analogue inhibited the actin-activated  bbbbb1 Mg2+ eeeee1  bbbbb2 actin eeeee2 -activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)
CRP11	Felodipine and the p-chloro analogue inhibited the actin-activated  bbbbb1 Mg2+ eeeee1 -ATPase activity of smooth muscle  bbbbb2 myosin eeeee2  (IC50 = 25.1 microM)
CRP11	Felodipine and the p-chloro analogue inhibited the actin-activated  bbbbb1 Mg2+ eeeee1  bbbbb2 Mg2+-ATPase eeeee2  activity of smooth muscle myosin (IC50 = 25.1 microM)
CRP11	Felodipine and the  bbbbb1 p-chloro eeeee1  analogue inhibited the  bbbbb2 actin eeeee2 -activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)
CRP11	 bbbbb1 Felodipine eeeee1  and the p-chloro analogue inhibited the  bbbbb2 actin eeeee2 -activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)
CRP11	Felodipine and the p-chloro analogue inhibited  bbbbb1 Ca2+ eeeee1 /calmodulin-dependent  bbbbb2 caldesmon kinase eeeee2  with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition
CRP11	Felodipine and the p-chloro analogue inhibited  bbbbb1 Ca2+ eeeee1 / bbbbb2 calmodulin eeeee2 -dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition
CRP11	Felodipine and the  bbbbb1 p-chloro eeeee1  analogue inhibited Ca2+/ bbbbb2 calmodulin eeeee2 -dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition
CRP11	Felodipine and the p-chloro analogue inhibited Ca2+/calmodulin-dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and  bbbbb1 t-butyl eeeee1  bbbbb2 calmodulin eeeee2 -dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition
CRP11	 bbbbb1 Felodipine eeeee1  and the p-chloro analogue inhibited Ca2+/ bbbbb2 calmodulin eeeee2 -dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and  bbbbb1 t-butyl eeeee1  bbbbb2 Ca2+ channel eeeee2  blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channel eeeee2  blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine  bbbbb1 Ca2+ eeeee1  bbbbb2 calmodulin-dependent enzymes eeeee2  (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes ( bbbbb1 cAMP eeeee1  phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine  bbbbb2 Ca2+ channel eeeee2  blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes ( bbbbb1 cAMP eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2 , caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes ( bbbbb1 cAMP eeeee1  bbbbb2 calmodulin-dependent enzymes eeeee2  (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes ( bbbbb1 cAMP eeeee1  phosphodiesterase, caldesmon kinase and  bbbbb2 myosin light chain kinase eeeee2 ) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes ( bbbbb1 cAMP eeeee1  phosphodiesterase,  bbbbb2 caldesmon kinase eeeee2  and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the  bbbbb1 dihydropyridine eeeee1   bbbbb2 Ca2+ channel eeeee2  blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the  bbbbb1 dihydropyridine eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2 , caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the  bbbbb1 dihydropyridine eeeee1  bbbbb2 myosin light chain kinase eeeee2 ) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the  bbbbb1 dihydropyridine eeeee1  bbbbb2 caldesmon kinase eeeee2  and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues ( bbbbb1 p-chloro eeeee1  bbbbb2 Ca2+ channel eeeee2  blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies
CRP11	Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated  bbbbb1 Mg2+ eeeee1  bbbbb2 actin eeeee2 -activated Mg2+-ATPase activity of myosin and the assembly of myosin filaments
CRP11	Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated  bbbbb1 Mg2+ eeeee1 -ATPase activity of myosin and the assembly of  bbbbb2 myosin eeeee2  filaments
CRP11	Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated  bbbbb1 Mg2+ eeeee1 -ATPase activity of  bbbbb2 myosin eeeee2  and the assembly of myosin filaments
CRP11	Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated  bbbbb1 Mg2+ eeeee1  bbbbb2 myosin eeeee2  phosphorylation were examined, namely the actin-activated Mg2+-ATPase activity of myosin and the assembly of myosin filaments
CRP11	Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated  bbbbb1 Mg2+ eeeee1  bbbbb2 Mg2+-ATPase eeeee2  activity of myosin and the assembly of myosin filaments
CRP11	Finally, the effects of  bbbbb1 felodipine eeeee1  and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the  bbbbb2 actin eeeee2 -activated Mg2+-ATPase activity of myosin and the assembly of myosin filaments
CRP11	Similarly, felodipine and the  bbbbb1 p-chloro eeeee1  analogue inhibited myosin light chain kinase activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact  bbbbb2 myosin eeeee2  (IC50 = 11.0 microM) was used as substrate
CRP11	Similarly,  bbbbb1 felodipine eeeee1  and the p-chloro analogue inhibited myosin light chain kinase activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact  bbbbb2 myosin eeeee2  (IC50 = 11.0 microM) was used as substrate
CRP11	Calmodulin was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by  bbbbb1 felodipine eeeee1  bbbbb2 Calmodulin eeeee2  was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue
CRP11	Calmodulin was relatively ineffective in preventing inhibition of  bbbbb1 cAMP eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2  by felodipine and the p-chloro analogue
CRP11	Calmodulin was relatively ineffective in preventing inhibition of  bbbbb1 cAMP eeeee1  bbbbb2 Calmodulin eeeee2  was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue
CRP11	Calmodulin was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the  bbbbb1 p-chloro eeeee1  bbbbb2 Calmodulin eeeee2  was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue
CRP11	Similarly, felodipine and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of calmodulin, whereas the oxidized and  bbbbb1 t-butyl eeeee1  bbbbb2 calmodulin eeeee2 , whereas the oxidized and t-butyl analogues did not
CRP11	Similarly, felodipine and the  bbbbb1 p-chloro eeeee1  analogue blocked myosin filament assembly induced by low concentrations of  bbbbb2 calmodulin eeeee2 , whereas the oxidized and t-butyl analogues did not
CRP11	Similarly,  bbbbb1 felodipine eeeee1  and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of  bbbbb2 calmodulin eeeee2 , whereas the oxidized and t-butyl analogues did not
CRP11	The  bbbbb1 cAMP eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2  was inhibited completely by felodipine and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively
CRP11	Effects of felodipine (a dihydropyridine  bbbbb1 calcium eeeee1  channel blocker) and analogues on  bbbbb2 calmodulin-dependent enzymes eeeee2 
CRP11	Effects of felodipine (a dihydropyridine  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  blocker) and analogues on calmodulin-dependent enzymes
CRP11	Effects of felodipine (a  bbbbb1 dihydropyridine eeeee1  calcium channel blocker) and analogues on  bbbbb2 calmodulin-dependent enzymes eeeee2 
CRP11	Effects of  bbbbb1 felodipine eeeee1  (a dihydropyridine calcium channel blocker) and analogues on  bbbbb2 calmodulin-dependent enzymes eeeee2 
CRP11	Felodipine and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of  bbbbb1 cAMP eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2  as well as the calmodulin-stimulated activity
CRP11	Felodipine and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of  bbbbb1 cAMP eeeee1  phosphodiesterase as well as the  bbbbb2 calmodulin eeeee2 -stimulated activity
CRP11	Felodipine and the p-chloro analogue inhibited the basal ( bbbbb1 Ca2+ eeeee1 /calmodulin-independent) activity of  bbbbb2 cAMP phosphodiesterase eeeee2  as well as the calmodulin-stimulated activity
CRP11	Felodipine and the p-chloro analogue inhibited the basal ( bbbbb1 Ca2+ eeeee1 /calmodulin-independent) activity of cAMP phosphodiesterase as well as the  bbbbb2 calmodulin eeeee2 -stimulated activity
CRP11	The oxidized and t-butyl analogues were relatively ineffective in inhibiting  bbbbb1 cAMP eeeee1  bbbbb2 cAMP phosphodiesterase eeeee2 
CRP11	After 30min of treatment, antofine induced a rapid increase in the intracellular  bbbbb1 Ca(2+) eeeee1  concentration and activation of  bbbbb2 protein kinase C (PKC)α/βII eeeee2 , which was maintained for at least 6h
CRP11	Moreover, co-treatment with  bbbbb1 antofine eeeee1  and a specific  bbbbb2 PKCβ eeeee2  inhibitor prevented endocytosis of gap junctions, downregulation of Cx43, and inhibition of GJIC
CRP11	Co-treatment of astrocytes with antofine and the intracellular  bbbbb1 Ca(2+) eeeee1  chelator BAPTA-AM prevented downregulation of  bbbbb2 Cx43 eeeee2  and inhibition of GJIC
CRP11	Double-labeling immunofluorescence microscopy showed that  bbbbb1 antofine eeeee1  (10ng/ml) induced endocytosis of surface gap junctions into the cytoplasm, where  bbbbb2 Cx43 eeeee2  was co-localized with the early endosome marker EEA1
CRP11	Double-labeling immunofluorescence microscopy showed that  bbbbb1 antofine eeeee1  (10ng/ml) induced endocytosis of surface gap junctions into the cytoplasm, where Cx43 was co-localized with the early endosome marker  bbbbb2 EEA1 eeeee2 
CRP11	Inhibition of lysosomes or proteasomes by co-treatment with  bbbbb1 antofine eeeee1  and their respective specific inhibitors, NH4Cl or MG132, partially inhibited the antofine-induced decrease in  bbbbb2 Cx43 eeeee2  protein levels, but did not inhibit the antofine-induced inhibition of GJIC
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or  bbbbb1 N-acetyl cysteine eeeee1  (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or  bbbbb1 N-acetyl cysteine eeeee1  (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by  bbbbb1 sulfhydryl eeeee1  antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by  bbbbb1 sulfhydryl eeeee1  antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione ( bbbbb1 GSH eeeee1 ) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione ( bbbbb1 GSH eeeee1 ) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as  bbbbb1 glutathione eeeee1  (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as  bbbbb1 glutathione eeeee1  (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not  bbbbb1 ascorbic acid eeeee1  (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not  bbbbb1 ascorbic acid eeeee1  (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione- bbbbb1 S eeeee1 -transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione- bbbbb1 S eeeee1  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by  bbbbb1 GSH eeeee1  to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by  bbbbb1 GSH eeeee1  to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine ( bbbbb1 NAC eeeee1 ), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine ( bbbbb1 NAC eeeee1 ), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb1 glutathione eeeee1 -S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb1 glutathione eeeee1  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid ( bbbbb1 ASC eeeee1 ). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid ( bbbbb1 ASC eeeee1 ). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of  bbbbb1 6-DHSG eeeee1  were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of  bbbbb1 6-DHSG eeeee1  were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a  bbbbb1 GSH eeeee1  conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( bbbbb2 GST eeeee2 )
CRP11	The biological activities of 6-DHSG were attenuated by sulfhydryl antioxidants such as glutathione (GSH) or N-acetyl cysteine (NAC), but not ascorbic acid (ASC). 6-DHSG was metabolised by GSH to form a  bbbbb1 GSH eeeee1  conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  bbbbb2 glutathione-S-transferase eeeee2  (GST)
CRP11	Upon activation by  bbbbb1 phenobarbital eeeee1 , nuclear receptor CAR binds the 97-bp response element (-2441/-2345) within the  bbbbb2 Kcnk1 promoter eeeee2 
CRP11	Hyperplasia further progressed in the livers of Kcnk1 ( -/- ) male mice compared with those of Kcnk1 ( +/+ ) males after  bbbbb1 phenobarbital eeeee1  bbbbb2 Kcnk1 eeeee2  ( -/- ) male mice compared with those of Kcnk1 ( +/+ ) males after phenobarbital treatment
CRP11	Hyperplasia further progressed in the livers of Kcnk1 ( -/- ) male mice compared with those of Kcnk1 ( +/+ ) males after  bbbbb1 phenobarbital eeeee1  bbbbb2 Kcnk1 eeeee2  ( +/+ ) males after phenobarbital treatment
CRP11	K1, a member of the family of two-pore  bbbbb1 K(+) eeeee1  bbbbb2 K(+) ion channels eeeee2 , is specifically induced in the livers of male mice after phenobarbital treatment
CRP11	Thus, KCNK1 suppresses  bbbbb1 phenobarbital eeeee1  bbbbb2 KCNK1 eeeee2  suppresses phenobarbital-induced hyperplasia
CRP11	Acarbose, an alpha-glucosidase inhibitor, delays the absorption of  bbbbb1 carbohydrate eeeee1  bbbbb2 alpha-glucosidase eeeee2  inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia
CRP11	Further, recently,  bbbbb1 acarbose eeeee1  has been shown to improve  bbbbb2 insulin eeeee2  resistance in vivo
CRP11	Further, recently, acarbose has been shown to improve  bbbbb1 insulin eeeee1  bbbbb2 acarbose has been shown to improve insulin resistance in vivo eeeee2 
CRP11	Swim training of  bbbbb1 monosodium L-glutamate eeeee1 -obese mice improves the impaired  bbbbb2 insulin receptor eeeee2  tyrosine phosphorylation in pancreatic islets
CRP11	The results showed that IR  bbbbb1 tyrosine eeeee1  phosphorylation (pIR) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased  bbbbb2 pIR eeeee2  by 76 % in MSG mice without affecting control mice (MSG, 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.)
CRP11	The results showed that IR  bbbbb1 tyrosine eeeee1  phosphorylation ( bbbbb2 pIR eeeee2 ) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice (MSG, 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.)
CRP11	Swim training of 90-day-old  bbbbb1 MSG eeeee1  mice was used to evaluate whether signalling pathways of the IR and  bbbbb2 IRS-1 eeeee2  in islets are involved with the insulin resistance and glucose intolerance observed in this obese animal model
CRP11	Swim training of 90-day-old  bbbbb1 MSG eeeee1  mice was used to evaluate whether signalling pathways of the IR and IRS-1 in islets are involved with the  bbbbb2 insulin eeeee2  resistance and glucose intolerance observed in this obese animal model
CRP11	Swim training of 90-day-old  bbbbb1 MSG eeeee1  mice was used to evaluate whether signalling pathways of the  bbbbb2 IR eeeee2  and IRS-1 in islets are involved with the insulin resistance and glucose intolerance observed in this obese animal model
CRP11	Swim training of 90-day-old MSG mice was used to evaluate whether signalling pathways of the IR and IRS-1 in islets are involved with the insulin resistance and  bbbbb1 glucose eeeee1  bbbbb2 IRS-1 eeeee2  in islets are involved with the insulin resistance and glucose intolerance observed in this obese animal model
CRP11	Swim training of 90-day-old MSG mice was used to evaluate whether signalling pathways of the IR and IRS-1 in islets are involved with the insulin resistance and  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  resistance and glucose intolerance observed in this obese animal model
CRP11	Swim training of 90-day-old MSG mice was used to evaluate whether signalling pathways of the IR and IRS-1 in islets are involved with the insulin resistance and  bbbbb1 glucose eeeee1  bbbbb2 IR eeeee2  and IRS-1 in islets are involved with the insulin resistance and glucose intolerance observed in this obese animal model
CRP11	Although the treatment with MSG increased IRS-1 tyrosine phosphorylation bbbbb1  (pIRS-1 eeeee1 ) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.), exercise training also bbbbb2  increased it in  eeeee2 both groups (control, 13.6 ± 0.1; MSG, 22.2 ± 1.1 a.u.)
CRP11	The goal of the present study was to investigate changes on  bbbbb1 glucose eeeee1  homoeostasis and of the  bbbbb2 insulin receptor eeeee2  (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on  bbbbb1 glucose eeeee1  homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 ( bbbbb2 IRS-1 eeeee2 ) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on  bbbbb1 glucose eeeee1  homoeostasis and of the insulin receptor ( bbbbb2 IR eeeee2 ) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on  bbbbb1 glucose eeeee1  homoeostasis and of the insulin receptor (IR) and  bbbbb2 insulin receptor substrate-1 eeeee2  (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from  bbbbb1 MSG eeeee1  bbbbb2 insulin receptor eeeee2  (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from  bbbbb1 MSG eeeee1  bbbbb2 IRS-1 eeeee2 ) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from  bbbbb1 MSG eeeee1  bbbbb2 IR eeeee2 ) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from  bbbbb1 MSG eeeee1  bbbbb2 insulin receptor substrate-1 eeeee2  (IRS-1) signalling in pancreatic islets from MSG-obese mice submitted to or not submitted to swim training
CRP11	Controversial results obtained from human and animal studies on the prevention of heart disease by estrogens and  bbbbb1 progestins eeeee1  warrant a better understanding of  bbbbb2 nuclear hormone receptor eeeee2  function and interaction
CRP11	Controversial results obtained from human and animal studies on the prevention of heart disease by  bbbbb1 estrogens eeeee1  and progestins warrant a better understanding of  bbbbb2 nuclear hormone receptor eeeee2  function and interaction
CRP11	The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired  bbbbb1 NO eeeee1  bbbbb2 osteopontin eeeee2  expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the  bbbbb1 progesterone eeeee1  receptor but may also be mediated by other  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in  bbbbb1 aldosterone eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in  bbbbb1 aldosterone eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and  bbbbb1 drospirenone eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and  bbbbb1 drospirenone eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other  bbbbb1 steroid eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other  bbbbb1 steroid eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of  bbbbb1 17beta-estradiol eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of  bbbbb1 17beta-estradiol eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol,  bbbbb1 medroxyprogesterone acetate eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol,  bbbbb1 medroxyprogesterone acetate eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new  bbbbb1 progestogen eeeee1  bbbbb2 progesterone receptor eeeee2  but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new  bbbbb1 progestogen eeeee1  bbbbb2 steroid receptors eeeee2 , we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity
CRP11	Concomitant administration of ambrisentan and ketoconazole was well tolerated bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Concomitant administration of ambrisentan and ketoconazole was well tolerated bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of  bbbbb1 ambrisentan eeeee1  bbbbb2 CYP3A4 eeeee2 , to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men
CRP11	The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite,  bbbbb1 4-hydroxymethyl ambrisentan eeeee1  bbbbb2 CYP3A4 eeeee2 , to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men
CRP11	 bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine D2 receptor eeeee2  occupancy by risperidone: implications for the timing and magnitude of clinical response
CRP11	The objective of the study is to investigate whether  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptor eeeee2  occupancy by risperidone and plasma levels over time can account for therapeutic efficacy and the latency period to response
CRP11	Proximal tubule cells extract dicarboxylates from filtrate and blood, using cotransporters located in the brush border [ bbbbb1 sodium eeeee1  dicarboxylate cotransporter ( bbbbb2 NaDC-1 eeeee2 )] and basolateral cell membrane (NaDC-3)
CRP11	Proximal tubule cells extract dicarboxylates from filtrate and blood, using cotransporters located in the brush border [ bbbbb1 sodium eeeee1  bbbbb2 sodium dicarboxylate cotransporter eeeee2  (NaDC-1)] and basolateral cell membrane (NaDC-3)
CRP11	Proximal tubule cells extract dicarboxylates from filtrate and blood, using cotransporters located in the brush border [ bbbbb1 sodium eeeee1  dicarboxylate cotransporter (NaDC-1)] and basolateral cell membrane ( bbbbb2 NaDC-3 eeeee2 )
CRP11	Substrate specificity of the human renal  bbbbb1 sodium eeeee1  bbbbb2 human renal sodium dicarboxylate cotransporter eeeee2 , hNaDC-3, under voltage-clamp conditions
CRP11	Substrate specificity of the human renal  bbbbb1 sodium eeeee1  dicarboxylate cotransporter,  bbbbb2 hNaDC-3 eeeee2 , under voltage-clamp conditions
CRP11	In the absence of sodium, however, lithium can mediate succinate-dependent currents bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Since  bbbbb1 gemfibrozil eeeee1  is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of  bbbbb2 iNOS eeeee2 
CRP11	Since  bbbbb1 gemfibrozil eeeee1  is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of  bbbbb2 PPAR-alpha eeeee2  in gemfibrozil-mediated inhibition of iNOS
CRP11	Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in  bbbbb1 gemfibrozil eeeee1  bbbbb2 peroxisome proliferator-activated receptor-alpha eeeee2  (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS
CRP11	Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in  bbbbb1 gemfibrozil eeeee1  bbbbb2 PPAR-alpha eeeee2 ), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS
CRP11	Inhibition of human iNOS promoter-driven luciferase activity by  bbbbb1 gemfibrozil eeeee1  in  bbbbb2 cytokine eeeee2 -stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 signal transducer and activator of transcription eeeee2  (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 interferon-gamma (IFN-gamma) regulatory factor-1 eeeee2  (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 activator protein-1 eeeee2  (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 CCAAT/enhancer-binding protein beta eeeee2  (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 AP-1 eeeee2 ), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 interferon-stimulated responsive element eeeee2  (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 NF-kappaB eeeee2 ), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 nuclear factor-kappaB eeeee2  (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 ISRE eeeee2 ), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 IRF-1 eeeee2 ) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 STAT eeeee2 ) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 C/EBPbeta eeeee2 ); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of  bbbbb1 gemfibrozil eeeee1  bbbbb2 human iNOS promoter eeeee2  contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors
CRP11	However, DeltahPPAR-alpha was unable to abrogate  bbbbb1 gemfibrozil eeeee1 -mediated inhibition of iNOS suggesting that gemfibrozil inhibits  bbbbb2 iNOS eeeee2  independent of PPAR-alpha
CRP11	However, DeltahPPAR-alpha was unable to abrogate  bbbbb1 gemfibrozil eeeee1  bbbbb2 DeltahPPAR-alpha eeeee2  was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha
CRP11	However, DeltahPPAR-alpha was unable to abrogate  bbbbb1 gemfibrozil eeeee1 -mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of  bbbbb2 PPAR-alpha eeeee2 
CRP11	However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that  bbbbb1 gemfibrozil eeeee1  bbbbb2 iNOS eeeee2  suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha
CRP11	However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that  bbbbb1 gemfibrozil eeeee1  bbbbb2 DeltahPPAR-alpha eeeee2  was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha
CRP11	 bbbbb1 Gemfibrozil eeeee1  induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of  bbbbb2 DeltahPPAR-alpha eeeee2 , the dominant-negative mutant of human PPAR-alpha
CRP11	 bbbbb1 Gemfibrozil eeeee1  induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of  bbbbb2 human PPAR-alpha eeeee2 
CRP11	Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of  bbbbb1 NO eeeee1  bbbbb2 cytokine eeeee2 -induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes
CRP11	Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible  bbbbb1 nitric-oxide eeeee1  bbbbb2 cytokine eeeee2 -induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes
CRP11	Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial ce bbbbb1 lls eeeee1  bbbbb2 F-ka eeeee2 ppaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells
CRP11	Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial ce bbbbb1 lls eeeee1  bbbbb2 kine eeeee2 -stimulated astroglial cells
CRP11	Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial ce bbbbb1 lls eeeee1  bbbbb2 GAS in cy eeeee2 tokine-stimulated astroglial cells
CRP11	Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial ce bbbbb1 lls eeeee1  bbbbb2 lated ast eeeee2 roglial cells
CRP11	Administration of the optimized  bbbbb1 β-Lapachone eeeee1 -poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through  bbbbb2 NAD(P)H:quinone oxidoreductase-1 eeeee2  (NQO1)
CRP11	Administration of the optimized  bbbbb1 β-Lapachone eeeee1 -poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 ( bbbbb2 NQO1 eeeee2 )
CRP11	Administration of the optimized β-Lapachone- bbbbb1 poloxamer eeeee1 -cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through  bbbbb2 NAD(P)H:quinone oxidoreductase-1 eeeee2  (NQO1)
CRP11	Administration of the optimized β-Lapachone- bbbbb1 poloxamer eeeee1 -cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 ( bbbbb2 NQO1 eeeee2 )
CRP11	Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through  bbbbb1 NAD(P)H eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase-1 eeeee2  (NQO1)
CRP11	Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through  bbbbb1 NAD(P)H eeeee1 :quinone oxidoreductase-1 ( bbbbb2 NQO1 eeeee2 )
CRP11	Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H: bbbbb1 quinone eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase-1 eeeee2  (NQO1)
CRP11	Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. β-Lapachone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase-1 ( bbbbb2 NQO1 eeeee2 )
CRP11	These findings highlight that the interaction between M6P/IGF2R and M6P-modified ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes, but is also crucial for the ability of the receptor to sup bbbbb1 press SCC-VI eeeee1  bbbbb2 ified eeeee2  ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes, but is also crucial for the ability of the receptor to suppress SCC-VII growth and invasion
CRP11	These findings highlight that the interaction between M6P/IGF2R and M6P bbbbb1 -mo eeeee1 d bbbbb2 ified eeeee2  ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes, but is also crucial for the ability of the receptor to suppress SCC-VII growth and invasion
CRP11	It has been shown that expression of wild-type  bbbbb1 M6P eeeee1 / bbbbb2 IGF2R eeeee2  reduces the tumorigenic and invasive properties of receptor-deficient SCC-VII squamous cell carcinoma cells
CRP11	The mannose 6-phosphate-binding sites of  bbbbb1 M6P eeeee1 / bbbbb2 IGF2R eeeee2  determine its capacity to suppress matrix invasion by squamous cell carcinoma cells
CRP11	The results of the present study demonstrate that  bbbbb1 M6P eeeee1 / bbbbb2 IGF2R eeeee2  does not require a functional binding site for insulin-like growth factor II for inhibition of anchorage-independent growth and matrix invasion by SCC-VII cells
CRP11	The results of the present study demonstrate that  bbbbb1 M6P eeeee1 /IGF2R does not require a functional binding site for  bbbbb2 insulin-like growth factor II eeeee2  for inhibition of anchorage-independent growth and matrix invasion by SCC-VII cells
CRP11	We have now used mutant forms of  bbbbb1 M6P eeeee1 / bbbbb2 IGF2R eeeee2  to assess the relevance of the different ligand-binding sites of the receptor for its biological activities in this cellular system
CRP11	Comparison of the monoamine oxidase inhibiting properties of two reversible and selective  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. 1
CRP11	Comparison of the monoamine oxidase inhibiting properties of two reversible and selective  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase-A eeeee2  inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. 1
CRP11	Comparison of the  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. 1
CRP11	Comparison of the  bbbbb1 monoamine eeeee1  oxidase inhibiting properties of two reversible and selective  bbbbb2 monoamine oxidase-A eeeee2  inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. 1
CRP11	The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors,  bbbbb1 moclobemide eeeee1  bbbbb2 MAO-A eeeee2 ) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase-A eeeee2  (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on  bbbbb1 monoamine eeeee1  bbbbb2 MAO-A eeeee2 ) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	The effects of two reversible, predominantly  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase-A eeeee2  (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	The effects of two reversible, predominantly  bbbbb1 monoamine eeeee1  oxidase-A ( bbbbb2 MAO-A eeeee2 ) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and  bbbbb1 toloxatone eeeee1  bbbbb2 MAO-A eeeee2 ) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects. 2
CRP11	Compared with placebo, both reversible monoamine oxidase inhibitors decreased the plasma concentration of  bbbbb1 DHPG eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibitors decreased the plasma concentration of DHPG and HVA
CRP11	Compared with placebo, both reversible  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibitors decreased the plasma concentration of DHPG and HVA
CRP11	Compared with placebo, both reversible monoamine oxidase inhibitors decreased the plasma concentration of DHPG and  bbbbb1 HVA eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibitors decreased the plasma concentration of DHPG and HVA
CRP11	Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma  bbbbb1 DHPG eeeee1  bbbbb2 MAO-A eeeee2  inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone. 5
CRP11	The mitochondrial respiratory chain complex IV (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular  bbbbb1 oxygen eeeee1  bbbbb2 cytochrome c eeeee2  to molecular oxygen, yielding water
CRP11	In general, rifampicin can act on a pattern: rifampicin activates the nuclear  bbbbb1 pregnane eeeee1  X receptor that in turn affects  bbbbb2 cytochromes P450 eeeee2 , glucuronosyltransferases and p-glycoprotein activities
CRP11	In general, rifampicin can act on a pattern: rifampicin activates the nuclear  bbbbb1 pregnane eeeee1  X receptor that in turn affects cytochromes P450,  bbbbb2 glucuronosyltransferases eeeee2  and p-glycoprotein activities
CRP11	In general, rifampicin can act on a pattern: rifampicin activates the nuclear  bbbbb1 pregnane eeeee1  bbbbb2 nuclear pregnane X receptor eeeee2  that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities
CRP11	In general, rifampicin can act on a pattern: rifampicin activates the nuclear  bbbbb1 pregnane eeeee1  X receptor that in turn affects cytochromes P450, glucuronosyltransferases and  bbbbb2 p-glycoprotein eeeee2  activities
CRP11	Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear  bbbbb1 pregnane eeeee1  bbbbb2 nuclear pregnane X receptor eeeee2 
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the  bbbbb1 nitric oxide eeeee1  (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1 ; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1 ; the mixed COX-1/ bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1 ; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1 ; the mixed  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor  bbbbb1 NS-398 eeeee1 ; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin,  bbbbb1 ibuprofen eeeee1  and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1 , ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1 , ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of  bbbbb1 indomethacin eeeee1 , ibuprofen and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1 ; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1 ; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor  bbbbb1 REV 5901 eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1 ) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1 ) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide ( bbbbb1 NO eeeee1 ) derivatives of indomethacin, ibuprofen and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor  bbbbb1 ibuprofen eeeee1 ; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor  bbbbb1 ibuprofen eeeee1 ; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor  bbbbb1 ibuprofen eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor  bbbbb1 ibuprofen eeeee1 ; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1 ; the 5-LOX inhibitor REV 5901; and the  bbbbb2 5-LOX activating protein eeeee2  (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1 ; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( bbbbb2 FLAP eeeee2 ) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and  bbbbb1 flurbiprofen eeeee1 ; the  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor  bbbbb1 MK-886 eeeee1  bbbbb2 COX-1 eeeee2  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor  bbbbb1 MK-886 eeeee1  bbbbb2 COX-2 eeeee2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor  bbbbb1 MK-886 eeeee1  bbbbb2 COX-2 eeeee2  inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor  bbbbb1 MK-886 eeeee1  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor  bbbbb1 MK-886 eeeee1  bbbbb2 5-LOX eeeee2  inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886
CRP11	The COX pathway generates inflammatory  bbbbb1 prostaglandins eeeee1 , while the  bbbbb2 5-LOX eeeee2  pathway generates inflammatory leukotrienes
CRP11	The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory  bbbbb1 leukotrienes eeeee1  bbbbb2 COX eeeee2  pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes
CRP11	As models of glial activation, production of inducible  bbbbb1 nitric-oxide eeeee1  synthase (iNOS) was studied in lipopolysaccharide-stimulated rat microglia, a murine microglial cell line BV-2, and  bbbbb2 IL-1beta eeeee2 -stimulated rat astrocytes
CRP11	As models of glial activation, production of inducible  bbbbb1 nitric-oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ) was studied in lipopolysaccharide-stimulated rat microglia, a murine microglial cell line BV-2, and IL-1beta-stimulated rat astrocytes
CRP11	As models of glial activation, production of inducible  bbbbb1 nitric-oxide eeeee1  bbbbb2 inducible nitric-oxide synthase eeeee2  (iNOS) was studied in lipopolysaccharide-stimulated rat microglia, a murine microglial cell line BV-2, and IL-1beta-stimulated rat astrocytes
CRP11	Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible  bbbbb1 nitric-oxide eeeee1  bbbbb2 inducible nitric-oxide synthase eeeee2  by 15-deoxy-Delta12,14-prostaglandin J2
CRP11	Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2. 15-Deoxy-Delta12,14-prostaglandin J2 ( bbbbb1 15d-PGJ2 eeeee1  bbbbb2 iNOS eeeee2  induction and were more effective than their precursors, prostaglandins E2 and D2. 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested
CRP11	Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2. 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent  bbbbb1 prostaglandin eeeee1  bbbbb2 iNOS eeeee2  induction and were more effective than their precursors, prostaglandins E2 and D2. 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested
CRP11	Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2.  bbbbb1 15-Deoxy-Delta12,14-prostaglandin J2 eeeee1  bbbbb2 iNOS eeeee2  induction and were more effective than their precursors, prostaglandins E2 and D2. 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested
CRP11	Several members of a new family of non- bbbbb1 sugar eeeee1 -type  bbbbb2 α-glycosidase eeeee2  inhibitors, bearing a 5-(p-toluenesulfonylamino)phthalimide moiety and various substituent at the N2 position, were synthesized and their activities were investigated
CRP11	Therefore, comparative histochemical and biochemical studies of u-PA and the effects of  bbbbb1 amiloride eeeee1  bbbbb2 u-PA eeeee2  and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin
CRP11	After inflammation was established mice were dosed with the H4R antagonist,  bbbbb1 JNJ 7777120 eeeee1 , or anti- bbbbb2 IL-13 eeeee2  antibody for comparison
CRP11	 bbbbb1 Histamine eeeee1  bbbbb2 Histamine H4 receptor eeeee2  (H4R) perturbation has previously been shown to modify acute inflammation and Th2 cytokine production in a murine model of asthma
CRP11	 bbbbb1 Histamine eeeee1  H4 receptor (H4R) perturbation has previously been shown to modify acute inflammation and  bbbbb2 Th2 cytokine eeeee2  production in a murine model of asthma
CRP11	 bbbbb1 Histamine eeeee1  H4 receptor ( bbbbb2 H4R eeeee2 ) perturbation has previously been shown to modify acute inflammation and Th2 cytokine production in a murine model of asthma
CRP11	Inhibitor of  bbbbb1 cGMP eeeee1  bbbbb2 cGMP-specific PDE5 eeeee2  (zaprinast; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis
CRP11	We also evaluated whether a PDE4 inhibitor could modulate the effect of a  bbbbb1 corticosteroid eeeee1  bbbbb2 PDE4 eeeee2  inhibitor could modulate the effect of a corticosteroid on eosinophil and neutrophil apoptosis
CRP11	The effect of  bbbbb1 budesonide eeeee1  on apoptosis was not significantly modulated by a  bbbbb2 PDE4 eeeee2  inhibitor in eosinophils or neutrophils
CRP11	Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of  bbbbb1 salbutamol eeeee1  bbbbb2 Phosphodiesterase 4 eeeee2  inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol
CRP11	A combination of a PDE4 or PDE3 inhibitor (10 microM) with  bbbbb1 salbutamol eeeee1  bbbbb2 PDE4 eeeee2  or PDE3 inhibitor (10 microM) with salbutamol (100 nM) further delayed eosinophil apoptosis maximally by 42-49%
CRP11	A combination of a PDE4 or PDE3 inhibitor (10 microM) with  bbbbb1 salbutamol eeeee1  bbbbb2 PDE3 eeeee2  inhibitor (10 microM) with salbutamol (100 nM) further delayed eosinophil apoptosis maximally by 42-49%
CRP11	Inhibitors of PDE4 ( bbbbb1 rolipram eeeee1 ; 0.1-10 microM) and  bbbbb2 PDE3 eeeee2  (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively
CRP11	Inhibitors of PDE4 (rolipram; 0.1-10 microM) and PDE3 ( bbbbb1 cilostazol eeeee1  bbbbb2 PDE4 eeeee2  (rolipram; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively
CRP11	These effects resemble those seen with  bbbbb1 N eeeee1 -terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to  bbbbb2 DeltaNK(ATP) channels eeeee2  decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK( bbbbb1 ATP eeeee1  bbbbb2 K(IR)6.0 eeeee2 , and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK( bbbbb1 ATP eeeee1  bbbbb2 DeltaNK(ATP) channels eeeee2  decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of  bbbbb1 Mg(2+) eeeee1  bbbbb2 K(IR)6.0 eeeee2 , and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of  bbbbb1 Mg(2+) eeeee1  bbbbb2 DeltaNK(ATP) channels eeeee2  decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for  bbbbb1 ATP eeeee1  bbbbb2 K(IR)6.0 eeeee2 , and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)
CRP11	Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the  bbbbb1 ATP eeeee1  inhibition of K(IR)6.2/SUR1, but had no effect on homomeric  bbbbb2 K(IR)6.2 eeeee2  channels
CRP11	The K(IR)  bbbbb1 N eeeee1  terminus and the TMD0-L0 segment of  bbbbb2 SUR1 eeeee2  are known to control the P(O(max))
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity bbbbb2  eeeee2 
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1  bbbbb2 ired  eeeee2 for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and bbbbb2  L0 eeeee2  of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (12 bbbbb2 5)I-a eeeee2 zidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamid bbbbb2 e, i eeeee2 mplying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azi bbbbb2 dogl eeeee2 ibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1 ltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are i bbbbb2 n p eeeee2 roximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and D bbbbb1 e eeeee1  bbbbb2 eltaNK(IR)6.2/S eeeee2 UR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity bbbbb2  eeeee2 
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and bbbbb2  L0 eeeee2  of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (12 bbbbb2 5)I-a eeeee2 zidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamid bbbbb2 e, i eeeee2 mplying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azi bbbbb2 dogl eeeee2 ibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are i bbbbb2 n p eeeee2 roximity
CRP11	The L0 linker has been reported to be required f bbbbb1 o eeeee1 r glibenclamide binding, and D bbbbb2 eltaNK(IR)6.2/S eeeee2 UR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity bbbbb2  eeeee2 
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1  bbbbb2 ired  eeeee2 for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and bbbbb2  L0 eeeee2  of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (12 bbbbb2 5)I-a eeeee2 zidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamid bbbbb2 e, i eeeee2 mplying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azi bbbbb2 dogl eeeee2 ibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1 K(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are i bbbbb2 n p eeeee2 roximity
CRP11	The L0 linker has been reported to be required for glibenclamide binding, and Del bbbbb1 taN eeeee1  bbbbb2 eltaNK(IR)6.2/S eeeee2 UR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity
CRP11	R-dependent modulation of KATP channels by an  bbbbb1 N eeeee1  bbbbb2 KATP channels eeeee2  by an N-terminal KIR6.2 peptide
CRP11	R-dependent modulation of  bbbbb1 KATP eeeee1  channels by an N-terminal  bbbbb2 KIR6.2 eeeee2  peptide
CRP11	R-dependent modulation of  bbbbb1 KATP eeeee1  bbbbb2 KATP channels eeeee2  by an N-terminal KIR6.2 peptide
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K( bbbbb1 ATP eeeee1  bbbbb2 K(IR)6.0 eeeee2 /SUR K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K( bbbbb1 ATP eeeee1  bbbbb2 SUR eeeee2  K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channels eeeee2 
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K( bbbbb1 ATP eeeee1  bbbbb2 K(IR)6.0 eeeee2 , respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and  bbbbb1 C eeeee1 -terminal sequences of K(IR)6.0, respectively, were used to probe gating of  bbbbb2 K(IR)6.0 eeeee2 /SUR K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and  bbbbb1 C eeeee1 -terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/ bbbbb2 SUR eeeee2  K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and  bbbbb1 C eeeee1 -terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb2 K(ATP) channels eeeee2 
CRP11	Ntp and Ctp, synthetic peptides based on the  bbbbb1 N eeeee1 - and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of  bbbbb2 K(IR)6.0 eeeee2 /SUR K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the  bbbbb1 N eeeee1 - and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/ bbbbb2 SUR eeeee2  K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the  bbbbb1 N eeeee1 - and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb2 K(ATP) channels eeeee2 
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb1 K eeeee1  bbbbb2 K(IR)6.0 eeeee2 /SUR K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb1 K eeeee1  bbbbb2 SUR eeeee2  K(ATP) channels
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb1 K eeeee1  bbbbb2 K(ATP) channels eeeee2 
CRP11	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR  bbbbb1 K eeeee1  bbbbb2 K(IR)6.0 eeeee2 , respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-)  bbbbb1 nucleotide(s) eeeee1  bbbbb2 K(IR)6.1 eeeee2 /SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-)  bbbbb1 nucleotide(s) eeeee1  bbbbb2 SUR1 eeeee2  channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-)  bbbbb1 nucleotide(s) eeeee1  and attenuated the coupling of high-affinity sulfonylurea binding with  bbbbb2 K(ATP) eeeee2  pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity  bbbbb1 sulfonylurea eeeee1  bbbbb2 K(IR)6.1 eeeee2 /SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity  bbbbb1 sulfonylurea eeeee1  bbbbb2 SUR1 eeeee2  channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with  bbbbb1 K eeeee1  bbbbb2 K(IR)6.1 eeeee2 /SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with  bbbbb1 K eeeee1  bbbbb2 SUR1 eeeee2  channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with  bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2  pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K( bbbbb1 ATP eeeee1  bbbbb2 K(IR)6.1 eeeee2 /SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K( bbbbb1 ATP eeeee1  bbbbb2 SUR1 eeeee2  channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure
CRP11	Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2  pore closure
CRP11	HG also increases the levels of Nox4 and Nox1 and  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity
CRP11	HG also increases the levels of Nox4 and Nox1 and  bbbbb1 NADPH eeeee1  bbbbb2 Nox4 eeeee2  and Nox1 and NADPH oxidase activity
CRP11	HG also increases the levels of Nox4 and Nox1 and  bbbbb1 NADPH eeeee1  bbbbb2 Nox1 eeeee2  and NADPH oxidase activity
CRP11	Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1,  bbbbb1 NADPH eeeee1  bbbbb2 Nox4 eeeee2  and Nox1, NADPH oxidase activity and podocyte apoptosis
CRP11	Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1,  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity and podocyte apoptosis
CRP11	Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1,  bbbbb1 NADPH eeeee1  bbbbb2 Nox1 eeeee2 , NADPH oxidase activity and podocyte apoptosis
CRP11	Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1,  bbbbb1 NADPH eeeee1  bbbbb2 mTOR eeeee2  by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis
CRP11	Our data provide  bbbbb1 evide eeeee1  bbbbb2 evidence for  eeeee2 a novel function of mTOR in Nox4-derived ROS generation and podocyte apoptosis that contributes to urinary albumin excretion in type 1 diabetes
CRP11	Our data provide  bbbbb1 evide eeeee1  bbbbb2 ata  eeeee2 provide evidence for a novel function of mTOR in Nox4-derived ROS generation and podocyte apoptosis that contributes to urinary albumin excretion in type 1 diabetes
CRP11	In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and  bbbbb1 NADPH eeeee1  bbbbb2 tuberin eeeee2  and activation of mTOR with increase in Nox4 and NADPH oxidase activity
CRP11	In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and  bbbbb1 NADPH eeeee1  bbbbb2 AMPK eeeee2  and tuberin and activation of mTOR with increase in Nox4 and NADPH oxidase activity
CRP11	In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity
CRP11	In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and  bbbbb1 NADPH eeeee1  bbbbb2 mTOR eeeee2  with increase in Nox4 and NADPH oxidase activity
CRP11	In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and  bbbbb1 NADPH eeeee1  bbbbb2 Nox4 eeeee2  and NADPH oxidase activity
CRP11	T is also found in rat kidney, albeit in substantially lower amounts, but it is not known whether kidney BHMT expression is regulated by dietary  bbbbb1 Met eeeee1  bbbbb2 BHMT eeeee2  expression is regulated by dietary Met or choline
CRP11	T is also found in rat kidney, albeit in substantially lower amounts, but it is not known whether kidney BHMT expression is regulated by dietary Met or  bbbbb1 choline eeeee1  bbbbb2 BHMT eeeee2  expression is regulated by dietary Met or choline
CRP11	Liver  bbbbb1 choline eeeee1  bbbbb2 choline dehydrogenase eeeee2  and kidney betaine-homocysteine methyltransferase expression are not affected by methionine or choline intake in growing rats
CRP11	Liver  bbbbb1 choline eeeee1  dehydrogenase and kidney  bbbbb2 betaine-homocysteine methyltransferase eeeee2  expression are not affected by methionine or choline intake in growing rats
CRP11	Liver choline dehydrogenase and kidney  bbbbb1 betaine eeeee1  bbbbb2 choline dehydrogenase eeeee2  and kidney betaine-homocysteine methyltransferase expression are not affected by methionine or choline intake in growing rats
CRP11	Liver choline dehydrogenase and kidney  bbbbb1 betaine eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  expression are not affected by methionine or choline intake in growing rats
CRP11	Liver choline dehydrogenase and kidney betaine- bbbbb1 homocysteine eeeee1  bbbbb2 choline dehydrogenase eeeee2  and kidney betaine-homocysteine methyltransferase expression are not affected by methionine or choline intake in growing rats
CRP11	Liver choline dehydrogenase and kidney betaine- bbbbb1 homocysteine eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  expression are not affected by methionine or choline intake in growing rats
CRP11	Liver BHMT activity was 1.3-fold higher in rats fed the  bbbbb1 Met eeeee1  bbbbb2 BHMT eeeee2  activity was 1.3-fold higher in rats fed the Met deficient diet containing choline, which was reflected in corresponding increases in mRNA content and immunodetectable protein
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of  bbbbb1 ziprasidone eeeee1  bbbbb2 5-HT(2) eeeee2  occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of  bbbbb1 ziprasidone eeeee1  bbbbb2 D(2) eeeee2  occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using  bbbbb1 [(11)C]raclopride eeeee1 ) and  bbbbb2 5-HT(2) eeeee2  occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using  bbbbb1 [(18)F]setoperone eeeee1  bbbbb2 D(2) eeeee2  occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2) eeeee2  occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	HOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and  bbbbb1 5-HT eeeee1  bbbbb2 D(2) eeeee2  occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with  bbbbb1 dopamine eeeee1  bbbbb2 5-HT(2) receptors eeeee2  compared with dopamine D(2) receptors in vitro
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D(2) receptors eeeee2  in vitro
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for  bbbbb1 serotonin eeeee1   bbbbb2 5-HT(2) receptors eeeee2  compared with dopamine D(2) receptors in vitro
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for  bbbbb1 serotonin eeeee1  5-HT(2) receptors compared with  bbbbb2 dopamine D(2) receptors eeeee2  in vitro
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2) receptors eeeee2  compared with dopamine D(2) receptors in vitro
CRP11	IVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin  bbbbb1 5-HT eeeee1 (2) receptors compared with  bbbbb2 dopamine D(2) receptors eeeee2  in vitro
CRP11	NS: These data affirm that ziprasidone is similar to other novel antipsychotics in having greater 5-HT(2) than D(2) receptor occupancy at therapeutic doses and suggest that the optimal effective dose of  bbbbb1 ziprasidone eeeee1  bbbbb2 D(2) receptor eeeee2  occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasidone is closer to 120 mg/day than to the lower doses suggested by previous PET studies
CRP11	NS: These data affirm that ziprasidone is similar to other novel antipsychotics in having greater 5-HT(2) than D(2) receptor occupancy at therapeutic doses and suggest that the optimal effective dose of  bbbbb1 ziprasidone eeeee1  bbbbb2 5-HT(2) eeeee2  than D(2) receptor occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasidone is closer to 120 mg/day than to the lower doses suggested by previous PET studies
CRP11	The mean  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2) eeeee2  receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively)
CRP11	The mean  bbbbb1 5-HT eeeee1 (2) receptor occupancy was significantly higher than the mean  bbbbb2 D(2) receptor eeeee2  occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively)
CRP11	Here we report the amino acid sequence of the bovine  bbbbb1 oxytocin eeeee1  bbbbb2 bovine oxytocin-neurophysin I (OT-NpI) precursor eeeee2  which was derived from sequence analysis of the cloned cDNA
CRP11	Among the primary translation products a single polypeptide of Mr approximately 16,500 was shown to contain antigenic determinants recognized by specific antisera against bovine neurophysin I and  bbbbb1 oxytocin eeeee1  bbbbb2 bovine neurophysin I eeeee2  and oxytocin
CRP11	Among the primary translation products a single polypeptide of Mr approximately 16,500 was shown to contain antigenic determinants recognized by specific antisera against bovine neurophysin I and  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 
CRP11	As is the case for the bovine arginine-vasopressin-neurophysin II (AVP-NpII) precursor, the signal se bbbbb1 que eeeee1 nce of the OT-NpI precursor is immediately followed by the nonapepti bbbbb2 de hormone which is c eeeee2 onnected to neurophysin I by a Gly-Lys-Arg sequence
CRP11	As is the case for the bovine arginine-vasopressin-neurophysin II (AVP-NpII) precursor, the signal se bbbbb1 que eeeee1  bbbbb2 quence of the OT-N eeeee2 pI precursor is immediately followed by the nonapeptide hormone which is connected to neurophysin I by a Gly-Lys-Arg sequence
CRP11	Deduced amino acid sequence from the bovine  bbbbb1 oxytocin eeeee1  bbbbb2 bovine oxytocin-neurophysin I precursor eeeee2  cDNA
CRP11	A protein of molecular weight (Mr) approximately 20,000 has been isolated from supraoptic nuclei of rat hypothalami which, after tryptic cleavage, released a neurophysin-like molecule of Mr approximately 10,000 and an oligopeptide related to  bbbbb1 oxytocin eeeee1  bbbbb2 neurophysin eeeee2 -like molecule of Mr approximately 10,000 and an oligopeptide related to oxytocin
CRP11	A protein of molecular weight (Mr) approximately 20,000 has been isolated from supraoptic nuclei of rat hypothalami which, after tryptic cleavage, released a neurophysin-like molecule of Mr approximately 10,000 and an oligopeptide related to  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 
CRP11	The nonapeptide hormone oxytocin-like arginine- bbbbb1 vasopressin eeeee1  bbbbb2 oxytocin eeeee2 -like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like arginine- bbbbb1 vasopressin eeeee1  ( bbbbb2 AVP eeeee2 ) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like arginine- bbbbb1 vasopressin eeeee1  bbbbb2 arginine-vasopressin eeeee2  (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like  bbbbb1 arginine eeeee1  bbbbb2 oxytocin eeeee2 -like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like  bbbbb1 arginine eeeee1 -vasopressin ( bbbbb2 AVP eeeee2 ) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like  bbbbb1 arginine eeeee1  bbbbb2 arginine-vasopressin eeeee2  (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like arginine-vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 oxytocin eeeee2 -like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like arginine-vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2 ) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone oxytocin-like arginine-vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 arginine-vasopressin eeeee2  (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 -like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone  bbbbb1 oxytocin eeeee1 -like arginine-vasopressin ( bbbbb2 AVP eeeee2 ) is synthesized as part of a larger precursor polypeptide
CRP11	The nonapeptide hormone  bbbbb1 oxytocin eeeee1 -like  bbbbb2 arginine-vasopressin eeeee2  (AVP) is synthesized as part of a larger precursor polypeptide
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 MRP-2 eeeee2 , Breast Cancer Resistance Protein - BCRP) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 Pgp eeeee2 , Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP,  bbbbb2 Peptide transporter 1 eeeee2  - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  Transporter 1 -  bbbbb2 MCT1 eeeee2 , Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 -  bbbbb2 PepT1 eeeee2 ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 MonoCarboxylate Transporter 1 eeeee2  - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  Transporter 1 - MCT1, Organic Anion Transporting Polypeptide -  bbbbb2 OATP eeeee2 , Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 BCRP eeeee2 ) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 P-glycoprotein eeeee2  - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  Transporter 1 - MCT1,  bbbbb2 Organic Anion Transporting Polypeptide eeeee2  - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 Breast Cancer Resistance Protein eeeee2  - BCRP) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	The increased activities of the most important intestinal efflux (P-glycoprotein - Pgp, Multidrug Resistance Associated Protein 2 - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake ( bbbbb1 MonoCarboxylate eeeee1  bbbbb2 Multidrug Resistance Associated Protein 2 eeeee2  - MRP-2, Breast Cancer Resistance Protein - BCRP) and uptake (MonoCarboxylate Transporter 1 - MCT1, Organic Anion Transporting Polypeptide - OATP, Peptide transporter 1 - PepT1) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications
CRP11	Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin,  bbbbb1 enkephalins eeeee1  bbbbb2 beta-endorphin eeeee2 , enkephalins and dynorphins, respectively)
CRP11	Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin,  bbbbb1 enkephalins eeeee1  bbbbb2 opioid peptides eeeee2  (beta-endorphin, enkephalins and dynorphins, respectively)
CRP11	Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin,  bbbbb1 enkephalins eeeee1  bbbbb2 enkephalins eeeee2  and dynorphins, respectively)
CRP11	Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin,  bbbbb1 enkephalins eeeee1  and  bbbbb2 dynorphins eeeee2 , respectively)
CRP11	Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin,  bbbbb1 enkephalins eeeee1  bbbbb2 opioid receptors (mu, delta and kappa) eeeee2  represent the respective targets of the major opioid peptides (beta-endorphin, enkephalins and dynorphins, respectively)
CRP11	Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors) have been shown to decrease  bbbbb1 alcohol eeeee1  bbbbb2 opioid receptors eeeee2 ) have been shown to decrease alcohol consumption under various experimental conditions
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1  bbbbb2 melanocortin eeeee2  analogs [Nle(4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP- bbbbb2 α-MSH eeeee2  and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of  bbbbb2 pJAK2 eeeee2 , pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and  bbbbb2 TNF-α eeeee2  levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and  bbbbb2 ACTH-(1-24) eeeee2  were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2,  bbbbb2 pERK1/2 eeeee2  and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 ( bbbbb2 JAK eeeee2 -dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in  bbbbb2 pJNK eeeee2  and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins  bbbbb2 HO-1 eeeee2  and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ bbbbb2 ACTH-(1-24) eeeee2 ], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and  bbbbb2 pTyr-STAT3 eeeee2  (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and  bbbbb2 adrenocorticotropic hormone 1-24 eeeee2  [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [ bbbbb1 Nle eeeee1 (4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and  bbbbb2 Bcl-XL eeeee2 , and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1  bbbbb2 melanocortin eeeee2  analogs [Nle(4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP- bbbbb2 α-MSH eeeee2  and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of  bbbbb2 pJAK2 eeeee2 , pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and  bbbbb2 TNF-α eeeee2  levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and  bbbbb2 ACTH-(1-24) eeeee2  were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2,  bbbbb2 pERK1/2 eeeee2  and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 ( bbbbb2 JAK eeeee2 -dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in  bbbbb2 pJNK eeeee2  and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins  bbbbb2 HO-1 eeeee2  and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ bbbbb2 ACTH-(1-24) eeeee2 ], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and  bbbbb2 pTyr-STAT3 eeeee2  (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and  bbbbb2 adrenocorticotropic hormone 1-24 eeeee2  [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size
CRP11	Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4),  bbbbb1 D-Phe eeeee1 (7)]α-melanocyte-stimulating hormone (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and  bbbbb2 Bcl-XL eeeee2 , and marked decrease of the myocardial infarct size
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 pERK1/2 eeeee2 , pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1 -terminal kinases ( bbbbb2 pJNK eeeee2 ), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 c-jun N-terminal kinases eeeee2  (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 pTyr-STAT3 eeeee2  and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 BAX eeeee2  and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 pJAK2 eeeee2 , pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 TNF-α eeeee2 ), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1 -terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme  bbbbb2 heme oxygenase-1 eeeee2  (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1 -terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 ( bbbbb2 HO-1 eeeee2 ), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 pSer-STAT3 eeeee2 , the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1  bbbbb2 tumor necrosis factor-α eeeee2  (TNF-α), the pro-apoptotic factors BAX and c-jun N-terminal kinases (pJNK), the anti-apoptotic protein Bcl-XL, as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	At the end of the 2-h reperfusion, western blot analysis of the cardioprotective transcription factors pJAK2, pERK1/2, pTyr-STAT3 and pSer-STAT3, the inflammatory mediator tumor necrosis factor-α (TNF-α), the pro-apoptotic factors BAX and c-jun  bbbbb1 N eeeee1 -terminal kinases (pJNK), the anti-apoptotic protein  bbbbb2 Bcl-XL eeeee2 , as well as of the cardioprotective enzyme heme oxygenase-1 (HO-1), was performed in the left ventricle and spleen
CRP11	Cocrystal structures of PDE5 catalytic (C) domain with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612,  bbbbb1 hydrogen eeeee1  bbbbb2 PDE5 catalytic (C) domain eeeee2  with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al. (2003) Nature 425, 98-102; Huai et al. (2004) J
CRP11	Cocrystal structures of PDE5 catalytic (C) domain with inhibitors reveal a  bbbbb1 hydrogen eeeee1  bbbbb2 PDE5 catalytic (C) domain eeeee2  with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al. (2003) Nature 425, 98-102; Huai et al. (2004) J
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1 -methyltransferase ( bbbbb2 GNMT eeeee2 , 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1  bbbbb2 MAT eeeee2 ) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1  bbbbb2 cystathionase eeeee2  (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1  bbbbb2 liver methionine adenosyltransferase eeeee2  (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1  bbbbb2 cystathionine synthase eeeee2  (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine  bbbbb1 N eeeee1  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase ( bbbbb2 GNMT eeeee2 , 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  adenosyltransferase ( bbbbb2 MAT eeeee2 ) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01),  bbbbb2 cystathionase eeeee2  (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  bbbbb2 liver methionine adenosyltransferase eeeee2  (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb2 cystathionine synthase eeeee2  (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver  bbbbb1 methionine eeeee1  adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase ( bbbbb2 GNMT eeeee2 , 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  bbbbb2 MAT eeeee2 ) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  synthase (50%, p<0.01),  bbbbb2 cystathionase eeeee2  (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  bbbbb2 liver methionine adenosyltransferase eeeee2  (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine synthase eeeee2  (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were  bbbbb1 cystathionine eeeee1  synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  N-methyltransferase ( bbbbb2 GNMT eeeee2 , 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  bbbbb2 MAT eeeee2 ) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  bbbbb2 cystathionase eeeee2  (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  bbbbb2 liver methionine adenosyltransferase eeeee2  (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  bbbbb2 cystathionine synthase eeeee2  (50%, p<0.01), cystathionase (83%, p<0.001), and glycine N-methyltransferase (GNMT, 91%, p<0.001) activities
CRP11	The specific activity of liver methionine adenosyltransferase (MAT) was significantly elevated (205%, p<0.0001) in the dwarf mice, as were cystathionine synthase (50%, p<0.01), cystathionase (83%, p<0.001), and  bbbbb1 glycine eeeee1  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT, 91%, p<0.001) activities
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2 com eeeee2 bination of the two drugs produced an additive effect
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2 itive effect eeeee2 
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2 com eeeee2 bination of the two drugs produced an additive effect
CRP11	The combination of the two drugs produced an additive effect bbbbb1  eeeee1  bbbbb2 itive effect eeeee2 
CRP11	 bbbbb1 Angiotensin eeeee1  bbbbb2 Angiotensin-converting enzyme eeeee2  inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes
CRP11	 bbbbb1 Angiotensin eeeee1 -converting enzyme inhibition and  bbbbb2 AT1 eeeee2  receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes
CRP11	Renal renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2  and nitric oxide (NO) system gene expression was also investigated
CRP11	Renal renin- bbbbb1 angiotensin eeeee1  bbbbb2 Renal renin eeeee2 -angiotensin and nitric oxide (NO) system gene expression was also investigated
CRP11	Renal renin-angiotensin and  bbbbb1 nitric oxide eeeee1  bbbbb2 angiotensin eeeee2  and nitric oxide (NO) system gene expression was also investigated
CRP11	Renal renin-angiotensin and  bbbbb1 nitric oxide eeeee1  bbbbb2 Renal renin eeeee2 -angiotensin and nitric oxide (NO) system gene expression was also investigated
CRP11	Renal renin-angiotensin and nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 angiotensin eeeee2  and nitric oxide (NO) system gene expression was also investigated
CRP11	Renal renin-angiotensin and nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 Renal renin eeeee2 -angiotensin and nitric oxide (NO) system gene expression was also investigated
CRP11	The pressure-natriuresis and -diuresis relationships in response to chronic  bbbbb1 angiotensin eeeee1 -converting enzyme (ACE) inhibition and  bbbbb2 AT1 eeeee2  receptor blockade were evaluated
CRP11	The pressure-natriuresis and -diuresis relationships in response to chronic  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibition and AT1 receptor blockade were evaluated
CRP11	The pressure-natriuresis and -diuresis relationships in response to chronic  bbbbb1 angiotensin eeeee1 -converting enzyme ( bbbbb2 ACE eeeee2 ) inhibition and AT1 receptor blockade were evaluated
CRP11	Therefore, submaximal ACE inhibition enhanced  bbbbb1 sodium eeeee1  bbbbb2 ACE eeeee2  inhibition enhanced sodium excretion mainly by increasing RBF and GFR, whereas submaximal AT1 receptor blockade decreased tubular sodium and water reabsorption
CRP11	Therefore, submaximal ACE inhibition enhanced  bbbbb1 sodium eeeee1  excretion mainly by increasing RBF and GFR, whereas submaximal  bbbbb2 AT1 eeeee2  receptor blockade decreased tubular sodium and water reabsorption
CRP11	Therefore, submaximal ACE inhibition enhanced sodium excretion mainly by increasing RBF and GFR, whereas submaximal AT1 receptor blockade decreased tubular  bbbbb1 sodium eeeee1  bbbbb2 ACE eeeee2  inhibition enhanced sodium excretion mainly by increasing RBF and GFR, whereas submaximal AT1 receptor blockade decreased tubular sodium and water reabsorption
CRP11	Therefore, submaximal ACE inhibition enhanced sodium excretion mainly by increasing RBF and GFR, whereas submaximal AT1 receptor blockade decreased tubular  bbbbb1 sodium eeeee1  bbbbb2 AT1 eeeee2  receptor blockade decreased tubular sodium and water reabsorption
CRP11	Endothelial  bbbbb1 NO eeeee1  bbbbb2 Endothelial NO synthase eeeee2  expression was increased by cilazapril but not by losartan
CRP11	Neither inducible  bbbbb1 NO eeeee1  synthase nor  bbbbb2 neural NO synthase eeeee2  gene expression was affected by drug treatments
CRP11	Neither inducible  bbbbb1 NO eeeee1  bbbbb2 inducible NO synthase eeeee2  nor neural NO synthase gene expression was affected by drug treatments
CRP11	Neither inducible NO synthase nor neural  bbbbb1 NO eeeee1  bbbbb2 neural NO synthase eeeee2  gene expression was affected by drug treatments
CRP11	Neither inducible NO synthase nor neural  bbbbb1 NO eeeee1  bbbbb2 inducible NO synthase eeeee2  nor neural NO synthase gene expression was affected by drug treatments
CRP11	Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor  bbbbb1 reserpine eeeee1  and a proton ionophore, but not by tetrabenazine, which has a high affinity for  bbbbb2 VMAT-2 eeeee2 
CRP11	Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by  bbbbb1 tetrabenazine eeeee1  bbbbb2 VMAT eeeee2  inhibitor reserpine and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2
CRP11	Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes
CRP11	Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 alpha-adrenergic receptors eeeee2  and various serotonin (5-HT) receptor subtypes
CRP11	Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various  bbbbb1 serotonin eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes
CRP11	Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various  bbbbb1 serotonin eeeee1  bbbbb2 alpha-adrenergic receptors eeeee2  and various serotonin (5-HT) receptor subtypes
CRP11	Epinastine (100 microM) did not displace the dose-response curve bbbbb1  to  eeeee1 exogenously applied substance P (0.01-10 microM) bbbbb2  eeeee2 
CRP11	Epinastine (100 microM) did not displace the dose-response curve bbbbb1  to  eeeee1 exogenously applied sub bbbbb2 stanc eeeee2 e P (0.01-10 microM)
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or  bbbbb1 phentolamine eeeee1  bbbbb2 5-HT3 eeeee2  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or  bbbbb1 phentolamine eeeee1  bbbbb2 histamine H3 eeeee2  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or  bbbbb1 phentolamine eeeee1  bbbbb2 5-HT2 eeeee2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist,  bbbbb1 thioperamide eeeee1  bbbbb2 5-HT3 eeeee2  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist,  bbbbb1 thioperamide eeeee1  bbbbb2 5-HT2 eeeee2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with  bbbbb1 tropisetron eeeee1  (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a  bbbbb2 histamine H3 eeeee2  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with  bbbbb1 tropisetron eeeee1  (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a  bbbbb2 5-HT2 eeeee2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a  bbbbb1 histamine eeeee1  bbbbb2 5-HT3 eeeee2  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 eeeee2  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a  bbbbb1 histamine eeeee1  bbbbb2 5-HT2 eeeee2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist,  bbbbb1 ketanserin eeeee1  bbbbb2 5-HT3 eeeee2  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist,  bbbbb1 ketanserin eeeee1  (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a  bbbbb2 histamine H3 eeeee2  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect
CRP11	Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant  bbbbb1 5-HT eeeee1  bbbbb2 5-HT receptor eeeee2  binding affinity, did not produce any inhibition of the eNANC contraction
CRP11	Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant  bbbbb1 5-HT eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction
CRP11	Chlorpheniramine (10 microM), another  bbbbb1 histamine eeeee1  H1 receptor antagonist without significant  bbbbb2 5-HT receptor eeeee2  binding affinity, did not produce any inhibition of the eNANC contraction
CRP11	Chlorpheniramine (10 microM), another  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction
CRP11	Risperidone is metabolized to its active metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1 , mainly by the cytochrome P450 enzymes  bbbbb2 CYP2D6 and 3A4 eeeee2 
CRP11	 bbbbb1 Risperidone eeeee1  is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes  bbbbb2 CYP2D6 and 3A4 eeeee2 
CRP11	The CYP3A5 genotype did not influence risperidone,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 CYP3A5 eeeee2  genotype did not influence risperidone, 9-hydroxyrisperidone, or active moiety C/Ds
CRP11	The CYP3A5 genotype did not influence  bbbbb1 risperidone eeeee1  bbbbb2 CYP3A5 eeeee2  genotype did not influence risperidone, 9-hydroxyrisperidone, or active moiety C/Ds
CRP11	The CYP2D6 genotype in these 46 patients was again associated with risperidone C/D (P = 0.001) but not with  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 CYP2D6 eeeee2  genotype in these 46 patients was again associated with risperidone C/D (P = 0.001) but not with 9-hydroxyrisperidone C/D or active moiety C/D, as previously shown by our group in 37 of these patients
CRP11	The CYP2D6 genotype in these 46 patients was again associated with  bbbbb1 risperidone eeeee1  bbbbb2 CYP2D6 eeeee2  genotype in these 46 patients was again associated with risperidone C/D (P = 0.001) but not with 9-hydroxyrisperidone C/D or active moiety C/D, as previously shown by our group in 37 of these patients
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of risperidone,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 ABCB1 eeeee2 ) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of risperidone,  bbbbb1 9-hydroxyrisperidone eeeee1 , and the active moiety, taking  bbbbb2 CYP2D6 eeeee2  genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of risperidone,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-gp eeeee2  (ABCB1) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of risperidone,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 CYP3A5 eeeee2  and P-gp (ABCB1) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 ABCB1 eeeee2 ) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of  bbbbb1 risperidone eeeee1 , 9-hydroxyrisperidone, and the active moiety, taking  bbbbb2 CYP2D6 eeeee2  genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 P-gp eeeee2  (ABCB1) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	The aim of the present study was to evaluate the influence of polymorphisms in genes encoding CYP3A5 and P-gp (ABCB1) on the steady-state plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 CYP3A5 eeeee2  and P-gp (ABCB1) on the steady-state plasma levels of risperidone, 9-hydroxyrisperidone, and the active moiety, taking CYP2D6 genotype status into account
CRP11	Patients homozygous for the ABCB1 3435T/2677T/1236T haplotype had significantly lower C/Ds of 9-hydroxyrisperidone (P = 0.026) and active moiety (P = 0.028) than patients carrying other ABCB1 genotyp bbbbb1 es eeeee1  bbbbb2  (P = eeeee2  0.028) than patients carrying other ABCB1 genotypes
CRP11	Patients homozygous for the ABCB1 3435T/2677T/1236T haplotype had significantly lower C/Ds of 9-hydroxyrisperidone (P = 0.026) and active moiety (P = 0.028) than patients carrying other ABCB1 genotyp bbbbb1 es eeeee1  bbbbb2 ad sig eeeee2 nificantly lower C/Ds of 9-hydroxyrisperidone (P = 0.026) and active moiety (P = 0.028) than patients carrying other ABCB1 genotypes
CRP11	Patients homozygous for the ABCB1 3435T/2677T/1236T haplotype had significantly lower C/Ds of 9-hydroxyrisperidone ( bbbbb1 P = 0.026)  eeeee1 and active moiety bbbbb2  (P = eeeee2  0.028) than patients carrying other ABCB1 genotypes
CRP11	Patients homozygous for the ABCB1 3435T/2677T/1236T haplotype had significantly lower C/Ds of 9-hydroxyrisperidone ( bbbbb1 P = 0.026)  eeeee1  bbbbb2 ad sig eeeee2 nificantly lower C/Ds of 9-hydroxyrisperidone (P = 0.026) and active moiety (P = 0.028) than patients carrying other ABCB1 genotypes
CRP11	After loperamide (16 mg orally) or placebo administration, 5 patients received  bbbbb1 LVP eeeee1  bbbbb2 LVP eeeee2  (0.06 IU/kg i.v. over 1 h) and 6 patients received oCRH (1 micrograms/kg i.v. as bolus)
CRP11	After loperamide (16 mg orally) or placebo administration, 5 patients received  bbbbb1 LVP eeeee1  (0.06 IU/kg i.v. over 1 h) and 6 patients received  bbbbb2 oCRH eeeee2  (1 micrograms/kg i.v. as bolus)
CRP11	After  bbbbb1 loperamide eeeee1  (16 mg orally) or placebo administration, 5 patients received  bbbbb2 LVP eeeee2  (0.06 IU/kg i.v. over 1 h) and 6 patients received oCRH (1 micrograms/kg i.v. as bolus)
CRP11	After  bbbbb1 loperamide eeeee1  (16 mg orally) or placebo administration, 5 patients received LVP (0.06 IU/kg i.v. over 1 h) and 6 patients received  bbbbb2 oCRH eeeee2  (1 micrograms/kg i.v. as bolus)
CRP11	 bbbbb1 LVP eeeee1  increased  bbbbb2 ACTH eeeee2  levels after both loperamide (from 48 +/- 17.3 to a peak of 95 +/- 21 pmol/l) and placebo (from 231 +/- 59.5 to 365 +/- 86.6 pmol/l): the interaction between treatments and time was not significant
CRP11	 bbbbb1 LVP eeeee1  bbbbb2 LVP eeeee2  increased ACTH levels after both loperamide (from 48 +/- 17.3 to a peak of 95 +/- 21 pmol/l) and placebo (from 231 +/- 59.5 to 365 +/- 86.6 pmol/l): the interaction between treatments and time was not significant
CRP11	LVP increased ACTH levels after both  bbbbb1 loperamide eeeee1  bbbbb2 ACTH eeeee2  levels after both loperamide (from 48 +/- 17.3 to a peak of 95 +/- 21 pmol/l) and placebo (from 231 +/- 59.5 to 365 +/- 86.6 pmol/l): the interaction between treatments and time was not significant
CRP11	LVP increased ACTH levels after both  bbbbb1 loperamide eeeee1  bbbbb2 LVP eeeee2  increased ACTH levels after both loperamide (from 48 +/- 17.3 to a peak of 95 +/- 21 pmol/l) and placebo (from 231 +/- 59.5 to 365 +/- 86.6 pmol/l): the interaction between treatments and time was not significant
CRP11	Loperamide, an opiate analog, differently modifies the adrenocorticotropin responses to corticotropin-releasing hormone and  bbbbb1 lysine vasopressin eeeee1  bbbbb2 corticotropin-releasing hormone eeeee2  and lysine vasopressin in patients with Addison's disease
CRP11	Loperamide, an opiate analog, differently modifies the adrenocorticotropin responses to corticotropin-releasing hormone and  bbbbb1 lysine vasopressin eeeee1  bbbbb2 lysine vasopressin eeeee2  in patients with Addison's disease
CRP11	Loperamide, an opiate analog, differently modifies the adrenocorticotropin responses to corticotropin-releasing hormone and  bbbbb1 lysine vasopressin eeeee1  bbbbb2 adrenocorticotropin eeeee2  responses to corticotropin-releasing hormone and lysine vasopressin in patients with Addison's disease
CRP11	These data demonstrate that loperamide differently modifies the stimulatory action of LVP and CRH on ACTH secretion: namely, LVP and bbbbb1  loperamid eeeee1  bbbbb2  and eeeee2  CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way
CRP11	CRH caused a rise in plasma ACTH after both  bbbbb1 loperamide eeeee1  bbbbb2 ACTH eeeee2  after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide
CRP11	CRH caused a rise in plasma ACTH after both  bbbbb1 loperamide eeeee1  (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced  bbbbb2 ACTH eeeee2  secretion was significantly lower after loperamide
CRP11	CRH caused a rise in plasma ACTH after both  bbbbb1 loperamide eeeee1  (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of  bbbbb2 CRH eeeee2 -induced ACTH secretion was significantly lower after loperamide
CRP11	CRH caused a rise in plasma ACTH after both  bbbbb1 loperamide eeeee1  bbbbb2 CRH eeeee2  caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide
CRP11	CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after  bbbbb1 loperamide eeeee1  bbbbb2 ACTH eeeee2  after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide
CRP11	CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after  bbbbb1 loperamide eeeee1  bbbbb2 CRH eeeee2  caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide
CRP11	In this work, the interactions between  bbbbb1 loperamide eeeee1  and two ACTH secretagogues, lysine vasopressin ( bbbbb2 LVP eeeee2 ) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between  bbbbb1 loperamide eeeee1  and two  bbbbb2 ACTH eeeee2  secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between  bbbbb1 loperamide eeeee1  and two ACTH secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone ( bbbbb2 CRH eeeee2 ), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between  bbbbb1 loperamide eeeee1  and two ACTH secretagogues, lysine vasopressin (LVP) and  bbbbb2 corticotropin-releasing hormone eeeee2  (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between  bbbbb1 loperamide eeeee1  and two ACTH secretagogues,  bbbbb2 lysine vasopressin eeeee2  (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues, lysine vasopressin ( bbbbb1 LVP eeeee1  bbbbb2 LVP eeeee2 ) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues, lysine vasopressin ( bbbbb1 LVP eeeee1  bbbbb2 ACTH eeeee2  secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues, lysine vasopressin ( bbbbb1 LVP eeeee1 ) and corticotropin-releasing hormone ( bbbbb2 CRH eeeee2 ), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues, lysine vasopressin ( bbbbb1 LVP eeeee1 ) and  bbbbb2 corticotropin-releasing hormone eeeee2  (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues, lysine vasopressin ( bbbbb1 LVP eeeee1  bbbbb2 lysine vasopressin eeeee2  (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues,  bbbbb1 lysine vasopressin eeeee1  ( bbbbb2 LVP eeeee2 ) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues,  bbbbb1 lysine vasopressin eeeee1  bbbbb2 ACTH eeeee2  secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues,  bbbbb1 lysine vasopressin eeeee1  (LVP) and corticotropin-releasing hormone ( bbbbb2 CRH eeeee2 ), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues,  bbbbb1 lysine vasopressin eeeee1  (LVP) and  bbbbb2 corticotropin-releasing hormone eeeee2  (CRH), were investigated in patients with Addison's disease
CRP11	In this work, the interactions between loperamide and two ACTH secretagogues,  bbbbb1 lysine vasopressin eeeee1  bbbbb2 lysine vasopressin eeeee2  (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) and Csk-binding protein ( bbbbb2 Cbp eeeee2 )/phosphoprotein associated with glycosphingolipid microdomains (PAG)
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains ( bbbbb2 PAG eeeee2 )
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1  bbbbb2 Src homology 2 (SH2) domain eeeee2  of C-terminal Src kinase (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG)
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1 -terminal Src kinase ( bbbbb2 Csk eeeee2 ) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG)
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) and Csk-binding protein (Cbp)/ bbbbb2 phosphoprotein associated with glycosphingolipid microdomains eeeee2  (PAG)
CRP11	Identification of a new interaction mode between the Src homology 2 (SH2) domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) and  bbbbb2 Csk-binding protein eeeee2  (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG)
CRP11	Proteins with Src homology 2 (SH2) domains play major roles in  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  signaling
CRP11	Proteins with Src homology 2 (SH2) domains play major roles in  bbbbb1 tyrosine eeeee1  bbbbb2 Src homology 2 (SH2) domains eeeee2  play major roles in tyrosine kinase signaling
CRP11	Here we report the solution structure of the SH2 domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) in complex with a longer phosphopeptide from  bbbbb2 Csk-binding protein eeeee2  (Cbp)
CRP11	Here we report the solution structure of the SH2 domain of  bbbbb1 C eeeee1  bbbbb2 SH2 domain eeeee2  of C-terminal Src kinase (Csk) in complex with a longer phosphopeptide from Csk-binding protein (Cbp)
CRP11	Here we report the solution structure of the SH2 domain of  bbbbb1 C eeeee1 -terminal Src kinase (Csk) in complex with a longer phosphopeptide from Csk-binding protein ( bbbbb2 Cbp eeeee2 )
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 CAR eeeee2  ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 MAPK eeeee2  abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 MAPK eeeee2  by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 p38 eeeee2  MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 p38 eeeee2  MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of  bbbbb1 anisomycin eeeee1  bbbbb2 CYP2B6 eeeee2  mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by  bbbbb1 anisomycin eeeee1  potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38  bbbbb2 MAPK eeeee2  abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	Here, we have now found that activation of p38 MAPK by  bbbbb1 anisomycin eeeee1  potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce  bbbbb2 CYP2B6 eeeee2  mRNA
CRP11	Here, we have now found that activation of p38 MAPK by  bbbbb1 anisomycin eeeee1  potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes. siRNA knockdown of  bbbbb2 p38 eeeee2  MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain transferases. p38  bbbbb2 mitogen activated protein kinase eeeee2  (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as  bbbbb2 cytochrome P450 eeeee2  (CYP) and certain transferases. p38 mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 ( bbbbb2 CYP eeeee2 ) and certain transferases. p38 mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain transferases. p38 mitogen activated protein kinase ( bbbbb2 MAPK eeeee2 ) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  bbbbb2 constitutive active/androstane receptor eeeee2  (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain transferases. p38 mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain  bbbbb2 transferases eeeee2 . p38 mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor ( bbbbb2 CAR eeeee2 ) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain transferases. p38 mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	The constitutive active/ bbbbb1 androstane eeeee1  receptor (CAR) regulates hepatic drug metabolism by activating genes such as cytochrome P450 (CYP) and certain transferases.  bbbbb2 p38 eeeee2  mitogen activated protein kinase (MAPK) is highly activated in human primary hepatocytes but barely in human hepatoma cell-lines including HepG2 cells
CRP11	In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or  bbbbb1 UDP eeeee1  bbbbb2 CYP2B6 eeeee2 , anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs
CRP11	In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or  bbbbb1 UDP eeeee1  bbbbb2 UDP-glucuronosyltransferase 1A1 eeeee2  mRNAs
CRP11	In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or  bbbbb1 UDP eeeee1  bbbbb2 CYP3A4 eeeee2  or UDP-glucuronosyltransferase 1A1 mRNAs
CRP11	In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or  bbbbb1 UDP eeeee1  bbbbb2 CYP2A7 eeeee2  and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs
CRP11	In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or  bbbbb1 UDP eeeee1  bbbbb2 CYP2C9 eeeee2  mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs
CRP11	Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog P=7.41; Aurora A IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of  bbbbb1 quinazoline eeeee1  bbbbb2 Aurora A eeeee2  IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM)
CRP11	Based on these suggestions, the rational redesign of  bbbbb1 furanopyrimidine eeeee1  24 (clog P=7.41; Aurora A IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28;  bbbbb2 Aurora A eeeee2  IC(50) =25 nM; HCT-116 IC(50) =23 nM)
CRP11	Characterization of the omega class of  bbbbb1 glutathione eeeee1  bbbbb2 omega class of glutathione transferases eeeee2 
CRP11	Other diverse actions of human GSTO1-1 include modulation of  bbbbb1 ryanodine eeeee1  receptors and interaction with  bbbbb2 cytokine eeeee2  release inhibitory drugs
CRP11	Other diverse actions of human GSTO1-1 include modulation of  bbbbb1 ryanodine eeeee1  bbbbb2 ryanodine receptors eeeee2  and interaction with cytokine release inhibitory drugs
CRP11	Other diverse actions of human GSTO1-1 include modulation of  bbbbb1 ryanodine eeeee1  bbbbb2 human GSTO1-1 eeeee2  include modulation of ryanodine receptors and interaction with cytokine release inhibitory drugs
CRP11	Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of  bbbbb1 arsenic eeeee1  bbbbb2 thioltransferase eeeee2  activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation
CRP11	Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of  bbbbb1 arsenic eeeee1  bbbbb2 Omega class GSTs eeeee2  have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation
CRP11	Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of  bbbbb1 arsenic eeeee1  bbbbb2 dehydroascorbate reductase eeeee2  and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation
CRP11	Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of  bbbbb1 monomethylarsonate eeeee1  bbbbb2 thioltransferase eeeee2  activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation
CRP11	Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of  bbbbb1 monomethylarsonate eeeee1  bbbbb2 dehydroascorbate reductase eeeee2  and thioltransferase activities and also catalyze the reduction of monomethylarsonate, an intermediate in the pathway of arsenic biotransformation
CRP11	A cysteine residue in place of the catalytic tyrosine or  bbbbb1 serine eeeee1  residues found in other  bbbbb2 GSTs eeeee2  was shown to form a mixed disulfide with glutathione
CRP11	A cysteine residue in place of the catalytic  bbbbb1 tyrosine eeeee1  or serine residues found in other  bbbbb2 GSTs eeeee2  was shown to form a mixed disulfide with glutathione
CRP11	A  bbbbb1 cysteine eeeee1  residue in place of the catalytic tyrosine or serine residues found in other  bbbbb2 GSTs eeeee2  was shown to form a mixed disulfide with glutathione
CRP11	A cysteine residue in place of the catalytic tyrosine or serine residues found in other GSTs was shown to form a mixed disulfide with  bbbbb1 glutathione eeeee1  bbbbb2 GSTs eeeee2  was shown to form a mixed disulfide with glutathione
CRP11	A cysteine residue in place of the catalytic tyrosine or serine residues found in other GSTs was shown to form a mixed  bbbbb1 disulfide eeeee1  bbbbb2 GSTs eeeee2  was shown to form a mixed disulfide with glutathione
CRP11	The Omega class of cytosolic  bbbbb1 glutathione eeeee1  bbbbb2 Omega class of cytosolic glutathione transferases eeeee2  was initially recognized by bioinformatic analysis of human sequence databases, and orthologous sequences were subsequently discovered in mouse, rat, pig, Caenorhabditis elegans, Schistosoma mansoni, and Drosophila melanogaster
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin ( bbbbb1 HFC eeeee1  bbbbb2 UDP-glucuronosyltransferases eeeee2  (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin ( bbbbb1 HFC eeeee1 ) for several UGTs. 3.  We have used this method to screen 11 recombinant  bbbbb2 human UGTs eeeee2  for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin ( bbbbb1 HFC eeeee1  bbbbb2 UGTs eeeee2 ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of  bbbbb1 7-hydroxy-4-trifluoromethylcoumarin eeeee1  bbbbb2 UDP-glucuronosyltransferases eeeee2  (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of  bbbbb1 7-hydroxy-4-trifluoromethylcoumarin eeeee1  (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant  bbbbb2 human UGTs eeeee2  for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of  bbbbb1 7-hydroxy-4-trifluoromethylcoumarin eeeee1  bbbbb2 UGTs eeeee2 ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.   bbbbb1 UDP eeeee1 -glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several  bbbbb2 UGTs eeeee2 . 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.   bbbbb1 UDP eeeee1  bbbbb2 UDP-glucuronosyltransferases eeeee2  (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.   bbbbb1 UDP eeeee1 -glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant  bbbbb2 human UGTs eeeee2  for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.   bbbbb1 UDP eeeee1 -glucuronosyltransferases ( bbbbb2 UGTs eeeee2 ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for  bbbbb1 HFC eeeee1  bbbbb2 UGTs eeeee2 . 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for  bbbbb1 HFC eeeee1  bbbbb2 UDP-glucuronosyltransferases eeeee2  (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for  bbbbb1 HFC eeeee1  bbbbb2 UGTs eeeee2 ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb1  eeeee1  bbbbb2 UGTs eeeee2 . 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb1  eeeee1  bbbbb2 UGT1A6 eeeee2  exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP- bbbbb1 glucuronic acid eeeee1  than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb2  eeeee2 
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both  bbbbb1 HFC eeeee1  and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb2  eeeee2 
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed  bbbbb1 HFC eeeee1  glucuronidation at high rates bbbbb2  eeeee2 
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed  bbbbb1 HFC eeeee1  bbbbb2 UGTs eeeee2 . 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed  bbbbb1 HFC eeeee1  bbbbb2 UGT1A6 eeeee2  exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates
CRP11	UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and  bbbbb1 UDP eeeee1 -glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates bbbbb2  eeeee2 
CRP11	A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human  bbbbb1 UDP eeeee1  bbbbb2 human UDP-glucuronosyltransferases eeeee2  and liver microsomes
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 > bbbbb2 UGT1A7 eeeee2  >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM  bbbbb2 UGT1A6 eeeee2  was about 10 times better catalyst than the other recombinant UGTs
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant  bbbbb2 UGTs eeeee2 
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were  bbbbb2 UGT1A10 eeeee2  followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 > bbbbb2 UGT2A1 eeeee2 , whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs
CRP11	We have also examined the  bbbbb1 HFC eeeee1  glucuronidation activity of liver microsomes from human, pig, rabbit and rat. 4.  At a substrate concentration of 20 µM, the most active HFC glucuronidation catalysts were UGT1A10 followed by  bbbbb2 UGT1A6 eeeee2  >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs
CRP11	The activities of UGTs 1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and UGT2B17 exhibited no  bbbbb1 HFC eeeee1  bbbbb2 UGTs 1A3, 1A8, 1A9, 2B4 and 2B7 eeeee2  were low, whereas UGT1A1 and UGT2B17 exhibited no HFC glucuronidation activity
CRP11	Previously, 3  bbbbb1 carbohydrate eeeee1 /insulin response elements were identified in the 5'-flanking region of the  bbbbb2 L-PK eeeee2  gene up to bp -170
CRP11	Previously, 3  bbbbb1 carbohydrate eeeee1  bbbbb2 carbohydrate/insulin response elements eeeee2  were identified in the 5'-flanking region of the L-PK gene up to bp -170
CRP11	Expression of L-type  bbbbb1 pyruvate eeeee1  kinase ( bbbbb2 L-PK eeeee2 ) is upregulated in the liver by dietary carbohydrate
CRP11	Expression of L-type  bbbbb1 pyruvate eeeee1  bbbbb2 L-type pyruvate kinase eeeee2  (L-PK) is upregulated in the liver by dietary carbohydrate
CRP11	Identification of the regulatory region of the L-type  bbbbb1 pyruvate eeeee1  bbbbb2 L-type pyruvate kinase eeeee2  gene in mouse liver by hydrodynamics-based gene transfection
CRP11	Although FGF-2 strongly binds to basement membrane heparan sulfate in skin and most other tissue sites examined, FGF-7 fails to bind to basement membrane heparan  bbbbb1 sulfate eeeee1  bbbbb2 FGF-2 eeeee2  strongly binds to basement membrane heparan sulfate in skin and most other tissue sites examined, FGF-7 fails to bind to basement membrane heparan sulfate in most locations
CRP11	Although FGF-2 strongly binds to basement membrane heparan  bbbbb1 sulfate eeeee1  in skin and most other tissue sites examined,  bbbbb2 FGF-7 eeeee2  fails to bind to basement membrane heparan sulfate in most locations
CRP11	Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan  bbbbb1 sulfate eeeee1  bbbbb2 fibroblast growth factor-2 and -7 eeeee2  to basement membrane heparan sulfate: comparison of normal and abnormal human tissues
CRP11	FGFs signal through transmembrane receptor  bbbbb1 tyrosine eeeee1  kinases, but heparan sulfate is also required for signaling by members of the  bbbbb2 FGF eeeee2  family
CRP11	FGFs signal through transmembrane receptor  bbbbb1 tyrosine eeeee1  bbbbb2 FGFs eeeee2  signal through transmembrane receptor tyrosine kinases, but heparan sulfate is also required for signaling by members of the FGF family
CRP11	FGFs signal through transmembrane receptor  bbbbb1 tyrosine eeeee1  bbbbb2 transmembrane receptor tyrosine kinases eeeee2 , but heparan sulfate is also required for signaling by members of the FGF family
CRP11	FGFs signal through transmembrane receptor tyrosine kinases, but heparan  bbbbb1 sulfate eeeee1  bbbbb2 FGFs eeeee2  signal through transmembrane receptor tyrosine kinases, but heparan sulfate is also required for signaling by members of the FGF family
CRP11	FGFs signal through transmembrane receptor tyrosine kinases, but heparan  bbbbb1 sulfate eeeee1  bbbbb2 transmembrane receptor tyrosine kinases eeeee2 , but heparan sulfate is also required for signaling by members of the FGF family
CRP11	Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan  bbbbb1 sulfates eeeee1  bbbbb2 FGF-2 eeeee2  and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan sulfates in human tissues
CRP11	Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan  bbbbb1 sulfates eeeee1  bbbbb2 FGF-7 eeeee2  (KGF) as probes, we have identified specific interactions between FGFs and heparan sulfates in human tissues
CRP11	Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan  bbbbb1 sulfates eeeee1  bbbbb2 KGF eeeee2 ) as probes, we have identified specific interactions between FGFs and heparan sulfates in human tissues
CRP11	Using the structure of the bacterial transporter homologue  bbbbb1 leucine eeeee1  bbbbb2 leucine transporter eeeee2  as a template, we developed a structural model of SERT
CRP11	Using the structure of the bacterial transporter homologue  bbbbb1 leucine eeeee1  transporter as a template, we developed a structural model of  bbbbb2 SERT eeeee2 
CRP11	Identification of an Allosteric Modulator of  bbbbb1 Serotonin eeeee1  bbbbb2 Serotonin Transporter eeeee2  with Novel Mechanism of Action
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the  bbbbb1 Na eeeee1  bbbbb2 EP1 eeeee2  and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the  bbbbb1 Na eeeee1  bbbbb2 Na,K-ATPase eeeee2  by prostaglandins in MDCK cells
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the  bbbbb1 Na eeeee1  bbbbb2 EP2 receptors eeeee2  in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the Na, bbbbb1 K eeeee1  bbbbb2 EP1 eeeee2  and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the Na, bbbbb1 K eeeee1  bbbbb2 Na,K-ATPase eeeee2  by prostaglandins in MDCK cells
CRP11	Involvement of EP1 and EP2 receptors in the regulation of the Na, bbbbb1 K eeeee1  bbbbb2 EP2 receptors eeeee2  in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  bbbbb1 butaprost eeeee1  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and  bbbbb2 EP2 eeeee2  specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  bbbbb1 butaprost eeeee1  bbbbb2 EP1 eeeee2  and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  bbbbb1 butaprost eeeee1  bbbbb2 EP1 eeeee2  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  bbbbb1 butaprost eeeee1  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 ( bbbbb2 EP1 eeeee2  and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  bbbbb1 SC-51089 eeeee1  (EP1 specific) and AH 6809 (EP1 and  bbbbb2 EP2 eeeee2  specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  bbbbb1 SC-51089 eeeee1  bbbbb2 EP2 receptors eeeee2  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  bbbbb1 SC-51089 eeeee1  bbbbb2 EP2 eeeee2  selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist  bbbbb1 17-phenyl trinor PGE2 eeeee1 , and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and  bbbbb2 EP2 eeeee2  specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist  bbbbb1 17-phenyl trinor PGE2 eeeee1 , and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 ( bbbbb2 EP1 eeeee2  and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist  bbbbb1 17-phenyl trinor PGE2 eeeee1  bbbbb2 EP2 receptors eeeee2  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist  bbbbb1 17-phenyl trinor PGE2 eeeee1 , and the  bbbbb2 EP2 eeeee2  selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)
CRP11	K cells, which model distal tubule cells, the transcription of the Na, bbbbb1 K eeeee1  bbbbb2 Na,K-ATPase beta1 eeeee2  subunit is regulated by PGE1 and PGE2
CRP11	K cells, which model distal tubule cells, the transcription of the  bbbbb1 Na eeeee1  bbbbb2 Na,K-ATPase beta1 eeeee2  subunit is regulated by PGE1 and PGE2
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl tri bbbbb1 nor eeeee1  bbbbb2 ed stimulation of Na, eeeee2 K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl tri bbbbb1 nor eeeee1  bbbbb2 f EP2 recepto eeeee2 rs), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl tri bbbbb1 nor eeeee1  bbbbb2 cept eeeee2 ors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl tri bbbbb1 nor eeeee1  bbbbb2 vo eeeee2 lvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl tri bbbbb1 nor eeeee1  bbbbb2 e b eeeee2 eta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit bbbbb1  gene t eeeee1  bbbbb2 ed stimulation of Na, eeeee2 K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit bbbbb1  gene t eeeee1  bbbbb2 f EP2 recepto eeeee2 rs), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit bbbbb1  gene t eeeee1 ranscription includes the stimu bbbbb2 latory eff eeeee2 ect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit bbbbb1  gene t eeeee1  bbbbb2 cept eeeee2 ors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit bbbbb1  gene t eeeee1  bbbbb2 vo eeeee2 lvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phe bbbbb1 ny eeeee1  bbbbb2 ed stimulation of Na, eeeee2 K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phe bbbbb1 ny eeeee1  bbbbb2 f EP2 recepto eeeee2 rs), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phe bbbbb1 ny eeeee1  bbbbb2 cept eeeee2 ors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phe bbbbb1 ny eeeee1  bbbbb2 vo eeeee2 lvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phe bbbbb1 ny eeeee1  bbbbb2 e b eeeee2 eta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), e bbbbb1 vide eeeee1 nce for the involvement of EP1 receptors in the PGE1 mediat bbbbb2 ed stimulation of Na, eeeee2 K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), e bbbbb1 vide eeeee1 nce for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimu bbbbb2 latory eff eeeee2 ect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), e bbbbb1 vide eeeee1 nce for the involvement of EP1 re bbbbb2 cept eeeee2 ors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), e bbbbb1 vide eeeee1  bbbbb2 vo eeeee2 lvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), e bbbbb1 vide eeeee1 nce for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPas bbbbb2 e b eeeee2 eta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene tra bbbbb1 nscription i eeeee1  bbbbb2 ed stimulation of Na, eeeee2 K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene tra bbbbb1 nscription i eeeee1  bbbbb2 f EP2 recepto eeeee2 rs), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene tra bbbbb1 nscription i eeeee1 ncludes the stimu bbbbb2 latory eff eeeee2 ect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene tra bbbbb1 nscription i eeeee1  bbbbb2 cept eeeee2 ors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene tra bbbbb1 nscription i eeeee1  bbbbb2 vo eeeee2 lvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089
CRP11	Consistent with the involvement of Gs coupled EP2 receptors, is that the  bbbbb1 PGE1 eeeee1  stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the  bbbbb2 myristolated PKA inhibitory peptide eeeee2  PKI
CRP11	Consistent with the involvement of Gs coupled EP2 receptors, is that the  bbbbb1 PGE1 eeeee1  bbbbb2 EP2 receptors eeeee2 , is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI
CRP11	Consistent with the involvement of Gs coupled EP2 receptors, is that the  bbbbb1 PGE1 eeeee1  stimulation is inhibited by the PKAI expression vector (encoding the  bbbbb2 protein kinase A (PKA) inhibitory protein eeeee2 ), as well as by the myristolated PKA inhibitory peptide PKI
CRP11	Consistent with the involvement of Gs coupled EP2 receptors, is that the  bbbbb1 PGE1 eeeee1  stimulation is inhibited by the  bbbbb2 PKAI eeeee2  expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI
CRP11	Consistent with the involvement of Gs coupled EP2 receptors, is that the  bbbbb1 PGE1 eeeee1  bbbbb2 Gs eeeee2  coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI
CRP11	This study focuses on determining whether treatment of TCDD-exposed UGS bbbbb1  org eeeee1  bbbbb2 term eeeee2 ining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of TCDD on canonical Wnt signaling and prostatic bud formation
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of  bbbbb2 Dickkopfs eeeee2  (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of  bbbbb2 R-spondins eeeee2  (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of  bbbbb2 Lgr5 eeeee2 , a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical  bbbbb2 Wnt eeeee2  signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a  bbbbb2 RSPO receptor eeeee2  that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of  bbbbb2 Lef1 eeeee2 , Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1,  bbbbb2 Tcf1 eeeee2 , and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical  bbbbb2 Wnt eeeee2  signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical  bbbbb2 Wnt eeeee2  target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical  bbbbb2 Wnt eeeee2  signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical  bbbbb2 Wnt eeeee2  signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs ( bbbbb2 Dkks eeeee2 ), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins ( bbbbb2 Rspo2 eeeee2  and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and  bbbbb2 Wif1 eeeee2 , established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that  bbbbb1 TCDD eeeee1  decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and  bbbbb2 Rspo3 eeeee2 ) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 R-spondins eeeee2  (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Lgr5 eeeee2 , a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 RSPO receptor eeeee2  that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Lef1 eeeee2 , Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Tcf1 eeeee2 , and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Rspo2 eeeee2  and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Wif1 eeeee2 , established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  bbbbb1 TCDD eeeee1  bbbbb2 Rspo3 eeeee2 ) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of  bbbbb2 Dickkopfs eeeee2  (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of  bbbbb2 R-spondins eeeee2  (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of  bbbbb2 Lgr5 eeeee2 , a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical  bbbbb2 Wnt eeeee2  signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a  bbbbb2 RSPO receptor eeeee2  that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of  bbbbb2 Lef1 eeeee2 , Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1,  bbbbb2 Tcf1 eeeee2 , and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical  bbbbb2 Wnt eeeee2  signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical  bbbbb2 Wnt eeeee2  target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical  bbbbb2 Wnt eeeee2  signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical  bbbbb2 Wnt eeeee2  signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs ( bbbbb2 Dkks eeeee2 ), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins ( bbbbb2 Rspo2 eeeee2  and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and  bbbbb2 Wif1 eeeee2 , established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of  bbbbb1 TCDD eeeee1  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and  bbbbb2 Rspo3 eeeee2 ) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of  bbbbb2 Dickkopfs eeeee2  (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical  bbbbb2 Wnt eeeee2  signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical  bbbbb2 Wnt eeeee2  signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical  bbbbb2 Wnt eeeee2  target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  bbbbb2 Wnt eeeee2  signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical  bbbbb2 Wnt eeeee2  signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  bbbbb1 TCDD eeeee1  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs ( bbbbb2 Dkks eeeee2 ), inhibitors of canonical Wnt signaling, is not increased by TCDD
CRP11	The lack of the effect of  bbbbb1 NO eeeee1  concentration on the geminate rebinding in  bbbbb2 SA-HNS eeeee2  could be due to an isolated second site
CRP11	We confirm the existence of a second  bbbbb1 NO eeeee1  site in the oxygenase domain of the  bbbbb2 reduced eNOS eeeee2  as previously hypothesized [A
CRP11	We confirm the existence of a second  bbbbb1 NO eeeee1  site in the  bbbbb2 oxygenase domain eeeee2  of the reduced eNOS as previously hypothesized [A
CRP11	Our data are consistent with different barriers for NO recombination in SA-HNS and BA-HNS and the presence of a second  bbbbb1 NO eeeee1  bbbbb2 SA-HNS eeeee2  and BA-HNS and the presence of a second NO-binding site
CRP11	Our data are consistent with different barriers for NO recombination in SA-HNS and BA-HNS and the presence of a second  bbbbb1 NO eeeee1  bbbbb2 BA-HNS eeeee2  and the presence of a second NO-binding site
CRP11	Our data are consistent with different barriers for  bbbbb1 NO eeeee1  recombination in  bbbbb2 SA-HNS eeeee2  and BA-HNS and the presence of a second NO-binding site
CRP11	Our data are consistent with different barriers for  bbbbb1 NO eeeee1  recombination in SA-HNS and  bbbbb2 BA-HNS eeeee2  and the presence of a second NO-binding site
CRP11	Martin, Nitric oxide (NO) traffic in endothelial  bbbbb1 NO eeeee1  bbbbb2 endothelial NO synthase eeeee2 
CRP11	Martin,  bbbbb1 Nitric oxide eeeee1  (NO) traffic in  bbbbb2 endothelial NO synthase eeeee2 
CRP11	Martin, Nitric oxide ( bbbbb1 NO eeeee1 ) traffic in  bbbbb2 endothelial NO synthase eeeee2 
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of  bbbbb1 NO eeeee1  Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian NO synthases ( bbbbb2 NOS eeeee2 )
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of  bbbbb1 NO eeeee1  bbbbb2 HNS eeeee2 , Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian NO synthases (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of  bbbbb1 NO eeeee1  Synthase-like proteins) with striking sequence identity to the  bbbbb2 oxygenase domain eeeee2  of mammalian NO synthases (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of  bbbbb1 NO eeeee1  Synthase-like proteins) with striking sequence identity to the oxygenase domain of  bbbbb2 mammalian NO synthases eeeee2  (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of  bbbbb1 NO eeeee1  bbbbb2 Heme domain of NO Synthase-like proteins eeeee2 ) with striking sequence identity to the oxygenase domain of mammalian NO synthases (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian  bbbbb1 NO eeeee1  synthases ( bbbbb2 NOS eeeee2 )
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian  bbbbb1 NO eeeee1  bbbbb2 HNS eeeee2 , Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian NO synthases (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian  bbbbb1 NO eeeee1  bbbbb2 oxygenase domain eeeee2  of mammalian NO synthases (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian  bbbbb1 NO eeeee1  bbbbb2 mammalian NO synthases eeeee2  (NOS)
CRP11	Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (HNS, Heme domain of NO Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian  bbbbb1 NO eeeee1  bbbbb2 Heme domain of NO Synthase-like proteins eeeee2 ) with striking sequence identity to the oxygenase domain of mammalian NO synthases (NOS)
CRP11	However, they lack the N-terminal and the  bbbbb1 Zn-cysteine eeeee1  bbbbb2 N-terminal and the Zn-cysteine motif eeeee2  participating to the stability of an active dimer in the mammalian isoforms
CRP11	However, they lack the  bbbbb1 N eeeee1  bbbbb2 N-terminal and the Zn-cysteine motif eeeee2  participating to the stability of an active dimer in the mammalian isoforms
CRP11	Dynamics of NO rebinding to the heme domain of  bbbbb1 NO eeeee1  bbbbb2 heme domain of NO synthase-like proteins eeeee2  from bacterial pathogens
CRP11	The hypothesis that an additional NO-binding cavity is present in BA-HNS is also consistent with the effect of the  bbbbb1 NO eeeee1  bbbbb2 BA-HNS eeeee2  is also consistent with the effect of the NO concentration on its rebinding
CRP11	The hypothesis that an additional  bbbbb1 NO eeeee1 -binding cavity is present in  bbbbb2 BA-HNS eeeee2  is also consistent with the effect of the NO concentration on its rebinding
CRP11	Chem. 277 (2002) 7581-7586] bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Chem. 277 (2002) 7581-7586] bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Chem. 277 (2002) 7581-7586] bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Chem. 277 (2002) 7581-7586] bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	NO rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of  bbbbb1 arginine eeeee1  bbbbb2 BA-HNS eeeee2 ) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine
CRP11	NO rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of  bbbbb1 arginine eeeee1  bbbbb2 HNS eeeee2  from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine
CRP11	NO rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of  bbbbb1 arginine eeeee1  bbbbb2 SA-HNS eeeee2 ) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine
CRP11	NO rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of  bbbbb1 arginine eeeee1  bbbbb2 eNOS(HD) eeeee2  in both oxidized and reduced forms in the presence of arginine
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes  bbbbb1 NO eeeee1  bbbbb2 HNS eeeee2  make it an excellent model system for probing how the heme environment tunes NO dynamics and for comparing it to the endothelial NO synthase heme domain (eNOS(HD)) using ultrafast transient spectroscopy
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes  bbbbb1 NO eeeee1  dynamics and for comparing it to the endothelial NO synthase heme domain ( bbbbb2 eNOS(HD) eeeee2 ) using ultrafast transient spectroscopy
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes  bbbbb1 NO eeeee1  dynamics and for comparing it to the  bbbbb2 endothelial NO synthase heme domain eeeee2  (eNOS(HD)) using ultrafast transient spectroscopy
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes NO dynamics and for comparing it to the endothelial  bbbbb1 NO eeeee1  bbbbb2 HNS eeeee2  make it an excellent model system for probing how the heme environment tunes NO dynamics and for comparing it to the endothelial NO synthase heme domain (eNOS(HD)) using ultrafast transient spectroscopy
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes NO dynamics and for comparing it to the endothelial  bbbbb1 NO eeeee1  synthase heme domain ( bbbbb2 eNOS(HD) eeeee2 ) using ultrafast transient spectroscopy
CRP11	The unique properties of HNS make it an excellent model system for probing how the heme environment tunes NO dynamics and for comparing it to the endothelial  bbbbb1 NO eeeee1  bbbbb2 endothelial NO synthase heme domain eeeee2  (eNOS(HD)) using ultrafast transient spectroscopy
CRP11	Pretreatment with loratadine has been shown to reduce the recovery of both histamine and prostaglandin D2 (PGD2) in nasal lavage fluid following nasal allergen challenge, a finding interpreted as indicative bbbbb1  of in vi eeeee1  bbbbb2 ostaglandin eeeee2  D2 (PGD2) in nasal lavage fluid following nasal allergen challenge, a finding interpreted as indicative of in vivo mast cell stabilization, and cetirizine has been shown in vivo at therapeutic doses to inhibit allergen-induced eosinophil chemotaxis
CRP11	While there is considerable indirect evidence to implicate  bbbbb1 histamine eeeee1  in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic,  bbbbb2 alpha-adrenoceptor eeeee2  antagonistic and anti-serotonin activity
CRP11	The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of  bbbbb1 histamine eeeee1  bbbbb2 H1 eeeee2 -antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of histamine in this condition
CRP11	To develop new drugs for treatment of Alzheimer's disease, a group of  bbbbb1 N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones eeeee1  was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of  bbbbb2 amyloid beta peptides (1-40, 1-42 and 1-40_1-42) eeeee2 
CRP11	Nitrooxy derivatives showed  bbbbb1 NO eeeee1 -dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective  bbbbb2 COX-2 eeeee2  inhibitors in in vitro experimental models
CRP11	New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and  bbbbb1 NO eeeee1  bbbbb2 COX-2 eeeee2  selective inhibitors and NO donors were synthesized and are herein reported
CRP11	Compound 9c was able to inhibit glycosamin bbbbb1 oglyc eeeee1 an (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties bbbbb2  eeeee2 
CRP11	Compound 9c was able to inhibit  bbbbb1 glyc eeeee1 osaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties bbbbb2  eeeee2 
CRP11	Selective protection of a putative alpha 1A-adrenoceptor population against the irreversible action of phenoxybenzamine also failed to increase the potency of  bbbbb1 RS-17053 eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  population against the irreversible action of phenoxybenzamine also failed to increase the potency of RS-17053 (pA2 = 8.25 +/- 0.06 against A61603). 6
CRP11	To illuminate the controversy on alpha 1A- or alpha 1L-adrenoceptor involvement in  bbbbb1 noradrenaline eeeee1 -mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective  bbbbb2 alpha 1-adrenoceptor eeeee2  agonists and antagonists under different experimental conditions. 2
CRP11	The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist  bbbbb1 chloroethylclonidine eeeee1  bbbbb2 alpha 1L-adrenoceptor eeeee2  antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA
CRP11	The putative alpha 1L-adrenoceptor antagonist  bbbbb1 JTH-601 eeeee1 , but not the  bbbbb2 alpha 1B-adrenoceptor eeeee2  antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA
CRP11	The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1B-adrenoceptor eeeee2  antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA
CRP11	The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1L-adrenoceptor eeeee2  antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist  bbbbb1 RS-17053 eeeee1  against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist  bbbbb1 RS-17053 eeeee1  bbbbb2 alpha 1D-adrenoceptor eeeee2  antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist  bbbbb1 RS-17053 eeeee1  against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for  bbbbb2 alpha 1D eeeee2 - and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist  bbbbb1 RS-17053 eeeee1  against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  bbbbb2 alpha 1A-adrenoceptor eeeee2  involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist  bbbbb1 A-61603 eeeee1  bbbbb2 alpha 1D-adrenoceptor eeeee2  antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist  bbbbb1 A-61603 eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist  bbbbb1 A-61603 eeeee1  (pKB = 8.40 +/- 0.09) were too low to account for  bbbbb2 alpha 1D eeeee2 - and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist  bbbbb1 A-61603 eeeee1  (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  bbbbb2 alpha 1A-adrenoceptor eeeee2  involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist  bbbbb1 BMY 7378 eeeee1  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist  bbbbb1 BMY 7378 eeeee1  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist  bbbbb1 BMY 7378 eeeee1  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for  bbbbb2 alpha 1D eeeee2 - and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist  bbbbb1 BMY 7378 eeeee1  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  bbbbb2 alpha 1A-adrenoceptor eeeee2  involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against  bbbbb1 noradrenaline eeeee1  (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1D-adrenoceptor eeeee2  antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against  bbbbb1 noradrenaline eeeee1  (pA2 = 6.16 +/- 0.13) and of the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against  bbbbb1 noradrenaline eeeee1  (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for  bbbbb2 alpha 1D eeeee2 - and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against  bbbbb1 noradrenaline eeeee1  (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  bbbbb2 alpha 1A-adrenoceptor eeeee2  involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against  bbbbb1 noradrenaline eeeee1  (pKB = 8.35 +/- 0.10) and against the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1D-adrenoceptor eeeee2  antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against  bbbbb1 noradrenaline eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against  bbbbb1 noradrenaline eeeee1  (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for  bbbbb2 alpha 1D eeeee2 - and alpha 1A-adrenoceptor involvement. 4
CRP11	The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against  bbbbb1 noradrenaline eeeee1  (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  bbbbb2 alpha 1A-adrenoceptor eeeee2  involvement. 4
CRP11	ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) ( bbbbb1 K eeeee1  bbbbb2 ATP-sensitive K(+) (K(ATP)) channel eeeee2  inhibitor
CRP11	ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) (K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K(+) (K(ATP)) channel eeeee2  inhibitor
CRP11	ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive  bbbbb1 K(+) eeeee1  bbbbb2 ATP-sensitive K(+) (K(ATP)) channel eeeee2  inhibitor
CRP11	ATB-429-induced antinociception was reversed by glibenclamide, a  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K(+) (K(ATP)) channel eeeee2  inhibitor
CRP11	 bbbbb1 ATB-429 eeeee1 -induced antinociception was reversed by glibenclamide, a  bbbbb2 ATP-sensitive K(+) (K(ATP)) channel eeeee2  inhibitor
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  bbbbb2 thymidilate synthase eeeee2  (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  bbbbb2 TK eeeee2 ), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  bbbbb2 thymidine kinase eeeee2  (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  bbbbb2 TP eeeee2 ) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  bbbbb1 thymidilate eeeee1  synthase ( bbbbb2 TS eeeee2 ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  kinase (TK), thymidine phosphorylase (TP) and  bbbbb2 thymidilate synthase eeeee2  (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  kinase (TK),  bbbbb2 thymidine phosphorylase eeeee2  (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  kinase ( bbbbb2 TK eeeee2 ), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  bbbbb2 thymidine kinase eeeee2  (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  kinase (TK), thymidine phosphorylase ( bbbbb2 TP eeeee2 ) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of  bbbbb1 thymidine eeeee1  kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase ( bbbbb2 TS eeeee2 ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  phosphorylase (TP) and  bbbbb2 thymidilate synthase eeeee2  (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  bbbbb2 thymidine phosphorylase eeeee2  (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  bbbbb2 TK eeeee2 ), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  bbbbb2 thymidine kinase eeeee2  (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  phosphorylase ( bbbbb2 TP eeeee2 ) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK),  bbbbb1 thymidine eeeee1  phosphorylase (TP) and thymidilate synthase ( bbbbb2 TS eeeee2 ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of  bbbbb1 TAS-102 eeeee1  bbbbb2 TK eeeee2 ), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of  bbbbb1 TAS-102 eeeee1  bbbbb2 TP eeeee2 ) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102
CRP11	However, our study ind bbbbb1 ica eeeee1 ted that the therapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone bbbbb2 ,  eeeee2 suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study ind bbbbb1 ica eeeee1 ted that the therapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone, s bbbbb2 ug eeeee2 gesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study ind bbbbb1 ica eeeee1  bbbbb2 ud eeeee2 y indicated that the therapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone, suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study indicated that the therapeutic index was clearly increased by FTD com bbbbb1 bined w eeeee1 ith TPI, compared with FTD alone bbbbb2 ,  eeeee2 suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study indicated that the therapeutic index was clearly increased by FTD com bbbbb1 bined w eeeee1  bbbbb2  t eeeee2 herapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone, suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study indicated that the therapeutic index was clearly increased by FTD com bbbbb1 bined w eeeee1 ith TPI, compared with FTD alone, s bbbbb2 ug eeeee2 gesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	However, our study indicated that the therapeutic index was clearly increased by FTD com bbbbb1 bined w eeeee1  bbbbb2 ud eeeee2 y indicated that the therapeutic index was clearly increased by FTD combined with TPI, compared with FTD alone, suggesting FTD-induced toxicity to sensitive host tissue can be selectively reversed with dThd
CRP11	These results suggested that the activation and degradation pattern of FTD plays an important role in the efficacy of  bbbbb1 TAS-102 eeeee1  and that it is possible to use the TK/ bbbbb2 TP eeeee2  ratio to predict response to TAS-102 therapy
CRP11	These results suggested that the activation and degradation pattern of FTD plays an important role in the efficacy of  bbbbb1 TAS-102 eeeee1  and that it is possible to use the  bbbbb2 TK eeeee2 /TP ratio to predict response to TAS-102 therapy
CRP11	These results suggested that the activation and degradation pattern of FTD plays an important role in the efficacy of TAS-102 and that it is possible to use the TK/TP ratio to predict response to  bbbbb1 TAS-102 eeeee1  bbbbb2 TP eeeee2  ratio to predict response to TAS-102 therapy
CRP11	These results suggested that the activation and degradation pattern of FTD plays an important role in the efficacy of TAS-102 and that it is possible to use the TK/TP ratio to predict response to  bbbbb1 TAS-102 eeeee1  bbbbb2 TK eeeee2 /TP ratio to predict response to TAS-102 therapy
CRP11	These results suggested that the activation and degradation pattern of  bbbbb1 FTD eeeee1  plays an important role in the efficacy of TAS-102 and that it is possible to use the TK/ bbbbb2 TP eeeee2  ratio to predict response to TAS-102 therapy
CRP11	These results suggested that the activation and degradation pattern of  bbbbb1 FTD eeeee1  plays an important role in the efficacy of TAS-102 and that it is possible to use the  bbbbb2 TK eeeee2 /TP ratio to predict response to TAS-102 therapy
CRP11	Thymidine kinase and  bbbbb1 thymidine eeeee1  bbbbb2 thymidine phosphorylase eeeee2  level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	Thymidine kinase and  bbbbb1 thymidine eeeee1  bbbbb2 Thymidine kinase eeeee2  and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to  bbbbb1 TAS-102 eeeee1  bbbbb2 thymidine phosphorylase eeeee2  level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to  bbbbb1 TAS-102 eeeee1  bbbbb2 Thymidine kinase eeeee2  and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	 bbbbb1 Thymidine eeeee1  kinase and  bbbbb2 thymidine phosphorylase eeeee2  level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	 bbbbb1 Thymidine eeeee1  bbbbb2 Thymidine kinase eeeee2  and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model
CRP11	Antitumor activity of  bbbbb1 TAS-102 eeeee1  appears to be associated with  bbbbb2 TK eeeee2 , tumor growth and TS
CRP11	Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I( bbbbb1 Na eeeee1  bbbbb2 DeltaKPQ eeeee2  I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)
CRP11	Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( bbbbb1 Na eeeee1  bbbbb2 DeltaKPQ eeeee2  I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)
CRP11	Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3)  bbbbb1 sodium eeeee1  channel alpha subunit mutation with three amino acids deleted ( bbbbb2 DeltaKPQ eeeee2 ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings
CRP11	Flecainide block of  bbbbb1 Na(+) eeeee1  current (I(Na)) was investigated in wild-type (WT) or the  bbbbb2 long QT syndrome 3 (LQT3) sodium channel alpha eeeee2  subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings
CRP11	Flecainide block of  bbbbb1 Na(+) eeeee1  current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ( bbbbb2 DeltaKPQ eeeee2 ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings
CRP11	Flecainide block of Na(+) current (I( bbbbb1 Na eeeee1 )) was investigated in wild-type (WT) or the  bbbbb2 long QT syndrome 3 (LQT3) sodium channel alpha eeeee2  subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings
CRP11	Flecainide block of Na(+) current (I( bbbbb1 Na eeeee1 )) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ( bbbbb2 DeltaKPQ eeeee2 ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings
CRP11	The IC(50) value of peak and late I( bbbbb1 Na eeeee1 ) for WT was 127 +/- 6 and 44 +/- 2 microM (n = 20) and for  bbbbb2 DeltaKPQ eeeee2  was 80 +/- 9 and 19 +/- 2 microM (n = 31) respectively
CRP11	For DeltaKPQ, UDB of late I(Na) was greater than for peak I( bbbbb1 Na eeeee1  bbbbb2 DeltaKPQ eeeee2 , UDB of late I(Na) was greater than for peak I(Na)
CRP11	For DeltaKPQ, UDB of late I( bbbbb1 Na eeeee1  bbbbb2 DeltaKPQ eeeee2 , UDB of late I(Na) was greater than for peak I(Na)
CRP11	UDB of peak I( bbbbb1 Na eeeee1 ) was greater and developed more slowly during pulse trains for  bbbbb2 DeltaKPQ eeeee2  than for WT
CRP11	Regucalcin has been shown to play a multifunctional role in cell regulation; maintaining of intracellular  bbbbb1 calcium eeeee1  bbbbb2 Regucalcin eeeee2  has been shown to play a multifunctional role in cell regulation; maintaining of intracellular calcium homeostasis and suppressing of signal transduction, translational protein synthesis, nuclear deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis, proliferation, and apoptosis in many cell types
CRP11	The expression of regucalcin is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by  bbbbb1 streptozotocin eeeee1  bbbbb2 insulin eeeee2  in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by streptozotocin administration in vivo
CRP11	Deficiency of regucalcin induces an impairment of  bbbbb1 glucose eeeee1  bbbbb2 regucalcin eeeee2  induces an impairment of glucose tolerance and lipid accumulation in the liver of mice in vivo
CRP11	Overexpression of endogenous regucalcin stimulates glucose utilization and lipid production in liver cells with  bbbbb1 glucose eeeee1  bbbbb2 regucalcin eeeee2  stimulates glucose utilization and lipid production in liver cells with glucose supplementation in vitro
CRP11	Overexpression of endogenous regucalcin stimulates  bbbbb1 glucose eeeee1  bbbbb2 regucalcin eeeee2  stimulates glucose utilization and lipid production in liver cells with glucose supplementation in vitro
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of  bbbbb1 calcium eeeee1  bbbbb2 RGN eeeee2 /SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of calcium-binding domain
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of  bbbbb1 calcium eeeee1  bbbbb2 Regucalcin eeeee2  (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of calcium-binding domain
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of  bbbbb1 calcium eeeee1  bbbbb2 EF-hand motif eeeee2  of calcium-binding domain
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of  bbbbb1 calcium eeeee1  bbbbb2 calcium-binding domain eeeee2 
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of  bbbbb1 calcium eeeee1  bbbbb2 SMP30 eeeee2 ) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of calcium-binding domain
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique  bbbbb1 calcium eeeee1 -binding protein that does not contain the  bbbbb2 EF-hand motif eeeee2  of calcium-binding domain
CRP11	Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique  bbbbb1 calcium eeeee1 -binding protein that does not contain the EF-hand motif of  bbbbb2 calcium-binding domain eeeee2 
CRP11	Overexpression of endogenous regucalcin has been shown to decrease  bbbbb1 triglyceride eeeee1  bbbbb2 regucalcin eeeee2  has been shown to decrease triglyceride, total cholesterol and glycogen contents in the liver of rats, inducing hyperlipidemia
CRP11	Overexpression of endogenous regucalcin has been shown to decrease triglyceride, total  bbbbb1 cholesterol eeeee1  bbbbb2 regucalcin eeeee2  has been shown to decrease triglyceride, total cholesterol and glycogen contents in the liver of rats, inducing hyperlipidemia
CRP11	Neuroprotective role of ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium channels eeeee2  in cerebral ischemia
CRP11	Neuroprotective role of  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium channels eeeee2  in cerebral ischemia
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the  bbbbb1 K eeeee1  bbbbb2 K(ATP) channels eeeee2  increases ischemic infarction, and overexpression of the Kir6.2 subunit reduces neuronal injury from ischemic insults
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the  bbbbb1 K eeeee1 (ATP) channels increases ischemic infarction, and overexpression of the  bbbbb2 Kir6.2 eeeee2  subunit reduces neuronal injury from ischemic insults
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the  bbbbb1 K eeeee1  bbbbb2 Kir6.2 eeeee2  subunit of the K(ATP) channels increases ischemic infarction, and overexpression of the Kir6.2 subunit reduces neuronal injury from ischemic insults
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) channels eeeee2  increases ischemic infarction, and overexpression of the Kir6.2 subunit reduces neuronal injury from ischemic insults
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the K( bbbbb1 ATP eeeee1 ) channels increases ischemic infarction, and overexpression of the  bbbbb2 Kir6.2 eeeee2  subunit reduces neuronal injury from ischemic insults
CRP11	In vivo animal studies confirmed that knocking out the Kir6.2 subunit of the K( bbbbb1 ATP eeeee1  bbbbb2 Kir6.2 eeeee2  subunit of the K(ATP) channels increases ischemic infarction, and overexpression of the Kir6.2 subunit reduces neuronal injury from ischemic insults
CRP11	ATP-sensitive potassium (K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium (K(ATP)) channels eeeee2  are weak, inward rectifiers that couple metabolic status to cell membrane electrical activity, thus modulating many cellular functions
CRP11	ATP-sensitive potassium ( bbbbb1 K eeeee1  bbbbb2 ATP-sensitive potassium (K(ATP)) channels eeeee2  are weak, inward rectifiers that couple metabolic status to cell membrane electrical activity, thus modulating many cellular functions
CRP11	 bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium (K(ATP)) channels eeeee2  are weak, inward rectifiers that couple metabolic status to cell membrane electrical activity, thus modulating many cellular functions
CRP11	ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium (K(ATP)) channels eeeee2  are weak, inward rectifiers that couple metabolic status to cell membrane electrical activity, thus modulating many cellular functions
CRP11	The specific enzymatic activity of four different aminopeptidases (aminopeptidase N,  bbbbb1 leucine eeeee1  aminopeptidase,  bbbbb2 aminopeptidase A eeeee2  and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared
CRP11	The specific enzymatic activity of four different aminopeptidases (aminopeptidase N,  bbbbb1 leucine eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , aminopeptidase A and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared
CRP11	The specific enzymatic activity of four different aminopeptidases (aminopeptidase N,  bbbbb1 leucine eeeee1  aminopeptidase, aminopeptidase A and  bbbbb2 aminopeptidase B eeeee2 ) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared
CRP11	The specific enzymatic activity of four different aminopeptidases (aminopeptidase N,  bbbbb1 leucine eeeee1  bbbbb2 aminopeptidase N eeeee2 , leucine aminopeptidase, aminopeptidase A and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared
CRP11	The specific enzymatic activity of four different aminopeptidases (aminopeptidase N,  bbbbb1 leucine eeeee1  bbbbb2 aminopeptidases eeeee2  (aminopeptidase N, leucine aminopeptidase, aminopeptidase A and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared
CRP11	Based on the results of the hydrolysis and inhibition of the  bbbbb1 4-methoxy-2-naphthylamide eeeee1  substrates, it was difficult to have an exact decision on the  bbbbb2 aminopeptidase eeeee2  type in the vaginal homogenates from the species studied
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  bbbbb1 L-leucine eeeee1  for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  bbbbb1 L-leucine eeeee1  for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  bbbbb1 L-leucine eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  bbbbb1 L-leucine eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  bbbbb1 L-alanine eeeee1  for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  bbbbb1 L-alanine eeeee1  for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  bbbbb1 L-alanine eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  bbbbb1 L-alanine eeeee1  for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  bbbbb1 L-glutamic acid eeeee1  for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  bbbbb1 L-glutamic acid eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  bbbbb1 L-glutamic acid eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  bbbbb1 L-glutamic acid eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  bbbbb1 L-arginine eeeee1  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  bbbbb1 L-arginine eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  bbbbb1 L-arginine eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  bbbbb1 L-arginine eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb1 leucine eeeee1  aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb1 leucine eeeee1  aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb1 leucine eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb1 leucine eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb1 leucine eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N,  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase N eeeee2 , 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for  bbbbb2 aminopeptidase A eeeee2  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for  bbbbb2 aminopeptidase B eeeee2 
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  bbbbb1 4-methoxy-2-naphthylamide eeeee1  bbbbb2 aminopeptidase eeeee2  enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  bbbbb1 4-methoxy-2-naphthylamide eeeee1  of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for  bbbbb2 leucine aminopeptidase eeeee2 , 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B
CRP11	Effective treatment requires drugs that can simultaneously protect by reversible binding to the acetylcholinesterase (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ( bbbbb1 [-]-Hup A eeeee1  bbbbb2 AChE eeeee2 ) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier
CRP11	Effective treatment requires drugs that can simultaneously protect by reversible binding to the acetylcholinesterase (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ( bbbbb1 [-]-Hup A eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier
CRP11	Effective treatment requires drugs that can simultaneously protect by reversible binding to the acetylcholinesterase (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration.  bbbbb1 [-]-Huperzine A eeeee1  bbbbb2 AChE eeeee2 ) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier
CRP11	Effective treatment requires drugs that can simultaneously protect by reversible binding to the acetylcholinesterase (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration.  bbbbb1 [-]-Huperzine A eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) and blocking cascades of seizure related brain damage, inflammation, neuronal degeneration as well as promoting induction of neuroregeneration. [-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier
CRP11	The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate (NMDA)-induced seizure in rats, reduce excitatory  bbbbb1 amino acid eeeee1  bbbbb2 AChE eeeee2  inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate (NMDA)-induced seizure in rats, reduce excitatory amino acid induced neurotoxicity and also prevent soman induced toxicity with minimum performance decrement
CRP11	The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 AChE eeeee2  inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate (NMDA)-induced seizure in rats, reduce excitatory amino acid induced neurotoxicity and also prevent soman induced toxicity with minimum performance decrement
CRP11	The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 AChE eeeee2  inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate (NMDA)-induced seizure in rats, reduce excitatory amino acid induced neurotoxicity and also prevent soman induced toxicity with minimum performance decrement
CRP11	The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.  bbbbb1 [+]-Hup A eeeee1  bbbbb2 AChE eeeee2  inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity. [+]-Hup A block the N-methyl-d-aspartate (NMDA)-induced seizure in rats, reduce excitatory amino acid induced neurotoxicity and also prevent soman induced toxicity with minimum performance decrement
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and  bbbbb1 dichlorvos eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6,  bbbbb1 2-PAM eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes ( bbbbb1 obidoxime eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime,  bbbbb1 HI-6 eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication ( bbbbb1 tabun eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used  bbbbb1 oximes eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun,  bbbbb1 paraoxon eeeee1  bbbbb2 ChE eeeee2  reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM)
CRP11	The inhibitors of PI3K and Akt suppressed  bbbbb1 S1P eeeee1  bbbbb2 Akt eeeee2  suppressed S1P-induced nuclear localization of β-catenin
CRP11	The inhibitors of PI3K and Akt suppressed  bbbbb1 S1P eeeee1  bbbbb2 PI3K eeeee2  and Akt suppressed S1P-induced nuclear localization of β-catenin
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of  bbbbb2 β-catenin eeeee2 , followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/ bbbbb2 Akt eeeee2  signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/Akt signaling, leading to the inhibition of  bbbbb2 glycogen synthase kinase-3β eeeee2  and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase ( bbbbb2 PI3K eeeee2 )/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by  bbbbb2 β-catenin eeeee2 /T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	S1P activated  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/ bbbbb2 T-cell factor eeeee2  complex formation in both SaOS-2 cells and MC3T3-E1 cells
CRP11	Pretreatment of rats wit bbbbb1 h the MAO inhib eeeee1 itor tranylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did n bbbbb2 ot  eeeee2 block the effect of VIG on GABA
CRP11	Pretreatment of rats with the MAO inhibitor  bbbbb1 tra eeeee1 nylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did n bbbbb2 ot  eeeee2 block the effect of VIG on GABA
CRP11	Pretreatment of rats with the MAO inhibitor tranylcypromine prevented the increase in brain GABA and bbbbb1  AL eeeee1 A levels with PLZ, but did n bbbbb2 ot  eeeee2 block the effect of VIG on GABA
CRP11	Pretreatment of rats with the MAO inhibitor tranylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA bbbbb1  eeeee1  bbbbb2 ot  eeeee2 block the effect of VIG on GABA
CRP11	Pretreatment of rats with the MAO inhibitor tranylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA bbbbb1  eeeee1  bbbbb2 ot  eeeee2 block the effect of VIG on GABA
CRP11	Only PLZ inhibited MAO and  bbbbb1 ALA eeeee1  bbbbb2 MAO eeeee2  and ALA-T and elevated ALA levels
CRP11	Only PLZ inhibited MAO and  bbbbb1 ALA eeeee1  bbbbb2 ALA-T eeeee2  and elevated ALA levels
CRP11	Only PLZ inhibited MAO and ALA-T and elevated  bbbbb1 ALA eeeee1  bbbbb2 MAO eeeee2  and ALA-T and elevated ALA levels
CRP11	Only PLZ inhibited MAO and ALA-T and elevated  bbbbb1 ALA eeeee1  bbbbb2 ALA-T eeeee2  and elevated ALA levels
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain  bbbbb1 GABA eeeee1  levels, but, unlike VIG, also inhibited  bbbbb2 MAO eeeee2  and ALA-T (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain  bbbbb1 GABA eeeee1  levels, but, unlike VIG, also inhibited MAO and  bbbbb2 ALA-T eeeee2  (and increased brain ALA levels)
CRP11	NS: At the doses studied,  bbbbb1 PLZ eeeee1  was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited  bbbbb2 MAO eeeee2  and ALA-T (and increased brain ALA levels)
CRP11	NS: At the doses studied,  bbbbb1 PLZ eeeee1  was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and  bbbbb2 ALA-T eeeee2  (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and ALA-T (and increased brain  bbbbb1 ALA eeeee1  bbbbb2 MAO eeeee2  and ALA-T (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and ALA-T (and increased brain  bbbbb1 ALA eeeee1  bbbbb2 ALA-T eeeee2  (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as  bbbbb1 VIG eeeee1  at elevating brain GABA levels, but, unlike VIG, also inhibited  bbbbb2 MAO eeeee2  and ALA-T (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as  bbbbb1 VIG eeeee1  at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and  bbbbb2 ALA-T eeeee2  (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and  bbbbb1 ALA eeeee1  bbbbb2 MAO eeeee2  and ALA-T (and increased brain ALA levels)
CRP11	NS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and  bbbbb1 ALA eeeee1  bbbbb2 ALA-T eeeee2  (and increased brain ALA levels)
CRP11	Both PLZ and VIG inhibited  bbbbb1 GABA eeeee1  bbbbb2 GABA-T eeeee2  and elevated GABA levels
CRP11	Both PLZ and VIG inhibited GABA-T and elevated  bbbbb1 GABA eeeee1  bbbbb2 GABA-T eeeee2  and elevated GABA levels
CRP11	The effects of PLZ on both  bbbbb1 amino acids eeeee1  and their  bbbbb2 transaminases eeeee2  were blocked by pre-treatment with the MAO inhibitor tranylcypromine
CRP11	The effects of PLZ on both  bbbbb1 amino acids eeeee1  and their transaminases were blocked by pre-treatment with the  bbbbb2 MAO eeeee2  inhibitor tranylcypromine
CRP11	The effects of  bbbbb1 PLZ eeeee1  on both amino acids and their transaminases were blocked by pre-treatment with the  bbbbb2 MAO eeeee2  inhibitor tranylcypromine
CRP11	On the basis of data obtained in rabbits, the  bbbbb1 imidazoline eeeee1  bbbbb2 imidazoline receptor eeeee2  ligand rilmenidine has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors
CRP11	On the basis of data obtained in rabbits, the  bbbbb1 imidazoline eeeee1  receptor ligand rilmenidine has been suggested to decrease blood pressure in humans by activating central  bbbbb2 alpha(2A)-adrenoceptors eeeee2 
CRP11	The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively) bbbbb1  eeeee1  bbbbb2 agonism and agonism, re eeeee2 spectively)
CRP11	The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively) bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively) bbbbb1  eeeee1  bbbbb2 ial appendages and rabbit pul eeeee2 monary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)
CRP11	Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by  bbbbb1 moxonidine eeeee1  bbbbb2 alpha(2)-adrenoceptor eeeee2  agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by moxonidine
CRP11	Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked  bbbbb1 [(3)H]norepinephrine eeeee1  bbbbb2 alpha(2)-adrenoceptor eeeee2  agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by moxonidine
CRP11	Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked  bbbbb1 [(3)H]norepinephrine eeeee1  release and of antagonists in counteracting the  bbbbb2 alpha(2)-adrenoceptor eeeee2 -mediated inhibition induced by moxonidine
CRP11	In addition, a partial nucleotide and  bbbbb1 amino acid eeeee1  sequence of the rabbit alpha(2A)-adrenoceptor (a region known to substantially influence the pharmacological characteristics of the  bbbbb2 alpha(2)-adrenoceptor eeeee2 ) revealed marked differences between the rabbit and the human alpha(2A)-adrenoceptor
CRP11	In addition, a partial nucleotide and  bbbbb1 amino acid eeeee1  sequence of the rabbit alpha(2A)-adrenoceptor (a region known to substantially influence the pharmacological characteristics of the alpha(2)-adrenoceptor) revealed marked differences between the rabbit and the human  bbbbb2 alpha(2A)-adrenoceptor eeeee2 
CRP11	Absence of correlation between oxysterol accumulation in lipid raft microdomains,  bbbbb1 calcium eeeee1  bbbbb2 lipid raft microdomains eeeee2 , calcium increase, and apoptosis induction on 158N murine oligodendrocytes
CRP11	Absence of correlation between  bbbbb1 oxysterol eeeee1  accumulation in  bbbbb2 lipid raft microdomains eeeee2 , calcium increase, and apoptosis induction on 158N murine oligodendrocytes
CRP11	It is noteworthy that α-tocopherol (but not ellagic acid and resveratrol) was able to counteract 7KC- and 7βOHC-induced apoptosis and to decrease the accumulation of 7KC a bbbbb1 nd 27O eeeee1  bbbbb2 and 7 eeeee2 βOHC-induced apoptosis and to decrease the accumulation of 7KC and 27OHC in lipid rafts
CRP11	It is noteworthy that α-tocopherol (but not ellagic acid and resveratrol) was able to counteract 7KC- and 7βOHC-induced apoptosis and to decrease the accumulation of 7KC a bbbbb1 nd 27O eeeee1  bbbbb2 induced a eeeee2 poptosis and to decrease the accumulation of 7KC and 27OHC in lipid rafts
CRP11	Potentiation of  bbbbb1 sulfonylurea eeeee1  action by an  bbbbb2 EPAC eeeee2 -selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of  bbbbb1 sulfonylurea eeeee1  action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for  bbbbb2 EPAC eeeee2  activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of  bbbbb1 tolbutamide eeeee1  bbbbb2 EPAC eeeee2 -selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of  bbbbb1 tolbutamide eeeee1  and gliclazide and a potential role for  bbbbb2 EPAC eeeee2  activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and  bbbbb1 gliclazide eeeee1  bbbbb2 EPAC eeeee2 -selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and  bbbbb1 gliclazide eeeee1  and a potential role for  bbbbb2 EPAC eeeee2  activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective  bbbbb1 cAMP eeeee1  bbbbb2 EPAC eeeee2 -selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx
CRP11	Potentiation of sulfonylurea action by an EPAC-selective  bbbbb1 cAMP eeeee1  analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for  bbbbb2 EPAC eeeee2  activation of a 2-APB-sensitive Ca2+ influx
CRP11	Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type  bbbbb1 Ca(2+) eeeee1  bbbbb2 Insulin eeeee2  secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type  bbbbb1 Ca(2+) eeeee1  bbbbb2 L-type Ca(2+) channel eeeee2  blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Insulin secretion stimulated by both 200 μM  bbbbb1 tolbutamide eeeee1  and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the  bbbbb2 L-type Ca(2+) channel eeeee2  blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by  bbbbb1 8-pCPT-2'-O-Me-cAMP-AM eeeee1  bbbbb2 L-type Ca(2+) channel eeeee2  blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM  bbbbb1 gliclazide eeeee1 , concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the  bbbbb2 L-type Ca(2+) channel eeeee2  blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by  bbbbb1 thapsigargin eeeee1  (1 μM) or the  bbbbb2 L-type Ca(2+) channel eeeee2  blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so  bbbbb1 independently of its a eeeee1 ctivity at K(ATP) channels, and this activity was partially inhibited by  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so  bbbbb1 independently of its a eeeee1 ctivity at K(ATP) channels, and  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated pho bbbbb1 spholipase  eeeee1 C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated pho bbbbb1 spholipase  eeeee1 C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration signif bbbbb1 icantl eeeee1  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration signif bbbbb1 icantl eeeee1  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C act bbbbb1 ivity; how eeeee1 ever, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C act bbbbb1 ivity; how eeeee1 ever, only gliclazide did so independently of its activity at K(ATP) channels, and  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone  bbbbb1 (5 μM) did not stimula eeeee1  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone  bbbbb1 (5 μM) did not stimula eeeee1  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) conc bbbbb1 entra eeeee1  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) conc bbbbb1 entra eeeee1  bbbbb2 this activity w eeeee2 as partially inhibited by pertussis toxin. 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity bbbbb1  at K(ATP) eeeee1  channels, and this activity was partially inhibited by  bbbbb2 pertussis toxin eeeee2 . 8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate insulin secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+). 8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM)
CRP11	To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  bbbbb1 fisetin eeeee1  bbbbb2 mTORC1 eeeee2  signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells
CRP11	To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  bbbbb1 fisetin eeeee1  bbbbb2 mTOR eeeee2  and Akt in fisetin-treated TSC2-knockdown cells
CRP11	To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  bbbbb1 fisetin eeeee1 -treated  bbbbb2 TSC2 eeeee2 -knockdown cells
CRP11	To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  bbbbb1 fisetin eeeee1  bbbbb2 Akt eeeee2  in fisetin-treated TSC2-knockdown cells
CRP11	To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  bbbbb1 fisetin eeeee1  bbbbb2 S6K1 eeeee2 , mTOR and Akt in fisetin-treated TSC2-knockdown cells
CRP11	To further our understanding of how  bbbbb1 fisetin eeeee1  negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated  bbbbb2 TSC2 eeeee2 -knockdown cells
CRP11	In this study, we have demonstrated that fisetin prevents diet-induced obesity through regulation of the signaling of mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 ( bbbbb2 mTORC1 eeeee2 ), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis
CRP11	In this study, we have demonstrated that fisetin prevents diet-induced obesity through regulation of the signaling of mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis
CRP11	 bbbbb1 Fisetin eeeee1  treatment inhibited adipocyte differentiation, consistent with the negative effect of fisetin on  bbbbb2 mTOR eeeee2 
CRP11	The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that  bbbbb1 fisetin eeeee1  bbbbb2 mTOR eeeee2  activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting mTORC1 signaling
CRP11	The inhibitory effect of  bbbbb1 fisetin eeeee1  on adipogenesis is dependent of mTOR activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting  bbbbb2 mTORC1 eeeee2  signaling
CRP11	The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular  bbbbb1 triglycerides eeeee1  during adipocyte differentiation by targeting  bbbbb2 mTORC1 eeeee2  signaling
CRP11	The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular  bbbbb1 triglycerides eeeee1  bbbbb2 mTOR eeeee2  activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting mTORC1 signaling
CRP11	These data suggest that HIF-induced low intracellular  bbbbb1 citrate eeeee1  bbbbb2 HIF eeeee2 -induced low intracellular citrate levels promote the reductive flux by mass action to maintain lipogenesis
CRP11	Using [(1-13)C]glutamine, we demonstrated in vivo RC a bbbbb1 ctivity i eeeee1  bbbbb2 1-1 eeeee2 3)C]glutamine, we demonstrated in vivo RC activity in VHL-deficient tumors growing as xenografts in mice
CRP11	Using [(1-13)C]glutamine, we demonstrated in vivo RC a bbbbb1 ctivity i eeeee1 n VHL-deficient tumors growing as xenografts in mice bbbbb2  eeeee2 
CRP11	Using [(1-13)C]glutamine, we demonstrated in vivo RC a bbbbb1 ctivity i eeeee1  bbbbb2 ine eeeee2 , we demonstrated in vivo RC activity in VHL-deficient tumors growing as xenografts in mice
CRP11	HIF expression drastically reduced intracellular  bbbbb1 citrate eeeee1  bbbbb2 HIF eeeee2  expression drastically reduced intracellular citrate levels
CRP11	In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to  bbbbb1 glutamine eeeee1  bbbbb2 VHL eeeee2 -deficient cells to glutamine deprivation
CRP11	In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to  bbbbb1 glutamine eeeee1  bbbbb2 HIF eeeee2 -mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation
CRP11	In vivo HIF-mediated reductive carboxylation is regulated by  bbbbb1 citrate eeeee1  levels and sensitizes  bbbbb2 VHL eeeee2 -deficient cells to glutamine deprivation
CRP11	Hypoxic and VHL-deficient cells use glutamine to generate  bbbbb1 citrate eeeee1  bbbbb2 VHL eeeee2 -deficient cells use glutamine to generate citrate and lipids through reductive carboxylation (RC) of α-ketoglutarate
CRP11	Hypoxic and VHL-deficient cells use glutamine to generate citrate and lipids through reductive carboxylation (RC) of  bbbbb1 α-ketoglutarate eeeee1  bbbbb2 VHL eeeee2 -deficient cells use glutamine to generate citrate and lipids through reductive carboxylation (RC) of α-ketoglutarate
CRP11	Hypoxic and VHL-deficient cells use  bbbbb1 glutamine eeeee1  bbbbb2 VHL eeeee2 -deficient cells use glutamine to generate citrate and lipids through reductive carboxylation (RC) of α-ketoglutarate
CRP11	Feeding VHL-deficient RCC cells with acetate or  bbbbb1 citrate eeeee1  bbbbb2 VHL eeeee2 -deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with acetate or  bbbbb1 citrate eeeee1  or knocking down  bbbbb2 PDK-1 eeeee2  and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with acetate or  bbbbb1 citrate eeeee1  or knocking down PDK-1 and  bbbbb2 ACLY eeeee2  restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored  bbbbb1 citrate eeeee1  bbbbb2 VHL eeeee2 -deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored  bbbbb1 citrate eeeee1  bbbbb2 PDK-1 eeeee2  and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored  bbbbb1 citrate eeeee1  bbbbb2 ACLY eeeee2  restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with  bbbbb1 acetate eeeee1  bbbbb2 VHL eeeee2 -deficient RCC cells with acetate or citrate or knocking down PDK-1 and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with  bbbbb1 acetate eeeee1  or citrate or knocking down  bbbbb2 PDK-1 eeeee2  and ACLY restored citrate levels and suppressed RC
CRP11	Feeding VHL-deficient RCC cells with  bbbbb1 acetate eeeee1  or citrate or knocking down PDK-1 and  bbbbb2 ACLY eeeee2  restored citrate levels and suppressed RC
CRP11	Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the  bbbbb1 cisapride eeeee1  mediated increase in plasma aldosterone (a  bbbbb2 5-HT(4) eeeee2  mediated response) and orocaecal transit in 18 subjects
CRP11	Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma  bbbbb1 aldosterone eeeee1  (a  bbbbb2 5-HT(4) eeeee2  mediated response) and orocaecal transit in 18 subjects
CRP11	Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma  bbbbb1 aldosterone eeeee1  bbbbb2 5-HT(4) eeeee2  receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects
CRP11	Part B: SB-207266 tended to delay colonic transit (geometric centre of isotope at 24 (p=0.06) a bbbbb1 nd 48 hou eeeee1  bbbbb2 t B: SB eeeee2 -207266 tended to delay colonic transit (geometric centre of isotope at 24 (p=0.06) and 48 hours (p=0.08)), but did not have dose related effects on transit, fasting or postprandial colonic motor activity, compliance, or sensation
CRP11	 bbbbb1 Serotonin eeeee1  5-HT(4) receptors are located on enteric cholinergic neurones and may regulate peristalsis.  bbbbb2 5-HT(4) eeeee2  receptors on primary afferent neurones have been postulated to modulate visceral sensation
CRP11	This protection was associated with a reduction in caspase 3 activation, a reduction in  bbbbb1 superoxide eeeee1  bbbbb2 caspase 3 eeeee2  activation, a reduction in superoxide generation and a trend to ameliorate the fall in mitochondrial membrane potential
CRP11	We demonstrate that rasagiline protects against cell death induced by the combination of free radicals generated by  bbbbb1 paraquat eeeee1  and either wild-type or  bbbbb2 A53T eeeee2  mutant alpha-synuclein over-expression
CRP11	We demonstrate that rasagiline protects against cell death induced by the combination of free radicals generated by  bbbbb1 paraquat eeeee1  and either wild-type or A53T mutant  bbbbb2 alpha-synuclein eeeee2  over-expression
CRP11	We have used a combination of alpha-synuclein and free radical mediated toxicity in a dopaminergic cell line to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that mediate  bbbbb1 rasagiline eeeee1  bbbbb2 alpha-synuclein eeeee2  and free radical mediated toxicity in a dopaminergic cell line to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that mediate rasagiline protection
CRP11	Rasagiline is a propargylamine and irreversible  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase (MAO) B eeeee2  inhibitor used for the treatment of Parkinson's disease (PD)
CRP11	Although these androgenic hormones are diverse in character, it is believed that their effects are mediated via the protein products of a single  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  gene encoded on the X-chromosome
CRP11	A great deal of information has now accumulated pertaining to the mechanisms by which nuclear receptors, such as the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 , modulate the activity of responsive genes
CRP11	The inhibitory effects of genistin were correlated with the stimulation of alpha adrenergic and beta adrenergic receptors since these inhibitory effects were significantly blocked in the presence of  bbbbb1 phentolamine eeeee1  bbbbb2 alpha adrenergic and beta adrenergic receptors eeeee2  since these inhibitory effects were significantly blocked in the presence of phentolamine and propranolol respectively
CRP11	The inhibitory effects of  bbbbb1 genistin eeeee1  were correlated with the stimulation of  bbbbb2 alpha adrenergic and beta adrenergic receptors eeeee2  since these inhibitory effects were significantly blocked in the presence of phentolamine and propranolol respectively
CRP11	The inhibitory effects of genistin were correlated with the stimulation of alpha adrenergic and beta adrenergic receptors since these inhibitory effects were significantly blocked in the presence of phentolamine and  bbbbb1 propranolol eeeee1  bbbbb2 alpha adrenergic and beta adrenergic receptors eeeee2  since these inhibitory effects were significantly blocked in the presence of phentolamine and propranolol respectively
CRP11	Although reducing LDL  bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2  cholesterol (LDL-c) levels decreases morbidity and mortality, this therapeutic intervention only translates into a 25-40% reduction in cardiovascular events
CRP11	Although reducing LDL  bbbbb1 cholesterol eeeee1  ( bbbbb2 LDL eeeee2 -c) levels decreases morbidity and mortality, this therapeutic intervention only translates into a 25-40% reduction in cardiovascular events
CRP11	Epidemiological studies have shown that a high LDL-c level is not the only risk factor for CAD; low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 LD eeeee2 L-c level is not the only risk factor for CAD; low HDL cholesterol (HDL-c) is an independent risk factor for CAD
CRP11	Epidemiological studies have shown that a high LDL-c level is not the only risk factor for CAD; low HDL  bbbbb1 cholesterol eeeee1  ( bbbbb2 HDL eeeee2 -c) is an independent risk factor for CAD
CRP11	Epidemiological studies have shown that a high LDL-c level is not the only risk factor for CAD; low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2  cholesterol (HDL-c) is an independent risk factor for CAD
CRP11	Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-c that mediates reverse  bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2 -c that mediates reverse cholesterol transport from tissues to the liver for excretion
CRP11	Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-c that mediates reverse  bbbbb1 cholesterol eeeee1  bbbbb2 Apolipoprotein A- eeeee2 I (ApoA-I) is the major protein component of HDL-c that mediates reverse cholesterol transport from tissues to the liver for excretion
CRP11	Apolipoprotein A-I (ApoA-I) is the major protein component of HDL-c that mediates reverse  bbbbb1 cholesterol eeeee1  bbbbb2 ApoA-I eeeee2 ) is the major protein component of HDL-c that mediates reverse cholesterol transport from tissues to the liver for excretion
CRP11	Mazindol analogues as potential inhibitors of the cocaine binding site at the  bbbbb1 dopamine eeeee1  bbbbb2 cocaine binding site eeeee2  at the dopamine transporter
CRP11	Mazindol analogues as potential inhibitors of the  bbbbb1 cocaine eeeee1  binding site at the  bbbbb2 dopamine transporter eeeee2 
CRP11	Mazindol analogues as potential inhibitors of the  bbbbb1 cocaine eeeee1  bbbbb2 cocaine binding site eeeee2  at the dopamine transporter
CRP11	Mazindane (26) was found to be a pro-drug, oxidizing (5-H --> 5-OH) to  bbbbb1 mazindol eeeee1  on rat striatal membranes and HEK- bbbbb2 hDAT eeeee2  cells
CRP11	 bbbbb1 Mazindane eeeee1  (26) was found to be a pro-drug, oxidizing (5-H --> 5-OH) to mazindol on rat striatal membranes and HEK- bbbbb2 hDAT eeeee2  cells
CRP11	Mazindane (26) was found to be a pro-drug, oxidizing (5-H -->  bbbbb1 5-OH eeeee1 ) to mazindol on rat striatal membranes and HEK- bbbbb2 hDAT eeeee2  cells
CRP11	Mazindane (26) was found to be a pro-drug, oxidizing ( bbbbb1 5-H eeeee1  --> 5-OH) to mazindol on rat striatal membranes and HEK- bbbbb2 hDAT eeeee2  cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of DA,  bbbbb1 5-HT eeeee1 , and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK- bbbbb2 hNET eeeee2  cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of DA,  bbbbb1 5-HT eeeee1 , and NE and inhibit binding of [(125)I] RTI-55 at HEK- bbbbb2 hDAT eeeee2 , HEK-hSERT, and HEK-hNET cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of  bbbbb1 DA eeeee1 , 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK- bbbbb2 hSERT eeeee2 , and HEK-hNET cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of  bbbbb1 DA eeeee1 , 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK- bbbbb2 hNET eeeee2  cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and  bbbbb1 NE eeeee1  and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK- bbbbb2 hSERT eeeee2 , and HEK-hNET cells
CRP11	Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and  bbbbb1 NE eeeee1  and inhibit binding of [(125)I] RTI-55 at HEK- bbbbb2 hDAT eeeee2 , HEK-hSERT, and HEK-hNET cells
CRP11	A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 ) on rat or guinea pig striatal membranes were determined
CRP11	A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT) on rat or guinea pig striatal membranes were determined
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of  bbbbb1 spermidine eeeee1  and spermine with a significant accumulation of putrescine and induction of  bbbbb2 ODC eeeee2 
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [ bbbbb1 diethylglyoxal bis-(guanylhydrazone) eeeee1 ; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of  bbbbb2 ODC eeeee2 
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of  bbbbb1 putrescine eeeee1  bbbbb2 S-adenosylmethionine decarboxylase eeeee2  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of  bbbbb1 putrescine eeeee1  and induction of  bbbbb2 ODC eeeee2 
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and  bbbbb1 spermine eeeee1  with a significant accumulation of putrescine and induction of  bbbbb2 ODC eeeee2 
CRP11	Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone);  bbbbb1 DEGBG eeeee1 ] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of  bbbbb2 ODC eeeee2 
CRP11	Inhibition of  bbbbb1 S-adenosylmethionine eeeee1  bbbbb2 S-adenosylmethionine decarboxylase eeeee2  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC
CRP11	Inhibition of  bbbbb1 S-adenosylmethionine eeeee1  decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of  bbbbb2 ODC eeeee2 
CRP11	 bbbbb1 Polyamine eeeee1  depletion did not change the level of  bbbbb2 caspase 3 eeeee2  protein
CRP11	Delayed apoptosis was accompanied by a decrease in caspase 3 activity in  bbbbb1 polyamine eeeee1  bbbbb2 caspase 3 eeeee2  activity in polyamine-depleted cells
CRP11	Addition of putrescine to DFMO-t bbbbb1 reated ce eeeee1 ll extracts did not increase caspase 3 activity bbbbb2  eeeee2 
CRP11	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for  bbbbb1 polyamine eeeee1  bbbbb2 ornithine decarboxylase eeeee2  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index
CRP11	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for  bbbbb1 polyamine eeeee1  bbbbb2 ODC eeeee2 ) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index
CRP11	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of  bbbbb1 ornithine eeeee1  bbbbb2 ornithine decarboxylase eeeee2  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index
CRP11	Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of  bbbbb1 ornithine eeeee1  decarboxylase ( bbbbb2 ODC eeeee2 ) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index
CRP11	Enalkiren ( bbbbb1 A-64662 eeeee1 ), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate,  bbbbb2 angiotensinogen eeeee2 
CRP11	Enalkiren (A-64662), a potent,  bbbbb1 dipeptide eeeee1  renin inhibitor, mimics the transition state of the human renin substrate,  bbbbb2 angiotensinogen eeeee2 
CRP11	 bbbbb1 Enalkiren eeeee1  (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate,  bbbbb2 angiotensinogen eeeee2 
CRP11	Enalkiren has been shown to produce dose-related suppression of plasma renin activity (PRA) and  bbbbb1 angiotensin II eeeee1  bbbbb2 renin eeeee2  activity (PRA) and angiotensin II when administered intravenously
CRP11	Enalkiren has been shown to produce dose-related suppression of plasma renin activity (PRA) and  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  when administered intravenously
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal  bbbbb1 histidine eeeee1  phosphatase domain ( bbbbb2 τ55 eeeee2 -HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal  bbbbb1 histidine eeeee1  bbbbb2 N-terminal histidine phosphatase domain eeeee2  (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal  bbbbb1 histidine eeeee1  bbbbb2 TFIIIC eeeee2 , comprises an N-terminal histidine phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal  bbbbb1 histidine eeeee1  phosphatase domain (τ55- bbbbb2 HPD eeeee2 ) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal  bbbbb1 histidine eeeee1  bbbbb2 RNA polymerase III eeeee2 -specific general transcription factor TFIIIC, comprises an N-terminal histidine phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an  bbbbb1 N eeeee1 -terminal histidine phosphatase domain ( bbbbb2 τ55 eeeee2 -HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an  bbbbb1 N eeeee1  bbbbb2 N-terminal histidine phosphatase domain eeeee2  (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an  bbbbb1 N eeeee1  bbbbb2 TFIIIC eeeee2 , comprises an N-terminal histidine phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an  bbbbb1 N eeeee1 -terminal histidine phosphatase domain (τ55- bbbbb2 HPD eeeee2 ) whose catalytic activity and cellular function is poorly understood
CRP11	Saccharomyces cerevisiae τ55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an  bbbbb1 N eeeee1  bbbbb2 RNA polymerase III eeeee2 -specific general transcription factor TFIIIC, comprises an N-terminal histidine phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and  bbbbb1 phospho-tyrosine eeeee1  bbbbb2 HPD eeeee2  and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and  bbbbb1 phospho-tyrosine eeeee1  bbbbb2 Huf eeeee2  and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and  bbbbb1 phospho-tyrosine eeeee1  bbbbb2 τ55 eeeee2 -HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and  bbbbb1 phospho-tyrosine eeeee1  containing peptides as possible substrates that were subsequently validated using in vitro  bbbbb2 phosphatase eeeee2  assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify  bbbbb1 phospho-serine eeeee1  bbbbb2 HPD eeeee2  and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify  bbbbb1 phospho-serine eeeee1  bbbbb2 Huf eeeee2  and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify  bbbbb1 phospho-serine eeeee1  bbbbb2 τ55 eeeee2 -HPD and its closely related paralogue Huf and used in silico docking methods to identify phospho-serine and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro phosphatase assays
CRP11	We solved the crystal structures of τ55-HPD and its closely related paralogue Huf and used in silico docking methods to identify  bbbbb1 phospho-serine eeeee1  and phospho-tyrosine containing peptides as possible substrates that were subsequently validated using in vitro  bbbbb2 phosphatase eeeee2  assays
CRP11	Drosophila GABA-gated  bbbbb1 chloride eeeee1  channel: modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of  bbbbb2 Rdl eeeee2  subunit
CRP11	Drosophila GABA-gated  bbbbb1 chloride eeeee1  bbbbb2 Drosophila GABA-gated chloride channel eeeee2 : modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of Rdl subunit
CRP11	Drosophila GABA-gated chloride channel: modified  bbbbb1 [3H]EBOB eeeee1  binding site associated with Ala-->Ser or Gly mutants of  bbbbb2 Rdl eeeee2  subunit
CRP11	Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala--> bbbbb1 Ser eeeee1  bbbbb2 Drosophila GABA-gated chloride channel eeeee2 : modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of Rdl subunit
CRP11	Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala-->Ser or  bbbbb1 Gly eeeee1  bbbbb2 Drosophila GABA-gated chloride channel eeeee2 : modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of Rdl subunit
CRP11	Drosophila  bbbbb1 GABA eeeee1 -gated chloride channel: modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of  bbbbb2 Rdl eeeee2  subunit
CRP11	Drosophila  bbbbb1 GABA eeeee1  bbbbb2 Drosophila GABA-gated chloride channel eeeee2 : modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of Rdl subunit
CRP11	Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with  bbbbb1 Ala eeeee1  bbbbb2 Drosophila GABA-gated chloride channel eeeee2 : modified [3H]EBOB binding site associated with Ala-->Ser or Gly mutants of Rdl subunit
CRP11	The non-competitive blocker site of the GABA-gated  bbbbb1 chloride eeeee1  bbbbb2 GABA-gated chloride ion channel eeeee2  in normal susceptible strains of Drosophila melanogaster and simulans binds 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate ([3H]EBOB) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein
CRP11	The non-competitive blocker site of the  bbbbb1 GABA eeeee1  bbbbb2 GABA-gated chloride ion channel eeeee2  in normal susceptible strains of Drosophila melanogaster and simulans binds 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate ([3H]EBOB) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or  bbbbb1 Gly eeeee1  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous  bbbbb1 Ala eeeee1  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	 bbbbb1 Cyclodiene eeeee1  resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the  bbbbb2 Rdl GABA receptor eeeee2  subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	 bbbbb1 Cyclodiene eeeee1  resistance in D. melanogaster has been attributed to a mutation resulting in an  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the Rdl  bbbbb1 GABA eeeee1  bbbbb2 Rdl GABA receptor eeeee2  subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the Rdl  bbbbb1 GABA eeeee1  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302--> bbbbb1 Ser eeeee1  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala--> bbbbb1 Ser eeeee1  bbbbb2 Ala302-->Ser eeeee2  replacement in the Rdl GABA receptor subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement
CRP11	Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treat bbbbb1 ment (0 eeeee1 .061 +/- 0.007  bbbbb2 vs 0.03 eeeee2 0 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation
CRP11	Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treat bbbbb1 ment (0 eeeee1  bbbbb2 ets displayed imp eeeee2 roved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation
CRP11	Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), w bbbbb1 ithout  eeeee1  bbbbb2 vs 0.03 eeeee2 0 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation
CRP11	Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), w bbbbb1 ithout  eeeee1  bbbbb2 ets displayed imp eeeee2 roved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation
CRP11	Intravenous arginine significantly increased the acute glucagon response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma  bbbbb1 glucose eeeee1  bbbbb2 glucagon eeeee2  response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose
CRP11	The early insulin response to oral glucose was reduced in mice on HFD + GRA (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  response to oral glucose was reduced in mice on HFD + GRA (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but glucose excursions were improved
CRP11	SIS: Increased glucagon secretion predicts deterioration of  bbbbb1 glucose eeeee1  tolerance, and high  bbbbb2 glucagon eeeee2  levels contribute to hyperglycaemia in type 2 diabetes
CRP11	SIS: Increased glucagon secretion predicts deterioration of  bbbbb1 glucose eeeee1  bbbbb2 glucagon eeeee2  secretion predicts deterioration of glucose tolerance, and high glucagon levels contribute to hyperglycaemia in type 2 diabetes
CRP11	Insulin secretion was studied after oral and intravenous administration of  bbbbb1 glucose eeeee1  and  bbbbb2 glucagon eeeee2  secretion after intravenous arginine
CRP11	Insulin secretion was studied after oral and intravenous administration of  bbbbb1 glucose eeeee1  bbbbb2 Insulin eeeee2  secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous arginine
CRP11	Insulin secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous  bbbbb1 arginine eeeee1  bbbbb2 glucagon eeeee2  secretion after intravenous arginine
CRP11	Insulin secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous  bbbbb1 arginine eeeee1  bbbbb2 Insulin eeeee2  secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous arginine
CRP11	These variants are expected to encode either a full length (OATP2B1-FL) or shortened protein lacking 22 N-terminus  bbbbb1 amino acids eeeee1  ( bbbbb2 OATP2B-Short eeeee2 )
CRP11	Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate ( bbbbb1 ECG eeeee1  bbbbb2 sodium channel eeeee2  agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate (ECG), a polyphenol extracted from green tea, has been proposed as an effective compound for improving cardiac contractility
CRP11	Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate (ECG), a  bbbbb1 polyphenol eeeee1  bbbbb2 sodium channel eeeee2  agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate (ECG), a polyphenol extracted from green tea, has been proposed as an effective compound for improving cardiac contractility
CRP11	Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes.  bbbbb1 (-)-Epicatechin-3-gallate eeeee1  bbbbb2 sodium channel eeeee2  agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate (ECG), a polyphenol extracted from green tea, has been proposed as an effective compound for improving cardiac contractility
CRP11	Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  agonist in cultured neonatal rat ventricular myocytes. (-)-Epicatechin-3-gallate (ECG), a polyphenol extracted from green tea, has been proposed as an effective compound for improving cardiac contractility
CRP11	Selective antagonism of GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons
CRP11	Selective antagonism of GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate-receptor eeeee2 -mediated synaptic currents by topiramate in rat basolateral amygdala neurons
CRP11	In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2  containing the GluR5 subunit
CRP11	In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by  bbbbb1 kainate eeeee1  receptors containing the  bbbbb2 GluR5 eeeee2  subunit
CRP11	Topiramate also partially depressed predominantly  bbbbb1 AMPA eeeee1  bbbbb2 AMPA-receptor eeeee2 -mediated EPSCs, but with lower efficacy
CRP11	The drug has been reported to interact with various ion channel types, including  bbbbb1 AMPA eeeee1  bbbbb2 ion channel eeeee2  types, including AMPA/kainate receptors
CRP11	The drug has been reported to interact with various ion channel types, including  bbbbb1 AMPA eeeee1  bbbbb2 AMPA/kainate receptors eeeee2 
CRP11	The drug has been reported to interact with various ion channel types, including AMPA/ bbbbb1 kainate eeeee1  bbbbb2 ion channel eeeee2  types, including AMPA/kainate receptors
CRP11	The drug has been reported to interact with various ion channel types, including AMPA/ bbbbb1 kainate eeeee1  bbbbb2 AMPA/kainate receptors eeeee2 
CRP11	Inhibition of GluR5 kainate receptors could represent a bbbbb1  key me eeeee1  bbbbb2  key mechanism un eeeee2 derlying the anticonvulsant activity of topiramate
CRP11	Inhibition of GluR5 kainate receptors could represent a bbbbb1  key me eeeee1  bbbbb2 sent  eeeee2 a key mechanism underlying the anticonvulsant activity of topiramate
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase ( bbbbb2 AchE eeeee2 ) activity, C-reactive protein (CRP), total nuclear factor kappa-B (NF-κB), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain  bbbbb2 acetylcholinesterase eeeee2  (AchE) activity, C-reactive protein (CRP), total nuclear factor kappa-B (NF-κB), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity, C-reactive protein (CRP), total nuclear factor kappa-B ( bbbbb2 NF-κB eeeee2 ), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity, C-reactive protein (CRP), total  bbbbb2 nuclear factor kappa-B eeeee2  (NF-κB), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity, C-reactive protein (CRP), total nuclear factor kappa-B (NF-κB), and monocyte chemoattractant protein-1 ( bbbbb2 MCP-1 eeeee2 ) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity, C-reactive protein ( bbbbb2 CRP eeeee2 ), total nuclear factor kappa-B (NF-κB), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity, C-reactive protein (CRP), total nuclear factor kappa-B (NF-κB), and  bbbbb2 monocyte chemoattractant protein-1 eeeee2  (MCP-1) were estimated
CRP11	Levels of brain  bbbbb1 acetylcholine eeeee1  (Ach), serum and brain acetylcholinesterase (AchE) activity,  bbbbb2 C-reactive protein eeeee2  (CRP), total nuclear factor kappa-B (NF-κB), and monocyte chemoattractant protein-1 (MCP-1) were estimated
CRP11	The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of lysine by  bbbbb1 glutamic acid eeeee1  bbbbb2 A to G transition at codon 557 eeeee2  (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid
CRP11	The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of lysine by  bbbbb1 glutamic acid eeeee1  bbbbb2 AAG-->GAG eeeee2 ) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid
CRP11	The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of  bbbbb1 lysine eeeee1  bbbbb2 A to G transition at codon 557 eeeee2  (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid
CRP11	The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of  bbbbb1 lysine eeeee1  bbbbb2 AAG-->GAG eeeee2 ) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid
CRP11	Using  bbbbb1 Ca(2+) eeeee1  imaging on  bbbbb2 TRPV1 eeeee2  receptors heterologously expressed in the human embryonic kidney (HEK) 293 cells and on dissociated primary sensory neurons, we find that in both systems, AS activate TRPV1 receptors, and, moreover, they sensitize these channels to acid and heat
CRP11	Using  bbbbb1 Ca(2+) eeeee1  imaging on TRPV1 receptors heterologously expressed in the human embryonic kidney (HEK) 293 cells and on dissociated primary sensory neurons, we find that in both systems, AS activate  bbbbb2 TRPV1 eeeee2  receptors, and, moreover, they sensitize these channels to acid and heat
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the C1- bbbbb1 THF eeeee1  synthase/ bbbbb2 SHMT eeeee2  route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the C1- bbbbb1 THF eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the  bbbbb1 C1 eeeee1 -THF synthase/ bbbbb2 SHMT eeeee2  route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the  bbbbb1 C1 eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in  bbbbb1 Ser eeeee1  synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the C1-THF synthase/ bbbbb2 SHMT eeeee2  route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in  bbbbb1 Ser eeeee1  synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the  bbbbb2 C1-THF synthase eeeee2 /SHMT route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of  bbbbb1 (13)C eeeee1  through both pathways together with a relatively higher contribution from the C1-THF synthase/ bbbbb2 SHMT eeeee2  route than in shoots
CRP11	In shoots, therefore, the pathway from formate plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of  bbbbb1 (13)C eeeee1  through both pathways together with a relatively higher contribution from the  bbbbb2 C1-THF synthase eeeee2 /SHMT route than in shoots
CRP11	In shoots, therefore, the pathway from  bbbbb1 formate eeeee1  plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the C1-THF synthase/ bbbbb2 SHMT eeeee2  route than in shoots
CRP11	In shoots, therefore, the pathway from  bbbbb1 formate eeeee1  plays only a small role in Ser synthesis; in the case of roots, results indicated that the 9 : 1 ratio was as a result of greater fluxes of (13)C through both pathways together with a relatively higher contribution from the  bbbbb2 C1-THF synthase eeeee2 /SHMT route than in shoots
CRP11	We also examined the synthesis of  bbbbb1 Ser eeeee1  in a  bbbbb2 GDC eeeee2 -deficient mutant of Arabidopsis (glyD) where the GDC/SHMT pathway was impaired
CRP11	We also examined the synthesis of  bbbbb1 Ser eeeee1  in a GDC-deficient mutant of Arabidopsis (glyD) where the GDC/ bbbbb2 SHMT eeeee2  pathway was impaired
CRP11	We also examined the synthesis of  bbbbb1 Ser eeeee1  in a GDC-deficient mutant of Arabidopsis (glyD) where the  bbbbb2 GDC eeeee2 /SHMT pathway was impaired
CRP11	We also examined the synthesis of Ser in a GDC-deficient mutant of Arabidopsis ( bbbbb1 glyD eeeee1  bbbbb2 GDC eeeee2 -deficient mutant of Arabidopsis (glyD) where the GDC/SHMT pathway was impaired
CRP11	We also examined the synthesis of Ser in a GDC-deficient mutant of Arabidopsis ( bbbbb1 glyD eeeee1 ) where the GDC/ bbbbb2 SHMT eeeee2  pathway was impaired
CRP11	We also examined the synthesis of Ser in a GDC-deficient mutant of Arabidopsis ( bbbbb1 glyD eeeee1 ) where the  bbbbb2 GDC eeeee2 /SHMT pathway was impaired
CRP11	An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as  bbbbb1 1-C eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT activities with formate as 1-C source
CRP11	An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as  bbbbb1 1-C eeeee1  bbbbb2 SHMT eeeee2  activities with formate as 1-C source
CRP11	An alternative THF-dependent pathway involves the C1- bbbbb1 THF eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT activities with formate as 1-C source
CRP11	An alternative THF-dependent pathway involves the C1- bbbbb1 THF eeeee1  synthase/ bbbbb2 SHMT eeeee2  activities with formate as 1-C source
CRP11	An alternative THF-dependent pathway involves the  bbbbb1 C1 eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT activities with formate as 1-C source
CRP11	An alternative THF-dependent pathway involves the  bbbbb1 C1 eeeee1 -THF synthase/ bbbbb2 SHMT eeeee2  activities with formate as 1-C source
CRP11	An alternative  bbbbb1 THF eeeee1 -dependent pathway involves the  bbbbb2 C1-THF synthase eeeee2 /SHMT activities with formate as 1-C source
CRP11	An alternative  bbbbb1 THF eeeee1 -dependent pathway involves the C1-THF synthase/ bbbbb2 SHMT eeeee2  activities with formate as 1-C source
CRP11	We concluded that FDH has no direct role in the regulation of the above two pathways of  bbbbb1 Ser eeeee1  synthesis; the breakdown of formate to CO(2) by the  bbbbb2 FDH eeeee2  reaction is the primary and preferred fate of the organic acid in Arabidopsis
CRP11	We concluded that FDH has no direct role in the regulation of the above two pathways of  bbbbb1 Ser eeeee1  bbbbb2 FDH eeeee2  has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis
CRP11	We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of  bbbbb1 formate eeeee1  bbbbb2 FDH eeeee2  has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis
CRP11	We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to  bbbbb1 CO(2) eeeee1  bbbbb2 FDH eeeee2  has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  decarboxylase complex ( bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  decarboxylase complex (GDC,  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the  bbbbb1 glycine eeeee1  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the glycine decarboxylase complex ( bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the glycine decarboxylase complex (GDC,  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate ( bbbbb1 THF eeeee1 )-dependent activities of the  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon ( bbbbb1 1-C eeeee1  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  hydroxymethyltransferase ( bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  hydroxymethyltransferase (SHMT,  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb1 serine eeeee1  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the glycine decarboxylase complex ( bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the glycine decarboxylase complex (GDC,  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the  bbbbb1 tetrahydrofolate eeeee1  (THF)-dependent activities of the  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 SHMT eeeee2 , EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 serine hydroxymethyltransferase eeeee2  (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 EC 2.1.2.1 eeeee2 ) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 GDC eeeee2 , EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 EC 2.1.1.10 eeeee2 ) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one- bbbbb1 carbon eeeee1  bbbbb2 glycine decarboxylase complex eeeee2  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source
CRP11	The ratio between the GDC/SHMT and  bbbbb1 C1 eeeee1  bbbbb2 SHMT eeeee2  and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and  bbbbb1 C1 eeeee1  bbbbb2 GDC eeeee2 /SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and  bbbbb1 C1 eeeee1 -THF synthase/ bbbbb2 SHMT eeeee2  pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and  bbbbb1 C1 eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from  bbbbb1 [alpha-(13)C]Gly eeeee1  bbbbb2 SHMT eeeee2  and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from  bbbbb1 [alpha-(13)C]Gly eeeee1  bbbbb2 SHMT eeeee2  pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from  bbbbb1 [alpha-(13)C]Gly eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and  bbbbb1 [(13)C]formate eeeee1  bbbbb2 SHMT eeeee2  and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and  bbbbb1 [(13)C]formate eeeee1  bbbbb2 GDC eeeee2 /SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and  bbbbb1 [(13)C]formate eeeee1  bbbbb2 SHMT eeeee2  pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of  bbbbb1 Ser eeeee1  bbbbb2 GDC eeeee2 /SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of  bbbbb1 Ser eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1- bbbbb1 THF eeeee1  bbbbb2 SHMT eeeee2  and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1- bbbbb1 THF eeeee1  bbbbb2 GDC eeeee2 /SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1- bbbbb1 THF eeeee1  synthase/ bbbbb2 SHMT eeeee2  pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	The ratio between the GDC/SHMT and C1- bbbbb1 THF eeeee1  bbbbb2 C1-THF synthase eeeee2 /SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1
CRP11	Firstly, transgenic plants overexpressing  bbbbb1 formate eeeee1  dehydrogenase ( bbbbb2 FDH eeeee2 , EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism
CRP11	Firstly, transgenic plants overexpressing  bbbbb1 formate eeeee1  dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of  bbbbb2 FDH eeeee2  in formate metabolism
CRP11	Firstly, transgenic plants overexpressing  bbbbb1 formate eeeee1  bbbbb2 formate dehydrogenase eeeee2  (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism
CRP11	Firstly, transgenic plants overexpressing  bbbbb1 formate eeeee1  dehydrogenase (FDH,  bbbbb2 EC 1.2.1.2 eeeee2 ) were used to continue our previous studies on the function of FDH in formate metabolism
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  C1-THF sy bbbbb2 ntha eeeee2 se/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  bbbbb2  of eeeee2  Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  bbbbb2 Ser  eeeee2 through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  bbbbb2 gh the C1-THF s eeeee2 ynthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through  bbbbb1 the eeeee1  C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 ntha eeeee2 se/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  of eeeee2  Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 Ser  eeeee2 through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 gh the C1-THF s eeeee2 ynthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 ntha eeeee2 se/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  of eeeee2  Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 Ser  eeeee2 through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 gh the C1-THF s eeeee2 ynthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  the C1-THF sy bbbbb2 ntha eeeee2 se/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  bbbbb2  of eeeee2  Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  bbbbb2 Ser  eeeee2 through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  bbbbb2 gh the C1-THF s eeeee2 ynthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser throu bbbbb1 gh eeeee1  the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 ntha eeeee2 se/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  of eeeee2  Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 Ser  eeeee2 through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2 gh the C1-THF s eeeee2 ynthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Phosphorylation of  bbbbb1 Ser eeeee1 112 by ERK1/2 inactivates  bbbbb2 Bad eeeee2  and protects the tumor cell from apoptosis
CRP11	Phosphorylation of  bbbbb1 Ser eeeee1 112 by  bbbbb2 ERK1/2 eeeee2  inactivates Bad and protects the tumor cell from apoptosis
CRP11	We propose a 3-D (three-dimensional) structural model for L-CPT I (liver CPT I), based on the similarity of this enzyme to the recently crystallized mouse  bbbbb1 carnitine eeeee1  bbbbb2 liver CPT I eeeee2 ), based on the similarity of this enzyme to the recently crystallized mouse carnitine acetyltransferase
CRP11	We propose a 3-D (three-dimensional) structural model for L-CPT I (liver CPT I), based on the similarity of this enzyme to the recently crystallized mouse  bbbbb1 carnitine eeeee1  bbbbb2 L-CPT I eeeee2  (liver CPT I), based on the similarity of this enzyme to the recently crystallized mouse carnitine acetyltransferase
CRP11	We propose a 3-D (three-dimensional) structural model for L-CPT I (liver CPT I), based on the similarity of this enzyme to the recently crystallized mouse  bbbbb1 carnitine eeeee1  bbbbb2 mouse carnitine acetyltransferase eeeee2 
CRP11	CPT I ( bbbbb1 carnitine eeeee1  bbbbb2 CPT I eeeee2  (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	CPT I ( bbbbb1 carnitine eeeee1  bbbbb2 carnitine palmitoyltransferase I eeeee2 ) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of  bbbbb1 L-carnitine eeeee1  bbbbb2 CPT I eeeee2  (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of  bbbbb1 L-carnitine eeeee1  bbbbb2 carnitine palmitoyltransferase I eeeee2 ) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of  bbbbb1 fatty acids eeeee1  bbbbb2 CPT I eeeee2  (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of  bbbbb1 fatty acids eeeee1  bbbbb2 carnitine palmitoyltransferase I eeeee2 ) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria
CRP11	Structural model of carnitine palmitoyltransferase I based on the  bbbbb1 carnitine eeeee1  bbbbb2 carnitine palmitoyltransferase I eeeee2  based on the carnitine acetyltransferase crystal
CRP11	Structural model of carnitine palmitoyltransferase I based on the  bbbbb1 carnitine eeeee1  bbbbb2 carnitine acetyltransferase eeeee2  crystal
CRP11	Structural model of  bbbbb1 carnitine eeeee1  bbbbb2 carnitine palmitoyltransferase I eeeee2  based on the carnitine acetyltransferase crystal
CRP11	Structural model of  bbbbb1 carnitine eeeee1  palmitoyltransferase I based on the  bbbbb2 carnitine acetyltransferase eeeee2  crystal
CRP11	In addition, individual mutation of amino acids forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants T686A and S687A and altered K(m) and the catalytic efficiency for  bbbbb1 carnitine eeeee1  in mutant  bbbbb2 S685A eeeee2 
CRP11	In addition, individual mutation of amino acids forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants T686A and S687A and altered K(m) and the catalytic efficiency for  bbbbb1 carnitine eeeee1  bbbbb2 S687 eeeee2 A and altered K(m) and the catalytic efficiency for carnitine in mutant S685A
CRP11	In addition, individual mutation of amino acids forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants T686A and S687A and altered K(m) and the catalytic efficiency for  bbbbb1 carnitine eeeee1  bbbbb2 T686A eeeee2  and S687A and altered K(m) and the catalytic efficiency for carnitine in mutant S685A
CRP11	In addition, individual mutation of  bbbbb1 amino acids eeeee1  forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants T686A and S687A and altered K(m) and the catalytic efficiency for carnitine in mutant  bbbbb2 S685A eeeee2 
CRP11	In addition, individual mutation of  bbbbb1 amino acids eeeee1  forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants T686A and  bbbbb2 S687 eeeee2 A and altered K(m) and the catalytic efficiency for carnitine in mutant S685A
CRP11	In addition, individual mutation of  bbbbb1 amino acids eeeee1  forming the conserved Ser685-Thr686-Ser687 motif abolished enzyme activity in mutants  bbbbb2 T686A eeeee2  and S687A and altered K(m) and the catalytic efficiency for carnitine in mutant S685A
CRP11	The model includes 607 of the 773 amino acids of L-CPT I, and the positions of  bbbbb1 carnitine eeeee1  bbbbb2 L-CPT I eeeee2 , and the positions of carnitine, CoA and the palmitoyl group were assigned by superposition and docking analysis
CRP11	The model includes 607 of the 773 amino acids of L-CPT I, and the positions of carnitine, CoA and the  bbbbb1 palmitoyl eeeee1  bbbbb2 L-CPT I eeeee2 , and the positions of carnitine, CoA and the palmitoyl group were assigned by superposition and docking analysis
CRP11	The model includes 607 of the 773 amino acids of L-CPT I, and the positions of carnitine,  bbbbb1 CoA eeeee1  bbbbb2 L-CPT I eeeee2 , and the positions of carnitine, CoA and the palmitoyl group were assigned by superposition and docking analysis
CRP11	Transcriptional control of the  bbbbb1 arginine eeeee1  bbbbb2 arginine/lysine transporter eeeee2 , cat-1, by physiological stress
CRP11	Transcriptional control of the  bbbbb1 arginine eeeee1 /lysine transporter,  bbbbb2 cat-1 eeeee2 , by physiological stress
CRP11	Transcriptional control of the arginine/ bbbbb1 lysine eeeee1  bbbbb2 arginine/lysine transporter eeeee2 , cat-1, by physiological stress
CRP11	Transcriptional control of the arginine/ bbbbb1 lysine eeeee1  transporter,  bbbbb2 cat-1 eeeee2 , by physiological stress
CRP11	This induction is triggered by  bbbbb1 amino acid eeeee1  depletion and the unfolded protein response ( bbbbb2 UPR eeeee2 ), which is caused by unfolded proteins in the endoplasmic reticulum
CRP11	This induction is triggered by  bbbbb1 amino acid eeeee1  depletion and the  bbbbb2 unfolded protein response eeeee2  (UPR), which is caused by unfolded proteins in the endoplasmic reticulum
CRP11	The stimulation of transcription by  bbbbb1 amino acid eeeee1  depletion requires activation of GCN2 kinase, which phosphorylates  bbbbb2 eIF2alpha eeeee2 
CRP11	The stimulation of transcription by  bbbbb1 amino acid eeeee1  depletion requires activation of  bbbbb2 GCN2 eeeee2  kinase, which phosphorylates eIF2alpha
CRP11	The stimulation of transcription by  bbbbb1 amino acid eeeee1  depletion requires activation of GCN2  bbbbb2 kinase eeeee2 , which phosphorylates eIF2alpha
CRP11	NS: The FADS2 deletion may prevent the conversion of ALA into  bbbbb1 very-long-chain PUFAs eeeee1  bbbbb2 FADS2 eeeee2  deletion may prevent the conversion of ALA into very-long-chain PUFAs
CRP11	NS: The FADS2 deletion may prevent the conversion of  bbbbb1 ALA eeeee1  bbbbb2 FADS2 eeeee2  deletion may prevent the conversion of ALA into very-long-chain PUFAs
CRP11	 bbbbb1 Methyl eeeee1  transfer in  bbbbb2 glycine N-methyltransferase eeeee2 
CRP11	Methyl transfer in  bbbbb1 glycine eeeee1  bbbbb2 glycine N-methyltransferase eeeee2 
CRP11	Methyl transfer in glycine  bbbbb1 N eeeee1  bbbbb2 glycine N-methyltransferase eeeee2 
CRP11	Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in  bbbbb1 glycine eeeee1  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT)
CRP11	Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in  bbbbb1 glycine eeeee1  N-methyltransferase ( bbbbb2 GNMT eeeee2 )
CRP11	Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine  bbbbb1 N eeeee1  bbbbb2 glycine N-methyltransferase eeeee2  (GNMT)
CRP11	Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine  bbbbb1 N eeeee1 -methyltransferase ( bbbbb2 GNMT eeeee2 )
CRP11	We investigated the effect of compound C, a well-known inhibitor of the intracellular energy sensor  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ), on proliferation and viability of human U251 and rat C6 glioma cell lines
CRP11	We investigated the effect of compound C, a well-known inhibitor of the intracellular energy sensor  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK), on proliferation and viability of human U251 and rat C6 glioma cell lines
CRP11	Compound C caused G(2)/M cell cycle block, accompanied by apoptotic glioma cell death characterized by caspase activation,  bbbbb1 phosphatidylserine eeeee1  bbbbb2 caspase eeeee2  activation, phosphatidylserine exposure and DNA fragmentation
CRP11	Loss of GLR3.3 did not affect lateral root primordia bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Loss of GLR3.3 did not affect lateral root primordia bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Interacting  bbbbb1 Glutamate eeeee1  bbbbb2 Glutamate Receptor eeeee2 -Like Proteins in Phloem Regulate Lateral Root Initiation in Arabidopsis
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an  bbbbb1 amino acid eeeee1  bbbbb2 amino acid-gated Ca(2+) channel eeeee2  at the plasma membrane
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an  bbbbb1 amino acid eeeee1  bbbbb2 GLR3.4 eeeee2 , functions as an amino acid-gated Ca(2+) channel at the plasma membrane
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an  bbbbb1 amino acid eeeee1  bbbbb2 Glu receptor eeeee2 -like molecules, GLR3.4, functions as an amino acid-gated Ca(2+) channel at the plasma membrane
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an amino acid-gated  bbbbb1 Ca(2+) eeeee1  bbbbb2 amino acid-gated Ca(2+) channel eeeee2  at the plasma membrane
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an amino acid-gated  bbbbb1 Ca(2+) eeeee1  bbbbb2 GLR3.4 eeeee2 , functions as an amino acid-gated Ca(2+) channel at the plasma membrane
CRP11	Molecular, genetic, and electrophysiological evidence indicates that at least one of the plant Glu receptor-like molecules, GLR3.4, functions as an amino acid-gated  bbbbb1 Ca(2+) eeeee1  bbbbb2 Glu receptor eeeee2 -like molecules, GLR3.4, functions as an amino acid-gated Ca(2+) channel at the plasma membrane
CRP11	The gene expressions for the secretory protein, cystatin  bbbbb1 S eeeee1  bbbbb2 cystatin S eeeee2  (CysS), and PDE subfamilies 3A and 4D in the submaxillary gland were quantified using RT-PCR
CRP11	The gene expressions for the secretory protein, cystatin  bbbbb1 S eeeee1  (CysS), and  bbbbb2 PDE subfamilies 3A and 4D eeeee2  in the submaxillary gland were quantified using RT-PCR
CRP11	The gene expressions for the secretory protein, cystatin  bbbbb1 S eeeee1  ( bbbbb2 CysS eeeee2 ), and PDE subfamilies 3A and 4D in the submaxillary gland were quantified using RT-PCR
CRP11	The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase (TK) domain eeeee2 
CRP11	The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular  bbbbb1 tyrosine eeeee1  bbbbb2 EGFR eeeee2 ) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain
CRP11	The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular  bbbbb1 tyrosine eeeee1  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain
CRP11	The Met790 side chain of the G719S/T790M double mutant, in the apo form and  bbbbb1 gefitinib eeeee1  bbbbb2 T790M eeeee2  double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands
CRP11	The Met790 side chain of the G719S/T790M double mutant, in the apo form and  bbbbb1 gefitinib eeeee1  bbbbb2 G719S eeeee2 /T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands
CRP11	The T790M mutation increases the  bbbbb1 ATP eeeee1  bbbbb2 T790M eeeee2  mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant
CRP11	In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers  bbbbb1 gefitinib eeeee1  bbbbb2 T790M eeeee2  mutation confers gefitinib resistance on the G719S mutant
CRP11	Thus, mutations that result in a loss of function of the voltage-gated  bbbbb1 chloride eeeee1  bbbbb2 voltage-gated chloride channel eeeee2 , CLC-5, are associated with Dent's disease, which is characterized by low-molecular weight proteinuria, hypercalciuria, nephrolithiasis, and renal failure
CRP11	Thus, mutations that result in a loss of function of the voltage-gated  bbbbb1 chloride eeeee1  channel,  bbbbb2 CLC-5 eeeee2 , are associated with Dent's disease, which is characterized by low-molecular weight proteinuria, hypercalciuria, nephrolithiasis, and renal failure
CRP11	Finally, mutations of the thiazide-sensitive sodium-chloride cotransporter (NCCT) are associated with Gitelman's syndrome bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	 bbbbb1 Chloride eeeee1  bbbbb2 Chloride channels eeeee2  in renal disease
CRP11	Recent studies of hereditary renal tubular disorders have facilitated the identification and roles of  bbbbb1 chloride eeeee1  bbbbb2 chloride channels and cotransporters eeeee2  in the regulation of the most abundant anion, Cl-, in the ECF
CRP11	Recent studies of hereditary renal tubular disorders have facilitated the identification and roles of chloride channels and cotransporters in the regulation of the most abundant anion,  bbbbb1 Cl- eeeee1  bbbbb2 chloride channels and cotransporters eeeee2  in the regulation of the most abundant anion, Cl-, in the ECF
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb1 bumetanide eeeee1  bbbbb2 CLC-Kb eeeee2 , are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb1 bumetanide eeeee1  bbbbb2 voltage-gated chloride channel eeeee2 , CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb1 bumetanide eeeee1 -sensitive sodium-potassium-chloride cotransporter ( bbbbb2 NKCC2 eeeee2 ) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb1 bumetanide eeeee1 -sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb2 potassium channel eeeee2 , ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb1 bumetanide eeeee1 -sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel,  bbbbb2 ROMK eeeee2 
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  bbbbb2 CLC-Kb eeeee2 , are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  bbbbb2 voltage-gated chloride channel eeeee2 , CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  bbbbb2 NKCC2 eeeee2 ) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  bbbbb2 bumetanide-sensitive sodium-potassium-chloride cotransporter eeeee2  (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  bbbbb2 potassium channel eeeee2 , ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb1 potassium eeeee1  channel,  bbbbb2 ROMK eeeee2 
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  bbbbb2 CLC-Kb eeeee2 , are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  bbbbb2 voltage-gated chloride channel eeeee2 , CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  cotransporter ( bbbbb2 NKCC2 eeeee2 ) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  bbbbb2 bumetanide-sensitive sodium-potassium-chloride cotransporter eeeee2  (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  cotransporter (NKCC2) and the  bbbbb2 potassium channel eeeee2 , ROMK
CRP11	Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive  bbbbb1 sodium-potassium-chloride eeeee1  cotransporter (NKCC2) and the potassium channel,  bbbbb2 ROMK eeeee2 
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  channel,  bbbbb2 CLC-Kb eeeee2 , are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  bbbbb2 voltage-gated chloride channel eeeee2 , CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter ( bbbbb2 NKCC2 eeeee2 ) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the  bbbbb2 bumetanide-sensitive sodium-potassium-chloride cotransporter eeeee2  (NKCC2) and the potassium channel, ROMK
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the  bbbbb2 potassium channel eeeee2 , ROMK
CRP11	Mutations of another voltage-gated  bbbbb1 chloride eeeee1  channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel,  bbbbb2 ROMK eeeee2 
CRP11	When isolated hepatocytes were treated for 2 h with V(5+) in the presence of TCDD, f bbbbb1 ollow eeeee1 ed by replacement of the medium with new medium containing Hb, the bbbbb2 re eeeee2  was further potentiation to the TCDD-mediated effect
CRP11	Upon treatment of isolated hepatocytes with Hb alone or in the presence of  bbbbb1 TCDD eeeee1  bbbbb2 Hb eeeee2  alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity
CRP11	As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood  bbbbb1 glucose eeeee1  bbbbb2 glucose oxidase eeeee2  (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and insulin levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay
CRP11	As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood  bbbbb1 glucose eeeee1  and  bbbbb2 insulin eeeee2  levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay
CRP11	As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both  bbbbb1 dimethyldiguanide eeeee1  bbbbb2 glucose oxidase eeeee2  (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and insulin levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay
CRP11	As revealed by  bbbbb1 glucose eeeee1  bbbbb2 glucose oxidase eeeee2  (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and insulin levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay
CRP11	As revealed by  bbbbb1 glucose eeeee1  oxidase (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and  bbbbb2 insulin eeeee2  levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  bbbbb2 IL-1β eeeee2  (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  bbbbb2 NF-kB eeeee2  p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  (NO) with an elevation in plasma  bbbbb2 insulin eeeee2 
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  bbbbb2 glycosylated hemoglobin eeeee2  (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  bbbbb2 HbA1c eeeee2 ), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum  bbbbb1 nitric oxide eeeee1  bbbbb2 p65 eeeee2  unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 IL-1β eeeee2  (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 NF-kB eeeee2  p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1 ) with an elevation in plasma  bbbbb2 insulin eeeee2 
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 glycosylated hemoglobin eeeee2  (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 HbA1c eeeee2 ), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 p65 eeeee2  unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 , glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and  bbbbb2 IL-1β eeeee2  (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 , glycosylated hemoglobin (HbA1c),  bbbbb2 NF-kB eeeee2  p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 , glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma  bbbbb2 insulin eeeee2 
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 ,  bbbbb2 glycosylated hemoglobin eeeee2  (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 , glycosylated hemoglobin ( bbbbb2 HbA1c eeeee2 ), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	Fisetin treatment showed a significant decline in the levels of blood  bbbbb1 glucose eeeee1 , glycosylated hemoglobin (HbA1c), NF-kB  bbbbb2 p65 eeeee2  unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin
CRP11	The calnexin and calreticulin interaction with factor VIII occurs primarily through  bbbbb1 amino eeeee1 -terminal linked oligosaccharides within the heavily glycosylated factor VIII B domain and this interaction appears to be required for  bbbbb2 factor VIII eeeee2  secretion
CRP11	The calnexin and calreticulin interaction with factor VIII occurs primarily through  bbbbb1 amino eeeee1  bbbbb2 calreticulin eeeee2  interaction with factor VIII occurs primarily through amino-terminal linked oligosaccharides within the heavily glycosylated factor VIII B domain and this interaction appears to be required for factor VIII secretion
CRP11	The calnexin and calreticulin interaction with factor VIII occurs primarily through  bbbbb1 amino eeeee1 -terminal linked oligosaccharides within the heavily glycosylated  bbbbb2 factor VIII B domain eeeee2  and this interaction appears to be required for factor VIII secretion
CRP11	The calnexin and calreticulin interaction with factor VIII occurs primarily through  bbbbb1 amino eeeee1  bbbbb2 factor VIII eeeee2  occurs primarily through amino-terminal linked oligosaccharides within the heavily glycosylated factor VIII B domain and this interaction appears to be required for factor VIII secretion
CRP11	The calnexin and calreticulin interaction with factor VIII occurs primarily through  bbbbb1 amino eeeee1  bbbbb2 calnexin eeeee2  and calreticulin interaction with factor VIII occurs primarily through amino-terminal linked oligosaccharides within the heavily glycosylated factor VIII B domain and this interaction appears to be required for factor VIII secretion
CRP11	We propose that Cu(I) binds the type-1  bbbbb1 copper eeeee1  ion-binding site in the  bbbbb2 A1 domain eeeee2  and provides the essential requirement for a stable interaction between the heavy and light chains
CRP11	We propose that Cu(I) binds the type-1  bbbbb1 copper eeeee1  bbbbb2 type-1 copper ion-binding site eeeee2  in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains
CRP11	Mutation of a single  bbbbb1 amino acid eeeee1  residue in the potential BiP binding site increased the secretion efficiency of  bbbbb2 factor VIII eeeee2  by threefold
CRP11	Although the interaction with BiP does not appear  bbbbb1 to be requir eeeee1 ed for factor VIII secretion, data suggest that the calnexin and/or calreticulin interaction  bbbbb2 is required eeeee2  for secretion
CRP11	Although the interaction with BiP does not appear  bbbbb1 to be requir eeeee1 ed for factor VI bbbbb2 II secre eeeee2 tion, data suggest that the calnexin and/or calreticulin interaction is required for secretion
CRP11	Although the interaction with BiP does not appear  bbbbb1 to be requir eeeee1 ed for factor VIII secret bbbbb2 ion, data su eeeee2 ggest that the calnexin and/or calreticulin interaction is required for secretion
CRP11	To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of  bbbbb1 glutamic acid eeeee1  bbbbb2 PSMA eeeee2  a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA
CRP11	To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of  bbbbb1 phenylalkylphosphonamidate eeeee1  bbbbb2 PSMA eeeee2  a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA
CRP11	The greatest inhibitory potency was obtained for the inhibitors in which the phenyl ring was extended furthest from the central phosphorus (1f, n=5 and 1g, n=6) bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The greatest inhibitory potency was obtained for t bbbbb1 he in eeeee1 hibitors in which the phenyl ring was extended furthest from the central phosphorus (1f, n=5 and 1g, n=6) bbbbb2  eeeee2 
CRP11	Lorglumide is therefore a useful pharmacological tool to study the functions of CCK bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide ( bbbbb1 caerulein eeeee1  bbbbb2 CCK-8 eeeee2  or ceruletide (caerulein)
CRP11	In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or  bbbbb1 ceruletide eeeee1  bbbbb2 CCK-8 eeeee2  or ceruletide (caerulein)
CRP11	It antagonizes the satiety effect of CCK-8 in the rat and is protective against  bbbbb1 ceruletide eeeee1  bbbbb2 CCK-8 eeeee2  in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis
CRP11	It antagonizes the satiety effect of CCK-8 in the rat and is protective against ceruletide-,  bbbbb1 taurocholate eeeee1  bbbbb2 CCK-8 eeeee2  in the rat and is protective against ceruletide-, taurocholate- and diet-induced pancreatitis
CRP11	The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ( bbbbb1 lorglumide eeeee1 , CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced  bbbbb2 amylase eeeee2  secretion of isolated pancreatic acini
CRP11	The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ( bbbbb1 lorglumide eeeee1 , CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  bbbbb2 CCK eeeee2 -induced amylase secretion of isolated pancreatic acini
CRP11	The most potent compound,  bbbbb1 D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid eeeee1  (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced  bbbbb2 amylase eeeee2  secretion of isolated pancreatic acini
CRP11	The most potent compound,  bbbbb1 D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid eeeee1  (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  bbbbb2 CCK eeeee2 -induced amylase secretion of isolated pancreatic acini
CRP11	The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide,  bbbbb1 CR 1409 eeeee1 ), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced  bbbbb2 amylase eeeee2  secretion of isolated pancreatic acini
CRP11	The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide,  bbbbb1 CR 1409 eeeee1 ), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  bbbbb2 CCK eeeee2 -induced amylase secretion of isolated pancreatic acini
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 PSA eeeee2 ) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 PSA eeeee2  genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 AR eeeee2 ) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 AR eeeee2  and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 androgen receptor eeeee2  (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without  bbbbb1 dihydrotestosterone eeeee1  bbbbb2 prostate-specific antigen eeeee2  (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  receptor (AR) and prostate-specific antigen ( bbbbb2 PSA eeeee2 ) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and  bbbbb2 PSA eeeee2  genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  receptor ( bbbbb2 AR eeeee2 ) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of  bbbbb2 AR eeeee2  and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of  bbbbb1 androgen eeeee1  receptor (AR) and  bbbbb2 prostate-specific antigen eeeee2  (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 PSA eeeee2 ) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 PSA eeeee2  genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 AR eeeee2 ) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 AR eeeee2  and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 androgen receptor eeeee2  (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone ( bbbbb1 DHT eeeee1  bbbbb2 prostate-specific antigen eeeee2  (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)
CRP11	The isolated YLR205c protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or  bbbbb1 NADH eeeee1  bbbbb2 NADPH-cytochrome P450 reductase eeeee2  or NADH-putidaredoxin-putidaredoxin reductase but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or  bbbbb1 NADH eeeee1  bbbbb2 YLR205c eeeee2  protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or NADH-putidaredoxin-putidaredoxin reductase but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or  bbbbb1 NADH eeeee1  bbbbb2 NADH-putidaredoxin-putidaredoxin reductase eeeee2  but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or  bbbbb1 NADH eeeee1 -putidaredoxin-putidaredoxin reductase but did not exhibit  bbbbb2 heme oxygenase eeeee2  activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either  bbbbb1 NADPH eeeee1  bbbbb2 NADPH-cytochrome P450 reductase eeeee2  or NADH-putidaredoxin-putidaredoxin reductase but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either  bbbbb1 NADPH eeeee1  bbbbb2 YLR205c eeeee2  protein underwent reduction in the presence of either NADPH-cytochrome P450 reductase or NADH-putidaredoxin-putidaredoxin reductase but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either  bbbbb1 NADPH eeeee1 -cytochrome P450 reductase or  bbbbb2 NADH-putidaredoxin-putidaredoxin reductase eeeee2  but did not exhibit heme oxygenase activity
CRP11	The isolated YLR205c protein underwent reduction in the presence of either  bbbbb1 NADPH eeeee1 -cytochrome P450 reductase or NADH-putidaredoxin-putidaredoxin reductase but did not exhibit  bbbbb2 heme oxygenase eeeee2  activity
CRP11	The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting TrxR with  bbbbb1 auranofin eeeee1  bbbbb2 Trx eeeee2  mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin (AuF)
CRP11	The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin ( bbbbb1 AuF eeeee1  bbbbb2 Trx eeeee2  mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin (AuF)
CRP11	Thioredoxin-mimetic peptides (TXM) reverse  bbbbb1 auranofin eeeee1  induced apoptosis and restore  bbbbb2 insulin eeeee2  secretion in insulinoma cells
CRP11	Thioredoxin-mimetic peptides (TXM) reverse  bbbbb1 auranofin eeeee1  bbbbb2 Thioredoxin eeeee2 -mimetic peptides (TXM) reverse auranofin induced apoptosis and restore insulin secretion in insulinoma cells
CRP11	Concomitant oral drugs included sulfonylureas, α-glucosidase inhibitors and  bbbbb1 metformin eeeee1  bbbbb2 α-glucosidase eeeee2  inhibitors and metformin
CRP11	Concomitant oral drugs included  bbbbb1 sulfonylureas eeeee1 ,  bbbbb2 α-glucosidase eeeee2  inhibitors and metformin
CRP11	Add-on therapy with the DPP-4 inhibitor  bbbbb1 sitagliptin eeeee1  improves glycemic control in  bbbbb2 insulin eeeee2 -treated Japanese patients with type 2 diabetes mellitus
CRP11	Stratified analysis based on the insulin regimen revealed a stronger  bbbbb1 antidiabeti eeeee1 c effect and bbbbb2  a high eeeee2  efficacy of sitagliptin when it was added to basal insulin therapy
CRP11	The effect of add-on therapy with  bbbbb1 sitagliptin eeeee1  on glycemic control was prospectively investigated in patients with type 2 diabetes mellitus (T2DM) receiving insulin alone or  bbbbb2 insulin eeeee2  combined with oral antidiabetic drugs
CRP11	The effect of add-on therapy with  bbbbb1 sitagliptin eeeee1  on glycemic control was prospectively investigated in patients with type 2 diabetes mellitus (T2DM) receiving  bbbbb2 insulin eeeee2  alone or insulin combined with oral antidiabetic drugs
CRP11	The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with  bbbbb1 sitagliptin eeeee1  (p<0.01), and the  bbbbb2 insulin eeeee2  dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001)
CRP11	There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  bbbbb1 parathion eeeee1  bbbbb2 EGFR eeeee2 , Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion-treated cells
CRP11	Parathion is a cholinesterase inhibitor that induces the hydrolysis of body choline esters, including  bbbbb1 acetylcholine eeeee1  bbbbb2 cholinesterase eeeee2  inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses
CRP11	Parathion is a cholinesterase inhibitor that induces the hydrolysis of body  bbbbb1 choline esters eeeee1  bbbbb2 cholinesterase eeeee2  inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses
CRP11	Phillyrin strongly inhibited high  bbbbb1 glucose eeeee1 -induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c ( bbbbb2 SREBP-1c eeeee2 ) activation
CRP11	Phillyrin strongly inhibited high  bbbbb1 glucose eeeee1 -induced fatty acid synthase (FAS) expression by modulating  bbbbb2 sterol regulatory element-binding protein-1c eeeee2  (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating  bbbbb1 sterol eeeee1  regulatory element-binding protein-1c ( bbbbb2 SREBP-1c eeeee2 ) activation
CRP11	Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating  bbbbb1 sterol eeeee1  bbbbb2 FAS eeeee2 ) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating  bbbbb1 sterol eeeee1  bbbbb2 sterol regulatory element-binding protein-1c eeeee2  (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating  bbbbb1 sterol eeeee1  bbbbb2 fatty acid synthase eeeee2  (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced  bbbbb1 fatty acid eeeee1  synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c ( bbbbb2 SREBP-1c eeeee2 ) activation
CRP11	Phillyrin strongly inhibited high glucose-induced  bbbbb1 fatty acid eeeee1  synthase ( bbbbb2 FAS eeeee2 ) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced  bbbbb1 fatty acid eeeee1  synthase (FAS) expression by modulating  bbbbb2 sterol regulatory element-binding protein-1c eeeee2  (SREBP-1c) activation
CRP11	Phillyrin strongly inhibited high glucose-induced  bbbbb1 fatty acid eeeee1  bbbbb2 fatty acid synthase eeeee2  (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation
CRP11	Phillyrin attenuates high  bbbbb1 glucose eeeee1 -induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/ bbbbb2 AMP-activated protein kinase eeeee2 -dependent signalling
CRP11	Phillyrin attenuates high  bbbbb1 glucose eeeee1 -induced lipid accumulation in human HepG2 hepatocytes through the activation of  bbbbb2 LKB1 eeeee2 /AMP-activated protein kinase-dependent signalling
CRP11	Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/ bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2 -dependent signalling
CRP11	Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/ bbbbb1 AMP eeeee1  bbbbb2 LKB1 eeeee2 /AMP-activated protein kinase-dependent signalling
CRP11	Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in  bbbbb1 phillyrin eeeee1  bbbbb2 SREBP-1c eeeee2  expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in  bbbbb1 phillyrin eeeee1  bbbbb2 AMPK eeeee2  is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in  bbbbb1 phillyrin eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in  bbbbb1 phillyrin eeeee1  bbbbb2 AMPK eeeee2 ) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological  bbbbb1 AMP eeeee1 -activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing  bbbbb2 SREBP-1c eeeee2  expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological  bbbbb1 AMP eeeee1 -activated protein kinase (AMPK) inhibitor compound C revealed that  bbbbb2 AMPK eeeee2  is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells
CRP11	Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor  bbbbb1 compound C eeeee1  revealed that AMPK is essential for suppressing  bbbbb2 SREBP-1c eeeee2  expression in phillyrin-treated cells
CRP11	Finally, we found that liver bbbbb1  kinase B eeeee1 1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes bbbbb2  eeeee2 
CRP11	Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes bbbbb1  eeeee1  bbbbb2 ytes eeeee2 
CRP11	Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes bbbbb1  eeeee1  bbbbb2  of AMPK eeeee2  in HepG2 hepatocytes
CRP11	Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes bbbbb1  eeeee1  bbbbb2 epG eeeee2 2 hepatocytes
CRP11	Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and  bbbbb1 cGMP eeeee1  (PDE10A). cDNA encoding a novel phosphodiesterase (PDE) was isolated from a human fetal lung cDNA library and designated  bbbbb2 PDE10A eeeee2 
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and  bbbbb1 cGMP eeeee1  (PDE10A). cDNA encoding a novel  bbbbb2 phosphodiesterase eeeee2  (PDE) was isolated from a human fetal lung cDNA library and designated PDE10A
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and  bbbbb1 cGMP eeeee1  (PDE10A). cDNA encoding a novel phosphodiesterase ( bbbbb2 PDE eeeee2 ) was isolated from a human fetal lung cDNA library and designated PDE10A
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both  bbbbb1 cAMP eeeee1  and cGMP (PDE10A). cDNA encoding a novel phosphodiesterase (PDE) was isolated from a human fetal lung cDNA library and designated  bbbbb2 PDE10A eeeee2 
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both  bbbbb1 cAMP eeeee1  and cGMP (PDE10A). cDNA encoding a novel  bbbbb2 phosphodiesterase eeeee2  (PDE) was isolated from a human fetal lung cDNA library and designated PDE10A
CRP11	Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both  bbbbb1 cAMP eeeee1  and cGMP (PDE10A). cDNA encoding a novel phosphodiesterase ( bbbbb2 PDE eeeee2 ) was isolated from a human fetal lung cDNA library and designated PDE10A
CRP11	The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in  bbbbb1 amino acid eeeee1  bbbbb2 cGMP binding sequence eeeee2  in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families
CRP11	The deduced amino acid sequence contains 779 amino acids, including a putative  bbbbb1 cGMP eeeee1  bbbbb2 cGMP binding sequence eeeee2  in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families
CRP11	The deduced amino acid sequence contains 779 amino acids, including a putative  bbbbb1 cGMP eeeee1  binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other  bbbbb2 PDE eeeee2  families
CRP11	The deduced  bbbbb1 amino acid eeeee1  sequence contains 779 amino acids, including a putative  bbbbb2 cGMP binding sequence eeeee2  in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families
CRP11	The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the  bbbbb1 amino eeeee1  bbbbb2 cGMP binding sequence eeeee2  in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families
CRP11	The deduced amino acid sequence contains 779  bbbbb1 amino acids eeeee1 , including a putative  bbbbb2 cGMP binding sequence eeeee2  in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a  bbbbb1 cAMP eeeee1  bbbbb2 PDE10A eeeee2  exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a  bbbbb1 cAMP eeeee1  bbbbb2 cAMP PDE eeeee2  and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-inhibited cGMP PDE eeeee2 
CRP11	Thus, PDE10A exhibited properties of a  bbbbb1 cAMP eeeee1  bbbbb2 PDE10A eeeee2  exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a  bbbbb1 cAMP eeeee1  bbbbb2 cAMP PDE eeeee2  and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a  bbbbb1 cAMP eeeee1  PDE and a  bbbbb2 cAMP-inhibited cGMP PDE eeeee2 
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited  bbbbb1 cGMP eeeee1  bbbbb2 PDE10A eeeee2  exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited  bbbbb1 cGMP eeeee1  bbbbb2 cAMP PDE eeeee2  and a cAMP-inhibited cGMP PDE
CRP11	Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited  bbbbb1 cGMP eeeee1  bbbbb2 cAMP-inhibited cGMP PDE eeeee2 
CRP11	Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited  bbbbb1 cGMP eeeee1  bbbbb2 PDE eeeee2  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 microM, respectively
CRP11	Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.  bbbbb1 cGMP eeeee1  bbbbb2 PDE eeeee2  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 microM, respectively
CRP11	Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and  bbbbb1 cAMP eeeee1  bbbbb2 PDE eeeee2  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 microM, respectively
CRP11	Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of  bbbbb1 cAMP eeeee1  bbbbb2 PDE eeeee2  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 microM, respectively
CRP11	This was also accompanied by a significant decrease in apoptosis bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This was also accompanied by a significant decrease in apoptosis bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Cardiomyocytes that were injured by ALD were assayed by the  bbbbb1 MTT eeeee1  and  bbbbb2 LDH eeeee2  leakage ratio
CRP11	Cardiomyocytes that were injured by  bbbbb1 ALD eeeee1  were assayed by the MTT and  bbbbb2 LDH eeeee2  leakage ratio
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS)  bbbbb1 serine eeeee1  bbbbb2 insulin eeeee2  resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS)  bbbbb1 serine eeeee1  bbbbb2 stress-regulated serine kinases eeeee2  and insulin receptor substrates (IRS) serine phosphorylation
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated  bbbbb1 serine eeeee1  kinases and insulin receptor substrates ( bbbbb2 IRS eeeee2 ) serine phosphorylation
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated  bbbbb1 serine eeeee1  kinases and  bbbbb2 insulin receptor substrates eeeee2  (IRS) serine phosphorylation
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated  bbbbb1 serine eeeee1  bbbbb2 insulin eeeee2  resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation
CRP11	Cellular mechanisms of insulin resistance: role of stress-regulated  bbbbb1 serine eeeee1  bbbbb2 stress-regulated serine kinases eeeee2  and insulin receptor substrates (IRS) serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 S6K eeeee2 , activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 Kinases eeeee2 , including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 insulin eeeee2  resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 JNK eeeee2 , ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 IKKbeta eeeee2 , JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 ERK eeeee2 , mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS  bbbbb1 serine eeeee1  bbbbb2 mTOR eeeee2 , and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation
CRP11	Insulin receptor substrates (IRS)  bbbbb1 serine eeeee1  phosphorylation is a time-controlled physiological feedback mechanism in insulin signaling that is hijacked by metabolic and inflammatory stresses to promote  bbbbb2 insulin eeeee2  resistance
CRP11	Insulin receptor substrates (IRS)  bbbbb1 serine eeeee1  phosphorylation is a time-controlled physiological feedback mechanism in  bbbbb2 insulin eeeee2  signaling that is hijacked by metabolic and inflammatory stresses to promote insulin resistance
CRP11	These unexpected and intriguing complexities seem likely to have  bbbbb1 some as ye eeeee1  bbbbb2 some as yet undefined role in regulat eeeee2 ing SSAT activity or stability as a part of polyamine homeostasis
CRP11	These unexpected and intriguing complexities seem likely to have  bbbbb1 some as ye eeeee1  bbbbb2 guin eeeee2 g complexities seem likely to have some as yet undefined role in regulating SSAT activity or stability as a part of polyamine homeostasis
CRP11	Spermidine/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of  bbbbb1 spermidine eeeee1  bbbbb2 SSAT eeeee2 ) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	Spermidine/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of  bbbbb1 polyamine eeeee1  bbbbb2 SSAT eeeee2 ) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	 bbbbb1 Spermidine eeeee1 /spermine N1-acetyltransferase ( bbbbb2 SSAT eeeee2 ) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	 bbbbb1 Spermidine eeeee1  bbbbb2 Spermidine/spermine N1-acetyltransferase eeeee2  (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	Spermidine/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and  bbbbb1 spermine eeeee1  bbbbb2 SSAT eeeee2 ) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	Spermidine/ bbbbb1 spermine eeeee1  N1-acetyltransferase ( bbbbb2 SSAT eeeee2 ) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	Spermidine/ bbbbb1 spermine eeeee1  bbbbb2 Spermidine/spermine N1-acetyltransferase eeeee2  (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA),  bbbbb1 spermine eeeee1  bbbbb2 human SSAT eeeee2  from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA),  bbbbb1 spermine eeeee1  bbbbb2 SSAT eeeee2 , as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with  bbbbb1 CoA eeeee1  bbbbb2 human SSAT eeeee2  from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with  bbbbb1 CoA eeeee1  bbbbb2 SSAT eeeee2 , as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA ( bbbbb1 AcCoA eeeee1  bbbbb2 human SSAT eeeee2  from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA ( bbbbb1 AcCoA eeeee1  bbbbb2 SSAT eeeee2 , as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA,  bbbbb1 acetyl-CoA eeeee1  bbbbb2 human SSAT eeeee2  from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA,  bbbbb1 acetyl-CoA eeeee1  bbbbb2 SSAT eeeee2 , as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor  bbbbb1 N1,N11bis-(ethyl)-norspermine eeeee1  bbbbb2 human SSAT eeeee2  from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	We have expressed human SSAT from the cloned cDNA in Escherichia coli and have determined high-resolution structures of wild-type and mutant SSAT, as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor  bbbbb1 N1,N11bis-(ethyl)-norspermine eeeee1  bbbbb2 SSAT eeeee2 , as the free dimer and in binary and ternary complexes with CoA, acetyl-CoA (AcCoA), spermine, and the inhibitor N1,N11bis-(ethyl)-norspermine (BE-3-3-3)
CRP11	Increased intracellular  bbbbb1 polyamine eeeee1  levels accompany several types of cancers as well as other human diseases, and compounds that affect the expression, activity, or stability of  bbbbb2 SSAT eeeee2  are being explored as potential therapeutic drugs
CRP11	Structures of wild-type and mutant human  bbbbb1 spermidine eeeee1  bbbbb2 human spermidine/spermine N1-acetyltransferase eeeee2 , a potential therapeutic drug target
CRP11	Structures of wild-type and mutant human spermidine/ bbbbb1 spermine eeeee1  bbbbb2 human spermidine/spermine N1-acetyltransferase eeeee2 , a potential therapeutic drug target
CRP11	On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and caly bbbbb1 culin-A  eeeee1 (0.1 fg/mou bbbbb2 se- eeeee2 1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception
CRP11	On the other hand, high doses of okadaic acid (10 ng/ bbbbb1 mouse, eeeee1  i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mou bbbbb2 se- eeeee2 1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception
CRP11	On the other hand, high doses of okadaic acid (10 ng/ bbbbb1 mouse, eeeee1  bbbbb2  (10 ng/mouse, i.c.v.) and cantharidin (1 mic eeeee2 rog/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception
CRP11	On the other hand, high doses of okadaic acid (10 ng/mouse,  bbbbb1 i.c.v.) a eeeee1 nd cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mou bbbbb2 se- eeeee2 1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception
CRP11	On the other hand, high doses of okadaic acid (10 ng/mouse,  bbbbb1 i.c.v.) a eeeee1  bbbbb2  (10 ng/mouse, i.c.v.) and cantharidin (1 mic eeeee2 rog/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception
CRP11	Effects of serine/threonine protein phosphatase inhibitors on  bbbbb1 morphine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  inhibitors on morphine-induced antinociception in the tail flick test in mice
CRP11	Effects of  bbbbb1 serine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  inhibitors on morphine-induced antinociception in the tail flick test in mice
CRP11	Effects of serine/ bbbbb1 threonine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  inhibitors on morphine-induced antinociception in the tail flick test in mice
CRP11	The i.c.v. administration of very low doses of okadaic acid (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit PP2A, produced a dose-dependent antagonism of the antinociception induced by  bbbbb1 morphine eeeee1  bbbbb2 PP2A eeeee2 , produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)
CRP11	However, L-nor-okadaone (0.001 pg/mouse-1 ng/mouse, i.c.v.), an analogue of okadaic acid lacking activity against protein phosphatases, did not affect the antinociceptive effect of  bbbbb1 morphine eeeee1  bbbbb2 protein phosphatases eeeee2 , did not affect the antinociceptive effect of morphine
CRP11	The aim of this study was to evaluate the effects of serine/ bbbbb1 threonine eeeee1  protein phosphatase ( bbbbb2 PP eeeee2 ) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of serine/ bbbbb1 threonine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on  bbbbb1 [3H]naloxone eeeee1  bbbbb2 PP eeeee2 ) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on  bbbbb1 [3H]naloxone eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on  bbbbb1 morphine eeeee1  bbbbb2 PP eeeee2 ) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on  bbbbb1 morphine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of  bbbbb1 serine eeeee1 /threonine protein phosphatase ( bbbbb2 PP eeeee2 ) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	The aim of this study was to evaluate the effects of  bbbbb1 serine eeeee1  bbbbb2 serine/threonine protein phosphatase eeeee2  (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction
CRP11	Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  bbbbb1 diacylglycerol eeeee1  acyltransferase ( bbbbb2 DGAT eeeee2 )
CRP11	Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  bbbbb1 diacylglycerol eeeee1  bbbbb2 diacylglycerol acyltransferase eeeee2  (DGAT)
CRP11	In vitro inhibition of  bbbbb1 diacylglycerol eeeee1  bbbbb2 diacylglycerol acyltransferase eeeee2  by prenylflavonoids from Sophora flavescens
CRP11	 bbbbb1 Iloprost eeeee1  was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for iloprost binding to the platelet  bbbbb2 prostacyclin receptor eeeee2 
CRP11	 bbbbb1 Methionine eeeee1  bbbbb2 Methionine synthase reductase eeeee2  (MTRR) is an enzyme involved in the conversion of Hcy to methionine
CRP11	 bbbbb1 Methionine eeeee1  synthase reductase ( bbbbb2 MTRR eeeee2 ) is an enzyme involved in the conversion of Hcy to methionine
CRP11	 bbbbb1 Methionine eeeee1  bbbbb2 Methionine synthase reductase eeeee2  polymorphisms are associated with serum osteocalcin levels in postmenopausal women
CRP11	 bbbbb1 Methionine eeeee1  synthase reductase polymorphisms are associated with serum  bbbbb2 osteocalcin eeeee2  levels in postmenopausal women
CRP11	The effect of  bbbbb1 ginseng saponins eeeee1  on plasma interleukin-6 ( bbbbb2 IL-6 eeeee2 ) in non-stressed and immobilization-stressed mice were investigated
CRP11	The effect of  bbbbb1 ginseng saponins eeeee1  on plasma  bbbbb2 interleukin-6 eeeee2  (IL-6) in non-stressed and immobilization-stressed mice were investigated
CRP11	The protein is formed by an N-terminal helicase-like domain, a  bbbbb1 C eeeee1  bbbbb2 N-terminal helicase-like domain eeeee2 , a C-terminal DNA polymerase domain, and a large central domain that spans between the two
CRP11	The protein is formed by an N-terminal helicase-like domain, a  bbbbb1 C eeeee1 -terminal DNA polymerase domain, and a  bbbbb2 large central domain eeeee2  that spans between the two
CRP11	The protein is formed by an  bbbbb1 N eeeee1 -terminal helicase-like domain, a C-terminal DNA polymerase domain, and a  bbbbb2 large central domain eeeee2  that spans between the two
CRP11	The protein is formed by an  bbbbb1 N eeeee1 -terminal helicase-like domain, a  bbbbb2 C-terminal DNA polymerase domain eeeee2 , and a large central domain that spans between the two
CRP11	PR mRNA abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing mifepristone treatment before the operation but not in the other 2 patients stopping  bbbbb1 RU486 eeeee1  bbbbb2 PR mRNA eeeee2  abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing mifepristone treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation
CRP11	PR mRNA abundance and PR protein levels in both myomatous center and marginal area were significantly greater than those in corporal myometrium (P < 0.01) in both follicular and luteal phases, but similar between myomatous center and marginal area (P > 0.05). 6 cases pretreated with  bbbbb1 mifepristone eeeee1  bbbbb2 PR protein eeeee2  levels in both myomatous center and marginal area were significantly greater than those in corporal myometrium (P < 0.01) in both follicular and luteal phases, but similar between myomatous center and marginal area (P > 0.05). 6 cases pretreated with mifepristone 25 mg/day for 3 months were operated, all but one patient displayed a decrease in leiomyomata volume
CRP11	PR mRNA abundance and PR protein levels in both myomatous center and marginal area were significantly greater than those in corporal myometrium (P < 0.01) in both follicular and luteal phases, but similar between myomatous center and marginal area (P > 0.05). 6 cases pretreated with  bbbbb1 mifepristone eeeee1  bbbbb2 PR mRNA eeeee2  abundance and PR protein levels in both myomatous center and marginal area were significantly greater than those in corporal myometrium (P < 0.01) in both follicular and luteal phases, but similar between myomatous center and marginal area (P > 0.05). 6 cases pretreated with mifepristone 25 mg/day for 3 months were operated, all but one patient displayed a decrease in leiomyomata volume
CRP11	Polymorphisms in  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers
CRP11	Polymorphisms in  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 SLC6A3 eeeee2 ) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers
CRP11	We evaluated associations between mood, cognitive and cardiovascular responses to  bbbbb1 d-amphetamine eeeee1  and four polymorphisms in the  bbbbb2 dopamine transporter eeeee2  (SLC6A3): rs460000, rs3756450, rs37022 and rs6869645
CRP11	We evaluated associations between mood, cognitive and cardiovascular responses to  bbbbb1 d-amphetamine eeeee1  and four polymorphisms in the dopamine transporter ( bbbbb2 SLC6A3 eeeee2 ): rs460000, rs3756450, rs37022 and rs6869645
CRP11	We evaluated associations between mood, cognitive and cardiovascular responses to d-amphetamine and four polymorphisms in the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (SLC6A3): rs460000, rs3756450, rs37022 and rs6869645
CRP11	We evaluated associations between mood, cognitive and cardiovascular responses to d-amphetamine and four polymorphisms in the  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 SLC6A3 eeeee2 ): rs460000, rs3756450, rs37022 and rs6869645
CRP11	In an animal study with  bbbbb1 (129)I eeeee1 -labeled EPO in Han-Wistar rats, an increase of (129)I- bbbbb2 EPO eeeee2  is observed after dose administration
CRP11	In an animal study with (129)I-labeled EPO in Han-Wistar rats, an increase of  bbbbb1 (129)I eeeee1 - bbbbb2 EPO eeeee2  is observed after dose administration
CRP11	In an animal study with (129)I-labeled EPO in Han-Wistar rats, an increase of  bbbbb1 (129)I eeeee1  bbbbb2 EPO eeeee2  in Han-Wistar rats, an increase of (129)I-EPO is observed after dose administration
CRP11	Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA: bbbbb1 cholesterol eeeee1  acyltransferase 2 ( bbbbb2 ACAT2 eeeee2 ) inhibitors: Part 2
CRP11	Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA: bbbbb1 cholesterol eeeee1  bbbbb2 acyl-CoA:cholesterol acyltransferase 2 eeeee2  (ACAT2) inhibitors: Part 2
CRP11	Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective  bbbbb1 acyl-CoA eeeee1 :cholesterol acyltransferase 2 ( bbbbb2 ACAT2 eeeee2 ) inhibitors: Part 2
CRP11	Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective  bbbbb1 acyl-CoA eeeee1  bbbbb2 acyl-CoA:cholesterol acyltransferase 2 eeeee2  (ACAT2) inhibitors: Part 2
CRP11	A previous crystal structure of a  bbbbb1 microcystin eeeee1  bound to the catalytic subunit of protein phosphatase-1 (PP-1c) showed distinct changes in the active site region when compared with  bbbbb2 protein phosphatase-1 eeeee2  structures bound to other toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 ural basis  eeeee2 for inhibition of protein phosphatases by these toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 xes reveal the struc eeeee2 tural basis for inhibition of protein phosphatases by these toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 ural basis  eeeee2 for inhibition of protein phosphatases by these toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 xes reveal the struc eeeee2 tural basis for inhibition of protein phosphatases by these toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 ural basis  eeeee2 for inhibition of protein phosphatases by these toxins
CRP11	The atomic structures of these complexes reveal the structural basis for inhibition of protein phosphatases by these toxins bbbbb1  eeeee1  bbbbb2 xes reveal the struc eeeee2 tural basis for inhibition of protein phosphatases by these toxins
CRP11	The toxins function by inhibiting broad specificity  bbbbb1 Ser eeeee1  bbbbb2 Ser/Thr protein phosphatases eeeee2  in the host cells, thereby disrupting signal transduction pathways
CRP11	The toxins function by inhibiting broad specificity Ser/ bbbbb1 Thr eeeee1  bbbbb2 Ser/Thr protein phosphatases eeeee2  in the host cells, thereby disrupting signal transduction pathways
CRP11	We have elucidated the crystal structures of the cyanotoxins, motuporin ( bbbbb1 nodularin-V eeeee1  bbbbb2 cyanotoxins eeeee2 , motuporin (nodularin-V) and dihydromicrocystin-LA bound to human protein phosphatase-1c (gamma isoform)
CRP11	We have elucidated the crystal structures of the cyanotoxins,  bbbbb1 motuporin eeeee1  bbbbb2 cyanotoxins eeeee2 , motuporin (nodularin-V) and dihydromicrocystin-LA bound to human protein phosphatase-1c (gamma isoform)
CRP11	We have elucidated the crystal structures of the cyanotoxins, motuporin (nodularin-V) and  bbbbb1 dihydromicrocystin-LA eeeee1  bbbbb2 cyanotoxins eeeee2 , motuporin (nodularin-V) and dihydromicrocystin-LA bound to human protein phosphatase-1c (gamma isoform)
CRP11	S: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human  bbbbb1 dopamine eeeee1  bbbbb2 human dopamine transporter eeeee2  (DAT) wild-type and mutants with altered conformational equilibria
CRP11	S: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 ) wild-type and mutants with altered conformational equilibria
CRP11	Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by  bbbbb1 [2-(trimethylammonium)ethyl]-methanethiosulfonate eeeee1  bbbbb2 DAT eeeee2  mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C
CRP11	Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by  bbbbb1 [2-(trimethylammonium)ethyl]-methanethiosulfonate eeeee1  bbbbb2 Y335A eeeee2  DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C
CRP11	Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than  bbbbb1 cocaine eeeee1 , which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the  bbbbb2 DAT eeeee2  E2C I159C
CRP11	Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than  bbbbb1 cocaine eeeee1 , which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT  bbbbb2 E2C eeeee2  I159C
CRP11	Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than  bbbbb1 cocaine eeeee1 , which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C  bbbbb2 I159C eeeee2 
CRP11	Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes  bbbbb1 acetyl eeeee1  bbbbb2 Histone deacetylase 3 eeeee2  (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression
CRP11	Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes  bbbbb1 acetyl eeeee1  bbbbb2 Hdac3 eeeee2 ) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression
CRP11	Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from  bbbbb1 lysine eeeee1  bbbbb2 Histone deacetylase 3 eeeee2  (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression
CRP11	Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from  bbbbb1 lysine eeeee1  bbbbb2 Hdac3 eeeee2 ) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression
CRP11	Similar to cocaine, other local anesthetics bind to the  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 ) and inhibit DA uptake in rodent and monkey brain
CRP11	Similar to cocaine, other local anesthetics bind to the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT) and inhibit DA uptake in rodent and monkey brain
CRP11	Similar to cocaine, other local anesthetics bind to the dopamine transporter (DAT) and inhibit  bbbbb1 DA eeeee1  bbbbb2 DAT eeeee2 ) and inhibit DA uptake in rodent and monkey brain
CRP11	Similar to cocaine, other local anesthetics bind to the dopamine transporter (DAT) and inhibit  bbbbb1 DA eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT) and inhibit DA uptake in rodent and monkey brain
CRP11	In vivo comparison of the reinforcing and  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  effects of local anesthetics in rhesus monkeys
CRP11	Significant increases in systolic blood pressure and Doppler stroke distance occurred with  bbbbb1 BRL eeeee1  and SAL which were unaffected by pretreatment with B5 and completely blocked by N20, in keeping with  bbbbb2 beta 2 eeeee2 -mediated effects
CRP11	Significant increases in systolic blood pressure and Doppler stroke distance occurred with BRL and  bbbbb1 SAL eeeee1  which were unaffected by pretreatment with B5 and completely blocked by N20, in keeping with  bbbbb2 beta 2 eeeee2 -mediated effects
CRP11	The aim of the present study was to evaluate the cardiac effects of the beta 3-adrenoceptor agonist  bbbbb1 BRL35135 eeeee1 , and determine whether  bbbbb2 beta 3-receptors eeeee2  are involved in mediating chronotropic or inotropic responses in man
CRP11	Eight normal males received single oral doses of  bbbbb1 BRL35135 eeeee1  8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of  bbbbb1 BRL35135 eeeee1  8 mg (BRL) or the selective  bbbbb2 beta 2-adrenoceptor eeeee2  agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of  bbbbb1 BRL35135 eeeee1  8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg ( bbbbb1 SAL eeeee1 ), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg ( bbbbb1 SAL eeeee1 ), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist  bbbbb1 salbutamol eeeee1  8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist  bbbbb1 salbutamol eeeee1  8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or  bbbbb1 nadolol eeeee1  20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or  bbbbb1 nadolol eeeee1  bbbbb2 beta 2-adrenoceptor eeeee2  agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or  bbbbb1 nadolol eeeee1  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg ( bbbbb1 BRL eeeee1 ) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of BRL35135 8 mg ( bbbbb1 BRL eeeee1 ) or the selective  bbbbb2 beta 2-adrenoceptor eeeee2  agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg ( bbbbb1 BRL eeeee1 ) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL),  bbbbb1 bisoprolol eeeee1  5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block  bbbbb2 beta 1- and beta 2- but not beta 3-receptors eeeee2 
CRP11	Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL),  bbbbb1 bisoprolol eeeee1  bbbbb2 beta 2-adrenoceptor eeeee2  agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors
CRP11	BRL and  bbbbb1 SAL eeeee1  produced significant chronotropic and minute distance responses which were unaffected by  bbbbb2 beta 1-adrenoceptor eeeee2  blockade
CRP11	 bbbbb1 BRL eeeee1  and SAL produced significant chronotropic and minute distance responses which were unaffected by  bbbbb2 beta 1-adrenoceptor eeeee2  blockade
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and  bbbbb1 warfarin eeeee1  bbbbb2 CYP2C9 eeeee2  and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on  bbbbb1 warfarin eeeee1  bbbbb2 CYP2C9 eeeee2  and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on  bbbbb1 warfarin eeeee1  bbbbb2 VKORC1 eeeee2 , confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on  bbbbb1 warfarin eeeee1  bbbbb2 vitamin K epoxide reductase complex 1 eeeee2  VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme,  bbbbb1 vitamin K epoxide eeeee1  bbbbb2 CYP2C9 eeeee2  and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme,  bbbbb1 vitamin K epoxide eeeee1  reductase complex 1  bbbbb2 VKORC1 eeeee2 , confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme,  bbbbb1 vitamin K epoxide eeeee1  bbbbb2 vitamin K epoxide reductase complex 1 eeeee2  VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the  bbbbb1 warfarin eeeee1  metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1  bbbbb2 VKORC1 eeeee2 , confirmed their influence on warfarin maintenance dose
CRP11	Pharmacogenetic analysis of two genes, the  bbbbb1 warfarin eeeee1  metabolic enzyme CYP2C9 and warfarin target enzyme,  bbbbb2 vitamin K epoxide reductase complex 1 eeeee2  VKORC1, confirmed their influence on warfarin maintenance dose
CRP11	Haplotypes based on these SNPs explain a large fraction of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9 bbbbb1  eeeee1  bbbbb2 e frac eeeee2 tion of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9
CRP11	Haplotypes based on these SNPs explain a large fraction of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9 bbbbb1  eeeee1  bbbbb2 lain a eeeee2  large fraction of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9
CRP11	Haplotypes based on these SNPs explain a large fraction of the interindividual variation in warfarin dos bbbbb1 e, and V eeeee1  bbbbb2 e frac eeeee2 tion of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9
CRP11	Haplotypes based on these SNPs explain a large fraction of the interindividual variation in warfarin dos bbbbb1 e, and V eeeee1  bbbbb2 lain a eeeee2  large fraction of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9
CRP11	Several single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs) in  bbbbb2 VKORC1 eeeee2  are associated with warfarin dose across the normal dose range
CRP11	In the local presence into the LC of the α2-adrenoceptor antagonist RS79948 (1 μM), systemic  bbbbb1 citalopram eeeee1  bbbbb2 α2-adrenoceptor eeeee2  antagonist RS79948 (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %)
CRP11	Local LC  bbbbb1 citalopram eeeee1  effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1 μM) but not the  bbbbb2 5-HT1/2 eeeee2  receptor antagonist methiothepin (1 μM)
CRP11	Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist  bbbbb1 MDL72222 eeeee1  (1 μM) but not the  bbbbb2 5-HT1/2 eeeee2  receptor antagonist methiothepin (1 μM)
CRP11	Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1 μM) but not the 5-HT1/2 receptor antagonist  bbbbb1 methiothepin eeeee1  bbbbb2 5-HT3 eeeee2  receptor antagonist MDL72222 (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM)
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  saturase activity, whereas zebrafish RetSat B ( bbbbb2 zRetSat B eeeee2 ) was inactive under similar conditions
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  bbbbb2 retinol saturase eeeee2  activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  bbbbb2 RetSat eeeee2  homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had retinol saturase activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  bbbbb2 zRetSat A eeeee2 ), also had retinol saturase activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  bbbbb2 zebrafish RetSat A eeeee2  (zRetSat A), also had retinol saturase activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions
CRP11	Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had  bbbbb1 retinol eeeee1  saturase activity, whereas  bbbbb2 zebrafish RetSat B eeeee2  (zRetSat B) was inactive under similar conditions
CRP11	Exogenous all-trans-retinol, all-trans-13,14-dihydroretinol, or all-trans-7,8-dihydroretinol led to the strong induction of the expr bbbbb1 ession of the r eeeee1  bbbbb2 s-7,8- eeeee2 dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, Cyp26A1, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish
CRP11	Specificity of zebrafish  bbbbb1 retinol eeeee1  bbbbb2 zebrafish retinol saturase eeeee2 : formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol
CRP11	The dual enzymatic activity of zRetSat A displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial  bbbbb1 phytoene eeeee1  desaturases and  bbbbb2 plant carotenoid isomerases eeeee2 
CRP11	The dual enzymatic activity of zRetSat A displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial  bbbbb1 phytoene eeeee1  bbbbb2 bacterial phytoene desaturases eeeee2  and plant carotenoid isomerases
CRP11	The dual enzymatic activity of zRetSat A displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial  bbbbb1 phytoene eeeee1  bbbbb2 zRetSat A eeeee2  displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial phytoene desaturases and plant carotenoid isomerases
CRP11	Metabolism of  bbbbb1 vitamin A eeeee1 , all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the  bbbbb2 retinoic acid receptor eeeee2 
CRP11	Metabolism of vitamin A,  bbbbb1 all-trans-retinol eeeee1 , leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the  bbbbb2 retinoic acid receptor eeeee2 
CRP11	Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid receptor eeeee2 
CRP11	Metabolism of vitamin A, all-trans-retinol, leads to the formation of  bbbbb1 11-cis-retinaldehyde eeeee1 , the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the  bbbbb2 retinoic acid receptor eeeee2 
CRP11	Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to  bbbbb1 all-trans-13,14-dihydroretinoic acid eeeee1  before being oxidized further by  bbbbb2 Cyp26 eeeee2  enzymes
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol ( bbbbb1 vitamin A2 eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol ( bbbbb1 vitamin A2 eeeee1  bbbbb2 zRetSat A eeeee2  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol ( bbbbb1 vitamin A2 eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-retinol eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-retinol eeeee1  to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.  bbbbb2 zRetSat A eeeee2  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-retinol eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-3,4-didehydroretinol eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-3,4-didehydroretinol eeeee1  bbbbb2 zRetSat A eeeee2  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of  bbbbb1 all-trans-3,4-didehydroretinol eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of  bbbbb1 vitamin A eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of  bbbbb1 vitamin A eeeee1  bbbbb2 zRetSat A eeeee2  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of  bbbbb1 vitamin A eeeee1  bbbbb2 zRetSat A eeeee2  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of  bbbbb1 vitamin A eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or  bbbbb1 all-trans-7,8-dihydroretinol eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or  bbbbb1 all-trans-7,8-dihydroretinol eeeee1 , respectively.  bbbbb2 zRetSat A eeeee2  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or  bbbbb1 all-trans-7,8-dihydroretinol eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either  bbbbb1 all-trans-13,14-dihydroretinol eeeee1  bbbbb2 mRetSat eeeee2 ), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either  bbbbb1 all-trans-13,14-dihydroretinol eeeee1  or all-trans-7,8-dihydroretinol, respectively.  bbbbb2 zRetSat A eeeee2  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either  bbbbb1 all-trans-13,14-dihydroretinol eeeee1  bbbbb2 mouse RetSat eeeee2  (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish
CRP11	Ethanol given to rats in drinking water decreased the level of p-CREB protein in the nucleus accumbens (-75 %) at the time of exposure to  bbbbb1 ethanol eeeee1  bbbbb2 p-CREB eeeee2  protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol
CRP11	Changes of phosphorylation of  bbbbb1 cAMP eeeee1  bbbbb2 cAMP response element binding protein eeeee2  in rat nucleus accumbens after chronic ethanol intake: naloxone reversal
CRP11	However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol bbbbb1  eeeee1  bbbbb2 it a eeeee2 ntagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol
CRP11	The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble  bbbbb1 guanylyl eeeee1  bbbbb2 soluble guanylyl cyclase eeeee2  pathway
CRP11	The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble  bbbbb1 guanylyl eeeee1  bbbbb2 HIF-1 eeeee2  activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway
CRP11	The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on  bbbbb1 nitric oxide eeeee1 - bbbbb2 soluble guanylyl cyclase eeeee2  pathway
CRP11	The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on  bbbbb1 nitric oxide eeeee1  bbbbb2 HIF-1 eeeee2  activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  affect HI eeeee2 F-1 activity
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  affect HI eeeee2 F-1 activity
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, NTG or ISDN does not affect HIF-1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	One of the most important transcription factors that activate the expression of  bbbbb1 O(2) eeeee1 -regulated genes is hypoxia-inducible factor 1 ( bbbbb2 HIF-1 eeeee2 )
CRP11	One of the most important transcription factors that activate the expression of  bbbbb1 O(2) eeeee1 -regulated genes is  bbbbb2 hypoxia-inducible factor 1 eeeee2  (HIF-1)
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 IL-1β eeeee2 ), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 IL-6 eeeee2 ), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 interleukin-1β eeeee2  (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 tumour necrosis factor-α eeeee2  (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 interleukin-6 eeeee2  (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and  bbbbb1 prostaglandin E2 eeeee1  bbbbb2 TNF-α eeeee2 ), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 IL-1β eeeee2 ), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 IL-6 eeeee2 ), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 interleukin-1β eeeee2  (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 tumour necrosis factor-α eeeee2  (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 interleukin-6 eeeee2  (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 ( bbbbb1 PGE2 eeeee1  bbbbb2 TNF-α eeeee2 ), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells
CRP11	Neoechinulin A treatment significantly inhibited the generation of reactive  bbbbb1 oxygen eeeee1  and nitrogen species in  bbbbb2 Aβ42 eeeee2 -activated BV-2 microglia cells
CRP11	Neoechinulin A treatment significantly inhibited the generation of reactive oxygen and  bbbbb1 nitrogen eeeee1  species in  bbbbb2 Aβ42 eeeee2 -activated BV-2 microglia cells
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS),  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), TNF-α, IL-1β and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ), cyclooxygenase-2 (COX-2), TNF-α, IL-1β and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2),  bbbbb2 TNF-α eeeee2 , IL-1β and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), cyclooxygenase-2 (COX-2), TNF-α, IL-1β and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), TNF-α, IL-1β and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α,  bbbbb2 IL-1β eeeee2  and IL-6
CRP11	Moreover, the treatment downregulated the protein and gene expressions of inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, IL-1β and  bbbbb2 IL-6 eeeee2 
CRP11	Vertebrate ALDH2 genes encode mitochondrial enzymes capable of metabolizing acetaldehyde and other biological  bbbbb1 aldehydes eeeee1  bbbbb2 Vertebrate ALDH2 eeeee2  genes encode mitochondrial enzymes capable of metabolizing acetaldehyde and other biological aldehydes in the body
CRP11	Vertebrate ALDH2 genes encode mitochondrial enzymes capable of metabolizing  bbbbb1 acetaldehyde eeeee1  bbbbb2 Vertebrate ALDH2 eeeee2  genes encode mitochondrial enzymes capable of metabolizing acetaldehyde and other biological aldehydes in the body
CRP11	Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing  bbbbb1 acetaldehyde eeeee1  but has a tissue distribution and pattern of activity distinct from that of  bbbbb2 ALDH2 eeeee2 
CRP11	TAN ( bbbbb1 NDP-MSH eeeee1  bbbbb2 MSH eeeee2 ) binds the MC1 receptor to significantly increase the eumelanin content of human skin cells
CRP11	Importantly, MELANOTAN increa bbbbb1 sed the m eeeee1 elanin density to a greater extent in individuals carrying the variant allele bbbbb2 s Va eeeee2 l60Leu, Asp84Glu, Val92Met, Arg142His, Arg151Cys, and Arg160Trp than in individuals with no variant alleles
CRP11	In this study of 77 Caucasian individuals, we investigated the effects of MELANOTAN in individuals with variant MC1R genotypes, as it has been suggested through in vitro studies that variant alleles decrease  bbbbb1 MELANOTAN eeeee1  bbbbb2 MC1R eeeee2  genotypes, as it has been suggested through in vitro studies that variant alleles decrease MELANOTAN binding efficacy, which would subsequently affect the synthesis of melanin
CRP11	In this study of 77 Caucasian individuals, we investigated the effects of  bbbbb1 MELANOTAN eeeee1  in individuals with variant  bbbbb2 MC1R eeeee2  genotypes, as it has been suggested through in vitro studies that variant alleles decrease MELANOTAN binding efficacy, which would subsequently affect the synthesis of melanin
CRP11	The high-affinity binding of L-noradrenaline to  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the sa bbbbb1 me site eeeee1  bbbbb2 ties of the inhibitor L-n eeeee2 oradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the sa bbbbb1 me site eeeee1  bbbbb2 f these effectors ar eeeee2 e due to their binding to the same site
CRP11	The many similarities in binding proper bbbbb1 ties of the i eeeee1  bbbbb2 ties of the inhibitor L-n eeeee2 oradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site
CRP11	The many similarities in binding proper bbbbb1 ties of the i eeeee1 nhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions o bbbbb2 f these effectors ar eeeee2 e due to their binding to the same site
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site bbbbb1  eeeee1  bbbbb2 ties of the inhibitor L-n eeeee2 oradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site bbbbb1  eeeee1  bbbbb2 f these effectors ar eeeee2 e due to their binding to the same site
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions o bbbbb1 f these  eeeee1  bbbbb2 ties of the inhibitor L-n eeeee2 oradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site
CRP11	The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions o bbbbb1 f these  eeeee1  bbbbb2 f these effectors ar eeeee2 e due to their binding to the same site
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine hydroxylase eeeee2 , EC 1.14.16.1)
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( bbbbb1 phenylalanine eeeee1  hydroxylase,  bbbbb2 EC 1.14.16.1 eeeee2 )
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine 4-monooxygenase eeeee2  (phenylalanine hydroxylase, EC 1.14.16.1)
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of  bbbbb1 phenylalanine eeeee1  4-monooxygenase ( bbbbb2 phenylalanine hydroxylase eeeee2 , EC 1.14.16.1)
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of  bbbbb1 phenylalanine eeeee1  4-monooxygenase (phenylalanine hydroxylase,  bbbbb2 EC 1.14.16.1 eeeee2 )
CRP11	Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine 4-monooxygenase eeeee2  (phenylalanine hydroxylase, EC 1.14.16.1)
CRP11	Cooperative homotropic interaction of L-noradrenaline with the catalytic site of  bbbbb1 phenylalanine eeeee1  bbbbb2 phenylalanine 4-monooxygenase eeeee2 
CRP11	Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and purine nucleoside phosphorylase was increased in the  bbbbb1 2-chlorodeoxyadenosine eeeee1  bbbbb2 Ribonucleotide reductase eeeee2  activity was found to be strongly increased in the gemcitabine-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line
CRP11	Ribonucleotide reductase activity was found to be strongly increased in the  bbbbb1 gemcitabine eeeee1 -selected line and  bbbbb2 purine nucleoside phosphorylase eeeee2  was increased in the 2-chlorodeoxyadenosine-selected line
CRP11	In addition a deletion in one of the alleles of the  bbbbb1 deoxycytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2  was detected in the fludarabine-resistant line
CRP11	There was a profound accumulation defect of all nucleoside analogues in the resistant variants but no significant defect in nucleoside transport in any of the variants. 5' nucleotidase activity was strongly increased and deoxycytidine kinase activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of  bbbbb1 triphosphate eeeee1  bbbbb2 5' nucleotidase eeeee2  activity was strongly increased and deoxycytidine kinase activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of triphosphate analogues
CRP11	There was a profound accumulation defect of all nucleoside analogues in the resistant variants but no significant defect in nucleoside transport in any of the variants. 5' nucleotidase activity was strongly increased and deoxycytidine kinase activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of  bbbbb1 triphosphate eeeee1  bbbbb2 deoxycytidine kinase eeeee2  activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of triphosphate analogues
CRP11	There was a profound accumulation defect of all nucleoside analogues in the resistant variants but no significant defect in nucleoside transport in any of the variants. 5' nucleotidase activity was strongly increased and  bbbbb1 deoxycytidine eeeee1  bbbbb2 5' nucleotidase eeeee2  activity was strongly increased and deoxycytidine kinase activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of triphosphate analogues
CRP11	There was a profound accumulation defect of all nucleoside analogues in the resistant variants but no significant defect in nucleoside transport in any of the variants. 5' nucleotidase activity was strongly increased and  bbbbb1 deoxycytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2  activity was moderately reduced in all of the resistant variants, resulting in reduced accumulation of triphosphate analogues
CRP11	To overcome the ABCC2-depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the  bbbbb1 cisplatin eeeee1  bbbbb2 ABCC2 eeeee2 -depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS
CRP11	To overcome the ABCC2-depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the  bbbbb1 cisplatin eeeee1  bbbbb2 ABCC2 eeeee2  small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS
CRP11	The  bbbbb1 adenosine triphosphate eeeee1  binding cassette (ABC)-transporter  bbbbb2 ABCC2 eeeee2  (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel
CRP11	The  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 adenosine triphosphate binding cassette (ABC)-transporter eeeee2  ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel
CRP11	The  bbbbb1 adenosine triphosphate eeeee1  binding cassette (ABC)-transporter ABCC2 ( bbbbb2 MRP2 eeeee2 /cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel
CRP11	The  bbbbb1 adenosine triphosphate eeeee1  binding cassette (ABC)-transporter ABCC2 (MRP2/ bbbbb2 cMOAT eeeee2 ) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel
CRP11	Effect of thiazinotrienomycin B, an  bbbbb1 ansamycin eeeee1  antibiotic, on the function of  bbbbb2 epidermal growth factor receptor eeeee2  in human stomach tumor cells
CRP11	Effect of  bbbbb1 thiazinotrienomycin B eeeee1 , an ansamycin antibiotic, on the function of  bbbbb2 epidermal growth factor receptor eeeee2  in human stomach tumor cells
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2 varied eeeee2  and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2 s been eeeee2  varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2 varied eeeee2  and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2 s been eeeee2  varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plerixafor results in the rapid and reversible mobilization of hematopoietic ste bbbbb1 m cells in eeeee1 to th bbbbb2 e per eeeee2 ipheral circulation and is synergistic when combined with G-CSF
CRP11	Plerixafor results in the rapid and reversible mobilization of hematopoietic ste bbbbb1 m cells in eeeee1 to the peripheral circulation and is synergistic when combined with G-CSF bbbbb2  eeeee2 
CRP11	 bbbbb1 Monoacylglycerol eeeee1  bbbbb2 Monoacylglycerol lipase eeeee2  inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice
CRP11	Monoacylglycerol lipase inhibition-induced changes in plasma  bbbbb1 corticosterone eeeee1  bbbbb2 Monoacylglycerol lipase eeeee2  inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice
CRP11	Here we studied the effects of the recently developed  bbbbb1 monoacylglycerol eeeee1  bbbbb2 monoacylglycerol lipase eeeee2  inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses
CRP11	Here we studied the effects of the recently developed monoacylglycerol lipase inhibitor JZL184 on basal and stress-induced  bbbbb1 corticosterone eeeee1  bbbbb2 monoacylglycerol lipase eeeee2  inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses
CRP11	These findings show that monoacylglycerol lipase inhibition dramatically increases basal levels o bbbbb1 f corticosterone eeeee1  bbbbb2 f corticosterone eeeee2 
CRP11	All together, they indicate that aversive property of  bbbbb1 ethanol eeeee1  is dependent on ethanol action on  bbbbb2 α2-containing GABA(A)-R eeeee2 
CRP11	All together, they indicate that aversive property of ethanol is dependent on ethanol action on α2-containing  bbbbb1 GABA eeeee1  bbbbb2 α2-containing GABA(A)-R eeeee2 
CRP11	Therefore, recovery of rotarod incoordination is under control of two  bbbbb1 GABA eeeee1  bbbbb2 GABA(A)-R subunits: α2 and α3 eeeee2 
CRP11	A type A receptors (GABA(A)-R) are important for ethanol actions and it is of interest to link individual subunits with specific  bbbbb1 ethanol eeeee1  bbbbb2 GABA(A)-R eeeee2 ) are important for ethanol actions and it is of interest to link individual subunits with specific ethanol behaviors
CRP11	A type A receptors ( bbbbb1 GABA eeeee1  bbbbb2 GABA(A)-R eeeee2 ) are important for ethanol actions and it is of interest to link individual subunits with specific ethanol behaviors
CRP11	We studied null mutant mice for six different  bbbbb1 GABA eeeee1  bbbbb2 GABA(A)-R subunits (α1, α2, α3, α4, α5 and δ eeeee2 )
CRP11	Inhibition of endogenous production of H(2)S by  bbbbb1 PAG eeeee1  significantly suppressed SP concentration, PPT-A expression and  bbbbb2 NK1-R eeeee2  expression in the acini
CRP11	Inhibition of endogenous production of H(2)S by  bbbbb1 PAG eeeee1  significantly suppressed SP concentration,  bbbbb2 PPT-A eeeee2  expression and NK1-R expression in the acini
CRP11	Inhibition of endogenous production of H(2)S by  bbbbb1 PAG eeeee1  significantly suppressed  bbbbb2 SP eeeee2  concentration, PPT-A expression and NK1-R expression in the acini
CRP11	Inhibition of endogenous production of H(2)S by PAG significantly suppressed  bbbbb1 SP eeeee1  concentration, PPT-A expression and  bbbbb2 NK1-R eeeee2  expression in the acini
CRP11	Inhibition of endogenous production of H(2)S by PAG significantly suppressed  bbbbb1 SP eeeee1  concentration,  bbbbb2 PPT-A eeeee2  expression and NK1-R expression in the acini
CRP11	Inhibition of endogenous production of H(2)S by PAG significantly suppressed  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2  concentration, PPT-A expression and NK1-R expression in the acini
CRP11	Caerulein increased the levels of  bbbbb1 H(2)S eeeee1  and  bbbbb2 CSE eeeee2  mRNA expression while CBS mRNA expression was decreased
CRP11	Caerulein increased the levels of  bbbbb1 H(2)S eeeee1  and CSE mRNA expression while  bbbbb2 CBS eeeee2  mRNA expression was decreased
CRP11	In this study, we investigated the presence of  bbbbb1 H(2)S eeeee1  and the expression of H(2)S synthesizing enzymes,  bbbbb2 CSE eeeee2  and CBS, in isolated mouse pancreatic acini
CRP11	In this study, we investigated the presence of  bbbbb1 H(2)S eeeee1  and the expression of H(2)S synthesizing enzymes, CSE and  bbbbb2 CBS eeeee2 , in isolated mouse pancreatic acini
CRP11	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in  bbbbb1 H(2)S eeeee1  bbbbb2 CSE eeeee2  inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with DL-propargylglycine ( bbbbb1 PAG eeeee1 , 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that  bbbbb2 CSE eeeee2  may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in  bbbbb1 caerulein eeeee1  bbbbb2 CSE eeeee2  inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in  bbbbb1 caerulein eeeee1  treated cells, suggesting that  bbbbb2 CSE eeeee2  may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of  bbbbb1 H(2)S eeeee1  bbbbb2 CSE eeeee2  inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of  bbbbb1 H(2)S eeeee1  in caerulein treated cells, suggesting that  bbbbb2 CSE eeeee2  may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	In addition, cells pre-treated with  bbbbb1 DL-propargylglycine eeeee1  (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that  bbbbb2 CSE eeeee2  may be the main enzyme involved in H(2)S formation in mouse acinar cells
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-gamma-lyase eeeee2  (CSE) and cystathionine-beta-synthase (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  bbbbb1 cystathionine eeeee1  bbbbb2 CSE eeeee2 ) and cystathionine-beta-synthase (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-beta-synthase eeeee2  (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  bbbbb1 cystathionine eeeee1 -beta-synthase ( bbbbb2 CBS eeeee2 )
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-gamma-lyase eeeee2  (CSE) and cystathionine-beta-synthase (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of  bbbbb1 cystathionine eeeee1 -gamma-lyase ( bbbbb2 CSE eeeee2 ) and cystathionine-beta-synthase (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of  bbbbb1 cystathionine eeeee1 -gamma-lyase (CSE) and  bbbbb2 cystathionine-beta-synthase eeeee2  (CBS)
CRP11	Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of  bbbbb1 cystathionine eeeee1 -gamma-lyase (CSE) and cystathionine-beta-synthase ( bbbbb2 CBS eeeee2 )
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and  bbbbb2 neurokinin-1 receptor eeeee2  (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of SP gene (preprotachykinin-A,  bbbbb2 PPT-A eeeee2 ) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1  bbbbb2 substance P eeeee2  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of SP gene ( bbbbb2 preprotachykinin-A eeeee2 , PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb2 SP eeeee2 , are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of  bbbbb2 SP eeeee2  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1  bbbbb2 SP eeeee2 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P ( bbbbb1 SP eeeee1 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor ( bbbbb2 NK-1R eeeee2 ), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue  bbbbb1 caerulein eeeee1  bbbbb2 SP eeeee2 , are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  gene (preprotachykinin-A, PPT-A) and  bbbbb2 neurokinin-1 receptor eeeee2  (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  gene (preprotachykinin-A,  bbbbb2 PPT-A eeeee2 ) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  bbbbb2 substance P eeeee2  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  gene ( bbbbb2 preprotachykinin-A eeeee2 , PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb2 SP eeeee2 , are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of  bbbbb1 SP eeeee1  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor ( bbbbb2 NK-1R eeeee2 ), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 neurokinin-1 receptor eeeee2  (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 PPT-A eeeee2 ) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 substance P eeeee2  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 preprotachykinin-A eeeee2 , PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2 , are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 SP eeeee2 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb1 SP eeeee1  bbbbb2 NK-1R eeeee2 ), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and  bbbbb2 neurokinin-1 receptor eeeee2  (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A,  bbbbb2 PPT-A eeeee2 ) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  bbbbb2 substance P eeeee2  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of SP gene ( bbbbb2 preprotachykinin-A eeeee2 , PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  bbbbb2 SP eeeee2 , are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of  bbbbb2 SP eeeee2  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  ( bbbbb2 SP eeeee2 ) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Furthermore,  bbbbb1 substance P eeeee1  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor ( bbbbb2 NK-1R eeeee2 ), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells
CRP11	Factor Xa or catalytically inactive  bbbbb1 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone eeeee1  bbbbb2 Factor Xa eeeee2  or catalytically inactive 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone-factor Xa bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells
CRP11	Factor Xa or catalytically inactive  bbbbb1 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone eeeee1 -factor Xa bound indistinguishably to HUVEC and  bbbbb2 EPR-1 eeeee2  transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells
CRP11	Factor Xa or catalytically inactive  bbbbb1 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone eeeee1 -factor Xa bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I- bbbbb2 factor Xa eeeee2  to these cells
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ( bbbbb1 Gly eeeee1 ) inhibited factor V/Va-independent  bbbbb2 prothrombin eeeee2  activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ( bbbbb1 Gly eeeee1  bbbbb2 inter-EGF sequence eeeee2  Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ( bbbbb1 Gly eeeee1 ) inhibited  bbbbb2 factor V/Va eeeee2 -independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ( bbbbb1 Gly eeeee1 ) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I- bbbbb2 factor Xa eeeee2  to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ( bbbbb1 Gly eeeee1  bbbbb2 Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) eeeee2  inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1  bbbbb2 prothrombin eeeee2  activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1  bbbbb2 inter-EGF sequence eeeee2  Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1  bbbbb2 factor V/Va eeeee2 -independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1  bbbbb2 factor X eeeee2  peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1 - bbbbb2 factor Xa eeeee2  to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of  bbbbb1 125I eeeee1  bbbbb2 Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) eeeee2  inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM)
CRP11	Furthermore, binding of  bbbbb1 125I eeeee1 - bbbbb2 factor Xa eeeee2  to immobilized JC15 was inhibited by molar excess of unlabeled factor Xa, but not by comparable concentrations of factors X or IXa
CRP11	Furthermore, binding of  bbbbb1 125I eeeee1 -factor Xa to immobilized JC15 was inhibited by molar excess of unlabeled  bbbbb2 factor Xa eeeee2 , but not by comparable concentrations of factors X or IXa
CRP11	Furthermore, binding of  bbbbb1 125I eeeee1 -factor Xa to immobilized JC15 was inhibited by molar excess of unlabeled factor Xa, but not by comparable concentrations of  bbbbb2 factors X or IXa eeeee2 
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1 -factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma  bbbbb2 IXa eeeee2  had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1  bbbbb2 factor IX eeeee2  backbone inhibited binding of 125I-factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1  bbbbb2 factor X eeeee2  sequence Leu83-Leu88 within a factor IX backbone inhibited binding of 125I-factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1 -factor Xa to HUVEC and  bbbbb2 EPR-1 eeeee2  transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1 -factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant  bbbbb2 factor IX eeeee2  or plasma IXa had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1  bbbbb2 Leu83-Leu88 eeeee2  within a factor IX backbone inhibited binding of 125I-factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect
CRP11	A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of  bbbbb1 125I eeeee1 - bbbbb2 factor Xa eeeee2  to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect
CRP11	The interaction between methionine adenosyltransferase II alpha2 and beta subunit was demonstrated in HuH7 cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The interaction between methionine adenosyltransferase II alpha2 and beta subunit was demonstrated in HuH7 cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  bbbbb1 methionine eeeee1  adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas  bbbbb2 MAT2A eeeee2  is expressed in extrahepatic tissues
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  bbbbb1 methionine eeeee1  bbbbb2 MAT2A eeeee2 ) encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  bbbbb1 methionine eeeee1  bbbbb2 methionine adenosyltransferase eeeee2 , the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  bbbbb1 methionine eeeee1  bbbbb2 MAT1A eeeee2 , MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  bbbbb1 methionine eeeee1  adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine,  bbbbb2 MAT1A eeeee2 , is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues
CRP11	D & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes  bbbbb1 S-adenosylmethionine eeeee1 , MAT1A, is expressed in liver, whereas  bbbbb2 MAT2A eeeee2  is expressed in extrahepatic tissues
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  bbbbb2 sodium calcium exchanger-1 eeeee2 , phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  exchanger-1, phospholamban (PLB), phospho-PLB, and  bbbbb2 calsequestrin 2 eeeee2  are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  exchanger-1, phospholamban ( bbbbb2 PLB eeeee2 ), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  exchanger-1, phospholamban (PLB),  bbbbb2 phospho-PLB eeeee2 , and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  bbbbb2 SERCA2a eeeee2 ), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  bbbbb2 sarcoendoplasmic reticulum ATPase 2a eeeee2  (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  bbbbb1 calcium eeeee1  exchanger-1,  bbbbb2 phospholamban eeeee2  (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 sodium calcium exchanger-1 eeeee2 , phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1 -PLB, and  bbbbb2 calsequestrin 2 eeeee2  are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 PLB eeeee2 ), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 phospho-PLB eeeee2 , and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 SERCA2a eeeee2 ), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 sarcoendoplasmic reticulum ATPase 2a eeeee2  (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB),  bbbbb1 phospho eeeee1  bbbbb2 phospholamban eeeee2  (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  bbbbb2 sodium calcium exchanger-1 eeeee2 , phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  calcium exchanger-1, phospholamban (PLB), phospho-PLB, and  bbbbb2 calsequestrin 2 eeeee2  are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  calcium exchanger-1, phospholamban ( bbbbb2 PLB eeeee2 ), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  calcium exchanger-1, phospholamban (PLB),  bbbbb2 phospho-PLB eeeee2 , and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  bbbbb2 SERCA2a eeeee2 ), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  bbbbb2 sarcoendoplasmic reticulum ATPase 2a eeeee2  (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a),  bbbbb1 sodium eeeee1  calcium exchanger-1,  bbbbb2 phospholamban eeeee2  (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in  bbbbb1 urethane eeeee1  bbbbb2 5-HT1F eeeee2  receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in  bbbbb1 urethane eeeee1  bbbbb2 c-fos eeeee2  protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in  bbbbb1 urethane eeeee1  bbbbb2 c-fos eeeee2  expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of  bbbbb1 sumatriptan eeeee1  with those of a selective  bbbbb2 5-HT1F eeeee2  receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of  bbbbb1 sumatriptan eeeee1  with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis.  bbbbb2 c-fos eeeee2  expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal  bbbbb1 capsaicin eeeee1  bbbbb2 5-HT1F eeeee2  receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal  bbbbb1 capsaicin eeeee1  bbbbb2 c-fos eeeee2  protein expression in the trigeminal nucleus caudalis. c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist ( bbbbb1 LY 344864 eeeee1 ) on c-fos protein expression in the trigeminal nucleus caudalis.  bbbbb2 c-fos eeeee2  expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not  bbbbb1 troleandomycin eeeee1  bbbbb2 CYP2B6 eeeee2  inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not  bbbbb1 troleandomycin eeeee1  (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against  bbbbb2 CYP3A4 eeeee2  inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not  bbbbb1 troleandomycin eeeee1  bbbbb2 CYP2B6 eeeee2  but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited  bbbbb1 ketamine eeeee1  bbbbb2 CYP2B6 eeeee2  inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited  bbbbb1 ketamine eeeee1  bbbbb2 CYP3A4 eeeee2  inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited  bbbbb1 ketamine eeeee1  bbbbb2 CYP2B6 eeeee2  but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited  bbbbb1 ketamine eeeee1  bbbbb2 CYP3A4 eeeee2  inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	 bbbbb1 ThioTEPA eeeee1  (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against  bbbbb2 CYP3A4 eeeee2  inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	 bbbbb1 ThioTEPA eeeee1  (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against  bbbbb2 CYP2B6 eeeee2  but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	 bbbbb1 ThioTEPA eeeee1  (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin ( bbbbb2 CYP3A4 eeeee2  inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations
CRP11	The degree of inhibition was significantly reduce bbbbb1 d in HLM eeeee1 s with the CYP2B6*6 allele (gene-dose P<0.05) bbbbb2  eeeee2 
CRP11	The degree of inhibition was significantly reduced in HLMs with the CYP2B6*6 allele (gene-dose P<0.05) bbbbb1  eeeee1  bbbbb2 tly re eeeee2 duced in HLMs with the CYP2B6*6 allele (gene-dose P<0.05)
CRP11	We examined the N-demethylation of individual  bbbbb1 ketamine eeeee1  enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant  bbbbb2 CYP2B6 eeeee2  and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant
CRP11	We examined the N-demethylation of individual  bbbbb1 ketamine eeeee1  enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and  bbbbb2 CYP2B6.6 eeeee2  protein variant
CRP11	We examined the N-demethylation of individual  bbbbb1 ketamine eeeee1  enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and  bbbbb2 CYP3A4 eeeee2  enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant
CRP11	We examined the N-demethylation of individual  bbbbb1 ketamine eeeee1  enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant  bbbbb2 CYP2B6.1 eeeee2  and CYP2B6.6 protein variant
CRP11	The intrinsic clearance for both  bbbbb1 ketamine eeeee1  enantiomers by the high affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and  bbbbb2 CYP2B6*6 eeeee2 /*6 genotype
CRP11	The intrinsic clearance for both  bbbbb1 ketamine eeeee1  enantiomers by the high affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for  bbbbb2 CYP2B6*1 eeeee2 /*6 genotype and CYP2B6*6/*6 genotype
CRP11	Ketamine is primarily metabolized to  bbbbb1 norketamine eeeee1  by hepatic  bbbbb2 cytochrome P450 (CYP) 2B6 eeeee2  and CYP3A4-mediated N-demethylation
CRP11	Ketamine is primarily metabolized to  bbbbb1 norketamine eeeee1  by hepatic cytochrome P450 (CYP) 2B6 and  bbbbb2 CYP3A4 eeeee2 -mediated N-demethylation
CRP11	Effects of CYP-selective inhibitors on  bbbbb1 norketamine eeeee1  bbbbb2 CYP eeeee2 -selective inhibitors on norketamine formation were also determined in HLMs
CRP11	Fasting and mean post- bbbbb1 MTT eeeee1  plasma bioactive  bbbbb2 GLP-1 eeeee2  were higher (P < 0.01) after S and M+S vs. M and P
CRP11	The increase in mean post- bbbbb1 MTT eeeee1  plasma  bbbbb2 insulin eeeee2  and in ISR was similar in P, M, and S and slightly greater in M+S
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive  bbbbb2 glucagon-like peptide eeeee2  (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and  bbbbb2 gastrointestinal insulinotropic peptide eeeee2  (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide ( bbbbb2 GIP eeeee2 ) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide ( bbbbb2 insulin eeeee2  secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide ( bbbbb2 GLP-1 eeeee2 ) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1  bbbbb2 insulin eeeee2 , C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma glucose (FPG), fasting plasma insulin,  bbbbb1 C eeeee1 -peptide (insulin secretory rate [ISR]), fasting plasma  bbbbb2 glucagon eeeee2 , and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive  bbbbb2 glucagon-like peptide eeeee2  (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and  bbbbb2 gastrointestinal insulinotropic peptide eeeee2  (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide ( bbbbb2 GIP eeeee2 ) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide ( bbbbb2 insulin eeeee2  secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide ( bbbbb2 GLP-1 eeeee2 ) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma  bbbbb2 insulin eeeee2 , C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin,  bbbbb2 C-peptide eeeee2  (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	Fasting plasma  bbbbb1 glucose eeeee1  (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma  bbbbb2 glucagon eeeee2 , and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate  bbbbb1 azidonorleucine eeeee1  bbbbb2 methionyl-tRNA synthetase eeeee2  (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate  bbbbb1 azidonorleucine eeeee1  bbbbb2 MetRS eeeee2 ) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the  bbbbb1 Met eeeee1  bbbbb2 methionyl-tRNA synthetase eeeee2  (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the  bbbbb1 Met eeeee1  bbbbb2 MetRS eeeee2 ) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA( bbbbb1 Met eeeee1  bbbbb2 methionyl-tRNA synthetase eeeee2  (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA( bbbbb1 Met eeeee1  bbbbb2 MetRS eeeee2 ) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate azidonorleucine ( bbbbb1 Anl eeeee1  bbbbb2 methionyl-tRNA synthetase eeeee2  (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected methionyl-tRNA synthetase (MetRS) that charges the Met surrogate azidonorleucine ( bbbbb1 Anl eeeee1  bbbbb2 MetRS eeeee2 ) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected  bbbbb1 methionyl eeeee1  bbbbb2 methionyl-tRNA synthetase eeeee2  (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	The centerpiece of the AND gate is a bisected  bbbbb1 methionyl eeeee1 -tRNA synthetase ( bbbbb2 MetRS eeeee2 ) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met)
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity bbbbb1  eeeee1  bbbbb2  into  eeeee2 the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity bbbbb1  eeeee1  bbbbb2 n o eeeee2 f HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance th bbbbb1 e efficiency of r eeeee1  bbbbb2  into  eeeee2 the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance th bbbbb1 e efficiency of r eeeee1  bbbbb2 n o eeeee2 f HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity bbbbb1  eeeee1  bbbbb2  into  eeeee2 the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Finally, titration of HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity bbbbb1  eeeee1  bbbbb2 n o eeeee2 f HLM into the purified b5R/cyt b5 system did not enhance the efficiency of reduction activity
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP ( bbbbb1 NHOH-PhIP eeeee1  bbbbb2 cyt b5 eeeee2  significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP ( bbbbb1 NHOH-PhIP eeeee1  bbbbb2 b5R eeeee2  or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and  bbbbb1 N-hydroxy-PhIP eeeee1  bbbbb2 cyt b5 eeeee2  significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and  bbbbb1 N-hydroxy-PhIP eeeee1  bbbbb2 b5R eeeee2  or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both  bbbbb1 NHOH-4-ABP eeeee1  bbbbb2 cyt b5 eeeee2  significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both  bbbbb1 NHOH-4-ABP eeeee1  bbbbb2 b5R eeeee2  or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)
CRP11	Reductive detoxification of arylhydroxylamine carcinogens by human  bbbbb1 NADH eeeee1  cytochrome b5 reductase and  bbbbb2 cytochrome b5 eeeee2 
CRP11	Reductive detoxification of arylhydroxylamine carcinogens by human  bbbbb1 NADH eeeee1  bbbbb2 human NADH cytochrome b5 reductase eeeee2  and cytochrome b5
CRP11	On the basis of our findings with structurally similar  bbbbb1 arylhydroxylamine eeeee1  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by  bbbbb2 NADH cytochrome b5 reductase eeeee2  (b5R) and cytochrome b5 (cyt b5)
CRP11	On the basis of our findings with structurally similar  bbbbb1 arylhydroxylamine eeeee1  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and  bbbbb2 cytochrome b5 eeeee2  (cyt b5)
CRP11	On the basis of our findings with structurally similar  bbbbb1 arylhydroxylamine eeeee1  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 ( bbbbb2 cyt b5 eeeee2 )
CRP11	On the basis of our findings with structurally similar  bbbbb1 arylhydroxylamine eeeee1  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase ( bbbbb2 b5R eeeee2 ) and cytochrome b5 (cyt b5)
CRP11	On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by  bbbbb1 NADH eeeee1  bbbbb2 NADH cytochrome b5 reductase eeeee2  (b5R) and cytochrome b5 (cyt b5)
CRP11	On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by  bbbbb1 NADH eeeee1  cytochrome b5 reductase (b5R) and  bbbbb2 cytochrome b5 eeeee2  (cyt b5)
CRP11	On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by  bbbbb1 NADH eeeee1  cytochrome b5 reductase (b5R) and cytochrome b5 ( bbbbb2 cyt b5 eeeee2 )
CRP11	On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by  bbbbb1 NADH eeeee1  cytochrome b5 reductase ( bbbbb2 b5R eeeee2 ) and cytochrome b5 (cyt b5)
CRP11	In the presence of alphaAR blockade, concentration-response curves for isoproterenol, norepinephrine, and  bbbbb1 epinephrine eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In the presence of alphaAR blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol >  bbbbb1 norepinephrine eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In the presence of alphaAR blockade, concentration-response curves for isoproterenol,  bbbbb1 norepinephrine eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In the presence of alphaAR blockade, concentration-response curves for  bbbbb1 isoproterenol eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In the presence of alphaAR blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine =  bbbbb1 epinephrine eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In the presence of alphaAR blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was  bbbbb1 isoproterenol eeeee1  bbbbb2 alphaAR eeeee2  blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a beta1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine
CRP11	In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively) bbbbb1  eeeee1  bbbbb2 nd but eeeee2 oxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)
CRP11	All mammalian isozymes of human (h) or murine (m) origin hCA I-hCA XII, mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM).  bbbbb1 p-Hydroxybenzoic acid eeeee1  bbbbb2 hCA XIV eeeee2  were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM). p-Hydroxybenzoic acid was the best inhibitor of all isozymes (K(I)s of 0.87-35.4 microM) and the different isozymes showed very variable inhibition profiles with these derivatives
CRP11	All mammalian isozymes of human (h) or murine (m) origin hCA I-hCA XII, mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM).  bbbbb1 p-Hydroxybenzoic acid eeeee1  bbbbb2 mCA XIII eeeee2  and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM). p-Hydroxybenzoic acid was the best inhibitor of all isozymes (K(I)s of 0.87-35.4 microM) and the different isozymes showed very variable inhibition profiles with these derivatives
CRP11	All mammalian isozymes of human (h) or murine (m) origin hCA I-hCA XII, mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM).  bbbbb1 p-Hydroxybenzoic acid eeeee1  bbbbb2 hCA XII eeeee2 , mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM). p-Hydroxybenzoic acid was the best inhibitor of all isozymes (K(I)s of 0.87-35.4 microM) and the different isozymes showed very variable inhibition profiles with these derivatives
CRP11	All mammalian isozymes of human (h) or murine (m) origin hCA I-hCA XII, mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM).  bbbbb1 p-Hydroxybenzoic acid eeeee1  bbbbb2 hCA I eeeee2 -hCA XII, mCA XIII and hCA XIV were inhibited in the low micromolar or submicromolar range by these (poly)phenols (K(I)s in the range of 0.87-7.79 microM). p-Hydroxybenzoic acid was the best inhibitor of all isozymes (K(I)s of 0.87-35.4 microM) and the different isozymes showed very variable inhibition profiles with these derivatives
CRP11	Amitriptyline, but not any other tricyclic or selective  bbbbb1 serotonin eeeee1  reuptake inhibitor antidepressants, promotes  bbbbb2 TrkA eeeee2  autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells
CRP11	In this work, we utilized magnetic circular dichroism spectroscopy to explore how the electronic structure of the reduced B12 cofactor (i.e., the post-homolysis product Co2+ Cbl) is modulated by the enzyme  bbbbb1 methylmalonyl-CoA eeeee1  bbbbb2 methylmalonyl-CoA mutase eeeee2 
CRP11	Co-C bond activation in  bbbbb1 methylmalonyl-CoA eeeee1  bbbbb2 methylmalonyl-CoA mutase eeeee2  by stabilization of the post-homolysis product Co2+ cobalamin
CRP11	These effects were associated with increased  bbbbb1 MDA eeeee1  level, lower level of reduced GSH and induction of apoptosis through elevation of  bbbbb2 Bax eeeee2 /Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	These effects were associated with increased  bbbbb1 MDA eeeee1  level, lower level of reduced GSH and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels),  bbbbb2 cytochrome c eeeee2  release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	These effects were associated with increased  bbbbb1 MDA eeeee1  level, lower level of reduced GSH and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation  bbbbb2 caspase 3 eeeee2  in cardiac tissue
CRP11	These effects were associated with increased  bbbbb1 MDA eeeee1  level, lower level of reduced GSH and induction of apoptosis through elevation of Bax/ bbbbb2 Bcl2 eeeee2  ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	These effects were associated with increased MDA level, lower level of reduced  bbbbb1 GSH eeeee1  and induction of apoptosis through elevation of  bbbbb2 Bax eeeee2 /Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	These effects were associated with increased MDA level, lower level of reduced  bbbbb1 GSH eeeee1  and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels),  bbbbb2 cytochrome c eeeee2  release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	These effects were associated with increased MDA level, lower level of reduced  bbbbb1 GSH eeeee1  and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation  bbbbb2 caspase 3 eeeee2  in cardiac tissue
CRP11	These effects were associated with increased MDA level, lower level of reduced  bbbbb1 GSH eeeee1  and induction of apoptosis through elevation of Bax/ bbbbb2 Bcl2 eeeee2  ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by  bbbbb1 DZN eeeee1  bbbbb2 CK-MB eeeee2 , increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased  bbbbb1 GSH eeeee1  content and attenuated the increase of  bbbbb2 Bax eeeee2 /Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased  bbbbb1 GSH eeeee1  content and attenuated the increase of Bax/Bcl2 ratio, activation of  bbbbb2 caspase 3 eeeee2  and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased  bbbbb1 GSH eeeee1  content and attenuated the increase of Bax/ bbbbb2 Bcl2 eeeee2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased  bbbbb1 GSH eeeee1  bbbbb2 CK-MB eeeee2 , increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased  bbbbb1 GSH eeeee1  content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  bbbbb2 cytochrome c eeeee2  to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased  bbbbb1 MDA eeeee1  and CK-MB, increased GSH content and attenuated the increase of  bbbbb2 Bax eeeee2 /Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased  bbbbb1 MDA eeeee1  and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of  bbbbb2 caspase 3 eeeee2  and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased  bbbbb1 MDA eeeee1  and CK-MB, increased GSH content and attenuated the increase of Bax/ bbbbb2 Bcl2 eeeee2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased  bbbbb1 MDA eeeee1  and  bbbbb2 CK-MB eeeee2 , increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased  bbbbb1 MDA eeeee1  and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  bbbbb2 cytochrome c eeeee2  to the cytosol induced by DZN
CRP11	Crocin (25 and 50mg/kg) or  bbbbb1 vitamin E eeeee1  improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  bbbbb2 cytochrome c eeeee2  to the cytosol induced by DZN
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde ( bbbbb1 MDA eeeee1  bbbbb2 CK-MB eeeee2 ), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde ( bbbbb1 MDA eeeee1  bbbbb2 Creatine phosphokinase MB eeeee2  (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB),  bbbbb1 malondealdehyde eeeee1  bbbbb2 CK-MB eeeee2 ), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB),  bbbbb1 malondealdehyde eeeee1  bbbbb2 Creatine phosphokinase MB eeeee2  (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde (MDA) and  bbbbb1 glutathione eeeee1  bbbbb2 CK-MB eeeee2 ), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde (MDA) and  bbbbb1 glutathione eeeee1  bbbbb2 Creatine phosphokinase MB eeeee2  (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	 bbbbb1 Creatine eeeee1  phosphokinase MB ( bbbbb2 CK-MB eeeee2 ), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	 bbbbb1 Creatine eeeee1  bbbbb2 Creatine phosphokinase MB eeeee2  (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde (MDA) and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 CK-MB eeeee2 ), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	Creatine phosphokinase MB (CK-MB), malondealdehyde (MDA) and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 Creatine phosphokinase MB eeeee2  (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments
CRP11	This led to the still controversial hypothesis that LRP5 influences bone formation indirectly by regulating the expression of thp1 and as a consequence influencing the production of  bbbbb1 serotonin eeeee1  bbbbb2 LRP5 eeeee2  influences bone formation indirectly by regulating the expression of thp1 and as a consequence influencing the production of serotonin in the gut
CRP11	This led to the still controversial hypothesis that LRP5 influences bone formation indirectly by regulating the expression of thp1 and as a consequence influencing the production of  bbbbb1 serotonin eeeee1  bbbbb2 thp1 eeeee2  and as a consequence influencing the production of serotonin in the gut
CRP11	No mutations in the  bbbbb1 serotonin eeeee1  related TPH1 and  bbbbb2 HTR1B eeeee2  genes in patients with monogenic sclerosing bone disorders
CRP11	Gene expression studies showed that mice lacking lrp5 have increased expression of tph1, the rate limiting enzyme for the production of  bbbbb1 serotonin eeeee1  bbbbb2 tph1 eeeee2 , the rate limiting enzyme for the production of serotonin in the gut
CRP11	Gene expression studies showed that mice lacking lrp5 have increased expression of tph1, the rate limiting enzyme for the production of  bbbbb1 serotonin eeeee1  bbbbb2 lrp5 eeeee2  have increased expression of tph1, the rate limiting enzyme for the production of serotonin in the gut
CRP11	Furthermore mice lacking either tph1 or htr1B, the receptor for  bbbbb1 serotonin eeeee1  bbbbb2 tph1 eeeee2  or htr1B, the receptor for serotonin on the osteoblasts, were reported to have an increased bone mass due to increased bone formation
CRP11	Furthermore mice lacking either tph1 or htr1B, the receptor for  bbbbb1 serotonin eeeee1  bbbbb2 htr1B eeeee2 , the receptor for serotonin on the osteoblasts, were reported to have an increased bone mass due to increased bone formation
CRP11	Experimental cystathioninuria was induced in rats by administration of the  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine gamma-lyase eeeee2  inhibitor, D,L-propargylglycine
CRP11	Remarkably, TFP binding results in the assembly of five  bbbbb1 Ca(2+) eeeee1 - bbbbb2 S100A4 eeeee2 /TFP dimers into a tightly packed pentameric ring
CRP11	S100A4, a member of the S100 family of  bbbbb1 Ca(2+) eeeee1 -binding proteins, regulates carcinoma cell motility via interactions with  bbbbb2 myosin-IIA eeeee2 
CRP11	S100A4, a member of the S100 family of  bbbbb1 Ca(2+) eeeee1  bbbbb2 S100 eeeee2  family of Ca(2+)-binding proteins, regulates carcinoma cell motility via interactions with myosin-IIA
CRP11	S100A4, a member of the S100 family of  bbbbb1 Ca(2+) eeeee1  bbbbb2 S100A4 eeeee2 , a member of the S100 family of Ca(2+)-binding proteins, regulates carcinoma cell motility via interactions with myosin-IIA
CRP11	To examine the interaction of S100A4 with  bbbbb1 TFP eeeee1 , we determined the 2.3 A crystal structure of human Ca(2+)- bbbbb2 S100A4 eeeee2  bound to TFP
CRP11	To examine the interaction of S100A4 with TFP, we determined the 2.3 A crystal structure of human Ca(2+)-S100A4 bound to  bbbbb1 TFP eeeee1  bbbbb2 S100A4 eeeee2  with TFP, we determined the 2.3 A crystal structure of human Ca(2+)-S100A4 bound to TFP
CRP11	To examine the interaction of S100A4 with TFP, we determined the 2.3 A crystal structure of human  bbbbb1 Ca(2+) eeeee1  bbbbb2 S100A4 eeeee2  with TFP, we determined the 2.3 A crystal structure of human Ca(2+)-S100A4 bound to TFP
CRP11	To examine the interaction of S100A4 with TFP, we determined the 2.3 A crystal structure of human  bbbbb1 Ca(2+) eeeee1 - bbbbb2 S100A4 eeeee2  bound to TFP
CRP11	The  bbbbb1 Ca(2+) eeeee1 - bbbbb2 S100A4 eeeee2 /prochlorperazine (PCP) complex exhibits a similar pentameric assembly
CRP11	Two TFP molecules bind within the hydrophobic target binding pocket of  bbbbb1 Ca(2+) eeeee1 - bbbbb2 S100A4 eeeee2  with no significant conformational changes observed in the protein upon complex formation
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of  bbbbb1 dioxin eeeee1  bbbbb2 Cyp1a1 eeeee2  and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of  bbbbb1 dioxin eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) activation and a warning of dioxin-like toxicity
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of  bbbbb1 dioxin eeeee1  bbbbb2 AhR eeeee2 ) activation and a warning of dioxin-like toxicity
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 Cyp1a1 eeeee2  and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) activation and a warning of dioxin-like toxicity
CRP11	Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 ) activation and a warning of dioxin-like toxicity
CRP11	Induction of cyp1a1 is a nonspecific biomarker of  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 cyp1a1 eeeee2  is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro
CRP11	Induction of cyp1a1 is a nonspecific biomarker of  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro
CRP11	These drugs do not produce dioxin-like toxicity in rats or in humans bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These drugs do not produce dioxin-like toxicity in rats or in humans bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These drugs do not produce dioxin-like toxicity in rats or in humans bbbbb1  eeeee1  bbbbb2 xicity eeeee2  in rats or in humans
CRP11	These drugs do not produce dioxin-like toxicity in rats or in humans bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe  bbbbb1 buspirone eeeee1  bbbbb2 cytochrome P450 3A eeeee2  in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone
CRP11	Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and  bbbbb1 6'-hydroxybuspirone eeeee1  bbbbb2 CYP3A eeeee2  activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone
CRP11	Single dose and 7-day AC administration at 0.125mg/kg had no effect on CYP3A activity since no change in the formation of  bbbbb1 1-(2-pyrimidinyl)piperazine eeeee1  bbbbb2 CYP3A eeeee2  activity since no change in the formation of 1-(2-pyrimidinyl)piperazine and 6'-hydroxybuspirone
CRP11	Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1 -induced apoptosis in U937 cells, whereas  bbbbb2 caspase-3 eeeee2  inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1 -induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 ( bbbbb2 p-p38MAPK eeeee2  inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1  bbbbb2 ERK1/2 eeeee2  inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore,  bbbbb1 PD98059 eeeee1  (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas  bbbbb2 caspase-3 eeeee2  inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore,  bbbbb1 PD98059 eeeee1  (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 ( bbbbb2 p-p38MAPK eeeee2  inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore,  bbbbb1 PD98059 eeeee1  ( bbbbb2 ERK1/2 eeeee2  inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or  bbbbb1 SB203580 eeeee1  bbbbb2 caspase-3 eeeee2  inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or  bbbbb1 SB203580 eeeee1  bbbbb2 ERK1/2 eeeee2  inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells
CRP11	The current study determines the role of mitogen-activated protein kinases (MAPK) in human leukemic U937 cells apoptosis induced by  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1  bbbbb2 MAPK eeeee2 ) in human leukemic U937 cells apoptosis induced by 2-hydroxy-3-methylanthraquinone from H. diffusa
CRP11	The current study determines the role of mitogen-activated protein kinases (MAPK) in human leukemic U937 cells apoptosis induced by  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1  bbbbb2 mitogen-activated protein kinases eeeee2  (MAPK) in human leukemic U937 cells apoptosis induced by 2-hydroxy-3-methylanthraquinone from H. diffusa
CRP11	Our results showed that  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1  decreased phosphorylation-ERK1/2 ( bbbbb2 p-ERK1/2 eeeee2 ), and increased p-p38MAPK, but did not affect expressions of p-JNK1/2 in U937 cells
CRP11	Our results showed that  bbbbb1 2-hydroxy-3-methylanthraquinone eeeee1  decreased phosphorylation- bbbbb2 ERK1/2 eeeee2  (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of p-JNK1/2 in U937 cells
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal  bbbbb1 DA eeeee1  bbbbb2 DA transporter eeeee2  (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal  bbbbb1 DA eeeee1  transporter (DAT) and vesicular monoamine transporter-2 ( bbbbb2 VMAT-2 eeeee2 ) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal  bbbbb1 DA eeeee1  transporter ( bbbbb2 DAT eeeee2 ) and vesicular monoamine transporter-2 (VMAT-2) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal  bbbbb1 DA eeeee1  transporter (DAT) and  bbbbb2 vesicular monoamine transporter-2 eeeee2  (VMAT-2) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular  bbbbb1 monoamine eeeee1  bbbbb2 DA transporter eeeee2  (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular  bbbbb1 monoamine eeeee1  transporter-2 ( bbbbb2 VMAT-2 eeeee2 ) were assessed
CRP11	To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular  bbbbb1 monoamine eeeee1  bbbbb2 DAT eeeee2 ) and vesicular monoamine transporter-2 (VMAT-2) were assessed
CRP11	However, a role for phosphorylation was suggested because pretreatment with protein kinase C inhibitors attenuated the deficit caused by  bbbbb1 MDMA eeeee1  bbbbb2 protein kinase C eeeee2  inhibitors attenuated the deficit caused by MDMA in an in vitro model system
CRP11	In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named Fc11a-2, for the treatment of dextran sulfate  bbbbb1 sodium eeeee1  (DSS)-induced experimental colitis in mice via targeting  bbbbb2 NLRP3 eeeee2  inflammasome
CRP11	In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named Fc11a-2, for the treatment of dextran  bbbbb1 sulfate eeeee1  sodium (DSS)-induced experimental colitis in mice via targeting  bbbbb2 NLRP3 eeeee2  inflammasome
CRP11	The structure shows that the conformation of the H-loop in the PDE5A1- bbbbb1 vardenafil eeeee1  complex is different from those of any known structures of the unliganded  bbbbb2 PDE5 eeeee2  and its complexes with the inhibitors
CRP11	The activation of the complement cascade, a cornerstone of the innate immune response, produces a number of small (74-77  bbbbb1 amino acid eeeee1  bbbbb2 complement eeeee2  cascade, a cornerstone of the innate immune response, produces a number of small (74-77 amino acid) fragments, originally termed anaphylatoxins, that are potent chemoattractants and secretagogues that act on a wide variety of cell types
CRP11	Trilisate also attenuated nasal symptoms in three out of five patients bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Trilisate also attenuated nasal symptoms in three out of fi bbbbb1 ve patien eeeee1 ts bbbbb2  eeeee2 
CRP11	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in  bbbbb1 ASA eeeee1 -intolerant patients, while sodium salicylate, hardly active on  bbbbb2 COX eeeee2  by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in  bbbbb1 ASA eeeee1  bbbbb2 COX eeeee2 ) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in  bbbbb1 ASA eeeee1  bbbbb2 cyclooxygenase eeeee2  (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	 bbbbb1 Aspirin eeeee1  (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on  bbbbb2 COX eeeee2  by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while  bbbbb1 sodium salicylate eeeee1  bbbbb2 COX eeeee2 ) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while  bbbbb1 sodium salicylate eeeee1  bbbbb2 cyclooxygenase eeeee2  (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on  bbbbb2 COX eeeee2  by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs, which are cyclooxygenase ( bbbbb2 COX eeeee2 ) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	Aspirin (ASA) and other non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs, which are  bbbbb2 cyclooxygenase eeeee2  (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients
CRP11	Aspirin ( bbbbb1 ASA eeeee1 ) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on  bbbbb2 COX eeeee2  by itself, is well tolerated by these patients
CRP11	The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that  bbbbb1 dfbp-o eeeee1  bbbbb2 cTnC eeeee2 -cTnI-dfbp-o ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI
CRP11	The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that  bbbbb1 dfbp-o eeeee1  bbbbb2 cTnI eeeee2 -dfbp-o ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI
CRP11	The high resolution NMR solution structure of the cTnC-cTnI- bbbbb1 dfbp-o eeeee1  ternary complex showed that dfbp-o bound at the hydrophobic interface formed by  bbbbb2 cTnC eeeee2  and cTnI making critical interactions with residues such as Arg147 of cTnI
CRP11	The high resolution NMR solution structure of the cTnC-cTnI- bbbbb1 dfbp-o eeeee1  ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and  bbbbb2 cTnI eeeee2  making critical interactions with residues such as Arg147 of cTnI
CRP11	The high resolution NMR solution structure of the cTnC-cTnI- bbbbb1 dfbp-o eeeee1  ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of  bbbbb2 cTnI eeeee2 
CRP11	A structural and functional perspective into the mechanism of  bbbbb1 Ca2+ eeeee1 -sensitizers that target the cardiac  bbbbb2 troponin complex eeeee2 
CRP11	In the absence of cTnI, docking localized dfbp-o to the same position in  bbbbb1 the hy eeeee1 drophobic groove of cTnC bbbbb2  eeeee2 
CRP11	In the absence of cTnI, docking localized dfbp-o to the same position in  bbbbb1 the hy eeeee1 drophobic groove of cTnC bbbbb2  eeeee2 
CRP11	In the absence of cTnI, docking localized dfbp-o to the same position in  bbbbb1 the hy eeeee1 drophobic groove of cTnC bbbbb2  eeeee2 
CRP11	When these inhibition studies were performed with the artificial oxidant  bbbbb1 tert-butyl hydroperoxide eeeee1 ,  bbbbb2 CYP2E1 eeeee2  did not significantly inhibit CYP2B4 activity
CRP11	When these inhibition studies were performed with the artificial oxidant  bbbbb1 tert-butyl hydroperoxide eeeee1 , CYP2E1 did not significantly inhibit  bbbbb2 CYP2B4 eeeee2  activity
CRP11	Interactions between CYP2E1 and CYP2B4: effects on affinity for  bbbbb1 NADPH eeeee1  bbbbb2 CYP2B4 eeeee2 : effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism
CRP11	Interactions between CYP2E1 and CYP2B4: effects on affinity for  bbbbb1 NADPH eeeee1  bbbbb2 CYP2E1 eeeee2  and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism
CRP11	Interactions between CYP2E1 and CYP2B4: effects on affinity for  bbbbb1 NADPH eeeee1  bbbbb2 NADPH-cytochrome P450 reductase eeeee2  and substrate metabolism
CRP11	However, CYP2B4 is not an inhibitor of CYP2E1-mediated  bbbbb1 p-nitrophenol eeeee1  bbbbb2 CYP2B4 eeeee2  is not an inhibitor of CYP2E1-mediated p-nitrophenol hydroxylation
CRP11	The results show that CYP2E1 inhibits CYP2B4-mediated metabolism of benzphetamine ( bbbbb1 BNZ eeeee1  bbbbb2 CYP2E1 eeeee2  inhibits CYP2B4-mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 µM
CRP11	The results show that CYP2E1 inhibits CYP2B4-mediated metabolism of  bbbbb1 benzphetamine eeeee1  bbbbb2 CYP2E1 eeeee2  inhibits CYP2B4-mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 µM
CRP11	Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of  bbbbb1 Na(+) eeeee1  bbbbb2 NCX eeeee2  inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular  bbbbb1 Na(+) eeeee1  bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/Ca(2+) exchanger eeeee2  (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The  bbbbb1 Na(+) eeeee1 /Ca(2+) exchanger ( bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/Ca(2+) exchanger eeeee2  (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) ( bbbbb1 Na(+) eeeee1  bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) ( bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/Ca(2+) exchanger eeeee2  (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes  bbbbb1 Ca(2+) eeeee1  bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/ bbbbb1 Ca(2+) eeeee1  exchanger ( bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/ bbbbb1 Ca(2+) eeeee1  bbbbb2 Na(+)/Ca(2+) exchanger eeeee2  (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings  bbbbb1 Ca(2+) eeeee1  bbbbb2 NCX eeeee2 ) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization
CRP11	It is possible that this property is partly responsible for their antiarrhythmic and cardioprotective effects bbbbb1  eeeee1  bbbbb2 hyt eeeee2 hmic and cardioprotective effects
CRP11	The pharmacology of NCX inhibitors has been studied extensively since the development of  bbbbb1 KB-R7943 eeeee1  bbbbb2 NCX eeeee2  inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996
CRP11	The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype  bbbbb1 benzyloxyphenyl eeeee1  bbbbb2 NCX eeeee2  inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996
CRP11	Allicin treatment showed reduced production of pro-inflammatory cytokines and  bbbbb1 NO eeeee1  bbbbb2 cytokines eeeee2  and NO and increased HO-1 activity
CRP11	Allicin treatment showed reduced production of pro-inflammatory cytokines and  bbbbb1 NO eeeee1  and increased  bbbbb2 HO-1 eeeee2  activity
CRP11	Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of NO and pro-inflammatory cytokines by downregulating  bbbbb1 allicin eeeee1  bbbbb2 cytokines eeeee2  by downregulating allicin activity in RAW 264.7 macrophages
CRP11	Short-term heating reduces the anti-inflammatory effects of fresh raw garlic extracts on the LPS-induced production of  bbbbb1 NO eeeee1  and pro-inflammatory  bbbbb2 cytokines eeeee2  by downregulating allicin activity in RAW 264.7 macrophages
CRP11	Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and  bbbbb1 NO eeeee1  bbbbb2 cytokine eeeee2  concentration (TNF-α, IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages
CRP11	Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and  bbbbb1 NO eeeee1  bbbbb2 TNF-α eeeee2 , IL-1β, and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages
CRP11	Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and  bbbbb1 NO eeeee1  bbbbb2 IL-1β eeeee2 , and IL-6) and NO through HO-1 upregulation in RAW 264.7 macrophages
CRP11	Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and  bbbbb1 NO eeeee1  bbbbb2 IL-6 eeeee2 ) and NO through HO-1 upregulation in RAW 264.7 macrophages
CRP11	Treatment with FRGE and HRGE significantly reduced the LPS-induced increase in the pro-inflammatory cytokine concentration (TNF-α, IL-1β, and IL-6) and  bbbbb1 NO eeeee1  through  bbbbb2 HO-1 eeeee2  upregulation in RAW 264.7 macrophages
CRP11	The results show that the decrease in LPS-induced  bbbbb1 NO eeeee1  and pro-inflammatory cytokines in RAW 264.7 macrophages through  bbbbb2 HO-1 eeeee2  induction was greater for FRGE compared with HRGE
CRP11	The results show that the decrease in LPS-induced  bbbbb1 NO eeeee1  and pro-inflammatory  bbbbb2 cytokines eeeee2  in RAW 264.7 macrophages through HO-1 induction was greater for FRGE compared with HRGE
CRP11	Within the class of  bbbbb1 AII eeeee1  bbbbb2 AII eeeee2  blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action
CRP11	Within the class of AII blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non- bbbbb1 tetrazole eeeee1  bbbbb2 AII eeeee2  blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action
CRP11	Within the class of AII blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non- bbbbb1 biphenyl eeeee1  bbbbb2 AII eeeee2  blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action
CRP11	Angiotensin II ( bbbbb1 AII eeeee1 ) receptor antagonists are a relatively new class of antihypertensive agent that block  bbbbb2 AII Type 1 (AT(1)) receptors eeeee2 , and reduce the pressor effects of AII in the vasculature
CRP11	Angiotensin II ( bbbbb1 AII eeeee1 ) receptor antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb2 AII eeeee2  in the vasculature
CRP11	Angiotensin II ( bbbbb1 AII eeeee1  bbbbb2 Angiotensin II (AII) receptor eeeee2  antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of AII in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  (AII) receptor antagonists are a relatively new class of antihypertensive agent that block  bbbbb2 AII Type 1 (AT(1)) receptors eeeee2 , and reduce the pressor effects of AII in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  (AII) receptor antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb2 AII eeeee2  in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  bbbbb2 Angiotensin II (AII) receptor eeeee2  antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of AII in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb1 AII eeeee1  bbbbb2 AII Type 1 (AT(1)) receptors eeeee2 , and reduce the pressor effects of AII in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb1 AII eeeee1  bbbbb2 AII eeeee2  in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb1 AII eeeee1  bbbbb2 Angiotensin II (AII) receptor eeeee2  antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of AII in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block  bbbbb1 AII eeeee1  bbbbb2 AII Type 1 (AT(1)) receptors eeeee2 , and reduce the pressor effects of AII in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block  bbbbb1 AII eeeee1  Type 1 (AT(1)) receptors, and reduce the pressor effects of  bbbbb2 AII eeeee2  in the vasculature
CRP11	Angiotensin II (AII) receptor antagonists are a relatively new class of antihypertensive agent that block  bbbbb1 AII eeeee1  bbbbb2 Angiotensin II (AII) receptor eeeee2  antagonists are a relatively new class of antihypertensive agent that block AII Type 1 (AT(1)) receptors, and reduce the pressor effects of AII in the vasculature
CRP11	Eprosartan acts at vascular AT(1) receptors (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated  bbbbb1 noradrenaline eeeee1  bbbbb2 AT(1) receptors eeeee2 , where it inhibits sympathetically stimulated noradrenaline release
CRP11	Eprosartan acts at vascular AT(1) receptors (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated  bbbbb1 noradrenaline eeeee1  bbbbb2 AT(1) receptors eeeee2  (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated noradrenaline release
CRP11	By this mechanism, they induce similar pharmacological effects compared with  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors, resulting in a lowering of blood pressure
CRP11	By this mechanism, they induce similar pharmacological effects compared with  bbbbb1 angiotensin eeeee1 -converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors, resulting in a lowering of blood pressure
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to  bbbbb1 bradykinin eeeee1  or other mediators such as s bbbbb2 ubstance P eeeee2 
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to  bbbbb1 bradykinin eeeee1  bbbbb2 bradykinin eeeee2  or other mediators such as substance P
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to  bbbbb1 bradykinin eeeee1  bbbbb2 ACE eeeee2  inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to  bbbbb1 bradykinin eeeee1  bbbbb2 AII receptor eeeee2  blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as  bbbbb1 substance P eeeee1  bbbbb2 ubstance P eeeee2 
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as  bbbbb1 substance P eeeee1  bbbbb2 bradykinin eeeee2  or other mediators such as substance P
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as  bbbbb1 substance P eeeee1  bbbbb2 ACE eeeee2  inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as  bbbbb1 substance P eeeee1  bbbbb2 AII receptor eeeee2  blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	However,  bbbbb1 AII eeeee1  receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as s bbbbb2 ubstance P eeeee2 
CRP11	However,  bbbbb1 AII eeeee1  receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to  bbbbb2 bradykinin eeeee2  or other mediators such as substance P
CRP11	However,  bbbbb1 AII eeeee1  receptor blockers differ from  bbbbb2 ACE eeeee2  inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	However,  bbbbb1 AII eeeee1  bbbbb2 AII receptor eeeee2  blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1 ) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1 ) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1 ) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1 ) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid ( bbbbb1 KA eeeee1  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and  bbbbb1 kainate eeeee1  preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb1 AMPA eeeee1  receptor agonist with moderate affinity for native  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb1 AMPA eeeee1  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at  bbbbb1 AMPA eeeee1  and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb1 KA eeeee1  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas  bbbbb1 (S)-E-4-(2,2-dimethylpropylidene)glutamic acid eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas  bbbbb1 (S)-E-4-(2,2-dimethylpropylidene)glutamic acid eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas  bbbbb1 (S)-E-4-(2,2-dimethylpropylidene)glutamic acid eeeee1  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of  bbbbb1 4-heteroarylmethylidene glutamate eeeee1  analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues.  bbbbb1 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid eeeee1  (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues.  bbbbb1 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid eeeee1  (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues.  bbbbb1 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid eeeee1  (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues.  bbbbb1 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues.  bbbbb1 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid eeeee1  (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb1 kainic acid eeeee1  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the  bbbbb2 GluR5 eeeee2  subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the  bbbbb2 GluR2 eeeee2  subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  bbbbb2 AMPA receptors eeeee2 
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent  bbbbb2 AMPA receptor eeeee2  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  bbbbb2 glutamate receptors eeeee2  of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of  bbbbb2 KA receptors eeeee2  and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	Synthesis and in vitro pharmacology at AMPA and kainate preferring  bbbbb1 glutamate eeeee1  receptors of 4-heteroarylmethylidene glutamate analogues. 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native  bbbbb2 kainic acid (KA) receptors eeeee2 , whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the  bbbbb1 AMPA eeeee1  bbbbb2 GluR5 eeeee2  receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the AMPA receptor subtypes GluR1-4 with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the  bbbbb1 AMPA eeeee1  receptor subtypes  bbbbb2 GluR1-4 eeeee2  with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the  bbbbb1 AMPA eeeee1  bbbbb2 GluR5 eeeee2  agonist and a high affinity ligand and to indiscriminately bind to the AMPA receptor subtypes GluR1-4 with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  subtypes GluR1-4 with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors,  bbbbb1 (S)-E-4-(2-thiazolylmethylene)glutamic acid eeeee1  bbbbb2 GluR5 eeeee2  receptors, (S)-E-4-(2-thiazolylmethylene)glutamic acid (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the AMPA receptor subtypes GluR1-4 with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors,  bbbbb1 (S)-E-4-(2-thiazolylmethylene)glutamic acid eeeee1  (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the AMPA receptor subtypes  bbbbb2 GluR1-4 eeeee2  with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors,  bbbbb1 (S)-E-4-(2-thiazolylmethylene)glutamic acid eeeee1  (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent  bbbbb2 GluR5 eeeee2  agonist and a high affinity ligand and to indiscriminately bind to the AMPA receptor subtypes GluR1-4 with lower affinities
CRP11	As an attempt to develop new pharmacological tools for studies of GluR5 receptors,  bbbbb1 (S)-E-4-(2-thiazolylmethylene)glutamic acid eeeee1  (4a) was designed as a structural hybrid between 1 and 3. 4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the  bbbbb2 AMPA receptor eeeee2  subtypes GluR1-4 with lower affinities
CRP11	One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of  bbbbb1 acetylcholine eeeee1  bbbbb2 cholinesterase eeeee2  inhibitors to delay the breakdown of acetylcholine released into synaptic clefts
CRP11	Imatinib was also found to inhibit M-CSF-in bbbbb1 duced os eeeee1 teoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effe bbbbb2 ct on eeeee2  interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS
CRP11	Our findings demonstrate that  bbbbb1 imatinib eeeee1  dose-dependently stimulates osteoclast apoptosis, a phenomenon which is blocked by the  bbbbb2 caspase I eeeee2  inhibitor Z-VAD-fmk
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor,  bbbbb2 c-FMS eeeee2 
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  kinase BCR- bbbbb2 ABL eeeee2  and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  bbbbb2 kinase eeeee2  inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  kinase  bbbbb2 BCR eeeee2 -ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  kinase BCR-ABL and the  bbbbb2 platelet derived growth factor (PDGF) receptor eeeee2 , is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS
CRP11	Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular  bbbbb1 tyrosine eeeee1  kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the  bbbbb2 macrophage colony stimulating factor (M-CSF) receptor eeeee2 , c-FMS
CRP11	Synthesis and biological evaluation of phosphorylated flavonoids as potent and selective inhibitors of  bbbbb1 cholesterol eeeee1  bbbbb2 cholesterol esterase eeeee2 
CRP11	A series of phosphorylated flavonoids were synthesized and investigated in vitro as inhibitors of pancreatic  bbbbb1 cholesterol eeeee1  esterase (CEase) and acetylcholinesterase ( bbbbb2 AChE eeeee2 )
CRP11	A series of phosphorylated flavonoids were synthesized and investigated in vitro as inhibitors of pancreatic  bbbbb1 cholesterol eeeee1  bbbbb2 cholesterol esterase eeeee2  (CEase) and acetylcholinesterase (AChE)
CRP11	A series of phosphorylated flavonoids were synthesized and investigated in vitro as inhibitors of pancreatic  bbbbb1 cholesterol eeeee1  esterase ( bbbbb2 CEase eeeee2 ) and acetylcholinesterase (AChE)
CRP11	A series of phosphorylated flavonoids were synthesized and investigated in vitro as inhibitors of pancreatic  bbbbb1 cholesterol eeeee1  esterase (CEase) and  bbbbb2 acetylcholinesterase eeeee2  (AChE)
CRP11	Striatum/cerebellum and striatum/occipital cortex ratios of count rate density were calculated as a semiquantitative measurement for striatal  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2-receptor eeeee2  binding potential
CRP11	No differences were found in striatal uptake of 123I-IBZM between heal bbbbb1 thy cont eeeee1  bbbbb2 thy controls and the  eeeee2 patients when on or off ergotamine
CRP11	Dopamine D2-receptor imaging with  bbbbb1 123I-iodobenzamide eeeee1  SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb2 dopamine D2-receptor eeeee2  specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb1 dopamine eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2-receptor eeeee2  specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing  bbbbb1 ergotamine eeeee1 : does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb2 dopamine D2-receptor eeeee2  specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide ( bbbbb1 123I-IBZM eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does  bbbbb1 ergotamine eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does  bbbbb1 ergotamine eeeee1  cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb2 dopamine D2-receptor eeeee2  specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	 bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	 bbbbb1 Dopamine eeeee1  D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the  bbbbb2 dopamine D2-receptor eeeee2  specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during  bbbbb1 ergotamine eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand  bbbbb1 123I-3-iodo-6-methoxybenzamide eeeee1  bbbbb2 Dopamine D2-receptor eeeee2  imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal
CRP11	After 10 days of treatment, basal ANP was increased and basal  bbbbb1 aldosterone eeeee1  bbbbb2 ANP eeeee2  was increased and basal aldosterone was decreased
CRP11	 bbbbb1 Candoxatril eeeee1  is a novel, orally active inhibitor of neutral endopeptidase EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide ( bbbbb2 ANP eeeee2 )
CRP11	 bbbbb1 Candoxatril eeeee1  is a novel, orally active inhibitor of neutral endopeptidase EC 3.4.24.11, the enzyme that degrades  bbbbb2 atrial natriuretic peptide eeeee2  (ANP)
CRP11	On study day 1, candoxatril acutely increased plasma ANP levels, suppressed  bbbbb1 aldosterone eeeee1  bbbbb2 ANP eeeee2  levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures
CRP11	Acromegaly: molecular expression of  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor eeeee2  subtypes and treatment outcome
CRP11	Such resistance is related to an overall reduction of  bbbbb1 somatostatin eeeee1  receptor ( bbbbb2 SSTR eeeee2 ) density or to a differentiated expression of SSTR subtypes
CRP11	Such resistance is related to an overall reduction of  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor eeeee2  (SSTR) density or to a differentiated expression of SSTR subtypes
CRP11	Such resistance is related to an overall reduction of  bbbbb1 somatostatin eeeee1  receptor (SSTR) density or to a differentiated expression of  bbbbb2 SSTR eeeee2  subtypes
CRP11	R2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and  bbbbb1 lanreotide eeeee1  bbbbb2 GH eeeee2 -secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5
CRP11	R2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and  bbbbb1 lanreotide eeeee1  bbbbb2 SSTR5 eeeee2  are usually expressed in GH-secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5
CRP11	R2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both  bbbbb1 octreotide eeeee1  bbbbb2 GH eeeee2 -secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5
CRP11	R2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both  bbbbb1 octreotide eeeee1  bbbbb2 SSTR5 eeeee2  are usually expressed in GH-secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5
CRP11	SA inhibitory effects on GH  bbbbb1 secretion an eeeee1 d tumor cell proliferation can occur together or be dissociated events, depending on the tumor expression of SSTR subtypes in bbbbb2 volved in each mec eeeee2 hanism
CRP11	SA inhibitory effects on GH  bbbbb1 secretion an eeeee1 d tumor cell proliferation can occur toget bbbbb2 her o eeeee2 r be dissociated events, depending on the tumor expression of SSTR subtypes involved in each mechanism
CRP11	SA inhibitory effects on GH  bbbbb1 secretion an eeeee1 d tumor cell proliferation can bbbbb2  occu eeeee2 r together or be dissociated events, depending on the tumor expression of SSTR subtypes involved in each mechanism
CRP11	SA inhibitory effects on GH  bbbbb1 secretion an eeeee1 d tumor cell proliferation can occur together or bbbbb2  be d eeeee2 issociated events, depending on the tumor expression of SSTR subtypes involved in each mechanism
CRP11	 bbbbb1 VP-16 eeeee1  induced the release of IL-8, and addition of MXF reduced enhanced release and the spontaneous release of  bbbbb2 VEGF eeeee2  from the cells
CRP11	The aim of this study was to investigate the effects of moxifloxacin ( bbbbb1 MXF eeeee1 ) and VP-16 on cellular  bbbbb2 topo II eeeee2  activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells
CRP11	The aim of this study was to investigate the effects of  bbbbb1 moxifloxacin eeeee1  (MXF) and VP-16 on cellular  bbbbb2 topo II eeeee2  activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells
CRP11	The aim of this study was to investigate the effects of moxifloxacin (MXF) and VP-16 on cellular topo II activity in drug-treated cells and evaluate the influence of  bbbbb1 MXF eeeee1  bbbbb2 topo II eeeee2  activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells
CRP11	The aim of this study was to investigate the effects of moxifloxacin (MXF) and  bbbbb1 VP-16 eeeee1  on cellular  bbbbb2 topo II eeeee2  activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells
CRP11	The aim of this study was to investigate the effects of moxifloxacin (MXF) and VP-16 on cellular topo II activity in drug-treated cells and evaluate the influence of MXF on the mode of action of  bbbbb1 VP-16 eeeee1  bbbbb2 topo II eeeee2  activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells
CRP11	Apoptosis studies ( bbbbb1 DAPI eeeee1  staining and  bbbbb2 caspase 3 eeeee2  activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis ( bbbbb1 DAPI eeeee1 -sulforhodamine staining and caspase 3 activity) and  bbbbb2 IL-8 eeeee2  and VEGF secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis ( bbbbb1 DAPI eeeee1 -sulforhodamine staining and caspase 3 activity) and IL-8 and  bbbbb2 VEGF eeeee2  secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis ( bbbbb1 DAPI eeeee1 -sulforhodamine staining and  bbbbb2 caspase 3 eeeee2  activity) and IL-8 and VEGF secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay ( bbbbb1 MTT eeeee1 ), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI-sulforhodamine staining and caspase 3 activity) and  bbbbb2 IL-8 eeeee2  and VEGF secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay ( bbbbb1 MTT eeeee1 ), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI-sulforhodamine staining and caspase 3 activity) and IL-8 and  bbbbb2 VEGF eeeee2  secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay ( bbbbb1 MTT eeeee1 ), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI-sulforhodamine staining and  bbbbb2 caspase 3 eeeee2  activity) and IL-8 and VEGF secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI- bbbbb1 sulforhodamine eeeee1  staining and caspase 3 activity) and  bbbbb2 IL-8 eeeee2  and VEGF secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI- bbbbb1 sulforhodamine eeeee1  staining and caspase 3 activity) and IL-8 and  bbbbb2 VEGF eeeee2  secretion were determined
CRP11	Decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (cell cycle and survivin expression), apoptosis (DAPI- bbbbb1 sulforhodamine eeeee1  staining and  bbbbb2 caspase 3 eeeee2  activity) and IL-8 and VEGF secretion were determined
CRP11	Moxifloxacin enhances  bbbbb1 etoposide eeeee1 -induced cytotoxic, apoptotic and anti- bbbbb2 topoisomerase II eeeee2  effects in a human colon carcinoma cell line
CRP11	 bbbbb1 Moxifloxacin eeeee1  enhances etoposide-induced cytotoxic, apoptotic and anti- bbbbb2 topoisomerase II eeeee2  effects in a human colon carcinoma cell line
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 proteinase eeeee2 , disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 disintegrin domain eeeee2 ; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 pro domain eeeee2  and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 pro eeeee2 , proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 SVMPs eeeee2 , have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 SVMPs eeeee2 , molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 SVMPs eeeee2 , have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 cysteine-rich domain eeeee2  structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 proteinase domain eeeee2 ; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 pro domain eeeee2 , proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 disintegrin-like eeeee2  and cysteine-rich domain structure
CRP11	The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P-I), the small SVMPs, have molecular masses of 20-30 kDa, contain only a pro domain and the proteinase domain; Class II (P-II), the medium size SVMPs, molecular masses of 30-60 kDa, contain the pro domain, proteinase domain and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and  bbbbb1 cysteine eeeee1  bbbbb2 proteinase domain eeeee2  and disintegrin domain; Class III (P-III), the large SVMPs, have molecular masses of 60-100 kDa, contain pro, proteinase, disintegrin-like and cysteine-rich domain structure
CRP11	Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by  bbbbb1 lisuride eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD
CRP11	Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD
CRP11	Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by  bbbbb1 LSD eeeee1  bbbbb2 5-HT(1A) eeeee2  antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD
CRP11	Nevertheless, this action has generally been ignored in the mechanism of action of  bbbbb1 lisuride eeeee1 , in favor of an exclusive role for dopamine receptors in considering its antiparkinsonian effects, or an exclusive role of  bbbbb2 5-HT(2A/2C) eeeee2  receptor activation in hallucinogenesis
CRP11	Nevertheless, this action has generally been ignored in the mechanism of action of lisuride, in favor of an exclusive role for  bbbbb1 dopamine eeeee1  bbbbb2 dopamine receptors eeeee2  in considering its antiparkinsonian effects, or an exclusive role of 5-HT(2A/2C) receptor activation in hallucinogenesis
CRP11	Nevertheless, this action has generally been ignored in the mechanism of action of lisuride, in favor of an exclusive role for  bbbbb1 dopamine eeeee1  receptors in considering its antiparkinsonian effects, or an exclusive role of  bbbbb2 5-HT(2A/2C) eeeee2  receptor activation in hallucinogenesis
CRP11	In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and  bbbbb1 DOI eeeee1  bbbbb2 5-HT(1A) eeeee2  agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine
CRP11	In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for  bbbbb1 (+)-amphetamine eeeee1  bbbbb2 5-HT(1A) eeeee2  agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine
CRP11	In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for  bbbbb1 LSD eeeee1  bbbbb2 5-HT(1A) eeeee2  agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 ( bbbbb2 mTORC1 eeeee2 ) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 AMPK eeeee2 ) activation by 2-deoxyglucose on protein synthesis and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by  bbbbb1 2-deoxyglucose eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) activation by 2-deoxyglucose on protein synthesis and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by  bbbbb1 2-deoxyglucose eeeee1  on protein synthesis and the mammalian target of rapamycin complex 1 ( bbbbb2 mTORC1 eeeee2 ) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by  bbbbb1 2-deoxyglucose eeeee1  bbbbb2 AMPK eeeee2 ) activation by 2-deoxyglucose on protein synthesis and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	The objective of this study was to examine the effect of AMP-activated protein kinase (AMPK) activation by  bbbbb1 2-deoxyglucose eeeee1  on protein synthesis and the  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1) signaling pathway in bovine mammary epithelial cells
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of 2-deoxyglucose exposure.  bbbbb1 2-Deoxyglucose eeeee1  bbbbb2 eIF2α eeeee2  was also increased but only at 30 min of 2-deoxyglucose exposure. 2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of  bbbbb1 2-deoxyglucose eeeee1  exposure. 2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 ( bbbbb2 TSC2 eeeee2 ) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of  bbbbb1 2-deoxyglucose eeeee1  exposure. 2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of  bbbbb2 TSC1 eeeee2  bound to TSC2
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of  bbbbb1 2-deoxyglucose eeeee1  exposure. 2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on  bbbbb2 AMPK eeeee2  consensus sites but did not change the amount of TSC1 bound to TSC2
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of  bbbbb1 2-deoxyglucose eeeee1  exposure. 2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to  bbbbb2 TSC2 eeeee2 
CRP11	Phosphorylation of ER-stress marker eIF2α was also increased but only at 30 min of  bbbbb1 2-deoxyglucose eeeee1  exposure. 2-Deoxyglucose increased phosphorylation of  bbbbb2 tuberous sclerosis complex 2 eeeee2  (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2
CRP11	The CBC physically associates with these complexes to recruit them during transcription and mediates phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 CBC eeeee2  physically associates with these complexes to recruit them during transcription and mediates phosphorylation at Ser-2 of the C-terminal domain (CTD) of RNA polymerase II
CRP11	The CBC physically associates with these complexes to recruit them during transcription and mediates phosphorylation at Ser-2 of the  bbbbb1 C eeeee1  bbbbb2 CBC eeeee2  physically associates with these complexes to recruit them during transcription and mediates phosphorylation at Ser-2 of the C-terminal domain (CTD) of RNA polymerase II
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of  bbbbb1 polyamines eeeee1 , such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell.  bbbbb1 bis(Ethyl) oligoamine eeeee1  analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the  bbbbb1 spermidine eeeee1  and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and  bbbbb1 SL-11158 eeeee1 , as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of  bbbbb1 spermine eeeee1  at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a  bbbbb1 bis(phenylbenzyl) eeeee1  3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as  bbbbb1 SL-11144 eeeee1  and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as  bbbbb1 arylamine eeeee1  analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [ bbbbb1 BW-1 eeeee1 , a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for  bbbbb2 PAO eeeee2 
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and  bbbbb1 polyamine eeeee1  oxidase ( bbbbb2 PAO eeeee2 )
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and  bbbbb1 polyamine eeeee1  bbbbb2 polyamine oxidase eeeee2  (PAO)
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and  bbbbb1 polyamine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and polyamine oxidase (PAO)
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and  bbbbb1 polyamine eeeee1  bbbbb2 SSAT eeeee2 ) and polyamine oxidase (PAO)
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine  bbbbb1 N(1) eeeee1 -acetyltransferase (SSAT) and polyamine oxidase ( bbbbb2 PAO eeeee2 )
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine  bbbbb1 N(1) eeeee1 -acetyltransferase (SSAT) and  bbbbb2 polyamine oxidase eeeee2  (PAO)
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine  bbbbb1 N(1) eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and polyamine oxidase (PAO)
CRP11	Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine  bbbbb1 N(1) eeeee1 -acetyltransferase ( bbbbb2 SSAT eeeee2 ) and polyamine oxidase (PAO)
CRP11	In the present study, we determined the dose-response effects of doxycycline and  bbbbb1 minocycline eeeee1  on cerebral MMP-9 using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (Ad bbbbb2 VEGF eeeee2 ) in the brain
CRP11	In the present study, we determined the dose-response effects of doxycycline and  bbbbb1 minocycline eeeee1  on cerebral  bbbbb2 MMP-9 eeeee2  using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain
CRP11	In the present study, we determined the dose-response effects of doxycycline and  bbbbb1 minocycline eeeee1  on cerebral MMP-9 using our mouse model with  bbbbb2 VEGF eeeee2  focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain
CRP11	In the present study, we determined the dose-response effects of  bbbbb1 doxycycline eeeee1  and minocycline on cerebral MMP-9 using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (Ad bbbbb2 VEGF eeeee2 ) in the brain
CRP11	In the present study, we determined the dose-response effects of  bbbbb1 doxycycline eeeee1  and minocycline on cerebral  bbbbb2 MMP-9 eeeee2  using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain
CRP11	In the present study, we determined the dose-response effects of  bbbbb1 doxycycline eeeee1  and minocycline on cerebral MMP-9 using our mouse model with  bbbbb2 VEGF eeeee2  focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain
CRP11	Dose-response effect of  bbbbb1 tetracyclines eeeee1  on cerebral matrix metalloproteinase-9 after  bbbbb2 vascular endothelial growth factor eeeee2  hyperstimulation
CRP11	Dose-response effect of  bbbbb1 tetracyclines eeeee1  on cerebral  bbbbb2 matrix metalloproteinase-9 eeeee2  after vascular endothelial growth factor hyperstimulation
CRP11	Results from 4'-6-diamidino-2-phenylindole and annexin-V/PI double-staining assay showed that caspase-3- and caspase-8-dependent, and dose-dependent apoptoses were detected after a 24-h  bbbbb1 dioscin eeeee1  bbbbb2 caspase-3 eeeee2 - and caspase-8-dependent, and dose-dependent apoptoses were detected after a 24-h dioscin treatment
CRP11	Results from 4'-6-diamidino-2-phenylindole and annexin-V/PI double-staining assay showed that caspase-3- and caspase-8-dependent, and dose-dependent apoptoses were detected after a 24-h  bbbbb1 dioscin eeeee1  bbbbb2 caspase-8 eeeee2 -dependent, and dose-dependent apoptoses were detected after a 24-h dioscin treatment
CRP11	Results from  bbbbb1 4'-6-diamidino-2-phenylindole eeeee1  and annexin-V/PI double-staining assay showed that  bbbbb2 caspase-3 eeeee2 - and caspase-8-dependent, and dose-dependent apoptoses were detected after a 24-h dioscin treatment
CRP11	Results from  bbbbb1 4'-6-diamidino-2-phenylindole eeeee1  and annexin-V/PI double-staining assay showed that caspase-3- and  bbbbb2 caspase-8 eeeee2 -dependent, and dose-dependent apoptoses were detected after a 24-h dioscin treatment
CRP11	The contractions to  bbbbb1 5-HT eeeee1  were inhibited by ketanserin and alosetron indicating involvement of  bbbbb2 5-HT(2A) eeeee2  and 5-HT(3) receptors, respectively
CRP11	The contractions to  bbbbb1 5-HT eeeee1  were inhibited by ketanserin and alosetron indicating involvement of 5-HT(2A) and  bbbbb2 5-HT(3) eeeee2  receptors, respectively
CRP11	The contractions to 5-HT were inhibited by  bbbbb1 ketanserin eeeee1  and alosetron indicating involvement of 5-HT(2A) and  bbbbb2 5-HT(3) eeeee2  receptors, respectively
CRP11	The contractions to 5-HT were inhibited by ketanserin and  bbbbb1 alosetron eeeee1  indicating involvement of  bbbbb2 5-HT(2A) eeeee2  and 5-HT(3) receptors, respectively
CRP11	However, only MDMA reduced SERT density bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, only MDMA reduced SERT density bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Low levels of serotonin may reduce the density of the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  (SERT) by either increasing trafficking or reducing synthesis; a "neuroadaptive response"
CRP11	Low levels of serotonin may reduce the density of the  bbbbb1 serotonin eeeee1  transporter ( bbbbb2 SERT eeeee2 ) by either increasing trafficking or reducing synthesis; a "neuroadaptive response"
CRP11	MA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  densities
CRP11	MA- and p-chlorophenylalanine-induced reduction in  bbbbb1 5-HT eeeee1  concentrations: effects on  bbbbb2 serotonin transporter eeeee2  densities
CRP11	MA- and  bbbbb1 p-chlorophenylalanine eeeee1 -induced reduction in 5-HT concentrations: effects on  bbbbb2 serotonin transporter eeeee2  densities
CRP11	To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or  bbbbb1 MDMA eeeee1  bbbbb2 SERT eeeee2  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured
CRP11	To determine whether 3,4-methylenedioxymethamphetamine ( bbbbb1 MDMA eeeee1 )-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and  bbbbb2 SERT eeeee2  density were measured
CRP11	To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain  bbbbb1 serotonin eeeee1  and  bbbbb2 SERT eeeee2  density were measured
CRP11	To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain  bbbbb1 serotonin eeeee1  bbbbb2 SERT eeeee2  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured
CRP11	To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism,  bbbbb1 p-chlorophenylalanine eeeee1  bbbbb2 SERT eeeee2  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured
CRP11	To determine whether  bbbbb1 3,4-methylenedioxymethamphetamine eeeee1  (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and  bbbbb2 SERT eeeee2  density were measured
CRP11	Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect methyltransferase inhibitor  bbbbb1 periodate eeeee1  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of  bbbbb1 DMAs(V) eeeee1  and the accumulation of RBC-bound DMAs, whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with glutathione (GSH) depletors ( bbbbb1 phorone eeeee1  or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with glutathione (GSH) depletors (phorone or  bbbbb1 BSO eeeee1 ) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound  bbbbb1 DMAs eeeee1 , whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with glutathione ( bbbbb1 GSH eeeee1 ) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Pretreatment of rats with  bbbbb1 glutathione eeeee1  (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect  bbbbb2 methyltransferase eeeee2  inhibitor periodate-oxidized adenosine was without effect
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and  bbbbb1 Sb(III) eeeee1 ) inhibited cytosolic DMAs(V) reduction, recombinant  bbbbb2 rat TRR eeeee2  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors ( bbbbb1 aurothioglucose eeeee1  and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant  bbbbb2 rat TRR eeeee2  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic  bbbbb1 DMAs(V) eeeee1  bbbbb2 thioredoxin reductase eeeee2  (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic  bbbbb1 DMAs(V) eeeee1  bbbbb2 TRR eeeee2 ) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic  bbbbb1 DMAs(V) eeeee1  reduction, recombinant  bbbbb2 rat TRR eeeee2  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus  bbbbb1 NADPH eeeee1  bbbbb2 thioredoxin reductase eeeee2  (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus  bbbbb1 NADPH eeeee1  bbbbb2 TRR eeeee2 ) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus  bbbbb1 NADPH eeeee1  bbbbb2 rat TRR eeeee2  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support  bbbbb1 DMAs(V) eeeee1  bbbbb2 thioredoxin reductase eeeee2  (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support  bbbbb1 DMAs(V) eeeee1  bbbbb2 TRR eeeee2 ) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support  bbbbb1 DMAs(V) eeeee1  bbbbb2 rat TRR eeeee2  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in  bbbbb1 DMAs(V) eeeee1  bbbbb2 arsenic methyltransferase eeeee2  have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in  bbbbb1 DMAs(V) eeeee1  bbbbb2 GSTO1 eeeee2 ) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in  bbbbb1 DMAs(V) eeeee1  bbbbb2 glutathione S-transferase omega 1 eeeee2  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze  bbbbb1 DMAs(V) eeeee1  bbbbb2 GSTO1 eeeee2 ) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and  bbbbb1 arsenic eeeee1  bbbbb2 arsenic methyltransferase eeeee2  have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and  bbbbb1 arsenic eeeee1  bbbbb2 GSTO1 eeeee2 ) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione S-transferase omega 1 (GSTO1) and  bbbbb1 arsenic eeeee1  bbbbb2 glutathione S-transferase omega 1 eeeee2  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although  bbbbb1 glutathione eeeee1  S-transferase omega 1 (GSTO1) and  bbbbb2 arsenic methyltransferase eeeee2  have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although  bbbbb1 glutathione eeeee1  S-transferase omega 1 ( bbbbb2 GSTO1 eeeee2 ) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase omega 1 eeeee2  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione  bbbbb1 S eeeee1 -transferase omega 1 (GSTO1) and  bbbbb2 arsenic methyltransferase eeeee2  have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione  bbbbb1 S eeeee1 -transferase omega 1 ( bbbbb2 GSTO1 eeeee2 ) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Although glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferase omega 1 eeeee2  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to  bbbbb1 TCDD eeeee1 , and the endpoints of decreased ATP production and differentiation, suggesting regulation by the  bbbbb2 AHR eeeee2 
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to  bbbbb1 TCDD eeeee1  bbbbb2 AHR eeeee2 ) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to  bbbbb1 TCDD eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2  (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  receptor (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the  bbbbb2 AHR eeeee2 
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  receptor ( bbbbb2 AHR eeeee2 ) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2  (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased  bbbbb1 ATP eeeee1  production and differentiation, suggesting regulation by the  bbbbb2 AHR eeeee2 
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased  bbbbb1 ATP eeeee1  bbbbb2 AHR eeeee2 ) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	Aryl hydrocarbon receptor (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased  bbbbb1 ATP eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2  (AHR) antagonists blocked the response of many transcripts to TCDD, and the endpoints of decreased ATP production and differentiation, suggesting regulation by the AHR
CRP11	Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive  bbbbb1 oxygen eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS),  bbbbb1 hydrogen peroxide eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial glutathione ( bbbbb1 GSH eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial glutathione (GSH) reductase activity and the  bbbbb1 GSH eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial  bbbbb1 glutathione eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and  bbbbb1 ATP eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Mitochondrial glutathione (GSH) reductase activity and the GSH/ bbbbb1 glutathione disulfide eeeee1  bbbbb2 glutathione (GSH) reductase eeeee2  activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide
CRP11	Lithium's effects on GluR3 desensitization are distinc bbbbb1 t fr eeeee1 om the effects of aniracetam on desensitization bbbbb2  eeeee2 
CRP11	Lithium's effects on GluR3 desensitization are distinc bbbbb1 t fr eeeee1 om the effects of aniracetam on desensitization bbbbb2  eeeee2 
CRP11	Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the  bbbbb1 glutamate eeeee1  bbbbb2 L507Y eeeee2 ) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors
CRP11	Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the  bbbbb1 glutamate eeeee1  bbbbb2 GluR3 eeeee2 (L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors
CRP11	Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of  bbbbb1 AMPA eeeee1  bbbbb2 L507Y eeeee2 ) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors
CRP11	Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of  bbbbb1 AMPA eeeee1  bbbbb2 GluR3 eeeee2 (L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors
CRP11	Administration of zuclopenthixol (0.7 and 1.4 mg/kg i.p.) neither affected dopamine ( bbbbb1 DA eeeee1 ) level nor  bbbbb2 AChE eeeee2  activity in rat cortex and hippocampus
CRP11	Administration of zuclopenthixol (0.7 and 1.4 mg/kg i.p.) neither affected  bbbbb1 dopamine eeeee1  (DA) level nor  bbbbb2 AChE eeeee2  activity in rat cortex and hippocampus
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine ( bbbbb1 3-NT eeeee1 ) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine ( bbbbb1 3-NT eeeee1 ) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn superoxide dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/ bbbbb1 Zn eeeee1  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/ bbbbb1 Zn eeeee1  superoxide dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in  bbbbb1 Cu eeeee1  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in  bbbbb1 Cu eeeee1 /Zn superoxide dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and  bbbbb1 thiobarbituric acid eeeee1  reactive substances (TBARS) formation and a significant decrease in  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and  bbbbb1 thiobarbituric acid eeeee1  reactive substances (TBARS) formation and a significant decrease in Cu/Zn superoxide dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased  bbbbb1 3-nitrotyrosine eeeee1  (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased  bbbbb1 3-nitrotyrosine eeeee1  (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn superoxide dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn  bbbbb1 superoxide eeeee1  bbbbb2 Cu/Zn superoxide dismutase eeeee2  (SOD) activity
CRP11	In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ) activity
CRP11	These control responses were: unaffected by SB224289, BR bbbbb1 L15572, ra eeeee1 uwolscine or the combinations of SB224289 + BRL15572, BRL15572 + r bbbbb2 auwolscine, rauwolscine eeeee2  + prazosin, SB224289 + prazosin, or SB224289 + prazosin + imiloxan; slightly blocked by SB224289 + rauwolscine; and markedly blocked by SB224289 + rauwolscine + prazosin, SB224289 + prazosin + BRL44408 or SB224289 + prazosin + MK912
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) +  bbbbb1 MK912 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) +  bbbbb1 MK912 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 +  bbbbb1 BRL15572 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 +  bbbbb1 BRL15572 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B),  bbbbb1 BRL15572 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+  bbbbb1 imiloxan eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+  bbbbb1 imiloxan eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D),  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D),  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each),  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each),  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each),  bbbbb1 SB224289 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) +  bbbbb1 prazosin eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each),  bbbbb1 BRL15572 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each),  bbbbb1 BRL15572 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) +  bbbbb1 rauwolscine eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) +  bbbbb1 BRL44408 eeeee1  bbbbb2 5-HT1B eeeee2 ), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) +  bbbbb1 BRL44408 eeeee1  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists  bbbbb1 SB224289 eeeee1  (300 microg/kg; 5-HT1B), BRL15572 (300 microg/kg;  bbbbb2 5-HT1D eeeee2 ), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)
CRP11	Alcohol modulates expression of DNA methyltranferases and  bbbbb1 methyl CpG eeeee1  bbbbb2 DNA methyltranferases eeeee2  and methyl CpG-/CpG domain-binding proteins in murine embryonic fibroblasts
CRP11	Alcohol modulates expression of DNA methyltranferases and  bbbbb1 methyl CpG eeeee1  bbbbb2 methyl CpG-/CpG domain-binding proteins eeeee2  in murine embryonic fibroblasts
CRP11	Alcohol modulates expression of DNA methyltranferases and methyl CpG-/ bbbbb1 CpG eeeee1  bbbbb2 DNA methyltranferases eeeee2  and methyl CpG-/CpG domain-binding proteins in murine embryonic fibroblasts
CRP11	Alcohol modulates expression of DNA methyltranferases and methyl CpG-/ bbbbb1 CpG eeeee1  bbbbb2 methyl CpG-/CpG domain-binding proteins eeeee2  in murine embryonic fibroblasts
CRP11	The present study was designed to test the hypothesis that alcohol alters global DNA methylation, and modulates expression of the DNA methyltransferases (DNMTs) and various  bbbbb1 methyl CpG eeeee1  bbbbb2 DNMTs eeeee2 ) and various methyl CpG-binding proteins
CRP11	The present study was designed to test the hypothesis that alcohol alters global DNA methylation, and modulates expression of the DNA methyltransferases (DNMTs) and various  bbbbb1 methyl CpG eeeee1  bbbbb2 CpG-binding proteins eeeee2 
CRP11	The present study was designed to test the hypothesis that alcohol alters global DNA methylation, and modulates expression of the DNA methyltransferases (DNMTs) and various  bbbbb1 methyl CpG eeeee1  bbbbb2 DNA methyltransferases eeeee2  (DNMTs) and various methyl CpG-binding proteins
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1  bbbbb2 DNMT- eeeee2 1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1  bbbbb2 DNA methyltransferases eeeee2  (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1  bbbbb2 DNMT-3b eeeee2 ), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1 -binding proteins (MeCP-2,  bbbbb2 MBD-2 eeeee2  and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1  bbbbb2 DNMT-3a eeeee2 , and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1  bbbbb2 methyl CpG-binding proteins eeeee2  (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1 -binding proteins ( bbbbb2 MeCP-2 eeeee2 , MBD-2 and MBD-3), in MEF cells by the proteasomal pathway
CRP11	In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  bbbbb1 methyl CpG eeeee1 -binding proteins (MeCP-2, MBD-2 and  bbbbb2 MBD-3 eeeee2 ), in MEF cells by the proteasomal pathway
CRP11	 bbbbb1 Methionine eeeee1  aminopeptidase-2 ( bbbbb2 MetAP2 eeeee2 ) is a novel target for cancer therapy
CRP11	 bbbbb1 Methionine eeeee1  bbbbb2 Methionine aminopeptidase-2 eeeee2  (MetAP2) is a novel target for cancer therapy
CRP11	Discovery and optimization of anthranilic acid sulfonamides as inhibitors of  bbbbb1 methionine eeeee1  aminopeptidase-2: a structural basis for the reduction of  bbbbb2 albumin eeeee2  binding
CRP11	Discovery and optimization of anthranilic acid sulfonamides as inhibitors of  bbbbb1 methionine eeeee1  bbbbb2 methionine aminopeptidase-2 eeeee2 : a structural basis for the reduction of albumin binding
CRP11	These micromolar hits were rapidly improved to nanomolar leads on the basis of insights from protein crystallography; however, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays bbbbb1  eeeee1  bbbbb2 in crystallography; h eeeee2 owever, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays
CRP11	These micromolar hits were rapidly improved to nanomolar leads on the basis of insights from protein crystallography; however, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays bbbbb1  eeeee1  bbbbb2  from  eeeee2 protein crystallography; however, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays
CRP11	Terfenadine and astemizole are chemically unrelated to  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists such as diphenhydramine and chlorpheniramine
CRP11	Nonsedating  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists
CRP11	The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists terfenadine, astemizole, loratadine, and acrivastine are reviewed
CRP11	Like other histamine H1-receptor antagonists, they competitively block  bbbbb1 histamine eeeee1  bbbbb2 histamine receptor eeeee2  sites rather than inhibiting histamine release
CRP11	Like other histamine H1-receptor antagonists, they competitively block  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists, they competitively block histamine receptor sites rather than inhibiting histamine release
CRP11	Like other  bbbbb1 histamine eeeee1  H1-receptor antagonists, they competitively block  bbbbb2 histamine receptor eeeee2  sites rather than inhibiting histamine release
CRP11	Like other  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists, they competitively block histamine receptor sites rather than inhibiting histamine release
CRP11	Like other histamine H1-receptor antagonists, they competitively block histamine receptor sites rather than inhibiting  bbbbb1 histamine eeeee1  bbbbb2 histamine receptor eeeee2  sites rather than inhibiting histamine release
CRP11	Like other histamine H1-receptor antagonists, they competitively block histamine receptor sites rather than inhibiting  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists, they competitively block histamine receptor sites rather than inhibiting histamine release
CRP11	The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not  bbbbb1 ATP eeeee1 , whereas mammalian  bbbbb2 serine racemase eeeee2  activity is increased by ATP
CRP11	The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian  bbbbb1 serine eeeee1  bbbbb2 serine racemase eeeee2  activity is increased by ATP
CRP11	In addition to the result bbbbb1 s rega eeeee1  bbbbb2 s regarding the  eeeee2 effect of ATP on enzyme activity and the phylogenetic analysis of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases
CRP11	In addition to the result bbbbb1 s rega eeeee1 rding the effect of ATP on enzyme activity and the phylo bbbbb2 genetic analysi eeeee2 s of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases
CRP11	In addition to the results regarding the effect of ATP on enzyme activity and the phylo bbbbb1 geneti eeeee1  bbbbb2 s regarding the  eeeee2 effect of ATP on enzyme activity and the phylogenetic analysis of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases
CRP11	In addition to the results regarding the effect of ATP on enzyme activity and the phylo bbbbb1 geneti eeeee1  bbbbb2 genetic analysi eeeee2 s of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases
CRP11	In this study, we cloned and sequenced a cDNA encoding a  bbbbb1 serine eeeee1  bbbbb2 serine racemase eeeee2  from barley which contained an open reading frame encoding 337 amino acid residues
CRP11	 bbbbb1 Serine eeeee1  bbbbb2 Serine racemases eeeee2  from barley, Hordeum vulgare L., and other plant species represent a distinct eukaryotic group: gene cloning and recombinant protein characterization
CRP11	The deduced amino acid sequence showed significant identity to plant and mammalian  bbbbb1 serine eeeee1  bbbbb2 serine racemases eeeee2  and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting amino acid residues
CRP11	The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and imatinib, a selective  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST
CRP11	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with  bbbbb1 imatinib eeeee1  bbbbb2 OCTN2 eeeee2  transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy
CRP11	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with  bbbbb1 imatinib eeeee1  bbbbb2 OCTN1 eeeee2  and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy
CRP11	Response to  bbbbb1 imatinib eeeee1  mainly depends from KIT and  bbbbb2 PDGFRα eeeee2  mutational status
CRP11	Response to  bbbbb1 imatinib eeeee1  mainly depends from  bbbbb2 KIT eeeee2  and PDGFRα mutational status
CRP11	Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the amiloride-sensitive epithelial  bbbbb1 sodium eeeee1  channel ( bbbbb2 ENaC eeeee2 )
CRP11	Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the amiloride-sensitive epithelial  bbbbb1 sodium eeeee1  bbbbb2 amiloride-sensitive epithelial sodium channel eeeee2  (ENaC)
CRP11	Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the amiloride-sensitive epithelial  bbbbb1 sodium eeeee1  bbbbb2 mineralocorticoid receptor eeeee2  or any of the three subunits assembling the amiloride-sensitive epithelial sodium channel (ENaC)
CRP11	Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the  bbbbb1 amiloride eeeee1  bbbbb2 mineralocorticoid receptor eeeee2  or any of the three subunits assembling the amiloride-sensitive epithelial sodium channel (ENaC)
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the  bbbbb1 amiloride eeeee1  bbbbb2 serum- and glucocorticoid-regulated kinases eeeee2 , respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the  bbbbb1 amiloride eeeee1  bbbbb2 alpha-spectrin eeeee2  and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the  bbbbb1 amiloride eeeee1  bbbbb2 ubiquitin-protein ligases eeeee2 , and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the  bbbbb1 amiloride eeeee1  bbbbb2 transmembrane serine proteases eeeee2 , ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of  bbbbb1 sodium eeeee1  bbbbb2 serum- and glucocorticoid-regulated kinases eeeee2 , respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of  bbbbb1 sodium eeeee1  bbbbb2 alpha-spectrin eeeee2  and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of  bbbbb1 sodium eeeee1  bbbbb2 ubiquitin-protein ligases eeeee2 , and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of  bbbbb1 sodium eeeee1  bbbbb2 transmembrane serine proteases eeeee2 , ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane  bbbbb1 serine eeeee1  proteases, ubiquitin-protein ligases, and  bbbbb2 serum- and glucocorticoid-regulated kinases eeeee2 , respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane  bbbbb1 serine eeeee1  bbbbb2 alpha-spectrin eeeee2  and members of the families of transmembrane serine proteases, ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane  bbbbb1 serine eeeee1  proteases,  bbbbb2 ubiquitin-protein ligases eeeee2 , and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	Recent studies have elucidated additional participants (alpha-spectrin and members of the families of transmembrane  bbbbb1 serine eeeee1  bbbbb2 transmembrane serine proteases eeeee2 , ubiquitin-protein ligases, and serum- and glucocorticoid-regulated kinases, respectively) regulating and/or interacting in the complex pathway of sodium retention in the amiloride-sensitive distal nephron
CRP11	These results are consistent with previous studies that found that: (1) pyridoxal kinase had a very low activity in children with autism and (2)  bbbbb1 pyridoxal 5 phosphate eeeee1  bbbbb2 pyridoxal kinase eeeee2  had a very low activity in children with autism and (2) pyridoxal 5 phosphate (PLP) levels are unusually low in children with autism
CRP11	These results are consistent with previous studies that found that: (1) pyridoxal kinase had a very low activity in children with autism and (2) pyridoxal 5 phosphate ( bbbbb1 PLP eeeee1  bbbbb2 pyridoxal kinase eeeee2  had a very low activity in children with autism and (2) pyridoxal 5 phosphate (PLP) levels are unusually low in children with autism
CRP11	These results are consistent with previous studies that found that: (1)  bbbbb1 pyridoxal eeeee1  bbbbb2 pyridoxal kinase eeeee2  had a very low activity in children with autism and (2) pyridoxal 5 phosphate (PLP) levels are unusually low in children with autism
CRP11	 bbbbb1 Histamine eeeee1  and Ca added to NSAIDs amplified the activating effect of the latter on  bbbbb2 CA II eeeee2 
CRP11	Previous studies by this research team proved that vasodilating  bbbbb1 prostaglandins eeeee1  (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of  bbbbb2 CA eeeee2  in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs
CRP11	Previous studies by this research team proved that vasodilating prostaglandins ( bbbbb1 PGs eeeee1 ) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of  bbbbb2 CA eeeee2  in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs
CRP11	Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of  bbbbb1 PGs eeeee1  bbbbb2 carbonic anhydrase eeeee2  (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs
CRP11	Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of  bbbbb1 PGs eeeee1  bbbbb2 CA eeeee2  in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs
CRP11	Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of  bbbbb1 PGs eeeee1  bbbbb2 CA eeeee2 ) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs
CRP11	The results show that the NSAIDs used here, which reduce the activity of cyclooxygenase and  bbbbb1 PG eeeee1  bbbbb2 cyclooxygenase eeeee2  and PG production, activated CA I and CA II in a dose-dependent manner by a mechanism of the noncompetitive type
CRP11	The results show that the NSAIDs used here, which reduce the activity of cyclooxygenase and  bbbbb1 PG eeeee1  production, activated  bbbbb2 CA I eeeee2  and CA II in a dose-dependent manner by a mechanism of the noncompetitive type
CRP11	The results show that the NSAIDs used here, which reduce the activity of cyclooxygenase and  bbbbb1 PG eeeee1  production, activated CA I and  bbbbb2 CA II eeeee2  in a dose-dependent manner by a mechanism of the noncompetitive type
CRP11	Using the mTOR inhibitor  bbbbb1 PP242, eeeee1  we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for  bbbbb2 deptor eeeee2  suppression
CRP11	Using the mTOR inhibitor  bbbbb1 PP242, eeeee1  we found that  bbbbb2 TGFβ eeeee2 -induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression
CRP11	Using the mTOR inhibitor  bbbbb1 PP242, eeeee1  we found that TGFβ-induced both early and sustained activation of  bbbbb2 TORC1 eeeee2  and TORC2 was necessary for deptor suppression
CRP11	Using the mTOR inhibitor  bbbbb1 PP242, eeeee1  we found that TGFβ-induced both early and sustained activation of TORC1 and  bbbbb2 TORC2 eeeee2  was necessary for deptor suppression
CRP11	Transforming growth factor β integrates Smad 3 to mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 Transforming growth factor β eeeee2  integrates Smad 3 to mechanistic target of rapamycin complexes to arrest deptor abundance for glomerular mesangial cell hypertrophy
CRP11	Transforming growth factor β integrates Smad 3 to mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 mechanistic target of rapamycin eeeee2  complexes to arrest deptor abundance for glomerular mesangial cell hypertrophy
CRP11	Transforming growth factor β integrates Smad 3 to mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 Smad 3 eeeee2  to mechanistic target of rapamycin complexes to arrest deptor abundance for glomerular mesangial cell hypertrophy
CRP11	Transforming growth factor β integrates Smad 3 to mechanistic target of  bbbbb1 rapamycin eeeee1  complexes to arrest  bbbbb2 deptor eeeee2  abundance for glomerular mesangial cell hypertrophy
CRP11	In many renal diseases, transforming growth factor β (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 mechanistic target of rapamycin eeeee2  (mTOR) promote increased protein synthesis and mesangial cell hypertrophy
CRP11	In many renal diseases, transforming growth factor β (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of  bbbbb1 rapamycin eeeee1  ( bbbbb2 mTOR eeeee2 ) promote increased protein synthesis and mesangial cell hypertrophy
CRP11	In many renal diseases, transforming growth factor β (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 TGFβ eeeee2 )-stimulated canonical Smad 3 and noncanonical mechanistic target of rapamycin (mTOR) promote increased protein synthesis and mesangial cell hypertrophy
CRP11	In many renal diseases, transforming growth factor β (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 transforming growth factor β eeeee2  (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of rapamycin (mTOR) promote increased protein synthesis and mesangial cell hypertrophy
CRP11	In many renal diseases, transforming growth factor β (TGFβ)-stimulated canonical Smad 3 and noncanonical mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 Smad 3 eeeee2  and noncanonical mechanistic target of rapamycin (mTOR) promote increased protein synthesis and mesangial cell hypertrophy
CRP11	 bbbbb1 PP242 eeeee1 -induced reversal of deptor suppression by TGFβ was associated with a significant inhibition of  bbbbb2 TGFβ eeeee2 -stimulated protein synthesis and hypertrophy
CRP11	 bbbbb1 PP242 eeeee1 -induced reversal of deptor suppression by  bbbbb2 TGFβ eeeee2  was associated with a significant inhibition of TGFβ-stimulated protein synthesis and hypertrophy
CRP11	The anorexigenic effects of centrally injected glucose or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that  bbbbb1 glucose eeeee1  sensing involves endozepinergic control of the  bbbbb2 melanocortin eeeee2  pathway
CRP11	The anorexigenic effects of centrally injected glucose or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that  bbbbb1 glucose eeeee1  bbbbb2 melanocortin-3/4 receptors eeeee2 , suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway
CRP11	The anorexigenic effects of centrally injected glucose or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that  bbbbb1 glucose eeeee1  bbbbb2 ODN eeeee2  agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway
CRP11	The anorexigenic effects of centrally injected  bbbbb1 glucose eeeee1  or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that glucose sensing involves endozepinergic control of the  bbbbb2 melanocortin eeeee2  pathway
CRP11	The anorexigenic effects of centrally injected  bbbbb1 glucose eeeee1  or ODN agonist were suppressed by blockade of the  bbbbb2 melanocortin-3/4 receptors eeeee2 , suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway
CRP11	The anorexigenic effects of centrally injected  bbbbb1 glucose eeeee1  or  bbbbb2 ODN eeeee2  agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway
CRP11	Gliotransmission and brain  bbbbb1 glucose eeeee1  sensing: critical role of  bbbbb2 endozepines eeeee2 
CRP11	 bbbbb1 Diazepam eeeee1 -binding inhibitor (DBI) and its processing product the octadecaneuropeptide (ODN), collectively named  bbbbb2 endozepines eeeee2 , are secreted by astroglia, and ODN is a potent anorexigenic factor
CRP11	 bbbbb1 Diazepam eeeee1 -binding inhibitor (DBI) and its processing product the  bbbbb2 octadecaneuropeptide eeeee2  (ODN), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor
CRP11	 bbbbb1 Diazepam eeeee1 -binding inhibitor (DBI) and its processing product the octadecaneuropeptide (ODN), collectively named endozepines, are secreted by astroglia, and  bbbbb2 ODN eeeee2  is a potent anorexigenic factor
CRP11	 bbbbb1 Diazepam eeeee1  bbbbb2 Diazepam-binding inhibitor eeeee2  (DBI) and its processing product the octadecaneuropeptide (ODN), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor
CRP11	 bbbbb1 Diazepam eeeee1 -binding inhibitor ( bbbbb2 DBI eeeee2 ) and its processing product the octadecaneuropeptide (ODN), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor
CRP11	 bbbbb1 Diazepam eeeee1 -binding inhibitor (DBI) and its processing product the octadecaneuropeptide ( bbbbb2 ODN eeeee2 ), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor
CRP11	Feeding experiments indicate that the anorexigenic effect of central administration of  bbbbb1 glucose eeeee1  was blunted by coinjection of an  bbbbb2 ODN eeeee2  antagonist
CRP11	Finally, we found that brain endozepines modulate blood glucose levels, suggestin bbbbb1 g their eeeee1  bbbbb2 s modulate  eeeee2 blood glucose levels, suggesting their involvement in a feedback loop controlling whole-body glucose homeostasis
CRP11	TSH and  bbbbb1 cAMP eeeee1  bbbbb2 TSH eeeee2  and cAMP also increase the levels of the specific mRNA for TPO in thyroid cells from different species
CRP11	Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular  bbbbb1 cAMP eeeee1  bbbbb2 TSH eeeee2 , through pathways which involve intracellular cAMP accumulation and protein synthesis
CRP11	The modulation of M/TPO-Ag surface expression by TSH can explain the decrease of circulating anti-MAb observed during  bbbbb1 L-thyroxine eeeee1  bbbbb2 TSH eeeee2  can explain the decrease of circulating anti-MAb observed during L-thyroxine therapy in hypothyroid patients with Hashimoto's thyroiditis
CRP11	The modulation of M/TPO-Ag surface expression by TSH can explain the decrease of circulating anti-MAb observed during  bbbbb1 L-thyroxine eeeee1  bbbbb2 M/TPO-Ag eeeee2  surface expression by TSH can explain the decrease of circulating anti-MAb observed during L-thyroxine therapy in hypothyroid patients with Hashimoto's thyroiditis
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by  bbbbb1 rofecoxib eeeee1  bbbbb2 COX-2 eeeee2 -dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 COX-2 eeeee2  inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 COX-2 eeeee2 -dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 cyclinB1 eeeee2 , since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 CIP1 eeeee2 ) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 p21 eeeee2 (WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous  bbbbb1 PGE2 eeeee1  bbbbb2 WAF1 eeeee2 /CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent  bbbbb1 PGE2 eeeee1  synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective  bbbbb2 COX-2 eeeee2  inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent  bbbbb1 PGE2 eeeee1  synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of  bbbbb2 cyclinB1 eeeee2 , since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent  bbbbb1 PGE2 eeeee1  synthesis in HT29 cells was involved in downregulation of p21(WAF1/ bbbbb2 CIP1 eeeee2 ) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent  bbbbb1 PGE2 eeeee1  synthesis in HT29 cells was involved in downregulation of  bbbbb2 p21 eeeee2 (WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Platelet-induced COX-2-dependent  bbbbb1 PGE2 eeeee1  synthesis in HT29 cells was involved in downregulation of p21( bbbbb2 WAF1 eeeee2 /CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor  bbbbb2 GPVI eeeee2 -Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti- bbbbb2 galectin-3 eeeee2  antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric  bbbbb2 collagen receptor eeeee2  GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1  bbbbb2 galectin-3 eeeee2  function(β-lactose, a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or  bbbbb2 collagen receptor eeeee2 -mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant  bbbbb2 COX-2 eeeee2  expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of  bbbbb2 galectin-3 eeeee2 ,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3,Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI- bbbbb2 Fc eeeee2 ) prevented aberrant COX-2 expression
CRP11	Inhibitors of galectin-3 function( bbbbb1 β-lactose eeeee1 , a dominant-negative form of galectin-3, bbbbb2 Gal-3C eeeee2 , and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion(revacept, a dimeric collagen receptor GPVI-Fc) prevented aberrant COX-2 expression
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb1 fibrinopeptide B eeeee1  bbbbb2 FPA eeeee2 ) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb1 fibrinopeptide B eeeee1  bbbbb2 fibrinopeptide A eeeee2  (FPA) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb1 fibrinopeptide B eeeee1  bbbbb2 fibrinopeptide B beta 15-42 eeeee2  (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb1 fibrinopeptide B eeeee1  beta 15-42 ( bbbbb2 B beta 15-42 eeeee2 )
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate ( bbbbb1 EO eeeee1 ), by means of serial determination of plasma fibrinopeptide A ( bbbbb2 FPA eeeee2 ) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate ( bbbbb1 EO eeeee1 ), by means of serial determination of plasma  bbbbb2 fibrinopeptide A eeeee2  (FPA) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate ( bbbbb1 EO eeeee1 ), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb2 fibrinopeptide B beta 15-42 eeeee2  (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate ( bbbbb1 EO eeeee1 ), by means of serial determination of plasma fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 ( bbbbb2 B beta 15-42 eeeee2 )
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent  bbbbb1 ethanolamine oleate eeeee1  (EO), by means of serial determination of plasma fibrinopeptide A ( bbbbb2 FPA eeeee2 ) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent  bbbbb1 ethanolamine oleate eeeee1  (EO), by means of serial determination of plasma  bbbbb2 fibrinopeptide A eeeee2  (FPA) and fibrinopeptide B beta 15-42 (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent  bbbbb1 ethanolamine oleate eeeee1  (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and  bbbbb2 fibrinopeptide B beta 15-42 eeeee2  (B beta 15-42)
CRP11	Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent  bbbbb1 ethanolamine oleate eeeee1  (EO), by means of serial determination of plasma fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 ( bbbbb2 B beta 15-42 eeeee2 )
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or  bbbbb1 benzyl alcohol eeeee1  bbbbb2 fibrin eeeee2  clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the  bbbbb1 Ca2+ eeeee1  bbbbb2 fibrin eeeee2  clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the  bbbbb1 Ca2+ eeeee1 -chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in  bbbbb2 FPA eeeee2  formation in vitro
CRP11	In vitro studies, however, revealed that  bbbbb1 EO eeeee1  inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in  bbbbb2 FPA eeeee2  formation in vitro
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent  bbbbb1 ethanolamine eeeee1  bbbbb2 fibrin eeeee2  clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent  bbbbb1 ethanolamine eeeee1 , although oleate or benzyl alcohol exhibited procoagulant activity in  bbbbb2 FPA eeeee2  formation in vitro
CRP11	In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although  bbbbb1 oleate eeeee1  bbbbb2 fibrin eeeee2  clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro
CRP11	Nevertheless, an external application of EO or oleate over decapsulized kidney of rat resulted in a significant accumulation of  bbbbb1 125I eeeee1 -labelled  bbbbb2 fibrin(ogen) eeeee2 
CRP11	Nevertheless, an external application of  bbbbb1 EO eeeee1  or oleate over decapsulized kidney of rat resulted in a significant accumulation of 125I-labelled  bbbbb2 fibrin(ogen) eeeee2 
CRP11	Nevertheless, an external application of EO or  bbbbb1 oleate eeeee1  over decapsulized kidney of rat resulted in a significant accumulation of 125I-labelled  bbbbb2 fibrin(ogen) eeeee2 
CRP11	PGE1 and PGE2 also inhibited the remaining ICa in a saturating concentration of  bbbbb1 nifedipine eeeee1 , omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that  bbbbb2 R-type Ca2+ channels eeeee2  are involved
CRP11	PGE1 and PGE2 also inhibited the remaining ICa in a saturating concentration of nifedipine, omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that R-type  bbbbb1 Ca2+ eeeee1  bbbbb2 R-type Ca2+ channels eeeee2  are involved
CRP11	The modulation of high-voltage-activated (HVA)  bbbbb1 Ca2+ eeeee1  bbbbb2 high-voltage-activated (HVA) Ca2+ channels eeeee2  by the prostaglandin E series (PGE1 and PGE2) was studied in the paratracheal ganglion cells
CRP11	The prostaglandin E series modulates high-voltage-activated  bbbbb1 calcium eeeee1  channels probably through the  bbbbb2 EP3 receptor eeeee2  in rat paratracheal ganglia
CRP11	The prostaglandin E series modulates high-voltage-activated  bbbbb1 calcium eeeee1  bbbbb2 high-voltage-activated calcium channels eeeee2  probably through the EP3 receptor in rat paratracheal ganglia
CRP11	The inhibitory effect of PGE1 or sulprostone was prevented by pret bbbbb1 reat eeeee1 ment with pertussis toxin [islet activating protein (IAP) bbbbb2 ] or phorbol eeeee2 -12-myristate-13-acetate (PMA), and the protein kinase C (PKC) inhibitor chelerythrine blocked the action of PMA
CRP11	The inhibitory effect of PGE1 or sulprostone was prevented by pret bbbbb1 reat eeeee1 ment with pertussis toxin  bbbbb2 [islet ac eeeee2 tivating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (PKC) inhibitor chelerythrine blocked the action of PMA
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that  bbbbb1 PGE1 eeeee1  bbbbb2 EP1-receptor eeeee2  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 EP1-receptor eeeee2  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA  bbbbb1 Ca2+ eeeee1  channels is possibly mediated by the  bbbbb2 EP3 receptor eeeee2 
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 HVA Ca2+ channels eeeee2  is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the  bbbbb1 PGE1 eeeee1  bbbbb2 EP1-receptor eeeee2  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the  bbbbb1 PGE1 eeeee1 - or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the  bbbbb2 EP3 receptor eeeee2 
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the  bbbbb1 PGE1 eeeee1 - or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the  bbbbb2 HVA Ca2+ channels eeeee2  is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or  bbbbb1 PGE2 eeeee1  bbbbb2 EP1-receptor eeeee2  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or  bbbbb1 PGE2 eeeee1 -induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the  bbbbb2 EP3 receptor eeeee2 
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or  bbbbb1 PGE2 eeeee1 -induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the  bbbbb2 HVA Ca2+ channels eeeee2  is possibly mediated by the EP3 receptor
CRP11	 bbbbb1 SC-51089 eeeee1  (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the  bbbbb2 EP3 receptor eeeee2 
CRP11	 bbbbb1 SC-51089 eeeee1  (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the  bbbbb2 HVA Ca2+ channels eeeee2  is possibly mediated by the EP3 receptor
CRP11	SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and  bbbbb1 PGE2 eeeee1  bbbbb2 EP1-receptor eeeee2  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of  bbbbb1 thromboxane A2 eeeee1 ), 17-phenyl-trinor-PGE2 (an  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of  bbbbb1 thromboxane A2 eeeee1 ), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was  bbbbb1 sulprostone eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was  bbbbb1 sulprostone eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	 bbbbb1 Prostaglandin E1, E2, eeeee1  STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	 bbbbb1 Prostaglandin E1, E2, eeeee1  STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	 bbbbb1 Prostaglandin E1, E2, eeeee1  STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  bbbbb2 HVA Ca2+ channels eeeee2  was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 HVA Ca2+ channels eeeee2  was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone> bbbbb1 PGE2 eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone> bbbbb1 PGE2 eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2,  bbbbb1 STA2 eeeee1  (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2,  bbbbb1 STA2 eeeee1  (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and  bbbbb1 sulprostone eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA  bbbbb1 Ca2+ eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA  bbbbb1 Ca2+ eeeee1  current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  bbbbb2 HVA Ca2+ channels eeeee2  was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2,  bbbbb1 PGE1 eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2,  bbbbb1 PGE1 eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  bbbbb1 17-phenyl-trinor-PGE2 eeeee1  (an EP1-selective agonist) and sulprostone (an  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1> bbbbb1 STA2 eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1> bbbbb1 STA2 eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>> bbbbb1 17-phenyl-trinor-PGE2 eeeee1  bbbbb2 EP1 eeeee2 -selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>> bbbbb1 17-phenyl-trinor-PGE2 eeeee1  bbbbb2 EP3 eeeee2 -selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2
CRP11	Vegfrecine, an Inhibitor of VEGF Receptor  bbbbb1 Tyrosine eeeee1  bbbbb2 VEGF Receptor Tyrosine Kinases eeeee2  Isolated from the Culture Broth of Streptomyces sp
CRP11	A new inhibitor of VEGF receptor  bbbbb1 tyrosine eeeee1  bbbbb2 VEGF receptor tyrosine kinases eeeee2 , vegfrecine (1), was isolated from the culture broth of Streptomyces sp
CRP11	Cells exposed to α-MeDA showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of  bbbbb1 γ-glutamylcysteine eeeee1  synthetase ( bbbbb2 γ-GCS eeeee2 ), revealing a possible transient effect
CRP11	Cells exposed to α-MeDA showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of  bbbbb1 γ-glutamylcysteine eeeee1  bbbbb2 γ-glutamylcysteine synthetase eeeee2  (γ-GCS), revealing a possible transient effect
CRP11	Cells exposed to α-MeDA showed an increase in intracellular  bbbbb1 glutathione eeeee1  (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of γ-glutamylcysteine synthetase ( bbbbb2 γ-GCS eeeee2 ), revealing a possible transient effect
CRP11	Cells exposed to α-MeDA showed an increase in intracellular  bbbbb1 glutathione eeeee1  (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of  bbbbb2 γ-glutamylcysteine synthetase eeeee2  (γ-GCS), revealing a possible transient effect
CRP11	Cells exposed to α-MeDA showed an increase in intracellular glutathione ( bbbbb1 GSH eeeee1 ) levels, which, at the 48 h time-point, was not dependent in the activity increase of γ-glutamylcysteine synthetase ( bbbbb2 γ-GCS eeeee2 ), revealing a possible transient effect
CRP11	Cells exposed to α-MeDA showed an increase in intracellular glutathione ( bbbbb1 GSH eeeee1 ) levels, which, at the 48 h time-point, was not dependent in the activity increase of  bbbbb2 γ-glutamylcysteine synthetase eeeee2  (γ-GCS), revealing a possible transient effect
CRP11	Neither the  bbbbb1 superoxide eeeee1  radical scavenger, tiron, nor the inhibitor of the  bbbbb2 dopamine (DA) transporter eeeee2 , GBR 12909, prevented the metabolites' toxicity
CRP11	Neither the superoxide radical scavenger, tiron, nor the inhibitor of the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine (DA) transporter eeeee2 , GBR 12909, prevented the metabolites' toxicity
CRP11	Importantly, pre-treatment with buthionine sulfoximine (BSO), an inhibitor of γ-GCS, prevented  bbbbb1 α-MeDA eeeee1  bbbbb2 γ-GCS eeeee2 , prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity
CRP11	Importantly, pre-treatment with buthionine sulfoximine (BSO), an inhibitor of γ-GCS, prevented α-MeDA induced increase in  bbbbb1 GSH eeeee1  bbbbb2 γ-GCS eeeee2 , prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity
CRP11	To investigate the effects of β-ionone on apoptosis initiation and its possible mechanisms of action, we qualified cell apoptosis, proteins related to apoptosis and a  bbbbb1 phosphatidylinositol eeeee1  3-kinase ( bbbbb2 PI3K eeeee2 )-AKT pathway in human gastric adenocarcinoma cancer SGC-7901 cells
CRP11	To investigate the effects of β-ionone on apoptosis initiation and its possible mechanisms of action, we qualified cell apoptosis, proteins related to apoptosis and a  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)- bbbbb2 AKT eeeee2  pathway in human gastric adenocarcinoma cancer SGC-7901 cells
CRP11	To investigate the effects of β-ionone on apoptosis initiation and its possible mechanisms of action, we qualified cell apoptosis, proteins related to apoptosis and a  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K)-AKT pathway in human gastric adenocarcinoma cancer SGC-7901 cells
CRP11	Apoptosis initiation of β-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.  bbbbb1 β-ionone eeeee1  bbbbb2 PI3K eeeee2 -AKT pathway. β-ionone has been shown to hold potent anti-proliferative and apoptosis induction properties in vitro and in vivo
CRP11	Apoptosis initiation of β-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.  bbbbb1 β-ionone eeeee1  bbbbb2 AKT eeeee2  pathway. β-ionone has been shown to hold potent anti-proliferative and apoptosis induction properties in vitro and in vivo
CRP11	The results demonstrated that  bbbbb1 β-ionone eeeee1 -induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with β-ionone (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved- bbbbb2 caspase-3 eeeee2  and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner
CRP11	The results demonstrated that  bbbbb1 β-ionone eeeee1 -induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with β-ionone (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit  bbbbb2 bcl-2 eeeee2  expression in SGC-7901 cells in a dose-dependent manner
CRP11	The results demonstrated that β-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with  bbbbb1 β-ionone eeeee1  (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved- bbbbb2 caspase-3 eeeee2  and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner
CRP11	The results demonstrated that β-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with  bbbbb1 β-ionone eeeee1  (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit  bbbbb2 bcl-2 eeeee2  expression in SGC-7901 cells in a dose-dependent manner
CRP11	Binding of the agonist angiotensin II (AngII) and inverse agonist  bbbbb1 losartan eeeee1  bbbbb2 angiotensin II eeeee2  (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific "lid" conformations of ECL2
CRP11	Binding of the agonist angiotensin II (AngII) and inverse agonist  bbbbb1 losartan eeeee1  bbbbb2 AngII eeeee2 ) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific "lid" conformations of ECL2
CRP11	Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter  bbbbb1 cysteines eeeee1  bbbbb2 angiotensin II eeeee2  (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific "lid" conformations of ECL2
CRP11	Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter  bbbbb1 cysteines eeeee1  bbbbb2 AngII eeeee2 ) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific "lid" conformations of ECL2
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1  bbbbb2 CK eeeee2 ), heart oxidative stress (MDA, SOD) and endothelial function (ET-1, VEGF) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1 , SOD) and endothelial function ( bbbbb2 ET-1 eeeee2 , VEGF) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1 , SOD) and endothelial function (ET-1,  bbbbb2 VEGF eeeee2 ) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1  bbbbb2 IL-6 eeeee2 , LDH, CK), heart oxidative stress (MDA, SOD) and endothelial function (ET-1, VEGF) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1 ,  bbbbb2 SOD eeeee2 ) and endothelial function (ET-1, VEGF) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1  bbbbb2 CRP eeeee2 , IL-6, LDH, CK), heart oxidative stress (MDA, SOD) and endothelial function (ET-1, VEGF) were analyzed after the 6th exposure
CRP11	Biomarkers of systemic inflammation and injuries (CRP, IL-6, LDH, CK), heart oxidative stress ( bbbbb1 MDA eeeee1  bbbbb2 LDH eeeee2 , CK), heart oxidative stress (MDA, SOD) and endothelial function (ET-1, VEGF) were analyzed after the 6th exposure
CRP11	Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and  bbbbb1 MDA eeeee1  bbbbb2 IL-6 eeeee2 , CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way
CRP11	Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and  bbbbb1 MDA eeeee1  bbbbb2 CRP eeeee2 , IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way
CRP11	Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and  bbbbb1 MDA eeeee1  bbbbb2 LDH eeeee2  and MDA increase, SOD and HRV decrease significantly in a dose-response way
CRP11	Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and  bbbbb1 MDA eeeee1  bbbbb2 CK eeeee2 , LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way
CRP11	Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and  bbbbb1 MDA eeeee1  increase,  bbbbb2 SOD eeeee2  and HRV decrease significantly in a dose-response way
CRP11	Results showed that PM(2.5) alone exposure could trigger the significant increase of CRP,  bbbbb1 MDA eeeee1 ,  bbbbb2 CK eeeee2 , ET-1 and SBP and decrease of heart rate variability (HRV), a marker of cardiac autonomic nervous system (ANS) function
CRP11	Results showed that PM(2.5) alone exposure could trigger the significant increase of CRP,  bbbbb1 MDA eeeee1 , CK,  bbbbb2 ET-1 eeeee2  and SBP and decrease of heart rate variability (HRV), a marker of cardiac autonomic nervous system (ANS) function
CRP11	Results showed that PM(2.5) alone exposure could trigger the significant increase of CRP,  bbbbb1 MDA eeeee1  bbbbb2 CRP eeeee2 , MDA, CK, ET-1 and SBP and decrease of heart rate variability (HRV), a marker of cardiac autonomic nervous system (ANS) function
CRP11	PSM pre-treatment decreased serum transaminases and LDH activities and  bbbbb1 MDA eeeee1  bbbbb2 LDH eeeee2  activities and MDA levels and increased the levels of cell protector GSH
CRP11	PSM pre-treatment decreased serum transaminases and LDH activities and  bbbbb1 MDA eeeee1  bbbbb2 serum transaminases eeeee2  and LDH activities and MDA levels and increased the levels of cell protector GSH
CRP11	PSM pre-treatment decreased serum transaminases and LDH activities and MDA levels and increased the levels of cell protector  bbbbb1 GSH eeeee1  bbbbb2 LDH eeeee2  activities and MDA levels and increased the levels of cell protector GSH
CRP11	PSM pre-treatment decreased serum transaminases and LDH activities and MDA levels and increased the levels of cell protector  bbbbb1 GSH eeeee1  bbbbb2 serum transaminases eeeee2  and LDH activities and MDA levels and increased the levels of cell protector GSH
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and  bbbbb1 aniline eeeee1  4-hydroxylase activity and  bbbbb2 cytochrome P450 eeeee2 , compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and  bbbbb1 aniline eeeee1  bbbbb2 ethylmorphine-N-demethylase eeeee2  and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and  bbbbb1 aniline eeeee1  bbbbb2 aniline 4-hydroxylase eeeee2  activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of  bbbbb1 ethylmorphine eeeee1 -N-demethylase and aniline 4-hydroxylase activity and  bbbbb2 cytochrome P450 eeeee2 , compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of  bbbbb1 ethylmorphine eeeee1  bbbbb2 ethylmorphine-N-demethylase eeeee2  and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of  bbbbb1 ethylmorphine eeeee1 -N-demethylase and  bbbbb2 aniline 4-hydroxylase eeeee2  activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the  bbbbb1 CCl4 eeeee1  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and  bbbbb2 cytochrome P450 eeeee2 , compared to the CCl4 only group
CRP11	In the  bbbbb1 CCl4 eeeee1  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of  bbbbb2 ethylmorphine-N-demethylase eeeee2  and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the  bbbbb1 CCl4 eeeee1  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and  bbbbb2 aniline 4-hydroxylase eeeee2  activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine- bbbbb1 N eeeee1 -demethylase and aniline 4-hydroxylase activity and  bbbbb2 cytochrome P450 eeeee2 , compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine- bbbbb1 N eeeee1  bbbbb2 ethylmorphine-N-demethylase eeeee2  and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group
CRP11	In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine- bbbbb1 N eeeee1 -demethylase and  bbbbb2 aniline 4-hydroxylase eeeee2  activity and cytochrome P450, compared to the CCl4 only group
CRP11	A significant decrease of aspartate aminotransferase,  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase,  bbbbb1 alanine eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase,  bbbbb1 alanine eeeee1  aminotransferase,  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase,  bbbbb1 alanine eeeee1  aminotransferase, lactate dehydrogenase ( bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of  bbbbb1 aspartate eeeee1  aminotransferase,  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of  bbbbb1 aspartate eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of  bbbbb1 aspartate eeeee1  aminotransferase, alanine aminotransferase,  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of  bbbbb1 aspartate eeeee1  aminotransferase, alanine aminotransferase, lactate dehydrogenase ( bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and  bbbbb1 glutathione eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and  bbbbb1 glutathione eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and  bbbbb1 glutathione eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and  bbbbb1 glutathione eeeee1  bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase,  bbbbb1 lactate eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase,  bbbbb1 lactate eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase,  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase,  bbbbb1 lactate eeeee1  dehydrogenase ( bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione ( bbbbb1 GSH eeeee1  bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of  bbbbb1 malondialdehyde eeeee1  bbbbb2 alanine aminotransferase eeeee2 , lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of  bbbbb1 malondialdehyde eeeee1  bbbbb2 aspartate aminotransferase eeeee2 , alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of  bbbbb1 malondialdehyde eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of  bbbbb1 malondialdehyde eeeee1  bbbbb2 LDH eeeee2 ) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone
CRP11	ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in  bbbbb1 tyrosine eeeee1  bbbbb2 oxidase eeeee2  activates Src, enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization
CRP11	ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in  bbbbb1 tyrosine eeeee1  bbbbb2 Src eeeee2 , enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization
CRP11	ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in  bbbbb1 tyrosine eeeee1  bbbbb2 EGFR eeeee2  that activates Stat3 in tyrosine, allowing its dimerization
CRP11	Hepatocytes display a compensatory survival response against  bbbbb1 cadmium eeeee1  toxicity by a mechanism mediated by EGFR and  bbbbb2 Src eeeee2 
CRP11	Hepatocytes display a compensatory survival response against  bbbbb1 cadmium eeeee1  toxicity by a mechanism mediated by  bbbbb2 EGFR eeeee2  and Src
CRP11	We provided evidence of a novel link among  bbbbb1 NADPH eeeee1  oxidase and Stat3 signaling, mediated by Src, EGFR, and  bbbbb2 Erk1/2 eeeee2 
CRP11	We provided evidence of a novel link among  bbbbb1 NADPH eeeee1  oxidase and  bbbbb2 Stat3 eeeee2  signaling, mediated by Src, EGFR, and Erk1/2
CRP11	We provided evidence of a novel link among  bbbbb1 NADPH eeeee1  oxidase and Stat3 signaling, mediated by Src,  bbbbb2 EGFR eeeee2 , and Erk1/2
CRP11	We provided evidence of a novel link among  bbbbb1 NADPH eeeee1  oxidase and Stat3 signaling, mediated by  bbbbb2 Src eeeee2 , EGFR, and Erk1/2
CRP11	We provided evidence of a novel link among  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  and Stat3 signaling, mediated by Src, EGFR, and Erk1/2
CRP11	Cadmium activates  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2 
CRP11	Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and  bbbbb1 crizotinib eeeee1  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and crizotinib, respectively
CRP11	Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and  bbbbb1 crizotinib eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitors (TKIs) and crizotinib, respectively
CRP11	Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and  bbbbb1 crizotinib eeeee1  bbbbb2 EGFR eeeee2  tyrosine kinase inhibitors (TKIs) and crizotinib, respectively
CRP11	Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and  bbbbb1 crizotinib eeeee1  bbbbb2 EGFR eeeee2 ) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and crizotinib, respectively
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/ bbbbb1 F3(d)Thd eeeee1  bbbbb2 TS eeeee2  mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/ bbbbb1 F3(d)Thd eeeee1  bbbbb2 orotate phosphoribosyltransferase eeeee2  activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/ bbbbb1 F3(d)Thd eeeee1  bbbbb2 thymidine kinase eeeee2  activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/ bbbbb1 5-FU eeeee1  cells, a 7-fold increase of  bbbbb2 TS eeeee2  mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/ bbbbb1 5-FU eeeee1  bbbbb2 orotate phosphoribosyltransferase eeeee2  activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/ bbbbb1 5-FU eeeee1  cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in  bbbbb2 thymidine kinase eeeee2  activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/ bbbbb1 FdUrd eeeee1  bbbbb2 TS eeeee2  mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/ bbbbb1 FdUrd eeeee1  bbbbb2 orotate phosphoribosyltransferase eeeee2  activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/ bbbbb1 FdUrd eeeee1  cells, and a 37-fold decrease in  bbbbb2 thymidine kinase eeeee2  activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in  bbbbb1 orotate eeeee1  phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of  bbbbb2 TS eeeee2  mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in  bbbbb1 orotate eeeee1  bbbbb2 orotate phosphoribosyltransferase eeeee2  activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with pyrimidine metabolism indicated that a significant decrease in  bbbbb1 orotate eeeee1  phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in  bbbbb2 thymidine kinase eeeee2  activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with  bbbbb1 pyrimidine eeeee1  metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of  bbbbb2 TS eeeee2  mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with  bbbbb1 pyrimidine eeeee1  metabolism indicated that a significant decrease in  bbbbb2 orotate phosphoribosyltransferase eeeee2  activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in thymidine kinase activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	Analysis of enzyme activities and gene expression associated with  bbbbb1 pyrimidine eeeee1  metabolism indicated that a significant decrease in orotate phosphoribosyltransferase activity in DLD-1/5-FU cells, a 7-fold increase of TS mRNA in DLD-1/FdUrd cells, and a 37-fold decrease in  bbbbb2 thymidine kinase eeeee2  activity of DLD-1/F3(d)Thd cells were the major mechanisms of drug resistance
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for on bbbbb1 ly 4 eeeee1  bbbbb2 tr eeeee2 eated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for on bbbbb1 ly 4 eeeee1  h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were mar bbbbb2 ke eeeee2 dly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for on bbbbb1 ly 4 eeeee1  h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb2 Urd and F3(d)Thd, suggesting that eeeee2  the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb1 Urd and eeeee1  bbbbb2 tr eeeee2 eated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb1 Urd and eeeee1  bbbbb2 ke eeeee2 dly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb1 Urd and eeeee1  bbbbb2 Urd and F3(d)Thd, suggesting that eeeee2  the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the  bbbbb1 resis eeeee1  bbbbb2 tr eeeee2 eated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the  bbbbb1 resis eeeee1 tance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were mar bbbbb2 ke eeeee2 dly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the  bbbbb1 resis eeeee1 tance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb2 Urd and F3(d)Thd, suggesting that eeeee2  the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUr bbbbb1 d cells  eeeee1 expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were mar bbbbb2 ke eeeee2 dly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	When DLD-1/FdUr bbbbb1 d cells  eeeee1 expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for Fd bbbbb2 Urd and F3(d)Thd, suggesting that eeeee2  the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure
CRP11	Different mechanisms of acquired resistance to  bbbbb1 fluorinated pyrimidines eeeee1  in human colorectal cancer cells. 5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  bbbbb2 thymidylate synthase eeeee2  (TS)
CRP11	Different mechanisms of acquired resistance to  bbbbb1 fluorinated pyrimidines eeeee1  in human colorectal cancer cells. 5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( bbbbb2 TS eeeee2 )
CRP11	Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. 5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS)
CRP11	Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. 5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 )
CRP11	Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive  bbbbb1 oxygen eeeee1  bbbbb2 EGFR eeeee2 ) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes
CRP11	Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive  bbbbb1 oxygen eeeee1  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes
CRP11	Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive  bbbbb1 oxygen eeeee1  bbbbb2 ERK eeeee2 ) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes
CRP11	Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive  bbbbb1 oxygen eeeee1  bbbbb2 IL-8 eeeee2  production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes
CRP11	Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive  bbbbb1 oxygen eeeee1  bbbbb2 extracelluar signal-regulated kinase eeeee2  (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes
CRP11	Mutation of Ser-530 to Ala or  bbbbb1 Val eeeee1 -349 to Ala or Leu abolished the potent inhibition observed with wild-type  bbbbb2 human COX-2 eeeee2  and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or  bbbbb1 Val eeeee1  bbbbb2 Ser-530 to Ala eeeee2  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or  bbbbb1 Val eeeee1  bbbbb2 Val-349 to Ala or Leu eeeee2  abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of  bbbbb1 Ser eeeee1 -530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type  bbbbb2 human COX-2 eeeee2  and key lumiracoxib analogs
CRP11	Mutation of  bbbbb1 Ser eeeee1  bbbbb2 Ser-530 to Ala eeeee2  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of  bbbbb1 Ser eeeee1 -530 to Ala or  bbbbb2 Val-349 to Ala or Leu eeeee2  abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to Ala or  bbbbb1 Leu eeeee1  abolished the potent inhibition observed with wild-type  bbbbb2 human COX-2 eeeee2  and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to Ala or  bbbbb1 Leu eeeee1  bbbbb2 Ser-530 to Ala eeeee2  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to Ala or  bbbbb1 Leu eeeee1  bbbbb2 Val-349 to Ala or Leu eeeee2  abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to  bbbbb1 Ala eeeee1  or Leu abolished the potent inhibition observed with wild-type  bbbbb2 human COX-2 eeeee2  and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to  bbbbb1 Ala eeeee1  bbbbb2 Ser-530 to Ala eeeee2  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to Ala or Val-349 to  bbbbb1 Ala eeeee1  bbbbb2 Val-349 to Ala or Leu eeeee2  abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to  bbbbb1 Ala eeeee1  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type  bbbbb2 human COX-2 eeeee2  and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to  bbbbb1 Ala eeeee1  bbbbb2 Ser-530 to Ala eeeee2  or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Mutation of Ser-530 to  bbbbb1 Ala eeeee1  or  bbbbb2 Val-349 to Ala or Leu eeeee2  abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs
CRP11	Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted  bbbbb1 inhibitors  eeeee1 and, in the case of lumiracoxib, actually showed  bbbbb2 an in eeeee2 crease in potency
CRP11	Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted  bbbbb1 inhibitors  eeeee1  bbbbb2 poten eeeee2 cy to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency
CRP11	Interestingly, a Val-349 to Ile mutant was inhibited bbbbb1  with equal eeeee1  potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed  bbbbb2 an in eeeee2 crease in potency
CRP11	Interestingly, a Val-349 to Ile mutant was inhibited bbbbb1  with equal eeeee1  potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-su bbbbb2 bstitu eeeee2 ted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency
CRP11	However, we show that hCTR1 is not the major entry route of platinum-drugs and that the  bbbbb1 copper eeeee1  bbbbb2 hCTR1 eeeee2  is not the major entry route of platinum-drugs and that the copper transporter is not internalized in response to extracellular drug
CRP11	Re-evaluation of the Role of hCTR1, the Human High Affinity  bbbbb1 Cu eeeee1  bbbbb2 Human High Affinity Cu Transporter eeeee2  in Pt-Drug Entry into Human Cells
CRP11	Re-evaluation of the Role of hCTR1, the Human High Affinity  bbbbb1 Cu eeeee1  bbbbb2 hCTR1 eeeee2 , the Human High Affinity Cu Transporter in Pt-Drug Entry into Human Cells
CRP11	Re-evaluation of the Role of hCTR1, the Human High Affinity Cu Transporter in  bbbbb1 Pt eeeee1  bbbbb2 Human High Affinity Cu Transporter eeeee2  in Pt-Drug Entry into Human Cells
CRP11	Re-evaluation of the Role of hCTR1, the Human High Affinity Cu Transporter in  bbbbb1 Pt eeeee1  bbbbb2 hCTR1 eeeee2 , the Human High Affinity Cu Transporter in Pt-Drug Entry into Human Cells
CRP11	Clinical trials have been initiated that depend upon regulating membrane levels of hCTR1 bbbbb1  eeeee1  bbbbb2 ulati eeeee2 ng membrane levels of hCTR1
CRP11	We have also compared the effects of extracellular  bbbbb1 copper eeeee1 , which causes regulatory endocytosis of  bbbbb2 hCTR1 eeeee2 , to those of cDDP
CRP11	We have also compared the effects of extracellular copper, which causes regulatory endocytosis of hCTR1, to those of  bbbbb1 cDDP eeeee1  bbbbb2 hCTR1 eeeee2 , to those of cDDP
CRP11	It has been claimed that hCTR1, the human high affinity  bbbbb1 copper eeeee1  bbbbb2 hCTR1 eeeee2 , the human high affinity copper transporter, is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper
CRP11	It has been claimed that hCTR1, the human high affinity  bbbbb1 copper eeeee1  bbbbb2 human high affinity copper transporter eeeee2 , is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper
CRP11	We compared the uptake rates of copper with cDDP (and several analogs) into HEK293 cells over-expressing wild-type or mutant hCTR1, mouse embryonic fibroblasts (mefs) that do or do not express CTR1, and human ovarian tumor cells, sensitive or resistant to  bbbbb1 cDDP eeeee1  bbbbb2 CTR1 eeeee2 , and human ovarian tumor cells, sensitive or resistant to cDDP
CRP11	We compared the uptake rates of copper with cDDP (and several analogs) into HEK293 cells over-expressing wild-type or mutant hCTR1, mouse embryonic fibroblasts (mefs) that do or do not express CTR1, and human ovarian tumor cells, sensitive or resistant to  bbbbb1 cDDP eeeee1  bbbbb2 hCTR1 eeeee2 , mouse embryonic fibroblasts (mefs) that do or do not express CTR1, and human ovarian tumor cells, sensitive or resistant to cDDP
CRP11	Moreover, inhibitory experiments addressed a central role for Rho A in the regulation of vinblastine-induced bbbbb1  apoptosis  eeeee1  bbbbb2 tion  eeeee2 of vinblastine-induced apoptosis of melanoma cells via mitochondrial and non-mitochondrial-dependent mechanisms
CRP11	Moreover, inhibitory experiments addressed a central role for Rho A in the regulation of vinblastine-induced apoptosis of melanoma cells via mitochondrial and non-mitochondrial-dependent mechanisms bbbbb1  eeeee1  bbbbb2 tion  eeeee2 of vinblastine-induced apoptosis of melanoma cells via mitochondrial and non-mitochondrial-dependent mechanisms
CRP11	In the present study, the exposure of melanoma cells to  bbbbb1 vinblastine eeeee1  was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of  bbbbb2 caspase-9 and 3 eeeee2 , and cleavage of Poly (ADP-ribose)-Polymerase
CRP11	In the present study, the exposure of melanoma cells to vinblastine was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of  bbbbb1 Poly (ADP-ribose) eeeee1  bbbbb2 caspase-9 and 3 eeeee2 , and cleavage of Poly (ADP-ribose)-Polymerase
CRP11	In the present study, the exposure of melanoma cells to vinblastine was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of  bbbbb1 Poly (ADP-ribose) eeeee1  bbbbb2 cytochrome c eeeee2  and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase
CRP11	In the present study, the exposure of melanoma cells to vinblastine was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of  bbbbb1 Poly (ADP-ribose) eeeee1  bbbbb2 Poly (ADP-ribose)-Polymerase eeeee2 
CRP11	In the present study, the exposure of melanoma cells to vinblastine was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of  bbbbb1 Poly (ADP-ribose) eeeee1  bbbbb2 apoptosis inducing factor eeeee2 , activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb2 inositol requiring enzyme 1α eeeee2 
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1,  bbbbb2 c-jun-N-terminal kinase eeeee2 , p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  bbbbb2 Ras homologous protein A eeeee2 , the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of  bbbbb2 apoptosis signal-regulating kinase 1 eeeee2 , c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα)  bbbbb2 kinase eeeee2 , and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα ( bbbbb2 IκBα eeeee2 ) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase,  bbbbb2 p38 eeeee2 , inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive  bbbbb1 oxygen eeeee1  species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38,  bbbbb2 inhibitor of kappaBα eeeee2  (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1 -terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb2 inositol requiring enzyme 1α eeeee2 
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1  bbbbb2 c-jun-N-terminal kinase eeeee2 , p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1  bbbbb2 Ras homologous protein A eeeee2 , the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1  bbbbb2 apoptosis signal-regulating kinase 1 eeeee2 , c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1 -terminal kinase, p38, inhibitor of kappaBα (IκBα)  bbbbb2 kinase eeeee2 , and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1 -terminal kinase, p38, inhibitor of kappaBα ( bbbbb2 IκBα eeeee2 ) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1 -terminal kinase,  bbbbb2 p38 eeeee2 , inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun- bbbbb1 N eeeee1 -terminal kinase, p38,  bbbbb2 inhibitor of kappaBα eeeee2  (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb2 inositol requiring enzyme 1α eeeee2 
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1,  bbbbb2 c-jun-N-terminal kinase eeeee2 , p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1  bbbbb2 Ras homologous protein A eeeee2 , the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of  bbbbb2 apoptosis signal-regulating kinase 1 eeeee2 , c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα)  bbbbb2 kinase eeeee2 , and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα ( bbbbb2 IκBα eeeee2 ) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase,  bbbbb2 p38 eeeee2 , inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular  bbbbb1 Ca(2+) eeeee1 , as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38,  bbbbb2 inhibitor of kappaBα eeeee2  (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 inositol requiring enzyme 1α eeeee2 
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 c-jun-N-terminal kinase eeeee2 , p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 Ras homologous protein A eeeee2 , the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 apoptosis signal-regulating kinase 1 eeeee2 , c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 kinase eeeee2 , and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 IκBα eeeee2 ) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 p38 eeeee2 , inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and  bbbbb1 inositol eeeee1  bbbbb2 inhibitor of kappaBα eeeee2  (IκBα) kinase, and inositol requiring enzyme 1α
CRP11	The potent  bbbbb1 histamine eeeee1  bbbbb2 histamine H(1)-receptor eeeee2  antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine
CRP11	Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonists
CRP11	In the presence of the system L inhibitor BCH,  bbbbb1 Na(+) eeeee1 -dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through  bbbbb2 ASCT2 eeeee2 
CRP11	The expression of ASCT2 in WKY and SHR PTE cells and kidney cortices from WKY and SHR was also evaluated. l-[(14)C]alanine uptake was highly dependent on extracellular  bbbbb1 Na(+) eeeee1  bbbbb2 ASCT2 eeeee2  in WKY and SHR PTE cells and kidney cortices from WKY and SHR was also evaluated. l-[(14)C]alanine uptake was highly dependent on extracellular Na(+)
CRP11	The expression of ASCT2 in WKY and SHR PTE cells and kidney cortices from WKY and SHR was also evaluated.  bbbbb1 l-[(14)C]alanine eeeee1  bbbbb2 ASCT2 eeeee2  in WKY and SHR PTE cells and kidney cortices from WKY and SHR was also evaluated. l-[(14)C]alanine uptake was highly dependent on extracellular Na(+)
CRP11	Underexpression of the Na+-dependent neutral  bbbbb1 amino acid eeeee1  transporter  bbbbb2 ASCT2 eeeee2  in the spontaneously hypertensive rat kidney
CRP11	Underexpression of the Na+-dependent neutral  bbbbb1 amino acid eeeee1  bbbbb2 Na+-dependent neutral amino acid transporter eeeee2  ASCT2 in the spontaneously hypertensive rat kidney
CRP11	Underexpression of the  bbbbb1 Na+ eeeee1 -dependent neutral amino acid transporter  bbbbb2 ASCT2 eeeee2  in the spontaneously hypertensive rat kidney
CRP11	Underexpression of the  bbbbb1 Na+ eeeee1  bbbbb2 Na+-dependent neutral amino acid transporter eeeee2  ASCT2 in the spontaneously hypertensive rat kidney
CRP11	Differences in magnitude of  bbbbb1 Na(+) eeeee1 -dependent l-alanine uptake through  bbbbb2 ASCT2 eeeee2  between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells
CRP11	The decapeptide sequence of  bbbbb1 GnRH-II eeeee1  bbbbb2 GnRH-II eeeee2  is conserved in all jawed vertebrate species studied to date
CRP11	Bovine and ovine  bbbbb1 gonadotropin-releasing hormone eeeee1  bbbbb2 Bovine and ovine gonadotropin-releasing hormone (GnRH)-II eeeee2  ligand precursors and type II GnRH receptor genes are functionally inactivated
CRP11	Bovine and ovine  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH)-II ligand precursors and  bbbbb2 type II GnRH receptor eeeee2  genes are functionally inactivated
CRP11	Bovine and ovine gonadotropin-releasing hormone  bbbbb1 (GnRH)-II eeeee1  bbbbb2 Bovine and ovine gonadotropin-releasing hormone (GnRH)-II eeeee2  ligand precursors and type II GnRH receptor genes are functionally inactivated
CRP11	Bovine and ovine gonadotropin-releasing hormone  bbbbb1 (GnRH)-II eeeee1  ligand precursors and  bbbbb2 type II GnRH receptor eeeee2  genes are functionally inactivated
CRP11	The updated bovine type II GnRH receptor gene sequence revealed inactivation by frame shifts, premature stop codons, and  bbbbb1 nucleotide eeeee1  changes specifying nonconservative replacement of amino acid residues, similar to inactivation of  bbbbb2 sheep type II GnRH receptor eeeee2 
CRP11	The updated bovine type II GnRH receptor gene sequence revealed inactivation by frame shifts, premature stop codons, and nucleotide changes specifying nonconservative replacement of  bbbbb1 amino acid eeeee1  residues, similar to inactivation of  bbbbb2 sheep type II GnRH receptor eeeee2 
CRP11	Thus, both species possess prepro- bbbbb1 GnRH-II eeeee1  bbbbb2 prepro-GnRH-II eeeee2  genes encoding inactive peptides, as previously described for chimpanzee GnRH-II
CRP11	Thus, both species possess prepro- bbbbb1 GnRH-II eeeee1  genes encoding inactive peptides, as previously described for  bbbbb2 chimpanzee GnRH-II eeeee2 
CRP11	Thus, both species possess prepro-GnRH-II genes encoding inactive peptides, as previously described for chimpanzee  bbbbb1 GnRH-II eeeee1  bbbbb2 prepro-GnRH-II eeeee2  genes encoding inactive peptides, as previously described for chimpanzee GnRH-II
CRP11	Thus, both species possess prepro-GnRH-II genes encoding inactive peptides, as previously described for chimpanzee  bbbbb1 GnRH-II eeeee1  bbbbb2 chimpanzee GnRH-II eeeee2 
CRP11	A premature stop codon (TGA) replaces the expected tryptophan codon at position seven of  bbbbb1 GnRH-II eeeee1  bbbbb2 GnRH-II eeeee2  in sheep DNA
CRP11	Bovine  bbbbb1 GnRH-II eeeee1  bbbbb2 Bovine GnRH-II eeeee2  peptide was synthesized and pharmacologically characterized
CRP11	New data for cattle (Bos taurus) indicates a gene encoding  bbbbb1 GnRH-II eeeee1  bbbbb2 GnRH-II eeeee2  decapeptide possessing arginine (codon: CGG) rather than tryptophan (TGG) at position three in the mature peptide
CRP11	Bovine primers facilitated cloning of ovine  bbbbb1 GnRH-II eeeee1  bbbbb2 ovine GnRH-II eeeee2  DNA
CRP11	We confirmed the DNA sequence after cloning part of the bovine prepro- bbbbb1 GnRH-II eeeee1  bbbbb2 bovine prepro-GnRH-II eeeee2  gene
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequences bbbbb1  eeeee1  bbbbb2 are intact, encoding well-c eeeee2 onserved protein sequences
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequences bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequences bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequences bbbbb1  eeeee1  bbbbb2 equences eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequences bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequence bbbbb1 s eeeee1  bbbbb2 are intact, encoding well-c eeeee2 onserved protein sequences
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequence bbbbb1 s eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequence bbbbb1 s eeeee1  bbbbb2  eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequence bbbbb1 s eeeee1  bbbbb2 equences eeeee2 
CRP11	In contrast, bovine prepro-GnRH-I and type I GnRH receptor genes are intact, encoding well-conserved protein sequence bbbbb1 s eeeee1  bbbbb2  eeeee2 
CRP11	To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon  bbbbb1 CPT eeeee1  bbbbb2 Top2β eeeee2 -deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells
CRP11	To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon  bbbbb1 CPT eeeee1  exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in  bbbbb2 Top2β eeeee2 -deficient cells
CRP11	To explore the molecular basis for  bbbbb1 CPT eeeee1  hypersensitivity in  bbbbb2 Top2β eeeee2 -deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells
CRP11	To explore the molecular basis for  bbbbb1 CPT eeeee1  hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas  bbbbb2 RNAP LS eeeee2  remained depleted without recovery in Top2β-deficient cells
CRP11	To explore the molecular basis for  bbbbb1 CPT eeeee1  hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in  bbbbb2 Top2β eeeee2 -deficient cells
CRP11	To explore the molecular basis for  bbbbb1 CPT eeeee1  hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the  bbbbb2 RNA polymerase II large subunit eeeee2  (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells
CRP11	To explore the molecular basis for  bbbbb1 CPT eeeee1  hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit ( bbbbb2 RNAP LS eeeee2 ) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells
CRP11	Second, ICRF-187, a Top2 catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to  bbbbb1 CPT eeeee1  bbbbb2 Top2β eeeee2 , specifically sensitized MEFs to CPT
CRP11	Second, ICRF-187, a Top2 catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to  bbbbb1 CPT eeeee1  bbbbb2 Top2 eeeee2  catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT
CRP11	Interestingly, RNAP LS depletion has been well documented to lead to p53-dep bbbbb1 end eeeee1  bbbbb2 ument eeeee2 ed to lead to p53-dependent apoptosis
CRP11	Topoisomerase IIβ deficiency enhances  bbbbb1 camptothecin eeeee1  bbbbb2 Topoisomerase IIβ eeeee2  deficiency enhances camptothecin-induced apoptosis
CRP11	First, quiescent mouse embryonic fibroblasts (MEFs) lacking Top2β were shown to be hypersensitive to  bbbbb1 CPT eeeee1  bbbbb2 Top2β eeeee2  were shown to be hypersensitive to CPT with prominent induction of apoptosis
CRP11	Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of  bbbbb1 tiapride eeeee1  bbbbb2 dopamine D2 receptor (DRD2) exon 8 eeeee2  genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal
CRP11	Influence of the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptor (DRD2) exon 8 eeeee2  genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal
CRP11	Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of  bbbbb1 alcohol eeeee1  bbbbb2 dopamine D2 receptor (DRD2) exon 8 eeeee2  genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal
CRP11	DRD2 E8 A/A genotype was associated with increased dose of  bbbbb1 tiapride eeeee1  bbbbb2 DRD2 E8 eeeee2  A/A genotype was associated with increased dose of tiapride during a 9-day detoxification therapy and with increased anxiety and depression scores on admission and 2 weeks later
CRP11	We tested the hypothesis that allelic variants of the human  bbbbb1 dopamine eeeee1  bbbbb2 human dopamine D2 receptor E8 eeeee2  genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	We tested the hypothesis that allelic variants of the human  bbbbb1 dopamine eeeee1  D2 receptor E8 genotype are associated with (i)  bbbbb2 dopamine D2 eeeee2  antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	We tested the hypothesis that allelic variants of the human dopamine D2 receptor E8 genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of  bbbbb1 alcohol eeeee1  bbbbb2 human dopamine D2 receptor E8 eeeee2  genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	We tested the hypothesis that allelic variants of the human dopamine D2 receptor E8 genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of  bbbbb1 alcohol eeeee1  bbbbb2 dopamine D2 eeeee2  antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	We tested the hypothesis that allelic variants of the human dopamine D2 receptor E8 genotype are associated with (i)  bbbbb1 dopamine eeeee1  bbbbb2 human dopamine D2 receptor E8 eeeee2  genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	We tested the hypothesis that allelic variants of the human dopamine D2 receptor E8 genotype are associated with (i)  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 eeeee2  antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50)
CRP11	Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of  bbbbb1 acetylcholine eeeee1  bbbbb2 cholinesterase eeeee2  inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase
CRP11	GPxs reduce hydroperoxides to the corresponding alcohols by means of glutathione ( bbbbb1 GSH eeeee1  bbbbb2 GPxs eeeee2  reduce hydroperoxides to the corresponding alcohols by means of glutathione (GSH)
CRP11	GPxs reduce hydroperoxides to the corresponding alcohols by means of  bbbbb1 glutathione eeeee1  bbbbb2 GPxs eeeee2  reduce hydroperoxides to the corresponding alcohols by means of glutathione (GSH)
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione peroxidases eeeee2  and redox-regulated transcription factors
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1),  bbbbb2 phospholipid hydroperoxide GPx eeeee2  (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx ( bbbbb2 cGPx eeeee2 , GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3),  bbbbb2 gastrointestinal GPx eeeee2  (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx ( bbbbb2 PHGPX eeeee2 , GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx,  bbbbb2 GPx2 eeeee2 ) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in  bbbbb2 humans, GPx6 eeeee2 , which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases ( bbbbb2 GPxs eeeee2 ) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx ( bbbbb2 pGPX eeeee2 , GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx ( bbbbb2 GI-GPx eeeee2 , GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX,  bbbbb2 GPx4 eeeee2 ), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx,  bbbbb2 GPx1 eeeee2 ), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4),  bbbbb2 plasma GPx eeeee2  (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals:  bbbbb2 cytosolic GPx eeeee2  (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidases eeeee2  (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX, GPx3), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	Analysis of the selenoproteome identified five  bbbbb1 glutathione eeeee1  peroxidases (GPxs) in mammals: cytosolic GPx (cGPx, GPx1), phospholipid hydroperoxide GPx (PHGPX, GPx4), plasma GPx (pGPX,  bbbbb2 GPx3 eeeee2 ), gastrointestinal GPx (GI-GPx, GPx2) and, in humans, GPx6, which is restricted to the olfactory system
CRP11	The activities of ABCA1 and other ATP binding cassette superfamily members are inhibited by the drug  bbbbb1 glyburide eeeee1 , and  bbbbb2 SR-BI eeeee2 -mediated lipid transport is blocked by small molecule inhibitors called BLTs
CRP11	The activities of ABCA1 and other  bbbbb1 ATP eeeee1  bbbbb2 ATP binding cassette superfamily eeeee2  members are inhibited by the drug glyburide, and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs
CRP11	The activities of ABCA1 and other  bbbbb1 ATP eeeee1  bbbbb2 ABCA1 eeeee2  and other ATP binding cassette superfamily members are inhibited by the drug glyburide, and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs
CRP11	The activities of ABCA1 and other  bbbbb1 ATP eeeee1  binding cassette superfamily members are inhibited by the drug glyburide, and  bbbbb2 SR-BI eeeee2 -mediated lipid transport is blocked by small molecule inhibitors called BLTs
CRP11	Here, we show that one  bbbbb1 BLT eeeee1 , [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor  bbbbb2 apoA-I eeeee2  at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)
CRP11	Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ( bbbbb1 BLT-4 eeeee1 ), blocked ABCA1-mediated cholesterol efflux to lipid-poor  bbbbb2 apoA-I eeeee2  at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)
CRP11	Here, we show that one BLT, [ bbbbb1 1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea eeeee1 ] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor  bbbbb2 apoA-I eeeee2  at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)
CRP11	Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated  bbbbb1 cholesterol eeeee1  efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of  bbbbb2 SR-BI eeeee2  (IC(50) approximately 55-60 microM)
CRP11	Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated  bbbbb1 cholesterol eeeee1  efflux to lipid-poor  bbbbb2 apoA-I eeeee2  at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)
CRP11	A1 mediates the efflux of unesterified  bbbbb1 cholesterol eeeee1  and phospholipids from cells to lipid-poor apolipoprotein A-I ( bbbbb2 apoA-I eeeee2 )
CRP11	A1 mediates the efflux of unesterified  bbbbb1 cholesterol eeeee1  and phospholipids from cells to lipid-poor  bbbbb2 apolipoprotein A-I eeeee2  (apoA-I)
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  dos eeeee2 es using Hill or Michaelis-Menten models
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  dos eeeee2 es using Hill or Michaelis-Menten models
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested doses using Hill or Michaelis-Menten models bbbbb1  eeeee1  bbbbb2  dos eeeee2 es using Hill or Michaelis-Menten models
CRP11	Plateau activities could be appropriately fitted versus ingested bbbbb1  dos eeeee1 es using Hill or Michaelis-Menten models bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested bbbbb1  dos eeeee1 es using Hill or Michaelis-Menten models bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested bbbbb1  dos eeeee1 es using Hill or Michaelis-Menten models bbbbb2  eeeee2 
CRP11	Plateau activities could be appropriately fitted versus ingested bbbbb1  dos eeeee1  bbbbb2  dos eeeee2 es using Hill or Michaelis-Menten models
CRP11	After 28days of exposure to a 6μg/day dose,  bbbbb1 EROD eeeee1  bbbbb2 EROD eeeee2  activity was found to be 91, 152 and 94-fold increased in lymphocytes, liver and brain, respectively, compared to day 0
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin  bbbbb1 A deficie eeeee1 ncy has been assigned to the ecosensitiveness of the unfavourable environment bbbbb2  eeeee2 
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin  bbbbb1 A deficie eeeee1 ncy has been assigned to the ecosensitiveness of the unfavourable environment bbbbb2  eeeee2 
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin  bbbbb1 A deficie eeeee1 ncy has been assigned to the ecosensitiveness of the unfavourable environment bbbbb2  eeeee2 
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin A deficiency has been assigned to the ecosensitiveness of the unfavourable environment bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin A deficiency has been assigned to the ecosensitiveness of the unfavourable environment bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The isolated increasing of alpha-1 glycoprotein acid in boys with vitamin A deficiency has been assigned to the ecosensitiveness of the unfavourable environment bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This study showed that the  bbbbb1 retinol eeeee1  bbbbb2 retinol binding protein eeeee2  and the immunoglobulin A are lower in children with vitamin A deficiency
CRP11	This study showed that the  bbbbb1 retinol eeeee1  binding protein and the  bbbbb2 immunoglobulin A eeeee2  are lower in children with vitamin A deficiency
CRP11	This study showed that the retinol binding protein and the immunoglobulin A are lower in children with  bbbbb1 vitamin A eeeee1  bbbbb2 retinol binding protein eeeee2  and the immunoglobulin A are lower in children with vitamin A deficiency
CRP11	This study showed that the retinol binding protein and the immunoglobulin A are lower in children with  bbbbb1 vitamin A eeeee1  bbbbb2 immunoglobulin A eeeee2  are lower in children with vitamin A deficiency
CRP11	On the other hand, an isolated increase of alpha-1 glycoprotein acid has been observed in boys with  bbbbb1 vitamin A eeeee1  bbbbb2 alpha-1 glycoprotein acid eeeee2  has been observed in boys with vitamin A deficiency
CRP11	Results showed that 96 children (36.6%) presented a  bbbbb1 vitamin A eeeee1  deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/ bbbbb2 Transthyretin eeeee2  molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a  bbbbb1 vitamin A eeeee1  deficiency (vitamin A < 200 microg/L with a retinol binding protein/ bbbbb2 transthyretin eeeee2  molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a  bbbbb1 vitamin A eeeee1  deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb2 Retinol Binding Protein eeeee2 /Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a  bbbbb1 vitamin A eeeee1  deficiency (vitamin A < 200 microg/L with a  bbbbb2 retinol binding protein eeeee2 /transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of  bbbbb1 vitamin A eeeee1  (vitamin A > or = 200 microg/L with a Retinol Binding Protein/ bbbbb2 Transthyretin eeeee2  molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of  bbbbb1 vitamin A eeeee1  bbbbb2 transthyretin eeeee2  molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of  bbbbb1 vitamin A eeeee1  (vitamin A > or = 200 microg/L with a  bbbbb2 Retinol Binding Protein eeeee2 /Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of  bbbbb1 vitamin A eeeee1  bbbbb2 retinol binding protein eeeee2 /transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency ( bbbbb1 vitamin A eeeee1  < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/ bbbbb2 Transthyretin eeeee2  molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency ( bbbbb1 vitamin A eeeee1  < 200 microg/L with a retinol binding protein/ bbbbb2 transthyretin eeeee2  molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency ( bbbbb1 vitamin A eeeee1  < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb2 Retinol Binding Protein eeeee2 /Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency ( bbbbb1 vitamin A eeeee1  < 200 microg/L with a  bbbbb2 retinol binding protein eeeee2 /transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A ( bbbbb1 vitamin A eeeee1  > or = 200 microg/L with a Retinol Binding Protein/ bbbbb2 Transthyretin eeeee2  molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A ( bbbbb1 vitamin A eeeee1  bbbbb2 transthyretin eeeee2  molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A ( bbbbb1 vitamin A eeeee1  > or = 200 microg/L with a  bbbbb2 Retinol Binding Protein eeeee2 /Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A ( bbbbb1 vitamin A eeeee1  bbbbb2 retinol binding protein eeeee2 /transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb1 Retinol eeeee1  Binding Protein/ bbbbb2 Transthyretin eeeee2  molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb1 Retinol eeeee1  bbbbb2 transthyretin eeeee2  molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb1 Retinol eeeee1  bbbbb2 Retinol Binding Protein eeeee2 /Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a  bbbbb1 Retinol eeeee1  bbbbb2 retinol binding protein eeeee2 /transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08)
CRP11	The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because  bbbbb1 Vitamin E eeeee1  bbbbb2 ENT1 eeeee2  because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs
CRP11	The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit  bbbbb1 [3H]adenosine eeeee1  bbbbb2 ENT1 eeeee2  because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs
CRP11	Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism
CRP11	Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in  bbbbb1 glucose eeeee1  bbbbb2 PPAR(gamma) eeeee2 ) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism
CRP11	Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 -responsive genes involved in glucose and lipid metabolism
CRP11	Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in  bbbbb1 glucose eeeee1  bbbbb2 peroxisome proliferator-activated receptor gamma eeeee2  (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism
CRP11	The present study studied the effects of three  bbbbb1 thiazolidinediones eeeee1 , troglitazone, pioglitazone and ciglitazone, on  bbbbb2 ENT1 eeeee2  in the human aortic smooth muscle cells (HASMCs)
CRP11	The present study studied the effects of three thiazolidinediones,  bbbbb1 troglitazone eeeee1 , pioglitazone and ciglitazone, on  bbbbb2 ENT1 eeeee2  in the human aortic smooth muscle cells (HASMCs)
CRP11	The present study studied the effects of three thiazolidinediones, troglitazone,  bbbbb1 pioglitazone eeeee1  and ciglitazone, on  bbbbb2 ENT1 eeeee2  in the human aortic smooth muscle cells (HASMCs)
CRP11	The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and  bbbbb1 ciglitazone eeeee1 , on  bbbbb2 ENT1 eeeee2  in the human aortic smooth muscle cells (HASMCs)
CRP11	The effect of  bbbbb1 troglitazone eeeee1  on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of  bbbbb2 ENT1 eeeee2 
CRP11	The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that  bbbbb1 troglitazone eeeee1  bbbbb2 ENT1 eeeee2  was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1
CRP11	The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that  bbbbb1 troglitazone eeeee1  bbbbb2 PPAR(gamma) eeeee2 -independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1
CRP11	Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that  bbbbb1 troglitazone eeeee1  bbbbb2 nucleoside transporter eeeee2  deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2
CRP11	Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that  bbbbb1 troglitazone eeeee1  bbbbb2 ENT2 eeeee2 , it was found that troglitazone inhibited ENT1 but had no effect on ENT2
CRP11	Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that  bbbbb1 troglitazone eeeee1  bbbbb2 ENT1 eeeee2  and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2
CRP11	Introduction: 5-Lipoxygenase (5-LO) is a crucial enzyme of the  bbbbb1 arachidonic acid eeeee1  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of  bbbbb2 FLAP eeeee2 , the 5-LO-activating protein
CRP11	Introduction: 5-Lipoxygenase (5-LO) is a crucial enzyme of the  bbbbb1 arachidonic acid eeeee1  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the  bbbbb2 5-LO-activating protein eeeee2 
CRP11	In the interaction of  bbbbb1 GAL eeeee1  and  bbbbb2 CAR eeeee2 , AChE inhibition was stronger but without any statistical significance
CRP11	In the interaction of GAL and  bbbbb1 CAR eeeee1  bbbbb2 CAR eeeee2 , AChE inhibition was stronger but without any statistical significance
CRP11	In the interaction of GAL and  bbbbb1 CAR eeeee1 ,  bbbbb2 AChE eeeee2  inhibition was stronger but without any statistical significance
CRP11	Above-median  bbbbb1 N eeeee1 -BNP and  bbbbb2 adrenomedullin eeeee2  levels conferred increased risks (all p < 0.001) of mortality (risk ratios [95% confidence intervals]: 4.67 [2-10.9] and 3.92 [1.76-8.7], respectively) and hospital admission with heart failure (4.7 [2.2-10.3] and 2.4 [1.3-4.5], respectively)
CRP11	Above-median  bbbbb1 N eeeee1  bbbbb2 N-BNP eeeee2  and adrenomedullin levels conferred increased risks (all p < 0.001) of mortality (risk ratios [95% confidence intervals]: 4.67 [2-10.9] and 3.92 [1.76-8.7], respectively) and hospital admission with heart failure (4.7 [2.2-10.3] and 2.4 [1.3-4.5], respectively)
CRP11	NS: In patients with established ischemic LV dysfunction, plasma N-BNP and adrenomedullin ar bbbbb1 e eeeee1  independ bbbbb2 ent predictors eeeee2  of mortality and heart failure
CRP11	NS: In patients with established ischemic LV dysfunction, plasma N-BNP and adrenomedullin ar bbbbb1 e eeeee1  bbbbb2 e ind eeeee2 ependent predictors of mortality and heart failure
CRP11	Plasma  bbbbb1 N eeeee1  bbbbb2 N-terminal pro-brain natriuretic peptide eeeee2  and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
CRP11	Plasma  bbbbb1 N eeeee1 -terminal pro-brain natriuretic peptide and  bbbbb2 adrenomedullin eeeee2 : prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
CRP11	Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from  bbbbb1 carvedilol eeeee1  bbbbb2 N-terminal pro-brain natriuretic peptide eeeee2  and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
CRP11	Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from  bbbbb1 carvedilol eeeee1  bbbbb2 adrenomedullin eeeee2 : prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
CRP11	Plasma  bbbbb1 N eeeee1 -BNP and  bbbbb2 adrenomedullin eeeee2  were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to carvedilol or placebo, added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without digoxin)
CRP11	Plasma  bbbbb1 N eeeee1  bbbbb2 N-BNP eeeee2  and adrenomedullin were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to carvedilol or placebo, added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without digoxin)
CRP11	Plasma N-BNP and adrenomedullin were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to  bbbbb1 carvedilol eeeee1  bbbbb2 adrenomedullin eeeee2  were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to carvedilol or placebo, added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without digoxin)
CRP11	Plasma N-BNP and adrenomedullin were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to  bbbbb1 carvedilol eeeee1  bbbbb2 N-BNP eeeee2  and adrenomedullin were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to carvedilol or placebo, added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without digoxin)
CRP11	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor,  bbbbb1 5-hydroxytryptophan eeeee1 , whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of minaprine on the  bbbbb1 cycloheximide eeeee1 -induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of  bbbbb1 minaprine eeeee1  on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin ( bbbbb1 5-HT eeeee1 ) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a  bbbbb1 serotonin eeeee1  (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser,  bbbbb1 p-chloroamphetamine eeeee1 , and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a  bbbbb1 5-HT eeeee1  precursor, 5-hydroxytryptophan, whereas a  bbbbb2 5-HT1A eeeee2 -selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive
CRP11	Clomipramine-induced hyperglycemia was reduced by prior adrenalectomy bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Clomipramine-induced hyperglycemia was reduced by prior adrenalectomy bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The 5-HT(2B/2C)-receptor antagonist  bbbbb1 SB 206553 eeeee1  facilitated hyperglycemia induced by clomipramine, although the  bbbbb2 5-HT(2A) eeeee2 -receptor antagonist ketanserin was without effect
CRP11	The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist  bbbbb1 ketanserin eeeee1  bbbbb2 5-HT(2B/2C)-receptor eeeee2  antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect
CRP11	The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by  bbbbb1 clomipramine eeeee1 , although the  bbbbb2 5-HT(2A) eeeee2 -receptor antagonist ketanserin was without effect
CRP11	The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by  bbbbb1 clomipramine eeeee1  bbbbb2 5-HT(2B/2C)-receptor eeeee2  antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist  bbbbb1 LY 53857 eeeee1  enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the  bbbbb2 5-HT(3/4)-receptor eeeee2  antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist  bbbbb1 LY 53857 eeeee1  enhanced clomipramine-induced hyperglycemia, while the  bbbbb2 5-HT(1A/1B)-receptor eeeee2  antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist  bbbbb1 LY 53857 eeeee1  bbbbb2 5-HT(1/2/5/7)-receptor eeeee2  antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist  bbbbb1 (-)-propranolol eeeee1  bbbbb2 5-HT(2A/2B/2C)-receptor eeeee2  antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist  bbbbb1 (-)-propranolol eeeee1  and the  bbbbb2 5-HT(3/4)-receptor eeeee2  antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist  bbbbb1 (-)-propranolol eeeee1  bbbbb2 5-HT(1/2/5/7)-receptor eeeee2  antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced  bbbbb1 clomipramine eeeee1  bbbbb2 5-HT(2A/2B/2C)-receptor eeeee2  antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced  bbbbb1 clomipramine eeeee1 -induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the  bbbbb2 5-HT(3/4)-receptor eeeee2  antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced  bbbbb1 clomipramine eeeee1 -induced hyperglycemia, while the  bbbbb2 5-HT(1A/1B)-receptor eeeee2  antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced  bbbbb1 clomipramine eeeee1  bbbbb2 5-HT(1/2/5/7)-receptor eeeee2  antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist  bbbbb1 tropisetron eeeee1  bbbbb2 5-HT(2A/2B/2C)-receptor eeeee2  antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist  bbbbb1 tropisetron eeeee1  bbbbb2 5-HT(1A/1B)-receptor eeeee2  antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist  bbbbb1 tropisetron eeeee1  bbbbb2 5-HT(1/2/5/7)-receptor eeeee2  antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it
CRP11	Rasagiline is a novel, potent, and irreversible  bbbbb1 monoamine eeeee1  oxidase type B ( bbbbb2 MAO-B eeeee2 ) inhibitor which has been approved for treatment of PD
CRP11	Rasagiline is a novel, potent, and irreversible  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase type B eeeee2  (MAO-B) inhibitor which has been approved for treatment of PD
CRP11	We report here that lovastatin, a drug clinically used for lowering  bbbbb1 cholesterol eeeee1  levels, inhibits the interaction of human LFA-1 with its counter-receptor  bbbbb2 intercellular adhesion molecule-1 eeeee2 
CRP11	We report here that lovastatin, a drug clinically used for lowering  bbbbb1 cholesterol eeeee1  levels, inhibits the interaction of  bbbbb2 human LFA-1 eeeee2  with its counter-receptor intercellular adhesion molecule-1
CRP11	This was accompanied by a significant increase in levels of serum alanine transaminase, aspartate transaminase, and liver  bbbbb1 malondialdehyde eeeee1  bbbbb2 alanine transaminase eeeee2 , aspartate transaminase, and liver malondialdehyde content
CRP11	This was accompanied by a significant increase in levels of serum alanine transaminase, aspartate transaminase, and liver  bbbbb1 malondialdehyde eeeee1  bbbbb2 aspartate transaminase eeeee2 , and liver malondialdehyde content
CRP11	This was accompanied by a significant increase in levels of serum  bbbbb1 alanine eeeee1  bbbbb2 alanine transaminase eeeee2 , aspartate transaminase, and liver malondialdehyde content
CRP11	This was accompanied by a significant increase in levels of serum  bbbbb1 alanine eeeee1  transaminase,  bbbbb2 aspartate transaminase eeeee2 , and liver malondialdehyde content
CRP11	This was accompanied by a significant increase in levels of serum alanine transaminase,  bbbbb1 aspartate eeeee1  bbbbb2 alanine transaminase eeeee2 , aspartate transaminase, and liver malondialdehyde content
CRP11	This was accompanied by a significant increase in levels of serum alanine transaminase,  bbbbb1 aspartate eeeee1  bbbbb2 aspartate transaminase eeeee2 , and liver malondialdehyde content
CRP11	Furthermore, sinapic acid reduced hepatic  bbbbb1 hydroxyproline eeeee1  content, which correlated with a reduction in the expression of  bbbbb2 type I collagen eeeee2  mRNA and histological analysis of collagen in liver tissue
CRP11	Furthermore, sinapic acid reduced hepatic  bbbbb1 hydroxyproline eeeee1  content, which correlated with a reduction in the expression of type I collagen mRNA and histological analysis of  bbbbb2 collagen eeeee2  in liver tissue
CRP11	Phthalide is structurally related to isatin and  bbbbb1 phthalimide eeeee1  and it is demonstrated here that substitution at C6 of the phthalide moiety yields compounds endowed with high binding affinities to both  bbbbb2 human MAO eeeee2  isoforms
CRP11	Phthalide is structurally related to  bbbbb1 isatin eeeee1  and phthalimide and it is demonstrated here that substitution at C6 of the phthalide moiety yields compounds endowed with high binding affinities to both  bbbbb2 human MAO eeeee2  isoforms
CRP11	 bbbbb1 Phthalide eeeee1  is structurally related to isatin and phthalimide and it is demonstrated here that substitution at C6 of the phthalide moiety yields compounds endowed with high binding affinities to both  bbbbb2 human MAO eeeee2  isoforms
CRP11	Phthalide is structurally related to isatin and phthalimide and it is demonstrated here that substitution at C6 of the  bbbbb1 phthalide eeeee1  moiety yields compounds endowed with high binding affinities to both  bbbbb2 human MAO eeeee2  isoforms
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [ bbbbb1 2-benzofuran-1(3H)-one eeeee1  bbbbb2 MAO eeeee2 ) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [ bbbbb1 2-benzofuran-1(3H)-one eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO eeeee2 ) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency  bbbbb1 monoamine eeeee1  oxidase (MAO) inhibitors, the present study examines the  bbbbb2 MAO eeeee2  inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules,  bbbbb1 isatin eeeee1  and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the  bbbbb2 MAO eeeee2  inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of  bbbbb1 phthalide eeeee1  bbbbb2 MAO eeeee2 ) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of  bbbbb1 phthalide eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Based on recent reports that the small molecules, isatin and  bbbbb1 phthalimide eeeee1 , are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the  bbbbb2 MAO eeeee2  inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues
CRP11	Inhibition of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  by phthalide analogues
CRP11	Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in  bbbbb1 imatinib eeeee1  bbbbb2 SRC eeeee2  and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance
CRP11	Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in  bbbbb1 imatinib eeeee1  bbbbb2 kinase eeeee2  inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance
CRP11	Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in  bbbbb1 imatinib eeeee1  bbbbb2 BCR eeeee2 -ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance
CRP11	Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in  bbbbb1 imatinib eeeee1  bbbbb2 ABL eeeee2 , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance
CRP11	Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3  bbbbb1 potassium eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties
CRP11	Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3  bbbbb1 potassium eeeee1  bbbbb2 potassium channel eeeee2  openers, depress cortical neuron activity and exhibit anticonvulsant properties
CRP11	Enhancement of KCNQ2/Q3  bbbbb1 potassium eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  potassium currents may provide an important target for antiepileptic drug development
CRP11	Finally, a third nonadrenergic internal membrane site, labeled by  bbbbb1 [3H]IDX eeeee1 , was consistent with a  bbbbb2 subtype-I2 imidazol(in)e receptor eeeee2  site (rank order: cirazoline > IDX >> amiloride > moxonidine > clonidine)
CRP11	Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a subtype-I2  bbbbb1 imidazol(in)e eeeee1  bbbbb2 subtype-I2 imidazol(in)e receptor eeeee2  site (rank order: cirazoline > IDX >> amiloride > moxonidine > clonidine)
CRP11	Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to human subtype-I1  bbbbb1 imidazol(in)e eeeee1  bbbbb2 human subtype-I1 imidazol(in)e receptor eeeee2  sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > IDX > amiloride)
CRP11	Affinities for the major nonadrenergic  bbbbb1 [125I]PIC eeeee1  binding site were highly comparable to  bbbbb2 human subtype-I1 imidazol(in)e receptor eeeee2  sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > IDX > amiloride)
CRP11	These nonadrenergic sites were radiolabeled even in the presence of a 10 microM  bbbbb1 norepinephrine eeeee1  mask of  bbbbb2 alpha-2 adrenoceptors eeeee2 
CRP11	Human platelets are shown to possess at least two high-affinity,  bbbbb1 imidazol(in)e eeeee1 -preferring binding sites that are pharmacologically distinct from  bbbbb2 alpha-2 adrenoceptors eeeee2 
CRP11	Thus, based on differential subcellular distributions and affinity constants, human platelets appear to possess imidazoline receptors (subtype-I1 imidazol(in)e receptor and subtype-I2 imidazol(in)e recepto bbbbb1 r), plus a  eeeee1  bbbbb2 r), plus a novel guan eeeee2 abenz-sensitive site, as well as an alpha-2A adrenoceptor
CRP11	Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as  bbbbb1 Serine eeeee1  bbbbb2 Serine and Cysteine Protease eeeee2  Inhibitors. α-Amino-α´-halomethylketones are interesting scaffolds bearing (at least) two sequential electrophilic carbons that by interacting with the nucleophilic moieties of several enzymes, represent the ideal candidates for in vivo and in vitro inhibition studies
CRP11	Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and  bbbbb1 Cysteine eeeee1  bbbbb2 Serine and Cysteine Protease eeeee2  Inhibitors. α-Amino-α´-halomethylketones are interesting scaffolds bearing (at least) two sequential electrophilic carbons that by interacting with the nucleophilic moieties of several enzymes, represent the ideal candidates for in vivo and in vitro inhibition studies
CRP11	Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors. α-Amino-α´-halomethylketones are interesting scaffolds bearing (at least) two sequential electrophilic  bbbbb1 carbons eeeee1  bbbbb2 Serine and Cysteine Protease eeeee2  Inhibitors. α-Amino-α´-halomethylketones are interesting scaffolds bearing (at least) two sequential electrophilic carbons that by interacting with the nucleophilic moieties of several enzymes, represent the ideal candidates for in vivo and in vitro inhibition studies
CRP11	Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors.  bbbbb1 α-Amino-α´-halomethylketones eeeee1  bbbbb2 Serine and Cysteine Protease eeeee2  Inhibitors. α-Amino-α´-halomethylketones are interesting scaffolds bearing (at least) two sequential electrophilic carbons that by interacting with the nucleophilic moieties of several enzymes, represent the ideal candidates for in vivo and in vitro inhibition studies
CRP11	In addition, the number and area of glutathione  bbbbb1 S eeeee1 -transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen ( bbbbb2 PCNA eeeee2 ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of glutathione  bbbbb1 S eeeee1 -transferase placental form (GST-P) positive foci and  bbbbb2 proliferating cell nuclear antigen eeeee2  (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferase placental form eeeee2  (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of glutathione  bbbbb1 S eeeee1 -transferase placental form ( bbbbb2 GST-P eeeee2 ) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of  bbbbb1 glutathione eeeee1  S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen ( bbbbb2 PCNA eeeee2 ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of  bbbbb1 glutathione eeeee1  S-transferase placental form (GST-P) positive foci and  bbbbb2 proliferating cell nuclear antigen eeeee2  (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase placental form eeeee2  (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In addition, the number and area of  bbbbb1 glutathione eeeee1  S-transferase placental form ( bbbbb2 GST-P eeeee2 ) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals
CRP11	In this study, a gpt delta transgenic rat model was used to clarify whether genotoxic mechanisms are involved in  bbbbb1 MEG eeeee1  bbbbb2 gpt eeeee2  delta transgenic rat model was used to clarify whether genotoxic mechanisms are involved in MEG-induced hepatocarcinogenesis following medium-term exposure
CRP11	The aim of the present study was to investigate the role of central 5-HT3 receptors on the control of blood  bbbbb1 glucose eeeee1  bbbbb2 5-HT3 eeeee2  receptors on the control of blood glucose in stressed and non-stressed rats in both fasted and fed states
CRP11	Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood  bbbbb1 glucose eeeee1  bbbbb2 5-HT3 eeeee2  receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states
CRP11	The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with  bbbbb1 m-CPBG eeeee1  bbbbb2 5-HT3 eeeee2  receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors
CRP11	The hyperglycemic effect of  bbbbb1 m-CPBG eeeee1  central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with  bbbbb2 5-HT3 eeeee2  receptors
CRP11	Central 5-HT3 receptor stimulation by m-CPBG increases blood  bbbbb1 glucose eeeee1  bbbbb2 5-HT3 eeeee2  receptor stimulation by m-CPBG increases blood glucose in rats
CRP11	The immunosuppressive effects of T3 SCI were caused by  bbbbb1 NE eeeee1  acting at beta2-adrenergic receptors (beta2AR) and could be reversed using  bbbbb2 beta2AR eeeee2  blockers
CRP11	Butyrylcholinesterase (BChE) is the leading pretreatment candidate against exposure to  bbbbb1 organophosphates eeeee1  bbbbb2 Butyrylcholinesterase eeeee2  (BChE) is the leading pretreatment candidate against exposure to organophosphates (OPs), which pose an ever increasing public and military health
CRP11	Butyrylcholinesterase (BChE) is the leading pretreatment candidate against exposure to  bbbbb1 organophosphates eeeee1  bbbbb2 BChE eeeee2 ) is the leading pretreatment candidate against exposure to organophosphates (OPs), which pose an ever increasing public and military health
CRP11	Pulmonary delivery of an aerosolized recombinant human butyrylcholinesterase pretreatment protects against aerosolized  bbbbb1 paraoxon eeeee1  bbbbb2 human butyrylcholinesterase eeeee2  pretreatment protects against aerosolized paraoxon in macaques
CRP11	In contrast to parenteral delivery of rBChE, which currently requires posttranslatio bbbbb1 nal modi eeeee1 fication for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-paraox bbbbb2 on (Px) eeeee2  was able to prevent inhibition of circulating cholinesterase in a dose-dependent manner
CRP11	In contrast to parenteral delivery of rBChE, which currently requires posttranslatio bbbbb1 nal modi eeeee1  bbbbb2  curr eeeee2 ently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-paraoxon (Px) was able to prevent inhibition of circulating cholinesterase in a dose-dependent manner
CRP11	Key marker of diabetes in cells is the insulin dependent  bbbbb1 glucose eeeee1  transporter-4 ( bbbbb2 Glut-4 eeeee2 ) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and palmatine, respectively
CRP11	Key marker of diabetes in cells is the insulin dependent  bbbbb1 glucose eeeee1  bbbbb2 insulin dependent glucose transporter-4 eeeee2  (Glut-4) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and palmatine, respectively
CRP11	Next to Glut-4, the predominant protein influencing glucose metabolism is PPARα and γ whose expressions w bbbbb1 ere also  eeeee1  bbbbb2 nant pr eeeee2 otein influencing glucose metabolism is PPARα and γ whose expressions were also positively modulated
CRP11	Next to Glut-4, the predominant protein influencing g bbbbb1 lucose  eeeee1 metabolism is PPARα and γ whose expressions were also positively modulated bbbbb2  eeeee2 
CRP11	Next to Glut-4, the predominant protein influencing g bbbbb1 lucose  eeeee1  bbbbb2 nant pr eeeee2 otein influencing glucose metabolism is PPARα and γ whose expressions were also positively modulated
CRP11	Conversely, AMPK inhibitor  bbbbb1 compound C eeeee1  or  bbbbb2 GSK3β eeeee2  inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells
CRP11	Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by  bbbbb1 ursolic acid eeeee1  bbbbb2 GSK3β eeeee2  inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells
CRP11	Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by  bbbbb1 ursolic acid eeeee1  bbbbb2 AMPK eeeee2  inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells
CRP11	Conversely, AMPK inhibitor compound C or GSK3β inhibitor  bbbbb1 SB216763 eeeee1  bbbbb2 AMPK eeeee2  inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells
CRP11	Activation of  bbbbb1 AMP eeeee1 -activated Protein Kinase and Phosphorylation of  bbbbb2 Glycogen Synthase Kinase3 β eeeee2  Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells
CRP11	Activation of  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated Protein Kinase eeeee2  and Phosphorylation of Glycogen Synthase Kinase3 β Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  polymerase ( bbbbb2 PARP eeeee2 ) and caspase3, attenuated the expression of astrocyte elevated gene (AEG1) and survivin in HepG2 cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  polymerase (PARP) and caspase3, attenuated the expression of  bbbbb2 astrocyte elevated gene eeeee2  (AEG1) and survivin in HepG2 cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  polymerase (PARP) and caspase3, attenuated the expression of astrocyte elevated gene (AEG1) and  bbbbb2 survivin eeeee2  in HepG2 cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  polymerase (PARP) and  bbbbb2 caspase3 eeeee2 , attenuated the expression of astrocyte elevated gene (AEG1) and survivin in HepG2 cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  bbbbb2 poly-ADP-ribose polymerase eeeee2  (PARP) and caspase3, attenuated the expression of astrocyte elevated gene (AEG1) and survivin in HepG2 cells
CRP11	Also, ursolic acid enhanced the cleavages of  bbbbb1 poly-ADP-ribose eeeee1  polymerase (PARP) and caspase3, attenuated the expression of astrocyte elevated gene ( bbbbb2 AEG1 eeeee2 ) and survivin in HepG2 cells
CRP11	Interestingly,  bbbbb1 ursolic acid eeeee1  increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and  bbbbb2 mTOR eeeee2  in HepG2 cells
CRP11	Interestingly,  bbbbb1 ursolic acid eeeee1  increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of  bbbbb2 AKT eeeee2  and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas  bbbbb1 ursolic acid eeeee1  bbbbb2 AMPK eeeee2  and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas  bbbbb1 ursolic acid eeeee1  bbbbb2 GSK3β eeeee2  at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas  bbbbb1 ursolic acid eeeee1  bbbbb2 coenzyme A carboxylase eeeee2  and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form  bbbbb1 serine eeeee1  bbbbb2 AMPK eeeee2  and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form  bbbbb1 serine eeeee1  9, whereas ursolic acid attenuated the phosphorylation of AKT and  bbbbb2 mTOR eeeee2  in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form  bbbbb1 serine eeeee1  9, whereas ursolic acid attenuated the phosphorylation of  bbbbb2 AKT eeeee2  and mTOR in HepG2 cells
CRP11	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form  bbbbb1 serine eeeee1  bbbbb2 coenzyme A carboxylase eeeee2  and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells
CRP11	Thus, in the present study, the roles of  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) and glycogen synthase kinase 3 beta (GSK3β) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells
CRP11	Thus, in the present study, the roles of  bbbbb1 AMP eeeee1 -activated protein kinase (AMPK) and  bbbbb2 glycogen synthase kinase 3 beta eeeee2  (GSK3β) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells
CRP11	Thus, in the present study, the roles of  bbbbb1 AMP eeeee1 -activated protein kinase (AMPK) and glycogen synthase kinase 3 beta ( bbbbb2 GSK3β eeeee2 ) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells
CRP11	Thus, in the present study, the roles of  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) and glycogen synthase kinase 3 beta (GSK3β) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells
CRP11	The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of  bbbbb1 navitoclax eeeee1 , a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some  bbbbb2 BCL-2 eeeee2 -dependent hematological cancers
CRP11	Ig module I and the  bbbbb1 C eeeee1 -terminus of Ig module III are dispensable for high-affinity binding of  bbbbb2 FGF-1 eeeee2 , FGF-2, and FGF-7
CRP11	Ig module I and the  bbbbb1 C eeeee1 -terminus of Ig module III are dispensable for high-affinity binding of FGF-1,  bbbbb2 FGF-2 eeeee2 , and FGF-7
CRP11	Ig module I and the  bbbbb1 C eeeee1  bbbbb2 Ig module I eeeee2  and the C-terminus of Ig module III are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7
CRP11	Ig module I and the  bbbbb1 C eeeee1 -terminus of Ig module III are dispensable for high-affinity binding of FGF-1, FGF-2, and  bbbbb2 FGF-7 eeeee2 
CRP11	Several site-specific alterations in the C-terminus of full-lengt bbbbb1 h FGFR1 eeeee1 IIIc, an isoform that otherwise absolut bbbbb2 ely rejects FGF eeeee2 -7, resulted in gain of FGF-7 binding
CRP11	Several site-specific alterations in the C-terminus of full-lengt bbbbb1 h FGFR1 eeeee1 IIIc, an isoform that otherwise absolutely rejects FGF-7, resulted in gain of FGF-7 binding bbbbb2  eeeee2 
CRP11	The assembly and activation of oligomeric complexes of FGF, the transmembrane receptor kinase (FGFR), and heparan  bbbbb1 sulfate eeeee1  bbbbb2 transmembrane receptor kinase eeeee2  (FGFR), and heparan sulfate transmit intracellular signals regulating growth and function of cells
CRP11	The assembly and activation of oligomeric complexes of FGF, the transmembrane receptor kinase (FGFR), and heparan  bbbbb1 sulfate eeeee1  bbbbb2 FGFR eeeee2 ), and heparan sulfate transmit intracellular signals regulating growth and function of cells
CRP11	The assembly and activation of oligomeric complexes of FGF, the transmembrane receptor kinase (FGFR), and heparan  bbbbb1 sulfate eeeee1  bbbbb2 FGF eeeee2 , the transmembrane receptor kinase (FGFR), and heparan sulfate transmit intracellular signals regulating growth and function of cells
CRP11	Addition of a specific number of FGFR sequences to the  bbbbb1 C eeeee1 -terminus of Ig module II resulted in a gain in affinity for  bbbbb2 FGF-7 eeeee2 
CRP11	Addition of a specific number of FGFR sequences to the  bbbbb1 C eeeee1  bbbbb2 FGFR eeeee2  sequences to the C-terminus of Ig module II resulted in a gain in affinity for FGF-7
CRP11	Firstly, the V(max) of GAD was increased when ApoCaM was present whereas the affinity for the substrate,  bbbbb1 glutamate eeeee1  bbbbb2 ApoCaM eeeee2  was present whereas the affinity for the substrate, glutamate, was not affected
CRP11	Effect of apocalmodulin on recombinant human brain  bbbbb1 glutamic acid eeeee1  bbbbb2 apocalmodulin eeeee2  on recombinant human brain glutamic acid decarboxylase
CRP11	Effect of apocalmodulin on recombinant human brain  bbbbb1 glutamic acid eeeee1  bbbbb2 human brain glutamic acid decarboxylase eeeee2 
CRP11	Secondly, the affinity of GAD for  bbbbb1 PLP eeeee1  was increased in the presence of  bbbbb2 ApoCaM eeeee2 
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) ( bbbbb2 GST eeeee2 -HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)- bbbbb2 human L-glutamic acid decarboxylase eeeee2  (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase ( bbbbb2 HGAD eeeee2 ) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated  bbbbb2 HGAD65 eeeee2 , were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase ( bbbbb2 GST eeeee2 )-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin ( bbbbb2 ApoCaM eeeee2 ) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by  bbbbb2 apocalmodulin eeeee2  (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase ( bbbbb2 GAD eeeee2 ) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST- bbbbb2 HGAD65 eeeee2 ) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione  bbbbb1 S eeeee1 -transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms,  bbbbb2 65-kDa L-glutamic acid decarboxylase eeeee2  (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) ( bbbbb2 GST eeeee2 -HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)- bbbbb2 human L-glutamic acid decarboxylase eeeee2  (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase ( bbbbb2 HGAD eeeee2 ) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated  bbbbb2 HGAD65 eeeee2 , were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase ( bbbbb2 GST eeeee2 )-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin ( bbbbb2 ApoCaM eeeee2 ) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by  bbbbb2 apocalmodulin eeeee2  (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase ( bbbbb2 GAD eeeee2 ) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST- bbbbb2 HGAD65 eeeee2 ) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant  bbbbb1 glutathione eeeee1  S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms,  bbbbb2 65-kDa L-glutamic acid decarboxylase eeeee2  (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) ( bbbbb2 GST eeeee2 -HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  bbbbb2 human L-glutamic acid decarboxylase eeeee2  (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase ( bbbbb2 HGAD eeeee2 ) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated  bbbbb2 HGAD65 eeeee2 , were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  bbbbb2 GST eeeee2 )-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin ( bbbbb2 ApoCaM eeeee2 ) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by  bbbbb2 apocalmodulin eeeee2  (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase ( bbbbb2 GAD eeeee2 ) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST- bbbbb2 HGAD65 eeeee2 ) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human  bbbbb1 L-glutamic acid eeeee1  decarboxylase (HGAD) isoforms,  bbbbb2 65-kDa L-glutamic acid decarboxylase eeeee2  (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase (GAD) ( bbbbb2 GST eeeee2 -HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  bbbbb2 human L-glutamic acid decarboxylase eeeee2  (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  bbbbb2 HGAD eeeee2 ) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated  bbbbb2 HGAD65 eeeee2 , were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  bbbbb2 GST eeeee2 )-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin ( bbbbb2 ApoCaM eeeee2 ) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by  bbbbb2 apocalmodulin eeeee2  (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase ( bbbbb2 GAD eeeee2 ) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa L-glutamic acid decarboxylase (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  decarboxylase (GAD) (GST- bbbbb2 HGAD65 eeeee2 ) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	In this work, we report that the recombinant glutathione S-transferase (GST)-human L-glutamic acid decarboxylase (HGAD) isoforms, 65-kDa  bbbbb1 L-glutamic acid eeeee1  bbbbb2 65-kDa L-glutamic acid decarboxylase eeeee2  (GAD) (GST-HGAD65) fusion protein or free truncated HGAD65, were activated by apocalmodulin (ApoCaM) to an extent of 60%
CRP11	First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the  bbbbb1 ATP eeeee1 -binding cassette transporter A1 ( bbbbb2 ABCA1 eeeee2 )-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner
CRP11	First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the  bbbbb1 ATP eeeee1  bbbbb2 ATP-binding cassette transporter A1 eeeee2  (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner
CRP11	First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the  bbbbb1 ATP eeeee1  bbbbb2 apolipoprotein A-I eeeee2  (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner
CRP11	First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the  bbbbb1 ATP eeeee1  bbbbb2 apoA-I eeeee2 ), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner
CRP11	Second, probucol, an antiatherogenic compound reported to be an inactivator of ABCA1 reduced hepatic  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 ABCA1 eeeee2  reduced hepatic alpha-tocopherol secretion
CRP11	From in vitro experiments using [(3)H]alpha-tocopheryl acetate and McARH7777 cells that stably express  bbbbb1 alpha-tocopherol eeeee1  transfer protein ( bbbbb2 alpha-TTP eeeee2 ), the following results were obtained
CRP11	From in vitro experiments using [(3)H]alpha-tocopheryl acetate and McARH7777 cells that stably express  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 alpha-tocopherol transfer protein eeeee2  (alpha-TTP), the following results were obtained
CRP11	From in vitro experiments using  bbbbb1 [(3)H]alpha-tocopheryl acetate eeeee1  and McARH7777 cells that stably express alpha-tocopherol transfer protein ( bbbbb2 alpha-TTP eeeee2 ), the following results were obtained
CRP11	From in vitro experiments using  bbbbb1 [(3)H]alpha-tocopheryl acetate eeeee1  and McARH7777 cells that stably express  bbbbb2 alpha-tocopherol transfer protein eeeee2  (alpha-TTP), the following results were obtained
CRP11	Vitamin E ( bbbbb1 alpha-tocopherol eeeee1 ) is an essential fat-soluble nutrient with antioxidant properties.  bbbbb2 alpha-Tocopherol transfer protein eeeee2  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	Vitamin E ( bbbbb1 alpha-tocopherol eeeee1 ) is an essential fat-soluble nutrient with antioxidant properties. alpha-Tocopherol transfer protein ( bbbbb2 alpha-TTP eeeee2 ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	Vitamin E (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties.  bbbbb1 alpha-Tocopherol eeeee1  bbbbb2 alpha-Tocopherol transfer protein eeeee2  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	Vitamin E (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties.  bbbbb1 alpha-Tocopherol eeeee1  transfer protein ( bbbbb2 alpha-TTP eeeee2 ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	 bbbbb1 Vitamin E eeeee1  (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties.  bbbbb2 alpha-Tocopherol transfer protein eeeee2  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	 bbbbb1 Vitamin E eeeee1  (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties. alpha-Tocopherol transfer protein ( bbbbb2 alpha-TTP eeeee2 ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	Vitamin E (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties. alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated  bbbbb1 vitamin E eeeee1  bbbbb2 alpha-Tocopherol transfer protein eeeee2  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	Vitamin E (alpha-tocopherol) is an essential fat-soluble nutrient with antioxidant properties. alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated  bbbbb1 vitamin E eeeee1  bbbbb2 alpha-TTP eeeee2 ), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver
CRP11	[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on  bbbbb1 alcohol eeeee1  bbbbb2 mu-opioid receptor eeeee2  antagonist naltrexone on alcohol dependence]
CRP11	In many countries, a mu-opioid receptor antagonist naltrexone has been used in the treatment of  bbbbb1 alcohol eeeee1  bbbbb2 mu-opioid receptor eeeee2  antagonist naltrexone has been used in the treatment of alcohol dependence
CRP11	The endogenous opioid agonists, such as beta-endorphin, increase the activity of the mesolimbic dopaminergic system through the inhibition of the  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 beta-endorphin eeeee2 , increase the activity of the mesolimbic dopaminergic system through the inhibition of the gamma-aminobutyric acid (GABA)-containing inhibitory interneurons in the ventral tegmental area, resulting in the expression of alcohol reinforcement and/or rewarding effect
CRP11	The endogenous opioid agonists, such as beta-endorphin, increase the activity of the mesolimbic dopaminergic system through the inhibition of the gamma-aminobutyric acid ( bbbbb1 GABA eeeee1  bbbbb2 beta-endorphin eeeee2 , increase the activity of the mesolimbic dopaminergic system through the inhibition of the gamma-aminobutyric acid (GABA)-containing inhibitory interneurons in the ventral tegmental area, resulting in the expression of alcohol reinforcement and/or rewarding effect
CRP11	The endogenous opioid agonists, such as beta-endorphin, increase the activity of the mesolimbic dopaminergic system through the inhibition of the gamma-aminobutyric acid (GABA)-containing inhibitory interneurons in the ventral tegmental area, resulting in the expression of  bbbbb1 alcohol eeeee1  bbbbb2 beta-endorphin eeeee2 , increase the activity of the mesolimbic dopaminergic system through the inhibition of the gamma-aminobutyric acid (GABA)-containing inhibitory interneurons in the ventral tegmental area, resulting in the expression of alcohol reinforcement and/or rewarding effect
CRP11	BP-rP1 (MAC25/Angiomodulin/ bbbbb1 prostacyclin eeeee1  bbbbb2 MAC25 eeeee2 /Angiomodulin/prostacyclin-stimulating factor) is a potential tumor-suppressor gene that is differentially expressed in meningiomas, mammary and prostatic cancers, compared with their malignant counterparts
CRP11	BP-rP1 (MAC25/Angiomodulin/ bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin-stimulating factor eeeee2 ) is a potential tumor-suppressor gene that is differentially expressed in meningiomas, mammary and prostatic cancers, compared with their malignant counterparts
CRP11	BP-rP1 (MAC25/Angiomodulin/ bbbbb1 prostacyclin eeeee1  bbbbb2 Angiomodulin eeeee2 /prostacyclin-stimulating factor) is a potential tumor-suppressor gene that is differentially expressed in meningiomas, mammary and prostatic cancers, compared with their malignant counterparts
CRP11	Vacuolar  bbbbb1 H(+) eeeee1  bbbbb2 Vacuolar H(+) -ATPase eeeee2  (V-ATPase), a multisubunit enzyme located at the ruffled border and in lysosomes of osteoclasts, is necessary for bone resorption
CRP11	Vacuolar  bbbbb1 H(+) eeeee1  -ATPase ( bbbbb2 V-ATPase eeeee2 ), a multisubunit enzyme located at the ruffled border and in lysosomes of osteoclasts, is necessary for bone resorption
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of  bbbbb1 leukotriene (LT) B(4), C(4) and E(4) eeeee1  and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of  bbbbb1 leukotriene (LT) B(4), C(4) and E(4) eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of  bbbbb1 leukotriene (LT) B(4), C(4) and E(4) eeeee1  and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of  bbbbb1 leukotriene (LT) B(4), C(4) and E(4) eeeee1  and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen,  bbbbb1 DNP eeeee1  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen,  bbbbb1 DNP eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen,  bbbbb1 DNP eeeee1  bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen,  bbbbb1 DNP eeeee1 -conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and  bbbbb1 prostaglandin D(2) eeeee1  (PGD(2)) was examined in dinitrophenol (DNP)-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and  bbbbb1 prostaglandin D(2) eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and  bbbbb1 prostaglandin D(2) eeeee1  (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and  bbbbb1 prostaglandin D(2) eeeee1  (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) ( bbbbb1 PGD(2) eeeee1 ) was examined in dinitrophenol (DNP)-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) ( bbbbb1 PGD(2) eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) ( bbbbb1 PGD(2) eeeee1 ) was examined in dinitrophenol (DNP)-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) ( bbbbb1 PGD(2) eeeee1 ) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of  bbbbb1 troglitazone eeeee1 , an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of  bbbbb1 troglitazone eeeee1 , an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of  bbbbb1 troglitazone eeeee1 , an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in  bbbbb1 dinitrophenol eeeee1  (DNP)-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in  bbbbb1 dinitrophenol eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in  bbbbb1 dinitrophenol eeeee1  (DNP)-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in  bbbbb1 dinitrophenol eeeee1  (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol ( bbbbb1 DNP eeeee1 )-specific  bbbbb2 immunoglobulin E eeeee2  (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol ( bbbbb1 DNP eeeee1  bbbbb2 insulin eeeee2 -sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol ( bbbbb1 DNP eeeee1 )-specific immunoglobulin E ( bbbbb2 IgE eeeee2 )-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin
CRP11	The effect of troglitazone, an anti-diabetic drug with insulin-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol ( bbbbb1 DNP eeeee1 )-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated  bbbbb2 human serum albumin eeeee2 
CRP11	Inhibition by  bbbbb1 troglitazone eeeee1  of the antigen-induced production of leukotrienes in  bbbbb2 immunoglobulin E eeeee2 -sensitized RBL-2H3 cells. 1
CRP11	Inhibition by troglitazone of the antigen-induced production of  bbbbb1 leukotrienes eeeee1  in  bbbbb2 immunoglobulin E eeeee2 -sensitized RBL-2H3 cells. 1
CRP11	 bbbbb1 Troglitazone eeeee1  inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that troglitazone inhibits LT production by direct inhibition of  bbbbb2 5-LOX eeeee2  activity. 4
CRP11	Troglitazone inhibited  bbbbb1 LTB(4) eeeee1  production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that troglitazone inhibits LT production by direct inhibition of  bbbbb2 5-LOX eeeee2  activity. 4
CRP11	 bbbbb1 Troglitazone eeeee1  inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton, a specific inhibitor of  bbbbb2 5-lipoxygenase eeeee2  (5-LOX) and a clinically used anti-asthmatic drug
CRP11	 bbbbb1 Troglitazone eeeee1  inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton, a specific inhibitor of 5-lipoxygenase ( bbbbb2 5-LOX eeeee2 ) and a clinically used anti-asthmatic drug
CRP11	Troglitazone inhibited the antigen-induced production of  bbbbb1 LTB(4) eeeee1 , C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton, a specific inhibitor of  bbbbb2 5-lipoxygenase eeeee2  (5-LOX) and a clinically used anti-asthmatic drug
CRP11	Troglitazone inhibited the antigen-induced production of  bbbbb1 LTB(4) eeeee1 , C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton, a specific inhibitor of 5-lipoxygenase ( bbbbb2 5-LOX eeeee2 ) and a clinically used anti-asthmatic drug
CRP11	Furthermore, it was shown that troglitazone as well as zileuton inhibited LTB(4) production in A23187-stimulated rat per bbbbb1 itonea eeeee1 l neutrophils. 5 bbbbb2  eeeee2 
CRP11	Furthermore, it was shown that troglitazone as well as zileuton inhibited LTB(4) production in A23187-stimulated rat per bbbbb1 itonea eeeee1  bbbbb2 tio eeeee2 n in A23187-stimulated rat peritoneal neutrophils. 5
CRP11	Furthermore, it was shown th bbbbb1 at troglitaz eeeee1 one as well as zileuton inhibited LTB(4) produc bbbbb2 tio eeeee2 n in A23187-stimulated rat peritoneal neutrophils. 5
CRP11	In addition, the effects on 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) and D2 autoreceptors in the ventral tegmental area (VTA) were compared with those of  bbbbb1 aripiprazole eeeee1  bbbbb2 5-HT1A eeeee2  autoreceptors in the dorsal raphe nucleus (DRN) and D2 autoreceptors in the ventral tegmental area (VTA) were compared with those of aripiprazole, an agent in wide clinical use
CRP11	In addition, the effects on 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) and D2 autoreceptors in the ventral tegmental area (VTA) were compared with those of  bbbbb1 aripiprazole eeeee1  bbbbb2 D2 autoreceptors eeeee2  in the ventral tegmental area (VTA) were compared with those of aripiprazole, an agent in wide clinical use
CRP11	Furthermore, it increased  bbbbb1 5-HT eeeee1  release by terminal alpha2-adrenergic heteroceptor but not  bbbbb2 5-HT1B eeeee2  autoreceptor antagonism
CRP11	Furthermore, it increased  bbbbb1 5-HT eeeee1  release by terminal  bbbbb2 alpha2-adrenergic heteroceptor eeeee2  but not 5-HT1B autoreceptor antagonism
CRP11	In the DRN, brexpiprazole completely inhibited the firing of  bbbbb1 5-HT eeeee1  neurons via  bbbbb2 5-HT1A eeeee2  agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively)
CRP11	In the locus coeruleus,  bbbbb1 brexpiprazole eeeee1  reversed the inhibitory effect of the preferential  bbbbb2 5-HT2A eeeee2  receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action
CRP11	In the locus coeruleus,  bbbbb1 brexpiprazole eeeee1  reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating  bbbbb2 5-HT2A eeeee2  antagonistic action
CRP11	In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI ( bbbbb1 2,5-dimethoxy-4-iodoamphetamine eeeee1 ) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating  bbbbb2 5-HT2A eeeee2  antagonistic action
CRP11	In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on  bbbbb1 norepinephrine eeeee1  bbbbb2 5-HT2A eeeee2  receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action
CRP11	In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on  bbbbb1 norepinephrine eeeee1  neuronal firing (ED50 = 110 mug/kg), demonstrating  bbbbb2 5-HT2A eeeee2  antagonistic action
CRP11	In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist  bbbbb1 DOI eeeee1  (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating  bbbbb2 5-HT2A eeeee2  antagonistic action
CRP11	Compared with aripiprazole, which significantly inhibited the firing activity of VTA  bbbbb1 DA eeeee1  neurons, brexpiprazole displayed less efficacy at  bbbbb2 D2 receptors eeeee2 
CRP11	Compared with  bbbbb1 aripiprazole eeeee1 , which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at  bbbbb2 D2 receptors eeeee2 
CRP11	Brexpiprazole reversed the inhibitory effect of the  bbbbb1 DA eeeee1  agonist apomorphine on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on  bbbbb2 D2 receptors eeeee2 
CRP11	 bbbbb1 Brexpiprazole eeeee1  reversed the inhibitory effect of the DA agonist apomorphine on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on  bbbbb2 D2 receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of  bbbbb1 brexpiprazole eeeee1  on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and  bbbbb2 alpha1- and alpha2-adrenergic receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1  bbbbb2 dopamine (DA) D2 autoreceptors eeeee2 , and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1  bbbbb2 5-HT1A eeeee2 , 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1  bbbbb2 5-HT2A eeeee2 ; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1  bbbbb2 5-HT1B eeeee2 , and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1 ) D2 autoreceptors, and  bbbbb2 alpha1- and alpha2-adrenergic receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine ( bbbbb1 DA eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1 ) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb2 dopamine (DA) D2 autoreceptors eeeee2 , and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1 ) receptor subtypes  bbbbb2 5-HT1A eeeee2 , 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1 ) receptor subtypes 5-HT1A, 5-HT1B, and  bbbbb2 5-HT2A eeeee2 ; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1 ) receptor subtypes 5-HT1A,  bbbbb2 5-HT1B eeeee2 , and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1 ) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and  bbbbb2 alpha1- and alpha2-adrenergic receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  bbbbb2 dopamine (DA) D2 autoreceptors eeeee2 , and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  bbbbb2 5-HT1A eeeee2 , 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  bbbbb2 5-HT2A eeeee2 ; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  bbbbb2 5-HT1B eeeee2 , and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  (DA) D2 autoreceptors, and  bbbbb2 alpha1- and alpha2-adrenergic receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb1 dopamine eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A;  bbbbb2 dopamine (DA) D2 autoreceptors eeeee2 , and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  (5-HT) receptor subtypes  bbbbb2 5-HT1A eeeee2 , 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and  bbbbb2 5-HT2A eeeee2 ; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  (5-HT) receptor subtypes 5-HT1A,  bbbbb2 5-HT1B eeeee2 , and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and  bbbbb2 alpha1- and alpha2-adrenergic receptors eeeee2 
CRP11	Using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on  bbbbb1 serotonin eeeee1  bbbbb2 serotonin (5-HT) receptor eeeee2  subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors
CRP11	Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2  in the vasculature
CRP11	Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of  bbbbb1 angiotensin eeeee1  bbbbb2 Angiotensin II receptor eeeee2  antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature
CRP11	Angiotensin II receptor antagonists block  bbbbb1 angiotensin II eeeee1  type 1 (AT1) receptors and reduce the pressor effects of  bbbbb2 angiotensin eeeee2  in the vasculature
CRP11	Angiotensin II receptor antagonists block  bbbbb1 angiotensin II eeeee1  bbbbb2 Angiotensin II receptor eeeee2  antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature
CRP11	Angiotensin II receptor antagonists block  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II type 1 (AT1) receptors eeeee2  and reduce the pressor effects of angiotensin in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of  bbbbb2 angiotensin eeeee2  in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  bbbbb2 Angiotensin II receptor eeeee2  antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature
CRP11	 bbbbb1 Angiotensin II eeeee1  receptor antagonists block  bbbbb2 angiotensin II type 1 (AT1) receptors eeeee2  and reduce the pressor effects of angiotensin in the vasculature
CRP11	Eprosartan acts not only at vascular AT1 receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated  bbbbb1 noradrenaline eeeee1  bbbbb2 AT1 eeeee2  receptors, causing inhibition of sympathetically stimulated noradrenaline release
CRP11	Eprosartan acts not only at vascular AT1 receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated  bbbbb1 noradrenaline eeeee1  bbbbb2 AT1 eeeee2  receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release
CRP11	The clinical profile of the  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II receptor eeeee2  blocker eprosartan
CRP11	By this mechanism, they induce similar pharmacological effects to  bbbbb1 angiotensin eeeee1 -converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors, resulting in a lowering of blood pressure (BP)
CRP11	By this mechanism, they induce similar pharmacological effects to  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors, resulting in a lowering of blood pressure (BP)
CRP11	Within the class of  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  antagonists, eprosartan differs from other currently clinically available agents in terms of its chemical structure and its dual pharmacological mode of action
CRP11	Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic  bbbbb1 aspartates eeeee1  bbbbb2 BACE-1 eeeee2  inhibitors that do not engage the catalytic aspartates
CRP11	We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells
CRP11	We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the  bbbbb1 aryl hydrocarbon eeeee1  receptor (AhR)- bbbbb2 CYP1A1 eeeee2  signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells
CRP11	We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 )-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells
CRP11	Similarly,  bbbbb1 pelargonidin eeeee1  induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of  bbbbb2 AhR eeeee2 
CRP11	Enzyme kinetic analyses bbbbb1  using human l eeeee1 iver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM)  bbbbb2 and eeeee2  pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses bbbbb1  using human l eeeee1 iver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pela bbbbb2 rgo eeeee2 nidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses bbbbb1  using human l eeeee1 iver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb2  eeeee2 
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 and eeeee2  pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 d inhi eeeee2 bition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 eal eeeee2 ed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 rgo eeeee2 nidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 and eeeee2  pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 d inhi eeeee2 bition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 eal eeeee2 ed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb1  eeeee1  bbbbb2 rgo eeeee2 nidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CY bbbbb1 P1A1 activit eeeee1  bbbbb2 d inhi eeeee2 bition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CY bbbbb1 P1A1 activit eeeee1  bbbbb2 eal eeeee2 ed inhibition of CYP1A1 activity by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM)
CRP11	Enzyme kinetic analyses using human liver microsomes revealed inhibition of CY bbbbb1 P1A1 activit eeeee1 y by delphinidin (IC50 78 μM) and pelargonidin (IC50 33 μM) bbbbb2  eeeee2 
CRP11	Cloning and expression of the liver and muscle isoforms of ovine  bbbbb1 carnitine eeeee1  bbbbb2 ovine carnitine palmitoyltransferase 1 eeeee2 : residues within the N-terminus of the muscle isoform influence the kinetic properties of the enzyme
CRP11	Cloning and expression of the liver and muscle isoforms of ovine carnitine palmitoyltransferase 1: residues within the  bbbbb1 N eeeee1  bbbbb2 ovine carnitine palmitoyltransferase 1 eeeee2 : residues within the N-terminus of the muscle isoform influence the kinetic properties of the enzyme
CRP11	 bbbbb1 Carnitine eeeee1  palmitoyltransferase 1 ( bbbbb2 CPT 1 eeeee2 ) is the key locus for the control of long-chain fatty acid beta-oxidation and liver ketogenesis
CRP11	 bbbbb1 Carnitine eeeee1  bbbbb2 Carnitine palmitoyltransferase 1 eeeee2  (CPT 1) is the key locus for the control of long-chain fatty acid beta-oxidation and liver ketogenesis
CRP11	Carnitine palmitoyltransferase 1 (CPT 1) is the key locus for the control of long-chain  bbbbb1 fatty acid eeeee1  bbbbb2 CPT 1 eeeee2 ) is the key locus for the control of long-chain fatty acid beta-oxidation and liver ketogenesis
CRP11	Carnitine palmitoyltransferase 1 (CPT 1) is the key locus for the control of long-chain  bbbbb1 fatty acid eeeee1  bbbbb2 Carnitine palmitoyltransferase 1 eeeee2  (CPT 1) is the key locus for the control of long-chain fatty acid beta-oxidation and liver ketogenesis
CRP11	Expression in yeast allowed kinetic characterization of the two native enzymes, and of a chimaera in which the disti bbbbb1 nctive N-term eeeee1 inal segment of ovine M-CPT 1 was replaced with that from rat M-CPT 1 bbbbb2  eeeee2 
CRP11	Expression in yeast allowed kinetic characterization of the two native enzymes, and of a chimaera in which the distinctive N-terminal segment of ovine M-CPT bbbbb1  1 was re eeeee1 placed with that from rat M-CPT 1 bbbbb2  eeeee2 
CRP11	Expression bbbbb1   eeeee1 in yeast allowed kinetic characterization of the two native enzymes, and of a chimaera in which the distinctive N-terminal segment of ovine M-CPT 1 was replaced with that from rat M-CPT 1 bbbbb2  eeeee2 
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers  bbbbb2 Y18830 eeeee2  and Y18829 respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver  bbbbb2 CPT1A eeeee2  clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and  bbbbb2 Y18829 eeeee2  respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and  bbbbb2 CPT1B eeeee2  cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of  bbbbb2 ovine CPT1A eeeee2  and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers  bbbbb2 Y18387 eeeee2  and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The  bbbbb1 nucleotide eeeee1  sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB Nucleotide Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and  bbbbb2 AJ272435 eeeee2  respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers  bbbbb2 Y18830 eeeee2  and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver  bbbbb2 CPT1A eeeee2  clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and  bbbbb2 Y18829 eeeee2  respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and  bbbbb2 CPT1B eeeee2  cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of  bbbbb2 ovine CPT1A eeeee2  and CPT1B cDNAs have the accession numbers Y18387 and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers  bbbbb2 Y18387 eeeee2  and AJ272435 respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	The nucleotide sequence data reported will appear in DDBJ, EMBL, GenBank(R) and GSDB  bbbbb1 Nucleotide eeeee1  Sequence Databases; the sequences of ovine CPT1A and CPT1B cDNAs have the accession numbers Y18387 and  bbbbb2 AJ272435 eeeee2  respectively and the partial adipose tissue and liver CPT1A clones have the accession numbers Y18830 and Y18829 respectively
CRP11	Their deduced  bbbbb1 amino acid eeeee1  sequences show a high degree of conservation compared with orthologues from other mammalian species, with the notable exception of the N-terminus of  bbbbb2 ovine M-CPT 1 eeeee2 
CRP11	Inhibition of SIRT1 significantly increased vascular  bbbbb1 superoxide eeeee1  production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and  bbbbb2 NOX4 eeeee2 , which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular  bbbbb1 superoxide eeeee1  production, enhanced  bbbbb2 NADPH oxidase eeeee2  activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular  bbbbb1 superoxide eeeee1  production, enhanced NADPH oxidase activity, and mRNA expression of its subunits  bbbbb2 p22(phox) eeeee2  and NOX4, which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  bbbbb1 NADPH eeeee1  oxidase activity, and mRNA expression of its subunits p22(phox) and  bbbbb2 NOX4 eeeee2 , which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  bbbbb1 NADPH eeeee1  oxidase activity, and mRNA expression of its subunits  bbbbb2 p22(phox) eeeee2  and NOX4, which were prevented by resveratrol
CRP11	Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  bbbbb1 NADPH eeeee1  bbbbb2 SIRT1 eeeee2  significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 rived  eeeee2 ROS production in the vascular wall, mimicking the vascular aging phenotype
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 all,  eeeee2 mimicking the vascular aging phenotype
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 tion  eeeee2 and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 rived  eeeee2 ROS production in the vascular wall, mimicking the vascular aging phenotype
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 all,  eeeee2 mimicking the vascular aging phenotype
CRP11	In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype bbbbb1  eeeee1  bbbbb2 tion  eeeee2 and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the  bbbbb1 NADPH eeeee1  bbbbb2 SIRT1 eeeee2  inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or superoxide dismutase
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the  bbbbb1 NADPH eeeee1  oxidase inhibitor apocynin or  bbbbb2 superoxide dismutase eeeee2 
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  inhibitor apocynin or superoxide dismutase
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor  bbbbb1 apocynin eeeee1  or  bbbbb2 superoxide dismutase eeeee2 
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or  bbbbb1 superoxide eeeee1  bbbbb2 SIRT1 eeeee2  inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or superoxide dismutase
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 
CRP11	Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or  bbbbb1 superoxide eeeee1  bbbbb2 NADPH oxidase eeeee2  inhibitor apocynin or superoxide dismutase
CRP11	To determine whether dysregulation of SIRT1 promotes  bbbbb1 NADPH eeeee1  bbbbb2 SIRT1 eeeee2  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes  bbbbb1 NADPH eeeee1  oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of  bbbbb2 SIRT1 eeeee2  (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2 -dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive  bbbbb1 oxygen eeeee1  bbbbb2 SIRT1 eeeee2  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive  bbbbb1 oxygen eeeee1  species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of  bbbbb2 SIRT1 eeeee2  (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide,  bbbbb1 sirtinol eeeee1  bbbbb2 SIRT1 eeeee2  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide,  bbbbb1 sirtinol eeeee1  bbbbb2 NADPH oxidase eeeee2 -dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol,  bbbbb1 EX527 eeeee1  bbbbb2 SIRT1 eeeee2  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol,  bbbbb1 EX527 eeeee1  bbbbb2 NADPH oxidase eeeee2 -dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 ( bbbbb1 nicotinamide eeeee1  bbbbb2 SIRT1 eeeee2  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 ( bbbbb1 nicotinamide eeeee1  bbbbb2 NADPH oxidase eeeee2 -dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats
CRP11	Inhibition of SIRT1 induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators acetylcholine and the  bbbbb1 calcium eeeee1  bbbbb2 SIRT1 eeeee2  induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators acetylcholine and the calcium ionophore A23187
CRP11	Inhibition of SIRT1 induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators  bbbbb1 acetylcholine eeeee1  bbbbb2 SIRT1 eeeee2  induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators acetylcholine and the calcium ionophore A23187
CRP11	Inhibition of SIRT1 induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators acetylcholine and the calcium ionophore  bbbbb1 A23187 eeeee1  bbbbb2 SIRT1 eeeee2  induced endothelial dysfunction, as shown by the significantly reduced relaxation to the endothelium-dependent vasodilators acetylcholine and the calcium ionophore A23187
CRP11	RT1 inhibits  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activation and protects endothelial function in the rat aorta: Implications for vascular aging
CRP11	Vascular aging is characterized by up-regulation of  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2 , oxidative stress and endothelial dysfunction
CRP11	T1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by  bbbbb1 resveratrol eeeee1  bbbbb2 PPARα eeeee2  coactivator PGC-1α, which was suppressed by resveratrol
CRP11	T1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by  bbbbb1 resveratrol eeeee1  bbbbb2 PPARα eeeee2  and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by resveratrol
CRP11	T1 co-precipitated with PPARα and  bbbbb1 nicotinamide eeeee1  increased the acetylation of the  bbbbb2 PPARα eeeee2  coactivator PGC-1α, which was suppressed by resveratrol
CRP11	T1 co-precipitated with PPARα and  bbbbb1 nicotinamide eeeee1  bbbbb2 PPARα eeeee2  and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by resveratrol
CRP11	Previous studies demonstrate that the activity of the evolutionarily conserved  bbbbb1 NAD(+) eeeee1  bbbbb2 NAD(+)-dependent deacetylase SIRT1 eeeee2  declines with age and that pharmacological activators of SIRT1 confer significant anti-aging cardiovascular effects
CRP11	Previous studies demonstrate that the activity of the evolutionarily conserved  bbbbb1 NAD(+) eeeee1 -dependent deacetylase SIRT1 declines with age and that pharmacological activators of  bbbbb2 SIRT1 eeeee2  confer significant anti-aging cardiovascular effects
CRP11	The effects of  bbbbb1 theophylline eeeee1  (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA ( bbbbb2 PDE2 eeeee2  inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of  bbbbb1 theophylline eeeee1  (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the  bbbbb2 PDE5 eeeee2  inhibitors zaprinast and E 4021 were weak
CRP11	The effects of  bbbbb1 theophylline eeeee1  (unspecific PDE inhibitor), vinpocetine ( bbbbb2 PDE1 eeeee2  inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and  bbbbb1 E 4021 eeeee1  bbbbb2 PDE eeeee2  inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and  bbbbb1 E 4021 eeeee1  bbbbb2 PDE2 eeeee2  inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and  bbbbb1 E 4021 eeeee1  bbbbb2 PDE1 eeeee2  inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors  bbbbb1 zaprinast eeeee1  bbbbb2 PDE eeeee2  inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors  bbbbb1 zaprinast eeeee1  bbbbb2 PDE2 eeeee2  inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors  bbbbb1 zaprinast eeeee1  bbbbb2 PDE1 eeeee2  inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor),  bbbbb1 vinpocetine eeeee1  bbbbb2 PDE eeeee2  inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor),  bbbbb1 vinpocetine eeeee1  (PDE1 inhibitor), EHNA ( bbbbb2 PDE2 eeeee2  inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak
CRP11	The effects of theophylline (unspecific PDE inhibitor),  bbbbb1 vinpocetine eeeee1  (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the  bbbbb2 PDE5 eeeee2  inhibitors zaprinast and E 4021 were weak
CRP11	In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of  bbbbb1 dexamethasone eeeee1  bbbbb2 TNF eeeee2  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced
CRP11	Following administration of the H3R antagonist (2.5, 5, and 10 mg/kg, i.p.), there was a significant dose-dependent decrease in  bbbbb1 alcohol eeeee1  bbbbb2 H3R eeeee2  antagonist (2.5, 5, and 10 mg/kg, i.p.), there was a significant dose-dependent decrease in alcohol consumption and preference
CRP11	The selectivity that  bbbbb1 darapladib eeeee1  and other  bbbbb2 Lp-PLA(2) eeeee2  inhibitors display across the larger serine hydrolase family has not, however, been reported
CRP11	The selectivity that  bbbbb1 darapladib eeeee1  and other Lp-PLA(2) inhibitors display across the larger  bbbbb2 serine hydrolase eeeee2  family has not, however, been reported
CRP11	The selectivity that darapladib and other Lp-PLA(2) inhibitors display across the larger  bbbbb1 serine eeeee1  bbbbb2 Lp-PLA(2) eeeee2  inhibitors display across the larger serine hydrolase family has not, however, been reported
CRP11	The selectivity that darapladib and other Lp-PLA(2) inhibitors display across the larger  bbbbb1 serine eeeee1  bbbbb2 serine hydrolase eeeee2  family has not, however, been reported
CRP11	We have used the polymerase chain reaction technique to selectively amplify a guanine nucleotide-binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned  bbbbb1 serotonin eeeee1  bbbbb2 serotonin receptors eeeee2 
CRP11	We have used the polymerase chain reaction technique to selectively amplify a guanine nucleotide-binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned  bbbbb1 serotonin eeeee1  bbbbb2 guanine nucleotide-binding protein-coupled receptor eeeee2  cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned serotonin receptors
CRP11	We have used the polymerase chain reaction technique to selectively amplify a  bbbbb1 guanine nucleotide eeeee1 -binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned  bbbbb2 serotonin receptors eeeee2 
CRP11	We have used the polymerase chain reaction technique to selectively amplify a  bbbbb1 guanine nucleotide eeeee1  bbbbb2 guanine nucleotide-binding protein-coupled receptor eeeee2  cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned serotonin receptors
CRP11	The inhibition of [125I]LSD binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described  bbbbb1 serotonin eeeee1  bbbbb2 serotonin receptor eeeee2  subtype
CRP11	Cloning and expression of a novel  bbbbb1 serotonin eeeee1  bbbbb2 serotonin receptor eeeee2  with high affinity for tricyclic psychotropic drugs
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A >  bbbbb2 5-HT1E eeeee2 
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors:  bbbbb2 5-HT2 eeeee2  > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1  bbbbb2 serotonin [5-hydroxytryptamine (5-HT)] receptors eeeee2 : 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B >  bbbbb2 5-HT1A eeeee2  > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors: 5-HT2 > 5-HT1D > 5-HT1C >  bbbbb2 5-HT1B eeeee2  > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors: 5-HT2 >  bbbbb2 5-HT1D eeeee2  > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine ( bbbbb1 5-HT eeeee1 )] receptors: 5-HT2 > 5-HT1D >  bbbbb2 5-HT1C eeeee2  > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A >  bbbbb2 5-HT1E eeeee2 
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors:  bbbbb2 5-HT2 eeeee2  > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 serotonin [5-hydroxytryptamine (5-HT)] receptors eeeee2 : 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B >  bbbbb2 5-HT1A eeeee2  > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C >  bbbbb2 5-HT1B eeeee2  > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors: 5-HT2 >  bbbbb2 5-HT1D eeeee2  > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [ bbbbb1 5-hydroxytryptamine eeeee1  (5-HT)] receptors: 5-HT2 > 5-HT1D >  bbbbb2 5-HT1C eeeee2  > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A >  bbbbb2 5-HT1E eeeee2 
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors:  bbbbb2 5-HT2 eeeee2  > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  bbbbb2 serotonin [5-hydroxytryptamine (5-HT)] receptors eeeee2 : 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B >  bbbbb2 5-HT1A eeeee2  > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C >  bbbbb2 5-HT1B eeeee2  > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 >  bbbbb2 5-HT1D eeeee2  > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following  bbbbb1 serotonin eeeee1  [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D >  bbbbb2 5-HT1C eeeee2  > 5-HT1B > 5-HT1A > 5-HT1E
CRP11	HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of  bbbbb1 adenylyl eeeee1  bbbbb2 adenylyl cyclase eeeee2  activity, which is blocked by antipsychotic and antidepressant drugs
CRP11	The twigs of Cudrania tricuspidata were found to show strong tyrosinase inhibitory activity, and further detailed component analysis resulted in the isolation of a new flavanol glucoside,  bbbbb1 (2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside eeeee1  bbbbb2 tyrosinase eeeee2  inhibitory activity, and further detailed component analysis resulted in the isolation of a new flavanol glucoside, (2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside (1), plus twenty-seven known compounds (2-28)
CRP11	The twigs of Cudrania tricuspidata were found to show strong tyrosinase inhibitory activity, and further detailed component analysis resulted in the isolation of a new  bbbbb1 flavanol glucoside eeeee1  bbbbb2 tyrosinase eeeee2  inhibitory activity, and further detailed component analysis resulted in the isolation of a new flavanol glucoside, (2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside (1), plus twenty-seven known compounds (2-28)
CRP11	Suppression of TβR1 by the pharmacological inhibitor ( bbbbb1 SB431542 eeeee1 ) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by  bbbbb2 TβR1 eeeee2  siRNA
CRP11	The interaction between mGluR1 and the  bbbbb1 calcium eeeee1  bbbbb2 mGluR1 eeeee2  and the calcium channel Cav₂.₁ preserves coupling in the presence of long Homer proteins
CRP11	The interaction between mGluR1 and the  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  Cav₂.₁ preserves coupling in the presence of long Homer proteins
CRP11	The interaction between mGluR1 and the  bbbbb1 calcium eeeee1  channel  bbbbb2 Cav₂.₁ eeeee2  preserves coupling in the presence of long Homer proteins
CRP11	The interaction between mGluR1 and the  bbbbb1 calcium eeeee1  channel Cav₂.₁ preserves coupling in the presence of  bbbbb2 long Homer proteins eeeee2 
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 Ca(V2.2) eeeee2  (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1 (V3.2) (T-type), and  bbbbb2 Ca(V2.1) eeeee2  (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1 (V3.2) (T-type), and Ca(V2.1) ( bbbbb2 P/Q-type eeeee2 ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 mGluR1 eeeee2  from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1 (V3.2) ( bbbbb2 T-type) eeeee2 , and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 N-type eeeee2 ), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 Ca(V3.2) eeeee2  (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type),  bbbbb1 Ca eeeee1  bbbbb2 Homer-2b eeeee2  to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1  bbbbb2 Ca(V2.2) eeeee2  (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1 (V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb2 Ca(V2.1) eeeee2  (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1 (V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) ( bbbbb2 P/Q-type eeeee2 ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1  bbbbb2 mGluR1 eeeee2  from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1 (V2.2) (N-type), Ca(V3.2) ( bbbbb2 T-type) eeeee2 , and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1 (V2.2) ( bbbbb2 N-type eeeee2 ), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1 (V2.2) (N-type),  bbbbb2 Ca(V3.2) eeeee2  (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including  bbbbb1 Ca eeeee1  bbbbb2 Homer-2b eeeee2  to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including  bbbbb2 Ca(V2.2) eeeee2  (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb2 Ca(V2.1) eeeee2  (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) ( bbbbb2 P/Q-type eeeee2 ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  bbbbb2 mGluR1 eeeee2  from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including Ca(V2.2) (N-type), Ca(V3.2) ( bbbbb2 T-type) eeeee2 , and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including Ca(V2.2) ( bbbbb2 N-type eeeee2 ), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  channels including Ca(V2.2) (N-type),  bbbbb2 Ca(V3.2) eeeee2  (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent  bbbbb1 calcium eeeee1  bbbbb2 Homer-2b eeeee2  to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 Ca(V2.2) eeeee2  (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 Ca(V2.1) eeeee2  (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1 (V2.1) ( bbbbb2 P/Q-type eeeee2 ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 mGluR1 eeeee2  from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 T-type) eeeee2 , and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 N-type eeeee2 ), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 Ca(V3.2) eeeee2  (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Here the selectivity of this uncoupling process was examined by testing the ability of Homer-2b to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and  bbbbb1 Ca eeeee1  bbbbb2 Homer-2b eeeee2  to uncouple mGluR1 from multiple voltage dependent calcium channels including Ca(V2.2) (N-type), Ca(V3.2) (T-type), and Ca(V2.1) (P/Q-type) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG)
CRP11	Group I metabotropic  bbbbb1 glutamate eeeee1  receptors (mGluR1 and 5) are  bbbbb2 G protein coupled receptors eeeee2  that regulate neuronal activity in a number of ways
CRP11	Group I metabotropic  bbbbb1 glutamate eeeee1  bbbbb2 Group I metabotropic glutamate receptors eeeee2  (mGluR1 and 5) are G protein coupled receptors that regulate neuronal activity in a number of ways
CRP11	Group I metabotropic  bbbbb1 glutamate eeeee1  receptors ( bbbbb2 mGluR1 and 5 eeeee2 ) are G protein coupled receptors that regulate neuronal activity in a number of ways
CRP11	Uncoupling from this channel was achieved by co-expression of a bbbbb1 n mGluR1  eeeee1  bbbbb2 pression of an mGluR1 C-terminal eeeee2  protein designed to disrupt a previously described direct interaction between these two proteins, suggesting that this interaction allows incorporation of Ca(V2.1) into the mGluR1/Homer signaling complex, thereby preserving modulation in the presence of scaffolding Homer proteins
CRP11	This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal  bbbbb1 C eeeee1  bbbbb2 Homer eeeee2  family of scaffolding proteins which bind to a small motif on the distal C-termini of mGluR1 and 5, localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the mGluRs from extra-synaptic effectors such as voltage dependent ion channels
CRP11	This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal  bbbbb1 C eeeee1 -termini of mGluR1 and 5, localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the  bbbbb2 mGluRs eeeee2  from extra-synaptic effectors such as voltage dependent ion channels
CRP11	This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal  bbbbb1 C eeeee1 -termini of mGluR1 and 5, localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the mGluRs from extra-synaptic effectors such as  bbbbb2 voltage dependent ion channels eeeee2 
CRP11	In intact CHO-K1 cells,  bbbbb1 I3A eeeee1  was able to translocate different  bbbbb2 green fluorescent protein eeeee2 -tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than PMA
CRP11	In intact CHO-K1 cells, I3A was able to translocate different green fluorescent protein-tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than  bbbbb1 PMA eeeee1  bbbbb2 green fluorescent protein eeeee2 -tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than PMA
CRP11	I3A bound to PKC-alpha in the presence of  bbbbb1 phosphatidylserine eeeee1  with high affinity; however, under these assay conditions, little  bbbbb2 PKC eeeee2  isoform selectivity was observed
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase,  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione and glutathione peroxidase which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase,  bbbbb1 glutathione eeeee1  and  bbbbb2 glutathione peroxidase eeeee2  which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione and glutathione peroxidase which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of  bbbbb1 superoxide eeeee1  dismutase, glutathione and  bbbbb2 glutathione peroxidase eeeee2  which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and glutathione peroxidase which were decreased by  bbbbb1 aflatoxin eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione and glutathione peroxidase which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the  bbbbb1 malondialdehyde eeeee1  level and increased amount of  bbbbb2 superoxide dismutase eeeee2 , glutathione and glutathione peroxidase which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the  bbbbb1 malondialdehyde eeeee1  level and increased amount of superoxide dismutase, glutathione and  bbbbb2 glutathione peroxidase eeeee2  which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione and glutathione peroxidase which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  which were decreased by aflatoxin
CRP11	Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with  bbbbb1 aflatoxin B(1) eeeee1  decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and  bbbbb2 glutathione peroxidase eeeee2  which were decreased by aflatoxin
CRP11	 bbbbb1 Quinone eeeee1  bbbbb2 Quinone oxidoreductase 2 eeeee2  (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol
CRP11	 bbbbb1 Quinone eeeee1  oxidoreductase 2 ( bbbbb2 QR2 eeeee2 ) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol
CRP11	Single-turnover kinetics of the reductive half-reaction are ch bbbbb1 emically a eeeee1 nd kinetically competent and confirm the inhibitor selectivity seen in the steady-state experiments bbbbb2  eeeee2 
CRP11	Kinetic mechanism of  bbbbb1 quinone eeeee1  bbbbb2 quinone oxidoreductase 2 eeeee2  and its inhibition by the antimalarial quinolines
CRP11	The anti-hyperthermic effect of  bbbbb1 Lu AF21934 eeeee1  (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of  bbbbb1 Lu AF21934 eeeee1  (5 mg/kg) in the SIH test was inhibited by the  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of  bbbbb1 Lu AF21934 eeeee1  (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by  bbbbb1 ritanserin eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by  bbbbb1 ritanserin eeeee1  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not  bbbbb1 serotonin eeeee1 -dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not  bbbbb1 serotonin eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not  bbbbb1 serotonin eeeee1 -dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist  bbbbb1 flumazenil eeeee1  (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist  bbbbb1 flumazenil eeeee1  (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb1 5-HT eeeee1 (1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb1 5-HT eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the  bbbbb1 benzodiazepine eeeee1  receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the  bbbbb1 benzodiazepine eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the  bbbbb1 benzodiazepine eeeee1  receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in  bbbbb1 serotonin eeeee1 -deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in  bbbbb1 serotonin eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in  bbbbb1 serotonin eeeee1 -deficient mice and upon blockade of either  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by  bbbbb1 WAY100635 eeeee1 , or  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by  bbbbb1 WAY100635 eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2A/2C) eeeee2  receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb1 5-HT eeeee1  bbbbb2 benzodiazepine receptor eeeee2  antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin
CRP11	AF21934 did not produce antidepressant-like effects in the tail bbbbb1  suspensi eeeee1  bbbbb2 s in the tail suspension test (T eeeee2 ST) in mice; however, it decreased the basal locomotor activity of mice that were not habituated to activity cages
CRP11	To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion ( bbbbb1 Wellbutrin SR eeeee1  bbbbb2 CYP2B6 eeeee2  activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate
CRP11	To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using  bbbbb1 bupropion eeeee1  bbbbb2 CYP2B6 eeeee2  activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate
CRP11	The influence of sex, ethnicity, and CYP2B6 genotype on  bbbbb1 bupropion eeeee1  metabolism as an index of hepatic  bbbbb2 CYP2B6 eeeee2  activity in humans
CRP11	This result suggests that TAS-102 efficacy a bbbbb1 nd the  eeeee1 pyrimidine synthetic pathway may differ depending on histological type bbbbb2  eeeee2 
CRP11	This result suggests that TAS-102 efficacy a bbbbb1 nd the  eeeee1 pyrimidine synthetic pathway may differ depending on histological type bbbbb2  eeeee2 
CRP11	 bbbbb1 Thymidine eeeee1  kinase-1 ( bbbbb2 TK-1) eeeee2  and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	 bbbbb1 Thymidine eeeee1  kinase-1 (TK-1) and thymidylate synthase ( bbbbb2 TS eeeee2 ) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	 bbbbb1 Thymidine eeeee1  bbbbb2 Thymidine kinase-1 eeeee2  (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	 bbbbb1 Thymidine eeeee1  kinase-1 (TK-1) and  bbbbb2 thymidylate synthase eeeee2  (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	Thymidine kinase-1 (TK-1) and  bbbbb1 thymidylate eeeee1  bbbbb2 TK-1) eeeee2  and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	Thymidine kinase-1 (TK-1) and  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	Thymidine kinase-1 (TK-1) and  bbbbb1 thymidylate eeeee1  bbbbb2 Thymidine kinase-1 eeeee2  (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	Thymidine kinase-1 (TK-1) and  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively
CRP11	Immunohistochemical characterization of pyrimidine synthetic enzymes,  bbbbb1 thymidine eeeee1  bbbbb2 thymidine kinase-1 eeeee2  and thymidylate synthase, in various types of cancer
CRP11	Immunohistochemical characterization of pyrimidine synthetic enzymes,  bbbbb1 thymidine eeeee1  kinase-1 and  bbbbb2 thymidylate synthase eeeee2 , in various types of cancer
CRP11	TAS-102 is a novel drug containing  bbbbb1 trifluorothymidine eeeee1 , which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit  bbbbb2 TS eeeee2 
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the  bbbbb1 glucose eeeee1  bbbbb2 sodium glucose transporter eeeee2  (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the  bbbbb1 glucose eeeee1  bbbbb2 SGLT2 eeeee2 ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium  bbbbb1 glucose eeeee1  bbbbb2 sodium glucose transporter eeeee2  (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with sodium  bbbbb1 glucose eeeee1  transporter ( bbbbb2 SGLT2 eeeee2 ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with  bbbbb1 sodium eeeee1  bbbbb2 insulin eeeee2  sensitivity with thiazolidinediones and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with  bbbbb1 sodium eeeee1  bbbbb2 sodium glucose transporter eeeee2  (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	To describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with thiazolidinediones and changes in renal threshold with  bbbbb1 sodium eeeee1  glucose transporter ( bbbbb2 SGLT2 eeeee2 ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments
CRP11	Manipulation of iHOMA2s renal excretion threshold variable suggested that a decrease bbbbb1  of 17% eeeee1  was required to obtain a 0.9 mmol/L dec bbbbb2 rease i eeeee2 n mean glucose.CONCLUSIONSiHOMA2 is an extended mathematical model for the assessment of insulin resistance and β-cell function
CRP11	The objectives of these studies were to explore the possibility of establishing of a link between the pharmacokinetics of  bbbbb1 TAK-441 eeeee1  and the responses of  bbbbb2 Gli1 eeeee2  mRNA in tumor-associated stromal or skin cells and the antitumor effect of hedgehog inhibition
CRP11	The objectives of these studies were to explore the possibility of establishing of a link between the pharmacokinetics of  bbbbb1 TAK-441 eeeee1  and the responses of Gli1 mRNA in tumor-associated stromal or skin cells and the antitumor effect of  bbbbb2 hedgehog eeeee2  inhibition
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor  bbbbb1 TAK-441 eeeee1  for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective  bbbbb2 hedgehog eeeee2  signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor  bbbbb1 TAK-441 eeeee1  for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to  bbbbb2 Smo eeeee2  and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ( bbbbb1 TAK-441 eeeee1  bbbbb2 Gli1 eeeee2  messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ( bbbbb1 TAK-441 eeeee1  bbbbb2 hedgehog eeeee2  inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.  bbbbb1 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide eeeee1  bbbbb2 Gli1 eeeee2  messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.  bbbbb1 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide eeeee1  (TAK-441) is a potent, selective  bbbbb2 hedgehog eeeee2  signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.  bbbbb1 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide eeeee1  bbbbb2 hedgehog eeeee2  inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer
CRP11	Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.  bbbbb1 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide eeeee1  (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to  bbbbb2 Smo eeeee2  and is being developed for the treatment of cancer
CRP11	Following chronic oral administ bbbbb1 ration (2 eeeee1 1 days, one dose daily), levels of NA, 5-HT and DA in hippocampus and striatum were unaffecte bbbbb2 d by  eeeee2 rasagiline at doses up to 1 mg x kg(-1)
CRP11	Following chronic oral administ bbbbb1 ration (2 eeeee1 1 days, one dose daily), levels of NA, 5-HT and DA in hippocampus and striatum were unaffected by rasagilin bbbbb2 e at  eeeee2 doses up to 1 mg x kg(-1)
CRP11	Following chronic oral administration (21 days, one dose d bbbbb1 aily), le eeeee1 vels of NA, 5-HT and DA in hippocampus and striatum were unaffecte bbbbb2 d by  eeeee2 rasagiline at doses up to 1 mg x kg(-1)
CRP11	Following chronic oral administration (21 days, one dose d bbbbb1 aily), le eeeee1 vels of NA, 5-HT and DA in hippocampus and striatum were unaffected by rasagilin bbbbb2 e at  eeeee2 doses up to 1 mg x kg(-1)
CRP11	 bbbbb1 Reserpine eeeee1 -induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit  bbbbb2 MAO-A eeeee2  as well as MAO-B, but not at MAO-B-selective doses
CRP11	 bbbbb1 Reserpine eeeee1 -induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at  bbbbb2 MAO-B eeeee2 -selective doses
CRP11	 bbbbb1 Reserpine eeeee1 -induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as  bbbbb2 MAO-B eeeee2 , but not at MAO-B-selective doses
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with  bbbbb1 L-DOPA eeeee1  or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  bbbbb2 MAO-B eeeee2  by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with  bbbbb1 L-DOPA eeeee1  or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  bbbbb2 MAO-A eeeee2  and MAO-B by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or  bbbbb1 rasagiline eeeee1  (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  bbbbb2 MAO-B eeeee2  by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or  bbbbb1 rasagiline eeeee1  (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  bbbbb2 MAO-A eeeee2  and MAO-B by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with  bbbbb1 fluoxetine eeeee1  (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  bbbbb2 MAO-B eeeee2  by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with  bbbbb1 fluoxetine eeeee1  (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  bbbbb2 MAO-A eeeee2  and MAO-B by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or  bbbbb1 L-tryptophan eeeee1  (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  bbbbb2 MAO-B eeeee2  by tranylcypromine together with the monoamine precursors
CRP11	However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or  bbbbb1 L-tryptophan eeeee1  (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  bbbbb2 MAO-A eeeee2  and MAO-B by tranylcypromine together with the monoamine precursors
CRP11	However, combination of  bbbbb1 rasagiline eeeee1  (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  bbbbb2 MAO-B eeeee2  by tranylcypromine together with the monoamine precursors
CRP11	However, combination of  bbbbb1 rasagiline eeeee1  (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  bbbbb2 MAO-A eeeee2  and MAO-B by tranylcypromine together with the monoamine precursors
CRP11	Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease
CRP11	Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO eeeee2 ) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease
CRP11	Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to  bbbbb1 5-MeO-DMT eeeee1  bbbbb2 MAO-A eeeee2 -mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations
CRP11	 bbbbb1 Harmaline eeeee1  (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg- bbbbb2 CYP2D6 eeeee2  mice
CRP11	Harmaline (5 mg/kg) also increased blood and brain  bbbbb1 bufotenine eeeee1  concentrations that were generally higher in Tg- bbbbb2 CYP2D6 eeeee2  mice
CRP11	This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects  bbbbb1 harmaline eeeee1  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT  bbbbb1 O eeeee1  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	This study is aimed at delineating  bbbbb1 harmaline eeeee1  and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce  bbbbb1 bufotenine eeeee1  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines  bbbbb1 5-MeO-DMT eeeee1  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	This study is aimed at delineating harmaline and  bbbbb1 5-MeO-DMT eeeee1  pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of  bbbbb2 CYP2D6 eeeee2  that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name " bbbbb1 5-MEO eeeee1  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name " bbbbb1 5-MEO eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.  bbbbb1 5-Methoxy-N,N-dimethyltryptamine eeeee1  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.  bbbbb1 5-Methoxy-N,N-dimethyltryptamine eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor  bbbbb1 Harmaline eeeee1  and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between  bbbbb1 Monoamine eeeee1  Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between  bbbbb1 Monoamine eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring  bbbbb1 indolealkylamines eeeee1  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring  bbbbb1 indolealkylamines eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine ( bbbbb1 5-MeO-DMT eeeee1  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine ( bbbbb1 5-MeO-DMT eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and  bbbbb1 5-Methoxy-N,N-Dimethyltryptamine eeeee1 , and the Impact of  bbbbb2 CYP2D6 eeeee2  Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and  bbbbb1 5-Methoxy-N,N-Dimethyltryptamine eeeee1  bbbbb2 Monoamine Oxidase A eeeee2  Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines
CRP11	Our recent study has demonstrated that coadministration of  bbbbb1 monoamine eeeee1  oxidase A ( bbbbb2 MAO-A eeeee2 ) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine
CRP11	Our recent study has demonstrated that coadministration of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase A eeeee2  (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine
CRP11	Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to  bbbbb1 5-MeO-DMT eeeee1  bbbbb2 MAO-A eeeee2 ) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine
CRP11	Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to  bbbbb1 5-MeO-DMT eeeee1  bbbbb2 monoamine oxidase A eeeee2  (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine
CRP11	Given these findings, a unified PK model includin bbbbb1 g the inh eeeee1 ibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmali bbbbb2 ne was eeeee2  developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models
CRP11	Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to descr bbbbb1 ibe blood eeeee1  bbbbb2 ne was eeeee2  developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models
CRP11	Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood  bbbbb1 harmaline eeeee1  bbbbb2 ne was eeeee2  developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models
CRP11	Given these findings, a unified PK model including the inhibiti bbbbb1 on of MAO eeeee1 -A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmali bbbbb2 ne was eeeee2  developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models
CRP11	A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to  bbbbb1 harmaline eeeee1  in wild-type mice than CYP2D6-humanized (Tg- bbbbb2 CYP2D6 eeeee2 ) mice
CRP11	A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to  bbbbb1 harmaline eeeee1  in wild-type mice than  bbbbb2 CYP2D6 eeeee2 -humanized (Tg-CYP2D6) mice
CRP11	A more pronounced effect on  bbbbb1 5-MeO-DMT eeeee1  PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg- bbbbb2 CYP2D6 eeeee2 ) mice
CRP11	A more pronounced effect on  bbbbb1 5-MeO-DMT eeeee1  PK was associated with greater exposure to harmaline in wild-type mice than  bbbbb2 CYP2D6 eeeee2 -humanized (Tg-CYP2D6) mice
CRP11	COX-1 inhibition was determined by measuring thromboxane B2 ( bbbbb1 TXB2 eeeee1  bbbbb2 COX-1 eeeee2  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)
CRP11	COX-1 inhibition was determined by measuring  bbbbb1 thromboxane B2 eeeee1  bbbbb2 COX-1 eeeee2  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)
CRP11	We found a substantial metabolism of the tested substrates, ranging from 26% ( bbbbb1 UDP eeeee1  bbbbb2 UDP-glucuronosyltransferase 1A1 eeeee2 ), 47% (CYP3A4), to 240% (CYP2C9) of primary human hepatocytes
CRP11	We found a substantial metabolism of the tested substrates, ranging from 26% ( bbbbb1 UDP eeeee1 -glucuronosyltransferase 1A1), 47% ( bbbbb2 CYP3A4 eeeee2 ), to 240% (CYP2C9) of primary human hepatocytes
CRP11	We found a substantial metabolism of the tested substrates, ranging from 26% ( bbbbb1 UDP eeeee1 -glucuronosyltransferase 1A1), 47% (CYP3A4), to 240% ( bbbbb2 CYP2C9 eeeee2 ) of primary human hepatocytes
CRP11	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and  bbbbb1 metformin eeeee1  bbbbb2 dipeptidyl peptidase-4 eeeee2  inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
CRP11	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on  bbbbb1 glimepiride eeeee1  bbbbb2 dipeptidyl peptidase-4 eeeee2  inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
CRP11	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on  bbbbb1 glimepiride eeeee1  bbbbb2 dipeptidyl peptidase-4 eeeee2  inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
CRP11	Everolimus (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin eeeee2 ) to reach the oncology clinic
CRP11	Everolimus (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mTOR eeeee2  (mammalian target of rapamycin) to reach the oncology clinic
CRP11	A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitors sunitinib and/or sorafenib
CRP11	A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR  bbbbb1 tyrosine eeeee1  bbbbb2 VEGFR eeeee2  tyrosine kinase inhibitors sunitinib and/or sorafenib
CRP11	A phase III randomized placebo-controlled trial has examined the impact of  bbbbb1 everolimus eeeee1  in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR  bbbbb2 tyrosine kinase eeeee2  inhibitors sunitinib and/or sorafenib
CRP11	A phase III randomized placebo-controlled trial has examined the impact of  bbbbb1 everolimus eeeee1  in patients with clear cell renal cancers and progressive disease on or within 6 months of the  bbbbb2 VEGFR eeeee2  tyrosine kinase inhibitors sunitinib and/or sorafenib
CRP11	Methylphenidate, an inhibitor of dopamine and  bbbbb1 norepinephrine eeeee1  transporters (DAT and  bbbbb2 NET eeeee2 , respectively), is a standard treatment for ADHD
CRP11	Methylphenidate, an inhibitor of dopamine and  bbbbb1 norepinephrine eeeee1  bbbbb2 dopamine and norepinephrine transporters eeeee2  (DAT and NET, respectively), is a standard treatment for ADHD
CRP11	Methylphenidate, an inhibitor of dopamine and  bbbbb1 norepinephrine eeeee1  transporters ( bbbbb2 DAT eeeee2  and NET, respectively), is a standard treatment for ADHD
CRP11	Methylphenidate, an inhibitor of  bbbbb1 dopamine eeeee1  and norepinephrine transporters (DAT and  bbbbb2 NET eeeee2 , respectively), is a standard treatment for ADHD
CRP11	Methylphenidate, an inhibitor of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine and norepinephrine transporters eeeee2  (DAT and NET, respectively), is a standard treatment for ADHD
CRP11	Methylphenidate, an inhibitor of  bbbbb1 dopamine eeeee1  and norepinephrine transporters ( bbbbb2 DAT eeeee2  and NET, respectively), is a standard treatment for ADHD
CRP11	Further, methylphenidate did not alter DAT cellular localization, indicating that methylphenidate treatment during adolescence regulated DAT function in SHR mPFC in a trafficking-independent manner bbbbb1  eeeee1  bbbbb2 d n eeeee2 ot alter DAT cellular localization, indicating that methylphenidate treatment during adolescence regulated DAT function in SHR mPFC in a trafficking-independent manner
CRP11	Adolescence  bbbbb1 methylphenidate eeeee1  treatment in a rodent model of attention deficit/hyperactivity disorder:  bbbbb2 Dopamine transporter eeeee2  function and cellular distribution in adulthood
CRP11	Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder:  bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine transporter eeeee2  function and cellular distribution in adulthood
CRP11	Our previous results showed that methylphenidate treatment in adolescent SHR enhanced  bbbbb1 cocaine eeeee1  self-administration during adulthood, and alterations in  bbbbb2 DAT eeeee2  function in prefrontal cortex play a role in this response
CRP11	DH inhibition occurs at lower concentrations of A77 1726 than that of  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  and is currently considered the major mode of action
CRP11	Duloxetine, a dual 5-HT and  bbbbb1 norepinephrine eeeee1  reuptake inhibitor, displayed a high affinity for both the  bbbbb2 5-HT and the norepinephrine transporters eeeee2 
CRP11	Duloxetine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed a high affinity for both the 5-HT and the  bbbbb1 norepinephrine eeeee1  bbbbb2 5-HT and the norepinephrine transporters eeeee2 
CRP11	 bbbbb1 Duloxetine eeeee1 , a dual 5-HT and norepinephrine reuptake inhibitor, displayed a high affinity for both the  bbbbb2 5-HT and the norepinephrine transporters eeeee2 
CRP11	Duloxetine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed a high affinity for both the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT and the norepinephrine transporters eeeee2 
CRP11	Duloxetine, a dual  bbbbb1 5-HT eeeee1  and norepinephrine reuptake inhibitor, displayed a high affinity for both the  bbbbb2 5-HT and the norepinephrine transporters eeeee2 
CRP11	Interestingly, venlafaxine, a dual  bbbbb1 5-HT eeeee1  and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the  bbbbb2 5-HT transporter eeeee2  (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual  bbbbb1 5-HT eeeee1  and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the  bbbbb2 norepinephrine transporter eeeee2  (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the  bbbbb1 norepinephrine eeeee1  bbbbb2 5-HT transporter eeeee2  (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and  bbbbb1 norepinephrine eeeee1  reuptake inhibitor, displayed only a moderate affinity for the  bbbbb2 5-HT transporter eeeee2  (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and  bbbbb1 norepinephrine eeeee1  reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the  bbbbb2 norepinephrine transporter eeeee2  (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT transporter eeeee2  (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM)
CRP11	Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the  bbbbb1 5-HT eeeee1  transporter (Ki = 74 nM) and a very low affinity for the  bbbbb2 norepinephrine transporter eeeee2  (Ki = 1.26 microM)
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and  bbbbb1 fluvoxamine eeeee1  displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective  bbbbb1 5-HT eeeee1  reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the  bbbbb2 5-HT transporter eeeee2 , whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter
CRP11	The selective  bbbbb1 5-HT eeeee1  reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective 5-HT reuptake inhibitors paroxetine,  bbbbb1 indalpine eeeee1  and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective 5-HT reuptake inhibitors  bbbbb1 paroxetine eeeee1 , indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the  bbbbb1 norepinephrine eeeee1  bbbbb2 5-HT transporter eeeee2 , whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the  bbbbb1 norepinephrine eeeee1  reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT transporter eeeee2 , whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the  bbbbb1 5-HT eeeee1  transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb2 norepinephrine transporter eeeee2 
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor  bbbbb1 desipramine eeeee1  bbbbb2 5-HT transporter eeeee2 , whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb1 norepinephrine eeeee1  bbbbb2 5-HT transporter eeeee2 , whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter
CRP11	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2 
CRP11	Affinities of venlafaxine and various reuptake inhibitors for the serotonin and  bbbbb1 norepinephrine eeeee1  bbbbb2 serotonin and norepinephrine transporters eeeee2 
CRP11	Affinities of  bbbbb1 venlafaxine eeeee1  and various reuptake inhibitors for the  bbbbb2 serotonin and norepinephrine transporters eeeee2 
CRP11	Affinities of venlafaxine and various reuptake inhibitors for the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin and norepinephrine transporters eeeee2 
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin ( bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine, 5-HT) and the  bbbbb1 norepinephrine eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine,  bbbbb1 5-HT eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters using the selective ligands  bbbbb1 [3H]cyanoimipramine eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters using the selective ligands [3H]cyanoimipramine and  bbbbb1 [3H]nisoxetine eeeee1  bbbbb2 serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters eeeee2  using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively
CRP11	 bbbbb1 Tryptophan eeeee1  bbbbb2 Tryptophan hydroxylase eeeee2  mRNA levels are elevated by repeated immobilization stress in rat raphe nuclei but not in pineal gland
CRP11	To begin to examine whether these changes are mediated by alterations in gene expression for  bbbbb1 tryptophan eeeee1  hydroxylase ( bbbbb2 TPH eeeee2 ), the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)
CRP11	To begin to examine whether these changes are mediated by alterations in gene expression for  bbbbb1 tryptophan eeeee1  bbbbb2 tryptophan hydroxylase eeeee2  (TPH), the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)
CRP11	Systemic administration of beta2-adrenoceptor agonists,  bbbbb1 formoterol eeeee1  and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.  bbbbb2 beta(2)-Adrenoceptor eeeee2  agonists provide a potential therapy for muscle wasting and weakness, but their use may be limited by adverse effects on the heart, mediated in part, by beta(1)-adrenoceptor activation
CRP11	Systemic administration of beta2-adrenoceptor agonists,  bbbbb1 formoterol eeeee1  and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. beta(2)-Adrenoceptor agonists provide a potential therapy for muscle wasting and weakness, but their use may be limited by adverse effects on the heart, mediated in part, by  bbbbb2 beta(1)-adrenoceptor eeeee2  activation
CRP11	Systemic administration of beta2-adrenoceptor agonists, formoterol and  bbbbb1 salmeterol eeeee1 , elicit skeletal muscle hypertrophy in rats at micromolar doses.  bbbbb2 beta(2)-Adrenoceptor eeeee2  agonists provide a potential therapy for muscle wasting and weakness, but their use may be limited by adverse effects on the heart, mediated in part, by beta(1)-adrenoceptor activation
CRP11	Systemic administration of beta2-adrenoceptor agonists, formoterol and  bbbbb1 salmeterol eeeee1 , elicit skeletal muscle hypertrophy in rats at micromolar doses. beta(2)-Adrenoceptor agonists provide a potential therapy for muscle wasting and weakness, but their use may be limited by adverse effects on the heart, mediated in part, by  bbbbb2 beta(1)-adrenoceptor eeeee2  activation
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the  bbbbb1 catecholamine eeeee1  marker tyrosine hydroxylase ( bbbbb2 TH eeeee2 ), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the  bbbbb1 catecholamine eeeee1  marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter ( bbbbb2 NET eeeee2 )-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the  bbbbb1 catecholamine eeeee1  marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb2 norepinephrine transporter eeeee2  (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the  bbbbb1 catecholamine eeeee1  marker  bbbbb2 tyrosine hydroxylase eeeee2  (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb1 norepinephrine eeeee1  bbbbb2 TH eeeee2 ), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb1 norepinephrine eeeee1  transporter ( bbbbb2 NET eeeee2 )-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb1 norepinephrine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2  (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker  bbbbb1 tyrosine eeeee1  hydroxylase ( bbbbb2 TH eeeee2 ), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker  bbbbb1 tyrosine eeeee1  hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter ( bbbbb2 NET eeeee2 )-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker  bbbbb1 tyrosine eeeee1  hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  bbbbb2 norepinephrine transporter eeeee2  (NET)-ir density
CRP11	PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2  (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and  bbbbb1 GW572016 eeeee1  bbbbb2 erbB eeeee2  tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and  bbbbb1 GW572016 eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include  bbbbb1 CI-1033 eeeee1 , an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and  bbbbb2 Her2 eeeee2 )
CRP11	Agents that have only begun to undergo clinical evaluation include  bbbbb1 CI-1033 eeeee1 , an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual  bbbbb2 kinase eeeee2  inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include  bbbbb1 CI-1033 eeeee1 , an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting  bbbbb2 epidermal growth factor receptor eeeee2  and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB  bbbbb1 tyrosine eeeee1  bbbbb2 erbB eeeee2  tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB  bbbbb1 tyrosine eeeee1  kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and  bbbbb2 Her2 eeeee2 )
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB  bbbbb1 tyrosine eeeee1  kinase inhibitor, and PKI166 and GW572016, both examples of dual  bbbbb2 kinase eeeee2  inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB  bbbbb1 tyrosine eeeee1  kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting  bbbbb2 epidermal growth factor receptor eeeee2  and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and  bbbbb1 PKI166 eeeee1  bbbbb2 erbB eeeee2  tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and  bbbbb1 PKI166 eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive  bbbbb1 oxygen eeeee1  species-mediated mechanism and independently of  bbbbb2 janus tyrosine kinase 2 eeeee2  and p-rex1
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive  bbbbb1 oxygen eeeee1  bbbbb2 rac1 eeeee2  activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive  bbbbb1 oxygen eeeee1  species-mediated mechanism and independently of janus tyrosine kinase 2 and  bbbbb2 p-rex1 eeeee2 
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus  bbbbb1 tyrosine eeeee1  bbbbb2 janus tyrosine kinase 2 eeeee2  and p-rex1
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus  bbbbb1 tyrosine eeeee1  bbbbb2 rac1 eeeee2  activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1
CRP11	Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus  bbbbb1 tyrosine eeeee1  kinase 2 and  bbbbb2 p-rex1 eeeee2 
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/ bbbbb2 Rac1 eeeee2  activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with  bbbbb2 ErbB eeeee2  receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 ( bbbbb2 Jak2 eeeee2 )/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/signal transducer and activator of transcription 3 ( bbbbb2 Stat3 eeeee2 ) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/ bbbbb2 signal transducer and activator of transcription 3 eeeee2  (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate  bbbbb2 P-Rex1 eeeee2 /Rac1 activation in response to ErbB ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to  bbbbb2 ErbB eeeee2  ligands
CRP11	As the Janus  bbbbb1 tyrosine eeeee1  bbbbb2 Janus tyrosine kinase 2 eeeee2  (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands
CRP11	Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of  bbbbb1 cucurbitacin I eeeee1  bbbbb2 RhoA eeeee2 -ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin
CRP11	Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of  bbbbb1 cucurbitacin I eeeee1  on Rac1 activation by  bbbbb2 heregulin eeeee2 
CRP11	Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of  bbbbb1 cucurbitacin I eeeee1  bbbbb2 ROCK eeeee2  pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin
CRP11	Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac- bbbbb1 guanine nucleotide eeeee1  exchange factor  bbbbb2 P-Rex1 eeeee2 
CRP11	Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac- bbbbb1 guanine nucleotide eeeee1  bbbbb2 Rac-guanine nucleotide exchange factor eeeee2  P-Rex1
CRP11	Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac- bbbbb1 guanine nucleotide eeeee1  bbbbb2 ErbB eeeee2  receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1
CRP11	Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac- bbbbb1 guanine nucleotide eeeee1  bbbbb2 Rac1 eeeee2  and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1
CRP11	However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of  bbbbb1 cucurbitacin I eeeee1  bbbbb2 Jak2 eeeee2  or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism
CRP11	However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of  bbbbb1 cucurbitacin I eeeee1  bbbbb2 Rac1 eeeee2  activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism
CRP11	However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of  bbbbb1 cucurbitacin I eeeee1  bbbbb2 Stat3 eeeee2  RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism
CRP11	In conclusion, these results indicate that ErbB-driven Ra bbbbb1 c1 activation  eeeee1 in breast cancer cells proceeds independently of the Jak2 pathway bbbbb2  eeeee2 
CRP11	In conclusion, these results indicate that ErbB-driven Ra bbbbb1 c1 activation  eeeee1 in breast cancer cells proceeds independently of the Jak2 pathway bbbbb2  eeeee2 
CRP11	Here we found that the anticancer agent  bbbbb1 cucurbitacin I eeeee1 , a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the  bbbbb2 ErbB3 eeeee2  ligand heregulin in breast cancer cells
CRP11	Here we found that the anticancer agent  bbbbb1 cucurbitacin I eeeee1 , a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand  bbbbb2 heregulin eeeee2  in breast cancer cells
CRP11	Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive  bbbbb1 oxygen eeeee1  bbbbb2 RhoA eeeee2  activation by cucurbitacin I is mediated by reactive oxygen species (ROS)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the  bbbbb1 acyl eeeee1  bbbbb2 acyl-binding pocket eeeee2  (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the  bbbbb1 acyl eeeee1  bbbbb2 TcAChE eeeee2 , interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the  bbbbb1 acyl eeeee1  bbbbb2 choline-binding site eeeee2  (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the  bbbbb1 choline eeeee1 -binding site (Trp-84) and the  bbbbb2 acyl-binding pocket eeeee2  (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the  bbbbb1 choline eeeee1  bbbbb2 TcAChE eeeee2 , interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the  bbbbb1 choline eeeee1  bbbbb2 choline-binding site eeeee2  (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (Phe-288,  bbbbb1 Phe eeeee1  bbbbb2 choline-binding site eeeee2  (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket ( bbbbb1 Phe eeeee1  bbbbb2 choline-binding site eeeee2  (Trp-84) and the acyl-binding pocket (Phe-288, Phe-290)
CRP11	The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site ( bbbbb1 Trp eeeee1 -84) and the  bbbbb2 acyl-binding pocket eeeee2  (Phe-288, Phe-290)
CRP11	Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.  bbbbb1 (-)-Galanthamine eeeee1  bbbbb2 acetylcholinesterase eeeee2  complexed with (-)-galanthamine at 2.3 A resolution. (-)-Galanthamine (GAL), an alkaloid from the flower, the common snowdrop (Galanthus nivalis), shows anticholinesterase activity
CRP11	Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. (-)-Galanthamine ( bbbbb1 GAL eeeee1  bbbbb2 acetylcholinesterase eeeee2  complexed with (-)-galanthamine at 2.3 A resolution. (-)-Galanthamine (GAL), an alkaloid from the flower, the common snowdrop (Galanthus nivalis), shows anticholinesterase activity
CRP11	Exposure of cells to 4mM NaF for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that  bbbbb1 fluoride eeeee1  bbbbb2 caspase-3 eeeee2  activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent
CRP11	Exposure of cells to 4mM NaF for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that  bbbbb1 fluoride eeeee1  bbbbb2 Bax eeeee2  to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent
CRP11	Exposure of cells to 4mM NaF for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that  bbbbb1 fluoride eeeee1  bbbbb2 cytochrome c eeeee2  from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent
CRP11	Degradation of  bbbbb1 MAC13243 eeeee1  and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone  bbbbb2 LolA eeeee2 
CRP11	Degradation of  bbbbb1 MAC13243 eeeee1  and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting  bbbbb2 chaperone eeeee2  LolA
CRP11	Degradation of  bbbbb1 MAC13243 eeeee1  and studies of the interaction of resulting thiourea compounds with the  bbbbb2 lipoprotein eeeee2  targeting chaperone LolA
CRP11	Herein, we demonstrate that the antibacterial activity of  bbbbb1 MAC13243 eeeee1  and the thiourea compounds are similar; these activities are suppressed or sensitized in response to increases or decreases of  bbbbb2 LolA eeeee2  copy number, respectively
CRP11	Herein, we demonstrate that the antibacterial activity of MAC13243 and the  bbbbb1 thiourea eeeee1  compounds are similar; these activities are suppressed or sensitized in response to increases or decreases of  bbbbb2 LolA eeeee2  copy number, respectively
CRP11	When selectively applied to channels after  bbbbb1 ind eeeee1  bbbbb2 inducing slo eeeee2 w inactivation with a 60-s pulse to -10 mV, mibefradil (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+,  bbbbb1 Cl- eeeee1  bbbbb2 T-type Ca2+ channel eeeee2  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+,  bbbbb1 Cl- eeeee1  bbbbb2 K+, Cl-, and Na+ channels eeeee2 
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and  bbbbb1 Na+ eeeee1  bbbbb2 T-type Ca2+ channel eeeee2  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and  bbbbb1 Na+ eeeee1  bbbbb2 K+, Cl-, and Na+ channels eeeee2 
CRP11	 bbbbb1 Mibefradil eeeee1  is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including  bbbbb2 K+, Cl-, and Na+ channels eeeee2 
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including  bbbbb1 K+ eeeee1  bbbbb2 T-type Ca2+ channel eeeee2  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels
CRP11	Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including  bbbbb1 K+ eeeee1  bbbbb2 K+, Cl-, and Na+ channels eeeee2 
CRP11	Mibefradil is a T-type  bbbbb1 Ca2+ eeeee1  bbbbb2 T-type Ca2+ channel eeeee2  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels
CRP11	Mibefradil is a T-type  bbbbb1 Ca2+ eeeee1  channel antagonist with reported cross-reactivity with other classes of ion channels, including  bbbbb2 K+, Cl-, and Na+ channels eeeee2 
CRP11	Using whole-cell voltage clamp, we examined mibefradil block of four  bbbbb1 Na+ eeeee1  channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac),  bbbbb2 Nav1.4 eeeee2  (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)
CRP11	Using whole-cell voltage clamp, we examined mibefradil block of four  bbbbb1 Na+ eeeee1  bbbbb2 Na+ channel eeeee2  isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)
CRP11	Using whole-cell voltage clamp, we examined mibefradil block of four  bbbbb1 Na+ eeeee1  channel isoforms expressed in human embryonic kidney cells:  bbbbb2 Nav1.5 eeeee2  (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)
CRP11	Using whole-cell voltage clamp, we examined mibefradil block of four  bbbbb1 Na+ eeeee1  channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle),  bbbbb2 Nav1.2 eeeee2  (brain), and Nav1.7 (peripheral nerve)
CRP11	Using whole-cell voltage clamp, we examined mibefradil block of four  bbbbb1 Na+ eeeee1  channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and  bbbbb2 Nav1.7 eeeee2  (peripheral nerve)
CRP11	Mibefradil blocked currents of all  bbbbb1 Na+ eeeee1  channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for  bbbbb2 Nav1.5 eeeee2 )
CRP11	Mibefradil blocked currents of all  bbbbb1 Na+ eeeee1  bbbbb2 Na+ channel eeeee2  isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5)
CRP11	State-dependent mibefradil block of  bbbbb1 Na+ eeeee1  bbbbb2 Na+ channels eeeee2 
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by  bbbbb2 peptidylglycine alpha-mono-oxygenase eeeee2  (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5)
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL,  bbbbb2 EC 4.3.2.5 eeeee2 )
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM, EC 1.14.17.3) and  bbbbb2 peptidylamidoglycolate lyase eeeee2  (PGL, EC 4.3.2.5)
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase ( bbbbb2 PAM eeeee2 , EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5)
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase ( bbbbb2 PGL eeeee2 , EC 4.3.2.5)
CRP11	 bbbbb1 C eeeee1 -terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM,  bbbbb2 EC 1.14.17.3 eeeee2 ) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5)
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid bbbbb1  is stere eeeee1 ospecific with respect to the moiety at the P(2) position, which is consistent with pre bbbbb2 vio eeeee2 us results with substrates and reversible inhibitors
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid bbbbb1  is stere eeeee1 ospecific with respect to the moiety at the P(2) position, which is consistent with previous re bbbbb2 sults with substrates and eeeee2  reversible inhibitors
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous re bbbbb1 sults wi eeeee1  bbbbb2 vio eeeee2 us results with substrates and reversible inhibitors
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous re bbbbb1 sults wi eeeee1  bbbbb2 sults with substrates and eeeee2  reversible inhibitors
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, whic bbbbb1 h is cons eeeee1 istent with pre bbbbb2 vio eeeee2 us results with substrates and reversible inhibitors
CRP11	Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, whic bbbbb1 h is cons eeeee1 istent with previous re bbbbb2 sults with substrates and eeeee2  reversible inhibitors
CRP11	Incubation of VSMCs with different concentrations of Ang II (from 10(-10) to 10(-6) mol/L) resulted in a dose-dependent rise of [ bbbbb1 Ca(2+) eeeee1  bbbbb2 Ang II eeeee2  (from 10(-10) to 10(-6) mol/L) resulted in a dose-dependent rise of [Ca(2+)](i) (pD(2)=7.5+/-0.3)
CRP11	Ang II-induced increases of intracellular free  bbbbb1 calcium eeeee1  bbbbb2 Ang II eeeee2 -induced increases of intracellular free calcium concentration ([Ca(2+)](i)) were also examined by image analysis in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats
CRP11	Ang II-induced increases of intracellular free calcium concentration ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 Ang II eeeee2 -induced increases of intracellular free calcium concentration ([Ca(2+)](i)) were also examined by image analysis in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats
CRP11	Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular  bbbbb1 calcium eeeee1  bbbbb2 angiotensin II eeeee2 -induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats
CRP11	The stimulatory effect of [ bbbbb1 Ca(2+) eeeee1 ](i) induced by a submaximal concentration of  bbbbb2 Ang II eeeee2  (10(-7) mol/L) was blocked by torasemide (IC(50)=0.5+/-0.3 nmol/L)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP), p53, procaspase 3, cleaved caspase 3,  bbbbb2 Bax eeeee2 ) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  bbbbb2 poly (ADP-ribose) polymerase eeeee2  (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT,  bbbbb2 Bcl-2 eeeee2 )
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP), p53,  bbbbb2 procaspase 3 eeeee2 , cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules ( bbbbb2 AKT eeeee2 , Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase ( bbbbb2 PARP eeeee2 ), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP),  bbbbb2 p53 eeeee2 , procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic DEX treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb1 poly (ADP-ribose) eeeee1  polymerase (PARP), p53, procaspase 3, cleaved  bbbbb2 caspase 3 eeeee2 , Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3,  bbbbb2 Bax eeeee2 ) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules ( bbbbb2 poly (ADP-ribose) polymerase eeeee2  (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT,  bbbbb2 Bcl-2 eeeee2 )
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53,  bbbbb2 procaspase 3 eeeee2 , cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules ( bbbbb2 AKT eeeee2 , Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase ( bbbbb2 PARP eeeee2 ), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP),  bbbbb2 p53 eeeee2 , procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The objective of the current study was to determine whether a low-dose subchronic  bbbbb1 DEX eeeee1  treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved  bbbbb2 caspase 3 eeeee2 , Bax) and cell-survival molecules (AKT, Bcl-2)
CRP11	The dependence of regulatory volume decrease (RVD) activity on  bbbbb1 potassium-chloride eeeee1  cotransporter ( bbbbb2 KCC eeeee2 ) isoform expression was characterized in corneal epithelial cells (CEC)
CRP11	The dependence of regulatory volume decrease (RVD) activity on  bbbbb1 potassium-chloride eeeee1  bbbbb2 potassium-chloride cotransporter eeeee2  (KCC) isoform expression was characterized in corneal epithelial cells (CEC)
CRP11	Functional and molecular characterization of multiple  bbbbb1 K-Cl eeeee1  bbbbb2 K-Cl cotransporter eeeee2  isoforms in corneal epithelial cells
CRP11	Co-administration of CNF maintained SOD activity, GSH and  bbbbb1 malondialdehyde eeeee1  bbbbb2 SOD eeeee2  activity, GSH and malondialdehyde levels close to those of the normal diet group
CRP11	Co-administration of CNF maintained SOD activity,  bbbbb1 GSH eeeee1  bbbbb2 SOD eeeee2  activity, GSH and malondialdehyde levels close to those of the normal diet group
CRP11	Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammat bbbbb1 ory cyt eeeee1 okines such as nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF bbbbb2  effectiv eeeee2 ely suppressed production of these cytokines dose-dependently
CRP11	Chronic consumption of alcohol also stimulated abrupt incr bbbbb1 eases i eeeee1 n pro-inflammatory cytokines such as nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF bbbbb2  effectiv eeeee2 ely suppressed production of these cytokines dose-dependently
CRP11	Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as  bbbbb1 aspartate eeeee1  bbbbb2 aspartate transaminase eeeee2 , alanine transaminase in serum whereas co-administration of CNF suppressed their increases
CRP11	Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as  bbbbb1 aspartate eeeee1  transaminase,  bbbbb2 alanine transaminase eeeee2  in serum whereas co-administration of CNF suppressed their increases
CRP11	Steady-state fluorescence was utilized to assess Ca(2+) affinity in isolated cardiac (c)TnCs containing F27W and did not necessarily mirror the fiber  bbbbb1 Ca(2+) eeeee1  bbbbb2 F27W eeeee2  and did not necessarily mirror the fiber Ca(2+) sensitivity
CRP11	Circular dichroism of mutant cTnCs revealed a trend where increased alpha-helical content correlated with increased Ca(2+) sensitivity in skinned fibers and vice versa bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Circular dichroism of mutant cTnCs revealed a trend where increased alpha-helical content correlated with increased Ca(2+) sensitivity in skinned fibers and vice versa bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Circular dichroism of mutant cTnCs revealed a trend where increased alpha-helical content correlated with increased Ca(2+) sensitivity in skinned fibers and vice versa bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Circular dichroism of mutant cTnCs revealed a trend where increased alpha-helical content correlated with increased Ca(2+) sensitivity in skinned fibers and vice versa bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	One mutant (A23Q) was found with HCM-like properties (increased  bbbbb1 Ca(2+) eeeee1  sensitivity of force and normal levels of  bbbbb2 ATPase eeeee2  inhibition)
CRP11	One mutant (A23Q) was found with HCM-like properties (increased  bbbbb1 Ca(2+) eeeee1  bbbbb2 A23Q eeeee2 ) was found with HCM-like properties (increased Ca(2+) sensitivity of force and normal levels of ATPase inhibition)
CRP11	Three mutants (S37G, V44Q, and L48Q) were identified with RCM-like properties (a large increase in  bbbbb1 Ca(2+) eeeee1  sensitivity, partial loss of  bbbbb2 ATPase eeeee2  inhibition, and increased basal force)
CRP11	Three mutants (S37G, V44Q, and L48Q) were identified with RCM-like properties (a large increase in  bbbbb1 Ca(2+) eeeee1  bbbbb2 L48Q eeeee2 ) were identified with RCM-like properties (a large increase in Ca(2+) sensitivity, partial loss of ATPase inhibition, and increased basal force)
CRP11	Three mutants (S37G, V44Q, and L48Q) were identified with RCM-like properties (a large increase in  bbbbb1 Ca(2+) eeeee1  bbbbb2 S37G eeeee2 , V44Q, and L48Q) were identified with RCM-like properties (a large increase in Ca(2+) sensitivity, partial loss of ATPase inhibition, and increased basal force)
CRP11	Three mutants (S37G, V44Q, and L48Q) were identified with RCM-like properties (a large increase in  bbbbb1 Ca(2+) eeeee1  bbbbb2 V44Q eeeee2 , and L48Q) were identified with RCM-like properties (a large increase in Ca(2+) sensitivity, partial loss of ATPase inhibition, and increased basal force)
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [ bbbbb1 Ca(2+) eeeee1  bbbbb2 E40A eeeee2  and I61Q) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [Ca(2+)])
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [ bbbbb1 Ca(2+) eeeee1  bbbbb2 ATPase eeeee2  at high [Ca(2+)])
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [ bbbbb1 Ca(2+) eeeee1  bbbbb2 I61Q eeeee2 ) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [Ca(2+)])
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased  bbbbb1 Ca(2+) eeeee1  bbbbb2 E40A eeeee2  and I61Q) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [Ca(2+)])
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased  bbbbb1 Ca(2+) eeeee1  sensitivity, maximal force recovery, and activation of the  bbbbb2 ATPase eeeee2  at high [Ca(2+)])
CRP11	Two mutations were identified (E40A and I61Q) with DCM properties (decreased  bbbbb1 Ca(2+) eeeee1  bbbbb2 I61Q eeeee2 ) with DCM properties (decreased Ca(2+) sensitivity, maximal force recovery, and activation of the ATPase at high [Ca(2+)])
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1  bbbbb2 3-phosphoinositide-dependent protein kinase PDK-1 eeeee2  oppose AKT-1 to promote DNA damage-induced apoptosis
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1  bbbbb2 insulin-like receptor eeeee2  DAF-2 and 3-phosphoinositide-dependent protein kinase PDK-1 oppose AKT-1 to promote DNA damage-induced apoptosis
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1  bbbbb2 insulin eeeee2 /IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3-phosphoinositide-dependent protein kinase PDK-1 oppose AKT-1 to promote DNA damage-induced apoptosis
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1  bbbbb2 IGF-1 eeeee2  pathway, whereby the insulin-like receptor DAF-2 and 3-phosphoinositide-dependent protein kinase PDK-1 oppose AKT-1 to promote DNA damage-induced apoptosis
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1  bbbbb2 DAF-2 eeeee2  and 3-phosphoinositide-dependent protein kinase PDK-1 oppose AKT-1 to promote DNA damage-induced apoptosis
CRP11	Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3- bbbbb1 phosphoinositide eeeee1 -dependent protein kinase PDK-1 oppose  bbbbb2 AKT-1 eeeee2  to promote DNA damage-induced apoptosis
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/ bbbbb1 Ser eeeee1  bbbbb2 Ser517/Ser473 eeeee2 
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/ bbbbb1 Ser eeeee1  bbbbb2 PDK-1 eeeee2  site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/ bbbbb1 Ser eeeee1  bbbbb2 Thr350/Thr308 eeeee2  of AKT-1, it increased phosphorylation at Ser517/Ser473
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 Ser517/Ser473 eeeee2 
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 PDK-1 eeeee2  site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473
CRP11	While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at  bbbbb1 Ser eeeee1  bbbbb2 Thr350/Thr308 eeeee2  of AKT-1, it increased phosphorylation at Ser517/Ser473
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1  bbbbb2 phospho-MPK-1 eeeee2 /ERK in their germ cells, indicating that the insulin/IGF-1 pathway promotes Ras signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1 -MPK-1/ERK in their germ cells, indicating that the insulin/IGF-1 pathway promotes  bbbbb2 Ras eeeee2  signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1  bbbbb2 daf-2 eeeee2  and pdk-1 mutants have reduced levels of phospho-MPK-1/ERK in their germ cells, indicating that the insulin/IGF-1 pathway promotes Ras signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1 -MPK-1/ERK in their germ cells, indicating that the insulin/ bbbbb2 IGF-1 eeeee2  pathway promotes Ras signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1  bbbbb2 pdk-1 eeeee2  mutants have reduced levels of phospho-MPK-1/ERK in their germ cells, indicating that the insulin/IGF-1 pathway promotes Ras signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1 -MPK-1/ERK in their germ cells, indicating that the  bbbbb2 insulin eeeee2 /IGF-1 pathway promotes Ras signaling in the germline
CRP11	In addition, daf-2 and pdk-1 mutants have reduced levels of  bbbbb1 phospho eeeee1 -MPK-1/ bbbbb2 ERK eeeee2  in their germ cells, indicating that the insulin/IGF-1 pathway promotes Ras signaling in the germline
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  3-kinase (PI3K)/Akt/  bbbbb2 glycogen synthase kinase 3β eeeee2  (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 phosphoinositide 3-kinase eeeee2  (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  3-kinase (PI3K)/ bbbbb2 Akt eeeee2 / glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 ocal adhesion kinase eeeee2  (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 c-Src eeeee2 /extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  3-kinase ( bbbbb2 PI3K eeeee2 )/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β ( bbbbb2 GSK-3β eeeee2 ) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 ERK eeeee2 ) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  bbbbb1 phosphoinositide eeeee1  bbbbb2 FAK eeeee2 )/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway
CRP11	Characterization of rat brain  bbbbb1 aldosterone eeeee1  bbbbb2 rat brain aldosterone receptors eeeee2  reveals high affinity for corticosterone
CRP11	However, due to the very high affinity of CBG for corticosterone at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for  bbbbb1 aldosterone eeeee1  bbbbb2 CBG eeeee2  for corticosterone at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for aldosterone-binding sites
CRP11	However, due to the very high affinity of CBG for corticosterone at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of  bbbbb1 steroids eeeee1  bbbbb2 CBG eeeee2  for corticosterone at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for aldosterone-binding sites
CRP11	Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney mineralocorticoid receptor (aldosterone greater than desoxycorticosterone greater than  bbbbb1 corticosterone eeeee1  bbbbb2 mineralocorticoid receptor eeeee2  (aldosterone greater than desoxycorticosterone greater than corticosterone)
CRP11	The high affinity site was at greatest  bbbbb1 density in  eeeee1  bbbbb2 density in limbic re eeeee2 gions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at greatest density in cortex and cerebellum
CRP11	The high affinity site was at greatest  bbbbb1 density in  eeeee1 limbic regions, whereas the low affinity receptor, apparently identical to the bbbbb2  glucocorticoid type II re eeeee2 ceptor, was at greatest density in cortex and cerebellum
CRP11	The high affinity site was at greatest density in limbic regions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at gre bbbbb1 atest density  eeeee1  bbbbb2 density in limbic re eeeee2 gions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at greatest density in cortex and cerebellum
CRP11	The high affinity site was at greatest density in limbic regions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at gre bbbbb1 atest density  eeeee1  bbbbb2  glucocorticoid type II re eeeee2 ceptor, was at greatest density in cortex and cerebellum
CRP11	The high affinity site was at greatest density in limbic regions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at greatest density in c bbbbb1 ortex and c eeeee1  bbbbb2 density in limbic re eeeee2 gions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at greatest density in cortex and cerebellum
CRP11	The high affinity site was at greatest density in limbic regions, whereas the low affinity receptor, apparently identical to the glucocorticoid type II receptor, was at greatest density in c bbbbb1 ortex and c eeeee1  bbbbb2  glucocorticoid type II re eeeee2 ceptor, was at greatest density in cortex and cerebellum
CRP11	The neuropeptide galanin has been shown to attenuate  bbbbb1 cAMP eeeee1  bbbbb2 galanin eeeee2  has been shown to attenuate cAMP signaling in multiple cell types
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased cAMP signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor  bbbbb1 cAMP eeeee1  regulatory element-binding protein ( bbbbb2 CREB eeeee2 )
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased cAMP signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor  bbbbb1 cAMP eeeee1  bbbbb2 cAMP regulatory element-binding protein eeeee2  (CREB)
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased cAMP signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor  bbbbb1 cAMP eeeee1  bbbbb2 galanin eeeee2  treatment blocks the consequences of increased cAMP signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor cAMP regulatory element-binding protein (CREB)
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased  bbbbb1 cAMP eeeee1  signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor cAMP regulatory element-binding protein ( bbbbb2 CREB eeeee2 )
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased  bbbbb1 cAMP eeeee1  signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor  bbbbb2 cAMP regulatory element-binding protein eeeee2  (CREB)
CRP11	The current study demonstrates that acute galanin treatment blocks the consequences of increased  bbbbb1 cAMP eeeee1  bbbbb2 galanin eeeee2  treatment blocks the consequences of increased cAMP signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor cAMP regulatory element-binding protein (CREB)
CRP11	Galanin attenuates  bbbbb1 cyclic AMP eeeee1  regulatory element-binding protein ( bbbbb2 CREB eeeee2 ) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
CRP11	Galanin attenuates  bbbbb1 cyclic AMP eeeee1  bbbbb2 cyclic AMP regulatory element-binding protein eeeee2  (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
CRP11	Galanin attenuates  bbbbb1 cyclic AMP eeeee1  bbbbb2 Galanin eeeee2  attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
CRP11	Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and  bbbbb1 naloxone eeeee1  bbbbb2 Galanin eeeee2  attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
CRP11	Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic  bbbbb1 morphine eeeee1  bbbbb2 Galanin eeeee2  attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
CRP11	Glioma cell sensitivity to topotecan: the role of p53 and  bbbbb1 topotecan eeeee1  bbbbb2 p53 eeeee2  and topotecan-induced DNA damage
CRP11	Glioma cell sensitivity to  bbbbb1 topotecan eeeee1 : the role of  bbbbb2 p53 eeeee2  and topotecan-induced DNA damage
CRP11	Peptidyl- bbbbb1 prolyl eeeee1  bbbbb2 Peptidyl-prolyl cis/trans-isomerase A1 eeeee2  (Pin1) is a target for modification by lipid electrophiles
CRP11	Peptidyl- bbbbb1 prolyl eeeee1  cis/trans-isomerase A1 ( bbbbb2 Pin1 eeeee2 ) is a target for modification by lipid electrophiles
CRP11	Here, we demonstrate that peptidyl- bbbbb1 prolyl eeeee1  bbbbb2 peptidyl-prolyl cis/trans-isomerase A1 eeeee2  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification
CRP11	Here, we demonstrate that peptidyl- bbbbb1 prolyl eeeee1  cis/trans-isomerase A1 ( bbbbb2 Pin1 eeeee2 ), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification
CRP11	Pin1 was adducted in MDA-MB-231 breast cancer cells treated with 8-alkynyl-HNE as judged by click chemistry conjugation with  bbbbb1 biotin eeeee1  bbbbb2 Pin1 eeeee2  was adducted in MDA-MB-231 breast cancer cells treated with 8-alkynyl-HNE as judged by click chemistry conjugation with biotin followed by streptavidin-based pulldown and Western blotting with anti-Pin1 antibody
CRP11	Pin1 was adducted in MDA-MB-231 breast cancer cells treated with 8-alkynyl-HNE as judged by click chemistry conjugation with  bbbbb1 biotin eeeee1  followed by streptavidin-based pulldown and Western blotting with anti- bbbbb2 Pin1 eeeee2  antibody
CRP11	Pin1 was adducted in MDA-MB-231 breast cancer cells treated with  bbbbb1 8-alkynyl-HNE eeeee1  as judged by click chemistry conjugation with biotin followed by streptavidin-based pulldown and Western blotting with anti- bbbbb2 Pin1 eeeee2  antibody
CRP11	Incubation of purified Pin1 with  bbbbb1 HNE eeeee1  bbbbb2 Pin1 eeeee2  with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues His-157 and Cys-113
CRP11	Furthermore, orbitrap MS data support the adduction of Cys-113 in the Pin1 active site upon  bbbbb1 HNE eeeee1  treatment of MDA-MB-231 cells. siRNA knockdown of  bbbbb2 Pin1 eeeee2  in MDA-MB-231 cells partially protected the cells from HNE-induced toxicity
CRP11	Furthermore, orbitrap MS data support the adduction of Cys-113 in the Pin1 active site upon HNE treatment of MDA-MB-231 cells. siRNA knockdown of Pin1 in MDA-MB-231 cells partially protected the cells from  bbbbb1 HNE eeeee1  bbbbb2 Pin1 eeeee2  active site upon HNE treatment of MDA-MB-231 cells. siRNA knockdown of Pin1 in MDA-MB-231 cells partially protected the cells from HNE-induced toxicity
CRP11	Furthermore, orbitrap MS data support the adduction of Cys-113 in the Pin1 active site upon HNE treatment of MDA-MB-231 cells. siRNA knockdown of Pin1 in MDA-MB-231 cells partially protected the cells from  bbbbb1 HNE eeeee1  bbbbb2 Pin1 eeeee2  in MDA-MB-231 cells partially protected the cells from HNE-induced toxicity
CRP11	Furthermore, orbitrap MS data support the adduction of  bbbbb1 Cys eeeee1 -113 in the Pin1 active site upon HNE treatment of MDA-MB-231 cells. siRNA knockdown of  bbbbb2 Pin1 eeeee2  in MDA-MB-231 cells partially protected the cells from HNE-induced toxicity
CRP11	An investigation is detailed of the structure activity relationships (SAR) of two  bbbbb1 sulfone eeeee1  side chains of compound (-)-1a (SCH 900229), a potent, PS1-selective  bbbbb2 γ-secretase eeeee2  inhibitor and clinical candidate for the treatment of Alzheimer's disease
CRP11	An investigation is detailed of the structure activity relationships (SAR) of two  bbbbb1 sulfone eeeee1  side chains of compound (-)-1a (SCH 900229), a potent,  bbbbb2 PS1 eeeee2 -selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and  bbbbb1 arachidonic acid eeeee1  bbbbb2 Cyclooxygenase eeeee2  activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and  bbbbb1 arachidonic acid eeeee1  bbbbb2 human recombinant COX-1 eeeee2  or COX-2 and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and  bbbbb1 arachidonic acid eeeee1  bbbbb2 COX-2 eeeee2  and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring  bbbbb1 prostaglandin E(2) eeeee1  (PGE(2)) production following incubation of varying concentrations of NSAID with  bbbbb2 human recombinant COX-1 eeeee2  or COX-2 and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring  bbbbb1 prostaglandin E(2) eeeee1  (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or  bbbbb2 COX-2 eeeee2  and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1 ) production following incubation of varying concentrations of NSAID with  bbbbb2 human recombinant COX-1 eeeee2  or COX-2 and arachidonic acid
CRP11	Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1 ) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or  bbbbb2 COX-2 eeeee2  and arachidonic acid
CRP11	NS:  bbbbb1 Ketorolac eeeee1  is relatively COX-1 selective while bromfenac is potently selective for COX-2 over  bbbbb2 COX-1 eeeee2 
CRP11	NS:  bbbbb1 Ketorolac eeeee1  is relatively COX-1 selective while bromfenac is potently selective for  bbbbb2 COX-2 eeeee2  over COX-1
CRP11	NS: Ketorolac is relatively COX-1 selective while  bbbbb1 bromfenac eeeee1  bbbbb2 COX-1 eeeee2  selective while bromfenac is potently selective for COX-2 over COX-1
CRP11	This study investigated the anti-glycative activity of LSOPC in a bovine serum albumin (BSA)- bbbbb1 glucose eeeee1  bbbbb2 BSA eeeee2 )-glucose model
CRP11	This study investigated the anti-glycative activity of LSOPC in a bovine serum albumin (BSA)- bbbbb1 glucose eeeee1  bbbbb2 bovine serum albumin eeeee2  (BSA)-glucose model
CRP11	A novel metabotropic  bbbbb1 glutamate eeeee1  bbbbb2 metabotropic glutamate receptor 5 eeeee2  positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling
CRP11	A novel metabotropic  bbbbb1 glutamate eeeee1  receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to  bbbbb2 mGlu5 eeeee2  signaling
CRP11	Metabotropic  bbbbb1 glutamate eeeee1  bbbbb2 Metabotropic glutamate receptor 5 eeeee2  (mGlu5) is a target for the treatment of central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease
CRP11	Metabotropic  bbbbb1 glutamate eeeee1  receptor 5 ( bbbbb2 mGlu5 eeeee2 ) is a target for the treatment of central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease
CRP11	However, NCFP provides greater mGlu5 subtype selectivity than does  bbbbb1 CPPHA eeeee1 , making it more suitable for studies of effects on  bbbbb2 mGlu5 eeeee2  in CNS preparations
CRP11	P binds to the  bbbbb1 CPPHA eeeee1  site on mGlu5 and potentiates  bbbbb2 mGlu5 eeeee2 -mediated responses in both recombinant and native systems
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  kinases  bbbbb2 VEGFR eeeee2 /PDGFR in tumor vasculature
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  kinases VEGFR/ bbbbb2 PDGFR eeeee2  in tumor vasculature
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  bbbbb2 RAF eeeee2 /MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  bbbbb2 MEK eeeee2 /ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  VEGFR/PDGFR in tumor vasculature
CRP11	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  bbbbb1 tyrosine eeeee1  bbbbb2 ERK eeeee2  pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
CRP11	In addition, several receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinases eeeee2 , acting upstream of Ras, were found either mutated or overexpressed in human tumors
CRP11	In addition, several receptor  bbbbb1 tyrosine eeeee1  kinases, acting upstream of  bbbbb2 Ras eeeee2 , were found either mutated or overexpressed in human tumors
CRP11	 bbbbb1 Dopamine eeeee1  D2 receptor priming was verified through a yawning behavioural test, a  bbbbb2 D2 receptor eeeee2 -mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	 bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine D2 receptor eeeee2  priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	Dopamine D2 receptor priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before  bbbbb1 olanzapine eeeee1  bbbbb2 D2 receptor eeeee2 -mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	Dopamine D2 receptor priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before  bbbbb1 olanzapine eeeee1  bbbbb2 Dopamine D2 receptor eeeee2  priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	Dopamine D2 receptor priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before olanzapine was administered as well as after  bbbbb1 olanzapine eeeee1  bbbbb2 D2 receptor eeeee2 -mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	Dopamine D2 receptor priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before olanzapine was administered as well as after  bbbbb1 olanzapine eeeee1  bbbbb2 Dopamine D2 receptor eeeee2  priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before olanzapine was administered as well as after olanzapine treatment and behavioural testing were complete
CRP11	The effects of adulthood  bbbbb1 olanzapine eeeee1  treatment on cognitive performance and  bbbbb2 neurotrophic factor eeeee2  content in male and female rats neonatally treated with quinpirole
CRP11	Neonatal quinpirole trea bbbbb1 tment prod eeeee1 uced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment bbbbb2  eeeee2 
CRP11	On the MWM place version, D2-primed rats demonstrated a significant impairment that was eliminated by olanzapine treatment, but  bbbbb1 olanzapine eeeee1  bbbbb2 D2 eeeee2 -primed rats demonstrated a significant impairment that was eliminated by olanzapine treatment, but olanzapine treatment to animals neonatally treated with saline produced a significant deficit on the place version of the MWM
CRP11	On the MWM place version, D2-primed rats demonstrated a significant impairment that was eliminated by  bbbbb1 olanzapine eeeee1  bbbbb2 D2 eeeee2 -primed rats demonstrated a significant impairment that was eliminated by olanzapine treatment, but olanzapine treatment to animals neonatally treated with saline produced a significant deficit on the place version of the MWM
CRP11	One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of  bbbbb1 glutamine eeeee1  to oxoglutaramic acid (GTK,  bbbbb2 EC 2.6.1.15 eeeee2 )
CRP11	One of the enzymes responsible for the production of KA,  bbbbb1 kynurenine eeeee1  aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK,  bbbbb2 EC 2.6.1.15 eeeee2 )
CRP11	One of the enzymes responsible for the production of KA,  bbbbb1 kynurenine eeeee1  aminotransferase I ( bbbbb2 KATI eeeee2 ), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)
CRP11	One of the enzymes responsible for the production of KA,  bbbbb1 kynurenine eeeee1  bbbbb2 kynurenine aminotransferase I eeeee2  (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)
CRP11	One of the enzymes responsible for the production of KA,  bbbbb1 kynurenine eeeee1  aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid ( bbbbb2 GTK eeeee2 , EC 2.6.1.15)
CRP11	One of the enzymes responsible for the production of  bbbbb1 KA eeeee1 , kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK,  bbbbb2 EC 2.6.1.15 eeeee2 )
CRP11	One of the enzymes responsible for the production of  bbbbb1 KA eeeee1 , kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid ( bbbbb2 GTK eeeee2 , EC 2.6.1.15)
CRP11	Kynurenic acid (KA) is an endogenous  bbbbb1 glutamate eeeee1  receptor antagonist at the level of the different  bbbbb2 ionotropic glutamate receptors eeeee2 
CRP11	Kynurenic acid (KA) is an endogenous  bbbbb1 glutamate eeeee1  bbbbb2 glutamate receptor eeeee2  antagonist at the level of the different ionotropic glutamate receptors
CRP11	Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic  bbbbb1 glutamate eeeee1  bbbbb2 ionotropic glutamate receptors eeeee2 
CRP11	Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic  bbbbb1 glutamate eeeee1  bbbbb2 glutamate receptor eeeee2  antagonist at the level of the different ionotropic glutamate receptors
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2 ied eeeee2 
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2 ATI/ eeeee2 GTK gene was also studied
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2 ied eeeee2 
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2 ATI/ eeeee2 GTK gene was also studied
CRP11	The structure of the rat KATI/GTK gene was also studied bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Tissue expression and translational control of rat  bbbbb1 kynurenine eeeee1  aminotransferase/ bbbbb2 glutamine transaminase K eeeee2  mRNAs
CRP11	Tissue expression and translational control of rat  bbbbb1 kynurenine eeeee1  bbbbb2 rat kynurenine aminotransferas eeeee2 e/glutamine transaminase K mRNAs
CRP11	Tissue expression and translational control of rat kynurenine aminotransferase/ bbbbb1 glutamine eeeee1  bbbbb2 glutamine transaminase K eeeee2  mRNAs
CRP11	Tissue expression and translational control of rat kynurenine aminotransferase/ bbbbb1 glutamine eeeee1  bbbbb2 rat kynurenine aminotransferas eeeee2 e/glutamine transaminase K mRNAs
CRP11	SiO(2) NPs (concentration range 25-200 µg/ml) induced dose-dependent cytotoxicity in both types of cells, which was demonstrated by cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) and  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  leakage assays
CRP11	SiO(2) NPs (concentration range 25-200 µg/ml) induced dose-dependent cytotoxicity in both types of cells, which was demonstrated by cell viability ( bbbbb1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide eeeee1 ) and  bbbbb2 lactate dehydrogenase eeeee2  leakage assays
CRP11	 bbbbb1 SiO(2) eeeee1  NPs (concentration range 25-200 µg/ml) induced dose-dependent cytotoxicity in both types of cells, which was demonstrated by cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) and  bbbbb2 lactate dehydrogenase eeeee2  leakage assays
CRP11	At the fifth challenge, the effects of  bbbbb1 CysLT eeeee1  antagonists and an anti- bbbbb2 IL-5 eeeee2  antibody (TRFK-5) on the occurrence of LAR, and blood and lung eosinophilia, which appeared at 5 h after challenge, were examined
CRP11	NS: CysLTs produced afte bbbbb1 r anti eeeee1 gen provocation sequentially induced IL-5 production fr bbbbb2 om s eeeee2 ome immune component cells via CysLT1 receptor activation
CRP11	Guinea-pigs inhaled ovalbumin (OVA) +  bbbbb1 Al(OH)3 eeeee1  and  bbbbb2 OVA eeeee2  mists alternately for sensitization and challenge, respectively, once every 2 weeks
CRP11	Guinea-pigs inhaled ovalbumin (OVA) +  bbbbb1 Al(OH)3 eeeee1  bbbbb2 OVA eeeee2 ) + Al(OH)3 and OVA mists alternately for sensitization and challenge, respectively, once every 2 weeks
CRP11	Guinea-pigs inhaled ovalbumin (OVA) +  bbbbb1 Al(OH)3 eeeee1  bbbbb2 ovalbumin eeeee2  (OVA) + Al(OH)3 and OVA mists alternately for sensitization and challenge, respectively, once every 2 weeks
CRP11	 bbbbb1 Angiotensin II eeeee1  bbbbb2 Angiotensin II type 1 receptor eeeee2  blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly
CRP11	In clinical studies,  bbbbb1 eprosartan eeeee1  has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitors
CRP11	In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitors
CRP11	Both the renin- bbbbb1 angiotensin eeeee1  bbbbb2 renin eeeee2 -angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension
CRP11	Both the renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2  system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension
CRP11	Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits  bbbbb1 noradrenaline eeeee1  bbbbb2 AT1 receptors eeeee2 , where it inhibits noradrenaline release
CRP11	Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits  bbbbb1 noradrenaline eeeee1  bbbbb2 AT1 receptors eeeee2  (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release
CRP11	The ARB eprosartan is a nonbiphenyl nontetrazole  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II type 1 receptor eeeee2  (AT1) antagonist, which acts to decrease total peripheral resistance
CRP11	The ARB eprosartan is a nonbiphenyl nontetrazole  bbbbb1 angiotensin II eeeee1  type 1 receptor ( bbbbb2 AT1 eeeee2 ) antagonist, which acts to decrease total peripheral resistance
CRP11	In preclinical studies, the mammalian target of rapamycin (mTOR) in the  bbbbb1 medial p eeeee1 refrontal cortex and the eukaryotic elongation factor bbbbb2  (eE eeeee2 F2) in the hippocampus have been proposed as critical mediators of ketamine's rapid antidepressant actions
CRP11	In preclinical studies, the mammalian target of rapamycin (mTOR) in the  bbbbb1 medial p eeeee1 refrontal cortex and the eukaryotic elongatio bbbbb2 n fa eeeee2 ctor (eEF2) in the hippocampus have been proposed as critical mediators of ketamine's rapid antidepressant actions
CRP11	However, recent clinical studies have shown that a single low-dose injection of ketamine, an  bbbbb1 N-methyl d-aspartate eeeee1  bbbbb2 N-methyl d-aspartate receptor eeeee2  (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting
CRP11	However, recent clinical studies have shown that a single low-dose injection of ketamine, an  bbbbb1 N-methyl d-aspartate eeeee1  receptor ( bbbbb2 NMDAR eeeee2 ) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists  bbbbb1 ONO-AE3-208 eeeee1  and AH 23848, inhibited tumor cell proliferation, indicating the significance of  bbbbb2 EP(1) eeeee2  and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists  bbbbb1 ONO-AE3-208 eeeee1  bbbbb2 EP(3) receptor eeeee2  antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists  bbbbb1 ONO-AE3-208 eeeee1  and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  bbbbb2 EP(4) eeeee2  for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists  bbbbb1 ONO-AE3-208 eeeee1  bbbbb2 EP(1) eeeee2  and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists  bbbbb1 ONO-AE3-208 eeeee1  and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and  bbbbb2 EP(3) eeeee2  but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and  bbbbb1 AH 23848 eeeee1 , inhibited tumor cell proliferation, indicating the significance of  bbbbb2 EP(1) eeeee2  and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and  bbbbb1 AH 23848 eeeee1  bbbbb2 EP(3) receptor eeeee2  antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and  bbbbb1 AH 23848 eeeee1 , inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  bbbbb2 EP(4) eeeee2  for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and  bbbbb1 AH 23848 eeeee1  bbbbb2 EP(1) eeeee2  and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and  bbbbb1 AH 23848 eeeee1 , inhibited tumor cell proliferation, indicating the significance of EP(1) and  bbbbb2 EP(3) eeeee2  but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists  bbbbb1 ONO-8713 eeeee1  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of  bbbbb2 EP(1) eeeee2  and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists  bbbbb1 ONO-8713 eeeee1  and ONO-AE3-240, but not the  bbbbb2 EP(4) eeeee2  antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists  bbbbb1 ONO-8713 eeeee1  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  bbbbb2 EP(4) eeeee2  for MB growth
CRP11	EP(1) and EP(3) receptor antagonists  bbbbb1 ONO-8713 eeeee1  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and  bbbbb2 EP(3) eeeee2  but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and  bbbbb1 ONO-AE3-240 eeeee1 , but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of  bbbbb2 EP(1) eeeee2  and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and  bbbbb1 ONO-AE3-240 eeeee1 , but not the  bbbbb2 EP(4) eeeee2  antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and  bbbbb1 ONO-AE3-240 eeeee1 , but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  bbbbb2 EP(4) eeeee2  for MB growth
CRP11	EP(1) and EP(3) receptor antagonists ONO-8713 and  bbbbb1 ONO-AE3-240 eeeee1 , but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and  bbbbb2 EP(3) eeeee2  but not EP(4) for MB growth
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin E synthases eeeee2  (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  synthases (PGES) and mediates its biological activity through binding to the four  bbbbb2 prostanoid receptors EP(1) eeeee2  through EP(4)
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through  bbbbb2 EP(4) eeeee2 
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  bbbbb2 cyclooxygenases eeeee2  (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  synthases ( bbbbb2 PGES eeeee2 ) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)
CRP11	PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and  bbbbb1 prostaglandin E eeeee1  bbbbb2 COX eeeee2 ) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)
CRP11	PGE(2) is synthesized from  bbbbb1 arachidonic acid eeeee1  by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four  bbbbb2 prostanoid receptors EP(1) eeeee2  through EP(4)
CRP11	PGE(2) is synthesized from  bbbbb1 arachidonic acid eeeee1  by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through  bbbbb2 EP(4) eeeee2 
CRP11	 bbbbb1 PGE(2) eeeee1  and the  bbbbb2 EP(2) receptor eeeee2  agonist butaprost stimulated MB cell proliferation
CRP11	Treatment of MB cells with COX inhibitors suppressed  bbbbb1 PGE(2) eeeee1  bbbbb2 COX eeeee2  inhibitors suppressed PGE(2) production and induced caspase-dependent apoptosis
CRP11	Treatment of MB cells with COX inhibitors suppressed  bbbbb1 PGE(2) eeeee1  production and induced  bbbbb2 caspase eeeee2 -dependent apoptosis
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes  bbbbb1 PGE(2) eeeee1  bbbbb2 COX-2 eeeee2 , microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes  bbbbb1 PGE(2) eeeee1  bbbbb2 EP(4) eeeee2  and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes  bbbbb1 PGE(2) eeeee1  bbbbb2 microsomal prostaglandin E synthase-1 eeeee2 , and EP(1) through EP(4) and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes  bbbbb1 PGE(2) eeeee1  bbbbb2 EP(1) eeeee2  through EP(4) and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal  bbbbb1 prostaglandin E eeeee1  bbbbb2 COX-2 eeeee2 , microsomal prostaglandin E synthase-1, and EP(1) through EP(4) and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal  bbbbb1 prostaglandin E eeeee1  synthase-1, and EP(1) through  bbbbb2 EP(4) eeeee2  and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal  bbbbb1 prostaglandin E eeeee1  bbbbb2 microsomal prostaglandin E synthase-1 eeeee2 , and EP(1) through EP(4) and secretes PGE(2)
CRP11	In this study, we show for the first time that medulloblastoma (MB), the most common malignant childhood brain tumor, expresses high levels of COX-2, microsomal  bbbbb1 prostaglandin E eeeee1  synthase-1, and  bbbbb2 EP(1) eeeee2  through EP(4) and secretes PGE(2)
CRP11	Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity
CRP11	Moreover, the production of intracellular reactive  bbbbb1 oxygen eeeee1  species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting  bbbbb2 NADPH oxidase eeeee2  activity
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  bbbbb2 monocyte chemotactic protein-1 eeeee2  (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  synthase (iNOS), and receptor for AGE ( bbbbb2 RAGE eeeee2 )
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  bbbbb2 tumor necrosis factor-α eeeee2  (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  synthase ( bbbbb2 iNOS eeeee2 ), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  bbbbb2 MCP-1 eeeee2 ), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  bbbbb2 TNF-α eeeee2 ), inducible NO synthase (iNOS), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  bbbbb2 inducible NO synthase eeeee2  (iNOS), and receptor for AGE (RAGE)
CRP11	Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible  bbbbb1 NO eeeee1  synthase (iNOS), and  bbbbb2 receptor for AGE eeeee2  (RAGE)
CRP11	NS: The data advance the novel hypothesis that central sympatholysis with dexmedetomidine constitutes a highly effective countermeasure for cocaine's sympathomimetic actions on the human cardiovascular system, even in individuals carrying the alpha2CDel322-325 polymorphism bbbbb1  eeeee1  bbbbb2 alpha2C eeeee2 Del322-325 polymorphism
CRP11	These compounds interact with voltage-gated sodium,  bbbbb1 potassium eeeee1  bbbbb2 voltage-gated sodium, potassium and calcium channels eeeee2  and modulate the flux of these ions into various cell types
CRP11	These compounds interact with voltage-gated  bbbbb1 sodium eeeee1  bbbbb2 voltage-gated sodium, potassium and calcium channels eeeee2  and modulate the flux of these ions into various cell types
CRP11	These compounds interact with voltage-gated sodium, potassium and  bbbbb1 calcium eeeee1  bbbbb2 voltage-gated sodium, potassium and calcium channels eeeee2  and modulate the flux of these ions into various cell types
CRP11	These illnesses are a result of saxitoxin's ability to bind to the voltage-gated  bbbbb1 sodium eeeee1  bbbbb2 voltage-gated sodium channel eeeee2 , blocking the passage of nerve impulses and leading to death via respiratory paralysis
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human  bbbbb1 NE eeeee1 , serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human  bbbbb1 NE eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	 bbbbb1 Atomoxetine eeeee1  inhibited binding of radioligands to clonal cell lines transfected with  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin ( bbbbb1 5-HT eeeee1 ) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine ( bbbbb1 DA eeeee1 ) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine ( bbbbb1 DA eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE,  bbbbb1 serotonin eeeee1  (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE,  bbbbb1 serotonin eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and  bbbbb1 dopamine eeeee1  (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and  bbbbb1 dopamine eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb1 NE eeeee1  bbbbb2 NE transporters eeeee2 
CRP11	Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for  bbbbb1 NE eeeee1  bbbbb2 human NE, serotonin (5-HT) and dopamine (DA) transporters eeeee2  with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters
CRP11	The selective  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine (NE) transporter eeeee2  inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD)
CRP11	The selective norepinephrine ( bbbbb1 NE eeeee1  bbbbb2 norepinephrine (NE) transporter eeeee2  inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD)
CRP11	We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with  bbbbb1 monoamine eeeee1  bbbbb2 monoamine transporters eeeee2 , the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions
CRP11	We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with  bbbbb1 monoamine eeeee1  transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker  bbbbb2 Fos eeeee2  in brain regions
CRP11	We investigated the mechanism of action of  bbbbb1 atomoxetine eeeee1  in ADHD by evaluating the interaction of atomoxetine with  bbbbb2 monoamine transporters eeeee2 , the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions
CRP11	We investigated the mechanism of action of  bbbbb1 atomoxetine eeeee1  in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker  bbbbb2 Fos eeeee2  in brain regions
CRP11	We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of  bbbbb1 monoamines eeeee1  bbbbb2 monoamine transporters eeeee2 , the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions
CRP11	We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of  bbbbb1 monoamines eeeee1 , and the expression of the neuronal activity marker  bbbbb2 Fos eeeee2  in brain regions
CRP11	It is not yet clear whether  bbbbb1 tamoxifen eeeee1  can reduce breast cancer incidence in women with  bbbbb2 BRCA1 eeeee2  and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation
CRP11	Reversal or prevention of advanced IEN as well as modulation of other risk biomarkers in randomized phase II and phase III trials is being evaluated as a means of more efficie bbbbb1 ntly eval eeeee1  bbbbb2 of eeeee2  more efficiently evaluating prevention drugs in the future
CRP11	Individuals in whom tamoxifen-associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER)-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%
CRP11	Individuals in whom tamoxifen-associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 )-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%
CRP11	Individuals in whom  bbbbb1 tamoxifen eeeee1 -associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or  bbbbb2 estrogen receptor eeeee2  (ER)-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%
CRP11	Individuals in whom  bbbbb1 tamoxifen eeeee1 -associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or estrogen receptor ( bbbbb2 ER eeeee2 )-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%
CRP11	Raloxifene is a selective ER modulator with less uterine  bbbbb1 estrogen eeeee1  bbbbb2 ER eeeee2  modulator with less uterine estrogen agonist activity than tamoxifen, and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer
CRP11	Raloxifene is a selective ER modulator with less uterine estrogen agonist activity than  bbbbb1 tamoxifen eeeee1  bbbbb2 ER eeeee2  modulator with less uterine estrogen agonist activity than tamoxifen, and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer
CRP11	Priorities in prevention research are to develop (a) biomarkers to refine short-term risk assessments based on epidemiologic models, (b) biomarkers predictive of response to specific classes of preventive agents, (c) drugs with fewer side-effects and/or effective in ER-negative or ER-positive  bbbbb1 tamoxifen eeeee1  bbbbb2 ER eeeee2 -negative or ER-positive tamoxifen-resistant precancerous disease, and (d) efficient clinical trial models to assess new agent efficacy
CRP11	Priorities in prevention research are to develop (a) biomarkers to refine short-term risk assessments based on epidemiologic models, (b) biomarkers predictive of response to specific classes of preventive agents, (c) drugs with fewer side-effects and/or effective in ER-negative or ER-positive  bbbbb1 tamoxifen eeeee1  bbbbb2 ER eeeee2 -positive tamoxifen-resistant precancerous disease, and (d) efficient clinical trial models to assess new agent efficacy
CRP11	Soy protein suppresses gene expression of  bbbbb1 acetyl-coA eeeee1  bbbbb2 acetyl-coA carboxylase alpha eeeee2  from promoter PI in rat liver
CRP11	Soy protein suppresses gene expression of  bbbbb1 acetyl-coA eeeee1  carboxylase alpha from  bbbbb2 promoter PI eeeee2  in rat liver
CRP11	SPI feeding decreased the hepatic contents of total ACC mRNA as well as  bbbbb1 triglyceride eeeee1  bbbbb2 ACC eeeee2  mRNA as well as triglyceride (TG) content, but dietary SPI affected the amount of sterol-regulatory element binding protein (SREBP)-1 mRNA and protein very little
CRP11	SPI feeding decreased the hepatic contents of total ACC mRNA as well as  bbbbb1 triglyceride eeeee1  (TG) content, but dietary SPI affected the amount of  bbbbb2 sterol-regulatory element binding protein (SREBP)-1 eeeee2  mRNA and protein very little
CRP11	SPI feeding decreased the hepatic contents of total ACC mRNA as well as triglyceride ( bbbbb1 TG eeeee1  bbbbb2 ACC eeeee2  mRNA as well as triglyceride (TG) content, but dietary SPI affected the amount of sterol-regulatory element binding protein (SREBP)-1 mRNA and protein very little
CRP11	SPI feeding decreased the hepatic contents of total ACC mRNA as well as triglyceride ( bbbbb1 TG eeeee1 ) content, but dietary SPI affected the amount of  bbbbb2 sterol-regulatory element binding protein (SREBP)-1 eeeee2  mRNA and protein very little
CRP11	Dietary soy protein isolate (SPI) reduces hepatic lipogenesis by suppressing gene expression of lipogenic enzymes, including  bbbbb1 acetyl-CoA eeeee1  carboxylase ( bbbbb2 ACC eeeee2 )
CRP11	Dietary soy protein isolate (SPI) reduces hepatic lipogenesis by suppressing gene expression of lipogenic enzymes, including  bbbbb1 acetyl-CoA eeeee1  bbbbb2 acetyl-CoA carboxylase eeeee2  (ACC)
CRP11	Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular  bbbbb1 monoamine eeeee1  bbbbb2 vesicular monoamine transporter 2 eeeee2 
CRP11	Inhibitory effect of selective  bbbbb1 serotonin eeeee1  reuptake inhibitors on the  bbbbb2 vesicular monoamine transporter 2 eeeee2 
CRP11	The neuronal vesicular  bbbbb1 monoamine eeeee1  bbbbb2 neuronal vesicular monoamine transporter eeeee2  (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA)
CRP11	The neuronal vesicular  bbbbb1 monoamine eeeee1  transporter ( bbbbb2 VMAT2 eeeee2 ) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA)
CRP11	Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for dopamine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high  bbbbb1 glucose eeeee1  bbbbb2 NF-κB eeeee2 ) mRNA expression levels in high glucose conditions
CRP11	The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high  bbbbb1 glucose eeeee1  bbbbb2 nuclear factor kappa B eeeee2  (NF-κB) mRNA expression levels in high glucose conditions
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ( bbbbb2 MMP eeeee2 -TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase ( bbbbb2 SOD eeeee2 ), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase ( bbbbb2 LDH eeeee2 ), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH),  bbbbb2 superoxide dismutase eeeee2  (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the  bbbbb2 tissue inhibitors of matrix metalloproteinases eeeee2  (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the  bbbbb2 matrix metalloproteinases eeeee2 -the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP- bbbbb2 TIM eeeee2 P) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  bbbbb2 lactic dehydrogenase eeeee2  (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and  bbbbb2 catalase eeeee2  (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  bbbbb1 lactic eeeee1  dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ( bbbbb2 CAT eeeee2 )) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ( bbbbb2 MMP eeeee2 -TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase ( bbbbb2 SOD eeeee2 ), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase ( bbbbb2 LDH eeeee2 ), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH),  bbbbb2 superoxide dismutase eeeee2  (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the  bbbbb2 tissue inhibitors of matrix metalloproteinases eeeee2  (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the  bbbbb2 matrix metalloproteinases eeeee2 -the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP- bbbbb2 TIM eeeee2 P) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ),  bbbbb2 lactic dehydrogenase eeeee2  (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and  bbbbb2 catalase eeeee2  (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide ( bbbbb1 NO eeeee1 ), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ( bbbbb2 CAT eeeee2 )) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ( bbbbb2 MMP eeeee2 -TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase ( bbbbb2 SOD eeeee2 ), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase ( bbbbb2 LDH eeeee2 ), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH),  bbbbb2 superoxide dismutase eeeee2  (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the  bbbbb2 tissue inhibitors of matrix metalloproteinases eeeee2  (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the  bbbbb2 matrix metalloproteinases eeeee2 -the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP- bbbbb2 TIM eeeee2 P) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO),  bbbbb2 lactic dehydrogenase eeeee2  (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and  bbbbb2 catalase eeeee2  (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances ( bbbbb1 nitric oxide eeeee1  (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ( bbbbb2 CAT eeeee2 )) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high  bbbbb1 glucose eeeee1  (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ( bbbbb2 MMP eeeee2 -TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high  bbbbb1 glucose eeeee1  (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the  bbbbb2 tissue inhibitors of matrix metalloproteinases eeeee2  (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high  bbbbb1 glucose eeeee1  (35mM) and restored vascular endothelial structure by balancing the  bbbbb2 matrix metalloproteinases eeeee2 -the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high  bbbbb1 glucose eeeee1  (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP- bbbbb2 TIM eeeee2 P) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ( bbbbb2 MMP eeeee2 -TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  bbbbb2 LDH eeeee2 ), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the  bbbbb2 tissue inhibitors of matrix metalloproteinases eeeee2  (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the  bbbbb2 matrix metalloproteinases eeeee2 -the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP- bbbbb2 TIM eeeee2 P) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  bbbbb2 lactic dehydrogenase eeeee2  (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and  bbbbb2 catalase eeeee2  (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  bbbbb1 superoxide eeeee1  dismutase (SOD), and catalase ( bbbbb2 CAT eeeee2 )) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system
CRP11	L8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2).  bbbbb1 (R)-Ketoprofen eeeee1  bbbbb2 CXCR2 eeeee2 ). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis
CRP11	L8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2).  bbbbb1 (R)-Ketoprofen eeeee1  bbbbb2 CXC chemokine receptor 1 eeeee2  (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis
CRP11	L8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2).  bbbbb1 (R)-Ketoprofen eeeee1  bbbbb2 CXC chemokine receptor 2 eeeee2  (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis
CRP11	L8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2).  bbbbb1 (R)-Ketoprofen eeeee1  bbbbb2 CXCR1 eeeee2 ) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis
CRP11	L8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2).  bbbbb1 (R)-Ketoprofen eeeee1  bbbbb2 seven-transmembrane (7-TM) G-protein-coupled receptors eeeee2  CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis
CRP11	In this study, we found that BGG showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited AR activity as measured by a decrease in  bbbbb1 sorbitol eeeee1  bbbbb2 AR eeeee2  activity as measured by a decrease in sorbitol accumulation
CRP11	Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of  bbbbb1 aldose eeeee1  bbbbb2 aldose reductase eeeee2  in murine macrophages and ocular tissues
CRP11	 bbbbb1 Aldose eeeee1  bbbbb2 Aldose reductase eeeee2  (AR) catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)
CRP11	 bbbbb1 Aldose eeeee1  reductase ( bbbbb2 AR eeeee2 ) catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2 -mediated disruption of contact inhibition is associated with connexin43 downregulation and inhibition of gap junctional intercellular communication
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  receptor-mediated disruption of contact inhibition is associated with  bbbbb2 connexin43 eeeee2  downregulation and inhibition of gap junctional intercellular communication
CRP11	The  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 ) contributes to the control of cell-to-cell communication, cell adhesion, migration or proliferation
CRP11	The  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) contributes to the control of cell-to-cell communication, cell adhesion, migration or proliferation
CRP11	Insulin stimulated Pak1 activation through increasing its  bbbbb1 Thr eeeee1 423 phosphorylation in gut gcg-expressing cell lines, associated with increased  bbbbb2 gcg eeeee2  mRNA levels
CRP11	Insulin stimulated Pak1 activation through increasing its  bbbbb1 Thr eeeee1  bbbbb2 Insulin eeeee2  stimulated Pak1 activation through increasing its Thr423 phosphorylation in gut gcg-expressing cell lines, associated with increased gcg mRNA levels
CRP11	Insulin stimulated Pak1 activation through increasing its  bbbbb1 Thr eeeee1 423 phosphorylation in gut  bbbbb2 gcg eeeee2 -expressing cell lines, associated with increased gcg mRNA levels
CRP11	Gut gcg levels were reduced in male Pak1(-/-) mice, associated with impaired glucose tolerance after an ip or oral  bbbbb1 glucose eeeee1  bbbbb2 Pak1 eeeee2 (-/-) mice, associated with impaired glucose tolerance after an ip or oral glucose challenge
CRP11	Gut gcg levels were reduced in male Pak1(-/-) mice, associated with impaired glucose tolerance after an ip or oral  bbbbb1 glucose eeeee1  bbbbb2 gcg eeeee2  levels were reduced in male Pak1(-/-) mice, associated with impaired glucose tolerance after an ip or oral glucose challenge
CRP11	Gut gcg levels were reduced in male Pak1(-/-) mice, associated with impaired  bbbbb1 glucose eeeee1  bbbbb2 Pak1 eeeee2 (-/-) mice, associated with impaired glucose tolerance after an ip or oral glucose challenge
CRP11	Gut gcg levels were reduced in male Pak1(-/-) mice, associated with impaired  bbbbb1 glucose eeeee1  bbbbb2 gcg eeeee2  levels were reduced in male Pak1(-/-) mice, associated with impaired glucose tolerance after an ip or oral glucose challenge
CRP11	Here we determined the role of Pak1 in gcg expression and the effect of Pak1 deletion on  bbbbb1 glucose eeeee1  bbbbb2 gcg eeeee2  expression and the effect of Pak1 deletion on glucose homeostasis
CRP11	Here we determined the role of Pak1 in gcg expression and the effect of Pak1 deletion on  bbbbb1 glucose eeeee1  bbbbb2 Pak1 eeeee2  deletion on glucose homeostasis
CRP11	Here we determined the role of Pak1 in gcg expression and the effect of Pak1 deletion on  bbbbb1 glucose eeeee1  bbbbb2 Pak1 eeeee2  in gcg expression and the effect of Pak1 deletion on glucose homeostasis
CRP11	Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatm bbbbb1 ent eeeee1  bbbbb2 1(-/ eeeee2 -) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatment
CRP11	Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatm bbbbb1 ent eeeee1  bbbbb2 em gcg  eeeee2 level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatment
CRP11	Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatm bbbbb1 ent eeeee1  bbbbb2  an eeeee2 d abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatment
CRP11	Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatm bbbbb1 ent eeeee1  bbbbb2 ion eeeee2  in brain neurons after insulin treatment
CRP11	Both insulin and  bbbbb1 cAMP eeeee1 -promoting agents activated β-cat Ser675 phosphorylation, which was attenuated by IPA3 or  bbbbb2 protein kinase A eeeee2  inhibition, respectively
CRP11	Both insulin and  bbbbb1 cAMP eeeee1  bbbbb2 insulin eeeee2  and cAMP-promoting agents activated β-cat Ser675 phosphorylation, which was attenuated by IPA3 or protein kinase A inhibition, respectively
CRP11	Both insulin and cAMP-promoting agents activated β-cat  bbbbb1 Ser eeeee1 675 phosphorylation, which was attenuated by IPA3 or  bbbbb2 protein kinase A eeeee2  inhibition, respectively
CRP11	Both insulin and cAMP-promoting agents activated β-cat  bbbbb1 Ser eeeee1  bbbbb2 insulin eeeee2  and cAMP-promoting agents activated β-cat Ser675 phosphorylation, which was attenuated by IPA3 or protein kinase A inhibition, respectively
CRP11	P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects  bbbbb1 glucose eeeee1  bbbbb2 Pak1 eeeee2 ) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice
CRP11	P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice
CRP11	P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects  bbbbb1 glucose eeeee1  bbbbb2 proglucagon eeeee2  gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice
CRP11	P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects  bbbbb1 glucose eeeee1  bbbbb2 P21-activated protein kinase 1 eeeee2  (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice
CRP11	P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects  bbbbb1 glucose eeeee1  bbbbb2 β-catenin eeeee2  on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice
CRP11	This stimulation was attenuated by the Pak inhibitor  bbbbb1 2,2'-dihydroxy-1,1'-dinaphthyldisulfide eeeee1  (IPA3) or dominant-negative  bbbbb2 Pak1 eeeee2 
CRP11	This stimulation was attenuated by the Pak inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide ( bbbbb1 IPA3 eeeee1 ) or dominant-negative  bbbbb2 Pak1 eeeee2 
CRP11	These mice had lower circulating active GLP-1 levels after a  bbbbb1 glucose eeeee1  bbbbb2 GLP-1 eeeee2  levels after a glucose challenge as well as reduced distal ileum GLP-1 content after insulin treatment
CRP11	These mice had lower circulating active GLP-1 levels after a  bbbbb1 glucose eeeee1  challenge as well as reduced distal ileum  bbbbb2 GLP-1 eeeee2  content after insulin treatment
CRP11	Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of  bbbbb1 BPDE glutathione eeeee1  bbbbb2 ABCC3 eeeee2  knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates
CRP11	The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by glutathione conjugate formation catalyzed by glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferases eeeee2 
CRP11	The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide ( bbbbb1 BPDE eeeee1 ) can be detoxified by glutathione conjugate formation catalyzed by  bbbbb2 glutathione S-transferases eeeee2 
CRP11	The ultimate carcinogenic Phase I BP metabolite anti- bbbbb1 BP-7,8-dihydrodiol-9,10-epoxide eeeee1  (BPDE) can be detoxified by glutathione conjugate formation catalyzed by  bbbbb2 glutathione S-transferases eeeee2 
CRP11	The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by glutathione conjugate formation catalyzed by  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferases eeeee2 
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the  bbbbb1 glutathione eeeee1 -cleaving enzyme  bbbbb2 γ-glutamyl transpeptidase eeeee2  at the cell surface
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the  bbbbb1 glutathione eeeee1  bbbbb2 glutathione-cleaving enzyme eeeee2  γ-glutamyl transpeptidase at the cell surface
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric  bbbbb1 glutathione eeeee1  conjugates in the presence of an inhibitor of the glutathione-cleaving enzyme  bbbbb2 γ-glutamyl transpeptidase eeeee2  at the cell surface
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric  bbbbb1 glutathione eeeee1  conjugates in the presence of an inhibitor of the  bbbbb2 glutathione-cleaving enzyme eeeee2  γ-glutamyl transpeptidase at the cell surface
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of  bbbbb1 BPDE eeeee1  and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the glutathione-cleaving enzyme  bbbbb2 γ-glutamyl transpeptidase eeeee2  at the cell surface
CRP11	In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of  bbbbb1 BPDE eeeee1  and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the  bbbbb2 glutathione-cleaving enzyme eeeee2  γ-glutamyl transpeptidase at the cell surface
CRP11	Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of  bbbbb1 benzo[a]pyrene eeeee1  bbbbb2 Multidrug resistance-associated proteins eeeee2  are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells
CRP11	PIP5K1B encodes  bbbbb1 phosphatidylinositol 4-phosphate eeeee1  5-kinase β type I (pip5k1β), an enzyme functionally linked to  bbbbb2 actin eeeee2  cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes  bbbbb1 phosphatidylinositol 4-phosphate eeeee1  bbbbb2 phosphatidylinositol 4-phosphate 5-kinase β type I eeeee2  (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes  bbbbb1 phosphatidylinositol 4-phosphate eeeee1  bbbbb2 PIP5K1B eeeee2  encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes  bbbbb1 phosphatidylinositol 4-phosphate eeeee1  5-kinase β type I ( bbbbb2 pip5k1β eeeee2 ), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ bbbbb1 PI(4)P eeeee1  bbbbb2 actin eeeee2  cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  bbbbb1 phosphatidylinositol 4-phosphate eeeee1  bbbbb2 actin eeeee2  cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate  bbbbb1 phosphatidylinositol-4,5-bisphosphate eeeee1  bbbbb2 actin eeeee2  cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [ bbbbb1 PI(4,5)P2 eeeee1  bbbbb2 actin eeeee2  cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
CRP11	As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and  bbbbb1 nitic oxide eeeee1 ), and  bbbbb2 xanthine oxidase eeeee2  was identified as the likely source of TES-stimulated superoxide production
CRP11	As predicted,  bbbbb1 TES eeeee1  enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and  bbbbb2 xanthine oxidase eeeee2  was identified as the likely source of TES-stimulated superoxide production
CRP11	As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and  bbbbb1 xanthine eeeee1  bbbbb2 xanthine oxidase eeeee2  was identified as the likely source of TES-stimulated superoxide production
CRP11	As predicted, TES enhanced the production of both peroxynitrite precursors (i.e.,  bbbbb1 superoxide eeeee1  and nitic oxide), and  bbbbb2 xanthine oxidase eeeee2  was identified as the likely source of TES-stimulated superoxide production
CRP11	As predicted, TES enhanced the production of both  bbbbb1 peroxynitrite eeeee1  precursors (i.e., superoxide and nitic oxide), and  bbbbb2 xanthine oxidase eeeee2  was identified as the likely source of TES-stimulated superoxide production
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of  bbbbb1 cGMP eeeee1  bbbbb2 protein kinase B eeeee2  (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of  bbbbb1 cGMP eeeee1  bbbbb2 androgen receptor eeeee2  and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of  bbbbb1 cGMP eeeee1  bbbbb2 phosphoinositide 3 (PI3) kinase eeeee2 -protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of  bbbbb1 cGMP eeeee1  bbbbb2 Akt eeeee2 ) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the  bbbbb1 phosphoinositide eeeee1  3 (PI3) kinase- bbbbb2 protein kinase B eeeee2  (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the  bbbbb1 phosphoinositide eeeee1  3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  bbbbb2 androgen receptor eeeee2  and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the  bbbbb1 phosphoinositide eeeee1  bbbbb2 phosphoinositide 3 (PI3) kinase eeeee2 -protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the  bbbbb1 phosphoinositide eeeee1  3 (PI3) kinase-protein kinase B ( bbbbb2 Akt eeeee2 ) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  bbbbb1 androgen eeeee1  bbbbb2 protein kinase B eeeee2  (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  bbbbb1 androgen eeeee1  bbbbb2 phosphoinositide 3 (PI3) kinase eeeee2 -protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  bbbbb1 androgen eeeee1  bbbbb2 Akt eeeee2 ) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation
CRP11	These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for  bbbbb1 androgen eeeee1  action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from  bbbbb2 xanthine oxidase eeeee2 -generated superoxide and NO
CRP11	These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from  bbbbb1 xanthine eeeee1  bbbbb2 xanthine oxidase eeeee2 -generated superoxide and NO
CRP11	These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature:  bbbbb1 TES eeeee1 -stimulated vasodilation mediated primarily by peroxynitrite formed from  bbbbb2 xanthine oxidase eeeee2 -generated superoxide and NO
CRP11	The expression of the  bbbbb1 NH2 eeeee1  terminally truncated ErbB2 receptor (p95ErbB2) in breast cancer correlates with metastatic disease progression compared with the expression of full-length  bbbbb2 p185ErbB2 eeeee2 
CRP11	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor  bbbbb1 GW572016 eeeee1  bbbbb2 p95ErbB2 eeeee2 ) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
CRP11	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor  bbbbb1 GW572016 eeeee1  bbbbb2 ErbB2 eeeee2  receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
CRP11	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor  bbbbb1 GW572016 eeeee1  bbbbb2 EGFR eeeee2 /ErbB2 kinase inhibitor GW572016
CRP11	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor  bbbbb1 GW572016 eeeee1  bbbbb2 heregulin eeeee2  through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
CRP11	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2  bbbbb1 tyrosine eeeee1  bbbbb2 EGFR eeeee2  and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts
CRP11	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2 , inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts
CRP11	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2  bbbbb1 tyrosine eeeee1  kinases, inhibits baseline  bbbbb2 p95ErbB2 eeeee2  phosphorylation in BT474 cells and tumor xenografts
CRP11	GW572016, a reversible small molecule inhibitor of EGFR and ErbB2  bbbbb1 tyrosine eeeee1  bbbbb2 ErbB2 eeeee2  tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts
CRP11	Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by  bbbbb1 GW572016 eeeee1  bbbbb2 HRG eeeee2  was abrogated to varying degrees by GW572016
CRP11	Furthermore, we showed that  bbbbb1 NAD(P)H eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase eeeee2  (NQO1) may participate in this stimulation
CRP11	Furthermore, we showed that  bbbbb1 NAD(P)H eeeee1 :quinone oxidoreductase ( bbbbb2 NQO1 eeeee2 ) may participate in this stimulation
CRP11	Furthermore, we showed that NAD(P)H: bbbbb1 quinone eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase eeeee2  (NQO1) may participate in this stimulation
CRP11	Furthermore, we showed that NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase ( bbbbb2 NQO1 eeeee2 ) may participate in this stimulation
CRP11	PH oxidase Nox4 is expressed in a wide range of tissues and plays a role in cellular signaling by providing reactive  bbbbb1 oxygen eeeee1  bbbbb2 Nox4 eeeee2  is expressed in a wide range of tissues and plays a role in cellular signaling by providing reactive oxygen species (ROS) as intracellular messengers
CRP11	Interestingly, Nox4 activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (Cys226, Cys270) located in the extracellular E-loop of Nox4 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Western blot analyses showed significant effects of Pb exposure o bbbbb1 n  eeeee1 DNMT1, DNMT3a, and MeCP2 expression, with effects often seen at the lowest level bbbbb2  of exposure and m eeeee2 odified by sex and developmental window of Pb exposure
CRP11	Influence of developmental lead exposure on expression of DNA methyltransferases and  bbbbb1 methyl cytosine eeeee1  bbbbb2 methyl cytosine-binding proteins eeeee2  in hippocampus
CRP11	Influence of developmental lead exposure on expression of DNA methyltransferases and  bbbbb1 methyl cytosine eeeee1  bbbbb2 DNA methyltransferases eeeee2  and methyl cytosine-binding proteins in hippocampus
CRP11	Since DNA methylation is regulated by DNA methyltransferases and  bbbbb1 methyl cytosine eeeee1  bbbbb2 DNA methyltransferases eeeee2  and methyl cytosine-binding proteins, this study assessed the extent to which developmental Pb exposure might affect expression of these proteins in the hippocampus
CRP11	Since DNA methylation is regulated by DNA methyltransferases and  bbbbb1 methyl cytosine eeeee1  bbbbb2 methyl cytosine-binding proteins eeeee2 , this study assessed the extent to which developmental Pb exposure might affect expression of these proteins in the hippocampus
CRP11	Moreover, S1611 and S3226, both specific inhibitors of NHE3 only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and  bbbbb1 CO2 eeeee1  bbbbb2 NHE3 eeeee2  only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH
CRP11	Moreover, S1611 and S3226, both specific inhibitors of NHE3 only, or perfusion with  bbbbb1 Na+ eeeee1  bbbbb2 NHE3 eeeee2  only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH
CRP11	Nevertheless, coperfusion with 0.1 and 0.3 mM 5-nitro-2-(3-phenylpropylamino) benzoic acid, which inhibits the cystic fibrosis transmembrane conductor regulator (CFTR), dose dependently inhibited  bbbbb1 S3226 eeeee1  bbbbb2 cystic fibrosis transmembrane conductor regulator eeeee2  (CFTR), dose dependently inhibited S3226-induced DBS
CRP11	Nevertheless, coperfusion with 0.1 and 0.3 mM 5-nitro-2-(3-phenylpropylamino) benzoic acid, which inhibits the cystic fibrosis transmembrane conductor regulator (CFTR), dose dependently inhibited  bbbbb1 S3226 eeeee1  bbbbb2 CFTR eeeee2 ), dose dependently inhibited S3226-induced DBS
CRP11	DBS was measured by using the pH-stat method and by using  bbbbb1 CO2 eeeee1 -sensitive electrodes. 5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms  bbbbb2 NHE1 eeeee2  and NHE2, but not NHE3, did not affect DBS
CRP11	DBS was measured by using the pH-stat method and by using  bbbbb1 CO2 eeeee1 -sensitive electrodes. 5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the  bbbbb2 NHE eeeee2  isoforms NHE1 and NHE2, but not NHE3, did not affect DBS
CRP11	DBS was measured by using the pH-stat method and by using  bbbbb1 CO2 eeeee1 -sensitive electrodes. 5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and  bbbbb2 NHE2 eeeee2 , but not NHE3, did not affect DBS
CRP11	DBS was measured by using the pH-stat method and by using  bbbbb1 CO2 eeeee1 -sensitive electrodes. 5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not  bbbbb2 NHE3 eeeee2 , did not affect DBS
CRP11	We examined the effect of inhibition of  bbbbb1 Na+ eeeee1 /H+ exchange ( bbbbb2 NHE eeeee2 ) on duodenal bicarbonate secretion (DBS) in rats to further understand DBS regulation
CRP11	We examined the effect of inhibition of  bbbbb1 Na+ eeeee1  bbbbb2 Na+/H+ exchange eeeee2  (NHE) on duodenal bicarbonate secretion (DBS) in rats to further understand DBS regulation
CRP11	We examined the effect of inhibition of Na+/ bbbbb1 H+ eeeee1  exchange ( bbbbb2 NHE eeeee2 ) on duodenal bicarbonate secretion (DBS) in rats to further understand DBS regulation
CRP11	We examined the effect of inhibition of Na+/ bbbbb1 H+ eeeee1  bbbbb2 Na+/H+ exchange eeeee2  (NHE) on duodenal bicarbonate secretion (DBS) in rats to further understand DBS regulation
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 IL-22 eeeee2  converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 CXCL10 eeeee2 , and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 STAT1 eeeee2  and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 CXCL9 eeeee2 , CXCL10, and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 cytokine eeeee2  robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 IFNα eeeee2 , IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible nitric oxide synthase (iNOS)
CRP11	Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFNα, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 )
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor  bbbbb1 tyrosine eeeee1  kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and  bbbbb2 epidermal growth-factor receptors eeeee2 
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor  bbbbb1 tyrosine eeeee1  kinase  bbbbb2 RET eeeee2  (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor  bbbbb1 tyrosine eeeee1  bbbbb2 growth-factor receptor tyrosine kinase eeeee2  RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor  bbbbb1 tyrosine eeeee1  kinase RET (constitutively activated in roughly 60 % of all MTCs),  bbbbb2 vascular endothelial growth-factor receptors 2 and 3 eeeee2 , and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral  bbbbb1 tyrosine eeeee1  kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and  bbbbb2 epidermal growth-factor receptors eeeee2 
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral  bbbbb1 tyrosine eeeee1  kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase  bbbbb2 RET eeeee2  (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral  bbbbb1 tyrosine eeeee1  kinase inhibitor that selectively inhibits signalling mediated by  bbbbb2 growth-factor receptor tyrosine kinase eeeee2  RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral  bbbbb1 tyrosine eeeee1  kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs),  bbbbb2 vascular endothelial growth-factor receptors 2 and 3 eeeee2 , and epidermal growth-factor receptors
CRP11	 bbbbb1 Vandetanib eeeee1  (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs),  bbbbb2 vascular endothelial growth-factor receptors 2 and 3 eeeee2 , and epidermal growth-factor receptors
CRP11	Vandetanib ( bbbbb1 Caprelsa eeeee1 (®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase  bbbbb2 RET eeeee2  (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib ( bbbbb1 Caprelsa eeeee1 (®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by  bbbbb2 growth-factor receptor tyrosine kinase eeeee2  RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors
CRP11	Vandetanib ( bbbbb1 Caprelsa eeeee1 (®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs),  bbbbb2 vascular endothelial growth-factor receptors 2 and 3 eeeee2 , and epidermal growth-factor receptors
CRP11	Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one ( bbbbb1 KCA-1490 eeeee1  bbbbb2 PDE3/4 eeeee2  inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent
CRP11	Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.  bbbbb1 (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one eeeee1  bbbbb2 PDE3/4 eeeee2  inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent
CRP11	Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4 bbbbb1 ,4-dimeth eeeee1  bbbbb2 on, ca eeeee2 n be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics
CRP11	A significant decrease in HLA-DR expression was observed in the AP and fractionated  bbbbb1 procyanidin eeeee1 -treated cells in the presence of  bbbbb2 ovalbumin eeeee2  (OVA), but no effect on CD86 expression was observed
CRP11	A significant decrease in HLA-DR expression was observed in the AP and fractionated  bbbbb1 procyanidin eeeee1 -treated cells in the presence of ovalbumin ( bbbbb2 OVA eeeee2 ), but no effect on CD86 expression was observed
CRP11	Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme  bbbbb1 glutamine eeeee1  synthetase ( bbbbb2 GS eeeee2 )
CRP11	Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme  bbbbb1 glutamine eeeee1  bbbbb2 glutamine synthetase eeeee2  (GS)
CRP11	However, it is unclear if withdrawal from free-choice  bbbbb1 ethanol eeeee1  drinking causes changes in the numbers of astrocytes expressing GS or the cytoskeletal protein of astrocytes glial fibrillary acidic protein ( bbbbb2 GFAP eeeee2 )
CRP11	However, it is unclear if withdrawal from free-choice  bbbbb1 ethanol eeeee1  drinking causes changes in the numbers of astrocytes expressing  bbbbb2 GS eeeee2  or the cytoskeletal protein of astrocytes glial fibrillary acidic protein (GFAP)
CRP11	However, it is unclear if withdrawal from free-choice  bbbbb1 ethanol eeeee1  drinking causes changes in the numbers of astrocytes expressing GS or the cytoskeletal protein of astrocytes  bbbbb2 glial fibrillary acidic protein eeeee2  (GFAP)
CRP11	In addition, there was a positive correlation between the pre-withdrawal ethanol consumption and the packing density of GS-IR astrocytes bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, there was a positive correlation between the pre-withdrawal ethanol consumption and the packing density of GS-IR astrocytes bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Withdrawal from free-choice ethanol consumption results in increased packing density of glutamine synthetase-immunoreactive astrocytes in the prelimbic cortex of  bbbbb1 alcohol eeeee1  bbbbb2 glutamine synthetase eeeee2 -immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats
CRP11	Withdrawal from free-choice ethanol consumption results in increased packing density of  bbbbb1 glutamine eeeee1  bbbbb2 glutamine synthetase eeeee2 -immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats
CRP11	The treatment of mice with Fe-NTA alone enhances  bbbbb1 ornithine eeeee1  bbbbb2 ornithine decarboxylase eeeee2  activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls
CRP11	The treatment of mice with Fe-NTA alone enhances ornithine decarboxylase activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of  bbbbb1 [(3)H] thymidine eeeee1  bbbbb2 ornithine decarboxylase eeeee2  activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls
CRP11	The treatment of mice with Fe-NTA alone enhances ornithine decarboxylase activity to 4.6 folds, protein  bbbbb1 carbonyl eeeee1  bbbbb2 ornithine decarboxylase eeeee2  activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls
CRP11	The  bbbbb1 potassium eeeee1  bbbbb2 potassium channel subunit Kvbeta3 eeeee2  interacts with pannexin 1 and attenuates its sensitivity to changes in redox potentials
CRP11	The  bbbbb1 potassium eeeee1  channel subunit Kvbeta3 interacts with  bbbbb2 pannexin 1 eeeee2  and attenuates its sensitivity to changes in redox potentials
CRP11	A candidate regulatory protein of Panx1 is the  bbbbb1 potassium eeeee1  bbbbb2 Panx1 eeeee2  is the potassium channel subunit Kvbeta3, previously identified by bacterial two-hybrid strategies
CRP11	A candidate regulatory protein of Panx1 is the  bbbbb1 potassium eeeee1  bbbbb2 potassium channel subunit Kvbeta3 eeeee2 , previously identified by bacterial two-hybrid strategies
CRP11	Kvbeta3 is known to accelerate inactivation of otherwise slowly inactivating  bbbbb1 potassium eeeee1  bbbbb2 potassium channels eeeee2  under reducing conditions
CRP11	Kvbeta3 is known to accelerate inactivation of otherwise slowly inactivating  bbbbb1 potassium eeeee1  bbbbb2 Kvbeta3 eeeee2  is known to accelerate inactivation of otherwise slowly inactivating potassium channels under reducing conditions
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [ bbbbb1 Fe-S eeeee1  bbbbb2 NifS eeeee2 ) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [ bbbbb1 Fe-S eeeee1  bbbbb2 NifU eeeee2 ) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a  bbbbb1 pyridoxal phosphate eeeee1 -dependent enzyme (NifS) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein ( bbbbb2 NifU eeeee2 ) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of sulphur from  bbbbb1 l-cysteine eeeee1 , and a molecular scaffold protein ( bbbbb2 NifU eeeee2 ) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [ bbbbb1 Fe-S eeeee1 ] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ( bbbbb2 NifS eeeee2 ) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [ bbbbb1 Fe-S eeeee1 ] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein ( bbbbb2 NifU eeeee2 ) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of  bbbbb1 sulphur eeeee1  bbbbb2 NifS eeeee2 ) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed
CRP11	Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS) that is involved in the activation of  bbbbb1 sulphur eeeee1  from l-cysteine, and a molecular scaffold protein ( bbbbb2 NifU eeeee2 ) upon which [Fe-S] cluster precursors are formed
CRP11	In addition to the  bbbbb1 N eeeee1 -terminal and Src homology 2 domains that mediate these interactions,  bbbbb2 SOCS eeeee2  proteins contain a C-terminal SOCS box
CRP11	In addition to the  bbbbb1 N eeeee1 -terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a C-terminal  bbbbb2 SOCS box eeeee2 
CRP11	In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a  bbbbb1 C eeeee1  bbbbb2 SOCS eeeee2  proteins contain a C-terminal SOCS box
CRP11	In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a  bbbbb1 C eeeee1  bbbbb2 Src homology 2 domains eeeee2  that mediate these interactions, SOCS proteins contain a C-terminal SOCS box
CRP11	Ankyrin repeat and suppressors of cytokine signaling box protein asb-9 targets  bbbbb1 creatine eeeee1  bbbbb2 asb-9 eeeee2  targets creatine kinase B for degradation
CRP11	Ankyrin repeat and suppressors of cytokine signaling box protein asb-9 targets  bbbbb1 creatine eeeee1  bbbbb2 cytokine signaling box protein eeeee2  asb-9 targets creatine kinase B for degradation
CRP11	Ankyrin repeat and suppressors of cytokine signaling box protein asb-9 targets  bbbbb1 creatine eeeee1  bbbbb2 Ankyrin eeeee2  repeat and suppressors of cytokine signaling box protein asb-9 targets creatine kinase B for degradation
CRP11	Ankyrin repeat and suppressors of cytokine signaling box protein asb-9 targets  bbbbb1 creatine eeeee1  bbbbb2 creatine kinase B eeeee2  for degradation
CRP11	Using a proteomics approach, we demonstrate that  bbbbb1 creatine eeeee1  kinase B (CKB) interacts with  bbbbb2 Asb-9 eeeee2  in a specific, SOCS box-independent manner
CRP11	Using a proteomics approach, we demonstrate that  bbbbb1 creatine eeeee1  bbbbb2 creatine kinase B eeeee2  (CKB) interacts with Asb-9 in a specific, SOCS box-independent manner
CRP11	Using a proteomics approach, we demonstrate that  bbbbb1 creatine eeeee1  kinase B (CKB) interacts with Asb-9 in a specific,  bbbbb2 SOCS box eeeee2 -independent manner
CRP11	Using a proteomics approach, we demonstrate that  bbbbb1 creatine eeeee1  kinase B ( bbbbb2 CKB eeeee2 ) interacts with Asb-9 in a specific, SOCS box-independent manner
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited  bbbbb2 NF-kappaB eeeee2 -dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B ( bbbbb2 NF-kappaB eeeee2 ), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of  bbbbb2 nuclear factor kappa B eeeee2  (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 ( bbbbb2 AP-1 eeeee2 ) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and  bbbbb2 activator protein-1 eeeee2  (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic  bbbbb2 NF-kappaB inhibitory protein eeeee2 , IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB),  bbbbb2 nuclear factor of activated T cells eeeee2  (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein,  bbbbb2 IkappaBalpha eeeee2  or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of  bbbbb1 PSE eeeee1  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells ( bbbbb2 NFAT eeeee2 ), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 NF-kappaB eeeee2 ), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 nuclear factor kappa B eeeee2  (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 AP-1 eeeee2 ) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 activator protein-1 eeeee2  (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 nuclear factor of activated T cells eeeee2  (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  bbbbb1 PSE eeeee1  bbbbb2 NFAT eeeee2 ), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces  bbbbb1 Na(+) eeeee1  influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other  bbbbb2 beta-adrenoceptor eeeee2  antagonists
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces  bbbbb1 Na(+) eeeee1  influx into cortical synaptosomes by direct interaction with  bbbbb2 Na(+) channels eeeee2 : comparison with other beta-adrenoceptor antagonists
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces  bbbbb1 Na(+) eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with  bbbbb1 Na(+) eeeee1  channels: comparison with other  bbbbb2 beta-adrenoceptor eeeee2  antagonists
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+) channels eeeee2 : comparison with other beta-adrenoceptor antagonists
CRP11	Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with  bbbbb1 Na(+) eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists
CRP11	Carteolol, levobunolol, timolol and atenolol were significantly less effective than betaxolol bbbbb1  at r eeeee1  bbbbb2 s effective t eeeee2 han betaxolol at reducing veratridine-evoked Na(+) influx
CRP11	Carteolol, levobunolol, timolol and atenolol were significantly les bbbbb1 s eff eeeee1  bbbbb2 s effective t eeeee2 han betaxolol at reducing veratridine-evoked Na(+) influx
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive  bbbbb1 sodium eeeee1  channel ( bbbbb2 Na(+) channel eeeee2 ) in rat cerebrocortical synaptosomes
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive  bbbbb1 sodium eeeee1  bbbbb2 voltage-sensitive sodium channel eeeee2  (Na(+) channel) in rat cerebrocortical synaptosomes
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive  bbbbb1 sodium eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel ( bbbbb1 Na(+) eeeee1  bbbbb2 Na(+) channel eeeee2 ) in rat cerebrocortical synaptosomes
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel ( bbbbb1 Na(+) eeeee1  bbbbb2 voltage-sensitive sodium channel eeeee2  (Na(+) channel) in rat cerebrocortical synaptosomes
CRP11	In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel ( bbbbb1 Na(+) eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes
CRP11	However,  bbbbb1 tryptophanyl eeeee1  bbbbb2 tryptophanyl-tRNA synthetase eeeee2  (WRS), which is coinduced with IDO by IFN-gamma, is downregulated by IL-4 and IL-13
CRP11	However,  bbbbb1 tryptophanyl eeeee1 -tRNA synthetase (WRS), which is coinduced with IDO by IFN-gamma, is downregulated by IL-4 and  bbbbb2 IL-13 eeeee2 
CRP11	However,  bbbbb1 tryptophanyl eeeee1 -tRNA synthetase (WRS), which is coinduced with  bbbbb2 IDO eeeee2  by IFN-gamma, is downregulated by IL-4 and IL-13
CRP11	However,  bbbbb1 tryptophanyl eeeee1 -tRNA synthetase (WRS), which is coinduced with IDO by IFN-gamma, is downregulated by  bbbbb2 IL-4 eeeee2  and IL-13
CRP11	However,  bbbbb1 tryptophanyl eeeee1 -tRNA synthetase (WRS), which is coinduced with IDO by  bbbbb2 IFN-gamma eeeee2 , is downregulated by IL-4 and IL-13
CRP11	However,  bbbbb1 tryptophanyl eeeee1 -tRNA synthetase ( bbbbb2 WRS eeeee2 ), which is coinduced with IDO by IFN-gamma, is downregulated by IL-4 and IL-13
CRP11	IDO expression is induced by IFN-gamma and leads to neurotoxicity by generating  bbbbb1 quinolinic acid eeeee1  bbbbb2 IFN-gamma eeeee2  and leads to neurotoxicity by generating quinolinic acid
CRP11	IDO expression is induced by IFN-gamma and leads to neurotoxicity by generating  bbbbb1 quinolinic acid eeeee1  bbbbb2 IDO eeeee2  expression is induced by IFN-gamma and leads to neurotoxicity by generating quinolinic acid
CRP11	 bbbbb1 Indoleamine eeeee1  2,3-dioxygenase ( bbbbb2 IDO eeeee2 ), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders
CRP11	 bbbbb1 Indoleamine eeeee1  bbbbb2 Indoleamine 2,3-dioxygenase eeeee2  (IDO), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders
CRP11	A series of pyrido-quinazolines have been synthesised, characterised and tested for their in vitro EGFR  bbbbb1 tyrosine eeeee1  bbbbb2 EGFR eeeee2  tyrosine kinase inhibitory activity
CRP11	A series of pyrido-quinazolines have been synthesised, characterised and tested for their in vitro EGFR  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitory activity
CRP11	We topically applied the  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 NOS eeeee2 ) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet
CRP11	We topically applied the  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2  (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet
CRP11	We topically applied the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a  bbbbb1 cilazapril eeeee1  bbbbb2 NOS eeeee2 ) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet
CRP11	 bbbbb1 These results  eeeee1  bbbbb2 These results suggest that diabe eeeee2 tic neuropathy may have an increasing vasopressor action with angiotensin II and this is likely to be the mechanism of NOS inhibition
CRP11	Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of  bbbbb1 nitric oxide eeeee1  bbbbb2 angiotensin II eeeee2  in experimental diabetic neuropathy: role of nitric oxide
CRP11	Altered vasoreactivity to  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  in experimental diabetic neuropathy: role of nitric oxide
CRP11	When applied locally to the sciatic nerve, the dose-response curve of  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  was more potent in experimental diabetic neuropathy (EDN) than control rats
CRP11	We evaluated the effects of  bbbbb1 angiotensin II eeeee1  and an  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats
CRP11	We evaluated the effects of  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  and an angiotensin-converting enzyme inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats
CRP11	We evaluated the effects of angiotensin II and an  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats
CRP11	We evaluated the effects of angiotensin II and an  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin II eeeee2  and an angiotensin-converting enzyme inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats
CRP11	No difference existed in plasma  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  levels between EDN and controls
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 DPP-4 eeeee2  inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 DPP-4 eeeee2 ) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 glucose-dependent insulinotropic polypeptide eeeee2 
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 incretin hormones eeeee2  glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 glucagon-like peptide-1 eeeee2  and glucose-dependent insulinotropic polypeptide
CRP11	Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  bbbbb1 glucose eeeee1  bbbbb2 dipeptidyl peptidase-4 eeeee2  (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load  bbbbb1 glucose eeeee1  bbbbb2 incretin eeeee2  and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load  bbbbb1 glucose eeeee1  bbbbb2 glucagon eeeee2  levels and post-glucose-load glucose excursion
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  levels, and decreases glucagon levels and post-glucose-load glucose excursion
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post- bbbbb1 glucose eeeee1  bbbbb2 incretin eeeee2  and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post- bbbbb1 glucose eeeee1  bbbbb2 glucagon eeeee2  levels and post-glucose-load glucose excursion
CRP11	This increases active incretin and insulin levels, and decreases glucagon levels and post- bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  levels, and decreases glucagon levels and post-glucose-load glucose excursion
CRP11	Inhibitors of the renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2  system (RAS) have proven to be successful treatments for hypertension
CRP11	Inhibitors of the renin- bbbbb1 angiotensin eeeee1  bbbbb2 renin eeeee2 -angiotensin system (RAS) have proven to be successful treatments for hypertension
CRP11	Sepracor in the US is developing  bbbbb1 arformoterol eeeee1  [R,R-formoterol], a single isomer form of the  bbbbb2 beta(2)-adrenoceptor eeeee2  agonist formoterol [eformoterol]
CRP11	Sepracor in the US is developing arformoterol [ bbbbb1 R,R-formoterol eeeee1 ], a single isomer form of the  bbbbb2 beta(2)-adrenoceptor eeeee2  agonist formoterol [eformoterol]
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb1 GnRH eeeee1  action by treating developing male rats with the specific  bbbbb2 GnRH eeeee2  antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin eeeee2  subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin eeeee2  subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is  bbbbb1 GnRH eeeee1  dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb2 GnRH eeeee2  antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is  bbbbb1 GnRH eeeee1  dependent, we have studied the effect of blocking the endogenous  bbbbb2 GnRH eeeee2  action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is  bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin eeeee2  subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the GnRH-R and gonadotropin subunit gene expression is  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the  bbbbb1 GnRH eeeee1 -R and gonadotropin subunit gene expression is  bbbbb2 GnRH eeeee2  dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the  bbbbb1 GnRH eeeee1 -R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific  bbbbb2 GnRH eeeee2  antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the  bbbbb1 GnRH eeeee1 -R and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous  bbbbb2 GnRH eeeee2  action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the  bbbbb1 GnRH eeeee1 -R and  bbbbb2 gonadotropin eeeee2  subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	To ascertain whether developmental activation of the  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression is GnRH dependent, we have studied the effect of blocking the endogenous GnRH action by treating developing male rats with the specific GnRH antagonist cetrorelix (1.5 mg/kg body weight/week, s.c.) through the infantile (Days 5-20) and the juvenile periods (Days 20-35)
CRP11	Thereafter, the levels of the  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  mRNA decline slightly until Day 55 (33% decrease vs. Day 35)
CRP11	These data demonstrate that sexual maturation of male rats is accompanied by a progressive and concerted induction of  bbbbb1 GnRH eeeee1 -R and  bbbbb2 gonadotropin eeeee2  subunit gene expression
CRP11	These data demonstrate that sexual maturation of male rats is accompanied by a progressive and concerted induction of  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression
CRP11	Developmental bbbbb1  act eeeee1 ivation of GnRH-R and gonadotro bbbbb2 pin beta subunit g eeeee2 enes is GnRH dependent
CRP11	Developmental bbbbb1  act eeeee1  bbbbb2  act eeeee2 ivation of GnRH-R and gonadotropin beta subunit genes is GnRH dependent
CRP11	Appropriate expression of the GnRH receptor (GnRH-R) in gonadotropes is critical for  bbbbb1 GnRH eeeee1  signaling and hence for  bbbbb2 gonadotropin eeeee2  secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor (GnRH-R) in gonadotropes is critical for  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2 ) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor (GnRH-R) in gonadotropes is critical for  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor (GnRH-R) in gonadotropes is critical for  bbbbb1 GnRH eeeee1  bbbbb2 GnRH receptor eeeee2  (GnRH-R) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor ( bbbbb1 GnRH eeeee1 -R) in gonadotropes is critical for GnRH signaling and hence for  bbbbb2 gonadotropin eeeee2  secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor ( bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2 ) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor ( bbbbb1 GnRH eeeee1 -R) in gonadotropes is critical for  bbbbb2 GnRH eeeee2  signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the GnRH receptor ( bbbbb1 GnRH eeeee1  bbbbb2 GnRH receptor eeeee2  (GnRH-R) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the  bbbbb1 GnRH eeeee1  receptor (GnRH-R) in gonadotropes is critical for GnRH signaling and hence for  bbbbb2 gonadotropin eeeee2  secretion and sexual development
CRP11	Appropriate expression of the  bbbbb1 GnRH eeeee1  receptor ( bbbbb2 GnRH-R eeeee2 ) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the  bbbbb1 GnRH eeeee1  receptor (GnRH-R) in gonadotropes is critical for  bbbbb2 GnRH eeeee2  signaling and hence for gonadotropin secretion and sexual development
CRP11	Appropriate expression of the  bbbbb1 GnRH eeeee1  bbbbb2 GnRH receptor eeeee2  (GnRH-R) in gonadotropes is critical for GnRH signaling and hence for gonadotropin secretion and sexual development
CRP11	 bbbbb1 Gonadotropin-releasing hormone eeeee1  bbbbb2 Gonadotropin-releasing hormone receptor eeeee2  gene expression during pubertal development of male rats
CRP11	In the present work, we have studied the ontogeny of the steady-state  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  mRNA levels in pituitaries of male rats from Day 5 to Day 55, when sexual maturity is attained
CRP11	Parallel changes were observed on the 4.5-kb transcript of the  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  gene
CRP11	In addition, the role of the endogenous GnRH on the maturational changes of  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression was investigated
CRP11	In addition, the role of the endogenous GnRH on the maturational changes of  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  on the maturational changes of GnRH-R and gonadotropin subunit gene expression was investigated
CRP11	In addition, the role of the endogenous GnRH on the maturational changes of  bbbbb1 GnRH eeeee1 -R and  bbbbb2 gonadotropin eeeee2  subunit gene expression was investigated
CRP11	In addition, the role of the endogenous  bbbbb1 GnRH eeeee1  on the maturational changes of  bbbbb2 GnRH-R eeeee2  and gonadotropin subunit gene expression was investigated
CRP11	In addition, the role of the endogenous  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  on the maturational changes of GnRH-R and gonadotropin subunit gene expression was investigated
CRP11	In addition, the role of the endogenous  bbbbb1 GnRH eeeee1  on the maturational changes of GnRH-R and  bbbbb2 gonadotropin eeeee2  subunit gene expression was investigated
CRP11	Amounts of the most abundant (5.0 kb)  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  mRNA increased slowly from Day 5 through the infantile and the juvenile periods, to peak at Day 35 (12-fold increase vs. Day 5)
CRP11	Cetrorelix completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the  bbbbb1 GnRH eeeee1  bbbbb2 GnRH-R eeeee2  mRNA, during both the infantile and the juvenile periods
CRP11	Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 ) antagonist abolishes this effect
CRP11	Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 gonadotrophin releasing hormone eeeee2  (GnRH) antagonist abolishes this effect
CRP11	Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a  bbbbb1 gonadotrophin releasing hormone eeeee1  ( bbbbb2 GnRH eeeee2 ) antagonist abolishes this effect
CRP11	Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a  bbbbb1 gonadotrophin releasing hormone eeeee1  bbbbb2 gonadotrophin releasing hormone eeeee2  (GnRH) antagonist abolishes this effect
CRP11	Kisspeptin is a 54- bbbbb1 amino acid eeeee1  peptide which is encoded by the KiSS-1 gene and activates the  bbbbb2 G protein-coupled receptor eeeee2  GPR54
CRP11	Kisspeptin is a 54- bbbbb1 amino acid eeeee1  peptide which is encoded by the  bbbbb2 KiSS-1 eeeee2  gene and activates the G protein-coupled receptor GPR54
CRP11	Kisspeptin is a 54- bbbbb1 amino acid eeeee1  peptide which is encoded by the KiSS-1 gene and activates the G protein-coupled receptor  bbbbb2 GPR54 eeeee2 
CRP11	In healthy human volunteers, the acute intravenous administration of kisspeptin potently increases plasma luteinising hormone (LH) levels and significantly increases plasma follicle stimulating hormone (FSH) and  bbbbb1 testosterone eeeee1  bbbbb2 follicle stimulating hormone eeeee2  (FSH) and testosterone without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle
CRP11	In healthy human volunteers, the acute intravenous administration of kisspeptin potently increases plasma luteinising hormone (LH) levels and significantly increases plasma follicle stimulating hormone (FSH) and  bbbbb1 testosterone eeeee1  bbbbb2 luteinising hormone eeeee2  (LH) levels and significantly increases plasma follicle stimulating hormone (FSH) and testosterone without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle
CRP11	In healthy human volunteers, the acute intravenous administration of kisspeptin potently increases plasma luteinising hormone (LH) levels and significantly increases plasma follicle stimulating hormone (FSH) and  bbbbb1 testosterone eeeee1  bbbbb2 LH eeeee2 ) levels and significantly increases plasma follicle stimulating hormone (FSH) and testosterone without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle
CRP11	In healthy human volunteers, the acute intravenous administration of kisspeptin potently increases plasma luteinising hormone (LH) levels and significantly increases plasma follicle stimulating hormone (FSH) and  bbbbb1 testosterone eeeee1  bbbbb2 FSH eeeee2 ) and testosterone without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle
CRP11	We report here the optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the  bbbbb1 phenyl eeeee1  bbbbb2 human 17β-HSD2 eeeee2  inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group
CRP11	We report here the optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the  bbbbb1 amide eeeee1  bbbbb2 human 17β-HSD2 eeeee2  inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 11β-HSD2 eeeee2  and the estrogen receptors α and β
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 17β-HSD4 eeeee2 , 17β-HSD5, 11β-HSD1, 11β-HSD2 and the estrogen receptors α and β
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 11β-HSD1 eeeee2 , 11β-HSD2 and the estrogen receptors α and β
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 17β-HSD5 eeeee2 , 11β-HSD1, 11β-HSD2 and the estrogen receptors α and β
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptors α and β eeeee2 
CRP11	The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the  bbbbb1 estrogen eeeee1  bbbbb2 17β-HSD1 eeeee2 , 17β-HSD4, 17β-HSD5, 11β-HSD1, 11β-HSD2 and the estrogen receptors α and β
CRP11	Structural optimization of 2,5-thiophene amides as highly potent and selective  bbbbb1 17β-hydroxysteroid eeeee1  bbbbb2 17β-hydroxysteroid dehydrogenase type 2 eeeee2  inhibitors for the treatment of osteoporosis
CRP11	Here we investigated the effects of recombinant adeno-associated virus (rAAV)-mediated CYP2J2 overexpression on angiotensin (Ang) II-induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased  bbbbb1 EETs eeeee1  bbbbb2 CYP2J2 eeeee2  overexpression on angiotensin (Ang) II-induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased EETs generation
CRP11	Here we investigated the effects of recombinant adeno-associated virus (rAAV)-mediated CYP2J2 overexpression on angiotensin (Ang) II-induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased  bbbbb1 EETs eeeee1  bbbbb2 CYP2J2 eeeee2  expression and increased EETs generation
CRP11	Here we investigated the effects of recombinant adeno-associated virus (rAAV)-mediated CYP2J2 overexpression on angiotensin (Ang) II-induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased  bbbbb1 EETs eeeee1  bbbbb2 angiotensin (Ang) II eeeee2 -induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased EETs generation
CRP11	Here we investigated the effects of recombinant adeno-associated virus (rAAV)-mediated CYP2J2 overexpression on angiotensin (Ang) II-induced AAA in apoE-deficient mice. rAAV-CYP2J2 delivery led to an abundant aortic CYP2J2 expression and increased  bbbbb1 EETs eeeee1  bbbbb2 CYP2J2 eeeee2  delivery led to an abundant aortic CYP2J2 expression and increased EETs generation
CRP11	In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and  bbbbb1 EETs eeeee1  bbbbb2 CYP2J2 eeeee2  overexpression and EETs markedly suppressed Ang II-induced inflammatory cytokine expression
CRP11	We further indicated that these protective effects were mediated by peroxisome proliferator-activated receptor (PPAR)γ activation bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	We further indicated that these protective effects were mediated by peroxisome proliferator-activated receptor (PPAR)γ activation bbbbb1  eeeee1  bbbbb2 y pero eeeee2 xisome proliferator-activated receptor (PPAR)γ activation
CRP11	P2J2 overexpression increases  bbbbb1 EETs eeeee1  and protects against  bbbbb2 angiotensin II eeeee2 -induced abdominal aortic aneurysm in mice
CRP11	Moreover, overexpressed CYP2J2 and  bbbbb1 EETs eeeee1  bbbbb2 CYP2J2 eeeee2  and EETs inhibited Ang II-induced macrophage migration in a VSMC-macrophage coculture system
CRP11	In normal subjects, total CA-repeat length was negatively correlated with fas bbbbb1 ting in eeeee1 sulin and HOMA-β bbbbb2  eeeee2 
CRP11	In normal subjects, total CA-repeat length was negatively correlated with fas bbbbb1 ting in eeeee1 sulin and HOMA-β bbbbb2  eeeee2 
CRP11	In normal subjects, total CA-repeat length was negatively correlated with fas bbbbb1 ting in eeeee1  bbbbb2 A-repeat l eeeee2 ength was negatively correlated with fasting insulin and HOMA-β
CRP11	Longer HSD11B2 CA-repeat in impaired  bbbbb1 glucose eeeee1  bbbbb2 CA-repeat eeeee2  in impaired glucose tolerance and type 2 diabetes
CRP11	Longer HSD11B2 CA-repeat in impaired  bbbbb1 glucose eeeee1  bbbbb2 HSD11B2 eeeee2  CA-repeat in impaired glucose tolerance and type 2 diabetes
CRP11	Subjects with normal  bbbbb1 glucose eeeee1  tolerance (n=585), impaired glucose tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic CA-repeat polymorphism in the first intron of  bbbbb2 HSD11B2 eeeee2 
CRP11	Subjects with normal  bbbbb1 glucose eeeee1  tolerance (n=585), impaired glucose tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic  bbbbb2 CA-repeat eeeee2  polymorphism in the first intron of HSD11B2
CRP11	Subjects with normal glucose tolerance (n=585), impaired  bbbbb1 glucose eeeee1  tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic CA-repeat polymorphism in the first intron of  bbbbb2 HSD11B2 eeeee2 
CRP11	Subjects with normal glucose tolerance (n=585), impaired  bbbbb1 glucose eeeee1  tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic  bbbbb2 CA-repeat eeeee2  polymorphism in the first intron of HSD11B2
CRP11	Type 2  bbbbb1 11β-hydroxysteroid eeeee1  bbbbb2 Type 2 11β-hydroxysteroid dehydrogenase eeeee2  encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids
CRP11	Type 2  bbbbb1 11β-hydroxysteroid eeeee1  dehydrogenase encoded by the  bbbbb2 HSD11B2 eeeee2  gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids
CRP11	Type 2 11β-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect  bbbbb1 glucose eeeee1  bbbbb2 Type 2 11β-hydroxysteroid dehydrogenase eeeee2  encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids
CRP11	Type 2 11β-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect  bbbbb1 glucose eeeee1  bbbbb2 HSD11B2 eeeee2  gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids
CRP11	Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the  bbbbb1 lysine eeeee1  bbbbb2 p300 eeeee2  acetylates the lysine residue at position 293 of TRF2
CRP11	Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the  bbbbb1 lysine eeeee1  bbbbb2 histone acetyltransferase p300 eeeee2 , and that p300 acetylates the lysine residue at position 293 of TRF2
CRP11	Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the  bbbbb1 lysine eeeee1  bbbbb2 TRF2 eeeee2  specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2
CRP11	Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly( bbbbb1 ADP eeeee1  bbbbb2 TRF2 eeeee2  such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of  bbbbb1 dihydropyridine eeeee1  bbbbb2 G-proteins eeeee2  in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of  bbbbb1 dihydropyridine eeeee1  bbbbb2 pertussis toxin eeeee2 -sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of  bbbbb1 dihydropyridine eeeee1 -sensitive Ca2+ currents in an  bbbbb2 insulin eeeee2 -secreting cell line (RINm5F)
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive  bbbbb1 Ca2+ eeeee1  bbbbb2 G-proteins eeeee2  in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive  bbbbb1 Ca2+ eeeee1  bbbbb2 pertussis toxin eeeee2 -sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)
CRP11	Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive  bbbbb1 Ca2+ eeeee1  currents in an  bbbbb2 insulin eeeee2 -secreting cell line (RINm5F)
CRP11	The present findings indicate that activated alpha 2-adrenoceptors of RINm5F cells  bbbbb1 interact with m eeeee1 ultiple G-proteins, i.e. two forms of Go and with Gi2 bbbbb2  eeeee2 
CRP11	The present findings indicate that activated alpha 2-adrenoceptors of RINm5F cells  bbbbb1 interact with m eeeee1  bbbbb2 esent find eeeee2 ings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-proteins, i.e. two forms of Go and with Gi2
CRP11	The present findings indicate that activated alpha bbbbb1  2-adrenoc eeeee1 eptors of RINm5F cells interact with multiple G-proteins, i.e. two forms of Go and with Gi2 bbbbb2  eeeee2 
CRP11	The present findings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-proteins, i.e. two forms of Go and with Gi2 bbbbb1  eeeee1  bbbbb2 esent find eeeee2 ings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-proteins, i.e. two forms of Go and with Gi2
CRP11	The present findings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-p bbbbb1 rote eeeee1 ins, i.e. two forms of Go and with Gi2 bbbbb2  eeeee2 
CRP11	The present findings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-p bbbbb1 rote eeeee1  bbbbb2 esent find eeeee2 ings indicate that activated alpha 2-adrenoceptors of RINm5F cells interact with multiple G-proteins, i.e. two forms of Go and with Gi2
CRP11	In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced  bbbbb1 Ca2+ eeeee1  bbbbb2 galanin eeeee2 , another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced  bbbbb1 Ca2+ eeeee1  currents by about 40% in a  bbbbb2 pertussis toxin eeeee2 -insensitive manner
CRP11	In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced  bbbbb1 Ca2+ eeeee1  bbbbb2 somatostatin eeeee2 , galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced  bbbbb1 Ca2+ eeeee1  bbbbb2 insulin eeeee2  secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to  bbbbb1 adrenaline eeeee1  and somatostatin,  bbbbb2 galanin eeeee2 , another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to  bbbbb1 adrenaline eeeee1  and somatostatin, galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a  bbbbb2 pertussis toxin eeeee2 -insensitive manner
CRP11	In contrast to  bbbbb1 adrenaline eeeee1  and  bbbbb2 somatostatin eeeee2 , galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to adrenaline and  bbbbb1 somatostatin eeeee1 ,  bbbbb2 galanin eeeee2 , another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	In contrast to adrenaline and  bbbbb1 somatostatin eeeee1 , galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a  bbbbb2 pertussis toxin eeeee2 -insensitive manner
CRP11	In contrast to adrenaline and  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2 , galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner
CRP11	Since voltage-dependent Ca2+ currents play a key role in insulin secretion, we examined whether adrenaline modulates voltage-dependent  bbbbb1 Ca2+ eeeee1  bbbbb2 insulin eeeee2  secretion, we examined whether adrenaline modulates voltage-dependent Ca2+ currents of the rat insulinoma cell line, RINm5F
CRP11	Since voltage-dependent Ca2+ currents play a key role in insulin secretion, we examined whether  bbbbb1 adrenaline eeeee1  bbbbb2 insulin eeeee2  secretion, we examined whether adrenaline modulates voltage-dependent Ca2+ currents of the rat insulinoma cell line, RINm5F
CRP11	Since voltage-dependent  bbbbb1 Ca2+ eeeee1  currents play a key role in  bbbbb2 insulin eeeee2  secretion, we examined whether adrenaline modulates voltage-dependent Ca2+ currents of the rat insulinoma cell line, RINm5F
CRP11	The hormonal inhibition of Ca2+ currents was not affected by intracellularly applied  bbbbb1 cAMP eeeee1  but blocked by the intracellularly applied GDP analog guanosine 5'-O-(2-thiodiphosphate) and by pretreatment of cells with  bbbbb2 pertussis toxin eeeee2 
CRP11	The hormonal inhibition of  bbbbb1 Ca2+ eeeee1  currents was not affected by intracellularly applied cAMP but blocked by the intracellularly applied GDP analog guanosine 5'-O-(2-thiodiphosphate) and by pretreatment of cells with  bbbbb2 pertussis toxin eeeee2 
CRP11	The hormonal inhibition of Ca2+ currents was not affected by intracellularly applied cAMP but blocked by the intracellularly applied  bbbbb1 GDP eeeee1  analog guanosine 5'-O-(2-thiodiphosphate) and by pretreatment of cells with  bbbbb2 pertussis toxin eeeee2 
CRP11	The hormonal inhibition of Ca2+ currents was not affected by intracellularly applied cAMP but blocked by the intracellularly applied GDP analog  bbbbb1 guanosine 5'-O-(2-thiodiphosphate) eeeee1  and by pretreatment of cells with  bbbbb2 pertussis toxin eeeee2 
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive  bbbbb1 GTP eeeee1  analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2,  bbbbb2 Go2 eeeee2 , and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive  bbbbb1 GTP eeeee1  bbbbb2 alpha 2-adrenoceptors eeeee2  stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive  bbbbb1 GTP eeeee1  analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of  bbbbb2 Gi2 eeeee2 , Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive  bbbbb1 GTP eeeee1  bbbbb2 pertussis toxin eeeee2 -treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive  bbbbb1 GTP eeeee1  analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified  bbbbb2 Go eeeee2  subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog  bbbbb1 [alpha-32P]GTP azidoanilide eeeee1  into pertussis toxin substrates comigrating with the alpha-subunits of Gi2,  bbbbb2 Go2 eeeee2 , and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog  bbbbb1 [alpha-32P]GTP azidoanilide eeeee1  bbbbb2 alpha 2-adrenoceptors eeeee2  stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog  bbbbb1 [alpha-32P]GTP azidoanilide eeeee1  into pertussis toxin substrates comigrating with the alpha-subunits of  bbbbb2 Gi2 eeeee2 , Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog  bbbbb1 [alpha-32P]GTP azidoanilide eeeee1  bbbbb2 pertussis toxin eeeee2 -treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog  bbbbb1 [alpha-32P]GTP azidoanilide eeeee1  into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified  bbbbb2 Go eeeee2  subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells,  bbbbb1 adrenaline eeeee1  via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2,  bbbbb2 Go2 eeeee2 , and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells,  bbbbb1 adrenaline eeeee1  via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of  bbbbb2 Gi2 eeeee2 , Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells,  bbbbb1 adrenaline eeeee1  bbbbb2 pertussis toxin eeeee2 -treated cells, adrenaline via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype
CRP11	In membranes of control but not of pertussis toxin-treated cells,  bbbbb1 adrenaline eeeee1  via alpha 2-adrenoceptors stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified  bbbbb2 Go eeeee2  subtype
CRP11	 bbbbb1 Somatostatin eeeee1  bbbbb2 Somatostatin eeeee2  which also inhibits insulin secretion was less efficient (inhibition by 20%)
CRP11	Adrenaline via alpha 2-adrenoceptors inhibited the  bbbbb1 Ca2+ eeeee1  bbbbb2 alpha 2-adrenoceptors eeeee2  inhibited the Ca2+ currents by about 50%
CRP11	From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of  bbbbb1 SR 141716A eeeee1  bbbbb2 CB2 eeeee2  receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A
CRP11	From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of  bbbbb1 SR 141716A eeeee1  bbbbb2 CB1 eeeee2  and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A
CRP11	From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of  bbbbb1 SR 141716A eeeee1  bbbbb2 CB1 eeeee2 /CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A
CRP11	From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of  bbbbb1 SR 141716A eeeee1  bbbbb2 CB1 eeeee2  implicated in the recognition of SR 141716A
CRP11	The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on  bbbbb1 SR 141716A eeeee1  bbbbb2 CB2 eeeee2  second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants
CRP11	The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on  bbbbb1 SR 141716A eeeee1  bbbbb2 CB1 eeeee2  and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants
CRP11	The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated  bbbbb1 CP 55,940 eeeee1  bbbbb2 CB2 eeeee2  second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants
CRP11	The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated  bbbbb1 CP 55,940 eeeee1  bbbbb2 CB1 eeeee2  and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants
CRP11	The antagonist SR 141716A has a high specificity for the central CB1  bbbbb1 cannabinoid eeeee1  bbbbb2 CB1 eeeee2  cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships
CRP11	The antagonist SR 141716A has a high specificity for the central CB1  bbbbb1 cannabinoid eeeee1  receptor and negligeable affinity for the peripheral  bbbbb2 CB2 eeeee2  receptor, making it an excellent tool for probing receptor structure-activity relationships
CRP11	The antagonist SR 141716A has a high specificity for the central CB1  bbbbb1 cannabinoid eeeee1  bbbbb2 cannabinoid receptor eeeee2  and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships
CRP11	Structural features of the central  bbbbb1 cannabinoid eeeee1   bbbbb2 CB1 eeeee2  receptor involved in the binding of the specific CB1 antagonist SR 141716A
CRP11	Structural features of the central  bbbbb1 cannabinoid eeeee1  CB1 receptor involved in the binding of the specific  bbbbb2 CB1 eeeee2  antagonist SR 141716A
CRP11	Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of  bbbbb1 dihydropteridinone eeeee1  bbbbb2 Plk-2 eeeee2 ) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors
CRP11	Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of  bbbbb1 dihydropteridinone eeeee1  bbbbb2 Polo-like kinase-2 eeeee2  (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors
CRP11	The concomitant application of subconvulsive dose of  bbbbb1 pentetrazole eeeee1  (55.0 mg/kg) with low dose of flumazenil (5.0 mg/kg) - a  bbbbb2 BDZ receptor eeeee2  antagonist, immediately induced BDZ withdrawal signs in these animals
CRP11	The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of flumazenil (5.0 mg/kg) - a  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptor eeeee2  antagonist, immediately induced BDZ withdrawal signs in these animals
CRP11	The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of flumazenil (5.0 mg/kg) - a BDZ receptor antagonist, immediately induced  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptor eeeee2  antagonist, immediately induced BDZ withdrawal signs in these animals
CRP11	Adenosine receptor antagonists intensify the  bbbbb1 benzodiazepine eeeee1  bbbbb2 Adenosine receptor eeeee2  antagonists intensify the benzodiazepine withdrawal signs in mice
CRP11	 bbbbb1 Adenosine eeeee1  bbbbb2 Adenosine receptor eeeee2  antagonists intensify the benzodiazepine withdrawal signs in mice
CRP11	The most apparent effects were observed after administration of DPCPX, indicating that the adenosine A1 recep bbbbb1 tor may p eeeee1  bbbbb2 tor may play a more i eeeee2 mportant role in these effects
CRP11	The most apparent effects were observed after administration of DPCPX, indi bbbbb1 cat eeeee1 ing that the adenosine A1 recep bbbbb2 tor may play a more i eeeee2 mportant role in these effects
CRP11	The aim of the present experiment was to assess the involvement of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptor eeeee2  antagonists in benzodiazepine (BDZ) withdrawal signs, observed as the seizure susceptibility in mice
CRP11	The aim of the present experiment was to assess the involvement of adenosine receptor antagonists in benzodiazepine ( bbbbb1 BDZ eeeee1  bbbbb2 adenosine receptor eeeee2  antagonists in benzodiazepine (BDZ) withdrawal signs, observed as the seizure susceptibility in mice
CRP11	The aim of the present experiment was to assess the involvement of adenosine receptor antagonists in  bbbbb1 benzodiazepine eeeee1  bbbbb2 adenosine receptor eeeee2  antagonists in benzodiazepine (BDZ) withdrawal signs, observed as the seizure susceptibility in mice
CRP11	The non-selective adenosine receptor antagonist ( bbbbb1 caffeine eeeee1 ), and the selective  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist ( bbbbb1 DPCPX eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and  bbbbb1 flumazenil eeeee1  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and  bbbbb1 flumazenil eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of  bbbbb1 pentetrazole eeeee1  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of  bbbbb1 pentetrazole eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify  bbbbb1 BDZ eeeee1  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify  bbbbb1 BDZ eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective  bbbbb1 adenosine eeeee1  receptor antagonist (caffeine), and the selective  bbbbb2 adenosine A1 receptor eeeee2  antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	The non-selective  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptor eeeee2  antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice
CRP11	In our mouse xenograft model of OVCAR-3 and HCT-8, we found that  bbbbb1 thalidomide eeeee1  could decrease intratumoral microvessel density in both tumors; it exerted antitumor effects only on OVCAR-3 expressing COX-2 but did not on HCT-8 not expressing  bbbbb2 COX-2 eeeee2 
CRP11	In our mouse xenograft model of OVCAR-3 and HCT-8, we found that  bbbbb1 thalidomide eeeee1  could decrease intratumoral microvessel density in both tumors; it exerted antitumor effects only on OVCAR-3 expressing  bbbbb2 COX-2 eeeee2  but did not on HCT-8 not expressing COX-2
CRP11	Moreover, cells not expressing COX-2 were insensitive to the growth-inhibitory and effects on cytokines of  bbbbb1 thalidomide eeeee1  bbbbb2 cytokines eeeee2  of thalidomide
CRP11	Moreover, cells not expressing COX-2 were insensitive to the growth-inhibitory and effects on cytokines of  bbbbb1 thalidomide eeeee1  bbbbb2 COX-2 eeeee2  were insensitive to the growth-inhibitory and effects on cytokines of thalidomide
CRP11	We evaluated the effects of  bbbbb1 thalidomide eeeee1  on the growth of human tumor cells expressing (MCF-7 and HL-60) or not expressing (HeLa and K562)  bbbbb2 COX-2 eeeee2  in vitro
CRP11	Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by  bbbbb1 cinobufagin eeeee1  bbbbb2 GSK-3β eeeee2  could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment
CRP11	These results suggest that ATP-bound TOP2 may be the specific targe bbbbb1 t o eeeee1  bbbbb2 results suggest that ATP-bound T eeeee2 OP2 may be the specific target of ATP-sensitive TOP2 poisons
CRP11	In the current studies, we show that two different classes (ATP-sensitive and -insensitive) of TOP2 poisons can be identified based on their differential sensitivity to the  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2  poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2
CRP11	In the current studies, we show that two different classes ( bbbbb1 ATP eeeee1 -sensitive and -insensitive) of  bbbbb2 TOP2 eeeee2  poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2
CRP11	In the current studies, we show that two different classes ( bbbbb1 ATP eeeee1 -sensitive and -insensitive) of TOP2 poisons can be identified based on their differential sensitivity to the ATP-bound conformation of  bbbbb2 TOP2 eeeee2 
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog  bbbbb1 adenosine 5'-(beta,gamma-imino)triphosphate eeeee1 , TOP2-mediated DNA cleavage induced by ATP-sensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog  bbbbb1 adenosine 5'-(beta,gamma-imino)triphosphate eeeee1 ,  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog  bbbbb1 adenosine 5'-(beta,gamma-imino)triphosphate eeeee1 , TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and  bbbbb1 4'-(9-acridinylamino)methanesulfon-m-anisidide eeeee1 ) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide,  bbbbb1 mitoxantrone eeeee1 , and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by  bbbbb1 ATP eeeee1 -insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm  bbbbb1 ATP eeeee1  or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm  bbbbb1 ATP eeeee1  or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate,  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm  bbbbb1 ATP eeeee1  or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g.  bbbbb1 doxorubicin eeeee1 , etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin,  bbbbb1 etoposide eeeee1 , mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.  bbbbb1 amonafide eeeee1  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.  bbbbb1 amonafide eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by  bbbbb1 ATP eeeee1 -sensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by  bbbbb1 ATP eeeee1 -sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide,  bbbbb1 batracylin eeeee1  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide,  bbbbb1 batracylin eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and  bbbbb1 menadione eeeee1  bbbbb2 TOP2 eeeee2  poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and  bbbbb1 menadione eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all  bbbbb1 ATP eeeee1 -sensitive but not ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all  bbbbb1 ATP eeeee1  bbbbb2 ATPase eeeee2  activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all  bbbbb1 ATP eeeee1  bbbbb2 C427A eeeee2  mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all  bbbbb1 ATP eeeee1  bbbbb2 human TOP2alpha eeeee2 , which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not  bbbbb1 ATP eeeee1 -insensitive  bbbbb2 TOP2 eeeee2  poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not  bbbbb1 ATP eeeee1  bbbbb2 C427A eeeee2  mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not  bbbbb1 ATP eeeee1  bbbbb2 human TOP2alpha eeeee2 , which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	In addition,  bbbbb1 ADP eeeee1  was shown to strongly antagonize TOP2-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons
CRP11	In addition, ADP was shown to strongly antagonize TOP2-mediated DNA cleavage induced by ATP-sensitive but not  bbbbb1 ATP eeeee1 -insensitive  bbbbb2 TOP2 eeeee2  poisons
CRP11	In addition, ADP was shown to strongly antagonize TOP2-mediated DNA cleavage induced by ATP-sensitive but not  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive TOP2 poisons
CRP11	In addition, ADP was shown to strongly antagonize TOP2-mediated DNA cleavage induced by  bbbbb1 ATP eeeee1 -sensitive but not ATP-insensitive  bbbbb2 TOP2 eeeee2  poisons
CRP11	Third, using ciprofloxacin competition assay, TOP2-mediated DNA cleavage induced by  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by ciprofloxacin
CRP11	Third, using ciprofloxacin competition assay, TOP2-mediated DNA cleavage induced by ATP-sensitive but not  bbbbb1 ATP eeeee1  bbbbb2 TOP2 eeeee2 -mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by ciprofloxacin
CRP11	Together, these observations indicate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors have a unique role in triggering epileptiform activity in the amygdala and could participate in long-term plasticity mechanisms that underlie some forms of epileptogenesis
CRP11	Together, these observations indicate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2  have a unique role in triggering epileptiform activity in the amygdala and could participate in long-term plasticity mechanisms that underlie some forms of epileptogenesis
CRP11	Accordingly, GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2  represent a potential target for antiepileptic and antiepileptogenic drug treatments
CRP11	Accordingly, GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors represent a potential target for antiepileptic and antiepileptogenic drug treatments
CRP11	Brain slice recordings indicate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors mediate a portion of the synaptic excitation of neurons in the rat basolateral amygdala
CRP11	Brain slice recordings indicate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2  mediate a portion of the synaptic excitation of neurons in the rat basolateral amygdala
CRP11	GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors, seizures, and the amygdala
CRP11	GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2 , seizures, and the amygdala
CRP11	Whole-cell voltage-clamp studies demonstrate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptor eeeee2 -mediated synaptic currents are inwardly rectifying and are likely to be calcium permeable
CRP11	Whole-cell voltage-clamp studies demonstrate that GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor-mediated synaptic currents are inwardly rectifying and are likely to be calcium permeable
CRP11	Whole-cell voltage-clamp studies demonstrate that GluR5 kainate receptor-mediated synaptic currents are inwardly rectifying and are likely to be  bbbbb1 calcium eeeee1  bbbbb2 kainate receptor eeeee2 -mediated synaptic currents are inwardly rectifying and are likely to be calcium permeable
CRP11	Whole-cell voltage-clamp studies demonstrate that GluR5 kainate receptor-mediated synaptic currents are inwardly rectifying and are likely to be  bbbbb1 calcium eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor-mediated synaptic currents are inwardly rectifying and are likely to be calcium permeable
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptor eeeee2  agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor antagonist LY293558
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptor eeeee2  antagonist LY293558
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	The selective GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptor eeeee2  agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	The selective GluR5  bbbbb1 kainate eeeee1  receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the  bbbbb2 GluR5 eeeee2  kainate receptor antagonist LY293558
CRP11	The selective GluR5  bbbbb1 kainate eeeee1  receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  bbbbb2 kainate receptor eeeee2  antagonist LY293558
CRP11	The selective GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist  bbbbb1 LY293558 eeeee1  bbbbb2 kainate receptor eeeee2  agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist  bbbbb1 LY293558 eeeee1  bbbbb2 GluR5 eeeee2  kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2 eptor eeeee2 s
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2 eptor eeeee2 s
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Most antiepileptic drugs do not act through effects on glutamate receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Prolonged activation of basolateral amygdala GluR5  bbbbb1 kainate eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors results in enduring synaptic facilitation through a calcium-dependent process
CRP11	Prolonged activation of basolateral amygdala GluR5  bbbbb1 kainate eeeee1  bbbbb2 kainate receptors eeeee2  results in enduring synaptic facilitation through a calcium-dependent process
CRP11	Prolonged activation of basolateral amygdala GluR5 kainate receptors results in enduring synaptic facilitation through a  bbbbb1 calcium eeeee1  bbbbb2 GluR5 eeeee2  kainate receptors results in enduring synaptic facilitation through a calcium-dependent process
CRP11	Prolonged activation of basolateral amygdala GluR5 kainate receptors results in enduring synaptic facilitation through a  bbbbb1 calcium eeeee1  bbbbb2 kainate receptors eeeee2  results in enduring synaptic facilitation through a calcium-dependent process
CRP11	Here, we present VMAT2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohi bbbbb1 stoc eeeee1  bbbbb2  VMAT eeeee2 2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohistochemical evidence
CRP11	Here, we present VMAT2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohistochemic bbbbb1 al  eeeee1  bbbbb2  VMAT eeeee2 2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohistochemical evidence
CRP11	The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase  bbbbb1 dopamine eeeee1  in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage,  bbbbb2 VMAT2 eeeee2 
CRP11	The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase  bbbbb1 dopamine eeeee1  in the synapse, by effects on either the plasma membrane transporter  bbbbb2 DAT eeeee2  or the vesicular transporter for monoamine storage, VMAT2
CRP11	The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for  bbbbb1 monoamine eeeee1  storage,  bbbbb2 VMAT2 eeeee2 
CRP11	The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for  bbbbb1 monoamine eeeee1  bbbbb2 DAT eeeee2  or the vesicular transporter for monoamine storage, VMAT2
CRP11	A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia
CRP11	A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia
CRP11	Folding pathway of  bbbbb1 guanidine eeeee1 -denatured disulfide-intact wild-type and mutant  bbbbb2 bovine pancreatic ribonuclease A eeeee2 
CRP11	The folding rate for wild-type bbbbb1  RNas eeeee1 e A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP bbbbb2  eeeee2 
CRP11	The folding rate for wild-type RNase A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-sta bbbbb1 te struc eeeee1 ture in the rate-determining step is stabilized by 2'CMP bbbbb2  eeeee2 
CRP11	The folding rate for wild-type RNase A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP bbbbb1  eeeee1  bbbbb2  2'CMP t eeeee2 han in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP
CRP11	The folding rate for wild-type RNase A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring  bbbbb1 tyrosine eeeee1  bbbbb2 Pro42Ala eeeee2 ) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring  bbbbb1 tyrosine eeeee1  bbbbb2 proline-42-to-alanine eeeee2  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring  bbbbb1 tyrosine eeeee1  bbbbb2 bovine pancreatic ribonuclease A eeeee2  (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring  bbbbb1 tyrosine eeeee1  bbbbb2 RNase A eeeee2 ) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of  bbbbb1 guanidine eeeee1 -denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ( bbbbb2 Pro42Ala eeeee2 ) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of  bbbbb1 guanidine eeeee1 -denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its  bbbbb2 proline-42-to-alanine eeeee2  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of  bbbbb1 guanidine eeeee1 -denatured disulfide-intact  bbbbb2 bovine pancreatic ribonuclease A eeeee2  (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of  bbbbb1 guanidine eeeee1 -denatured disulfide-intact bovine pancreatic ribonuclease A ( bbbbb2 RNase A eeeee2 ) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its  bbbbb1 proline eeeee1 -42-to-alanine mutant ( bbbbb2 Pro42Ala eeeee2 ) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its  bbbbb1 proline eeeee1  bbbbb2 proline-42-to-alanine eeeee2  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured  bbbbb1 disulfide eeeee1 -intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ( bbbbb2 Pro42Ala eeeee2 ) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured  bbbbb1 disulfide eeeee1 -intact bovine pancreatic ribonuclease A (RNase A) and its  bbbbb2 proline-42-to-alanine eeeee2  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to- bbbbb1 alanine eeeee1  mutant ( bbbbb2 Pro42Ala eeeee2 ) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to- bbbbb1 alanine eeeee1  bbbbb2 proline-42-to-alanine eeeee2  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding
CRP11	Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates  bbbbb1 NO eeeee1  bbbbb2 alpha-2D adrenoceptor eeeee2  subtype mediates NO-induced relaxation in rat arteries
CRP11	Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates  bbbbb1 NO eeeee1  bbbbb2 alpha-2A adrenoceptor eeeee2  subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries
CRP11	Ka values for  bbbbb1 rauwolscine eeeee1  and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the  bbbbb2 alpha-2D adrenoceptor eeeee2  subtype mediates NO-induced relaxation in rat arteries
CRP11	Ka values for rauwolscine and  bbbbb1 WB-4101 eeeee1 , drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the  bbbbb2 alpha-2D adrenoceptor eeeee2  subtype mediates NO-induced relaxation in rat arteries
CRP11	Alpha-2 adrenoceptor subtype causing  bbbbb1 nitric oxide eeeee1  bbbbb2 Alpha-2 adrenoceptor eeeee2  subtype causing nitric oxide-mediated vascular relaxation in rats
CRP11	We used forskolin to oppose alpha-2 adrenoceptor-m bbbbb1 ediated  eeeee1 inhibition of cAMP formation by directly stimulating cAMP  bbbbb2 formation in endothel eeeee2 ium
CRP11	 bbbbb1 We used f eeeee1 orskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP  bbbbb2 formation in endothel eeeee2 ium
CRP11	We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium bbbbb1  eeeee1  bbbbb2 formation in endothel eeeee2 ium
CRP11	The role of platelet/lymphocyte  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  in depression and beyond
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD,  bbbbb1 sorafenib eeeee1  bbbbb2 FLT3 eeeee2 -WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD,  bbbbb1 sorafenib eeeee1  bbbbb2 FLT3 eeeee2 -ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated  bbbbb1 tyrosine eeeee1  bbbbb2 FLT3 eeeee2 -WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated  bbbbb1 tyrosine eeeee1  bbbbb2 FLT3 eeeee2 -mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated  bbbbb1 tyrosine eeeee1  bbbbb2 FLT3 eeeee2 -ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated  bbbbb1 tyrosine eeeee1  autophosphorylation as well as  bbbbb2 extracellular signal-regulated kinase1/2 eeeee2  and Stat5 phosphorylation
CRP11	HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated  bbbbb1 tyrosine eeeee1  autophosphorylation as well as extracellular signal-regulated kinase1/2 and  bbbbb2 Stat5 eeeee2  phosphorylation
CRP11	Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival
CRP11	Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3  bbbbb1 tyrosine eeeee1  bbbbb2 juxtamembrane domain eeeee2  of the FLT3 tyrosine kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival
CRP11	Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3  bbbbb1 tyrosine eeeee1  bbbbb2 FLT3 eeeee2  tyrosine kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival
CRP11	Orlistat has a lowering effect on serum cholesterol independent of weight lo bbbbb1 ss eeeee1  bbbbb2  eeeee2 
CRP11	In the long term, orlistat has been shown to be more effective than placebo in reducing body weight and serum total and low-density lipoprotein  bbbbb1 cholesterol eeeee1  bbbbb2 low-density lipoprotein eeeee2  cholesterol levels
CRP11	 bbbbb1 Nitric oxide eeeee1  products of VP-16 displayed significantly diminished  bbbbb2 topoisomerase II eeeee2 -dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells
CRP11	LPS-mediated induction of  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2  in murine macrophages resulted in VP-16 resistance compared to Raw cells
CRP11	LPS-mediated induction of nitric oxide synthase in murine macrophages resulted in  bbbbb1 VP-16 eeeee1  bbbbb2 nitric oxide synthase eeeee2  in murine macrophages resulted in VP-16 resistance compared to Raw cells
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and  bbbbb1 cyanate eeeee1  bbbbb2 CA I eeeee2 ; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and  bbbbb1 cyanate eeeee1  bbbbb2 mouse CA V eeeee2  is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by  bbbbb1 acetazolamide eeeee1  bbbbb2 CA I eeeee2 ; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by  bbbbb1 acetazolamide eeeee1  bbbbb2 mouse CA V eeeee2  is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide,  bbbbb1 ethoxzolamide eeeee1  bbbbb2 CA I eeeee2 ; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide,  bbbbb1 ethoxzolamide eeeee1  bbbbb2 mouse CA V eeeee2  is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II
CRP11	Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has hi bbbbb1 sti eeeee1 dine serving as a proton shuttle in the cataly bbbbb2 tic  eeeee2 pathway
CRP11	Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has hi bbbbb1 sti eeeee1  bbbbb2 I has histi eeeee2 dine serving as a proton shuttle in the catalytic pathway
CRP11	Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway bbbbb1  eeeee1  bbbbb2 here eeeee2  the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway
CRP11	Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway bbbbb1  eeeee1  bbbbb2 I has histi eeeee2 dine serving as a proton shuttle in the catalytic pathway
CRP11	These latter two forms of CA V had identical steady-state constants for the hydration of  bbbbb1 CO2 eeeee1  bbbbb2 CA V eeeee2  had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km
CRP11	Mn was also shown to decrease DA uptake and  bbbbb1 amphetamine eeeee1 -induced DA efflux in  bbbbb2 DAT eeeee2  containing cells
CRP11	Although dopaminergic neurons within the nigrostriatal pathway appear intact, Mn-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT)
CRP11	Although dopaminergic neurons within the nigrostriatal pathway appear intact, Mn-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 )
CRP11	Although dopaminergic neurons within the nigrostriatal pathway appear intact, Mn-induced irregularities in DA transmission have been observed including decreased  bbbbb1 amphetamine eeeee1 -induced DA release and loss of the  bbbbb2 dopamine transporter eeeee2  (DAT)
CRP11	Although dopaminergic neurons within the nigrostriatal pathway appear intact, Mn-induced irregularities in DA transmission have been observed including decreased  bbbbb1 amphetamine eeeee1 -induced DA release and loss of the dopamine transporter ( bbbbb2 DAT eeeee2 )
CRP11	The effect of manganese on  bbbbb1 dopamine eeeee1  toxicity and dopamine transporter ( bbbbb2 DAT eeeee2 ) in control and DAT transfected HEK cells
CRP11	The effect of manganese on  bbbbb1 dopamine eeeee1  toxicity and  bbbbb2 dopamine transporter eeeee2  (DAT) in control and DAT transfected HEK cells
CRP11	The effect of manganese on  bbbbb1 dopamine eeeee1  toxicity and dopamine transporter (DAT) in control and  bbbbb2 DAT eeeee2  transfected HEK cells
CRP11	The effect of  bbbbb1 manganese eeeee1  on dopamine toxicity and dopamine transporter ( bbbbb2 DAT eeeee2 ) in control and DAT transfected HEK cells
CRP11	The effect of  bbbbb1 manganese eeeee1  on dopamine toxicity and  bbbbb2 dopamine transporter eeeee2  (DAT) in control and DAT transfected HEK cells
CRP11	The effect of  bbbbb1 manganese eeeee1  on dopamine toxicity and dopamine transporter (DAT) in control and  bbbbb2 DAT eeeee2  transfected HEK cells
CRP11	The effect of manganese on dopamine toxicity and  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 ) in control and DAT transfected HEK cells
CRP11	The effect of manganese on dopamine toxicity and  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT) in control and DAT transfected HEK cells
CRP11	The effect of manganese on dopamine toxicity and  bbbbb1 dopamine eeeee1  transporter (DAT) in control and  bbbbb2 DAT eeeee2  transfected HEK cells
CRP11	When Mn and DA were added simultaneously to the media, cell toxicity was similar to that produced by Mn alone suggesting that  bbbbb1 Mn eeeee1  may suppress DA uptake in the  bbbbb2 DAT eeeee2  containing cells
CRP11	When  bbbbb1 Mn eeeee1  and DA were added simultaneously to the media, cell toxicity was similar to that produced by Mn alone suggesting that Mn may suppress DA uptake in the  bbbbb2 DAT eeeee2  containing cells
CRP11	When Mn and DA were added simultaneously to the media, cell toxicity was similar to that produced by  bbbbb1 Mn eeeee1  alone suggesting that Mn may suppress DA uptake in the  bbbbb2 DAT eeeee2  containing cells
CRP11	Results of studies to evaluate the effect of Mn and DA on cell viability in control and DAT-transfected HEK cells reveal that  bbbbb1 Mn eeeee1  bbbbb2 DAT eeeee2 -transfected HEK cells reveal that Mn is equally toxic to both cell lines whereas DA was only toxic to cells containing DAT
CRP11	Results of studies to evaluate the effect of  bbbbb1 Mn eeeee1  and DA on cell viability in control and  bbbbb2 DAT eeeee2 -transfected HEK cells reveal that Mn is equally toxic to both cell lines whereas DA was only toxic to cells containing DAT
CRP11	Results of studies to evaluate the effect of  bbbbb1 Mn eeeee1  and DA on cell viability in control and DAT-transfected HEK cells reveal that Mn is equally toxic to both cell lines whereas DA was only toxic to cells containing  bbbbb2 DAT eeeee2 
CRP11	Success of pyridostigmine, physostigmine,  bbbbb1 eptastigmine eeeee1  and  bbbbb2 phosphotriesterase eeeee2  treatments in acute sarin intoxication
CRP11	Success of pyridostigmine,  bbbbb1 physostigmine eeeee1 , eptastigmine and  bbbbb2 phosphotriesterase eeeee2  treatments in acute sarin intoxication
CRP11	Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2  treatments in acute sarin intoxication
CRP11	Success of  bbbbb1 pyridostigmine eeeee1 , physostigmine, eptastigmine and  bbbbb2 phosphotriesterase eeeee2  treatments in acute sarin intoxication
CRP11	In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2  and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity
CRP11	In phosphotriesterase and  bbbbb1 physostigmine eeeee1  bbbbb2 phosphotriesterase eeeee2  and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity
CRP11	In phosphotriesterase and  bbbbb1 physostigmine eeeee1 -treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain  bbbbb2 AChE eeeee2  activity
CRP11	Both the phosphotriesterase and  bbbbb1 physostigmine eeeee1  bbbbb2 phosphotriesterase eeeee2  and physostigmine treatments protected the brain AChE activities measured 24 h after sarin exposure
CRP11	Both the phosphotriesterase and physostigmine treatments protected the brain AChE activities measured 24 h after  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2  and physostigmine treatments protected the brain AChE activities measured 24 h after sarin exposure
CRP11	The mice received  bbbbb1 pyridostigmine eeeee1  (0.06 mg/kg body weight), physostigmine (0.09 mg/kg body weight), the physostigmine derivative eptastigmine (0.90 mg/kg body weight) or  bbbbb2 phosphotriesterase eeeee2  (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of sarin
CRP11	The mice received pyridostigmine (0.06 mg/kg body weight), physostigmine (0.09 mg/kg body weight), the  bbbbb1 physostigmine eeeee1  derivative eptastigmine (0.90 mg/kg body weight) or  bbbbb2 phosphotriesterase eeeee2  (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of sarin
CRP11	The mice received pyridostigmine (0.06 mg/kg body weight), physostigmine (0.09 mg/kg body weight), the physostigmine derivative eptastigmine (0.90 mg/kg body weight) or phosphotriesterase (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2  (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of sarin
CRP11	The mice received pyridostigmine (0.06 mg/kg body weight), physostigmine (0.09 mg/kg body weight), the physostigmine derivative  bbbbb1 eptastigmine eeeee1  (0.90 mg/kg body weight) or  bbbbb2 phosphotriesterase eeeee2  (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of sarin
CRP11	The mice received pyridostigmine (0.06 mg/kg body weight),  bbbbb1 physostigmine eeeee1  (0.09 mg/kg body weight), the physostigmine derivative eptastigmine (0.90 mg/kg body weight) or  bbbbb2 phosphotriesterase eeeee2  (104 U/g, 10.7 microg/g body weight) 10 min prior to the i.g. administration of sarin
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine,  bbbbb1 eptastigmine eeeee1 , and an  bbbbb2 organophosphate hydrolase eeeee2 , phosphotriesterase, in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine,  bbbbb1 eptastigmine eeeee1 , and an organophosphate hydrolase,  bbbbb2 phosphotriesterase eeeee2 , in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine, eptastigmine, and an organophosphate hydrolase, phosphotriesterase, in acute  bbbbb1 sarin eeeee1  bbbbb2 organophosphate hydrolase eeeee2 , phosphotriesterase, in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine, eptastigmine, and an organophosphate hydrolase, phosphotriesterase, in acute  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2 , in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered  bbbbb1 pyridostigmine eeeee1 , physostigmine, eptastigmine, and an  bbbbb2 organophosphate hydrolase eeeee2 , phosphotriesterase, in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered  bbbbb1 pyridostigmine eeeee1 , physostigmine, eptastigmine, and an organophosphate hydrolase,  bbbbb2 phosphotriesterase eeeee2 , in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine, eptastigmine, and an  bbbbb1 organophosphate eeeee1  bbbbb2 organophosphate hydrolase eeeee2 , phosphotriesterase, in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine, physostigmine, eptastigmine, and an  bbbbb1 organophosphate eeeee1  hydrolase,  bbbbb2 phosphotriesterase eeeee2 , in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine,  bbbbb1 physostigmine eeeee1 , eptastigmine, and an  bbbbb2 organophosphate hydrolase eeeee2 , phosphotriesterase, in acute sarin intoxication were studied in mice
CRP11	The protective actions of intravenously (i.v.) administered pyridostigmine,  bbbbb1 physostigmine eeeee1 , eptastigmine, and an organophosphate hydrolase,  bbbbb2 phosphotriesterase eeeee2 , in acute sarin intoxication were studied in mice
CRP11	The animals pretreated with phosphotriesterase- bbbbb1 ephysostigmine eeeee1  bbbbb2 phosphotriesterase eeeee2 -ephysostigmine tolerated four times the lethal dose in control animals, furthermore their survival time was 2-3 h in comparison to 20 min in controls
CRP11	Moreover, the combination of phosphotriesterase-physostigmine increased the LD50 value for  bbbbb1 sarin eeeee1  bbbbb2 phosphotriesterase eeeee2 -physostigmine increased the LD50 value for sarin 4.3-fold
CRP11	Moreover, the combination of phosphotriesterase- bbbbb1 physostigmine eeeee1  bbbbb2 phosphotriesterase eeeee2 -physostigmine increased the LD50 value for sarin 4.3-fold
CRP11	 bbbbb1 Physostigmine eeeee1  was also administered with  bbbbb2 phosphotriesterase eeeee2 
CRP11	The LD50 value for  bbbbb1 sarin eeeee1  increased 3.4-fold in mice receiving  bbbbb2 phosphotriesterase eeeee2 
CRP11	Phosphotriesterase was the most effective antidote in  bbbbb1 sarin eeeee1  bbbbb2 Phosphotriesterase eeeee2  was the most effective antidote in sarin intoxication
CRP11	Prazosin was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), 5-methyl-urapidil, indoramin and (+)-niguldipine were confirmed as selective for the alpha 1A-adrenoceptor, whereas  bbbbb1 spiperone eeeee1  bbbbb2 alpha 1A-adrenoceptor eeeee2 , whereas spiperone was weakly alpha 1B-selective
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free  bbbbb1 cortisol eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free  bbbbb1 cortisol eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free  bbbbb1 cortisol eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S ( bbbbb1 DHEA eeeee1 -S0),  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S ( bbbbb1 DHEA eeeee1 -S0), cortisol binding globulin ( bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S ( bbbbb1 DHEA eeeee1 -S0), cortisol binding globulin (CBG),  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free  bbbbb1 cortisol eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free  bbbbb1 cortisol eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free  bbbbb1 cortisol eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0),  bbbbb1 cortisol eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0),  bbbbb1 cortisol eeeee1  binding globulin ( bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0),  bbbbb1 cortisol eeeee1  binding globulin (CBG),  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S ( bbbbb1 ΔDHEA eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S ( bbbbb1 ΔDHEA eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S ( bbbbb1 ΔDHEA eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and  bbbbb1 DHEA eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and  bbbbb1 DHEA eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and  bbbbb1 DHEA eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline  bbbbb1 cortisol eeeee1  (Cor0), DHEA-S (DHEA-S0),  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline  bbbbb1 cortisol eeeee1  (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin ( bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline  bbbbb1 cortisol eeeee1  (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG),  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol ( bbbbb1 ΔCor eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol ( bbbbb1 ΔCor eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol ( bbbbb1 ΔCor eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min  bbbbb1 cortisol eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min  bbbbb1 cortisol eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min  bbbbb1 cortisol eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S ( bbbbb1 DHEA eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S ( bbbbb1 DHEA eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S ( bbbbb1 DHEA eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0),  bbbbb1 DHEA eeeee1 -S (DHEA-S0),  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0),  bbbbb1 DHEA eeeee1 -S (DHEA-S0), cortisol binding globulin ( bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0),  bbbbb1 DHEA eeeee1 -S (DHEA-S0), cortisol binding globulin (CBG),  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60),  bbbbb1 delta cortisol eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60),  bbbbb1 delta cortisol eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60),  bbbbb1 delta cortisol eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor),  bbbbb1 delta DHEA eeeee1  bbbbb2 cortisol binding globulin eeeee2  (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor),  bbbbb1 delta DHEA eeeee1  bbbbb2 CBG eeeee2 ), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), ACTH, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor),  bbbbb1 delta DHEA eeeee1  bbbbb2 ACTH eeeee2 , calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated
CRP11	Norethisterone metabolites modulate the uteroglobin and  bbbbb1 progesterone eeeee1  bbbbb2 uteroglobin eeeee2  and progesterone receptor gene expression in prepubertal rabbits
CRP11	Norethisterone metabolites modulate the uteroglobin and  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  gene expression in prepubertal rabbits
CRP11	The effects of these metabolites on the expression of uteroglobin (UG) and  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  (PR) genes, both regulated by progesterone (P4), were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days
CRP11	The effects of these metabolites on the expression of uteroglobin (UG) and  bbbbb1 progesterone eeeee1  bbbbb2 uteroglobin eeeee2  (UG) and progesterone receptor (PR) genes, both regulated by progesterone (P4), were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days
CRP11	The effects of these metabolites on the expression of uteroglobin (UG) and  bbbbb1 progesterone eeeee1  bbbbb2 UG eeeee2 ) and progesterone receptor (PR) genes, both regulated by progesterone (P4), were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days
CRP11	The effects of these metabolites on the expression of uteroglobin (UG) and  bbbbb1 progesterone eeeee1  receptor ( bbbbb2 PR eeeee2 ) genes, both regulated by progesterone (P4), were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days
CRP11	Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by  bbbbb1 venlafaxine eeeee1  bbbbb2 5-HT1A eeeee2  antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone
CRP11	Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular  bbbbb1 5-HT eeeee1  bbbbb2 5-HT1A eeeee2  antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone
CRP11	Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on  bbbbb1 NA eeeee1  bbbbb2 5-HT1A eeeee2  antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone
CRP11	Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of  bbbbb1 venlafaxine eeeee1  bbbbb2 5-HT1A eeeee2  antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of  bbbbb1 venlafaxine eeeee1  bbbbb2 5-HT1B/D eeeee2  antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of  bbbbb1 venlafaxine eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist  bbbbb1 (+/-)pindolol eeeee1  and the selective  bbbbb2 5-HT1B/D eeeee2  antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or  bbbbb1 NA eeeee1  bbbbb2 5-HT1B/D eeeee2  antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or  bbbbb1 NA eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either  bbbbb1 5-HT eeeee1  bbbbb2 5-HT1B/D eeeee2  antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either  bbbbb1 5-HT eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist  bbbbb1 GR127935 eeeee1  bbbbb2 5-HT1B/D eeeee2  antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist  bbbbb1 GR127935 eeeee1  bbbbb2 5-HT1A eeeee2  receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA
CRP11	Effects of venlafaxine on extracellular concentrations of 5-HT and  bbbbb1 noradrenaline eeeee1  in the rat frontal cortex: augmentation via  bbbbb2 5-HT1A eeeee2  receptor antagonism
CRP11	Effects of  bbbbb1 venlafaxine eeeee1  on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via  bbbbb2 5-HT1A eeeee2  receptor antagonism
CRP11	Effects of venlafaxine on extracellular concentrations of  bbbbb1 5-HT eeeee1  and noradrenaline in the rat frontal cortex: augmentation via  bbbbb2 5-HT1A eeeee2  receptor antagonism
CRP11	Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective  bbbbb1 melatonin eeeee1  MT(1)/ bbbbb2 MT(2) eeeee2  receptor agonist
CRP11	Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective  bbbbb1 melatonin eeeee1   bbbbb2 MT(1) eeeee2 /MT(2) receptor agonist
CRP11	Ramelteon ( bbbbb1 Rozerem eeeee1 ; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/ bbbbb2 MT(2) eeeee2  receptor agonist
CRP11	Ramelteon ( bbbbb1 Rozerem eeeee1 ; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin  bbbbb2 MT(1) eeeee2 /MT(2) receptor agonist
CRP11	However, current treatment of insomnia with hypnotics,  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 gamma-aminobutyric acid A (GABA(A)) receptor eeeee2  modulators, induces various side effects, including cognitive impairment, motor disturbance, dependence, tolerance, hangover, and rebound insomnia
CRP11	In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of  bbbbb1 tunicamycin eeeee1 , higher fold change of TCF7L2 and VEGFA mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for  bbbbb2 TCF7L2 eeeee2 ; P = 0.004 for VEGFA), suggesting ER stress plays a role in PDR pathogenesis
CRP11	In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of  bbbbb1 tunicamycin eeeee1 , higher fold change of TCF7L2 and VEGFA mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for TCF7L2; P = 0.004 for  bbbbb2 VEGFA eeeee2 ), suggesting ER stress plays a role in PDR pathogenesis
CRP11	Pasireotide has a receptor binding profile that is distinct from that of other  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  analogues, binding with high affinity to somatostatin receptor subtype 5, which is strongly over expressed in corticotroph adenoma cells
CRP11	Pasireotide has a receptor binding profile that is distinct from that of other  bbbbb1 somatostatin eeeee1  analogues, binding with high affinity to  bbbbb2 somatostatin receptor subtype 5 eeeee2 , which is strongly over expressed in corticotroph adenoma cells
CRP11	 bbbbb1 Pasireotide eeeee1  has a receptor binding profile that is distinct from that of other  bbbbb2 somatostatin eeeee2  analogues, binding with high affinity to somatostatin receptor subtype 5, which is strongly over expressed in corticotroph adenoma cells
CRP11	Pasireotide has a receptor binding profile that is distinct from that of other somatostatin analogues, binding with high affinity to  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  analogues, binding with high affinity to somatostatin receptor subtype 5, which is strongly over expressed in corticotroph adenoma cells
CRP11	Pasireotide has a receptor binding profile that is distinct from that of other somatostatin analogues, binding with high affinity to  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor subtype 5 eeeee2 , which is strongly over expressed in corticotroph adenoma cells
CRP11	Pasireotide ( bbbbb1 Signifor eeeee1 (®)) is a new subcutaneous  bbbbb2 somatostatin eeeee2  analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptors eeeee2  to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via  bbbbb1 somatostatin eeeee1  receptors to inhibit the secretion of  bbbbb2 corticotropin eeeee2  from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous  bbbbb1 somatostatin eeeee1  analogue that acts via  bbbbb2 somatostatin receptors eeeee2  to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Pasireotide (Signifor(®)) is a new subcutaneous  bbbbb1 somatostatin eeeee1  analogue that acts via somatostatin receptors to inhibit the secretion of  bbbbb2 corticotropin eeeee2  from the pituitary adenoma in patients with Cushing's disease
CRP11	 bbbbb1 Pasireotide eeeee1  (Signifor(®)) is a new subcutaneous  bbbbb2 somatostatin eeeee2  analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease
CRP11	Despite more than a decade of research in the field of endocrine active compounds targeting the  bbbbb1 androgen eeeee1  receptor ( bbbbb2 AR eeeee2 ), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available
CRP11	Despite more than a decade of research in the field of endocrine active compounds targeting the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available
CRP11	Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2 ), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available
CRP11	Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available
CRP11	Cytotoxicity was assessed in parallel as  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  release
CRP11	Based upon bbbbb1  our resu eeeee1 lts, further evaluation of dasatinib for the treatment of systemic masto-cy bbbbb2 tos eeeee2 is in clinical trials is warranted
CRP11	In this study, we demonstrate significant inhibitory activity of  bbbbb1 dasatinib eeeee1  against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based  bbbbb2 kinase eeeee2  assays
CRP11	Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR- bbbbb2 ABL eeeee2  isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant  bbbbb2 BCR eeeee2 -ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	 bbbbb1 Dasatinib eeeee1  (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR- bbbbb2 ABL eeeee2  isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	 bbbbb1 Dasatinib eeeee1  (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant  bbbbb2 BCR eeeee2 -ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple  bbbbb1 imatinib eeeee1  bbbbb2 ABL eeeee2  inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple  bbbbb1 imatinib eeeee1  bbbbb2 SRC eeeee2 /ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)
CRP11	Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) inhibits  bbbbb2 KIT eeeee2 D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
CRP11	Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by  bbbbb1 dasatinib eeeee1  bbbbb2 KIT activation loop eeeee2  to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib
CRP11	Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by  bbbbb1 dasatinib eeeee1  bbbbb2 D816V eeeee2  mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib
CRP11	Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which  bbbbb1 imatinib eeeee1  bbbbb2 D816V eeeee2  mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib
CRP11	Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced  bbbbb1 [3H]-oxotremorine-M eeeee1  bbbbb2 acetylcholinesterase eeeee2  also displaced [3H]-oxotremorine-M to the greatest extent
CRP11	Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced  bbbbb1 [3H]-oxotremorine-M eeeee1  bbbbb2 acetylcholinesterase eeeee2  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent
CRP11	In the present study, the capacity of acetylcholinesterase inhibitors to interact with muscarinic receptors was assessed by their ability to displace both [3H]-oxotremorine-M and  bbbbb1 [3H]-quinuclinidyl benzilate eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors to interact with muscarinic receptors was assessed by their ability to displace both [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding in rat brain membranes
CRP11	In the present study, the capacity of acetylcholinesterase inhibitors to interact with muscarinic receptors was assessed by their ability to displace both  bbbbb1 [3H]-oxotremorine-M eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors to interact with muscarinic receptors was assessed by their ability to displace both [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding in rat brain membranes
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only  bbbbb1 ambenonium eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine= bbbbb1 tacrine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced  bbbbb1 [3H]-quinuclinidyl benzilate eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine>  bbbbb1 edrophonium eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine> bbbbb1 desoxypeganine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency ( bbbbb1 ambenonium eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine> bbbbb1 physostigmine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine= bbbbb1 pyridostigmine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium> bbbbb1 neostigmine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and  bbbbb1 tacrine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced  bbbbb1 [3H]-oxotremorine-M eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium= bbbbb1 galanthamine eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding
CRP11	The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound  bbbbb1 [3H]-oxotremorine-M eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors
CRP11	The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to  bbbbb1 [3H]quinuclinidyl benzilate eeeee1  bbbbb2 acetylcholinesterase eeeee2  inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors
CRP11	The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and  bbbbb1 ambenonium eeeee1 , to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at  bbbbb2 muscarinic receptors eeeee2 
CRP11	The capacity of acetylcholinesterase inhibitors, with the exception of  bbbbb1 tacrine eeeee1  and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at  bbbbb2 muscarinic receptors eeeee2 
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors bbbbb1  eeeee1  bbbbb2 tremorine-M binding  eeeee2 preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the preven bbbbb1 tion of acety eeeee1  bbbbb2 tremorine-M binding  eeeee2 preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the preven bbbbb1 tion of acety eeeee1 lcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors bbbbb2  eeeee2 
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being req bbbbb1 uired to estimate t eeeee1  bbbbb2 tremorine-M binding  eeeee2 preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarin bbbbb1 ic receptors eeeee1  bbbbb2 tremorine-M binding  eeeee2 preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarinic receptors
CRP11	The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [3H]-oxotremorine-M-labelled muscarin bbbbb1 ic receptors eeeee1  bbbbb2  eeeee2 
CRP11	Differential inhibition of [3H]-oxotremorine-M and  bbbbb1 [3H]-quinuclinidyl benzilate eeeee1  binding to muscarinic receptors in rat brain membranes with  bbbbb2 acetylcholinesterase eeeee2  inhibitors
CRP11	Differential inhibition of  bbbbb1 [3H]-oxotremorine-M eeeee1  and [3H]-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with  bbbbb2 acetylcholinesterase eeeee2  inhibitors
CRP11	Real-time quantitative reverse-transcription polymerase chain reaction and immunohistochemical analysis were performed to determine mRNA levels and receptor protein expressions respectively, for alpha(1A)-, alpha(1B)- and alpha(1D)-adrenoceptors in hamster ureteral smooth muscle. alpha(1)-Adrenoceptor antagonists were tested against the  bbbbb1 phenylephrine eeeee1  bbbbb2 alpha(1A)-, alpha(1B)- and alpha(1D)-adrenoceptors eeeee2  in hamster ureteral smooth muscle. alpha(1)-Adrenoceptor antagonists were tested against the phenylephrine (alpha(1)-adrenoceptor agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach
CRP11	Real-time quantitative reverse-transcription polymerase chain reaction and immunohistochemical analysis were performed to determine mRNA levels and receptor protein expressions respectively, for alpha(1A)-, alpha(1B)- and alpha(1D)-adrenoceptors in hamster ureteral smooth muscle. alpha(1)-Adrenoceptor antagonists were tested against the  bbbbb1 phenylephrine eeeee1  bbbbb2 alpha(1)-Adrenoceptor eeeee2  antagonists were tested against the phenylephrine (alpha(1)-adrenoceptor agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and  bbbbb1 BMY-7378 eeeee1  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and  bbbbb1 BMY-7378 eeeee1  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	 bbbbb1 Prazosin eeeee1  (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  bbbbb2 alpha(1D)-adrenoceptor eeeee2  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	 bbbbb1 Prazosin eeeee1  (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 ( bbbbb1 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride eeeee1  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 ( bbbbb1 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride eeeee1  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist),  bbbbb1 silodosin eeeee1  (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  bbbbb2 alpha(1D)-adrenoceptor eeeee2  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Prazosin (nonselective alpha(1)-adrenoceptor antagonist),  bbbbb1 silodosin eeeee1  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)
CRP11	Nizatidine (LY139037), a selective  bbbbb1 histamine eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, is a potent inhibitor of gastric acid secretion
CRP11	Actions of nizatidine, a selective  bbbbb1 histamine eeeee1  bbbbb2 histamine H2-receptor eeeee2  antagonist, on gastric acid secretion in dogs, rats and frogs
CRP11	Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of histamine,  bbbbb1 methacholine eeeee1  and  bbbbb2 gastrin eeeee2 , nizatidine was, respectively, 6.5, 5 and 4.7 times as active as cimetidine by i.v. administration
CRP11	Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of  bbbbb1 histamine eeeee1 , methacholine and  bbbbb2 gastrin eeeee2 , nizatidine was, respectively, 6.5, 5 and 4.7 times as active as cimetidine by i.v. administration
CRP11	Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of histamine, methacholine and gastrin, nizatidine was, respectively, 6.5, 5 and 4.7 times as active as  bbbbb1 cimetidine eeeee1  bbbbb2 gastrin eeeee2 , nizatidine was, respectively, 6.5, 5 and 4.7 times as active as cimetidine by i.v. administration
CRP11	Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of histamine, methacholine and gastrin,  bbbbb1 nizatidine eeeee1  bbbbb2 gastrin eeeee2 , nizatidine was, respectively, 6.5, 5 and 4.7 times as active as cimetidine by i.v. administration
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  or a dominant-negative  bbbbb2 SGK1 eeeee2 
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 insulin eeeee2  stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 NHE3 eeeee2  through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 serum- and glucocorticoid-dependent kinase 1 eeeee2  (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 insulin eeeee2  effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 SGK1 eeeee2 ) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 SGK1 eeeee2  phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  bbbbb1 wortmannin eeeee1  bbbbb2 insulin eeeee2  (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative  bbbbb2 SGK1 eeeee2 
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as  bbbbb2 insulin eeeee2  stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 ( bbbbb2 PI3K eeeee2 -SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 NHE3 eeeee2  through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase- bbbbb2 serum- and glucocorticoid-dependent kinase 1 eeeee2  (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the  bbbbb2 insulin eeeee2  effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2 -serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the  bbbbb2 PI3K eeeee2  inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K- bbbbb2 SGK1 eeeee2 ) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates  bbbbb2 SGK1 eeeee2  phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	Chronic insulin (24 h) activates NHE3 through the classic  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 insulin eeeee2  (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/H(+) exchanger eeeee2  NHE3
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the  bbbbb1 Na(+) eeeee1 /H(+) exchanger  bbbbb2 NHE3 eeeee2 
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the  bbbbb1 Na(+) eeeee1  bbbbb2 insulin eeeee2  regulates volume and acid-base regulation through stimulation of the Na(+)/H(+) exchanger NHE3
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the Na(+)/ bbbbb1 H(+) eeeee1  bbbbb2 Na(+)/H(+) exchanger eeeee2  NHE3
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the Na(+)/ bbbbb1 H(+) eeeee1  exchanger  bbbbb2 NHE3 eeeee2 
CRP11	In the proximal tubule, insulin regulates volume and acid-base regulation through stimulation of the Na(+)/ bbbbb1 H(+) eeeee1  bbbbb2 insulin eeeee2  regulates volume and acid-base regulation through stimulation of the Na(+)/H(+) exchanger NHE3
CRP11	Characterization of the regulation of renal Na+/ bbbbb1 H+ eeeee1  exchanger NHE3 by  bbbbb2 insulin eeeee2 
CRP11	Characterization of the regulation of renal Na+/ bbbbb1 H+ eeeee1  exchanger  bbbbb2 NHE3 eeeee2  by insulin
CRP11	Characterization of the regulation of renal Na+/ bbbbb1 H+ eeeee1  bbbbb2 renal Na+/H+ exchanger eeeee2  NHE3 by insulin
CRP11	Characterization of the regulation of renal  bbbbb1 Na+ eeeee1 /H+ exchanger NHE3 by  bbbbb2 insulin eeeee2 
CRP11	Characterization of the regulation of renal  bbbbb1 Na+ eeeee1 /H+ exchanger  bbbbb2 NHE3 eeeee2  by insulin
CRP11	Characterization of the regulation of renal  bbbbb1 Na+ eeeee1  bbbbb2 renal Na+/H+ exchanger eeeee2  NHE3 by insulin
CRP11	Kinetic studies of tetrameric recombinant human  bbbbb1 tyrosine eeeee1  bbbbb2 human tyrosine hydroxylase isoform 1 eeeee2  (hTH1) have revealed properties so far not reported for this enzyme
CRP11	Kinetic studies of tetrameric recombinant human  bbbbb1 tyrosine eeeee1  hydroxylase isoform 1 ( bbbbb2 hTH1 eeeee2 ) have revealed properties so far not reported for this enzyme
CRP11	These findings indicate that the binding of H4biopterin at the active site induces a destabilizing conformational change in the enzyme which could be related to the observed ne bbbbb1 gative cooper eeeee1  bbbbb2 e  eeeee2 active site induces a destabilizing conformational change in the enzyme which could be related to the observed negative cooperativity
CRP11	 bbbbb1 Tyrosine eeeee1  bbbbb2 Tyrosine hydroxylase eeeee2  binds tetrahydrobiopterin cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection
CRP11	 bbbbb1 Terbinafine eeeee1  resistance was transmitted with the mutated alleles in gene replacement experiments, proving that single amino acid substitutions in the  bbbbb2 Erg1 eeeee2  protein were sufficient to confer the resistance phenotype
CRP11	Molecular analysis of these mutants revealed single base pair exchanges in the ERG1 gene coding for  bbbbb1 squalene eeeee1  bbbbb2 squalene epoxidase eeeee2 , the target of terbinafine
CRP11	Molecular analysis of these mutants revealed single base pair exchanges in the ERG1 gene coding for  bbbbb1 squalene eeeee1  bbbbb2 ERG1 eeeee2  gene coding for squalene epoxidase, the target of terbinafine
CRP11	Two mutations that were generated by PCR mutagenesis of the ERG1 gene and that conferred terbi bbbbb1 nafine r eeeee1  bbbbb2  terbinafine resistance  eeeee2 mapped in the same regions of the Erg1 protein, with one resulting in an L251F exchange and the other resulting in an F433S exchange
CRP11	Interestingly, all exchanges identified involved amino acids which are conserved in the  bbbbb1 squalene eeeee1  bbbbb2 squalene epoxidases eeeee2  of yeasts and mammals
CRP11	Seven mutants carried the amino acid substitutions F402L (one mutant), F420L (one mutant), and P430S (five mutants) in the  bbbbb1 C eeeee1 -terminal part of the protein; and three mutants carried an  bbbbb2 L251F eeeee2  exchange in the central part of the protein
CRP11	Seven mutants carried the amino acid substitutions F402L (one mutant), F420L (one mutant), and P430S (five mutants) in the  bbbbb1 C eeeee1  bbbbb2 F402L eeeee2  (one mutant), F420L (one mutant), and P430S (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	Seven mutants carried the amino acid substitutions F402L (one mutant), F420L (one mutant), and P430S (five mutants) in the  bbbbb1 C eeeee1  bbbbb2 F420L eeeee2  (one mutant), and P430S (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	Seven mutants carried the amino acid substitutions F402L (one mutant), F420L (one mutant), and P430S (five mutants) in the  bbbbb1 C eeeee1  bbbbb2 P430S eeeee2  (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	Seven mutants carried the  bbbbb1 amino acid eeeee1  substitutions F402L (one mutant), F420L (one mutant), and P430S (five mutants) in the C-terminal part of the protein; and three mutants carried an  bbbbb2 L251F eeeee2  exchange in the central part of the protein
CRP11	Seven mutants carried the  bbbbb1 amino acid eeeee1  substitutions  bbbbb2 F402L eeeee2  (one mutant), F420L (one mutant), and P430S (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	Seven mutants carried the  bbbbb1 amino acid eeeee1  substitutions F402L (one mutant),  bbbbb2 F420L eeeee2  (one mutant), and P430S (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	Seven mutants carried the  bbbbb1 amino acid eeeee1  substitutions F402L (one mutant), F420L (one mutant), and  bbbbb2 P430S eeeee2  (five mutants) in the C-terminal part of the protein; and three mutants carried an L251F exchange in the central part of the protein
CRP11	LA-4 containing membrane preparation of MV3 cells was immobilised at the sensors to allow for detection of kinetic binding constants of  bbbbb1 tinzaparin eeeee1  compared to  bbbbb2 VCAM-1 eeeee2 
CRP11	The Ves a 1 structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the Gly-X-Ser-X- bbbbb1 Gly eeeee1  bbbbb2 Gly-X-Ser-X-Gly eeeee2  consensus sequence
CRP11	The Ves a 1 structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the  bbbbb1 Gly eeeee1  bbbbb2 Gly-X-Ser-X-Gly eeeee2  consensus sequence
CRP11	The Ves a 1 structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the Gly-X- bbbbb1 Ser eeeee1  bbbbb2 Gly-X-Ser-X-Gly eeeee2  consensus sequence
CRP11	Cisapride was found to bind the human ether-a-go-go-related gene (HERG)  bbbbb1 potassium eeeee1  bbbbb2 human ether-a-go-go-related gene (HERG) potassium channel eeeee2 , which provides a plausible mechanism for QTc interval prolongation/arrhythmia
CRP11	Albumin nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 ( bbbbb1 PEG eeeee1 ) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor ( bbbbb2 EGFR eeeee2 )
CRP11	Albumin nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 ( bbbbb1 PEG eeeee1 ) and a nanobody-the single variable domain of an antibody-(Ega1) against the  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR)
CRP11	Albumin nanoparticles were surface-coated with bifunctional  bbbbb1 polyethylene glycol eeeee1  3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor ( bbbbb2 EGFR eeeee2 )
CRP11	Albumin nanoparticles were surface-coated with bifunctional  bbbbb1 polyethylene glycol eeeee1  3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR)
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to  bbbbb1 methionine eeeee1  bbbbb2 albumin eeeee2  nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to  bbbbb1 methionine eeeee1  bbbbb2 multikinase eeeee2  inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a  bbbbb1 platinum eeeee1  bbbbb2 albumin eeeee2  nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a  bbbbb1 platinum eeeee1 -bound sunitinib analogue-which couples the drug to methionine residues of  bbbbb2 albumin eeeee2  and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a  bbbbb1 platinum eeeee1  bbbbb2 multikinase eeeee2  inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound  bbbbb1 sunitinib eeeee1  bbbbb2 albumin eeeee2  nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound  bbbbb1 sunitinib eeeee1  analogue-which couples the drug to methionine residues of  bbbbb2 albumin eeeee2  and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound  bbbbb1 sunitinib eeeee1  bbbbb2 multikinase eeeee2  inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor  bbbbb1 17864 eeeee1  bbbbb2 albumin eeeee2  nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor  bbbbb1 17864 eeeee1 -L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of  bbbbb2 albumin eeeee2  and is released in a reductive environment
CRP11	 bbbbb1 Glutaraldehyde eeeee1  crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of  bbbbb2 albumin eeeee2  and is released in a reductive environment
CRP11	 bbbbb1 Glutaraldehyde eeeee1  crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the  bbbbb2 multikinase eeeee2  inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment
CRP11	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor  bbbbb1 17864 eeeee1  bbbbb2 albumin eeeee2  nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells
CRP11	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor  bbbbb1 17864 eeeee1  to  bbbbb2 EGFR eeeee2  overexpressing tumor cells
CRP11	The intracellular routing of EGa1 targeted nanoparticles leads to a successful release of the kinase inhibitor in the cell and inhibition of proliferation whereas the non-targeted formulations had no antiproliferative effects on  bbbbb1 14C eeeee1  bbbbb2 kinase eeeee2  inhibitor in the cell and inhibition of proliferation whereas the non-targeted formulations had no antiproliferative effects on 14C cells
CRP11	EGa1- bbbbb1 PEG eeeee1  functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by  bbbbb2 clathrin eeeee2 -mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1- bbbbb1 PEG eeeee1  functionalized nanoparticles showed a 40-fold higher binding to  bbbbb2 EGFR eeeee2 -positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles.  bbbbb1 17864 eeeee1 -L(x) loaded EGa1-PEG nanoparticles were internalized by  bbbbb2 clathrin eeeee2 -mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles.  bbbbb1 17864 eeeee1  bbbbb2 EGFR eeeee2 -positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive  bbbbb1 14C eeeee1  squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by  bbbbb2 clathrin eeeee2 -mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive  bbbbb1 14C eeeee1  bbbbb2 EGFR eeeee2 -positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1- bbbbb1 PEG eeeee1  nanoparticles were internalized by  bbbbb2 clathrin eeeee2 -mediated endocytosis and ultimately digested in lysosomes
CRP11	EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1- bbbbb1 PEG eeeee1  bbbbb2 EGFR eeeee2 -positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone system-mediated impairment of renal sodium excretion
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone system-mediated impairment of renal sodium excretion
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin-angiotensin-aldosterone system-mediated impairment of renal  bbbbb1 sodium eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone system-mediated impairment of renal sodium excretion
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin-angiotensin-aldosterone system-mediated impairment of renal  bbbbb1 sodium eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone system-mediated impairment of renal sodium excretion
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone system-mediated impairment of renal sodium excretion
CRP11	In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of renin- bbbbb1 angiotensin eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone system-mediated impairment of renal sodium excretion
CRP11	Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the  bbbbb1 N eeeee1  terminus of leukocyte P-selectin glycoprotein ligand-1 ( bbbbb2 PSGL-1 eeeee2 ) in humans and mice
CRP11	Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the  bbbbb1 N eeeee1  bbbbb2 selectin eeeee2 -ligand at the N terminus of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) in humans and mice
CRP11	Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the  bbbbb1 N eeeee1  bbbbb2 FUT4 eeeee2 , forms the selectin-ligand at the N terminus of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) in humans and mice
CRP11	Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the  bbbbb1 N eeeee1  bbbbb2 FUT7 eeeee2 , and to a lesser extent FUT4, forms the selectin-ligand at the N terminus of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) in humans and mice
CRP11	Leukocyte adhesion during inflammation is initiated by the binding of sialofucosylated  bbbbb1 carbohydrates eeeee1  expressed on leukocytes to endothelial  bbbbb2 E/P-selectin eeeee2 
CRP11	Suppression of nuclear factor erythroid 2-related factor 2 via extracellular signal-regulated kinase contributes to  bbbbb1 bleomycin eeeee1  bbbbb2 extracellular signal-regulated kinase eeeee2  contributes to bleomycin-induced oxidative stress and fibrogenesis
CRP11	Suppression of nuclear factor erythroid 2-related factor 2 via extracellular signal-regulated kinase contributes to  bbbbb1 bleomycin eeeee1  bbbbb2 nuclear factor erythroid 2-related factor 2 eeeee2  via extracellular signal-regulated kinase contributes to bleomycin-induced oxidative stress and fibrogenesis
CRP11	In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and  bbbbb1 thiobarbituric acid eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and  bbbbb1 thiobarbituric acid eeeee1  bbbbb2 catalase eeeee2  activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In addition, prominent oxidative stress was indicated by changes in  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , catalase activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In addition, prominent oxidative stress was indicated by changes in  bbbbb1 superoxide eeeee1  dismutase,  bbbbb2 catalase eeeee2  activity, and glutathione and thiobarbituric acid-reactive substance levels
CRP11	In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive  bbbbb1 oxygen eeeee1  bbbbb2 extracellular signal-related kinase eeeee2  phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion
CRP11	In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive  bbbbb1 oxygen eeeee1  bbbbb2 Nrf2 eeeee2  activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion
CRP11	Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor),  bbbbb1 ibuprofen eeeee1  bbbbb2 cyclooxygenase 2 eeeee2  inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial
CRP11	T6 is a novel target gene of caveolin-1 promoting chemoresistance to  bbbbb1 epirubicin eeeee1  bbbbb2 caveolin-1 eeeee2  promoting chemoresistance to epirubicin in human gastric cancer cells
CRP11	GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin,  bbbbb1 5-fluorouracil eeeee1  bbbbb2 WNT6 eeeee2  expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy
CRP11	GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF ( bbbbb1 Epi eeeee1  bbbbb2 WNT6 eeeee2  expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy
CRP11	GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi,  bbbbb1 cisplatin eeeee1  bbbbb2 WNT6 eeeee2  expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the  bbbbb1 anthracycline eeeee1  bbbbb2 WNT6 eeeee2  increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the  bbbbb1 anthracycline eeeee1  bbbbb2 WNT6 eeeee2  knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and  bbbbb1 doxorubicin eeeee1  bbbbb2 WNT6 eeeee2  increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and  bbbbb1 doxorubicin eeeee1  bbbbb2 WNT6 eeeee2  knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin ( bbbbb1 Epi eeeee1  bbbbb2 WNT6 eeeee2  increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin ( bbbbb1 Epi eeeee1  bbbbb2 WNT6 eeeee2  knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics  bbbbb1 epirubicin eeeee1  bbbbb2 WNT6 eeeee2  increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics  bbbbb1 epirubicin eeeee1  bbbbb2 WNT6 eeeee2  knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin ( bbbbb1 Dox eeeee1  bbbbb2 WNT6 eeeee2  increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin ( bbbbb1 Dox eeeee1  bbbbb2 WNT6 eeeee2  knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox)
CRP11	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of  bbbbb1 the hydroxymethy eeeee1  bbbbb2 synthes eeeee2 is through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene
CRP11	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of  bbbbb1 the hydroxymethy eeeee1  bbbbb2 ated melanogenesi eeeee2 s by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene
CRP11	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regul bbbbb1 ated me eeeee1 lanogenesis by inhibiting cholesterol  bbbbb2 synthes eeeee2 is through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene
CRP11	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regul bbbbb1 ated me eeeee1  bbbbb2 ated melanogenesi eeeee2 s by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene
CRP11	Furthermore,  bbbbb1 cAMP eeeee1  production and  bbbbb2 protein kinase A eeeee2  (PKA) activity were suppressed by artemisinic acid
CRP11	Furthermore,  bbbbb1 cAMP eeeee1  production and protein kinase A ( bbbbb2 PKA eeeee2 ) activity were suppressed by artemisinic acid
CRP11	Artemisinic acid inhibits melanogenesis through downregulation of C/EBP α-dependent expression of  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  gene
CRP11	Artemisinic acid inhibits melanogenesis through downregulation of C/EBP α-dependent expression of  bbbbb1 HMG-CoA eeeee1  bbbbb2 C/EBP α eeeee2 -dependent expression of HMG-CoA reductase gene
CRP11	Reboxetine, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human  bbbbb1 norepinephrine eeeee1  bbbbb2 human norepinephrine transporter eeeee2 
CRP11	Reboxetine, a selective  bbbbb1 norepinephrine eeeee1  reuptake inhibitor, exhibits high affinity and selectivity for the  bbbbb2 human norepinephrine transporter eeeee2 
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent  bbbbb1 methyl alpha-D-glucopyranoside eeeee1  bbbbb2 lactoferrin eeeee2  and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent  bbbbb1 methyl alpha-D-glucopyranoside eeeee1  bbbbb2 apoE3 eeeee2 , lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent  bbbbb1 methyl alpha-D-glucopyranoside eeeee1  (AMG) uptake and levels of  bbbbb2 SGLT1 eeeee2  expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent  bbbbb1 methyl alpha-D-glucopyranoside eeeee1  bbbbb2 bovine serum albumin eeeee2  with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside ( bbbbb1 AMG eeeee1  bbbbb2 lactoferrin eeeee2  and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside ( bbbbb1 AMG eeeee1  bbbbb2 apoE3 eeeee2 , lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside ( bbbbb1 AMG eeeee1 ) uptake and levels of  bbbbb2 SGLT1 eeeee2  expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside ( bbbbb1 AMG eeeee1  bbbbb2 bovine serum albumin eeeee2  with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of  bbbbb1 GMC eeeee1  bbbbb2 lactoferrin eeeee2  and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of  bbbbb1 GMC eeeee1 , and the  bbbbb2 SGLT1 eeeee2 -dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of  bbbbb1 GMC eeeee1  bbbbb2 apoE3 eeeee2 , lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of  bbbbb1 GMC eeeee1 , and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of  bbbbb2 SGLT1 eeeee2  expression were determined
CRP11	Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of  bbbbb1 GMC eeeee1  bbbbb2 bovine serum albumin eeeee2  with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined
CRP11	As a result, we demonstrated that the apoE3 significantly protects these cells from GMC-induced reduction in  bbbbb1 AMG eeeee1  bbbbb2 apoE3 eeeee2  significantly protects these cells from GMC-induced reduction in AMG uptake, but neither lactoferrin nor albumin does
CRP11	As a result, we demonstrated that the apoE3 significantly protects these cells from GMC-induced reduction in  bbbbb1 AMG eeeee1  uptake, but neither  bbbbb2 lactoferrin eeeee2  nor albumin does
CRP11	As a result, we demonstrated that the apoE3 significantly protects these cells from GMC-induced reduction in  bbbbb1 AMG eeeee1  uptake, but neither lactoferrin nor  bbbbb2 albumin eeeee2  does
CRP11	As a result, we demonstrated that the apoE3 significantly protects these cells from  bbbbb1 GMC eeeee1  bbbbb2 apoE3 eeeee2  significantly protects these cells from GMC-induced reduction in AMG uptake, but neither lactoferrin nor albumin does
CRP11	In accord with a rise in  bbbbb1 AMG eeeee1  uptake activity, the mRNA and protein levels of  bbbbb2 SGLT1 eeeee2  were apparently up-regulated in the presence of apoE3
CRP11	In accord with a rise in  bbbbb1 AMG eeeee1  uptake activity, the mRNA and protein levels of SGLT1 were apparently up-regulated in the presence of  bbbbb2 apoE3 eeeee2 
CRP11	We previously reported that aminoglycoside antibiotics reduce SGLT1-dependent  bbbbb1 glucose eeeee1  bbbbb2 SGLT1 eeeee2 -dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity
CRP11	Furthermore, we found that the uptake of [3H] gentamicin is decreased by apoE3, and tha bbbbb1 t apoE3 showed eeeee1  bbbbb2 ake o eeeee2 f [3H] gentamicin is decreased by apoE3, and that apoE3 showed obvious protection against the GMC-dependent N-acetyl-beta-D-glucosamidase (NAG) release from LLC-PK1 cells
CRP11	Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by  bbbbb1 gentamicin C eeeee1  bbbbb2 Apolipoprotein E3 eeeee2  (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C
CRP11	Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by  bbbbb1 gentamicin C eeeee1  bbbbb2 apoE3 eeeee2 ) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C
CRP11	In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the  bbbbb1 GMC eeeee1  bbbbb2 SGLT1 eeeee2  activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity
CRP11	In this study, using a model of  bbbbb1 gentamicin C eeeee1  (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in  bbbbb2 SGLT1 eeeee2  activity
CRP11	In this study, using a model of gentamicin C ( bbbbb1 GMC eeeee1 )-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in  bbbbb2 SGLT1 eeeee2  activity
CRP11	 bbbbb1 Histamine eeeee1  content, HDC activity and  bbbbb2 HDC eeeee2  mRNA expression in nasal mucosa were also significantly increased after TDI provocation
CRP11	 bbbbb1 Histamine eeeee1  content,  bbbbb2 HDC eeeee2  activity and HDC mRNA expression in nasal mucosa were also significantly increased after TDI provocation
CRP11	Histamine synthesized by  bbbbb1 histidine eeeee1  bbbbb2 histidine decarboxylase eeeee2  (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity
CRP11	Histamine synthesized by  bbbbb1 histidine eeeee1  decarboxylase ( bbbbb2 HDC eeeee2 ) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity
CRP11	 bbbbb1 Histamine eeeee1  content and  bbbbb2 HDC eeeee2  activity in the nasal mucosa were determined using fluorometric high performance liquid chromatography
CRP11	 bbbbb1 ATP eeeee1  bbbbb2 ATP-gated P2X3 receptors eeeee2  of sensory ganglion neurons are important transducers of painful stimuli and are modulated by extracellular algogenic substances, via changes in the receptor phosphorylation state
CRP11	The present study investigated the role of  bbbbb1 calcium eeeee1  bbbbb2 calcium/calmodulin-dependent serine protein kinase eeeee2  CASK in interacting and controlling P2X3 receptor expression and function in mouse trigeminal ganglia
CRP11	The present study investigated the role of  bbbbb1 calcium eeeee1 /calmodulin-dependent serine protein kinase CASK in interacting and controlling  bbbbb2 P2X3 receptor eeeee2  expression and function in mouse trigeminal ganglia
CRP11	The present study investigated the role of  bbbbb1 calcium eeeee1 /calmodulin-dependent serine protein kinase  bbbbb2 CASK eeeee2  in interacting and controlling P2X3 receptor expression and function in mouse trigeminal ganglia
CRP11	The present study investigated the role of calcium/calmodulin-dependent  bbbbb1 serine eeeee1  bbbbb2 calcium/calmodulin-dependent serine protein kinase eeeee2  CASK in interacting and controlling P2X3 receptor expression and function in mouse trigeminal ganglia
CRP11	The present study investigated the role of calcium/calmodulin-dependent  bbbbb1 serine eeeee1  protein kinase CASK in interacting and controlling  bbbbb2 P2X3 receptor eeeee2  expression and function in mouse trigeminal ganglia
CRP11	The present study investigated the role of calcium/calmodulin-dependent  bbbbb1 serine eeeee1  protein kinase  bbbbb2 CASK eeeee2  in interacting and controlling P2X3 receptor expression and function in mouse trigeminal ganglia